{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "collapsed_sections": [
        "_HA-KOzZZ4uf",
        "L4glkMm-aB_n",
        "_Sp8jfd2aShW",
        "dGbiluv9akAS",
        "Pqybo4J_aon6",
        "dbk-8hc7a3MJ"
      ]
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "source": [
        "# Install"
      ],
      "metadata": {
        "id": "_HA-KOzZZ4uf"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install pyserini\n",
        "!pip install faiss-cpu"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "qkxxq91-YpzT",
        "outputId": "edb98d29-e198-4611-d420-8e1c5cd1e8f9"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Looking in indexes: https://pypi.org/simple, https://us-python.pkg.dev/colab-wheels/public/simple/\n",
            "Collecting pyserini\n",
            "  Downloading pyserini-0.18.0-py3-none-any.whl (114.8 MB)\n",
            "\u001b[K     |████████████████████████████████| 114.8 MB 76 kB/s \n",
            "\u001b[?25hRequirement already satisfied: spacy>=3.2.1 in /usr/local/lib/python3.7/dist-packages (from pyserini) (3.4.1)\n",
            "Requirement already satisfied: numpy>=1.18.1 in /usr/local/lib/python3.7/dist-packages (from pyserini) (1.21.6)\n",
            "Collecting nmslib>=2.1.1\n",
            "  Downloading nmslib-2.1.1-cp37-cp37m-manylinux2010_x86_64.whl (13.5 MB)\n",
            "\u001b[K     |████████████████████████████████| 13.5 MB 38.9 MB/s \n",
            "\u001b[?25hRequirement already satisfied: scikit-learn>=0.22.1 in /usr/local/lib/python3.7/dist-packages (from pyserini) (1.0.2)\n",
            "Requirement already satisfied: scipy>=1.4.1 in /usr/local/lib/python3.7/dist-packages (from pyserini) (1.7.3)\n",
            "Collecting transformers>=4.6.0\n",
            "  Downloading transformers-4.23.1-py3-none-any.whl (5.3 MB)\n",
            "\u001b[K     |████████████████████████████████| 5.3 MB 35.2 MB/s \n",
            "\u001b[?25hCollecting pyjnius>=1.4.0\n",
            "  Downloading pyjnius-1.4.2-cp37-cp37m-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (1.3 MB)\n",
            "\u001b[K     |████████████████████████████████| 1.3 MB 48.4 MB/s \n",
            "\u001b[?25hCollecting sentencepiece>=0.1.95\n",
            "  Downloading sentencepiece-0.1.97-cp37-cp37m-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (1.3 MB)\n",
            "\u001b[K     |████████████████████████████████| 1.3 MB 43.7 MB/s \n",
            "\u001b[?25hCollecting onnxruntime>=1.8.1\n",
            "  Downloading onnxruntime-1.12.1-cp37-cp37m-manylinux_2_27_x86_64.whl (4.9 MB)\n",
            "\u001b[K     |████████████████████████████████| 4.9 MB 42.8 MB/s \n",
            "\u001b[?25hRequirement already satisfied: pandas>=1.1.5 in /usr/local/lib/python3.7/dist-packages (from pyserini) (1.3.5)\n",
            "Collecting lightgbm>=3.3.2\n",
            "  Downloading lightgbm-3.3.3-py3-none-manylinux1_x86_64.whl (2.0 MB)\n",
            "\u001b[K     |████████████████████████████████| 2.0 MB 25.6 MB/s \n",
            "\u001b[?25hRequirement already satisfied: Cython>=0.29.21 in /usr/local/lib/python3.7/dist-packages (from pyserini) (0.29.32)\n",
            "Requirement already satisfied: tqdm in /usr/local/lib/python3.7/dist-packages (from pyserini) (4.64.1)\n",
            "Requirement already satisfied: wheel in /usr/local/lib/python3.7/dist-packages (from lightgbm>=3.3.2->pyserini) (0.37.1)\n",
            "Requirement already satisfied: psutil in /usr/local/lib/python3.7/dist-packages (from nmslib>=2.1.1->pyserini) (5.4.8)\n",
            "Collecting pybind11<2.6.2\n",
            "  Downloading pybind11-2.6.1-py2.py3-none-any.whl (188 kB)\n",
            "\u001b[K     |████████████████████████████████| 188 kB 47.4 MB/s \n",
            "\u001b[?25hRequirement already satisfied: sympy in /usr/local/lib/python3.7/dist-packages (from onnxruntime>=1.8.1->pyserini) (1.7.1)\n",
            "Requirement already satisfied: flatbuffers in /usr/local/lib/python3.7/dist-packages (from onnxruntime>=1.8.1->pyserini) (1.12)\n",
            "Requirement already satisfied: protobuf in /usr/local/lib/python3.7/dist-packages (from onnxruntime>=1.8.1->pyserini) (3.17.3)\n",
            "Requirement already satisfied: packaging in /usr/local/lib/python3.7/dist-packages (from onnxruntime>=1.8.1->pyserini) (21.3)\n",
            "Collecting coloredlogs\n",
            "  Downloading coloredlogs-15.0.1-py2.py3-none-any.whl (46 kB)\n",
            "\u001b[K     |████████████████████████████████| 46 kB 3.3 MB/s \n",
            "\u001b[?25hRequirement already satisfied: python-dateutil>=2.7.3 in /usr/local/lib/python3.7/dist-packages (from pandas>=1.1.5->pyserini) (2.8.2)\n",
            "Requirement already satisfied: pytz>=2017.3 in /usr/local/lib/python3.7/dist-packages (from pandas>=1.1.5->pyserini) (2022.4)\n",
            "Requirement already satisfied: six>=1.7.0 in /usr/local/lib/python3.7/dist-packages (from pyjnius>=1.4.0->pyserini) (1.15.0)\n",
            "Requirement already satisfied: joblib>=0.11 in /usr/local/lib/python3.7/dist-packages (from scikit-learn>=0.22.1->pyserini) (1.2.0)\n",
            "Requirement already satisfied: threadpoolctl>=2.0.0 in /usr/local/lib/python3.7/dist-packages (from scikit-learn>=0.22.1->pyserini) (3.1.0)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.7/dist-packages (from spacy>=3.2.1->pyserini) (2.11.3)\n",
            "Requirement already satisfied: murmurhash<1.1.0,>=0.28.0 in /usr/local/lib/python3.7/dist-packages (from spacy>=3.2.1->pyserini) (1.0.8)\n",
            "Requirement already satisfied: requests<3.0.0,>=2.13.0 in /usr/local/lib/python3.7/dist-packages (from spacy>=3.2.1->pyserini) (2.23.0)\n",
            "Requirement already satisfied: pydantic!=1.8,!=1.8.1,<1.10.0,>=1.7.4 in /usr/local/lib/python3.7/dist-packages (from spacy>=3.2.1->pyserini) (1.9.2)\n",
            "Requirement already satisfied: typer<0.5.0,>=0.3.0 in /usr/local/lib/python3.7/dist-packages (from spacy>=3.2.1->pyserini) (0.4.2)\n",
            "Requirement already satisfied: preshed<3.1.0,>=3.0.2 in /usr/local/lib/python3.7/dist-packages (from spacy>=3.2.1->pyserini) (3.0.7)\n",
            "Requirement already satisfied: cymem<2.1.0,>=2.0.2 in /usr/local/lib/python3.7/dist-packages (from spacy>=3.2.1->pyserini) (2.0.6)\n",
            "Requirement already satisfied: catalogue<2.1.0,>=2.0.6 in /usr/local/lib/python3.7/dist-packages (from spacy>=3.2.1->pyserini) (2.0.8)\n",
            "Requirement already satisfied: langcodes<4.0.0,>=3.2.0 in /usr/local/lib/python3.7/dist-packages (from spacy>=3.2.1->pyserini) (3.3.0)\n",
            "Requirement already satisfied: wasabi<1.1.0,>=0.9.1 in /usr/local/lib/python3.7/dist-packages (from spacy>=3.2.1->pyserini) (0.10.1)\n",
            "Requirement already satisfied: thinc<8.2.0,>=8.1.0 in /usr/local/lib/python3.7/dist-packages (from spacy>=3.2.1->pyserini) (8.1.3)\n",
            "Requirement already satisfied: spacy-legacy<3.1.0,>=3.0.9 in /usr/local/lib/python3.7/dist-packages (from spacy>=3.2.1->pyserini) (3.0.10)\n",
            "Requirement already satisfied: setuptools in /usr/local/lib/python3.7/dist-packages (from spacy>=3.2.1->pyserini) (57.4.0)\n",
            "Requirement already satisfied: pathy>=0.3.5 in /usr/local/lib/python3.7/dist-packages (from spacy>=3.2.1->pyserini) (0.6.2)\n",
            "Requirement already satisfied: spacy-loggers<2.0.0,>=1.0.0 in /usr/local/lib/python3.7/dist-packages (from spacy>=3.2.1->pyserini) (1.0.3)\n",
            "Requirement already satisfied: typing-extensions<4.2.0,>=3.7.4 in /usr/local/lib/python3.7/dist-packages (from spacy>=3.2.1->pyserini) (4.1.1)\n",
            "Requirement already satisfied: srsly<3.0.0,>=2.4.3 in /usr/local/lib/python3.7/dist-packages (from spacy>=3.2.1->pyserini) (2.4.4)\n",
            "Requirement already satisfied: zipp>=0.5 in /usr/local/lib/python3.7/dist-packages (from catalogue<2.1.0,>=2.0.6->spacy>=3.2.1->pyserini) (3.9.0)\n",
            "Requirement already satisfied: pyparsing!=3.0.5,>=2.0.2 in /usr/local/lib/python3.7/dist-packages (from packaging->onnxruntime>=1.8.1->pyserini) (3.0.9)\n",
            "Requirement already satisfied: smart-open<6.0.0,>=5.2.1 in /usr/local/lib/python3.7/dist-packages (from pathy>=0.3.5->spacy>=3.2.1->pyserini) (5.2.1)\n",
            "Requirement already satisfied: idna<3,>=2.5 in /usr/local/lib/python3.7/dist-packages (from requests<3.0.0,>=2.13.0->spacy>=3.2.1->pyserini) (2.10)\n",
            "Requirement already satisfied: chardet<4,>=3.0.2 in /usr/local/lib/python3.7/dist-packages (from requests<3.0.0,>=2.13.0->spacy>=3.2.1->pyserini) (3.0.4)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.7/dist-packages (from requests<3.0.0,>=2.13.0->spacy>=3.2.1->pyserini) (2022.9.24)\n",
            "Requirement already satisfied: urllib3!=1.25.0,!=1.25.1,<1.26,>=1.21.1 in /usr/local/lib/python3.7/dist-packages (from requests<3.0.0,>=2.13.0->spacy>=3.2.1->pyserini) (1.24.3)\n",
            "Requirement already satisfied: blis<0.8.0,>=0.7.8 in /usr/local/lib/python3.7/dist-packages (from thinc<8.2.0,>=8.1.0->spacy>=3.2.1->pyserini) (0.7.8)\n",
            "Requirement already satisfied: confection<1.0.0,>=0.0.1 in /usr/local/lib/python3.7/dist-packages (from thinc<8.2.0,>=8.1.0->spacy>=3.2.1->pyserini) (0.0.3)\n",
            "Collecting tokenizers!=0.11.3,<0.14,>=0.11.1\n",
            "  Downloading tokenizers-0.13.1-cp37-cp37m-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (7.6 MB)\n",
            "\u001b[K     |████████████████████████████████| 7.6 MB 29.5 MB/s \n",
            "\u001b[?25hCollecting huggingface-hub<1.0,>=0.10.0\n",
            "  Downloading huggingface_hub-0.10.1-py3-none-any.whl (163 kB)\n",
            "\u001b[K     |████████████████████████████████| 163 kB 69.7 MB/s \n",
            "\u001b[?25hRequirement already satisfied: regex!=2019.12.17 in /usr/local/lib/python3.7/dist-packages (from transformers>=4.6.0->pyserini) (2022.6.2)\n",
            "Requirement already satisfied: filelock in /usr/local/lib/python3.7/dist-packages (from transformers>=4.6.0->pyserini) (3.8.0)\n",
            "Requirement already satisfied: importlib-metadata in /usr/local/lib/python3.7/dist-packages (from transformers>=4.6.0->pyserini) (5.0.0)\n",
            "Requirement already satisfied: pyyaml>=5.1 in /usr/local/lib/python3.7/dist-packages (from transformers>=4.6.0->pyserini) (6.0)\n",
            "Requirement already satisfied: click<9.0.0,>=7.1.1 in /usr/local/lib/python3.7/dist-packages (from typer<0.5.0,>=0.3.0->spacy>=3.2.1->pyserini) (7.1.2)\n",
            "Collecting humanfriendly>=9.1\n",
            "  Downloading humanfriendly-10.0-py2.py3-none-any.whl (86 kB)\n",
            "\u001b[K     |████████████████████████████████| 86 kB 6.1 MB/s \n",
            "\u001b[?25hRequirement already satisfied: MarkupSafe>=0.23 in /usr/local/lib/python3.7/dist-packages (from jinja2->spacy>=3.2.1->pyserini) (2.0.1)\n",
            "Requirement already satisfied: mpmath>=0.19 in /usr/local/lib/python3.7/dist-packages (from sympy->onnxruntime>=1.8.1->pyserini) (1.2.1)\n",
            "Installing collected packages: humanfriendly, tokenizers, pybind11, huggingface-hub, coloredlogs, transformers, sentencepiece, pyjnius, onnxruntime, nmslib, lightgbm, pyserini\n",
            "  Attempting uninstall: lightgbm\n",
            "    Found existing installation: lightgbm 2.2.3\n",
            "    Uninstalling lightgbm-2.2.3:\n",
            "      Successfully uninstalled lightgbm-2.2.3\n",
            "Successfully installed coloredlogs-15.0.1 huggingface-hub-0.10.1 humanfriendly-10.0 lightgbm-3.3.3 nmslib-2.1.1 onnxruntime-1.12.1 pybind11-2.6.1 pyjnius-1.4.2 pyserini-0.18.0 sentencepiece-0.1.97 tokenizers-0.13.1 transformers-4.23.1\n",
            "Looking in indexes: https://pypi.org/simple, https://us-python.pkg.dev/colab-wheels/public/simple/\n",
            "Collecting faiss-cpu\n",
            "  Downloading faiss_cpu-1.7.2-cp37-cp37m-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (8.6 MB)\n",
            "\u001b[K     |████████████████████████████████| 8.6 MB 1.6 MB/s \n",
            "\u001b[?25hInstalling collected packages: faiss-cpu\n",
            "Successfully installed faiss-cpu-1.7.2\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# Mount Drive and change path"
      ],
      "metadata": {
        "id": "L4glkMm-aB_n"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "import os\n",
        "from google.colab import drive\n",
        "drive.mount('/content/drive')\n",
        "os.chdir('/content/drive/MyDrive/Introduction-to-Information-Retrieval/HW/3')"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "TmSK7fD1YvDL",
        "outputId": "ac5cd4ce-1c4d-4184-a4fb-ef0afa1e45d3"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Mounted at /content/drive\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# Text Preprocessing"
      ],
      "metadata": {
        "id": "_Sp8jfd2aShW"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "import json\n",
        "from json.decoder import JSONDecodeError\n",
        "\n",
        "dic = { \"\\n\": \"\", \"\\t\": \"\", \".\": \"\", \"BACKGROUND\": \"\", \"METHODS\": \"\", \"RESULTS\": \"\", \"CONCLUSIONS\": \"\", \n",
        "        \"OBJECTIVE\": \"\", \"`\": \"\", \"'\": \"\", \",\": \"\", \";\": \"\", \":\": \"\", \"(\": \"\", \")\": \"\"}\n",
        "\n",
        "def replace_all(text):\n",
        "  for i, j in dic.items():\n",
        "    text = text.replace(i, j)\n",
        "  return text\n",
        "\n",
        "def remove_whitespace(text):\n",
        "    text = \" \".join(text.split())\n",
        "    return \"\".join(text.rstrip().lstrip())\n",
        "\n",
        "data = {\"id\":[],\"contents\":[]}\n",
        "first_time = True\n",
        "\n",
        "\n",
        "with open('pubmed 220 train.txt') as file:\n",
        "    string = \"\"\n",
        "    for line in file:\n",
        "      if \"###\" in line:\n",
        "        line = line.replace(\"###\", \"\").replace(\"\\n\", \"\")\n",
        "        data[\"id\"].append(line)\n",
        "        if first_time:\n",
        "          first_time = False\n",
        "        else:\n",
        "          string = remove_whitespace(string)\n",
        "          data[\"contents\"].append(string)\n",
        "        string = \"\"\n",
        "      \n",
        "      else:\n",
        "        string = string + replace_all(line)\n",
        "\n",
        "string = remove_whitespace(string)\n",
        "data[\"contents\"].append(string)\n",
        "\n",
        "\n",
        "json_data = []\n",
        "for i in range(len(data[\"contents\"])):\n",
        "  json_data.append({\"id\": data[\"id\"][i], \"contents\": data[\"contents\"][i]})\n",
        "\n",
        "\n",
        "with open(\"./json/data.json\", \"w\") as file:\n",
        "  json.dump(json_data, file, indent=2)\n",
        "\n",
        "\n",
        "\n",
        "\n",
        "\n",
        "\n",
        "\n",
        "\n"
      ],
      "metadata": {
        "id": "NHF7SDDrZNXX"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "# Index documents"
      ],
      "metadata": {
        "id": "dGbiluv9akAS"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "!python -m pyserini.index.lucene \\\n",
        "  --collection JsonCollection \\\n",
        "  --input ./json \\\n",
        "  --index ./json \\\n",
        "  --generator DefaultLuceneDocumentGenerator \\\n",
        "  --threads 1 \\\n",
        "  --storePositions --storeDocvectors --storeRaw"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "y3PcYgHxNRKN",
        "outputId": "5e876e1a-54d0-4e1e-950e-5153d3ad2b05"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "WARNING: sun.reflect.Reflection.getCallerClass is not supported. This will impact performance.\n",
            "2022-10-14 07:08:38,052 INFO  [main] index.IndexCollection (IndexCollection.java:248) - Setting log level to INFO\n",
            "2022-10-14 07:08:38,056 INFO  [main] index.IndexCollection (IndexCollection.java:251) - Starting indexer...\n",
            "2022-10-14 07:08:38,056 INFO  [main] index.IndexCollection (IndexCollection.java:252) - ============ Loading Parameters ============\n",
            "2022-10-14 07:08:38,056 INFO  [main] index.IndexCollection (IndexCollection.java:253) - DocumentCollection path: ./json\n",
            "2022-10-14 07:08:38,070 INFO  [main] index.IndexCollection (IndexCollection.java:254) - CollectionClass: JsonCollection\n",
            "2022-10-14 07:08:38,070 INFO  [main] index.IndexCollection (IndexCollection.java:255) - Generator: DefaultLuceneDocumentGenerator\n",
            "2022-10-14 07:08:38,071 INFO  [main] index.IndexCollection (IndexCollection.java:256) - Threads: 1\n",
            "2022-10-14 07:08:38,071 INFO  [main] index.IndexCollection (IndexCollection.java:257) - Language: en\n",
            "2022-10-14 07:08:38,072 INFO  [main] index.IndexCollection (IndexCollection.java:258) - Stemmer: porter\n",
            "2022-10-14 07:08:38,072 INFO  [main] index.IndexCollection (IndexCollection.java:259) - Keep stopwords? false\n",
            "2022-10-14 07:08:38,073 INFO  [main] index.IndexCollection (IndexCollection.java:260) - Stopwords: null\n",
            "2022-10-14 07:08:38,073 INFO  [main] index.IndexCollection (IndexCollection.java:261) - Store positions? true\n",
            "2022-10-14 07:08:38,074 INFO  [main] index.IndexCollection (IndexCollection.java:262) - Store docvectors? true\n",
            "2022-10-14 07:08:38,074 INFO  [main] index.IndexCollection (IndexCollection.java:263) - Store document \"contents\" field? false\n",
            "2022-10-14 07:08:38,075 INFO  [main] index.IndexCollection (IndexCollection.java:264) - Store document \"raw\" field? true\n",
            "2022-10-14 07:08:38,075 INFO  [main] index.IndexCollection (IndexCollection.java:265) - Additional fields to index: []\n",
            "2022-10-14 07:08:38,076 INFO  [main] index.IndexCollection (IndexCollection.java:266) - Optimize (merge segments)? false\n",
            "2022-10-14 07:08:38,076 INFO  [main] index.IndexCollection (IndexCollection.java:267) - Whitelist: null\n",
            "2022-10-14 07:08:38,076 INFO  [main] index.IndexCollection (IndexCollection.java:268) - Pretokenized?: false\n",
            "2022-10-14 07:08:38,077 INFO  [main] index.IndexCollection (IndexCollection.java:269) - Index path: ./json\n",
            "2022-10-14 07:08:38,092 INFO  [main] index.IndexCollection (IndexCollection.java:307) - ============ Indexing Collection ============\n",
            "2022-10-14 07:08:38,715 INFO  [main] index.IndexCollection (IndexCollection.java:417) - Thread pool with 1 threads initialized.\n",
            "2022-10-14 07:08:38,716 INFO  [main] index.IndexCollection (IndexCollection.java:419) - Initializing collection in ./json\n",
            "2022-10-14 07:08:38,723 INFO  [main] index.IndexCollection (IndexCollection.java:428) - 1 file found\n",
            "2022-10-14 07:08:38,724 INFO  [main] index.IndexCollection (IndexCollection.java:429) - Starting to index...\n",
            "2022-10-14 07:09:38,731 INFO  [main] index.IndexCollection (IndexCollection.java:441) - 160,000 documents indexed\n",
            "2022-10-14 07:09:49,381 DEBUG [pool-2-thread-1] index.IndexCollection$LocalIndexerThread (IndexCollection.java:213) - json/data.json: 190655 docs added.\n",
            "2022-10-14 07:09:59,542 INFO  [main] index.IndexCollection (IndexCollection.java:485) - Indexing Complete! 190,655 documents indexed\n",
            "2022-10-14 07:09:59,542 INFO  [main] index.IndexCollection (IndexCollection.java:486) - ============ Final Counter Values ============\n",
            "2022-10-14 07:09:59,543 INFO  [main] index.IndexCollection (IndexCollection.java:487) - indexed:          190,655\n",
            "2022-10-14 07:09:59,543 INFO  [main] index.IndexCollection (IndexCollection.java:488) - unindexable:            0\n",
            "2022-10-14 07:09:59,543 INFO  [main] index.IndexCollection (IndexCollection.java:489) - empty:                  1\n",
            "2022-10-14 07:09:59,543 INFO  [main] index.IndexCollection (IndexCollection.java:490) - skipped:                0\n",
            "2022-10-14 07:09:59,544 INFO  [main] index.IndexCollection (IndexCollection.java:491) - errors:                 0\n",
            "2022-10-14 07:09:59,568 INFO  [main] index.IndexCollection (IndexCollection.java:494) - Total 190,655 documents indexed in 00:01:21\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# Search documents using inverted index"
      ],
      "metadata": {
        "id": "Pqybo4J_aon6"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from pyserini.search.lucene import LuceneSearcher\n",
        "import time\n",
        "\n",
        "start = time.time()\n",
        "searcher = LuceneSearcher('./json')\n",
        "hits = searcher.search('cancer')\n",
        "end = time.time()\n",
        "\n",
        "for i in range(len(hits)):\n",
        "    print(f'{i+1:2} {hits[i].docid:4} {hits[i].score:.5f}')\n",
        "    print(f\"{hits[i].raw}\")\n",
        "\n",
        "print(\"Elapsed time :\", end - start, \"s\")\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "xJ11uaSGOPhU",
        "outputId": "9df5ce4e-2391-43ac-cafd-bdb094b20ee8"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            " 1 24747090 2.50920\n",
            "{\n",
            "  \"id\" : \"24747090\",\n",
            "  \"contents\" : \"We examine the role of body mass index in the assessment of prostate cancer risk A total of 3258 participants who underwent biopsy including 1902 men with a diagnosis of prostate cancer were identified from the Selenium and Vitamin E Cancer Prevention Trial The associations of body mass index with prostate cancer and high grade prostate cancer were examined using logistic regression adjusting for age race body mass index adjusted prostate specific antigen digital rectal examination family history of prostate cancer biopsy history prostate specific antigen velocity and time between study entry and the last biopsy The prediction models were compared with our previously developed body mass index adjusted Prostate Cancer Prevention Trial prostate cancer risk calculator Of the study subjects 491 % were overweight and 293 % were obese After adjustment among men without a known family history of prostate cancer increased body mass index was not associated with a higher risk of prostate cancer per one-unit increase in logBMI OR 083 p = 054 but was significantly associated with a higher risk of high grade prostate cancer ieGleason score 7 or greater prostate cancer OR 231 p = 003 For men with a known family history of prostate cancer the risks of prostate cancer and high grade prostate cancer increased rapidly as body mass index increased prostate cancer OR 373 p = 002 high grade prostate cancer OR 795 p = 0002 The previously developed risk calculator generally underestimated the risks of prostate cancer and high grade prostate cancer Body mass index provided independently predictive information regarding the risks of prostate cancer and high grade prostate cancer after adjusting for other risk factors Body mass index especially in men with a known family history of prostate cancer should be considered for inclusion in any clinical assessment of prostate cancer risk and recommendations regarding prostate biopsy\"\n",
            "}\n",
            " 2 24645632 2.50460\n",
            "{\n",
            "  \"id\" : \"24645632\",\n",
            "  \"contents\" : \"Skin cancer survivors experience an increased risk for subsequent malignancies but the associated risk factors are poorly understood This study examined the risk of a new primary cancer following an initial skin cancer and assessed risk factors associated with second primary cancers All invasive cutaneous malignant melanomas CMM N = 28 069 and squamous cell carcinomas SCC N = 24 620 diagnosed in Norway during 1955-2008 were included Rates of new primary cancers in skin cancer survivors were compared to rates of primary malignancies in the general population using standardized incidence ratios SIR Discrete-time logistic regression models were applied to individual-level data to estimate cancer risk among those with and without a prior skin cancer accounting for residential region education income parenthood marital status and parental cancer status using a 20 % random sample of the entire Norwegian population as reference Further analyses of the skin cancer cohort were undertaken to determine risk factors related to subsequent cancers During follow-up 9608 new primary cancers occurred after an initial skin cancer SIR analyses showed 50 % and 90 % increased risks for any cancer after CMM and SCC respectively p < 001 The logistic regression model suggested even stronger increase after SCC 130 % The highest risk was seen for subsequent skin cancers but several non-skin cancers were also diagnosed in excess oral lung colon breast prostate thyroid leukemia lymphoma and central nervous system Factors that were associated with increased risk of subsequent cancers include male sex older age lower residential latitude being married and low education and income Parental cancer did not increase the risk of a subsequent cancer after SCC but was a significant predictor among younger CMM survivors Our results provide information on shared environmental and genetic risk factors for first and later cancers and may help to identify individuals at high risk for subsequent cancers which will be important as skin cancer incidence continues to rise\"\n",
            "}\n",
            " 3 24569437 2.49760\n",
            "{\n",
            "  \"id\" : \"24569437\",\n",
            "  \"contents\" : \"NSABP P-1 provides an opportunity to examine the association of behavioral factors with prospectively monitored cancer incidence and interactions with tamoxifen From 1992 to 1997 13388 women with estimated 5-year breast cancer risk greater than 166 % or a history of lobular carcinoma in situ 87 % younger than age 65 67 % postmenopausal were randomly assigned to tamoxifen versus placebo Invasive breast cancer lung cancer colon cancer and endometrial cancer were analyzed with Cox regression Predictors were baseline cigarette smoking leisure-time physical activity alcohol consumption and established risk factors At median 7 years follow-up we observed 395 66 35 and 74 breast cancer lung cancer colon cancer and endometrial cancer respectively Women who had smoked were at increased risk of breast cancer P = 0007 HR = 13 for 15-35 years smoking HR = 16 for 35 years lung cancer P < 0001 HR = 39 for 15-35 years HR = 184 for 35 years and colon cancer P < 0001 HR = 51 for 35 years versus never-smokers Low activity predicted increased breast cancer risk only among women assigned to placebo P = 0021 activity main effect P = 0013 activity-treatment interaction HR = 14 for the placebo group and endometrial cancer among all women P = 0026 HR = 17 Moderate alcohol > 0-1 drink/day was associated with decreased risk of colon cancer P = 0019 HR = 035 versus no alcohol There were no other significant associations between these behaviors and cancer risk Among women with elevated risk of breast cancer smoking has an even greater impact on breast cancer risk than observed in past studies in the general population Women who smoke or are inactive should be informed of the increased risk of multiple types of cancer\"\n",
            "}\n",
            " 4 20859673 2.49170\n",
            "{\n",
            "  \"id\" : \"20859673\",\n",
            "  \"contents\" : \"To assess the association between dietary acrylamide intake and the risk of cancer among male smokers The study consisted of 27111 male smokers aged 50-69 years without history of cancer They were participants of the Alpha-Tocopherol Beta-Carotene Cancer Prevention ATBC Study in Finland The men completed a validated dietary questionnaire and a questionnaire on general background characteristics including smoking habits at baseline Incident cases of cancer were identified through the national Finnish Cancer Registry During an average 102 year follow-up 1703 lung cancers 799 prostate cancers 365 urothelial cancers 316 colorectal cancers 224 stomach cancers 192 pancreatic cancers 184 renal cell cancers and 175 lymphomas were diagnosed Dietary acrylamide intake was positively associated with the risk of lung cancer relative risk RR in the highest versus the lowest quintile in the multivariable-adjusted model was 118 95 % confidence interval CI 101-1 38 p for trend 011 Other cancers were not associated with acrylamide intake High acrylamide intake is associated with increased risk of lung cancer but not with other cancers in male smokers\"\n",
            "}\n",
            " 5 7752269 2.48940\n",
            "{\n",
            "  \"id\" : \"7752269\",\n",
            "  \"contents\" : \"Tamoxifen is being increasingly used for the treatment of breast cancer and is undergoing study for the primary prevention of breast cancer However concerns have been raised that the drug may increase the incidence of new primary malignancies such as endometrial liver and colorectal cancers Our goal was to assess the carcinogenic risks associated with long-term use of tamoxifen in women with early stage breast cancer The incidence of new primary cancers among 2729 women participants of the Stockholm Trial was determined at a median follow-up of 9 years In this trial after primary surgery postmenopausal patients aged less than 71 years with unilateral invasive breast cancer were randomly allocated to receive either 2 years of adjuvant tamoxifen 40 mg daily or no adjuvant endocrine therapy Information on second cancers was obtained by retrospective linkage to the Swedish Cancer Registry To increase statistical power a joint analysis of the incidence of endometrial and gastrointestinal cancers was performed in the following three major studies in Scandinavia evaluating adjuvant tamoxifen therapy the Stockholm Trial the Danish Breast Cancer Group Trial and the South-Swedish Trial These studies included a total of 4914 patients with a median follow-up of 8-9 years All P values were calculated from two-tailed tests of statistical significance In the Stockholm Trial there was a statistically significant P = 008 reduction in the incidence of second primary cancers in the contralateral breast among the tamoxifen-treated patients However there was a nearly sixfold increase in endometrial cancers P < 001 and a threefold increase in gastrointestinal cancers in the tamoxifen-treated patients The results of the joint studies showed a statistically significant increase in endometrial cancers among the tamoxifen-treated patients relative risk [ RR ] = 41 95 % confidence interval [ CI ] = 19-8 9 There was also an excess of gastrointestinal cancers associated with tamoxifen Most of this excess involved colorectal cancers RR = 19 95 % CI = 11-3 3 and stomach cancer RR = 32 95 % CI = 09-11 7 There was no substantial increase in any other type of gastrointestinal cancer eg liver cancer among the tamoxifen-treated patients The endometrium and gastrointestinal organs may be target sites for tamoxifen-induced carcinogenesis in humans The increased incidence of colorectal and stomach cancers reported here should be regarded as tentative until supported by long-term data from a larger number of tamoxifen trials Also appropriate surveillance of cancer incidence is warranted for the protection of participants enrolled in current tamoxifen chemoprevention trials\"\n",
            "}\n",
            " 6 25017249 2.48910\n",
            "{\n",
            "  \"id\" : \"25017249\",\n",
            "  \"contents\" : \"The World Cancer Research Fund WCRF and the American Institute for Cancer Research AICR published eight recommendations for cancer prevention but they are not targeted at prostate cancer prevention We investigated whether adherence to the WCRF/AICR recommendations and a prostate cancer dietary index is associated with prostate cancer risk We conducted a nested case-control study of 1806 prostate-specific antigen PSA - detected prostate cancer cases and 12005 controls in the ProtecT trial We developed a prostate cancer dietary index by incorporating three dietary factors most strongly associated with prostate cancer Scores were computed to quantify adherence to the WCRF/AICR recommendations and the prostate cancer dietary index separately The prostate cancer dietary index score was associated with decreased risk of prostate cancer [ OR per 1 score increment 091 95 % confidence interval CI 084-0 99 Ptrend = 004 ] but the WCRF/AICR index score was not OR 099 95 % CI 094-1 05 Ptrend = 071 There was no heterogeneity in association by prostate cancer stage P = 081 or grade P = 061 Greater adherence to recommendations to increase plant foods OR per 025 index score increment 094 95 % CI 089-0 99 Ptrend = 002 and tomato products OR adherence vs nonadherence 082 95 % CI 070-0 97 P = 002 was inversely associated with overall prostate cancer risk Adherence to the prostate cancer-specific dietary recommendations was associated with decreased risk of prostate cancer High intake of plant foods and tomato products in particular may help protect against prostate cancer Meeting the WCRF/AICR recommendations alone is insufficient for prostate cancer prevention Additional dietary recommendations should be developed\"\n",
            "}\n",
            " 7 23448100 2.48700\n",
            "{\n",
            "  \"id\" : \"23448100\",\n",
            "  \"contents\" : \"The Michigan Prevention Research Center the University of Michigan Schools of Nursing Public Health and Medicine and the Michigan Department of Community Health propose a multidisciplinary academic-clinical practice three-year project to increase breast cancer screening among young breast cancer survivors and their cancer-free female relatives at greatest risk for breast cancer The study has three specific aims 1 Identify and survey 3000 young breast cancer survivors diagnosed at 20-45 years old regarding their breast cancer screening utilization 2 Identify and survey survivors high-risk relatives regarding their breast cancer screening utilization 3 Test two versions Targeted vs Enhanced Tailored of an intervention to increase breast cancer screening among survivors and relatives Following approval by human subjects review boards 3000 young breast cancer survivors will be identified through the Michigan Cancer Registry and mailed an invitation letter and a baseline survey The baseline survey will obtain information on the survivors a current breast cancer screening status and use of genetic counseling b perceived barriers and facilitators to screening c family health history Based on the family history information provided by survivors we will identify up to two high-risk relatives per survivor Young breast cancer survivors will be mailed consent forms and baseline surveys to distribute to their selected high-risk relatives Relatives baseline survey will obtain information on their a current breast cancer screening status and use of genetic counseling and b perceived barriers and facilitators to screening Young breast cancer survivors and high-risk relatives will be randomized as a family unit to receive two versions of an intervention aiming to increase breast cancer screening and use of cancer genetic services A follow-up survey will be mailed 9 months after the intervention to survivors and high-risk relatives to evaluate the efficacy of each intervention version on a use of breast cancer screening and genetic counseling b perceived barriers and facilitators to screening c self-efficacy in utilizing cancer genetic and screening services d family support related to screening e knowledge of breast cancer genetics and f satisfaction with the intervention The study will enhance efforts of the state of Michigan surrounding cancer prevention control and public health genomics\"\n",
            "}\n",
            " 8 10214599 2.48430\n",
            "{\n",
            "  \"id\" : \"10214599\",\n",
            "  \"contents\" : \"To evaluate the effectiveness of a video intervention in decreasing cancer fatalism increasing knowledge of colorectal cancer and increasing participation in fecal-occult blood testing FOBT Repeated measures pretest/post-test Senior citizen centers in a rural southern state Individuals were selected and assigned to the study group based on the center they attended Centers were selected and assigned randomly to an intervention n = 42 or control n = 28 group The age of the participants ranged from 52-92 years X = 75 Pretest measures included the Powe Fatalism inventory the Colorectal Cancer Knowledge Questionnaire and the Demographic Data Questionnaire The intervention group viewed the Medical University of South Carolina s video Telling the Story To Live is God s Will and the control group viewed the American Cancer Society ACS video Colorectal Cancer The Cancer No One Talks About Hemoccult II kits were distributed to both groups at no cost Post-test data were collected using the Powe Fatalism Inventory and the Colorectal Cancer Knowledge Questionnaire Cancer fatalism knowledge of colorectal cancer and participation in FOBT People who viewed the intervention video had a greater decrease in cancer fatalism scores and a greater increase in knowledge of colorectal cancer scores than the control group Both groups had greater than 60 % participation in FOBT Telling the Story To Live is God s Will is an effective self-contained cost-effective intervention to decrease cancer fatalism and increase knowledge of colorectal cancer The video was as effective as the ACS video on colorectal cancer in increasing participation in FOBT among rural elders But because Telling the Story To Live is God s Will also decreases cancer fatalism and increases knowledge the potential exists for the increased screening behaviors to be maintained over time Showing the video in waiting areas of community health centers to facilitate the discussion of colorectal cancer and cancer screening with the healthcare professional is a possibility Nursing students may benefit from using the video as a model for the integration of beliefs and attitudes in developing culturally appropriate community-based interventions More research is needed to determine if the positive outcomes of the intervention ie decreased cancer fatalism increased knowledge increased participation in colorectal cancer screening can be maintained over time\"\n",
            "}\n",
            " 9 23694983 2.48430\n",
            "{\n",
            "  \"id\" : \"23694983\",\n",
            "  \"contents\" : \"Eastern Africa has the highest incidence and mortality rates from cervical cancer worldwide It is important to describe the differences among women and their perceived risk of cervical cancer to determine target groups to increase cervical cancer screening In this cross-sectional study we surveyed women seeking reproductive health services in Kisumu Kenya to assess their perceived risk of cervical cancer and risk factors influencing cervical cancer screening uptake statistics and t tests were used to determine significant factors which were incorporated into a logistic model to determine factors independently associated with cervical cancer risk perception Whereas 91 % of the surveyed women had heard of cancer only 29 % of the 388 surveyed women had previously heard of cervical cancer Most had received their information from health care workers Few women 6 % had ever been screened for cervical cancer and cited barriers such as fear time and lack of knowledge about cervical cancer Nearly all previously screened women 22/24 [ 92 % ] believed that cervical cancer was curable if detected early and that screening should be conducted annually 86 % Most women 254/388 [ 65 % ] felt they were at risk for cervical cancer Women with perceived risk of cervical cancer were older odds ratio [ OR ] 106 95 % confidence interval [ CI ] 102-1 10 reported a history of marriage OR 208 CI 100-4 30 were less likely to feel adequately informed about cervical cancer by health care providers OR 076 CI 018-0 83 and more likely to intend to have cervical cancer screening in the future OR 1059 CI 396-28 30 Only 5 % of the women reported that they would not be willing to undergo screening regardless of cost Cervical cancer is a major health burden for women in sub-Saharan Africa yet only one third of the women had ever heard of cervical cancer in Kisumu Kenya Understanding factors associated with women s perceived risk of cervical cancer could guide future educational and clinical interventions to increase cervical cancer screening\"\n",
            "}\n",
            "10 25008853 2.47790\n",
            "{\n",
            "  \"id\" : \"25008853\",\n",
            "  \"contents\" : \"Recent posttrial analysis of a completed randomized trial found an increased risk of prostate cancer among healthy men taking high-dose vitamin E supplements Trials that examined the effect of vitamin C supplements on cancer risk are few We examined whether vitamin E or vitamin C supplementation affects the risk of cancer events during posttrial follow-up of the Physicians Health Study II Beginning in 1997 a total of 14641 US male physicians aged 50 y were randomly assigned to receive 400 IU of vitamin E every other day 500 mg of vitamin C daily or their respective placebos The vitamin E and vitamin C treatment ended in 2007 and observational follow-up continued through June 2011 This study included an additional 356 cases of incident prostate cancer and 771 total cancers that developed during a mean maximum of 28 38 y of posttrial observation During an overall mean of 103 138 y there were a total of 1373 incident prostate cancers and 2669 total cancers documented In comparison with placebo vitamin E supplementation had no effect on the incidence of prostate cancer HR 099 95 % CI 089 110 or total cancers HR 102 95 % CI 095 110 There was also no effect of vitamin C supplementation on total cancers HR 102 95 % CI 094 110 or incident prostate cancer HR 103 95 % CI 093 115 Neither vitamin E nor vitamin C supplementation had effects on other site-specific cancers overall Stratification by known cancer risk factors history of cancer other randomized treatment and follow-up time showed no significant interactions In this large-scale randomized trial in men vitamin E and C supplementation had no immediate or long-term effects on the risk of total cancers prostate cancer or other site-specific cancers\"\n",
            "}\n",
            "Elapsed time : 0.05839371681213379 s\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# Search documents using brute force"
      ],
      "metadata": {
        "id": "dbk-8hc7a3MJ"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "import re\n",
        "\n",
        "hits = []\n",
        "\n",
        "def Brute_force_search(term):\n",
        "  for i in range(len(data[\"contents\"])):\n",
        "    if term in data[\"contents\"][i].lower():\n",
        "      hits.append({\"id\": data[\"id\"][i], \"contents\": data[\"contents\"][i]})\n",
        "      \n",
        "start = time.time()\n",
        "Brute_force_search(\"cancer\")\n",
        "end = time.time()\n",
        "\n",
        "for i in range(len(hits)):\n",
        "  print(i + 1)\n",
        "  print(\"{\")\n",
        "  print(\"  \\\"id\\\" : \\\"{}\\\",\".format(hits[i][\"id\"]))\n",
        "  print(\"  \\\"contents\\\" : \\\"{}\\\",\".format(hits[i][\"contents\"]))\n",
        "  print(\"}\")\n",
        "\n",
        "print(\"Elapsed time :\", end - start, \"s\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Sl_TVdhSU9an",
        "outputId": "6b502025-7efd-45b0-b534-31d463dfb0b9"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\u001b[1;30;43mStreaming output truncated to the last 5000 lines.\u001b[0m\n",
            "{\n",
            "  \"id\" : \"25038542\",\n",
            "  \"contents\" : \"Rectal cancer continues to be devastating malignancy worldwide Sphincter preservation is the need of the hour Distal anastomosis is more prone to leaks Proximal diversion in form of ileostomy may be used to protect distal anastomosis To compare two groups of low anterior resection with and without diversion ileostomy in rectal cancer patients A prospective hospital based study of 78 rectal carcinoma patients were taken for the study Inclusion criteria was operable rectal cancer 4-12 cm from anal verge Patients were randomized into two groups Group - A 34 patient patients with low anterior resection with ileostomy LAR with ileostomy Group - B 44 patients patients with low anterior resection without ileostomy LAR without ileostomy Quality of life was assessed by scoring done by self designed method A total score of 0-20 given for various parameters Skin excoriation was the commonest complication Stomal retraction and stomal obstruction was seen in 1 patient each 3 % Hypokalemia was the commonest electrolyte imbalance present in ileostomy group Anastomotic leak was present in 6 % of Group A and 11 % of Group B patients Mean time of closure of ileostomy was 16 43 weeks LAR with ileostomy has certain advantages over LAR without ileostomy in terms of anastomotic leak postoperative ileus resumption of diet wound infection small bowel obstruction and in terms mortality and recurrence However stoma related complications were main disadvantage in LAR with ileostomy\",\n",
            "}\n",
            "13049\n",
            "{\n",
            "  \"id\" : \"19952360\",\n",
            "  \"contents\" : \"Ursodeoxycholic acid UDCA was one of the earliest agents investigated as a drug for colorectal cancer prevention However UDCA failed to show efficacy to prevent the development of colorectal adenomas in a large phase III randomized placebo-controlled trial We re-evaluated the effect of UDCA in men and women separately based on sex-specific differences in bile acid metabolism and suspected variation in etiologic factors contributing to colorectal cancer risk We conducted a secondary analysis of the efficacy of UDCA to prevent colorectal adenoma in men n = 804 and women n = 388 We found no reduction in risk of any metachronous adenoma with UDCA treatment in men or women However UDCA treatment significantly lowered the odds of advanced lesions [ odds ratio OR 062 95 % confidence interval CI 043-0 89 ] in men but not women We also observed significantly higher odds of advanced lesions with UDCA treatment in women who were younger age < 65 years OR 324 95 % CI 110-9 56 obese body mass index > or = 30 kg/m 2 OR 545 95 % CI 142-20 9 or in the highest tertile of total dietary fat > or = 562 g/day OR 348 95 % CI 135-8 95 In a multivariate model the interactive effect of fat intake accounted for the modulating effects of age and body mass index in women Our findings support the use of UDCA for preventing advanced colorectal adenomas in men The increased odds of adenoma among women with high fat intake suggest a previously unrecognized harm that warrants further study especially given the chronic exposure to UDCA in patients with primary biliary cirrhosis and the increasing investigational use of UDCA for several other conditions\",\n",
            "}\n",
            "13050\n",
            "{\n",
            "  \"id\" : \"20965387\",\n",
            "  \"contents\" : \"Prostate cancer screening with prostate-specific antigen PSA is frequently performed counter to clinical practice guidelines It was hypothesized that an e-mail-based intervention termed spaced education could reduce clinicians inappropriate screening for prostate cancer The study was conducted as an RCT The study involved 95 primary care clinicians in eight Veterans Affairs medical centers from January 2007 to February 2009 Participants were randomized into two cohorts spaced education clinicians received four isomorphic cycles of nine e-mails over 36 weeks zero to two e-mails per week whereas control clinicians received no intervention Each e-mail presented a clinical scenario and asked whether it was appropriate to obtain a PSA test Participants received immediate feedback after submitting their answers The primary outcome was the number and percentage of inappropriate PSA screening tests ordered Inappropriate testing was defined as use of PSA for prostate cancer screening in patients aged > 76 or < 40 years Appropriateness of screening was dichotomized based on patient age at time of screening Patients with PSA testing for non-screening reasons were excluded using a validated protocol Logistic regression with adjustment for patient clustering by clinician was performed Analyses were conducted in 2009 During the intervention period Weeks 1-36 clinicians receiving spaced education e-mails ordered significantly fewer inappropriate PSA screening tests than control clinicians 105 % vs 142 % p = 0041 Over the 72-week period following the intervention Weeks 37-108 spaced education clinicians continued to order fewer inappropriate tests compared to controls 78 % vs 131 % respectively p = 0011 representing a 40 % relative reduction in inappropriate screening Spaced education durably improves the prostate cancer screening behaviors of clinicians and represents a promising new methodology to improve patient care across healthcare systems\",\n",
            "}\n",
            "13051\n",
            "{\n",
            "  \"id\" : \"18465343\",\n",
            "  \"contents\" : \"During the period from January 1990 to January 1996 a total of 953 patients with lymph node negative primary breast cancer were randomised to oral pamidronate n = 460 150 mg twice daily for 4 years or no adjuvant pamidronate n = 493 in order to investigate whether oral pamidronate can prevent the occurrence of bone metastases and fractures The patients received adjuvant chemotherapy loco-regional radiation therapy but no endocrine treatment During the follow-up period the number of patients with pure bone metastases was 35 in the control group and 31 in the pamidronate group The number of patients with a combination of bone and other distant metastases were 22 in the control group and 20 in the pamidronate group The hazard rate ratio for recurrence in bone in the pamidronate group compared to the control group was 103 95 % confidence interval 075-1 40 and p = 086 No effect was observed on overall survival In a small subgroup of 27 patients from the study 12 of whom were treated with pamidronate a significant bone preserving effect was observed on bone mineral density in the lumbar spine but not in the proximal femur The results from the trial do not support a beneficial effect of oral pamidronate on the occurrence of bone metastases or fractures in patients with primary breast cancer receiving adjuvant chemotherapy\",\n",
            "}\n",
            "13052\n",
            "{\n",
            "  \"id\" : \"24332238\",\n",
            "  \"contents\" : \"Second-line chemotherapy for patients with oesophagogastric adenocarcinoma refractory to platinum and fluoropyrimidines has not shown benefits in health-related quality of life HRQoL We assessed whether the addition of docetaxel to active symptom control alone can improve survival and HRQoL for patients For this open-labelled multicentre trial we recruited patients aged 18 years or older from 30 UK centres Patients were eligible if they had an advanced histologically confirmed adenocarcinoma of the oesophagus oesophagogastric junction or stomach that had progressed on or within 6 months of treatment with a platinum-fluoropyrimidine combination Patients could have an Eastern Cooperative Oncology Group performance status of 0-2 We randomly assigned patients using a central computerised minimisation procedure to receive docetaxel plus active symptom control or active symptom control alone 11 stratified by disease status disease site duration of response to previous chemotherapy and performance status Docetaxel was given at a dose of 75 mg/m 2 by intravenous infusion every 3 weeks for up to six cycles The primary endpoint was overall survival analysed by intention to treat This is the report of the planned final analysis This study is an International Standardised Randomised Controlled Trial number ISRCTN13366390 Between April 21 2008 and April 26 2012 we recruited 168 patients allocating 84 to each treatment group After a median follow-up of 12 months [ IQR 10-21 ] and 161 96 % deaths 80 in the docetaxel group 81 in the active symptom control group median overall survival in the docetaxel group was 52 months 95 % CI 41-5 9 versus 36 months 33-4 4 in the active symptom control group hazard ratio 067 95 % CI 049-0 92 p = 001 Docetaxel was associated with higher incidence of grade 3-4 neutropenia 12 [ 15 % ] patients vs no patients infection 15 [ 19 % ] patients vs two [ 3 % ] patients and febrile neutropenia six [ 7 % ] patients vs no patients Patients receiving docetaxel reported less pain p = 00008 and less nausea and vomiting p = 002 and constipation p = 002 Global HRQoL was similar between the groups p = 053 Disease specific HRQoL measures also showed benefits for docetaxel in reducing dysphagia p = 002 and abdominal pain p = 001 Our findings suggest that docetaxel can be recommended as an appropriate second-line treatment for patients with oesophagogastric adenocarcinoma that is refractory to treatment with platinum and fluoropyrimidine Cancer Research UK\",\n",
            "}\n",
            "13053\n",
            "{\n",
            "  \"id\" : \"10694560\",\n",
            "  \"contents\" : \"Patients with invasive breast cancer may develop a local recurrence LR after breast-conserving therapy BCT Younger age has been found to be an independent risk factor for LR Within a group of premenopausal node-negative breast cancer patients we studied risk factors for LR and the effect of perioperative chemotherapy PeCT on LR The European Organization for Research and Treatment of Cancer EORTC conducted a randomized trial EORTC 10854 to compare surgery followed by one course of PeCT fluorouracil doxorubicin and cyclophosphamide with surgery alone From patients treated on this trial we selected premenopausal patients with node-negative breast cancer who were treated with BCT to examine whether histologic characteristics and the expression of various proteins estrogen receptor progesterone receptor p53 Ki-67 bcl-2 CD31 c-erbB-2 / neu are risk factors for subsequent LR Also the effect of one course of PeCT on the LR risk LRR was studied Using multivariate analysis age younger than 43 years relative risk [ RR ] 275 95 % confidence interval [ CI ] 146 to 518 P = 002 multifocal growth RR 334 95 % CI 127 to 877 P = 014 and elevated levels of p53 RR 214 95 % CI 113 to 405 P = 02 were associated with higher LRR Also PeCT was found to reduce LRR by more than 50 % RR 047 95 % CI 025 to 086 P = 02 Patients younger than 43 years who received PeCT achieved similar LR rates as those of patients younger than 43 years who were treated with BCT alone In premenopausal node-negative patients age younger than 43 years is the most important risk factor for LR after BCT this risk is greatly reduced by one course of PeCT The main reason for administering systemic adjuvant treatment is to improve overall survival The important reduction of LR after BCT is an additional reason for considering systemic treatment in young node-negative patients with breast cancer\",\n",
            "}\n",
            "13054\n",
            "{\n",
            "  \"id\" : \"23756360\",\n",
            "  \"contents\" : \"We report the long-term results of a randomised trial comparing tamoxifen with tamoxifen plus cyclophosphamide methotrexate and fluorouracil CMF in postmenopausal high-risk breast cancer patients In addition we analyse the prognostic and predictive value of centrally assessed subtypes Postmenopausal patients with breast cancer and positive nodes deep invasion or size exceeding 5 cm were randomly assigned to 1 year of tamoxifen or cyclophosphamide 600 mg/m2 methotrexate 40 mg/m2 and fluorouracil 600 mg/m2 intravenously on day 1 every 4 weeks for nine cycles plus tamoxifen CMFT Tissue microarrays were constructed retrospectively and oestrogen receptor ER progesterone receptor PgR human epidermal growth factor receptor 2 HER2 and proliferation-related Ki-67 antigen Ki67 status were assessed From October 1982 through March 1990 we randomised 1445 patients and 969 67 % were eligible for the biomarker analysis At 10-years 936 women had suffered a disease-free survival DFS event tamoxifen 495 events in 686 patients CMFT 441 events in 642 patients The addition of CMF to tamoxifen significantly improved DFS adjusted hazard ratio 082 95 % confidence interval CI 071-0 93 P = 0003 but not overall survival adjusted hazard ratio 095 95 % CI 085-1 08 P = 044 DFS was superior in Luminal A tumours ER or PgR positive HER2 negative and Ki67 14 % when compared to Luminal B or non-luminal ER and PgR negative tumours There was no statistical evidence of heterogeneity by subtype in the benefit from CMF P interaction = 045 CMF added to 1 year of tamoxifen reduces the risk of a DFS event The benefit from CMF was not significantly different in Luminal A and B subtypes\",\n",
            "}\n",
            "13055\n",
            "{\n",
            "  \"id\" : \"15014015\",\n",
            "  \"contents\" : \"O 6 - alkylguanine-DNA alkyltransferase AGAT is modulated by methylating agents which in turn abrogates nitrosourea resistance in preclinical studies The feasibility of administering various sequences of 13-bis 2-chloroethyl -1 - nitrosourea BCNU and temozolomide TEM in patients with advanced solid neoplasms was evaluated in this Phase I and pharmacological study to assess this premise in the clinical setting The study also sought to determine the maximum tolerated dose MTD levels of BCNU and TEM as a function of Seq to characterize the pharmacokinetic PK behavior of TEM administered both before and after BCNU assess AGAT fluctuations in peripheral blood mononuclear cells PBMCs and seek preliminary evidence of anticancer activity Sixty-three patients were randomized to receive treatment with oral TEM daily on days 1-5 and BCNU administered iv either on day 1 before TEM [ Sequence Seq B -- > T ] or day 5 after TEM Seq T -- > B Treatment was repeated every 6 weeks Blood sampling for PK studies was performed on both days 1 and 5 of course one PBMCs were sampled to evaluate major sequence-dependent effects on AGAT levels Neutropenia and thrombocytopenia were the principal dose-limiting toxicities of the BCNU/TEM regimen These effects were more prominent in patients receiving Seq T -- > B resulting in a much lower MTD of 80/100 mg/m 2 / day compared with 150/110 mg/m 2 / day for Seq B -- > T Notable antitumor activity was observed in patients with glioblastoma multiforme sarcoma and ovarian carcinoma No sequence-dependent PK effects were noted to account for sequence-dependent toxicological effects At the MTD level AGAT activity in PBMCs decreased 3-fold on average and AGAT fluctuations did not appear to be sequence-dependent The principal toxicities of the BCNU/TEM regimen were neutropenia and thrombocytopenia which were consistent and predictable albeit sequence-dependent Seq T -- > B was substantially more myelosuppressive resulting in disparate MTDs and dose levels recommended for subsequent disease-directed evaluations 150/110 and 80/100 mg/m 2 / day for Seq B -- > T and T -- > B respectively Sequence-dependent differences in TEM PK do not account for this clinically relevant magnitude of sequence-dependent toxicity The characteristics of the myelosuppressive effects of BCNU/TEM the paucity of severe nonhematological toxicities and antitumor activity at tolerable doses warrant disease-directed evaluations on this schedule\",\n",
            "}\n",
            "13056\n",
            "{\n",
            "  \"id\" : \"21347821\",\n",
            "  \"contents\" : \"Although a novel technique for the performance of intestinal sutureless anastomosis using a compression device has recently been investigated it has not yet received widespread acceptance We performed a multicenter prospective randomized trial in order to determine the clinical efficacy of the NiTi Hand CAC 30 a type of compression anastomosis clip CAC for jejunojejunostomy in gastric cancer surgery Forty-seven patients from 6 institutions who were diagnosed with gastric adenocarcinoma were enrolled these patients were randomized to a CAC group and a hand-sewn control group Three patients dropped out for various reasons and results for 44 patients were finally analyzed The CAC group consisted of 20 patients and there were 24 patients in the control group Anastomosis time the primary endpoint of this trial was shorter in the CAC group than in the control group P < 0001 However total operation times P = 0055 did not differ All reconstructions were completed by Roux-en-Y anastomosis and the complication rates of the two groups did not differ P = 0908 however jejunojejunostomy leakage occurred in two patients in the CAC group Our prospective multicenter clinical trial showed that the use of the NiTi Hand CAC 30 for jejunojejunostomy in gastric cancer surgery was feasible and could reduce anastomosis time However considering that there were two cases of leakage extended use of the NiTi Hand CAC 30 should be carefully applied\",\n",
            "}\n",
            "13057\n",
            "{\n",
            "  \"id\" : \"14675243\",\n",
            "  \"contents\" : \"5-fluorouracil 5-FU is the most useful chemotherapeutic agent for colorectal carcinoma Recently the effectiveness of multidrug therapy in modifying the anticancer activity of 5-FU for advanced cases was clarified We conducted a randomized comparative study of surgical adjuvant chemotherapy comparing cis-diamminedichloroplatinum CDDP 5-FU and dl-leucovorin LV PFL therapy with dl-LV and 5-FU FL therapy in patients who underwent curative resection of stage II and III colorectal carcinoma Thirty-one patients 13 ungergoing PFL therapy and 18 undergoing FL therapy completed the scheduled administration while 20 dropped out Administration schedules were as follows PFL therapy consisted of 13 mg/m2 CDDP 300 mg/m2 5-FU and 30 mg/body weight LV for 5 consecutive days The FL therapy consisted of 300 mg/m2 5-FU and 30 mg/body weight LV for 5 consecutive days in hospital Both regimens were followed by biweekly administration of the same dosages of LV and 5-FU in an outpatient setting Seven of 23 patients in the PFL therapy group and five of 28 patients in the FL therapy group experienced recurrence of colorectal carcinomas Regarding prognosis of stage II patients both groups showed similar results in 5-year disease specific survival and disease-free survival However stage III patients obtained better prognostic results in the FL therapy group than in the PFL therapy group Major toxicities in these regimens were vomiting and leukopenia both being more frequent in the PFL therapy group Symptoms of toxicity resolved completely in all patients From the present study we found that PFL therapy brought no benefit for stage II and III colorectal carcinoma compared with FL therapy We should search for more appropriate adjuvant therapy increasing the therapeutic effect of 5-FU + LV for stage II and III colorectal carcinoma\",\n",
            "}\n",
            "13058\n",
            "{\n",
            "  \"id\" : \"17285234\",\n",
            "  \"contents\" : \"Health-related quality of life has become an important outcome in cancer treatment Detailed health-related quality of life measures were taken as part of a trial of follow-up of patients with colon cancer by general practitioners and surgeons This study was designed as a longitudinal assessment of health-related quality of life after treatment for carcinoma of the colon and patient satisfaction with two different settings of follow-up general practitioners vs surgeons A total of 338 patients were recruited into randomized n = 203 and patient preference n = 135 follow-up groups Prospectively assessed physical and mental health-related quality of life measures and patient satisfaction are reported during two years Elderly and less educated patients prefer follow-up by general practitioners over surgeons Overall physical health-related quality of life is reduced early after treatment however this returns to normal levels at one year Mental quality of life anxiety and depression are at or above population levels throughout the two-year follow-up period There were no differences in physical or psychologic health-related quality of life measures between general practitioner and surgeon groups at any time during follow-up Overall more advanced Dukes stage is associated with a trend to improved mental health-related quality of life Patients ability to choose the setting of follow-up has no influence on health-related quality of life compared with random allocation to general practitioner or surgeon Patients are equally highly satisfied with follow-up by general practitioner or surgeon After recovery from treatment for colon cancer health-related quality of life is similar to the general population Good health-related quality of life outcomes and high patient satisfaction are as well provided by general practitioners in the community setting as by surgeon review\",\n",
            "}\n",
            "13059\n",
            "{\n",
            "  \"id\" : \"25533223\",\n",
            "  \"contents\" : \"To evaluate the incremental prognostic value of the number and maximum volume of coronary artery calcifications over modified Agatston score strata age pack-years and smoking status for predicting cardiovascular events A total of 3559 male current and former smokers received a CT examination for lung cancer screening Smoking characteristics patient demographics and physician-diagnosed cardiovascular events were collected Images were acquired without electrocardiography gating on 16-slice CT scanners The association between the presence of both fatal and nonfatal cardiovascular events and the predictors was quantified using Cox proportional hazard analysis Median follow-up period was 29 years Incident cardiovascular events occurred in 186 participants Adjusted hazard ratios for modified Agatston score strata of 1 to 10 11 to 100 101 to 400 and > 400 were 339 95 % confidence interval [ CI ] 120-9 59 652 95 % CI 273-15 60 658 95 % CI 275-15 78 and 1258 95 % CI 542-29 16 respectively Moreover comparing the models with and without modified Agatston score strata to the model with age pack-years and smoking status yielded a significantly better net reclassification improvement NRI 273 % P < 0001 Adding the number of calcifications to the model with age pack-years smoking status and modified Agatston score strata resulted in a slightly better NRI 168 % P = 0490 with a hazard ratio of 113 95 % CI 105-1 21 per 10 calcifications The incremental prognostic information contained in the volume of the largest calcification was not statistically significant NRI 014 % P = 3458 Cardiovascular event rate increased with higher numbers of calcified lesions The number but not maximum volume of calcifications has independent although minimal prognostic value over age pack-years smoking status and modified Agatston score strata in our population\",\n",
            "}\n",
            "13060\n",
            "{\n",
            "  \"id\" : \"25271396\",\n",
            "  \"contents\" : \"This randomised trial tested i whether a home-based expressive writing EW intervention improves quality of life in patients with colorectal cancer CRC and ii whether the intervention is more beneficial for men or for people who feel constrained in disclosing cancer-related concerns and feelings Patients treated for CRC were randomised to an EW n = 101 or control writing CW n = 92 group Assessments were completed at 1 month pre - and post-intervention Sex and perceived social constraints on disclosure were evaluated as moderators Primary outcomes were depressive symptoms sleep problems and quality of life indicators Eighty-one per cent of participants completed all writing assignments Consistent with hypotheses relative to the CW group participants in the EW group expressed more negative emotion in writing and rated their writings as more meaningful personal and emotionally revealing There were no significant main effects of EW or moderating effects of sex or social constraints on outcomes Although EW is feasible to use with persons who have CRC it was not effective as a stand-alone psychotherapeutic intervention Neither was it more effective for men nor for people who felt they could not freely disclose cancer-related concerns and feelings\",\n",
            "}\n",
            "13061\n",
            "{\n",
            "  \"id\" : \"25408262\",\n",
            "  \"contents\" : \"Erlotinib is a drug used to treat non-small cell lung cancer pancreatic cancer and several other types of cancer It is a reversible tyrosine kinase inhibitor that acts on the epidermal growth factor receptor and inhibits cell proliferation growth migration invasion and survival This study was performed for the subsequent marketing of a test erlotinib formulation in Korea We evaluated the comparative bioavailability and tolerability of the test and reference formulations in healthy adult volunteers A total of 46 healthy male subjects were enrolled in a single-dose randomized open-label two-period two-sequence crossover bioequivalence study During each treatment period subjects received 150 mg of erlotinib in either the test or reference formulation There was a 2-week washout period between each period Blood samples were obtained 15 times during each period before dosing and 05 1 15 2 25 3 4 6 8 12 24 48 72 and 96 h after oral administration Plasma concentrations of erlotinib were determined using liquid chromatography-tandem mass spectrometry Pharmacokinetic parameters including maximum plasma concentration C max area under the plasma concentration-time curve to the last sampling time AUC t AUC from time zero to infinity AUC and time to reach C max t max were measured and all treatment-emergent adverse events and their relationships with the study medications were recorded throughout the study An additional analysis was performed to characterize the association between the cytochrome P450 CYP 1A1 CYP1A2 and CYP3A4 genotypes and the erlotinib pharmacokinetic parameters A total of 41 subjects completed the study There were no significant differences in the prevalence of adverse events between the two formulations and there were no serious or unexpected adverse events during the study Both formulations had very similar C max AUC terminal half-life t and t max values The 90 % confidence intervals of the geometric least-squares mean ratios of the test to reference formulation were 109 098-1 22 for C max and 110 101-1 21 for AUCt Statistical significance was observed between the CYP1A2 * 1M genotype and the erlotinib pharmacokinetic parameter particularly C max p = 0015 This study suggests that the test and reference formulations of 150 mg erlotinib have similar pharmacokinetic characteristics Both had no major safety issues and were well-tolerated The test formulation met the regulatory criteria for assuming bioequivalence to the reference formulation for both AUCt and C max The additional genetic analysis demonstrated that the major metabolic enzymes of erlotinib did not significantly affect erlotinib metabolism with the exception of CYP1A2 * 1M\",\n",
            "}\n",
            "13062\n",
            "{\n",
            "  \"id\" : \"16682725\",\n",
            "  \"contents\" : \"Recently a Dutch randomized phase III trial demonstrated that in small-cell lung cancer patients at risk of chemotherapy-induced febrile neutropenia FN the addition of granulocyte colony-stimulating factor GCSF to prophylactic antibiotics significantly reduced the incidence of FN in cycle 1 24 % v 10 % P = 01 We hypothesized that selecting patients at risk of FN might increase the cost-effectiveness of GCSF prophylaxis Economic analysis was conducted alongside the clinical trial and was focused on the health care perspective Primary outcome was the difference in mean total costs per patient in cycle 1 between both prophylactic strategies Cost-effectiveness was expressed as costs per percent-FN-prevented For the first cycle the mean incremental costs of adding GCSF amounted to 681 euro 95 % CI -36 to 1397 euro per patient For the entire treatment period the mean incremental costs were substantial 5123 euro 95 % CI 3908 to 6337 euro despite a significant reduction in the incidence of FN and related savings in medical care consumption The incremental cost-effectiveness ratio was 50 euro per percent decrease of the probability of FN 95 % CI -2 to 433 euro in cycle 1 and the acceptability for this willingness to pay was approximately 50 % Despite the selection of patients at risk of FN the addition of GCSF to primary antibiotic prophylaxis did not result in cost savings If policy makers are willing to pay 240 euro for each percent gain in effect ie 3360 euro for a 14 % reduction in FN the addition of GCSF can be considered cost effective\",\n",
            "}\n",
            "13063\n",
            "{\n",
            "  \"id\" : \"22335487\",\n",
            "  \"contents\" : \"The literature has described the use of ketamine as an adjuvant treatment for opioid-refractory cancer pain None of these studies have used the drug in a palliative care patient population The primary objective of the study was to assess the efficacy of continuous intravenous infusion of ketamine in patients suffering from cancer pain refractory to opiates who had been admitted to palliative care units Secondary objectives were to assess patients satisfaction with and tolerance of ketamine A randomized double-blind placebo-controlled study was designed and the study setting included seven French adult palliative care units Inclusion criteria were age 18 years and cancer pain refractory to standard opiates Evaluations were conducted at randomization baseline at ketamine or placebo introduction time T0 and at 2 hours T1 24 hours T2 and 48 hours T3 after T0 The primary evaluation criterion was pain efficacy assessed using a patient self-rated Numeric Pain Intensity Scale NPIS at T1 The main secondary evaluation criteria were daily morphine dose symptom evaluation Edmonton Symptom Assessment Scale [ ESAS ] and patient satisfaction Pain Treatment Satisfaction Scale [ PTSS ] Twenty patients were analyzed 11 received ketamine and 9 received placebo Self-reported pain did not differ between the two groups as the symptoms continued to evolve during the study period The tolerance for ketamine was satisfactory The present study did not confirm the efficacy of the ketamine-morphine combination in refractory cancer pain The results suggest that specific populations could be good responders for this therapeutic approach Further studies should be performed that take into account the difficulties of conducting clinical research in the palliative care context\",\n",
            "}\n",
            "13064\n",
            "{\n",
            "  \"id\" : \"24079752\",\n",
            "  \"contents\" : \"The effectiveness of specific regimens of adjuvant therapy for gastric cancer has not been verified by large clinical trials Recently several large trials attempted to verify the effectiveness of adjuvant therapy The Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer in Japan a randomized controlled trial of adjuvant S-1 therapy for resected gastric cancer demonstrated significant improvement in overall and relapse-free survival compared to surgery alone To evaluate value for money of S-1 therapy cost-effective analysis was carried out The analysis was carried out from a payer s perspective As an economic measure cost per quality-adjusted life-year QALY gained was estimated Overall survival was estimated by the Kaplan-Meier method up to 5-year observation Beyond this period it was simulated by the modified Boag model Utility score is derived from interviews with sampled patients using a time trade-off method Costs were estimated from trial data during observation while in the period beyond observation they were estimated using simulation results To explore uncertainty of the results qualitative and stochastic sensitivity analyses were done Adjuvant S-1 therapy gained 124 QALYs per patient and increased costs by $ 3722 per patient for over lifetime 3 % discount rate for both effect and costs The incremental cost-effectiveness ratio 95 % confidence intervals for over lifetime was estimated to be $ 3016 $ 1441 $ 8840 per QALY The sensitivity analyses showed the robustness of these results Adjuvant S-1 therapy for curatively resected gastric cancer is likely cost-effective This therapy can be accepted for wide use in Japan\",\n",
            "}\n",
            "13065\n",
            "{\n",
            "  \"id\" : \"25893930\",\n",
            "  \"contents\" : \"Antioxidants effectiveness in prostate cancer PCa chemoprevention has been severely questioned especially after the recent results of the Selenium and Vitamin E Cancer Prevention Trial We present the results of a double-blind randomized controlled trial dbRCT on the pharmacokinetic clinical and molecular activity of dietary supplements containing lycopene selenium and green tea catechins GTCs in men with multifocal high grade prostatic intraepithelial neoplasia mHGPIN and/or atypical small acinar proliferation ASAP From 2009 to 2014 we conducted a dbRCT including 60 patients with primary mHGPIN and/or ASAP receiving daily lycopene 35mg selenium 55g and GTCs 600mg or placebo for 6 months Pharmacokinetic analysis were performed with UV-Visible spectrophotometric assay under standard SC and accelerated AC conditions Upon plasma lycopene concentrations falling within the expected range 12-90mcg / l and no side-effects of grade > 1 study proceeded to phase II n = 50 After unblinding of results eight men 4 per arm 2 without and 2 with PCa respectively were randomly selected and totRNA extracted from non-pathological tissues MicroRNA profiling was performed with the Agilent platform Raw data processing used R-statistical language and linear models for microarray analysis Samples were stable except for lycopene showing significant degradation SC = 56 % AC = 59 % and consequently stabilized under vacuum in a dark packaging Mean plasmatic lycopene concentration was 14504 MAt 6 months 53 men underwent re-biopsy and 13 245 % were diagnosed with PCa supplementation n = 10 placebo n = 3 [ P = 0053 ] At a mean 37 months follow-up 3 additional PCa were found in the placebo group No significant variations in PSA IPSS and PR25 questionnaires were observed Stronger modulation of miRNAs was present on re-biopsy in the supplementation group compared to the placebo including i overexpression of miRNAs present in PCa versus non-cancer tissue ii underexpression of miRNAs suppressing PCa proliferation iii detection of 35 miRNAs in PCa patients versus disease-free men including androgen-regulated miR-125b-5p and PTEN-targeting miR-92a-3p both upregulated Administration of high doses of lycopene GTCs and selenium in men harboring HGPIN and/or ASAP was associated with a higher incidence of PCa at re-biopsy and expression of microRNAs implicated in PCa progression at molecular analysis The use of these supplements should be avoided\",\n",
            "}\n",
            "13066\n",
            "{\n",
            "  \"id\" : \"11034245\",\n",
            "  \"contents\" : \"Postoperative adjuvant chemoradiation treatment after curative resection for rectal cancer was needed to reduce recurrence and improve a survival rate Intravenous 5-fluorouracil 5-FU and leucovorin has been a mainstay of chemotherapy but oral 5-FU derivatives have been shown a comparable antitumor activity Intravenous 5-FU and oral doxifluridine were compared with respect to therapeutic efficacy drug toxicity and quality of life A total of 166 patients were randomized to receive intravenous 5-FU 450 mg/m2/day or oral doxifluridine 900 mg/m2/day in combination with leucovorin 20 mg/m2/day for depth of invasion nodal status metastasis TNM stage II and III patients between October 1997 and February 1999 Consecutive daily intravenous infusion for 5 days per every month for a total of 12 cycles IV arm n = 74 and oral doxifluridine daily for 3 weeks and 1 week rest for a total of 12 cycles oral arm n = 92 Drug toxicity and quality of life were observed Quality of life was scored according to 22 daily activity items good > or = 71 fair < 70 poor < 52 There was no difference of sex between two groups IV arm male/female = 45/29 oral arm male/female = 59/33 The mean age was 523 vs 595 respectively There was also no difference of TNM stage distribution and type of operation between groups P > 05 Mean numbers of chemotherapy cycles were 65 + / -37 IV arm vs 72 + / -43 oral arm respectively The rate of recurrence was 9/74 121 % in the IV arm and 6/92 65 % in the oral arm respectively P = 937 Local recurrence was 2/74 stage III 27 % in the IV arm and 1/92 stage II 11 % in the oral arm respectively Systemic recurrence was 7/74 stage III 94 % in the IV arm and 5/92 stage III 54 % in the oral arm respectively The most common site of systemic recurrence was the liver Toxicity profile was as follows leukopenia 30/74 vs 17/92 and alopecia 21/74 vs 13/92 were statistically more common in the IV arm Diarrhea was more common in the oral arm Poor quality of life score between two groups was observed at 1 month 239 % vs 13 % and 2 months 158 % vs 37 % after chemotherapy Good quality of life score was observed at 1 month 195 % vs 49 % and 2 months 47 % vs 72 % respectively P < 05 Oral doxifluridine with leucovorin shows a comparable therapeutic efficacy to intravenous 5-FU regimen with high quality of life as postoperative adjuvant therapy The oral regimen also can be safely given with appropriate toxicity and tolerability\",\n",
            "}\n",
            "13067\n",
            "{\n",
            "  \"id\" : \"15738536\",\n",
            "  \"contents\" : \"To investigate the efficacy and safety of zoledronic acid for the treatment of bone metastases from breast cancer Women with bone metastases N = 228 were randomly assigned to receive 4 mg zoledronic acid n = 114 or placebo n = 114 via 15-minute infusions every 4 weeks for 1 year The primary efficacy end point was the skeletal-related event SRE rate ratio between treatment groups An SRE was defined as pathologic fracture spinal cord compression and radiation or surgery to bone Secondary end points included percentage of patients with at least one SRE time-to-first SRE and Andersen-Gill multiple-event analysis The SRE rate ratio at 1 year excluding HCM and adjusted for prior fracture was 061 permutation test P = 027 indicating that zoledronic acid reduced the rate of SRE by 39 % compared with placebo The percentage of patients with at least one SRE excluding HCM was significantly reduced by 20 % by zoledronic acid 298 % v 496 % for placebo P = 003 Zoledronic acid significantly delayed time-to-first SRE median not reached v 364 days Cox regression P = 007 and reduced the risk of SREs by 41 % in multiple event analysis risk ratio = 059 P = 019 compared with placebo Zoledronic acid was well tolerated with a safety profile similar to placebo No patient treated with zoledronic acid had grade 3 or 4 serum creatinine increase Zoledronic acid significantly reduced skeletal complications compared with placebo across multiple end points in Japanese women with bone metastases from breast cancer\",\n",
            "}\n",
            "13068\n",
            "{\n",
            "  \"id\" : \"24411639\",\n",
            "  \"contents\" : \"The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer NSCLC Patients from 211 centres in 27 countries with stage IIIB/IV recurrent NSCLC progressing after first-line chemotherapy stratified by ECOG performance status previous bevacizumab treatment histology and presence of brain metastases were allocated by computer-generated sequence through an interactive third-party system in 11 ratio to receive docetaxel 75 mg/m 2 by intravenous infusion on day 1 plus either nintedanib 200 mg orally twice daily or matching placebo on days 2-21 every 3 weeks until unacceptable adverse events or disease progression Investigators and patients were masked to assignment The primary endpoint was progression-free survival PFS by independent central review analysed by intention to treat after 714 events in all patients The key secondary endpoint was overall survival analysed by intention to treat after 1121 events had occurred in a prespecified stepwise order first in patients with adenocarcinoma who progressed within 9 months after start of first-line therapy then in all patients with adenocarcinoma then in all patients This trial is registered with ClinicalTrialsgov number NCT00805194 Between Dec 23 2008 and Feb 9 2011 655 patients were randomly assigned to receive docetaxel plus nintedanib and 659 to receive docetaxel plus placebo The primary analysis was done after a median follow-up of 71 months IQR 38-110 PFS was significantly improved in the docetaxel plus nintedanib group compared with the docetaxel plus placebo group median 34 months [ 95 % CI 29-39 ] vs 27 months [ 26-28 ] hazard ratio [ HR ] 079 [ 95 % CI 068-092 ] p = 00019 After a median follow-up of 317 months IQR 278-361 overall survival was significantly improved for patients with adenocarcinoma histology who progressed within 9 months after start of first-line treatment in the docetaxel plus nintedanib group 206 patients compared with those in the docetaxel plus placebo group 199 patients median 109 months [ 95 % CI 85-126 ] vs 79 months [ 67-91 ] HR 075 [ 95 % CI 060-092 ] p = 00073 Similar results were noted for all patients with adenocarcinoma histology 322 patients in the docetaxel plus nintedanib group and 336 in the docetaxel plus placebo group median overall survival 126 months [ 95 % CI 106-151 ] vs 103 months [ 95 % CI 86-122 ] HR 083 [ 95 % CI 070-099 ] p = 00359 but not in the total study population median 101 months [ 95 % CI 88-112 ] vs 91 months [ 84-104 ] HR 094 95 % CI 083-105 p = 02720 Grade 3 or worse adverse events that were more common in the docetaxel plus nintedanib group than in the docetaxel plus placebo group were diarrhoea 43 [ 66 % ] of 652 vs 17 [ 26 % ] of 655 reversible increases in alanine aminotransferase 51 [ 78 % ] vs six [ 09 % ] and reversible increases in aspartate aminotransferase 22 [ 34 % ] vs three [ 05 % ] 35 patients in the docetaxel plus nintedanib group and 25 in the docetaxel plus placebo group died of adverse events possibly unrelated to disease progression the most common of these events were sepsis five with docetaxel plus nintedanib vs one with docetaxel plus placebo pneumonia two vs seven respiratory failure four vs none and pulmonary embolism none vs three Nintedanib in combination with docetaxel is an effective second-line option for patients with advanced NSCLC previously treated with one line of platinum-based therapy especially for patients with adenocarcinoma Boehringer Ingelheim\",\n",
            "}\n",
            "13069\n",
            "{\n",
            "  \"id\" : \"21640520\",\n",
            "  \"contents\" : \"To evaluate the very long-term results of the randomized Post Operative Radiation Therapy in Endometrial Carcinoma PORTEC -1 trial for patients with Stage I endometrial carcinoma EC focusing on the role of prognostic factors for treatment selection and the long-term risk of second cancers The PORTEC trial 1990-1997 included 714 patients with Stage IC Grade 1-2 or Stage IB Grade 2-3 EC After surgery patients were randomly allocated to external-beam pelvic radiotherapy EBRT or no additional treatment NAT Analysis was by intention to treat 426 patients were alive at the date of analysis The median follow-up time was 133 years The 15-year actuarial locoregional recurrence LRR rates were 6 % for EBRT vs 155 % for NAT p < 00001 The 15-year overall survival was 52 % vs 60 % p = 014 and the failure-free survival was 50 % vs 54 % p = 094 For patients with high-intermediate risk criteria the 15-year overall survival was 41 % vs 48 % p = 051 and the 15-year EC-related death was 14 % vs 13 % Most LRR in the NAT group were vaginal recurrences 110 % of 155 % The 15-year rates of distant metastases were 9 % vs 7 % p = 025 Second primary cancers had been diagnosed over 15 years in 19 % of all patients 22 % vs 16 % for EBRT vs NAT p = 010 with observed vs expected ratios of 16 EBRT and 12 NAT compared with a matched population p = NS Multivariate analysis confirmed the prognostic significance of Grade 3 for LRR hazard ratio [ HR ] 34 p = 00003 and for EC death HR 73 p < 00001 of age > 60 HR 39 p = 0002 for LRR and 27 p = 001 for EC death and myometrial invasion > 50 % HR 19 p = 003 and HR 19 p = 002 The 15-year outcomes of PORTEC-1 confirm the relevance of HIR criteria for treatment selection and a trend for long-term risk of second cancers EBRT should be avoided in patients with low - and intermediate-risk EC\",\n",
            "}\n",
            "13070\n",
            "{\n",
            "  \"id\" : \"10700419\",\n",
            "  \"contents\" : \"Human papillomavirus HPV infections appear to be central to the development of cervical cancer This study addresses the question of whether testing women who have low-grade squamous intraepithelial lesions LSILs of the uterine cervix for HPV DNA is useful as a triage strategy Four clinical centers in different areas of the United States participated in a randomized clinical trial of the use of HPV DNA testing in women with cytologic evidence of atypical squamous cells of undetermined significance ASCUS or LSIL The study sample in this article consists only of women who had LSIL at enrollment Within 6 months of an LSIL diagnosis based on a Pap smear read by a community-based cytopathologist women who were 18 years of age or older completed a standardized questionnaire and underwent a pelvic examination that included collection of cervical specimens for HPV DNA testing by Hybrid Capture II HCII R assay Among the 642 women referred with LSIL who had analyzable test results the mean chronologic age and age at first coitus were similar among the four clinical centers despite the centers ethnic and geographic diversity Overall HPV DNA was detected in cervical samples from 532 829 % of the 642 women 95 % confidence interval = 797 % -857 % This high frequency of HPV positivity was confirmed by polymerase chain reaction PCR assays in a subset of 210 paired specimens tested by HCII and PCR 814 % were positive by both methods Because a very high percentage of women with an LSIL diagnosis from Pap smears are positive for HPV DNA by HCII testing there is limited potential for this assay to direct decisions about the clinical management of women with LSIL The role of HPV testing in the management of women with ASCUS is still under study\",\n",
            "}\n",
            "13071\n",
            "{\n",
            "  \"id\" : \"10550151\",\n",
            "  \"contents\" : \"To determine the feasibility and safety of multiple sequential courses of high-dose chemotherapy and peripheral-blood progenitor cells PBPCs administered in a multicenter setting to patients with small-cell lung cancer Sixty-nine patients limited disease n = 30 extensive disease n = 39 treated at 15 European centers were scheduled to receive three courses of high-dose chemotherapy with ifosfamide 10 g/m 2 carboplatin 1200 mg/m 2 and etoposide 1200 mg/m 2 ICE divided over 4 days at 28-day intervals PBPCs were harvested before treatment and mobilized with epirubicin 150 mg/m 2 administered via an intravenous bolus divided over 2 days and filgrastim 5 microg/kg/d administered subcutaneously The performed leukaphereses one to five per patient yielded a median of 166 x 10 6 / kg range 10 to 966 x 10 6 / kg CD34 + cells which was sufficient for three reinfusions Fifty patients 72 % completed the treatment according to schedule Nine patients completed two courses and six patients completed one course of treatment The increase in dose-intensity was 290 % that of a standard ICE regimen The median duration of myelosuppression was similar between courses namely 4 days range 1 to 12 days for leukocytes less than 05 x 10 9 / L and 4 days range 0 to 22 days for thrombocytes less than 20 x 10 9 / L Febrile neutropenia developed in 66 % of courses severe diarrhea in 14 % mucositis in 10 % and nausea and vomiting in 21 % of courses There were six cases of toxic death 9 % most of which occurred in the first year of accrual and thus were attributable to the learning curve The antitumor effect of the regimen was reflected in an 86 % remission rate 95 % confidence interval [ CI ] 74 % to 93 % with 51 % of patients achieving a complete response 95 % CI 38 % to 63 % Median overall survival was 18 months for patients with limited disease and 11 months for patients with extensive disease This multiple sequential high-dose ICE regimen could be safely administered on a multicenter basis to patients with small-cell lung cancer The dose-intensity could be increased to 290 % that of standard ICE regimen The benefit of this approach is currently being tested in a randomized trial that aims to double the long-term rate of survival for patients with small-cell lung cancer\",\n",
            "}\n",
            "13072\n",
            "{\n",
            "  \"id\" : \"23808950\",\n",
            "  \"contents\" : \"There is a paucity of data on the cell block CB method for bile cytology We compared the diagnostic efficacy of the CB method with that of conventional smear cytology for bile obtained by endoscopic retrograde cholangiopancreatography ERCP in a randomized controlled trial manner A total of 137 patients with biliary tract lesions suspicious of malignancy who had undergone bile collection under ERCP were recruited to this study After sampling the bile was randomized to the CB method n = 69 or to smear cytology n = 68 CB sections were prepared using the sodium alginate method and subjected to hematoxylin-eosin Alcian blue-periodic acid-Schiff stain and immunohistochemical stains Both Papanicolaou and Giemsa stains were used for smear cytology The final diagnosis was malignancy in 94 patients bile duct cancer 42 pancreatic head cancer 34 gallbladder cancer 16 and ampullary cancer two The diagnostic accuracy of the CB method and that of smear cytology were 64 % and 53 % respectively P = 020 The sensitivity of the CB method 53 % was significantly better than that of smear cytology 28 % P = 0014 Their respective sensitivities were 80 % and 31 % P = 0002 for bile duct cancer 20 % and 15 % P = 10 for pancreatic head cancer and 30 % and 67 % P = 030 for gallbladder cancer The CB method for bile cytology showed a higher diagnostic yield than smear cytology Its diagnostic sensitivity was satisfactory in cases of bile duct cancer\",\n",
            "}\n",
            "13073\n",
            "{\n",
            "  \"id\" : \"23606201\",\n",
            "  \"contents\" : \"Despite median survival of less than 6 months there is a significant proportion of advanced pancreatic cancer patients who progress on gemcitabine that remains fit and these patients are candidates for second-line treatment The objective of this study is to evaluate the efficacy and safety of oxaliplatin plus 5-fluorouracil and folinic acid in patients with gemcitabine-pretreated advanced pancreatic cancer Thirty patients with advanced pancreatic cancer who were pretreated with gemcitabine received oxaliplatin 85 mg/m 2 on days 1 and 15 followed by leucovorin 20 mg/m 2 and 5-fluorouracil 500 mg/m 2 on days 1 8 and 15 The cycle was repeated every 3 weeks The majority of patients 80 % had locally advanced disease Median age was 63 years and 60 % were males The liver was the most common site of metastasis Partial response was observed in 2 patients 67 % and stable disease in 6 patients 20 % while 12 patients progressed 40 % Improved performance status was reported in 10 patients 333 % The median duration of response was 13 weeks and median overall survival was 22 weeks There was no grade 4 toxicity apart from grade 4 neutropenia in 66 % of patients Neutropenia 465 % and neuropathy 432 % were the most common toxicities while hand-foot syndrome was the least frequent one 20 % There were no treatment-related deaths The 6-month survival rate was 30 % This regimen is feasible and active with an acceptable toxicity however further investigation in phase III trial is needed\",\n",
            "}\n",
            "13074\n",
            "{\n",
            "  \"id\" : \"22315364\",\n",
            "  \"contents\" : \"Coronary artery disease CAD and prostate cancer PCa are not only common diseases but share many risk factors To date only a few studies have explored the relationship between CAD and PCa risk with conflicting results The four-year REDUCE study tested dutasteride 05 mg daily for PCa risk reduction in men with prostate specific antigen PSA of 25 to 100 ng/mL and a negative biopsy Among men who underwent at least one on-study biopsy n = 6729 828 % the association between CAD and overall PCa risk and disease grade was examined with logistic and multinomial logistic regression adjusting for clinicopathologic features respectively Overall 547 men 86 % had a history of CAD Men with CAD were significantly older and had higher body mass index PSA and larger prostate volumes and were more likely to have diabetes hypertension and hypercholesterolemia and take aspirin and statins On multivariate analysis CAD was associated with a 35 % increased risk of PCa diagnosis OR = 135 95 % CI 108-1 67 P = 0007 while elevating risk of both low - OR = 134 95 % CI 105-1 73 P = 002 and high-grade disease OR = 134 95 % CI 095-1 88 P = 009 In a post hoc hypothesis developing secondary analysis of the REDUCE study CAD was significantly associated with increased PCa diagnosis If confirmed in other studies this suggests CAD may be a novel PCa risk factor and suggests common shared etiologies Whether lifestyle changes shown to reduce CAD risk ie weight loss exercise cholesterol reduction etc can reduce PCa risk warrants further study\",\n",
            "}\n",
            "13075\n",
            "{\n",
            "  \"id\" : \"11256836\",\n",
            "  \"contents\" : \"This prospective and randomized clinical study was initiated to compare the efficacy and safety of combined androgen blockade with combination with UFT in patients with untreated prostate cancer A total of 142 patients were entered in this study between April 1990 and December 1992 All patients received bilateral orchiectomy and 200 mg/day of diethylstilbestrol diphosphate Of these patients 70 patients were administered an additional 400 mg/day of UFT after randomization Either treatment was continued for at least 1 year or until objective progression occurred if the initial response was equal to or better than no change The endpoints of this study were progression-free survival cancer-specific survival and change of QOL scores A total of 136 patients were evaluable and 131 patients 963 % could be followed up with a median follow-up period of 1469 days Both groups showed similar initial treatment response at 12 weeks adverse effect and change of quality of life score during the first year after initiation of the treatment There was a significantly longer progression-free survival and better but not significant cancer-specific survival in the endocrine chemotherapy group The patients with earlier stage and initial serum prostate-specific antigen values < 40 ng/ml showed a good indication for this endocrine chemotherapy This endocrine chemotherapy was confirmed to be tolerable and significantly effective in the delay of disease progression which leads to longer survival in patients with prostate cancer\",\n",
            "}\n",
            "13076\n",
            "{\n",
            "  \"id\" : \"16438891\",\n",
            "  \"contents\" : \"To demonstrate the feasibility of breast conserving therapy BCT and establish a multimodality BCT model for early breast cancer in China A prospective multicenter case control study consisting of 4461 patients was carried out by the Cancer Hospital Chinese Academy of Medical Sciences CAMS and nine other hospitals across China from November 2001 to November 2004 the result of BCT and mastectomy on early stage breast cancer were compared Patients entry-primary tumor < or = 3 cm primary tumor in periphery quadrant pathology showed infiltrating carcinoma and clinical absence of locoregional lymphatic or distant metastasis Patients rejection-multiple center cancer or diffused malignant calcified spots previous radical radiation therapy in the chest accompanying collogenolytic vascular granuloma and simultaneous pregnancy Of these 4461 patients breast conserving surgery was performed in 872 195 % patients who were eligible for BCT accounting for 90 % of all operated breast cancer patients during the same period The rates of local recurrence metastasis and death were 10 % 9/872 13 % 11/872 and 01 % 1/872 in BCT group versus 05 % 18/3589 14 % 49/3589 and 01 % 4/3589 in the mastectomy group No statistical significant difference was found between these two groups P > 005 Cosmetic evaluation of breast in BCT group was carried out postoperatively at points of six months one year and two years with 897 % 911 % and 866 % of the patients assessed as excellent or fine cosmetic state respectively Breast conserving therapy for early stage breast cancer is feasible in China with no ominous effect on the survival and recurrence rate Breast conserving therapy is able to improve not only the quality of life but also enhance the confidence of the patients in addition to quasi-perfect cosmetic results Standard comprehensive BCT involving multi-centers all concentrating on combination treatment should be widely adopted in China in the future However breast conserving surgery should selectively be used only for early stage breast cancer and should be combined with postoperative radiotherapy chemotherapy and hormone therapy in order to guarantee success\",\n",
            "}\n",
            "13077\n",
            "{\n",
            "  \"id\" : \"24835379\",\n",
            "  \"contents\" : \"Esophagogastrostomy for oesophageal cancer is the standard surgical treatment However traditional techniques have been associated with high frequency of anastomotic complications The purpose of this study is to clarify the superiority of the oesophageal flap valvuloplasty and wrapping suturing technique in preventing postoperative complications after oesophagectomy for oesophageal cancer A prospective randomised study was performed on 394 patients treated for esophageal cancer between January 2006 and December 2010 The trial registry number is ChiCTR-TRC-13003817 in the Chinese Clinical Trial Registry Anastomotic leaks occurred in four patients in group A 21 % and in twelve patients in group B 62 % with statistically significant P = 0038 During the evaluation of benign stricture seven patients were excluded for hospital mortality Thirty three patients in group A 69 % and 25 patients in group B 132 % occurred anastomotic stricture respectively P = 0044 Furthermore reflux oesophagitis and Barrett s epithelium were found in 105 patients 553 % of group B and 54 287 % patients in group A P < 0001 The oesophageal flap valvuloplasty and wrapping suturing technique decreased anastomotic leakage incidence and stricture rate thereby decreasing the morbidity and mortality This procedure also prevented the occurrence of gastroesophageal reflux after esophagectomy\",\n",
            "}\n",
            "13078\n",
            "{\n",
            "  \"id\" : \"14678367\",\n",
            "  \"contents\" : \"To determine whether different approaches in the choice of treatment affect the treatment chosen by the patient for prostate cancer We conducted a randomized trial with 210 men who had a histologically confirmed diagnosis of prostate cancer in 1993-94 at four major hospitals in Finland After obtaining informed consent the men were randomized either to an intervention arm in which there was greater patient participation in the choice of treatment following a structured procedure or a control arm in which the standard approach ie a standardized treatment protocol was used The main outcome measure of the analysis was the primary treatment chosen for prostate cancer In the enhanced participation arm patients not eligible for radical prostatectomy chose orchidectomy less frequently and favoured nonsurgical endocrine treatment than in the treatment protocol arm Radical prostatectomy was the most commonly chosen treatment option in both arms among men with operable cancer The way treatment options were presented affected the treatment chosen for prostate cancer Patients with prostate cancer are willing and able to take an active role in making decisions The preferences of patients with prostate cancer in the choice of treatment may differ from the priorities of the physicians\",\n",
            "}\n",
            "13079\n",
            "{\n",
            "  \"id\" : \"24972577\",\n",
            "  \"contents\" : \"To observe the efficacy and the influence on quality of life QOL of syndrome differentiation treatment with Chinese medicine CM for opioid-induced constipation as well as the safety and influence on analgesic effect of opioids Totally 406 cases enrolled from 53 collaborating medical centers were randomly assigned to a CM group and a control group The CM group were treated with CM decoction based on syndrome differentiation and the control group were treated with Phenolphthalein Tablet Both groups were treated for 14 days Cleveland constipation score CCS numerical rating scale NRS of pain and Chinese version of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 V3 0 EORTC QLQ-C30 V3 0 were used to evaluate the efficacy pain controlled and QOL status The comparisons of CCS score reduction and QOL between the two groups after treatment suggested that the improvements of constipation and QOL in the CM group were better than that in the control group P < 005 The total efficiency of the CM group was better than the control group 935 % vs 864 % P < 005 There was no significant difference in NRS scores between before and after treatment in both groups There was no serious drug-related adverse event during the course of study CM decoction could effectively treat opioid-induced constipation and improve patients QOL at the same time It is safe and does nt affect the analgesic effect of opioids when treating constipation\",\n",
            "}\n",
            "13080\n",
            "{\n",
            "  \"id\" : \"25590215\",\n",
            "  \"contents\" : \"The benefits of prophylactic central compartment lymph node dissection pCCND in papillary thyroid cancer PTC are still under investigation This treatment seems to reduce PTC recurrence/mortality rates but has a higher risk of surgical complications The lack of prospective randomized trials does not allow definitive recommendations The aim of this prospective randomized controlled study was to evaluate the clinical advantages and disadvantages of pCCND A total of 181 patients with PTC without evidence of preoperative/intraoperative lymph node metastases cN0 were randomly assigned to either Group A n = 88 and treated with total thyroidectomy TTx or Group B n = 93 and treated with TTx + pCCND After 5 years of followup no difference was observed in the outcome of the two groups However a higher percentage of Group A were treated with a higher number of 131 I courses P = 002 whereas a higher prevalence of permanent hypoparathyroidism was observed in Group B P = 02 No preoperative predictors of central compartment lymph node metastases N1a were identified Only three patients were upstaged and the therapeutic strategy changed in only one case cN0 patients with PTC treated either with TTx or TTx + pCCND showed a similar outcome One advantage of TTx + pCCND was a reduced necessity to repeat 131 I treatments but the disadvantage was a higher prevalence of permanent hypoparathyroidism Almost 50 % of patients with PTC had micrometastatic lymph nodes in the central compartment but none of the presurgical features analyzed including BRAF mutation was able to predict their presence moreover to be aware of their presence does not seem to have any effect on the outcome\",\n",
            "}\n",
            "13081\n",
            "{\n",
            "  \"id\" : \"11466135\",\n",
            "  \"contents\" : \"The prognostic value of QT interval dispersion measured from a standard 12-lead electrocardiogram ECG in the general population is not well established The purpose of the present study was primarily to assess the value of QT interval dispersion obtained from 12-lead ECG in the prediction of total cardiac stroke and cancer mortality in the elderly A random population sample of community-living elderly people n = 330 age > or = 65 years mean 74 + / - 6 years underwent a comprehensive clinical evaluation laboratory tests and 12-lead ECG recordings By the end of the 10-year follow-up 180 subjects 55 % had died and 150 45 % were still alive Heart rate corrected QT QTc dispersion had been longer in those who had died than in the survivors 75 + / - 32 ms vs 63 + / - 35 ms P = 001 After adjustment for age and sex in the Cox proportional hazards model prolonged QTc dispersion > or = 70 msec predicted all-cause mortality relative risk [ RR ] 138 95 % confidence interval [ CI ] 102-1 86 and particularly stroke mortality RR 27 95 % CI 129-5 73 but not cardiac RR 138 95 % CI 087-2 18 or cancer RR 151 95 % CI 091-2 50 mortality After adjustment for age sex body mass index blood pressure blood glucose and cholesterol concentrations functional class history of cerebrovascular disease diabetes smoking previous myocardial infarction angina pectoris congestive heart failure medication left ventricular hypertrophy on ECG presence of atrial fibrillation and R-R interval increased QTc dispersion still predicted stroke mortality RR 321 95 % CI 109-9 47 but not total mortality or mortality from other causes The combination of increased QTc dispersion and left ventricular hypertrophy on ECG was a powerful independent predictor of stroke mortality in the present elderly population RR 1652 95 % CI 337-80 89 QTcmin the shortest QTc interval among the 12 leads of ECG independently predicted total mortality RR 10082 95 % CI 10028-1 0136 P = 0003 cardiac mortality RR 10191 95 % CI 10102-1 0281 P < 00001 and cancer mortality RR 10162 95 % CI 10049-1 0277 P = 0005 Increased QTc dispersion yields independent information on the risk of dying from stroke among the elderly and its component QTcmin from the other causes of death\",\n",
            "}\n",
            "13082\n",
            "{\n",
            "  \"id\" : \"20393269\",\n",
            "  \"contents\" : \"Acute pressure applied to the sciatic nerve has been recently reported to offer immediate short-term pain relief in patients with various diseases This study examined the analgesic effect of this novel method on cold pressor pain compared with clinical pain We conducted 2 randomized parallel group studies The cold pressor study involved 152 undergraduate students and the clinical study included 22 cancer patients Acute pressure of 11 to 20 kg was simultaneously applied to the sciatic nerves at the back of both thighs for 2 minutes The placebo intervention was pressure applied to parallel regions on the fronts of the thighs Next patients rated pain attributable to their diseases and the students evaluated pain after their hands were submerged in cold water Acute pressure applied to the sciatic nerve produced immediate clinical pain relief but did not alleviate cold pressor pain Our study indicated that cold pressor pain and clinical pain responded differently to acute pressure blockade of the sciatic nerve Our findings indicate that caution should be exercised when attempting to extrapolate cold pressor pain findings to clinical pain\",\n",
            "}\n",
            "13083\n",
            "{\n",
            "  \"id\" : \"9667264\",\n",
            "  \"contents\" : \"Cisplatin has played a major role in the treatment of non-small-cell lung cancer NSCLC This randomized trial was performed by the Southwest Oncology Group SWOG to determine whether the combination of vinorelbine and cisplatin has any advantage with regard to response rate survival and time to treatment failure over single-agent cisplatin in the treatment of patients with advanced NSCLC Between October 1993 and April 1995 432 patients with advanced stage NSCLC were randomized to receive arm I cisplatin 100 mg/m2 every 4 weeks or arm II cisplatin 100 mg/m2 every 4 weeks and vinorelbine 25 mg/m2 weekly All patients were chemotherapy-naive had performance status PS 0 or 1 and had adequate hematologic renal and hepatic function Four hundred fifteen patients were eligible and assessable On arm I cisplatin there was a 12 % partial response rate Arm II cisplatin and vinorelbine had a 26 % response rate 2 % complete responses and 24 % partial responses P = 0002 There was a statistically significant advantage with regard to progression-free survival median 2 v 4 months P = 0001 and overall survival median 6 v 8 months P = 0018 for the cisplatin and vinorelbine arm One-year survival was 20 % for cisplatin alone and 36 % for the combination arm There was more hematologic toxicity on arm II of the study 81 % grades 3 and 4 granulocytopenia v 5 % on arm I Other toxicities such as renal insufficiency ototoxicity and nausea and vomiting and neuropathy were similar The results of this study indicate that the combination of cisplatin and vinorelbine is a superior treatment when compared with single-agent cisplatin in the treatment of advanced NSCLC Cisplatin and vinorelbine is the new standard for SWOG against which new therapies will be evaluated\",\n",
            "}\n",
            "13084\n",
            "{\n",
            "  \"id\" : \"10080588\",\n",
            "  \"contents\" : \"BMS-182248-1 BR96-doxorubicin immunoconjugate is a chimeric human/mouse monoclonal antibody linked to approximately eight doxorubicin molecules The antibody is directed against the Lewis-Y antigen which is expressed on 75 % of all breast cancers but is limited in expression on normal tissues Preclinical xenograft models demonstrated significant antitumor activity including cures A randomized phase II design was chosen to estimate the activity of the BR96-doxorubicin conjugate in metastatic breast cancer in a study population with confirmed sensitivity to single-agent doxorubicin Patients with measurable metastatic breast cancer and immunohistochemical evidence of Lewis-Y expression on their tumor received either BR96-doxorubicin conjugate 700 mg/m2 IV over 24 hours or doxorubicin 60 mg/m2 every 3 weeks Patients were stratified on the basis of prior doxorubicin exposure visceral disease and institution Cross-over to the opposite treatment arm was allowed with progressive or persistently stable disease Twenty-three patients who had received a median of one prior chemotherapy regimen were assessable There was one partial response 7 % in 14 patients receiving the BR96-doxorubicin conjugate and one complete response and three partial responses 44 % in nine assessable patients receiving doxorubicin No patient experienced a clinically significant hypersensitivity reaction The toxicities were significantly different between the two treatment groups with the BR96-doxorubicin conjugate group having limited hematologic toxicity whereas gastrointestinal toxicities including marked serum amylase and lipase elevations nausea and vomiting with gastritis were prominent The BR96-doxorubicin immunoconjugate has limited clinical antitumor activity in metastatic breast cancer The gastrointestinal toxicities likely represent binding of the agent to normal tissues expressing the target antigen and may have compromised the delivery of the immunoconjugate to the tumor sites\",\n",
            "}\n",
            "13085\n",
            "{\n",
            "  \"id\" : \"22515794\",\n",
            "  \"contents\" : \"Over 40 % of children with cancer have reported that chemotherapy-induced nausea and vomiting CINV are the two most distressing side-effects of treatment even when antiemetic drugs have been used The purpose of this article is to report the findings from a feasibility and pilot study using auricular point acupressure point for CINV in a small group of children in Taiwan This was a crossover randomized design study CINV symptoms were assessed on 10 patients just prior to and for 7 days following each of three rounds of chemotherapy drugs CTX They received standard care SC and were not entered into a test treatment group until they completed the baseline assessment which was conducted during their first round of chemotherapy after entering the study Just prior to receiving the second round of CTX patients were randomized into one of two treatment conditions auricular acupressure intervention in addition to standard care AAP or auricular acupressure using sham auricular points SAP in addition to standard care For the third round of CTX they were switched to the other treatment group The enrollment rate for this study was 77 % of the children invited to participate and of those 88 % provided completed data sets for all three treatment conditions Patients in the AAP group reported significantly lower occurrence and severity of nausea and vomiting than patients in the SC group p < 005 There were no significant differences of nausea and vomiting for patients between the AAP and SAP groups All of the patients took antiemetic medication on the day they received CTX and 80 % of patients reported that the antiemetics did not help to treat CINV These preliminary findings did show evidence that AAP is acceptable to the children and their parents to prevent/treat CINV However there were no statistically significant differences between the AAP and SAP groups in the prevention/treatment of CINV There were clinical trend differences between the groups which may due to the small sample size In a larger study it would be important to determine whether the effects of the AAP and SAP treatment are independent of any psychologic effects such as the researcher s increased presence in both treatment groups\",\n",
            "}\n",
            "13086\n",
            "{\n",
            "  \"id\" : \"22680341\",\n",
            "  \"contents\" : \"Cannabis based medicines are registered as a treatment for various indications such as pain and spasms in multiple sclerosis MS patients and anorexia and nausea in patients with HIV or receiving cancer treatment the pharmacokinetics of the various administration routes of cannabis and cannabis based medicines are variable and dosing is hard to regulate Namisol is a new tablet containing pure THC > 98 % that has a beneficial pharmacokinetic profile after oral administration Namisol gives a quick onset of pharmacodynamic effects in healthy volunteers which implies a rapid initiation of therapeutic effects in patients Among the main disadvantages of currently available 9 - tetrahydrocannabinol THC formulations are dosing difficulties due to poor pharmacokinetic characteristics Namisol is a novel THC formulation designed to improve THC absorption The study objectives were to investigate the optimal administration route pharmacokinetics PK pharmacodynamics PD and tolerability of Namisol This first in human study consisted of two parts Panel I included healthy males and females n = 6/6 in a double-blind double-dummy randomized crossover study with sublingual crushed tablet and oral administration of Namisol 5 mg THC Based on these results male and female n = 4/5 participants from panel I received oral THC 65 and 80 mg or matching placebo in a randomized crossover rising dose study during panel II PD measurements were body sway visual analogue scales VAS mood psychedelic and heart rate THC and 11-OH-THC population PK analysis was performed Sublingual administration showed a flat concentration profile compared with oral administration Oral THC apparent t 1/2 was 72-80 min t max was 39-56 min and C max 292-4 69 ng ml -1 THC affected body sway 608 % 95 % CI 295 998 external perception 0078 log mm 95 % CI 0019 0137 alertness -27 mm 95 % CI -45 -09 feeling high 0256 log mm 95 % CI 0093 0418 and heart rate 56 beats min -1 95 % CI 27 65 Namisol was well tolerated Oral Namisol showed promising PK and PD characteristics Variability and t max of THC plasma concentrations were smaller for Namisol than reported for studies using oral dronabinol and nabilone This study was performed in a limited number of healthy volunteers Therefore future research on Namisol should study clinical effects in patient populations\",\n",
            "}\n",
            "13087\n",
            "{\n",
            "  \"id\" : \"16968874\",\n",
            "  \"contents\" : \"To assess the prognostic and predictive significance of p53 and Bcl-2 protein expression in high risk patients with breast cancer treated with dose-dense sequential chemotherapy From June 1997 until November 2000 595 patients were randomized to three cycles of epirubicin E 110 mg/m2 followed by three cycles of paclitaxel P 250 mg/m2 followed by three cycles of intensified CMF cyclophosphamide 840 mg/m2 methotrexate 47 mg/m2 and fluorouracil 840 mg/m2 or to four cycles of E followed by four cycles of CMF p53 and Bcl-2 expression was investigated by immunohistochemistry in 392 and 397 patients respectively Positive expression of p53 was detected in 104 265 % patients and was significantly associated with negative hormonal status worse histologic grade higher incidence of disease relapse and higher rate of death p53 positive expression was a significant negative predictor of overall survival OS P = 0002 and disease-free survival DFS P = 0001 Negative expression of Bcl-2 was detected in 203 51 % patients and was significantly associated with negative hormonal status Multivariate analysis revealed that positive p53 expression higher number of positive nodes and worse tumor grade were related to significantly poorer OS and DFS For both treatments p53 positive expression was a significant negative prognostic factor for OS and DFS while Bcl-2 was not No predictive ability of p53 status or Bcl-2 status for paclitaxel treatment was evident\",\n",
            "}\n",
            "13088\n",
            "{\n",
            "  \"id\" : \"12431972\",\n",
            "  \"contents\" : \"Propose a phase II study design to evaluate the activity of a putative cytostatic agent acknowledging heterogeneity of tumor growth rates in the population of patients In the setting of renal cell carcinoma some patients tumors will grow slowly naturally An appropriate design has to distinguish antiproliferative activity attributable to the novel agent from indolent disease We propose a randomized discontinuation design that initially treats all patients with the study agent stage 1 and then randomizes in a double-blind fashion to continuing therapy or placebo only those patients whose disease is stable stage 2 This design allows the investigators to determine if apparent slow tumor growth is attributable to the drug or to selection of patients with naturally slow-growing tumors By selecting a more homogeneous population the randomized portion of the study requires fewer patients than would a study randomizing all patients at entry The design also avoids potential confounding because of heterogeneous tumor growth Because the two randomly assigned treatment groups each comprise patients with apparently slow growing tumors any difference between the groups in disease progression after randomization is more likely a result of the study drug and less likely a result of imbalance with respect to tumor growth rates Stopping rules during the initial open-label stage and the subsequent randomized trial stage allow one to reduce the overall sample size Expected average tumor growth rate is an important consideration when deciding the duration of follow-up for the two stages The randomized discontinuation design is a feasible alternative phase II study design for determining activity of possibly cytostatic anticancer agents\",\n",
            "}\n",
            "13089\n",
            "{\n",
            "  \"id\" : \"20978446\",\n",
            "  \"contents\" : \"This randomized phase II study investigated pemetrexed in combination with the epidermal growth factor receptor EGFR - targeting monoclonal antibody matuzumab compared with pemetrexed alone as second-line therapy for patients with advanced non-small cell lung cancer Patients received pemetrexed 500 mg/m every 3 weeks either alone n = 50 or in combination with matuzumab at either 800 mg weekly n = 51 or 1600 mg every 3 weeks n = 47 The primary end point was objective response as assessed by an independent review committee Tumor EGFR expression was detected in 87 % of randomized patients The objective response rate for the pooled matuzumab-treated arms was 11 % compared with 5 % for pemetrexed alone p = 0332 Apart from one patient in the pemetrexed alone group all responses occurred in patients whose tumors expressed EGFR The objective response rate for patients receiving weekly matuzumab was 16 % compared with 2 % for those receiving matuzumab every 3 weeks There was also a trend for improved overall survival in patients receiving matuzumab weekly versus every 3 weeks 124 months versus 59 months respectively versus 79 months for pemetrexed alone The combination of pemetrexed and matuzumab demonstrated an acceptable safety profile with the most common grade 3/4 adverse event being neutropenia Although the analysis on the pooled matuzumab-treated arms did not demonstrate a statistically significant improvement in objective response for the addition of matuzumab to pemetrexed compared with pemetrexed alone the trends for improvement in objective response and overall survival for pemetrexed plus weekly matuzumab compared with pemetrexed alone warrant confirmation in additional clinical trials\",\n",
            "}\n",
            "13090\n",
            "{\n",
            "  \"id\" : \"21502556\",\n",
            "  \"contents\" : \"Because of promising efficacy signals in single-arm studies a placebo-controlled double-blind randomized phase II trial was designed to assess the efficacy and safety of adding bevacizumab to first-line standard chemotherapy for treatment of extensive-stage small-cell lung cancer SCLC Patients with SCLC were randomly assigned to receive bevacizumab or placebo with cisplatin or carboplatin plus etoposide for four cycles followed by single-agent bevacizumab or placebo until progression or unacceptable toxicity The primary end point was progression-free survival PFS Fifty-two patients were randomly assigned to the bevacizumab group and 50 to the placebo group 69 % versus 66 % respectively completed four cycles of therapy Median PFS was higher in the bevacizumab group 55 months than in the placebo group 44 months hazard ratio [ HR ] 053 95 % CI 032 to 086 Median overall survival OS was similar for both groups 94 v 109 months for bevacizumab and placebo groups respectively with an HR of 116 95 % CI 066 to 204 Overall response rates were 58 % 95 % CI 43 % to 71 % for the bevacizumab group and 48 % 95 % CI 34 % to 62 % for the placebo group Median duration of response was 47 months for the bevacizumab group and 32 months for the placebo group In the bevacizumab and placebo groups 75 % versus 60 % of patients respectively experienced one or more grade 3 or higher adverse events No new or unexpected safety signals for bevacizumab were observed The addition of bevacizumab to cisplatin or carboplatin plus etoposide for treatment of extensive-stage SCLC improved PFS with an acceptable toxicity profile However no improvement in OS was observed\",\n",
            "}\n",
            "13091\n",
            "{\n",
            "  \"id\" : \"15566660\",\n",
            "  \"contents\" : \"The majority of cancer chemotherapy can lead to bone marrow depression which often affects clinical response as chemotherapy can not be carried out with enough dosage on time The platelets decrease is one of the problems caused by bone marrow depression Though the clinical response of hyodermic IL-11 is affirmed to advance platelets presently it is limited by expensive price Other agents that can be taken orally with suitable price and equal authenticity are less reported The author observed clinical response of platelets decrease adopting traditional Chinese medicine Sheng Ban Recipe SBR Totally 103 patients with platelets decrease after chemotherapy from July 1994 to Jannary 2002 They were randomly divided into two groups SBR plus common treatment group and common treatment alone group The previous group take 1 package SBR for twice drink per day Common treatment group give common therapy only The follow-up period is 2 weeks Among the 55 cases in SBR group noticeable efficiency 20 % efficiency 509 % total efficiency 709 % which is evidently superior to common group Sheng Ban Recipe can effectively treat thrombocytopenia after chemotherapy which helps to reduce the necessary of intravenous drip of platelets and the risk of hemorrhage\",\n",
            "}\n",
            "13092\n",
            "{\n",
            "  \"id\" : \"12364308\",\n",
            "  \"contents\" : \"Recruitment to randomised trials is often difficult and many important trials are not mounted because recruitment is thought to be impossible Controversial ProtecT prostate testing for cancer and treatment trial embedded within qualitative research Screening for prostate cancer is hotly debated and evidence from trials about the effectiveness of treatments surgery radiotherapy and monitoring is lacking Mounting a treatment trial is controversial because of past failures and concerns that differences in complications of treatment but not survival make randomisation unacceptable to patients and clinicians particularly for a trial including monitoring In-depth interviews explored interpretation of study information Audiotape recordings of recruitment appointments enabled scrutiny of content and presentation of study information by recruiters Initial qualitative findings showed that recruiters had difficulty discussing equipoise and presenting treatments equally they unknowingly used terminology that was misinterpreted by participants Findings were used to determine changes to content and presentation of information Changes to the order of presenting treatments encouraged emphasis on equivalence misinterpreted terms were avoided the non-radical arm was redefined and randomisation and clinical equipoise were presented more convincingly The randomisation rate increased from 40 % to 70 % all treatments became acceptable and the three arm trial became the preferred design Changes to information and presentation resulted in efficient recruitment acceptable to patients and clinicians Embedding this controversial trial within qualitative research improved recruitment Such methods probably have wider applicability and may enable even the most difficult evaluative questions to be tackled\",\n",
            "}\n",
            "13093\n",
            "{\n",
            "  \"id\" : \"9164203\",\n",
            "  \"contents\" : \"To assess the prognostic importance of thymidylate synthase TS expression in breast tumors of patients with early-stage breast cancer and to determine whether the benefit of chemotherapy CT is associated with TS expression The level of TS expression was evaluated in 210 node-negative and 278 node-positive patients enrolled onto Trial V of the International Breast Cancer Study Group [ IBCSG ] formerly the Ludwig Breast Cancer Study Group with a median follow-up time of 85 years TS expression was assessed using the immunohistochemical method with the monoclonal antibody TS 106 on paraffin-embedded tissue specimens High TS expression was associated with a significantly worse prognosis in node-positive but not in node-negative breast cancer patients Twenty-seven percent of node-positive patients with high TS expression were disease-free at 10 years compared with 44 % of node-positive patients with low TS expression P = 03 Forty-one percent of patients with node-positive high-TS-expressing tumors were alive after 10 years compared with 49 % of those with low TS expression P = 06 The association between TS and disease-free survival DFS and overall survival OS was independent of other prognostic factors such as tumor size tumor grade nodal status vessel invasion estrogen receptor ER / progestin receptor PR status c-erb B-2 or Ki-67 expression In node-positive patients six cycles of standard adjuvant cyclophosphamide methotrexate and fluorouracil [ 5-FU ] CMF CT improved DFS and OS compared with one cycle of perioperative CMF therapy The magnitude of this benefit was greatest in patients whose tumors had high TS expression P < 01 for DFS P < 01 for OS Node-negative patients demonstrated no difference in outcome to CT based on TS expression however the power to detect differences was limited by the small number of events in this group In early-stage breast cancer high TS expression is associated with a significantly worse prognosis in node-positive patients Node-positive patients with high TS levels demonstrate the most significant improvement in DFS and OS when treated with six cycles of conventional adjuvant CMF therapy\",\n",
            "}\n",
            "13094\n",
            "{\n",
            "  \"id\" : \"22694829\",\n",
            "  \"contents\" : \"In an international randomized Phase III trial ipilimumab demonstrated a significant overall survival benefit in previously treated advanced melanoma patients This report summarizes health-related quality of life HRQL outcomes for ipilimumab with/without gp100 vaccine compared to gp100 alone during the clinical trial s 12 week treatment induction period The Phase III clinical trial MDX010-20 was a double-blind fixed dose study in 676 previously treated advanced unresectable stage III or IV melanoma patients Patients were randomized 311 to receive either ipilimumab 3 mg/kg q3w x 4 doses + gp100 peptide vaccine 1 mg q3w x 4 doses ipilimumab plus gp100 n = 403 gp100 vaccine + placebo gp100 alone n = 136 or ipilimumab + placebo ipilimumab alone n = 137 The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire EORTC QLQ-C30 assessed HRQL Baseline to Week 12 changes in EORTC QLQ-C30 function global health status and symptom scores were analyzed for ipilimumab with/without gp100 vaccine compared to gp100 alone Mean change in scores were categorized no change 0-5 a little 5-10 points moderate 10-20 points and very much > 20 In the ipilimumab plus gp100 and ipilimumab alone groups mean changes from baseline to Week 12 generally indicated no change or a little impairment across EORTC QLQ-C30 global health status function and symptom subscales Significant differences in constipation favoring ipilimumab were observed p < 005 For ipilimumab alone arm subscales with no or a little impairment were physical emotional cognitive social function global health nausea pain dyspnea constipation and diarrhea subscales For the gp100 alone group the observed changes were moderate to large for global health role function fatigue and for pain Ipilimumab with/without gp100 vaccine does not have a significant negative HRQL impact during the treatment induction phase relative to gp100 alone in stage III or IV melanoma patients Clinicaltrialsgov identification number NCT00094653\",\n",
            "}\n",
            "13095\n",
            "{\n",
            "  \"id\" : \"25641452\",\n",
            "  \"contents\" : \"The ideal bioptic strategy for CaP detection is still to be completely defined The aim of our study is to compare transperineal TP and transrectal TR approaches in a 14-core initial prostate biopsy for CaP detection A prospective controlled study was conducted enrolling 108 consecutive patients with a PSA level greater than 4 ng/mL and/or an abnormal DRE TR versus TP 14-core initial prostatic biopsies were performed on 54 and 54 patients respectively with a randomisation ratio of 11 The cancer detection rates were 4629 25 out of 54 patients and 4444 % 24 out of 54 patients respectively using the TR or the TP approach p = 0846 The overall cancer core rate was significantly higher when the TP approach was used 2143 % 162 out of 756 cores and 1679 % 127 out of 756 cores with the TP and the TR approach respectively p = 0022 The cores were significantly longer performing TP approach at the site 1 1492 versus 1297 mm p = 002 at 5 1553 versus 1369 mm p = 0037 at 7 1506 versus 1286 mm p = 0001 at 9 1492 versus 1338 mm p = 0038 at 11 1632 versus 1231 mm p = 00001 at 12 1514 versus 1219 mm p = 00001 at 13 1749 versus 1398 mm p = 00001 at 14 1677 versus 1336 mm p = 00001 As to the biopsy related pain the mean pain level perceived by patients during the TR approach was 156 173 versus 142 137 registered during TP approach p = 0591 No significant differences were found in cancer detection rate cancer core rate between TP and TR approaches for prostatic biopsy Even in terms of complication rate or pain level it can not be concluded that one procedure is superior to the other one Apparently strictly following our protocol TP approach seems to offer a better sampling at the level of the apex and the TZ however without adding any significant advantage in terms of overall cancer detection rate\",\n",
            "}\n",
            "13096\n",
            "{\n",
            "  \"id\" : \"22504044\",\n",
            "  \"contents\" : \"The mechanisms by which trastuzumab imparts clinical benefit remain incompletely understood Antibody-dependent cellular cytotoxicity via interactions with Fc receptors FcR on leukocytes may contribute to its antitumor effects Single-nucleotide polymorphisms SNP in FCGR3A and FCGR2A genes lead to amino acid substitutions at positions 158 and 131 respectively and affect binding of antibodies to FcR such that 158V/V and 131H/H bind with highest affinity This study aimed to determine whether high-affinity SNPs are associated with disease-free survival DFS among patients with HER2-positive nonmetastatic breast cancer Genomic DNA was isolated from 1286 patients enrolled in a trial of adjuvant trastuzumab-based chemotherapy Genotyping was conducted using Sanger sequencing and Sequenom mass spectrometry Patient samples N = 1189 were successfully genotyped for FCGR3A and 1218 for FCGR2A Compared with the overall results of the BCIRG006 study in the subset of patients genotyped in this analysis a less robust improvement in DFS was observed for the trastuzumab arms than control arm HR 0842 P = 01925 When stratified for prognostic features the HR in favor of trastuzumab was consistent with that of the overall study HR 074 P = 0036 No correlation between DFS and FCGR3A/2A genotypes was seen for trastuzumab-treated patients 158V/V vs V/F vs F/F P = 098 131H/H vs H/R vs R/R P = 076 158V/V and/or 131H/H vs others P = 067 This analysis evaluating the association between FCGR3A/2A genotypes and trastuzumab efficacy in HER2-positive breast cancer did not show a correlation between FCGR3A-V/F and FCGR2A-H/R SNPs and DFS in patients treated with trastuzumab\",\n",
            "}\n",
            "13097\n",
            "{\n",
            "  \"id\" : \"12749718\",\n",
            "  \"contents\" : \"This study evaluated the joint effects of tobacco smoking and alcohol consumption on the risk of second primary tumors SPT in patients with early-stage head and neck squamous cell carcinoma HNSCC Data are presented for 1181 patients enrolled in a placebo-controlled chemoprevention trial of 13-cis-retinoic acid Nearly 17 % of patients presented with a SPT The log rank test and Cox proportional hazards model were used to examine risk factors for SPT development After adjusting for the time from the index diagnosis to randomization age at diagnosis stage and site of the primary cancer the factors that emerged as simultaneous predictors of SPT development were continued smoking and alcohol intake after the index diagnosis Increased SPT risk was associated with older age RR = 21 95 % CI 15-2 8 stage II diagnosis RR = 15 95 % CI 11-2 1 index diagnosis of pharyngeal cancer RR = 16 95 % CI 11-2 5 current smoking at registration RR = 21 95 % CI 13-3 6 and continued alcohol consumption post-diagnosis RR = 13 95 % CI 10-1 7 Important associations exist between SPT development and continued smoking and alcohol consumption after treatment for HNSCC\",\n",
            "}\n",
            "13098\n",
            "{\n",
            "  \"id\" : \"23690321\",\n",
            "  \"contents\" : \"The purpose of this study was to evaluate a primary care practice-based quality improvement QI intervention aimed at improving colorectal cancer screening rates The Supporting Colorectal Cancer Outcomes through Participatory Enhancements SCOPE study was a cluster randomized trial of New Jersey primary care practices On-site facilitation and learning collaboratives were used to engage multiple stakeholders throughout the change process to identify and implement strategies to enhance colorectal cancer screening Practices were analyzed using quantitative medical records surveys and qualitative data observations interviews and audio recordings at baseline and a 12-month follow-up Comparing intervention and control arms of the 23 participating practices did not yield statistically significant improvements in patients colorectal cancer screening rates Qualitative analyses provide insights into practices QI implementation including associations between how well leaders fostered team development and the extent to which team members felt psychologically safe Successful QI implementation did not always translate into improved screening rates Although single-target incremental QI interventions can be effective practice transformation requires enhanced organizational learning and change capacities The SCOPE model of QI may not be an optimal strategy if short-term guideline concordant numerical gains are the goal Advancing the knowledge base of QI interventions requires future reports to address how and why QI interventions work rather than simply measuring whether they work\",\n",
            "}\n",
            "13099\n",
            "{\n",
            "  \"id\" : \"12798752\",\n",
            "  \"contents\" : \"A prospective randomized study was executed comparing two regimens of regional therapy for liver metastases from colorectal cancer Eighteen patients were allocated to hepatic artery occlusion for 16 h followed by intraportal 5-fluorouracil 5-Fu infusion 1000 mg/m 2 for 5 days every sixth week HAO Twenty-one patients received intra-arterial 5-Fu infusion + Leucovorin 100 mg iv for 2 days every second week HAI The follow up every third month included CT and CEA Thirteen patients had limited extrahepatic cancer At tumor progression regional therapy was stopped and systemic chemotherapy or the best supportive care was administered The study was discontinued after randomization of 39 patients No significant difference in survival within patients with and without extrahepatic cancer was present The mean survival was longer in the HAI group than for the HAO group 19 months versus 13 months p = 00147 median 18 8-37 versus 12 2-26 PR and SD were registered in 8/18 in the HAO group and 17/21 patients in HAI group The median time to progress was 4 1-22 months versus 7 1-23 months for the HAO and HAI group respectively Regional intraarterial infusion with 5-Fu gives significantly better survival than hepatic artery occlusion followed by portal infusion A limited amount of extrahepatic cancer does not influence survival time A trial comparing hepatic artery 5-FU infusion and Leucovorin versus the most effective systemic therapy is warranted\",\n",
            "}\n",
            "13100\n",
            "{\n",
            "  \"id\" : \"25035199\",\n",
            "  \"contents\" : \"To compare hyperfractionation versus standard fractionation for T2N0 vocal cord carcinoma in a randomized controlled trial Patients with T2 vocal cord cancer were stratified by substage T2a vs T2b and randomly assigned to receive either hyperfractionation HFX to 792 Gy in 66 fractions of 12 Gy given twice a day or standard fractionation SFX to 70 Gy in 35 fractions given once a day The trial was designed to detect a 55 % reduction in the local failure hazard rate with 80 % statistical power Between April 1996 and July 2003 a total of 250 patients were enrolled Of 239 patients analyzable for outcomes 94 % were male 83 % had a Karnofsky performance status of 90-100 and 62 % had T2a tumor Median follow-up for all surviving patients was 79 years range 06-13 1 years The 5-year local control LC rate was 8 points higher but not statistically significant P = 14 for HFX [ 78 % ] vs SFX [ 70 % ] corresponding to a 30 % hazard rate reduction The 5-year disease-free survival DFS was 49 % versus 40 % P = 13 and overall survival OS was 72 % versus 63 % P = 29 HFX was associated with higher rates of acute skin mucosal and laryngeal toxicity Grade 3-4 late effects were similar with a 5-year cumulative incidence of 85 % 34 % -136 % after SFX and 85 % 34 % -135 % after HFX The 5-year local control was modestly higher with HFX compared to SFX for T2 glottic carcinoma but the difference was not statistically significant These results are consistent with prior studies of hyperfractionation showing a benefit in local control Substaging by T2a versus T2b carries prognostic value for DFS and OS For cost and convenience reasons other altered fractionation schedules have been adopted in routine practice\",\n",
            "}\n",
            "13101\n",
            "{\n",
            "  \"id\" : \"19380692\",\n",
            "  \"contents\" : \"To assess in vivo volumetric repeatability of an automated software algorithm in pulmonary nodules detected during a lung cancer screening trial This study was approved by an institutional review board Written informed consent was obtained from all participants Data were collected from the Multicentric Italian Lung Detection project a randomized controlled lung cancer screening trial The first 1236 consecutive baseline computed tomographic CT studies performed at the Istituto Nazionale Tumori of Milan were evaluated Among the enrolled participants those who underwent repeat low-dose CT after 3 months and had at least one indeterminate nodule with a volume of more than 60 mm 3 diameter of 48 mm or greater were considered Nonsolid part-solid and pleural-based nodules were excluded from this study A descriptive analysis was performed by calculating means and standard deviations of nodule volumes at three assessment times at baseline and 3 and 12 months later The volume measurement repeatability was determined by using the approach described by Bland and Altman One hundred one subjects 70 men 31 women mean age 58 years with 233 eligible nodules mean volume 983 mm 3 range 5-869 mm 3 were identified The 95 % confidence interval for difference in measured volumes was in the range of + / -27 % About 70 % of measurements had a relative difference in nodule volume of less than 10 % No malignant lesions were registered during the follow-up of these subjects Semiautomatic volumetry is sufficiently accurate and repeatable and may be useful in assisting with lung nodule management in a lung cancer screening program\",\n",
            "}\n",
            "13102\n",
            "{\n",
            "  \"id\" : \"10691065\",\n",
            "  \"contents\" : \"To investigate the impact on subject response of an information brochure and cash incentives included with mailed questionnaires in case-control studies A randomized trial was carried out within a case-control study investigating cancer in the Province of Ontario Brochures were included with half of the mailed questionnaires sent to 7487 cases and 2561 controls Controls were also sent cash incentives of $ 2 $ 5 or no money With the brochure response changed from 750 % to 758 % in cases and from 703 % to 711 % in controls Adjusting for differences in age residence sex and cancer site/status the change was 02 % [ 95 % confidence interval CI = -17 -21 ] in cases and 06 % 95 % CI = -31 -43 in controls The $ 2 and $ 5 incentives increased overall response in controls from 619 % to 728 % and 772 % respectively ie by 109 % 95 % CI = 61-15 6 and 151 % 95 % CI = 104-19 7 after adjustment This effect was largely confined to urban areas for $ 2 and $ 5 respectively 55 % and 142 % in Toronto 153 % and 204 % in other urban areas vs 27 % and 10 % in rural areas p = 002 Response time showed little or no improvement when the brochure was included but was markedly reduced for both the $ 2 and $ 5 incentives Cash incentives can improve subject response in epidemiologic studies whereas information brochures do not appear to have an effect\",\n",
            "}\n",
            "13103\n",
            "{\n",
            "  \"id\" : \"19347940\",\n",
            "  \"contents\" : \"Oral mucositis is a dose-limiting and painful side effect of radiotherapy RT and/or chemotherapy in cancer patients The purpose of the present study was to analyze the effect of different protocols of laser phototherapy LPT on the grade of mucositis and degree of pain in patients under RT Thirty-nine patients were divided into three groups G1 where the irradiations were done three times a week using low power laser G2 where combined high and low power lasers were used three time a week and G3 where patients received low power laser irradiation once a week The low power LPT was done using an InGaAlP laser 660 nm/40 mW/6 J cm -2 / 024 J per point In the combined protocol the high power LPT was done using a GaAlAs laser 808 nm 1 W/cm 2 Oral mucositis was assessed at each LPT session in accordance to the oral-mucositis scale of the National Institute of the Cancer-Common Toxicity criteria NIC-CTC The patient self-assessed pain was measured by means of the visual analogue scale All protocols of LPT led to the maintenance of oral mucositis scores in the same levels until the last RT session Moreover LPT three times a week also maintained the pain levels However the patients submitted to the once a week LPT had significant pain increase and the association of low/high LPT led to increased healing time These findings are desired when dealing with oncologic patients under RT avoiding unplanned radiation treatment breaks and additional hospital costs\",\n",
            "}\n",
            "13104\n",
            "{\n",
            "  \"id\" : \"21626363\",\n",
            "  \"contents\" : \"To determine patient acceptability of barium enema BE or CT colonography CTC After ethical approval 921 consenting patients with symptoms suggestive of colorectal cancer who had been randomly assigned and completed either BE N = 606 or CTC N = 315 received a questionnaire to assess experience of the clinical episode including bowel preparation procedure and complications Satisfaction worry and physical discomfort were assessed using an adapted version of a validated acceptability scale Non-parametric methods assessed differences between the randomised tests and the effect of patient characteristics Patients undergoing BE were significantly less satisfied median 61 interquartile range [ IQR ] 54-67 vs median 64 IQR 56-69 p = 0003 and experienced more physical discomfort median 40 IQR 29-52 vs median 355 IQR 25-47 p < 0001 than those undergoing CTC Post-test BE patients were significantly more likely to experience abdominal pain/cramps 68 % vs 57 % p = 0007 soreness 57 % vs 37 % p < 0001 nausea/vomiting 16 % vs 8 % p = 0009 soiling 31 % vs 23 % p = 0034 and wind 92 % vs 84 % p = 0001 and in the case of wind to also rate it as severe 27 % vs 15 % p < 0001 CTC is associated with significant improvements in patient experience These data support the case for CTC to replace BE\",\n",
            "}\n",
            "13105\n",
            "{\n",
            "  \"id\" : \"12789464\",\n",
            "  \"contents\" : \"Experimental and clinical data suggest a reduction of radiation-induced acute toxicity by amifostine A We investigated this issue in a randomized trial comparing radiochemotherapy RT + CT versus radiochemotherapy plus amifostine RC + CT + A in patients with head and neck cancer 56 patients with oro - / hypopharynx or larynx cancer T1-2 N1-2 G3 T3-4 N0-2 G1-3 were randomized to receive RC + CT alone or RC + CT + A Patients were irradiated up to 60 Gy R0 or 70 Gy R1/2 and received chemotherapy 70 mg/m 2 carboplatin day 1-5 in week 1 and 5 of radiotherapy 250 mg amifostine were applied daily before each radiotherapy session Acute toxicity was evaluated according to the Common Toxicity Criteria CTC As for acute xerostomia patients with laryngeal cancer were excluded from evaluation 50 patients were evaluable 25 patients in the RC + CT 25 patients in the RC + CT + A group Clinical characteristics were well balanced in both treatment groups Amifostine provided reduction in acute xerostomia and mucositis but had no obvious influence on Karnofsky performance status body weight cutaneous side effects and alopecia The differences between both groups were statistically significant for acute xerostomia and nonsignificant but with a trend for mucositis According to our results there is a radioprotective effect on salivary glands and a potential effect on oral mucosa by amifostine in postoperative radiotherapy combined with carboplatin To improve the radio - and chemoprotective effects of amifostine in clinical practice the application of a higher dose > 250 mg seems to be necessary\",\n",
            "}\n",
            "13106\n",
            "{\n",
            "  \"id\" : \"23739063\",\n",
            "  \"contents\" : \"Certain somatic alterations in breast cancer can define prognosis and response to therapy This study investigated the frequencies prognostic effects and predictive effects of known cancer somatic mutations using a randomized adjuvant phase III clinical trial dataset The FinHER trial was a phase III randomized adjuvant breast cancer trial involving 1010 women Patients with human epidermal growth factor receptor 2 HER2 - positive breast cancer were further randomized to 9 weeks of trastuzumab or no trastuzumab Seven hundred five of 1010 tumors had sufficient DNA for genotyping of 70 somatic hotspot mutations in 20 genes using mass spectrometry Distant disease-free survival DDFS overall survival OS and interactions with trastuzumab were explored with Kaplan-Meier and Cox regression analyses All statistical tests were two-sided Median follow-up was 62 months Of 705 tumors 687 were successfully genotyped PIK3CA mutations exons 1 2 4 9 13 18 and 20 were present in 253 % 174 of 687 and TP53 mutations in 102 % 70 of 687 Few other mutations were found three ERBB2 and single cases of KRAS ALK STK11/LKB1 and AKT2 PIK3CA mutations were associated with estrogen receptor positivity P < 001 and the luminal-A phenotype P = 04 but were not statistically significantly associated with prognosis DDFS hazard ratio [ HR ] = 088 95 % confidence [ CI ] = 058 to 134 P = 56 OS HR = 0603 95 % CI = 32 to 113 P = 11 although a statistically significant nonproportional prognostic effect was observed for DDFS P = 002 PIK3CA mutations were not statistically significantly associated with trastuzumab benefit P interaction DDFS P = 14 OS P = 24 In this dataset targeted genotyping revealed only two alterations at a frequency greater than 10 % with other mutations observed infrequently PIK3CA mutations were associated with a better outcome however this effect disappeared after 3 years There were no statistically significant associations with trastuzumab benefit\",\n",
            "}\n",
            "13107\n",
            "{\n",
            "  \"id\" : \"12667380\",\n",
            "  \"contents\" : \"To evaluate the roles of folic acid and beta-carotene in the chemoprevention of gastric and other gastrointestinal GI cancers In a randomized double-blind placebo-controlled trial a total of 216 patients with atrophic gastritis were randomly assigned to one of the four groups 1 folate FA 20 mg per day plus vitamin B 12 1 mg intramuscularly per month for one year then 20 mg two times a week plus 1 mg per three months for the next year 2 natural beta-carotene N-betaC 30 mg per day for first year then 30 mg two times a week for the next 3 synthetic beta-carotene S-betaC administered as in N-betaC and 4 placebo Follow-ups continued from 1994 to 2001 A total of 7 new cases of gastrointestinal cancers were diagnosed with 3 stomach 1 colon and 1 esophageal cancers occurring in the placebo group 1 stomach cancer in both of the N-betaC and S-betaC groups and no cancer occurring in FA group In terms of GI cancers there was a significant reduction in the FA group compared with the placebo group P = 004 A similar trend was observed in both N-betaC and S-betaC groups P = 007 - 008 Taken together the three intervention groups displayed a highly significant decrease in occurrence P = 0004 vs placebo and a lower risk for GI cancers OR = 012 95 % confidence interval 003 - 051 For development of gastric cancer any one of the three active-treated groups did not reach statistically significant reduction The FA group showed obvious improvement of the gastric mucosal lesions with more patients displaying lesions reversed or stable atrophy and inflammation P = 004 reversed intestinal metaplasia P = 006 at the end of follow-up and reversed displasia P = 0017 at 12 months Two cases of false jaundice were found in beta-carotene groups with no influence on administration and no side-effects were reported in FA group This trial revealed the interventional effect of folic acid on the development of GI cancers a similar effect of beta-carotene was also detected Also folic acid may be of use to treat atrophic gastritis by preventing or reversing the precancerous lesions\",\n",
            "}\n",
            "13108\n",
            "{\n",
            "  \"id\" : \"22243774\",\n",
            "  \"contents\" : \"S-1 or capecitabine plus oxaliplatin are considered active and tolerable in gastric cancer patients We conducted a randomized phase II trial in gastric cancer patients to compare the activity and safety of these combinations The patients received S-1 at 80 mg/m2 for 14 days followed by a 7-day rest period within a 3-week schedule in the S-1 / oxaliplatin SOX arm and capecitabine at 2000 mg/m2 for 14 days followed by a 7-day rest period within a 3-week schedule in the capecitabine/oxaliplatin CAPOX arm Oxaliplatin 130 mg/m2 was administered every 3 weeks in both arms One hundred twenty-nine patients were randomly assigned to SOX N = 65 or CAPOX N = 64 The median time to progression and the overall survival were 62 and 124 months with SOX respectively and 72 and 133 months with CAPOX respectively The overall response rates were 40 % and 44 % for SOX and CAPOX respectively The most frequent grade 3 or 4 toxicities were thrombocytopenia 154 % for SOX and neutropenia 188 % for CAPOX The median time to 10 % deteriorations in global health scores was similar in both arms SOX 43 months CAPOX 49 months Both the SOX and CAPOX regimens were equally active and well tolerated in advanced gastric cancer patients\",\n",
            "}\n",
            "13109\n",
            "{\n",
            "  \"id\" : \"18492416\",\n",
            "  \"contents\" : \"Breast cancer is the most common type of cancer in women worldwide In Mexico > 34 % of patients are in locally advanced stages at the time of diagnosis Neoadjuvant chemotherapy is administered to control local disease make surgical resection possible and increase the possibility of breast tissue conservation We performed a double-blind randomized clinical trial in patients with locally advanced breast cancer stages IIB and IIIA with two therapy schemes 5-fluorouracil-epirubicin-cyclophosphamide control group vs docetaxel-epirubicin study group Both were indicated in three preoperative cycles and patients were submitted afterwards to surgery Pathological response was measured Forty one patients were included in our study They were distributed in two homogeneous groups 21 in the control group and 20 in the study group Dimensional pathological response was higher in the study group than in the control one p < 005 Five patients in the control group and ten patients of the study group experienced complete pathological response p < 005 The most common secondary events were leucopenia neutropenia and fever Morbidity number of lymph nodes disease-free survival and general survival did not show significant differences between groups No mortality was reported during a minimum follow-up of 28 months Our results confirm the effectiveness of docetaxel-epirubicin to obtain complete pathological response Neoadjuvant therapy has been shown to increase the pathological response when a taxane is added to an anthracycline This combination presented more secondary events but they can be effectively managed medically Neoadjuvant docetaxel-epirubicin followed by surgery is an appropriate regimen for patients with locally advanced breast cancer\",\n",
            "}\n",
            "13110\n",
            "{\n",
            "  \"id\" : \"25439694\",\n",
            "  \"contents\" : \"Primary results from the phase 3 ALSYMPCA trial showed that radium-223 dichloride radium-223 a targeted - emitter improved overall survival compared with placebo and was well tolerated in patients with castration-resistant prostate cancer and symptomatic bone metastases We did a prespecified subgroup analysis from ALSYMPCA to assess the effect of previous docetaxel use on the efficacy and safety of radium-223 In the phase 3 randomised double-blind ALSYMPCA trial patients with symptomatic castration-resistant prostate cancer at least two symptomatic bone metastases no known visceral metastases and who were receiving best standard of care were randomly assigned 21 via an interactive voice response system to receive six injections of radium-223 50 kBq/kg intravenously or matching placebo with one injection given every 4 weeks Patients had either received previous docetaxel treatment or were unsuitable for or declined docetaxel previous docetaxel use yes or no was a trial stratification factor We investigated the effect of previous docetaxel use on radium-223 treatment for the primary endpoint of overall survival the main secondary efficacy endpoints and safety Efficacy analyses were done for the intention-to-treat population safety analyses were done for the safety population The trial has been completed and is registered with ClinicalTrialsgov number NCT00699751 Randomisation took place between June 12 2008 and Feb 1 2011526 57 % of 921 randomly assigned patients had received previous docetaxel treatment 352 in the radium-223 group and 174 in the placebo group and 395 43 % had not 262 in the radium-223 group and 133 in the placebo group Radium-223 prolonged median overall survival compared with placebo irrespective of previous docetaxel use previous docetaxel use hazard ratio [ HR ] 070 95 % CI 056-088 p = 0002 no previous docetaxel use HR 069 052-092 p = 001 The benefit of radium-223 compared with placebo was seen in both docetaxel subgroups for most main secondary efficacy endpoints risk for time to time to first symptomatic skeletal event was reduced with radium-223 versus placebo in patients with previous docetaxel use but the difference was not significant in those with no previous docetaxel use 322 62 % of 518 patients previously treated with docetaxel had grade 3-4 adverse events compared with 205 54 % of 383 patients without docetaxel Patients who had previously been treated with docetaxel had a higher incidence of grade 3-4 thrombocytopenia with radium-223 than with placebo 31 [ 9 % ] of 347 patients vs five [ 3 % ] of 171 patients whereas the incidence was similar between treatment groups among patients with no previous docetaxel use seven [ 3 % ] of 253 patients vs one [ 1 % ] of 130 patients The incidences of grade 3-4 anaemia and neutropenia were similar between the radium-223 and placebo groups within both docetaxel subgroups Radium-223 is effective and well tolerated in patients with castration-resistant prostate cancer and symptomatic bone metastases irrespective of previous docetaxel use Algeta ASA and Bayer HealthCare Pharmaceuticals\",\n",
            "}\n",
            "13111\n",
            "{\n",
            "  \"id\" : \"12930422\",\n",
            "  \"contents\" : \"To compare the efficacy of lycopene plus orchidectomy with orchidectomy alone in the management of advanced prostate cancer Fifty-four patients with histologically confirmed metastatic prostatic cancer M1b or D2 and a performance status of 0-2 World Health Organization were entered into the trial between March 2000 and June 2002 The trial comprised two treatment arms ie patients were randomized to orchidectomy alone or orchidectomy plus lycopene OL each of 27 patients Lycopene was started on the day of orchidectomy at 2 mg twice daily Patients were evaluated clinically before and every 3 months after the intervention with measurements of prostate-specific antigen PSA a bone scan and uroflowmetry with the clinical response assessed as the change in these variables At 6 months there was a significant reduction in PSA level in both treatments but more marked in the OL group mean 91 and 264 ng/mL P = 09 After 2 years these changes were more consistent in the OL group mean 301 and 902 ng/mL P < 0001 Eleven 40 % patients in orchidectomy and 21 78 % in the OL group had a complete PSA response P < 005 with a partial response in nine 33 % and four 15 % and progression in seven 25 % and two 7 % respectively P < 005 Bone scans showed that in the orchidectomy arm only four 15 % patients had a complete response vs eight 30 % in the OL group P < 002 with a partial response in 19 70 % and 17 63 % and progression in four 15 % and two 7 % respectively P < 002 There was a significant improvement in peak flow rate in the OL group with a mean difference of +117 mL/s P < 004 Of the 54 patients who entered the trial 19 35 % died 12 22 % in orchidectomy and seven 13 % in OL group P < 0001 Adding lycopene to orchidectomy produced a more reliable and consistent decrease in serum PSA level it not only shrinks the primary tumour but also diminishes the secondary tumours providing better relief from bone pain and lower urinary tract symptoms and improving survival compared with orchidectomy alone\",\n",
            "}\n",
            "13112\n",
            "{\n",
            "  \"id\" : \"16281501\",\n",
            "  \"contents\" : \"To investigate the expressions of telomerase reverse transcriptase TRT and vascular endothelial growth factor VEGF and their correlation in prostate cancer PCa TRT and VEGF expressions were assayed in 30 cases of PCa and 30 cases of benign prostatic hyperplasia BPH by means of immunohistochemistry SP combined with computer assisted image analysis The expression of TRT was detected in 19 of the 30 cases of PCa and 5 of 30 cases of BPH and that of VEGF in 23 of the 30 PCa and 14 of the 30 BPH patients TRT and VEGF expressions were significantly higher in cancer tissues than in BPH P < 005 A significant correlation was observed between TRT and VEGF expressions r = 08333 P < 005 The expression of TRT or VEGF might be a malignant phenotype in PCa The expression of TRT is significantly correlated with that of VEGF but the mechanisms are yet to be further studied\",\n",
            "}\n",
            "13113\n",
            "{\n",
            "  \"id\" : \"23352604\",\n",
            "  \"contents\" : \"The combination of bevacizumab and bolus 5-fluorouracil leucovorin and irinotecan is highly effective in patients with metastatic colorectal cancer mCRC This randomised multicenter non-comparative phase II trial assessed the efficacy and safety of bevacizumab plus oral capecitabine plus irinotecan XELIRI or infusional 5-fluorouracil leucovorin plus irinotecan FOLFIRI as first-line therapy for patients with mCRC Patients received bevacizumab 75 mg/kg on day 1 plus XELIRI irinotecan 200mg/m 2 on day 1 and oral capecitabine 1000 mg/m 2 bid on days 1-14 every 3 weeks or bevacizumab 5mg/kg on day 1 plus FOLFIRI 5-fluorouracil 400mg/m 2 on day 1 plus 2400 mg/m 2 as a 46-h infusion leucovorin 400mg/m 2 on day 1 and irinotecan 180 mg/m 2 on day 1 every 2 weeks Patients aged 65 years received a lower dose of capecitabine 800 mg/m 2 twice daily The primary endpoint was 6-month progression-free survival PFS rate A total of 145 patients were enrolled bevacizumab-XELIRI n = 72 bevacizumab-FOLFIRI n = 73 The 6-month PFS rate was 82 % 95 % confidence intervals CI 71-90 % in the bevacizumab-XELIRI arm and 85 % 95 % CI 75-92 % in the bevacizumab-FOLFIRI arm In both the bevacizumab-XELIRI and bevacizumab-FOLFIRI arms median PFS and overall survival OS were 9 and 23 months respectively The most frequent toxicities were grade 3/4 neutropenia bevacizumab-XELIRI 18 % bevacizumab-FOLFIRI 26 % and grade 3 diarrhoea 12 % and 5 % respectively This randomised non-comparative study demonstrates that bevacizumab-XELIRI and bevacizumab-FOLFIRI are effective regimens for the first-line treatment of patients with mCRC with manageable toxicity profiles\",\n",
            "}\n",
            "13114\n",
            "{\n",
            "  \"id\" : \"18174609\",\n",
            "  \"contents\" : \"This paper evaluates the prognostic and predictive impact of protein expression of various molecular markers in high-risk breast cancer HRBC patients with > 9 involved lymph nodes who received different chemotherapy dose-intensification strategies within a prospective randomized WSG AM-01 trial Paraffin-embedded tumors from 236 patients who were randomly assigned to dose-dense conventional chemotherapy with four cycles of E 90 C 600 followed by three cycles of C 600 M 40 F 600 every 2 weeks DD or a rapidly cycled tandem high-dose regimen with two cycles of E 90 C 600 every 2 weeks followed by two cycles of E 90 C 3000 Thiotepa 400 every 3 weeks HD were available for retrospective central pathological review 116 HD/120 DD Expression of estrogen receptor ER progesterone receptor PR MIB-1 epidermal growth factor receptor and Her-2 / neu was evaluated immunohistochemically using tissue microarrays Results were correlated with follow-up data and treatment effects by proportional hazard Cox regression models including interaction analysis After a median follow-up of 617 months 5-year event-free survival EFS as well as overall survival OS rates for the 236 patients were significantly better in the HD arm EFS 62 % versus 41 % [ hazard ratio HR = 060 95 % CI 043-0 85 P = 0004 ] OS 76 % versus 61 % HR = 058 95 % CI 039-0 87 P = 0007 In multivariate analysis HD tumor size < 3 cm positive PR negative MIB-1 staining and grade 1/2 were associated with favorable outcome Interaction analysis showed that regarding predictive effects triple negative ER/PR/Her -2 / neu and G3 tumors derived most benefit from HD Tandem HD improves both EFS and OS in HRBC This therapy effect may be partly attributable to superior efficacy in the subgroup of triple-negative tumors and/or G3 with their poor prognostic marker profile\",\n",
            "}\n",
            "13115\n",
            "{\n",
            "  \"id\" : \"12153376\",\n",
            "  \"contents\" : \"The use of warfarin sodium for treating venous thromboembolism in patients with cancer is associated with a significant risk of recurrence and bleeding The use of low-molecular-weight heparin sodium for secondary prevention of venous thromboembolism in cancer patients may reduce the complication rate To determine whether a fixed dose of subcutaneous low-molecular-weight heparin is superior to oral warfarin for the secondary prophylaxis of venous thromboembolism in patients with cancer and venous thromboembolism In a randomized open-label multicenter trial performed between April 1995 and March 1999 we compared subcutaneous enoxaparin sodium 15 mg/kg once a day with warfarin given for 3 months in 146 patients with venous thromboembolism and cancer A combined outcome event defined as major bleeding or recurrent venous thromboembolism within 3 months Of the 71 evaluable patients assigned to receive warfarin 15 211 % 95 % confidence interval [ CI ] 123 % -324 % experienced one major outcome event compared with 7 105 % of the 67 evaluable patients assigned to receive enoxaparin 95 % CI 43 % -203 % P = 09 There were 6 deaths owing to hemorrhage in the warfarin group compared with none in the enoxaparin group In the warfarin group 17 patients 227 % died 95 % CI 138 % -338 % compared with 8 113 % in the enoxaparin group 95 % CI 50 % -210 % P = 07 No difference was observed regarding the progression of the underlying cancer or cancer-related death These results confirm that warfarin is associated with a high bleeding rate in patients with venous thromboembolism and cancer Prolonged treatment with low-molecular-weight heparin may be as effective as oral anticoagulants and may be safer in these cancer patients\",\n",
            "}\n",
            "13116\n",
            "{\n",
            "  \"id\" : \"23821379\",\n",
            "  \"contents\" : \"Cancer often affects the quality of life and well-being of patients as well as their relatives Previous studies have suggested that relatives should be involved in psychosocial rehabilitation to address the needs for an interpersonal relationship with others in the disease trajectory We developed an innovative rehabilitation program to be offered to the patient and a relative as a pair The aim of the present pilot study was to examine the feasibility of the intervention in a randomized controlled trial RCT and to evaluate the impact on quality of life The study was designed as an RCT comparing the new multimodal psychosocial rehabilitation with the usual services The intervention comprised three supportive talks and a residential rehabilitation course From March 2010 to March 2011 participation was offered at the time of diagnosis to patients with lung or gynecological cancer from two departments at Odense University Hospital in Denmark Questionnaires were used to estimate changes in quality of life EORTC-QLQ-C30 on global health status and well-being WHO-Five Well-Being Index at baseline and after 2 and 12 months Information on the participants views about the rehabilitation intervention was obtained from assessment charts and qualitative interviews A total of 209 patients were assessed for eligibility but only 42 pairs were randomized to the study The 2-month follow-up was completed by 34 patients and 32 relatives and 19 patients and 21 relatives completed the 12-month follow-up A higher dropout rate at the 12-month follow-up was reported in the intervention group compared with controls Quality of life and well-being increased for patients and relatives in both the intervention and the control group and no clinically significant difference was observed between the intervention and the control group Pairs reported that the time of inclusion was inconvenient and that rehabilitation ought to meet their changing needs The pilot study showed that it may be difficult to conduct an RCT of a psychosocial rehabilitation intervention for pairs and difficulties with inclusion and drop out have to be addressed Interventions need to be carefully developed and tested before evaluating an effect in a large-scale study\",\n",
            "}\n",
            "13117\n",
            "{\n",
            "  \"id\" : \"20334685\",\n",
            "  \"contents\" : \"In the HPV FOCAL trial we will establish the efficacy of hr-HPV DNA testing as a stand-alone screening test followed by liquid based cytology LBC triage of hr-HPV-positive women compared to LBC followed by hr-HPV triage with > or = CIN3 as the outcome HPV-FOCAL is a randomized controlled three-armed study over a four year period conducted in British Columbia It will recruit 33000 women aged 25-65 through the province s population based cervical cancer screening program Control arm LBC at entry and two years and combined LBC and hr-HPV at four years among those with initial negative results and hr-HPV triage of ASCUS cases Two Year Safety Check arm hr-HPV at entry and LBC at two years in those with initial negative results with LBC triage of hr-HPV positives Four Year Intervention Arm hr-HPV at entry and combined hr-HPV and LBC at four years among those with initial negative results with LBC triage of hr-HPV positive casesTo date 6150 participants have a completed sample and epidemiologic questionnaire Of the 2019 women enrolled in the control arm 1908 945 % were cytology negative Women aged 25-29 had the highest rates of HSIL 14 % In the safety arm 922 % of women were hr-HPV negative with the highest rate of hr-HPV positivity found in 25-29 year old women 235 % Similar results were obtained in the intervention arm HPV FOCAL is the first randomized trial in North America to examine hr-HPV testing as the primary screen for cervical cancer within a population-based cervical cancer screening program International Standard Randomised Controlled Trial Number Register ISRCTN79347302\",\n",
            "}\n",
            "13118\n",
            "{\n",
            "  \"id\" : \"19309726\",\n",
            "  \"contents\" : \"To determine if depression portends a worse prognosis in patients with head and neck cancer we conducted a retrospective chart analysis of subjects who participated in a randomized placebo-controlled trial of citalopram for the prevention of depression during head and neck cancer treatment Thirty-five patients were randomized 34 with 1 or more evaluations form the basis of this report We used the Hamilton Depression Rating Scale HDRS with a minimum follow-up of 24 months if no evidence of disease or until recurrence or death from disease Fourteen of 34 subjects were depressed at any time during the 16 week RCT HAMD > 15 Seven of the 14 subjects in the depressed group were dead from disease or had recurrence compared to 4 of 20 who never developed depression p = 03 Stage of disease was equivalent in the 2 groups This study suggests that depression in patients with head and neck cancer reduces survival\",\n",
            "}\n",
            "13119\n",
            "{\n",
            "  \"id\" : \"25923550\",\n",
            "  \"contents\" : \"Non-small-cell lung cancer NSCLC with a mutation in the gene encoding epidermal growth factor receptor EGFR is sensitive to approved EGFR inhibitors but resistance develops mediated by the T790M EGFR mutation in most cases Rociletinib CO-1686 is an EGFR inhibitor active in preclinical models of EGFR-mutated NSCLC with or without T790M In this phase 1-2 study we administered rociletinib to patients with EGFR-mutated NSCLC who had disease progression during previous treatment with an existing EGFR inhibitor In the expansion phase 2 part of the study patients with T790M-positive disease received rociletinib at a dose of 500 mg twice daily 625 mg twice daily or 750 mg twice daily Key objectives were assessment of safety side-effect profile pharmacokinetics and preliminary antitumor activity of rociletinib Tumor biopsies to identify T790M were performed during screening Treatment was administered in continuous 21-day cycles A total of 130 patients were enrolled The first 57 patients to be enrolled received the free-base form of rociletinib 150 mg once daily to 900 mg twice daily The remaining patients received the hydrogen bromide salt HBr form 500 mg twice daily to 1000 mg twice daily A maximum tolerated dose the highest dose associated with a rate of dose-limiting toxic effects of less than 33 % was not identified The only common dose-limiting adverse event was hyperglycemia In an efficacy analysis that included patients who received free-base rociletinib at a dose of 900 mg twice daily or the HBr form at any dose the objective response rate among the 46 patients with T790M-positive disease who could be evaluated was 59 % 95 % confidence interval [ CI ] 45 to 73 and the rate among the 17 patients with T790M-negative disease who could be evaluated was 29 % 95 % CI 8 to 51 Rociletinib was active in patients with EGFR-mutated NSCLC associated with the T790M resistance mutation Funded by Clovis Oncology ClinicalTrialsgov number NCT01526928\",\n",
            "}\n",
            "13120\n",
            "{\n",
            "  \"id\" : \"25572008\",\n",
            "  \"contents\" : \"Renal impairment in cancer patients can affect treatment tolerability and outcomes This analysis evaluated the safety and efficacy of nab-paclitaxel nab-P versus solvent-based paclitaxel sb-P both in combination with carboplatin C in patients with advanced non-small-cell lung cancer NSCLC and renal impairment Untreated patients with stage IIIB/IV disease with NSCLC and a performance status of 0/1 were randomly assigned 11 to receive 100 mg/m 2 nab-P weekly plus C under the curve = 6 every 3 weeks or 200 mg/m 2 sb-P plus C under the curve = 6 every 3 weeks The primary end point was overall response rate Of 1038 treated patients in the phase III trial 38 % had mild renal impairment creatinine clearance > 50 to 80 mL/min n = 198 for nab-P/C and n = 206 for sb-P/C and 5 % had moderate renal impairment creatinine clearance 50 mL/min n = 26 for nab-P/C and n = 27 for sb-P/C For nab-P/C versus sb-P/C the treatment difference in efficacy in patients with either level of renal impairment was comparable to the overall population but did not reach statistical significance with an overall response rate of 35 % versus 27 % response rate ratio 1324 P = 060 in patients with mild renal impairment and 31 % versus 19 % response rate ratio 1662 P = 300 in patients with moderate renal impairment Overall survival and progression-free survival were nonsignificantly longer for nab-P/C versus sb-P/C in these subsets Patients with renal impairment experienced less grade 3 or higher neutropenia and sensory neuropathy but more thrombocytopenia and anemia with nab-P/C versus sb-P/C nab-P/C proved beneficial and tolerable in patients with advanced NSCLC and mild and moderate renal impairment\",\n",
            "}\n",
            "13121\n",
            "{\n",
            "  \"id\" : \"18323548\",\n",
            "  \"contents\" : \"Preclinical data showed that the combination of exemestane and celecoxib has synergistic effects Therefore a study was undertaken to explore the efficacy and tolerability of this combination in postmenopausal patients with advanced hormone-sensitive breast cancer A randomized phase II study was conducted in postmenopausal patients with hormone-sensitive breast cancer and measurable disease who had progressive disease after treatment with tamoxifen Patients were randomly assigned to either exemestane 25 mg daily or the combination of exemestane 25 mg daily with celecoxib 400 mg twice daily Response Evaluation Criteria in Solid Tumors Group criteria were used to determine antitumor efficacy Primary end point was the rate of clinical benefit Secondary end points were tolerability objective response rate time to progression TTP and duration of clinical benefit A pharmacodynamic and a pharmacokinetic study were conducted in parallel One hundred eleven patients exemestane n = 55 combination n = 56 were enrolled in 2002 The demographic characteristics and prognostic factors were similar in both arms In the assessable population 24 of 51 patients in the combination arm and 24 of 49 patients in the exemestane arm achieved clinical benefit TTP was similar in both groups Duration of clinical benefit was longer in the combination group median 966 v 491 weeks The addition of celecoxib did not change the tolerability profile of exemestane alone Similar rates of clinical benefit were achieved in both groups\",\n",
            "}\n",
            "13122\n",
            "{\n",
            "  \"id\" : \"25403211\",\n",
            "  \"contents\" : \"To assess the effectiveness of a telephone-based peer-delivered intervention in reducing distress among women with a BRCA1 or BRCA2 gene mutation The intervention involved trained peer volunteers contacting women multiple times over a 4-month period to provide informational emotional and practical support Three hundred thirty-seven participants completed the baseline questionnaire and those reporting interest in talking to other mutation carriers were randomly assigned to either the usual care group UCG n = 102 or the intervention group IG n = 105 Participants and researchers were not blinded to group allocation Two follow-up questionnaires were completed one at the end of the intervention 4 months after random assignment time 2 and one 2 months later time 3 Outcomes included breast cancer distress primary outcome unmet information needs cognitive appraisals about mutation testing and feelings of isolation There was a greater decrease in breast cancer distress scores in the IG than UCG at time 2 mean difference -596 95 % CI -980 to -212 P = 002 and time 3 mean difference -394 95 % CI -770 to -017 P = 04 There was a greater reduction in unmet information needs in the IG than UCG P < 01 with unmet needs being lower in the IG than UCG at time 2 There was a greater reduction in Cognitive Appraisals About Genetic Testing stress subscale scores in the IG than UCG P = 02 with significantly lower scores among the IG than UCG at time 2 P < 01 The intervention is effective in reducing distress and unmet information needs for this group of women Identifying strategies for prolonging intervention effects is warranted\",\n",
            "}\n",
            "13123\n",
            "{\n",
            "  \"id\" : \"21796050\",\n",
            "  \"contents\" : \"This study theoretically based on the Exercise Self-Esteem Model EXSEM examined effects of exercise modality on physical and global self-esteem PSE GSE in breast cancer survivors The EXSEM posits GSE at the apex with PSE feeding into GSE PSE has three subdomains physical condition PC attractive body AB and physical strength PS The goals were to compare the effect of combination modality versus single-modality exercise on PSE and GSE and to explore the relationship between exercise modality and the subdomains of PSE Survivors were randomly allocated to flexibility F aerobic A resistance R or aerobic plus resistance AR 12-wk individualized home-based exercise program Pre/posttesting included submaximal treadmill test six-repetition maximum chest press and leg press YMCA bench press shoulder/hip flexibility and bioelectric impedance analysis body composition Esteem measures were the Physical Self-Perception Profile and the Rosenberg Self-Esteem Scale Forty-two women completed the study F = 12 A = 10 R = 9 and AR = 11 Fitness improvements congruent with exercise modality were seen in all groups PSE and GSE outcomes did not reveal a greater effect from the combination modality program AR compared with the single-modality programs A and RThe relationships between the single-modality groups and the subdomains of PC PS and AB were supported in the R group PS and AB increased and were partially supported in the A group PC not AB increased A single-modality R program significantly improved all domains of PSE and participation in the A program improved the PC subdomain The combination exercise program did not enhance PSE greater than the single-modality programs EXSEM was a useful framework for exploring esteem in breast cancer survivors\",\n",
            "}\n",
            "13124\n",
            "{\n",
            "  \"id\" : \"23497838\",\n",
            "  \"contents\" : \"Despite a fairly good prognosis many breast-cancer patients suffer from symptoms such as anxiety depression and fatigue which may affect health-related quality of life and may persist for several years The aim of the present study was to perform a long-term follow-up of a randomized study of support group intervention in women after primary breast cancer treatment Three hundred and eighty two women with primary breast cancer were randomized to support group intervention or control group 181 in each group Women in the intervention group participated in 1 week of intervention followed by 4 days of follow-up 2 months later This is a long-term follow-up undertaken in average 65 years after randomization Patients answered the questionnaires the European Organisation for Research and Treatment of Cancer quality of life questionnaire EORTC QLQ-C30 and the breast cancer module questionnaire BR 23 the hospital anxiety and depression scale HAD and the Norwegian version of the fatigue scale FQ After adjusting for treatment with chemotherapy age marriage education and children at home there was a significant improvement in physical mental and total fatigue FQ cognitive function body image and future perspective EORTC QLQ C30 and BR23 in the intervention group compared with controls The proportion of women affected by high anxiety and depression scores were not significantly different between the groups Support intervention significantly improved cognitive function body image future perspective and fatigue compared with to the findings in the control group\",\n",
            "}\n",
            "13125\n",
            "{\n",
            "  \"id\" : \"24812024\",\n",
            "  \"contents\" : \"Lower concentrations of serum bilirubin an endogenous antioxidant have been associated with risk of many smoking-related diseases including lung cancer and cardiovascular disease and current smokers are reported to have lower bilirubin levels than nonsmokers and past smokers This study evaluates the effects of smoking cessation on bilirubin levels In a secondary analysis of a 6-week placebo-controlled trial of naltrexone for smoking cessation indirect and total bilirubin concentrations were evaluated at baseline and following smoking cessation Individuals who were continuously abstinent for 6 weeks n = 155 were compared to those who were not n = 193 Participants reported smoking 20 cigarettes daily at baseline and received smoking cessation counseling 21 mg nicotine patch daily and either placebo or 1 of 3 doses of naltrexone 25 50 or 100mg for 6 weeks Change in indirect and total bilirubin following the quit date was measured at Weeks 1 4 and 6 compared to baseline Individuals who were continuously abstinent from smoking independent of naltrexone condition showed a significantly greater mean increase in indirect ~ unconjugated bilirubin 006 mg/dl SD = 0165 compared to those who did not mean = 002 SD = 0148 p = 015 Similar results were obtained for total bilirubin p = 037 Smoking cessation is followed by increases in bilirubin concentration that have been associated with lower risk of lung cancer and cardiovascular disease\",\n",
            "}\n",
            "13126\n",
            "{\n",
            "  \"id\" : \"17442659\",\n",
            "  \"contents\" : \"Phase III study comparing the effect of oral ibandronate and intravenous zoledronic acid on bone markers Breast cancer patients with bone metastases received ibandronate 50 mg/day n = 137 or zoledronic acid 4 mg every 4 weeks n = 138 for 12 weeks The primary end point was mean percentage change in serum levels of cross-linked C-terminal telopeptide of type I collagen S-CTX at week 12 Urinary CTX U-CTX bone alkaline phosphatase ALP amino-terminal procollagen propeptide of type I collagen PINP and osteocalcin OC were also measured and bone pain and safety assessed Both bisphosphonates significantly reduced S-CTX mean ibandronate 76 % + / - 29 SD versus mean zoledronic acid 73 % + / - 47 P < 0001 for both versus baseline and U-CTX ibandronate 78 % + / - 50 versus zoledronic acid 86 % + / - 17 P < 0001 The difference in S-CTX between treatments was 06 % confidence interval -17 % to 30 % which was within the prespecified noninferiority margin Bone ALP PINP and OC decreased by 26 % -47 % compared with baseline with both bisphosphonates Compared with zoledronic acid ibandronate patients reported fewer adverse events overall 650 % versus 759 % and on days 1-3 80 % versus 475 % including less pyrexia overall incidence 0 % versus 168 % and bone pain 58 % versus 124 % Oral ibandronate was well tolerated and statistically noninferior to zoledronic acid for percentage change in the bone resorption marker S-CTX\",\n",
            "}\n",
            "13127\n",
            "{\n",
            "  \"id\" : \"16877725\",\n",
            "  \"contents\" : \"To evaluate the effects of once-weekly epoetin alfa EPO on health-related quality of life HRQOL hemoglobin Hb transfusions and tolerability in children with cancer Anemic patients 5 years to 18 years of age receiving myelosuppressive chemotherapy for nonmyeloid malignancies excluding brain tumors received intravenous EPO 600 units/kg to 900 units/kg or placebo once-weekly for 16 weeks Patients and parents completed the pediatric health-related quality-of-life generic scales GS and cancer-specific scales CS One hundred eleven patients received EPO and 111 patients received placebo Mean final values for GS total score P = 763 among patients P = 219 among parents and CS domain scores P > or = 238 P > or = 081 respectively were not significantly different between treatment groups EPO-treated patients had greater increases in Hb overall P = 002 and were more likely to be transfusion free after 4 weeks 387 % v 225 % P = 010 Change in Hb was correlated with change in PedsQL-GCS total score in the EPO group r = 0242 P = 018 but was not in the placebo group r = 0086 P = 430 Adverse events were comparable between treatment groups This study confirmed the tolerability and hematologic benefits of once-weekly EPO in children with cancer No significant difference in HRQOL was detected between treatment groups but a significant positive correlation was observed between Hb changes and HRQOL changes in the EPO group Additional studies are warranted to assess HRQOL when anemia is managed optimally in children with cancer\",\n",
            "}\n",
            "13128\n",
            "{\n",
            "  \"id\" : \"18845996\",\n",
            "  \"contents\" : \"To develop a cycle-based risk prediction model for neutropenic complications NC during chemotherapy with doxorubicin DOX or a pegylated liposomal formulation PLD for patients with metastatic breast cancer MBC Data analyzed was from a phase III randomized clinical trial of DOX 60 mg/m 2 every 3 weeks or PLD 50 mg/m 2 every 4 weeks for the first line therapy for MBC n = 509 OBrien et al Ann Oncol 2004 15440 -449 NC were defined as an absolute neutrophil count < or = 15 x 10 9 cells/L ie > or = grade II before the next cycle febrile neutropenia or neutropenia with a documented infection Patient and hematologic factors potentially associated with NC were evaluated Factors with a P value of < or = 025 within a cycle were included in a generalized estimating equations regression model Using backward elimination we derived a risk scoring algorithm range 0-63 from the final reduced model Risk factors retained in the model included poor performance status absolute neutrophil count < or = 20 x 10 9 cells/L in the previous cycle the first cycle of chemotherapy DOX versus PLD and advanced age A precycle risk score from > or = 25 to < 40 for a given patient was identified as being the optimal threshold for sensitivity 580 % and specificity 787 % Patients with a score at or beyond this threshold would be considered at high risk for developing NC in later cycles The use of this model may enhance patient care by targeting preventative therapies eg granulocyte colony stimulating factor or PLD to those MBC patients most likely to experience NC during anthracycline-based chemotherapy\",\n",
            "}\n",
            "13129\n",
            "{\n",
            "  \"id\" : \"17561562\",\n",
            "  \"contents\" : \"Although acute radiation dermatitis ARD is a common side-effect of radiotherapy RT currently there is no general consensus about its prevention or treatment of choice The purpose of this study was to investigate whether prophylactic use of topical betamethasone 01 % can prevent ARD caused by chest wall irradiation Fifty-one patients who underwent modified radical mastectomy for breast cancer and were going to receive RT were randomly assigned to receive topical betamethasone 01 % petrolatum or none during RT The frequency and severity of ARD measured using Radiation Therapy Oncology Group acute radiation morbidity scoring criteria were recorded at the end of each week during RT and two weeks after its completion Clinical outcomes were analyzed by relevant statistical methods All patients developed some degree of ARD the frequency and severity of which increased with time and reached the maximum at the end of the seventh week for all groups Patients receiving betamethasone had less severe ARD than the other two groups throughout the course of the study but this difference was significant only at the end of the third week p = 0027 No significant difference was observed between the petrolatum and control arms Prophylactic and ongoing use of topical betamethasone 01 % during chest wall RT for breast cancer delays occurrence of ARD but does not prevent it Petrolatum has no effect on the prevention of ARD in these patients\",\n",
            "}\n",
            "13130\n",
            "{\n",
            "  \"id\" : \"25410653\",\n",
            "  \"contents\" : \"The protective effect of beta-blockers ACE inhibitors and ARBs on anthracycline cardiotoxicity has already been demonstrated but the effect of aldosterone antagonism which inhibits the last step of the renin-angiotensin-aldosterone system RAAS was questioned This study sought to investigate whether spironolactone protects the heart against anthracycline-induced cardiotoxicity Eighty-three female patients who were diagnosed with breast cancer were included in the study The study population was randomized into spironolactone and control groups A dose of 25 mg/day spironolactone was administered to the patients in the spironolactone group There were 43 patients mean age 5011 years in the spironolactone group and 40 patients mean age 5110 years in the control group LVEF decreased from 67061 to 65774 P = 0094 in the spironolactone group and from 67763 to 53668 in the control group P < 0001 When the general linear model was applied the interaction of LVEF decrease between groups was significantly lower in the spironolactone group than in the control group P < 0001 The diastolic functional grade of subjects in the spironolactone group was protected P = 0096 whereas it deteriorated in the control group P < 0001 We showed that spironolactone administration used simultaneously with anthracycline group chemotherapeutics protects both myocardial systolic and diastolic functions Spironolactone can be used to protect against anthracycline-induced cardiotoxicity NCT02053974\",\n",
            "}\n",
            "13131\n",
            "{\n",
            "  \"id\" : \"24952281\",\n",
            "  \"contents\" : \"Breast cancer is the most common cancer and the leading cause of death among Latinas in the United States The Multi-level Intervention to Increase Participation in Mammography Screening study Fortaleza Latina ! is a partnership among research institutions a Latino-serving community-based primary care clinic organization and a cancer treatment center The study will assess the efficacy of a clinic - and patient-level program to increase breast cancer screening among Latinas in Western Washington The intervention is a multi-level breast cancer screening program in four participating primary care clinics The study is a parallel randomized controlled trial of 600 Latino women aged 42-74 who are non-compliant with breast cancer screening guidelines Participants will be randomized within clinic using block randomization to 1 a control arm usual care and 2 a theory-based counseling program consisting of a promotora or community health worker-led home-based intervention to encourage breast cancer screening At the clinic-level two clinics will offer additional mammography services provided by a mobile mammography unit operated by the Seattle Cancer Care Alliance The primary endpoint is the rate of mammography uptake over the 1-year follow-up period This multi-level intervention aims to raise rates of participation in breast cancer screening among Latino women If effective the program may improve rates of early detection of breast cancer in Latino women ClinicaltrialsgovNCT02010008\",\n",
            "}\n",
            "13132\n",
            "{\n",
            "  \"id\" : \"16877628\",\n",
            "  \"contents\" : \"Privacy laws have recently created restrictions on how researchers can approach study participants In a randomised trial of 152 patients 50-74 years old in a family practice 60 were randomly selected to opt-out and 92 to opt-in methods Patients were sent an introductory letter by their doctor in two phases opt-out before and opt-in after introduction of the new Privacy Legislation in December 2001 Opt-out patients were contacted by researchers Opt-in patients were contacted if patients responded by email free telephone number or a reply-paid card Opt-in recruited fewer patients 47 % 43/92 after invitation compared with opt-out 67 % 40/60 -20 % [ -4 % to -36 % ] No proportional difference in recruitment was found between opt-in and opt-out groups varied by age sex or socioeconomic status The opt-in group had significantly more people in active decision-making roles +30 % [ 10 % to 50 % ] p = 0003 Non-significant trends were observed towards opt-in being less likely to include people with lower education -118 % [ -30 % to 64 % ] p = 013 and people who were not screened -191 % [ -401 % to 19 % ] p = 008 Opt-in was more likely to recruit people with a family history of colorectal cancer +127 % [ -28 % 282 % ] p = 012 The number of participants required to be approached was markedly increased in opt-in recruitment Existing participants eg screening attendees with a vested interest such as increased risk and those preferring an active role in health decision making and with less education were likely to be recruited in opt-in Research costs and generalisability are affected by implementing privacy legislation\",\n",
            "}\n",
            "13133\n",
            "{\n",
            "  \"id\" : \"17848673\",\n",
            "  \"contents\" : \"The Prostate Cancer Prevention Trial PCPT reported a decreased incidence of prostate cancer overall but an increase in the incidence of high-grade prostate cancer with finasteride compared with placebo We assessed whether the increased high-grade prostate cancer associated with finasteride in the PCPT was due to finasteride s potential effects on tumor morphology or prostate size Prostate biopsies with Gleason score 8-10 n = 90 finasteride n = 52 placebo were examined histologically for hormonal effects and those with Gleason score 7-10 n = 282 finasteride n = 244 placebo were examined for pathologic surrogates of disease extent Prostate volumes were measured at biopsy Samples from radical prostatectomies n = 222 finasteride n = 306 placebo were examined for tumor grade and extent and where possible grades at biopsy and prostatectomy were compared between the groups Logistic regression was used to analyze differences between treatment groups with respect to pathologic criteria All statistical tests were two-sided Degenerative hormonal changes in high-grade biopsies were equivalent between the finasteride and placebo groups but prostate volumes were lower in the finasteride group median = 251 versus 344 cm3 P < 001 Pathologic surrogates for tumor extent were lower with finasteride than with placebo including mean percentage of positive cores 34 % versus 38 % P = 016 mean tumor linear extent greatest [ 44 versus 48 mm P = 19 ] and aggregate [ 76 versus 92 mm P = 13 ] bilaterality 228 % versus 306 % P = 046 and perineural invasion 142 % versus 203 % P = 07 Among patients who had prostatectomy the finasteride-associated increase in high-grade disease Gleason score > or = 7 at biopsy 427 % finasteride versus 254 % placebo P < 001 was diminished at prostatectomy 464 % finasteride versus 386 % placebo P = 10 Biopsy identified a greater proportion of patients with high-grade disease present at prostatectomy in the finasteride group than in the placebo group 697 % versus 505 % P = 01 The rate of upgrading from low-grade cancer at biopsy to high-grade cancer at prostatectomy and pathologic stage at prostatectomy were similar in both groups Effects of finasteride on prostate volume and selective inhibition of low-grade cancer rather than effects on tumor morphology may have contributed to the increase in high-grade cancers with finasteride in the PCPT Although induction of high-grade cancer can not be excluded the results suggest that high-grade cancer was detected earlier and was less extensive in the finasteride group than in the placebo group\",\n",
            "}\n",
            "13134\n",
            "{\n",
            "  \"id\" : \"20070299\",\n",
            "  \"contents\" : \"To evaluate the efficacy of 1-year maintenance after a 6-week cycle of early intravesical chemotherapy as the role of maintenance in intravesical chemotherapy is debated Between May 2002 and August 2003 577 patients with non-muscle-invasive bladder cancer NMI-BC underwent transurethral resection TUR and early intravesical chemotherapy epirubicin 80 mg/50 mL They were randomized between a 6-week induction cycle and the induction cycle plus maintenance with 10 monthly instillations In all 95 patients with T1G3 Tis or single and primary Ta-T1 G1-G2 tumours were excluded 482 patients at intermediate risk of recurrence continued the study All patients had cytology and cystoscopy at 3-monthly intervals for the first 2-years and 6-monthly thereafter The tumours characteristics were equally distributed between the two arms Treatment interruption for toxicity was required in 39 patients One death due to toxicity of early instillation occurred The median follow-up was 48 months Ten patients 25 % progressed and 117 patients 296 % recurred No statistically significant difference in the recurrence-free rate RFS was detected between the two arms P = 043 An advantage in favour of the maintenance arm was evident only at 18 months after TUR P = 003 A trend for a higher benefit from maintenance in primary and multiple tumours was detected In patients with intermediate risk NMI-BC treated by TUR and early adjuvant chemotherapy adding a maintenance regimen with monthly instillations for 1 year is of limited efficacy in preventing recurrence\",\n",
            "}\n",
            "13135\n",
            "{\n",
            "  \"id\" : \"15042673\",\n",
            "  \"contents\" : \"The purpose of the current study was to evaluate the effectiveness of a prostate carcinoma screening program in which serum prostate-specific antigen PSA levels were measured From a group of 20000 men born between January 1 1930 and December 31 1944 10000 men were randomized into a screening group and 10000 were randomized into a control group Patients in the screening group were invited to undergo initial PSA testing between 1995 and 1996 and then were invited to receive testing every second year thereafter for 8 years for a total of 4 PSA tests Men with PSA levels > or = 3 ng/mL or > or = 254 ng/mL in the third and fourth screening rounds were invited to undergo clinical investigation which included sextant biopsy of the prostate By linking to the regional cancer registry the authors were able to obtain the true and expected incidence rates for the screening and control groups The screening participation rate was high 73 % A total of 884 malignancies have been detected to date with 640 having been detected in the screening group There was an early and marked shift toward more favorable disease stage and grade for malignancies detected on repeat screening In the fourth screening round only 2 of 82 detected malignancies were classified as advanced disease Of the 227 screen-detected tumors on which surgery was performed only 20 88 % had small volume < 02 cm3 Forty-three interval malignancies were detected but only five were accompanied by symptoms At 8 years the cumulative disease incidence rate among screening participants was 73 % compared with 24 % in the control arm The incidence rate observed in the screening population corresponds to the cumulative incidence rate observed in the Swedish male population at age 72 years Biennial PSA screening was very successful in diagnosing prostate carcinoma at an early stage when curative treatment typically is effective In addition the results regarding interval malignancies were favorable Thus decreased mortality should be observed on long-term follow-up The lead time associated with screening appears to fall within the range described in earlier studies involving frozen sera ie 5-9 years\",\n",
            "}\n",
            "13136\n",
            "{\n",
            "  \"id\" : \"10360847\",\n",
            "  \"contents\" : \"Guidelines for cancer pain management include nonsteroidal antiinflammatory drugs with opioids administered in a time-contingent manner This study was designed to evaluate the role of oral ketamine or transdermal nitroglycerin polymer a nitric oxide donor as coadjuvants to oral morphine in cancer pain therapy After institutional approval and informed patient consent were obtained 60 patients with cancer pain were randomized to one of four groups n = 15 and studied prospectively to evaluate analgesia and any adverse effects A visual analog scale that consisted of a 10-cm line with 0 representing no pain at all and 10 representing the worst possible pain was introduced All patients were regularly taking oral amitriptyline 50 mg at bedtime The morphine regimen was adjusted individually to a maximal oral dose of 80-90 mg/day to keep the visual analog scale score less than 4 When patients reported pain visual analog scale of 4 or more despite taking 80-90 mg oral morphine daily the test drug was added as follows the control group CG received an additional 20 mg oral morphine 10 mg at 12-h intervals the nitroglycerin group NG received a 5-mg nitroglycerin patch daily the ketamine group KG received 05 mg/kg oral ketamine at 12-h intervals and the dipyrone group DG received 500 mg oral dipyrone at 6-h intervals Patients were free to manipulate their daily morphine consumption when the test drug was introduced to keep their visual analog scale score less than 4 The groups were similar with respect to demographic data and visual analog scale pain scores before treatment The visual analog scale scores after the test drug was introduced were similar among the groups The daily consumption of oral morphine was as follows on day 15 CG = DG = NG P > 005 CG > KG P = 0036 on day 20 CG > NG = KG P < 002 CG > KG P < 0005 CG > NG P < 002 DG > KG P < 005 on day 30 CG = DG > KG = NG P < 005 Patients in the CG and DG groups reported somnolence but patients in the NG and KG groups did not Low-dose ketamine and transdermal nitroglycerin were effective coadjuvant analgesics In conjunction with their opioid tolerance-sparing function joint delivery of ketamine or nitric oxide donors with opiates may be of significant benefit in cancer pain management\",\n",
            "}\n",
            "13137\n",
            "{\n",
            "  \"id\" : \"20861195\",\n",
            "  \"contents\" : \"Recent clinical trials in cancer patients treated with erythropoiesis-stimulating agents ESAs and in CKD patients treated to haemoglobin Hb targets above the labeled range of 10-12 g/dL with ESAs raised safety concerns regarding ESA therapy Subsequently product labeling was revised including addition of a black-box warning and removal of many quality of life claims not supported by current standards and there were changes in reimbursement and anaemia guidelines The extent to which these events influenced ESA dosing and Hb levels in patients with chronic kidney disease not on dialysis CKD-NOD is not known We used data collected in a series of cross-sectional surveys between March 2005 and July 2009 Patients with CKD-NOD were selected from a random sample of free-standing US nephrology clinics Information on demographics insurance information laboratory data and ESA use was abstracted from medical records by site investigators We evaluated ESA treatment use and dosing and Hb levels over time and used multivariate linear regression to assess changes in ESA doses and Hb levels over time adjusting for case-mix differences Between 2005 and 2009 15 836 CKD-NOD patients were sampled During this period ESA use declined from 60 to 46 % and the mean dose declined from 176 to 136 mcg/month the largest decline in use and in dose occurred beginning in 2007 Simultaneously the mean standard deviation Hb level in ESA-treated patients declined from 115 14 to 106 12 g/dL though the decline was most pronounced starting in 2007 As the mean Hb declined the percent of treated patients with an Hb > 12 g/dL dropped from 27 to 12 % and the mean dose in this sub-population declined from 173 to 111 mcg/month The emergence of safety concerns and the subsequent changes in product labeling reimbursement and clinical practice guidelines all appear to have influenced physician dosing practices resulting in less frequent use of ESAs lower ESA doses and lower achieved Hb levels in CKD-NOD patients\",\n",
            "}\n",
            "13138\n",
            "{\n",
            "  \"id\" : \"19833819\",\n",
            "  \"contents\" : \"Paclitaxel-carboplatin is used as the standard regimen for patients with advanced or metastatic non-small-cell lung cancer NSCLC This trial was designed to compare gemcitabine + carboplatin or gemcitabine + paclitaxel to the standard regimen A total of 1135 chemonaive patients with stage IIIB or IV NSCLC were randomly allocated to receive gemcitabine 1000 mg/m 2 on days 1 and 8 plus carboplatin area under the concentration-time curve AUC 55 on day 1 GC gemcitabine 1000 mg/m 2 on days 1 and 8 plus paclitaxel 200 mg/m 2 on day 1 GP or paclitaxel 225 mg/m 2 plus carboplatin AUC 60 on day 1 PC Stratification was based on disease stage baseline weight loss and presence or absence of brain metastases Cycles were repeated every 21 days for up to six cycles or disease progression Median survival months with GC was 79 compared with 85 for GP and 87 for PC Response rates RRs were as follows GC 253 % GP 321 % and PC 298 % The GC arm was associated with a greater incidence of grade 3 or 4 hematologic events but a lower rate of neurotoxicity and alopecia when compared with GP and PC Non-platinum and non-paclitaxel gemcitabine-containing doublets demonstrate similar overall survival and RR compared with the standard PC regimen However the treatment arms had distinct toxicity profiles\",\n",
            "}\n",
            "13139\n",
            "{\n",
            "  \"id\" : \"12081830\",\n",
            "  \"contents\" : \"Elevated iron stores oxidative stress and estrogen deficiency may place postmenopausal women at greater risk of heart disease and cancer than premenopausal women The objective was to determine the effect of soy-protein isolate SPI intake and iron indexes on plasma total antioxidant status TAS in perimenopausal women after control for other contributing factors Perimenopausal women n = 69 were randomly assigned double blind to treatment isoflavone-rich SPI SPI + n = 24 isoflavone-poor SPI SPI - n = 24 or whey protein control n = 21 Each subject consumed 40 g soy or whey protein daily for 24 wk Plasma TAS serum ferritin serum iron transferrin saturation and hemoglobin were measured at baseline week 12 and week 24 No significant time-by-treatment interactions on iron indexes or TAS were observed whereas time had an effect on serum ferritin P < or = 00001 and hemoglobin P = 0004 but not on TAS Multiple regression analysis showed that at week 12 48 % P < or = 00001 of the variability in TAS was accounted for by baseline TAS alcohol intake soy intake soy compared with control P = 0016 plasma lipoprotein a and dietary iron At week 24 47 % of the variability in TAS was accounted for by baseline TAS serum ferritin serum estrone dietary zinc and dietary meat fish and poultry SPI intake had no significant effect on iron status but our results suggest that dietary soy protein and low iron stores may protect perimenopausal women from oxidative stress\",\n",
            "}\n",
            "13140\n",
            "{\n",
            "  \"id\" : \"15890591\",\n",
            "  \"contents\" : \"To investigate the cytoprotective effect of subcutaneous vs intrarectal administration of amifostine against acute radiation toxicity Patients were randomized to receive amifostine either intrarectally Group A n = 27 or a 500-mg flat dose subcutaneously Group B n = 26 before irradiation Therapy was delivered using a four-field technique with three-dimensional conformal planning In Group A 1500 mg of amifostine was administered intrarectally as an aqueous solution in 40 mL of enema Two different toxicity scales were used the European Organization for Research and Treatment of Cancer/Radiation Therapy Oncology Group RTOG rectal and urologic toxicity criteria and the Subjective-RectoSigmoid scale based on the endoscopic terminology of the World Organization for Digestive Endoscopy Objective measurements with rectosigmoidoscopy were performed at baseline and 1-2 days after radiotherapy completion The area under the curve for the time course of mucositis RTOG criteria during irradiation represented the mucositis index Intrarectal amifostine was feasible and well tolerated without any systemic or local side effects According to the RTOG toxicity scale Group A had superior results with a significantly lower incidence of Grades I-II rectal radiation morbidity 11 % vs 42 % p = 004 but inferior results concerning urinary toxicity 48 % vs 15 % p = 003 The mean rectal mucositis index and Subjective-RectoSigmoid score were significantly lower in Group A 044 vs 245 [ p = 0015 ] and 39 vs 60 [ p = 001 ] respectively and the mean urinary mucositis index was lower in Group B 239 vs 034 p < 0028 Intrarectal administration of amifostine 1500 mg seemed to have a cytoprotective efficacy in acute radiation rectal mucositis but was inferior to subcutaneous administration in terms of urinary toxicity Additional randomized studies are needed for definitive decisions concerning the cytoprotection of pelvic irradiated areas\",\n",
            "}\n",
            "13141\n",
            "{\n",
            "  \"id\" : \"21347523\",\n",
            "  \"contents\" : \"Achieving acceptable levels of adherence to exercise may be a challenge with head and neck cancer HNC survivors given the high morbidity associated with treatment The purpose of the present trial was to identify the key predictors of adherence during our shoulder exercise rehabilitation trial Fifty-two HNC survivors were randomly assigned to a 12-week progressive resistance exercise training protocol n = 27 or a standardized therapeutic exercise protocol n = 25 that was prescribed to address shoulder pain and dysfunction Baseline data were collected on standard demographic medical behavioral symptom psychosocial and motivational variables from the theory of planned behavior The exercise adherence rate for the trial was 91 % In multivariate analysis the independent predictors of reduced adherence were undergoing a more extensive neck dissection procedure = -0361 P = 0007 and reporting daily alcohol consumption = -0298 P = 0031 Higher exercise adherence was achieved by HNC participants who had undergone nerve sparing neck dissection procedures and who were not regular drinkers Excellent adherence to exercise was achieved in the trial despite high morbidity associated with HNC treatment The high adherence achieved was likely due to the select and highly motivated sample of HNC survivors as well as to factors associated with trial design such as the support offered to participants The findings of this trial need to be further explored and confirmed in a larger study that includes a more diverse sample of HNC survivors\",\n",
            "}\n",
            "13142\n",
            "{\n",
            "  \"id\" : \"16943401\",\n",
            "  \"contents\" : \"Overexpression of cyclooxygenase 2 COX-2 has been associated with colorectal adenomatous polyps and cancer prompting researchers to propose its inhibition as a chemopreventive intervention The Prevention of Colorectal Sporadic Adenomatous Polyps trial was a randomized placebo-controlled double-blind study of the COX-2 inhibitor celecoxib given daily in a single 400-mg dose At 107 centers in 32 countries we randomly assigned 1561 subjects who had had adenomas removed before enrollment to receive celecoxib 933 subjects or placebo 628 subjects daily after stratification according to the use or nonuse of low-dose aspirin The primary outcome was detection of adenomas at either year 1 or year 3 by colonoscopy and was compared among the groups with the use of the Mantel-Cox test Colonoscopies were performed at year 1 on 887 percent of the subjects who had undergone randomization and at year 3 on 792 percent Of the 557 subjects in the placebo group and the 840 subjects in the celecoxib group who were included in the efficacy analysis 264 and 270 respectively were found to have at least one adenoma at year 1 at year 3 or both The cumulative rate of adenomas detected through year 3 was 336 percent in the celecoxib group and 493 percent in the placebo group relative risk 064 95 percent confidence interval 056 to 075 P < 0001 The cumulative rate of advanced adenomas detected through year 3 was 53 percent in the celecoxib group and 104 percent in the placebo group relative risk 049 95 percent confidence interval 033 to 073 P < 0001 Adjudicated serious cardiovascular events occurred in 25 percent of subjects in the celecoxib group and 19 percent of those in the placebo group relative risk 130 95 percent confidence interval 065 to 262 The use of 400 mg of celecoxib once daily significantly reduced the occurrence of colorectal adenomas within three years after polypectomy ClinicalTrialsgov number NCT00141193 [ ClinicalTrialsgov ]\",\n",
            "}\n",
            "13143\n",
            "{\n",
            "  \"id\" : \"10893592\",\n",
            "  \"contents\" : \"Several studies suggest that sextant transrectal ultrasound guided biopsy of the prostate provides insufficient material to detect all clinically important prostate cancer and obtaining more biopsy cores may improve the cancer detection rate We performed a prospective randomized trial comparing 6 to 12 prostate biopsy cores to determine the impact on the cancer detection rate We prospectively randomized 244 men including 71 29 % black men with a mean age plus or minus standard deviation of 65 + / - 8 years to undergo biopsy with 6 or 12 peripheral zone tissue cores In our study subjects serum total prostate specific antigen PSA was between 25 and 20 ng / ml and/or digital rectal examination was suspicious for cancer All men completed a self-administered pre-biopsy and 2 post-biopsy questionnaires at 2 and 4 weeks Cancer detection rates were compared in the groups and correlated with race biopsy history digital rectal examination findings total PSA transrectal ultrasound volume and PSA density as determined by the formula total PSA/transrectal ultrasound volume The cancer detection rate in the 6 and 12 core groups was almost identical 26 % and 27 % p = 09 There was no significant difference in cancer detection in the 2 trial arms with respect to subject race biopsy history digital rectal examination findings total PSA transrectal ultrasound volume or PSA density However our study did not have the statistical power to rule out small differences The overall cancer detection rate is not materially increased by 12 core peripheral zone biopsy in men in whom prostate cancer was mainly detected by screening\",\n",
            "}\n",
            "13144\n",
            "{\n",
            "  \"id\" : \"18467719\",\n",
            "  \"contents\" : \"Lapatinib is an orally reversible inhibitor of epidermal growth factor receptor EGFR / human epidermal growth factor receptor 2 HER-2 tyrosine kinases with demonstrated activity in patients with HER-2-positive breast cancer In the current phase III open-label trial lapatinib was compared with hormone therapy HT in patients with advanced renal cell carcinoma RCC that express EGFR and/or HER-2 Patients with advanced RCC who had experienced disease progression through first-line cytokine therapy -- stratified by Karnofsky performance status and number of metastatic sites -- were randomly assigned to lapatinib 1250 mg daily or HT The primary end point was time to progression TTP secondary end points included overall survival OS safety and biomarker analyses Four hundred sixteen patients were enrolled onto the study Median TTP was 153 weeks for lapatinib versus 154 weeks for HT hazard ratio [ HR ] = 094 P = 60 and median OS was 469 weeks for lapatinib versus 431 weeks for HT HR = 088 P = 29 In a biomarker analysis of patients with EGFR-overexpressed tumors 3 + by immunohistochemistry [ IHC ] n = 241 median TTP was 151 weeks for lapatinib versus 109 weeks for HT HR = 076 P = 06 and median OS was 460 weeks for lapatinib versus 379 weeks for HT HR = 069 P = 02 These results were confirmed by Cox regression analysis No unexpected toxicities were observed the most commonly reported drug-related adverse events all grades for lapatinib were rash 44 % and diarrhea 40 % Lapatinib was well tolerated with equivalent overall efficacy to HT in advanced RCC patients who had experienced disease progression while receiving cytokines and the study supports that lapatinib prolonged OS relative to HT in patients with 3 + EGFR status determined by IHC\",\n",
            "}\n",
            "13145\n",
            "{\n",
            "  \"id\" : \"15817602\",\n",
            "  \"contents\" : \"The purpose of this study was to assess whether a short course of anthracycline containing chemotherapy followed by high dose therapy with autologous stem-cell support improves disease-free and overall survival as compared with conventional anthracycline containing chemotherapy in patients with primary breast cancer and four or more histologically involved lymph nodes Two hundred and eighty one patients entered into a randomised clinical trial were allocated to receive standard conventional treatment 5-fluorouracil epirubicin and cyclophosphamide-FEC for six cycles or FEC for three cycles followed by high dose therapy consisting of cyclophosphamide thiotepa and carboplatin and stem cell rescue HDT To be eligible patients had to be free of overt metastatic disease and be < or = 60 years of age Analyses were according to intention to treat At a median follow up of 68 months 118 patients have experienced a relapse or death from breast cancer 62 in the FEC followed by HDT arm and 56 in the conventional FEC arm and a total of 100 patients have died 54 in the FEC followed by HDT arm and 46 in the conventional FEC arm No significant difference was observed in relapse-free survival [ hazard ratio 106 95 % CI 074-1 52 p = 076 ] or overall survival [ hazard ratio 118 95 % CI 080-1 75 p = 040 ] Five patients died from treatment related causes three as a consequence of HDT and two in the conventional FEC arm At the present time no benefit has been observed from replacing three cycles of conventional chemotherapy with the HDT regimen described here Patients should continue to receive conventional chemotherapy as adjuvant therapy for breast cancer\",\n",
            "}\n",
            "13146\n",
            "{\n",
            "  \"id\" : \"20673972\",\n",
            "  \"contents\" : \"Effective patient - clinician communication at diagnosis is important yet decreased provider time for face-to-face interactions makes traditional paradigms in cancer care difficult We evaluated the effects of an educational video on patients distress cancer knowledge coping skills and attitudes regarding learning about cancer at the time of ovarian cancer diagnosis An educational video was developed in which oncology professionals women with ovarian cancer and their relatives discussed cancer information and experiences Women admitted for initial diagnostic surgical staging for ovarian cancer were randomized to the educational or placebo video Before and after the video patients completed measures of 1 ovarian cancer information 2 emotional distress 3 learning attitudes and 4 coping self-efficacy Outcomes were analyzed for differences in mean change between intervention and placebo groups using t-tests Fifty-nine subjects were randomized 30 intervention/29 placebo The majority were advanced staged white insured high school educated employed and rated their disease seriousness as high Anxiety general distress and cancer-specific distress were high Pre-post video distress and self-efficacy between groups were unchanged intervention subjects answered more knowledge items correctly p = 00004 and developed more negative learning attitudes p = 0037 Following the educational video patients who developed more negative attitudes also had increased intrusive thinking p = 0046 a sign of increased distress Video presentation of cancer-related information increases learning under conditions of high distress and disease threat however it is not without risk for some Differing information needs may affect women s emotional response under these conditions\",\n",
            "}\n",
            "13147\n",
            "{\n",
            "  \"id\" : \"20350786\",\n",
            "  \"contents\" : \"We sought to compare the prognostic value of early prostate-specific antigen PSA test-based variables for the 802 eligible patients treated in the Trans-Tasman Radiation Oncology Group 9601 randomized trial Patients in this trial had T2b T2c T3 and T4 N0 prostate cancer and were randomized to 0 3 or 6 months of neoadjuvant androgen deprivation therapy NADT prior to and during radiation treatment at 66 Gy to the prostate and seminal vesicles The early PSA test-based variables evaluated were the pretreatment initial PSA iPSA value PSA values at 2 and 4 months into NADT the PSA nadir nPSA value after radiation in all patients and PSA response signatures in men receiving radiation Comparisons of endpoints were made using Cox models of local progression-free survival distant failure-free survival biochemical failure-free survival and prostate cancer-specific survival The nPSA value was a powerful predictor of all endpoints regardless of whether NADT was given before radiation PSA response signatures also predicted all endpoints in men treated by radiation alone iPSA and PSA results at 2 and 4 months into NADT predicted biochemical failure-free survival but not any of the clinical endpoints nPSA values correlated with those of iPSA Gleason grade and T stage and were significantly higher in men receiving radiation alone than in those receiving NADT The postradiation nPSA value is the strongest prognostic indicator of all early PSA-based variables However its use as a surrogate endpoint needs to take into account its dependence on pretreatment variables and treatment method\",\n",
            "}\n",
            "13148\n",
            "{\n",
            "  \"id\" : \"20124183\",\n",
            "  \"contents\" : \"Pertuzumab is a humanized monoclonal antibody inhibiting human epidermal growth factor receptor 2 HER2 dimerization The aim of this phase II trial was to assess the antitumor activity and safety profile of pertuzumab monotherapy in patients with HER2-negative metastatic breast cancer The utility of biomarkers detected in paraffin-embedded tissue as predictors of response was also explored This was an international multicenter open-label randomized phase II study Patients n = 79 with centrally confirmed HER2-negative metastatic breast cancer were randomly assigned to receive pertuzumab once every 3 weeks with a loading dose of 840 mg followed thereafter by either 420 mg arm A or 1050 mg arm B Patients were stratified by country and prior taxane therapy Of 79 patients who were randomly assigned 78 were included in the intent-to-treat population In arm A n = 41 two patients had partial responses and 18 patients 44 % experienced stable disease SD lasting > or = 12 weeks In arm B n = 37 SD was observed in 14 patients 38 % Overall six of 78 patients responded or had SD > or = 6 months Pertuzumab was generally well tolerated and most adverse events were mild to moderate Decline in left ventricular ejection fraction of > or = 10 % and/or to less than 50 % was observed in eight patients with one case of congestive heart failure in arm A Pharmacokinetic data supported a fixed dose of pertuzumab once every 3 weeks The limited efficacy observed in this study generally SD of relatively short duration suggested little benefit of further investigation of single-agent pertuzumab in unselected patients with HER2-negative disease\",\n",
            "}\n",
            "13149\n",
            "{\n",
            "  \"id\" : \"21111754\",\n",
            "  \"contents\" : \"Understanding mediators for behavioral change is important for the optimization of intervention strategies This report examines mediators of change in the context of a randomized controlled intervention trial Los Angeles 2004-2009 that successfully increased colorectal cancer CRC screening among Filipino Americans The intervention based on the Health Behavior Framework targeted knowledge/awareness of CRC screening communication with health care provider health beliefs social support and barriers to CRC screening Health Behavior Framework variables were assessed at baseline and 6-month follow-up N = 432 Variables targeted for change were tested as potential mediators of the primary outcome self-reported receipt of CRC screening during the follow-up period which was previously found to have increased significantly among intervention participants Consistent with the Health Behavior Framework knowledge/awareness of CRC screening and patient-provider communication mediated receipt of screening Increase in knowledge/awareness of CRC screening accounted for 13 % 95 % confidence interval 2 % -24 % of the total intervention effect size while patient-provider communication accounted for 20 % 5 % -36 % Combined these two variables accounted for 28 % 10 % -46 % of the total effect size Examining the roles of potential mediators in intervention trials may help identify constructs to target in order to enhance the effectiveness of interventions to increase screening\",\n",
            "}\n",
            "13150\n",
            "{\n",
            "  \"id\" : \"19218306\",\n",
            "  \"contents\" : \"Adjuvant treatment of hormone receptor-positive breast cancer in postmenopausal women with aromatase inhibitors may be associated with increased bone loss Two hundred patients were randomised to receive exemestane or tamoxifen as adjuvant treatment of hormone receptor-positive breast cancer Bone mineral density BMD was assessed by dual-energy X-ray absorptiometry at baseline and after 6 and 12 months treatment One hundred and sixty-one patients were assessable Tamoxifen treatment resulted in a 05 % increase from baseline in BMD at the spine which was maintained at 12 months Exemestane-treated patients experienced a 26 % decrease from baseline in BMD at the spine at 6 months and a further 02 % decrease at 12 months There were significant differences in the changes in BMD between tamoxifen and exemestane at 6 and 12 months P = 00026 and P = 00008 respectively The mean changes in BMD from baseline at the total hip were also significantly different between exemestane and tamoxifen at 6 and 12 months P = 00009 and P = 004 respectively There was no difference between tamoxifen and exemestane in mean changes in BMD from baseline at the femoral neck Exemestane treatment resulted in an increase in bone loss at 6 months bone loss stabilised after 6 - to 12-month treatment\",\n",
            "}\n",
            "13151\n",
            "{\n",
            "  \"id\" : \"17627004\",\n",
            "  \"contents\" : \"A change in diet is known to affect micronutrient levels in blood but to what extent diet can affect micronutrient levels in the breast is not yet well established Healthy premenopausal women with a family history of breast cancer were randomized across four diet arms for 1 year in a 2 x 2 factorial design study control low-fat high fruit-vegetable and combination low-fat/high fruit-vegetable diets Subjects were asked to collect breast nipple aspirate fluid NAF at 0 6 and 12 months and levels of micronutrients were measured in the fluid A total of 122 women were enrolled 97 were retained for 12 months and sufficient NAF for analysis was available from 59 women at baseline 49 at 6 months and 50 at 12 months Repeated measures mixed-model ANOVA was used to model the data using cholesterol levels and lactation duration as covariates where appropriate The high fruit-vegetable intervention regardless of fat intake significantly increased total carotenoid levels in NAF In the low-fat arm levels of total carotenoids decreased over time relative to control Levels of total tocopherols and retinol did not change significantly Levels of 15-F 2t - isoprostane a marker of lipid peroxidation also did not change significantly over time although there was a decrease observed in the combination arm These results indicate that total carotenoid levels in NAF can be significantly increased in the breast NAF with a high fruit-vegetable diet A low-fat diet that was achieved with little increase in fruit and vegetable intake however decreased NAF carotenoid levels\",\n",
            "}\n",
            "13152\n",
            "{\n",
            "  \"id\" : \"22843943\",\n",
            "  \"contents\" : \"This post-hoc analysis aimed to compare an intense dose-dense sequential chemotherapy DD-CT and a conventionally-dosed chemotherapy CD-CT in the neoadjuvant AGO-1 study focusing on the subgroup with inflammatory breast cancer IBC Out of 668 randomised patients 101 patients presented with IBC Patients received epirubicin followed by paclitaxel every 2 weeks DD-CT or simultaneously every 3 weeks CD-CT No differences in pathological complete response rates were observed [ odds ratio OR = 127 p = 033 ] Most patients were scheduled for mastectomy before starting therapy however in 217 % breast-conserving surgery was performed Disease-free survival rates [ Hazard Ratio HR = 065 p = 0597 ] and overall survival rates HR = 140 p = 0327 were similar for both treatment arms Patients with breast-conserving surgery had a significantly better outcome than patients treated with mastectomy disease-free survival HR = 041 p = 0034 and overall survival HR = 009 p = 0003 Patients with IBC benefited not from DD-CT but from breast-conserving surgery after neoadjuvant chemotherapy\",\n",
            "}\n",
            "13153\n",
            "{\n",
            "  \"id\" : \"16189764\",\n",
            "  \"contents\" : \"High-resolution endoscopy HRE may improve the detection of early neoplasia in Barrett s esophagus Indigo carmine chromoendoscopy ICC and narrow-band imaging NBI may be useful techniques to complement HRE The aim of this study was to compare HRE-ICC with HRE-NBI for the detection of high-grade dysplasia or early cancer HGD/EC in patients with Barrett s esophagus Twenty-eight patients with Barrett s esophagus underwent HRE-ICC and HRE-NBI separated by 6 - 8 weeks in a randomized sequence The two procedures were performed by two different endoscopists who were blinded to the findings of the other examination Targeted biopsies were taken from all detected lesions followed by four-quadrant biopsies at 2-cm intervals Biopsy evaluation was supervised by a single expert pathologist who was blinded to the imaging technique used Fourteen patients were diagnosed with HGD/EC The sensitivity for HGD/EC was 93 % and 86 % for HRE-ICC and HRE-NBI respectively Targeted biopsies had a sensitivity of 79 % with HRE alone HGD was diagnosed from random biopsies alone in only one patient ICC and NBI detected a limited number of additional lesions occult to HRE but these lesions did not alter the sensitivity for identifying patients with HGD/EC In most patients with high-grade dysplasia or early cancer in Barrett s esophagus subtle lesions can be identified with high-resolution endoscopy Indigo carmine chromoendoscopy and narrow-band imaging are comparable as adjuncts to high-resolution endoscopy\",\n",
            "}\n",
            "13154\n",
            "{\n",
            "  \"id\" : \"16215308\",\n",
            "  \"contents\" : \"To compare the efficacy of diethylstilboestrol DES with bicalutamide in the treatment of hormone refractory prostate cancer in relation to its effect on prostate-specific antigen PSA and survival Patients on LHRH analogues for prostate carcinoma with evidence of biochemical or clinical progression were randomized into one of the treatment arms n = 58 The first group group A n = 26 received 1 mg of DES with 75 mg of aspirin per day in addition to the primary hormonal treatment The second group group B n = 32 received bicalutamide at a dose of 50 mg/day in addition to the primary treatment Patients were followed up every 3 months with their PSA being checked and were also monitored for any clinical progression and adverse effects as a result of treatment Any adverse event occurring after patients were started on treatment was attributed to the drug and patients were clinically assessed at each visit Failure of treatment was defined as a 50 % or greater increase in PSA after commencing treatment Once randomized all patients were followed up for survival regardless of failure of second-line hormonal manipulation The mean age of the patients was 767 years 60-88 SD 74 in group A and 76 years 67-86 SD 69 in group B Twelve patients in each group had metastatic disease The median follow-up periods for both groups were 24 months range 6-48 in group A range 3-54 in group B 65 % of the patients in group A 17/26 and 435 % 14/32 in group B had a fall in their PSA levels p = 008 Fisher s exact test with 23 % 6/26 and 31 % 10/32 having a > 50 % response respectively p = 034 Fisher s exact test Mean PSA nadir in those who responded were 206 ng/ml range 16-59 4 and 741 ng/ml range 01-42 6 in groups A and B respectively The median duration of response was 9 months 3-18 months for group A and 12 months 3-18 months for group B Seven patients in group A and 6 in group B experienced adverse events Three of the 7 in the group A experienced cardiovascular related adverse effects 1 congestive cardiac failure 1 pulmonary embolism and 1 stroke At the end of the study period 14 54 % of group A patients were alive and 12 46 % were dead In group B 15 47 % were alive 16 50 % were dead and 1 3 % lost to follow-up At the completion of the study 3 patients in each group were still on treatment Low-dose DES and 50 mg of bicalutamide per day are equally effective in hormone refractory prostate carcinoma with respect to biochemical response although DES has more severe adverse effects This is a small sample and larger multicentre trials are needed to give us a definite conclusion\",\n",
            "}\n",
            "13155\n",
            "{\n",
            "  \"id\" : \"14733381\",\n",
            "  \"contents\" : \"Maternal and pediatric residential pesticide exposure has been identified as a risk factor for birth defects pediatric cancers and neurological damage and it may play a role in other disease processes To examine whether the use of a pamphlet with a brief educational message in a clinic setting would increase the knowledge and/or change the attitudes of pregnant women and mothers about pesticide use and alternatives as well as promote pesticide safety A group of 103 women currently pregnant and/or with children less than 6 years of age were recruited at 2 Special Supplemental Nutrition Program for Women Infants and Children WIC clinics for the study Participants were given a 16-question true/false oral survey testing their baseline knowledge about pesticide safety and safer alternatives to pesticide use Participants were then randomly assigned to a control group or to the intervention group which received the pamphlet and a 2-minute scripted overview of its contents Approximately 2 to 3 weeks later all participants received a follow-up telephone call by a researcher blinded to the original group assignment and the original survey questions were repeated Follow-up assessments were completed for 73 71 % of the participants The mean improvement in correct responses on the follow-up survey was +039 for the control group and +31 for the intervention group P < 001 Item analysis revealed that the intervention produced a significantly higher number of correct answers to 9 of the 16 survey questions Providing mothers and pregnant womenProviding mothers and pregnant women with a pamphlet and a brief message about pesticide safety and safer alternatives to pesticides in a clinic setting may be effective in improving knowledge and beliefs about pesticides\",\n",
            "}\n",
            "13156\n",
            "{\n",
            "  \"id\" : \"10368039\",\n",
            "  \"contents\" : \"Hypoxia a frequent characteristic of cervical cancer is associated with reduced sensitivity to irradiation and thus may be a source of radiotherapy failure This study was planned to test the hypothesis that inhalation of oxygen during radiotherapy may increase the radiation effect on the tumor and improve loco-regional control and overall survival From 1963 to 1965 a consecutive series of 208 patients with cervical cancer stage II/III who were to be treated by external irradiation plus radium inserts were included in this study They were randomly assigned to either receive oxygen inhalations during the radiotherapy sessions or just breathing air Due to technical reasons the oxygen group was divided For the first 10 months they did receive oxygen during the radium inserts only the last 13 months during all radiotherapy sessions After median 33 years follow-up there are no differences in overall survival cancer-specific survival or loco-regional control Subgroup analysis shows significantly improved loco-regional control in the stage IIB patients with squamous cell carcinoma who received oxygen during all radiotherapy sessions This improvement was especially pronounced among the patients who also received blood transfusions There was no influence of normobaric oxygen treatment on the overall outcome to radiotherapy in patients with stage II cervical cancer but subgroup analyses support the hypothesis that there is tumor areas of hypoxia-based radioresistance that may be counteracted by oxygen administration\",\n",
            "}\n",
            "13157\n",
            "{\n",
            "  \"id\" : \"9193328\",\n",
            "  \"contents\" : \"A potential application of hematopoietic growth factors is to obtain an increased dose-intensity This can be achieved by either higher doses of chemotherapy with standard intervals or by standard doses with shorter intervals The potential of these approaches has not been investigated systematically In a randomized multicenter study 49 advanced breast cancer patients were treated with granulocyte colony-stimulating factor G-CSF and either increasing doses of epirubicin and cyclophosphamide with fixed intervals arm one or progressively shorter intervals with fixed doses of epirubicin and cyclophosphamide arm two A cohort of at least six patients was studied at each interval/dose A more intensified interval/dose was given if less than 50 % of patients encountered a dose-intensity limiting criterium DILC in the first three courses In arm one epirubicin 140 mg/m2 and cyclophosphamide 800 mg/m2 every 21 days was too toxic Subsequently epirubicin 120 mg/m2 and cyclophosphamide 700 mg/m2 was tested with two of 10 patients encountering a DILC All initial DILCs consisted of febrile neutropenia In arm two epirubicin 75 mg/m2 and cyclophosphamide 500 mg/m2 could be administered safely with 14 - and 12-day intervals In the 10-day interval eight of 12 patients completed the first three cycles without a DILC In the 8-day interval seven of eight patients encountered a DILC Incomplete neutrophil recovery and to a lesser extent stomatitis were dose-limiting In combination with G-CSF epirubicin 120 mg/m2 and cyclophosphamide 700 mg/m2 every 21 days was feasible projected dose-intensity 40 mg/m2/wk and 233 mg/m2/wk respectively Epirubicin 75 mg/m2 and cyclophosphamide 500 mg/m2 could be administered safely every 10 days allowing a projected dose-intensity of 525 mg/m2/wk and 350 mg/m2/wk respectively\",\n",
            "}\n",
            "13158\n",
            "{\n",
            "  \"id\" : \"8996129\",\n",
            "  \"contents\" : \"To compare the efficacy characteristics of onset/recovery and safety of ketamine/atropine/midazolam with meperidine/midazolam used as premedication for painful procedures in children with cancer A randomized double-blind crossover trial for two successive painful procedures bone marrow aspiration or biopsy lumbar puncture or combined procedures was performed at a referral-based pediatric hematology-oncology clinic and associated inpatient service of a university teaching hospital Twenty-two children aged 24 to 178 months were enrolled and 18 818 % completed the double-blind crossover trial Each child received intravenous premedication with either meperidine 2 mg/kg and midazolam 01 mg/kg MM or atropine 001 mg/kg midazolam 005 mg/kg and ketamine 15 mg/kg KM on one occasion followed by the alternative regimen on a second occasion The initial premedication regimen was chosen by random assignment Efficacy was assessed by a trained observer using the Observational Scale of Behavioral Distress-Revised OSBD-R Operator nurse parent and patient opinions of efficacy were recorded on a visual analog scale VAS Side effects were monitored by pulse oximetry nasal end-tidal capnography and serial blood pressure measurements Use of KM resulted in significantly less procedural distress than MM 137 + / - 220 v 704 + / - 806 OSBD-R units P < 05 Both operators and nurses rated KM more effective than MM KM use was associated with earlier readiness for the procedure 192 v 240 minutes and more rapid recovery 393 v 746 minutes for removal of monitoring devices and 585 v 871 minutes for discharge Procedures undertaken after ketamine sedation were associated with fewer side effects than observed with MM sedation hypoxia 177 % v 824 % hypotension 166 % v 556 % reduced respiratory rate 0 % v 389 % The incidence of emergence reactions or behavioral abnormalities within 24 hours postprocedure was similar in both treatment groups At 7 days postprocedure no child had persistent behavioral abnormalities and all children had amnesia for the procedure Parents and children expressed a preference for KM over MM in 12 of 18 cases P < 05 A premedication regimen of KM produced superior sedation with a faster onset and recovery and fewer side effects than a MM combination\",\n",
            "}\n",
            "13159\n",
            "{\n",
            "  \"id\" : \"17386108\",\n",
            "  \"contents\" : \"Brain metastases BM are the most common form of intracranial cancer The incidence of BM seems to have increased over the past decade Recursive partitioning analysis RPA of data from three Radiation Therapy Oncology Group RTOG trials 1200 patients has allowed three prognostic groups to be identified More recently a simplified stratification system that uses the evaluation of three main prognostics factors for radiosurgery in BM was developed To analyze the overall survival rate OS prognostic factors affecting outcomes and to estimate the potential improvement in OS for patients with BM from breast cancer stratified by RPA class and brain metastases score BS-BM From January 1996 to December 2004 174 medical records of patients with diagnosis of BM from breast cancer who received WBRT were analyzed The surgery followed by WBRT was used in 155 % of patients and 845 % of others patients were submitted at WBRT alone 108 patients 621 % received the fractionation schedule of 30 Gy in 10 fractions Solitary BM was present in 379 % of patients The prognostic factors evaluated for OS were age Karnofsky Performance Status KPS number of lesions localization of lesions neurosurgery chemotherapy absence extracranial disease RPA class BS-BM and radiation doses and fractionation The OS in 1 2 and 3 years was 334 % 167 % and 88 % respectively The RPA class analysis showed strong relation with OS p < 00001 The median survival time by RPA class in months was class I 117 class II 62 and class III 30 The significant prognostic factors associated with better OS were higher KPS p < 00001 neurosurgery P < 00001 single metastases p = 0003 BS-BM p < 00001 control primary tumor p = 0002 and absence of extracranial metastases p = 0001 In multivariate analysis the factors associated positively with OS were neurosurgery p < 00001 absence of extracranial metastases p < 00001 and RPA class I p < 00001 Our data suggests that patients with BM from breast cancer classified as RPA class I may be effectively treated with local resection followed by WBRT mainly in those patients with single BM higher KPS and cranial extra disease controlled RPA class was shown to be the most reliable indicators of survival\",\n",
            "}\n",
            "13160\n",
            "{\n",
            "  \"id\" : \"8133536\",\n",
            "  \"contents\" : \"Tamoxifen is advantageous in treating all stages of breast cancer However studies have suggested that incidence and severity of endometrial cancer increase in women treated with tamoxifen We compared rates of endometrial and other cancers in tamoxifen - and non-tamoxifen-treated patients and described the pathologic characteristics of the endometrial cancers Data were analyzed on 2843 patients with node-negative estrogen receptor-positive invasive breast cancer randomly assigned to placebo or tamoxifen 20 mg/d and on 1220 tamoxifen-treated patients registered in NSABP B-14 subsequent to randomization Average time on study is 8 years for randomly assigned patients and 5 years for registered patients The incidence rates of liver gastrointestinal urinary tract and nonuterine genital tumors were not increased by tamoxifen treatment Twenty-five endometrial cancers were originally reported one of which was reclassified after subsequent review Two cases occurred in the placebo group in patients whose medical status subsequent to random assignment had required tamoxifen treatment Twenty-three occurred in the tamoxifen groups Twenty-one of the 24 originally reported endometrial cancers were FIGO stage 1 18 of 23 gradable cases were of good to moderate histologic grade Four tamoxifen-treated women died of uterine cancer The average annual hazard rate of endometrial cancer as a first event within the first 5 years of follow-up in the randomized tamoxifen-treated group was 12 / 1000 patient-years the cumulative hazard rate was 63 / 1000 Findings for the registered tamoxifen-treated group were similar Including all originally reported endometrial cancers the annual hazard rate through all follow-up was 02 / 1000 in the placebo group and 16 / 1000 in the randomized tamoxifen-treated group the relative risk of endometrial cancer for the latter versus the former group was 75 Again for the latter group using population-based rates of endometrial cancer from SEER data and information from another NSABP B-06 trial relative risks were 22 and 23 respectively The 5-year cumulative hazard rate for disease-free survival in the randomized tamoxifen group was 38 % less than that in the placebo group Some data in this paper were provided by an investigator who submitted fraudulent data to the NSABP [ see the News section ] therefore the reader must read the entire text including Table 10 and the Editor s notes In brief data on 182 of the 2843 randomly assigned patients and 37 of the 1220 registered patients were provided by the investigator in question After review 24 of the 182 records showed falsification all involving characteristics of patients prior to random assignment Of the 37 registered-patient records 8 showed falsification Risk of endometrial cancer increases following tamoxifen therapy for invasive breast cancer however net benefit greatly outweighs risk Endometrial cancers occurring after tamoxifen therapy do not appear to be of a different type with a worse prognosis than are such tumors in non-tamoxifen-treated patients Tamoxifen treatment for breast cancer should continue In addition the relative risk of endometrial cancer observed in B-14 tamoxifen-treated patients is consistent with the twofold relative risk used in the initial risk-benefit computation for the NSABP breast cancer prevention trial\",\n",
            "}\n",
            "13161\n",
            "{\n",
            "  \"id\" : \"8874455\",\n",
            "  \"contents\" : \"Non-surgical management of anal cancer by radiotherapy alone or combined with chemotherapy has in uncontrolled studies yielded similar local tumour control and survival rates to surgery However whether the addition of chemotherapy improves outcome without adding to morbidity is not known Our trial was designed to compare combined modality therapy CMT with radiotherapy alone in patients with epidermoid anal cancer From 856 patients considered for entry to our multicentre trial 585 patients were randomised to receive initially either 45 Gy radiotherapy in twenty or twenty-five fractions over 4-5 weeks 290 patients or the same regimen of radiotherapy combined with 5-fluorouracil 1000 mg/m2 for 4 days or 750 mg/m2 for 5 days by continuous infusion during the first and the final weeks of radiotherapy and mitomycin 12 mg/m2 on day 1 of the first course 295 patients We assessed clinical response 6 weeks after initial treatment good responders were recommended for boost radiotherapy and poor responders for salvage surgery The main endpoint was local-failure rate > or = 6 weeks after initial treatment secondary endpoints were overall and cause-specific survival Analysis was by intention-to-treat In the radiotherapy and CMT arms respectively five and three were ineligible and six and nine died 6 weeks after initial treatment After a median follow-up of 42 months interquartile range 28-62 164 of 279 59 % radiotherapy patients had a local failure compared with 101 of 283 36 % CMT patients This gave a 46 % reduction in the risk of local failure in the patients receiving CMT relative risk 054 95 % CI 042-0 69 p < 00001 The risk of death from anal cancer was also reduced in the CMT arm 071 053-0 95 p = 002 There was no overall survival advantage 086 067-1 11 p = 025 Early morbidity was significantly more frequent in the CMT arm p = 003 but late morbidity occurred at similar rates Our trial shows that the standard treatment for most patients with epidermoid anal cancer should be a combination of radiotherapy and infused 5-fluorouracil and mitomycin with surgery reserved for those who fall on this regimen\",\n",
            "}\n",
            "13162\n",
            "{\n",
            "  \"id\" : \"22567742\",\n",
            "  \"contents\" : \"Leucovorin Sodium LV/Na has a high solubility and is stable when given with continuous infusion of 5-FU It could maintain significant plasma concentration of 5 10-meTHF during the whole 5-FU perfusion with the potential of increasing 5-FU cytotoxicity We conducted a randomized phase II clinical trial on leucovorin calcium LV/Ca and LV/Na in metastatic colorectal cancer patients mCRC Main objectives were to assess efficacy and safety Fifty seven patients with mCRC and no previous chemotherapy for metastatic disease were randomized to receive LV/Na or LV/Ca with irinotecan or oxaliplatine combined with infusional 5-FU LV/Na was defined as warranting further evaluation in phase III if true overall response rate ORR > 35 % = 5 % = 10 % in case of true ORR > 55 % 51 evaluable patients planned/arm Results for LV/Ca and LV/Na arm respectively were observed ORR 55 % significantly higher than 35 % p = 002 and 61 % p = 0004 Median overall survival durations were 119 months and 229 months p = 002 and PFS 80 vs 115 months ns Grade 3 events were 64 % and 46 % p = 028 Both LV/Na and LV/Ca disclosed an ORR > 35 % with comparable safety\",\n",
            "}\n",
            "13163\n",
            "{\n",
            "  \"id\" : \"25151488\",\n",
            "  \"contents\" : \"Oral mucositis OM is a painful complication of radiation therapy RT for head and neck cancer H&NC OM can compromise nutrition require opioid analgesics and hospitalization for pain control and lead to treatment interruptions Based on the role of inflammatory pathways in OM pathogenesis we investigated effect of cyclooxygenase-2 COX-2 inhibition on severity and morbidity of OM In this double-blind placebo-controlled trial 40 H&NC patients were randomized to daily use of 200 mg celecoxib or placebo for the duration of RT Clinical OM normalcy of diet pain scores and analgesic use were assessed 2-3 times/week by blinded investigators during the 6-7 week RT period using validated scales Twenty subjects were randomized to each arm which were similar with respect to tumor location radiation dose and concomitant chemotherapy In both arms mucositis and pain scores increased over course of RT Intention-to-treat analyses demonstrated no significant difference in mean Oral Mucositis Assessment Scale OMAS scores at 5000 cGy primary endpoint There was also no difference between the two arms in mean OMAS scores over the period of RT mean worst pain scores mean normalcy of diet scores or mean daily opioid medication use in IV morphine equivalents There were no adverse events attributed to celecoxib use Daily use of a selective COX-2 inhibitor during period of RT for H&NC did not reduce the severity of clinical OM pain dietary compromise or use of opioid analgesics These findings also have implications for celecoxib use in H&NC treatment regimens NCT00698204\",\n",
            "}\n",
            "13164\n",
            "{\n",
            "  \"id\" : \"14736927\",\n",
            "  \"contents\" : \"On the basis of a previous meta-analysis the International Adjuvant Lung Cancer Trial was designed to evaluate the effect of cisplatin-based adjuvant chemotherapy on survival after complete resection of non-small-cell lung cancer We randomly assigned patients either to three or four cycles of cisplatin-based chemotherapy or to observation Before randomization each center determined the pathological stages to include its policy for chemotherapy the dose of cisplatin and the drug to be combined with cisplatin and its postoperative radiotherapy policy The main end point was overall survival A total of 1867 patients underwent randomization 365 percent had pathological stage I disease 242 percent stage II and 393 percent stage III The drug allocated with cisplatin was etoposide in 565 percent of patients vinorelbine in 268 percent vinblastine in 110 percent and vindesine in 58 percent Of the 932 patients assigned to chemotherapy 738 percent received at least 240 mg of cisplatin per square meter of body-surface area The median duration of follow-up was 56 months Patients assigned to chemotherapy had a significantly higher survival rate than those assigned to observation 445 percent vs 404 percent at five years [ 469 deaths vs 504 ] hazard ratio for death 086 95 percent confidence interval 076 to 098 P < 003 Patients assigned to chemotherapy also had a significantly higher disease-free survival rate than those assigned to observation 394 percent vs 343 percent at five years [ 518 events vs 577 ] hazard ratio 083 95 percent confidence interval 074 to 094 P < 0003 There were no significant interactions with prespecified factors Seven patients 08 percent died of chemotherapy-induced toxic effects Cisplatin-based adjuvant chemotherapy improves survival among patients with completely resected non-small-cell lung cancer\",\n",
            "}\n",
            "13165\n",
            "{\n",
            "  \"id\" : \"10329340\",\n",
            "  \"contents\" : \"The WISEWOMAN projects are examining the feasibility and effectiveness of adding a cardiovascular disease CVD prevention component to a nationwide program of early detection for breast and cervical cancer aimed at financially disadvantaged women This paper describes the rationale and design of the WISEWOMAN projects the baseline findings of the screenings and the plans for evaluation In selected breast and cervical cancer screening sites throughout Massachusetts Arizona and North Carolina blood pressure body weight cholesterol smoking diet and physical activity were assessed at baseline 6 months and 12 months To evaluate the effectiveness of CVD prevention these sites were assigned to either a minimum or an enhanced intervention group The enhanced interventions tailored to the populations served featured skill building and facilitating activities to improve nutrition and increase physical activity Baseline screenings of 4842 women revealed a high prevalence of CVD risk factors High cholesterol was found among 40 % of the women in North Carolina and Massachusetts hypertension was found among 63 % of the women in North Carolina and overweight was found among 83 % of the women in Arizona It is appropriate to expand breast and cervical cancer screening programs to include screening for CVD\",\n",
            "}\n",
            "13166\n",
            "{\n",
            "  \"id\" : \"19481335\",\n",
            "  \"contents\" : \"Bicalutamide monotherapy is a valuable option for prostate cancer PCa patients who wish to avoid the consequences of androgen deprivation however this treatment induces gynaecomastia and mastalgia in most patients Tamoxifen is safe and effective in preventing breast events induced by bicalutamide monotherapy without affecting antitumor activity but possible interference between bicalutamide and tamoxifen remains a matter of concern To reduce the exposure to tamoxifen we considered the putative advantages of weekly administration To compare the efficacy of two different schedules of tamoxifen in preventing breast events Toxicity prostate-specific antigen behaviour and sexual-functioning scores were also evaluated This was a noninferiority trial From December 2003 to February 2006 80 patients with localised/locally advanced or biochemically recurrent PCa who were also candidates for bicalutamide single therapy were randomised to receive two different schedules of tamoxifen daily n = 41 and weekly n = 39 Median follow-up was 242 mo Daily bicalutamide 150 mg plus daily tamoxifen 20mg continuously daily group or the same but with tamoxifen at 20mg weekly after the first 8 wk of daily treatment weekly group Three patients in the weekly group and one in the daily group were discontinued for adverse events For gynaecomastia we used ultrasonography For mastalgia and sexual functioning we used questionnaires Gynaecomastia developed in 317 % of patients in the daily group and in 744 % of patients in the weekly group p < 00001 and it was more severe in patients who switched to weekly tamoxifen p = 0001 Mastalgia occurred in 122 % and 461 % of patients respectively p = 0001 There were no major differences among treatment schedules relative to sexual functioning scores and incidence and severity of adverse events No differences between groups in PSA behaviour and disease progression have been detected so far This study demonstrated that tamoxifen 20mg/wk is inferior to tamoxifen 20mg/d in preventing the incidence and severity of bicalutamide-induced breast events The safety and efficacy of tamoxifen at the common daily dose of 20mg for the prophylaxis of bicalutamide-induced breast events were confirmed\",\n",
            "}\n",
            "13167\n",
            "{\n",
            "  \"id\" : \"26163093\",\n",
            "  \"contents\" : \"To optimize palliation in incurable locally advanced non-small cell lung cancer NSCLC the International Atomic Energy Agency conducted a prospective randomized study NCT00864331 comparing protracted palliative radiotherapy RT course with chemotherapy CHT followed by short-course palliative RT Treatment-naive patients with histologically confirmed NSCLC stage IIIA/IIIB received either 39Gy in 13 fractions as RT alone arm A n = 31 or 2-3 platinum-based CHT cycles followed by 10Gy in a single fraction or 16Gy in 2 fractions separated by one week arm B n = 34 Primary outcome was overall survival Treatment groups were balanced with respect to various variables Median survival for all 65 patients was 8months while median survival was 71 and 81 months for the two arms respectively log-rank p = 04 by study arm and p = 06 by Cox regression and stratified by country and sub-stage One and three year survival rates for the two arms were 29 % and 9 % and 41 % and 6 % respectively There were no differences in any of the following endpoints any failure local failure regional failure contralateral thoracic failure and distant failure between the two arms High-grade 3 toxicity was similar between the two arms Symptoms adverse events of any kind KPS and body-mass index were not different during treatment and during follow-up There was no grade 5 toxicity This incomplete and underpowered trial only hinted similar outcome between the treatment arms Therefore combined CHT-RT can perhaps be considered in limited resource setting where access to RT remains inadequate\",\n",
            "}\n",
            "13168\n",
            "{\n",
            "  \"id\" : \"17969893\",\n",
            "  \"contents\" : \"To observe the efficacy of Zhiling Capsule ZLC in improving symptoms and quality of life QOL in patients with various types of cancer in mid-advanced stage A multi-centre randomized and controlled trial was conducted Four hundred patients with mid-advanced cancer were assigned to two groups the treatment group 300 cases treated with ZLC and the control group 100 cases with Pingxiao Capsule PXC both were given orally for two weeks Clinical symptoms QOL weight and adverse reactions were observed before and after treatment Improving rate of symptom increasing rates of QOL and weight in the treatment group were all higher than those in the control group P < 005 and no obvious adverse reaction was observed in the two groups ZLC could alleviate the qi-yin deficiency syndrome and pain syndrome and improve QOL in patients with various types of cancer in mid-advanced stage\",\n",
            "}\n",
            "13169\n",
            "{\n",
            "  \"id\" : \"11993588\",\n",
            "  \"contents\" : \"To assess the feasibility of offering health promotion and preventive medicine initiatives in primary care A pilot study aimed at men in general practice to establish the uptake acceptability and effectiveness of interventions in health initiatives One thousand men aged 18-65 were selected at random from five general practices in the Western Health Board area Practices were randomly allocated to one of four brief interventions cardiovascular screening cancer screening stress management or general lifestyle advice Fifty-five per cent of men responded with 357 % actually attending There were minor but significant short-term changes in health status and behaviours Participants expressed high levels of satisfaction but tended to prefer interventions with an explicit clinical component It is at least as feasible to offer health promotion for men in primary care as it is for other demographic groups but adequate training and resources are required\",\n",
            "}\n",
            "13170\n",
            "{\n",
            "  \"id\" : \"18786981\",\n",
            "  \"contents\" : \"The combination of cisplatin and etoposide PE has been a standard treatment for patients with poor-prognosis small cell lung cancer SCLC This non-inferiority design trial aimed to determine whether the combination of gemcitabine and carboplatin GC results in similar survival but is less toxic with better quality of life Previously untreated patients with SCLC with extensive disease or limited stage with poor prognostic factors were randomly assigned to six 3-weekly cycles of GC or PE 241 patients 121 GC 120 PE were recruited of which 216 90 % had died There was no difference in overall survival HR 101 95 % CI 077 to 132 Median survival with GC and PE was 80 and 81 months respectively Median progression-free survival was 59 months with GC and 63 months with PE Grade 3 or 4 myelosuppressions were more frequent with GC anaemia 14 % GC vs 2 % PE leucopenia 32 % GC vs 13 % PE thrombocytopenia 22 % GC vs 4 % PE but these were not associated with increased hospital admissions infections or fatalities Grade 2-3 alopecia 68 % PE vs 17 % GC and nausea 43 % PE vs 26 % GC were more frequent with PE Patients given GC received more chemotherapy as outpatients 89 % GC vs 66 % PE of treatment cycles In QoL questionnaires more patients receiving PE reported being upset by hair loss p = 0004 and impaired cognitive functioning p = 004 GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients ISRCTN 39679215\",\n",
            "}\n",
            "13171\n",
            "{\n",
            "  \"id\" : \"20878572\",\n",
            "  \"contents\" : \"To evaluate the clinical efficacy and the toxicity of neoadjuvant chemotherapy with paclitaxel and FOLFOX4 5-fluorouracil/leucovorin combined and oxaliplatin regimen for advanced gastric cancer Seventy-eight patients with cTNM stage III or IV M0 gastric cancer were enrolled and 39 were randomized into the treatment arm n = 39 paclitaxel combined with FOLFOX4 regimen neoadjuvant chemotherapy every two weeks in each cycle and control group n = 39 Clinical response was evaluated with RECIST criteria after 3 cycles Patients in experimental group received surgery after 2-4 weeks and postoperative chemotherapy of 3 cycles of the original regimen When disease progressed postoperative chemotherapy regimen was changed into ECF regimen The control group of 39 patients received surgery within 2 weeks and postoperative chemotherapy of 6 cycles of paclitaxel combined with FOLFOX4 regimen The clinical response rate was 667 % in the treatment arm The R0 resection rate 590 % was significantly higher than that in the control group P = 0025 and the number of lymph node metastasis in the treatment arm 323280 was significantly lower than that in the control group 579269 P = 0001 There were no significant differences in postoperative complication rate 51 % vs 26 % and the number of lymph node dissection 1969295 vs 2059322 between the two groups P > 005 The median survival time and 2-year survival rate in the treatment arm [ 2710232 months and 590 % ] was significantly higher than that in the control group [ 1820130 months and 282 % ] P = 0001 P = 0006 Cox regression multivariable analysis showed that tumor differentiation R0 resection lymph node metastasis were independent prognostic factors Adverse reaction of chemotherapy mainly hematological adverse reactions and peripheral nerve toxicity were tolerable No significant differences were noted between the two groups in adverse reactions P > 005 The efficacy of paclitaxel combined with FOLFOX4 as neoadjuvant chemotherapy is high Patients tolerance and compliance are satisfactory It can improve in patients with advanced gastric cancer the R0 resection rate reduce lymph node metastasis and improve survival\",\n",
            "}\n",
            "13172\n",
            "{\n",
            "  \"id\" : \"25355723\",\n",
            "  \"contents\" : \"To improve the therapeutic index of whole-brain radiation therapy WBRT in the treatment of brain metastases BM from breast cancer we investigated the efficacy and safety of WBRT combined with temozolomide TMZ in this population This phase II multicenter prospective randomized study included patients with newly diagnosed intraparenchymal BMs from breast cancer unsuitable for surgery or radiosurgery All patients received conformal WBRT 3 Gy 10-30 Gy with or without concomitant TMZ administered at a dosage of 75 mg/m 2 / day during the irradiation period The primary end point was objective response rate ORR 6 weeks after the end of treatment defined as a partial or complete response on systematic brain MRI modified WHO criteria Secondary end points were progression-free survival PFS and overall survival OS neurologic symptoms and tolerability Between February 2008 and November 2010 100 patients were enrolled in the study 50 in the WBRT + TMZ arm 50 in the WBRT arm Median age was 55 years 29-79 Median follow-up was 94 months [ 10-68 1 ] ORRs at 6 weeks were 36 % in the WBRT arm and 30 % in the WBRT + TMZ arm NS In the WBRT arm median PFS was 74 months and median OS was 111 months In the WBRT + TMZ arm median PFS was 69 months and median OS was 94 months Treatment was well tolerated in this arm the most common grade 2 acute toxicity was reversible lymphopenia WBRT combined with TMZ did not significantly improve local control and survival in patients with BMs from breast cancer CLINICALTRIALSGOV NCT00875355\",\n",
            "}\n",
            "13173\n",
            "{\n",
            "  \"id\" : \"12775739\",\n",
            "  \"contents\" : \"Quality of life QOL outcomes in patients with chronic myeloid leukemia CML were evaluated in an international phase III study Newly diagnosed patients with chronic phase CML were randomly assigned to imatinib or interferon alfa plus subcutaneous low-dose cytarabine IFN+LDAC Cross-over to the other treatment was permitted because of intolerance or lack of efficacy Patients completed cancer-specific QOL Functional Assessment of Cancer Therapy-Biologic Response Modifiers and utility Euro QoL-5D questionnaires at baseline and during treatment n = 1049 The primary QOL end point was the Trial Outcome Index TOI a measure of physical function and well-being Secondary end points included social and family well-being SFWB emotional well-being EWB and the utility score Primary analyses were intention to treat with secondary analyses accounting for cross-over Patients receiving IFN+LDAC experienced a large decline in the TOI whereas those receiving imatinib maintained their baseline level Treatment differences at each visit were significant P < 001 and clinically relevant in favor of imatinib Mean SFWB EWB and utility scores were also significantly better for those patients taking imatinib Patients who crossed over to imatinib experienced a large increase in TOI significant P < 001 differences were observed between patients who did and did not cross over in favor of imatinib Imatinib offers clear QOL advantages compared with IFN+LDAC as first-line treatment of chronic phase CML In addition patients who cross over to imatinib from IFN+LDAC experience a significant improvement in QOL compared with patients who continue to take IFN+LDAC\",\n",
            "}\n",
            "13174\n",
            "{\n",
            "  \"id\" : \"16673060\",\n",
            "  \"contents\" : \"To explore the role of religious belief in coping with disease symptoms and treatment-related side effects in patients with head-and-neck cancer under radiotherapy Prospectively collected data were used with a cohort of head-and-neck cancer patients treated by radiotherapy and epoetin beta or placebo within a double-blind multicenter trial All patients were divided into believers and nonbelievers Answers to a quality of life questionnaire at four points in time during radiotherapy were analyzed according to both groups Clinical parameters and therapy side effects were controlled regularly 621 % of the patients 66/105 sent back a baseline questionnaire discriminating between believers and nonbelievers For 342 % 40/105 data of all four measures could be obtained On average believers felt better in all categories of side effects at all points of time before during and directly after therapy Religious faith seems to play an important role in coping strategies of radiotherapy patients More research in this area would be worthwhile\",\n",
            "}\n",
            "13175\n",
            "{\n",
            "  \"id\" : \"25417042\",\n",
            "  \"contents\" : \"Breathlessness in patients with lung cancer is a common and distressing symptom affecting 50-70 % of patients rising to some 90 % for those with advanced lung cancer The aim of the current study was to assess how feasible inspiratory muscle training IMT is in the lung cancer population and explore changes in outcome variables A pilot feasibility randomised trial was conducted in patients with clinically stable lung cancer The experimental group received training using a pressure threshold device Patients were instructed to carry out five IMT sessions weekly for 12 weeks for a total of 30 mins/day Patients in the control group received standard care Outcome measures were completed at baseline and monthly for 3 months and included physiological parameters FEV1 FVC perceived severity of breathlessness using six 10-point NRS modified Borg Scale quality of life using the short form Chronic Respiratory Disease Questionnaire Hospital Anxiety and Depression Scale and safety Forty-six patients M = 37 F = 9 at a mean age of 695 years old and a mean of 16 months post-diagnosis who were not currently receiving chemotherapy and/or radiotherapy were recruited Seventy-percent had NSCLC and advanced disease Statistical area under the curve-AUC and clinically important differences were seen with regard to distress from breathlessness p = 003 ability to cope with breathlessness p = 001 satisfaction with breathlessness management p = 0001 fatigue p = 0005 emotional function p = 0011 breathlessness mastery p = 0015 and depression p = 0028 The m-Borg difference between the two groups at 3 months was 080 which is borderline clinically significant Changes were more evident in the 3-month assessment where the effect of the intervention came to its peak This trial shows the IMT is feasible and potentially effective in patients with lung cancer These findings warrant a fully powered larger randomised controlled trial\",\n",
            "}\n",
            "13176\n",
            "{\n",
            "  \"id\" : \"19508716\",\n",
            "  \"contents\" : \"The Screening Inventory of Psychosocial Problems SIPP is a short validated self-reported questionnaire to identify psychosocial problems in Dutch cancer patients The one-page 24-item questionnaire assesses physical complaints psychological complaints and social and sexual problems Very little is known about the effects of using the SIPP in consultation settings Our study aims are to test the hypotheses that using the SIPP a may contribute to adequate referral to relevant psychosocial caregivers b should facilitate communication between radiotherapists and cancer patients about psychosocial distress and c may prevent underdiagnosis of early symptoms reflecting psychosocial problems This paper presents the design of a cluster randomised controlled trial CRCT evaluating the effectiveness of using the SIPP in cancer patients treated with radiotherapy A CRCT is developed using a Solomon four-group design two intervention and two control groups to evaluate the effects of using the SIPP Radiotherapists instead of cancer patients are randomly allocated to the experimental or control groups Within these groups all included cancer patients are randomised into two subgroups with and without pre-measurement Self-reported assessments are conducted at four times a pre-test at baseline before the first consultation and a post-test directly following the first consultation and three and 12 months after baseline measurement The primary outcome measures are the number and types of referrals of cancer patients with psychosocial problems to relevant psychosocial caregivers The secondary outcome measures are patients satisfaction with the radiotherapist-patient communication psychosocial distress and quality of life Furthermore a process evaluation will be carried out Data of the effect-evaluation will be analysed according to the intention-to-treat principle and data regarding the types of referrals to health care providers and patient satisfaction about the with radiotherapists will be analysed by means of descriptive techniques The process evaluation data will also be analysed by means of descriptive techniques Using the SIPP may prevent underdiagnosis of early symptoms reflecting psychosocial problems should facilitate communication between physicians and patients about psychosocial distress and may contribute to adequate referral to relevant psychosocial caregivers NCT00859768\",\n",
            "}\n",
            "13177\n",
            "{\n",
            "  \"id\" : \"18427147\",\n",
            "  \"contents\" : \"Limited data are available on the efficacy of oral bisphosphonate therapy in breast cancer survivors Our goal was to examine prevention of breast cancer-related bone loss in this cohort Eighty-seven postmenopausal women after chemotherapy for breast cancer were randomly assigned to once-weekly risedronate 35 mg or placebo for 24 months Outcomes included bone mineral density BMD and turnover markers At study initiation 13 % of patients were on an aromatase inhibitor AI After 24 months there were differences of 16 to 25 % P < 05 at the spine and hip BMD between the placebo and risedronate groups At study completion 44 % were on an AI Adjusting for an AI women on placebo plus AI had a decrease in BMD of mean + / - SE 48 % + / - 08 % at the spine and 28 % + / - 05 % at the total hip both P < 001 In women on risedronate + AI the spine decreased by 24 % + / - 11 % P < 05 and was stable at the hip Women in the placebo group not on an AI maintained BMD at the spine and had a 12 % + / - 05 % loss at the total hip P < 05 Women who received risedronate but no AI had the greatest improvement in BMD of 22 % + / - 09 % P < 05 at the total hip Bone turnover was reduced with risedronate There were no differences in adverse events between the groups We conclude that in postmenopausal women with breast cancer with or without AI therapy once-weekly oral risedronate was beneficial for spine and hip BMD reduced bone turnover and was well tolerated\",\n",
            "}\n",
            "13178\n",
            "{\n",
            "  \"id\" : \"24246414\",\n",
            "  \"contents\" : \"Nowadays advanced irradiation techniques make it possible to escalate safely the dose in prostate cancer We studied the effect of a higher dose on tumor control in a randomized trial with a median follow-up of 110 months Patients with T1b-T4N0 prostate cancer n = 664 were randomized between 78 Gy and 68 Gy Primary endpoint was biochemical and/or clinical failure BCF according to the American Society for Therapeutic Radiology and Oncology ASTRO guidelines 3 consecutive rises and to Phoenix nadir plus 2 g/L Secondary endpoints were clinical failure CF local failure LF prostate cancer death PCD and overall survival OS Explorative subgroup analyses were performed BCF rate HR = 08 20 % less events and LF rate HR = 05 50 % less events were significantly lower in the 78 Gy arm p < 005 CF PCD and OS were similar in both arms A significant heterogeneity of treatment effect was found for PSA cutoffs between 7 and 10 g/L We observed significantly less BCF and LF in the high-dose arm This suggests improvement of the therapeutic ratio However we observed similar rates of CF and PCD at the current update More follow-up is needed to investigate which patients benefit in terms of prolonged OS\",\n",
            "}\n",
            "13179\n",
            "{\n",
            "  \"id\" : \"19815651\",\n",
            "  \"contents\" : \"The optimal platinum doublet regimen in elderly patients with non-small-cell lung cancer NSCLC is still uncertain We conducted a randomized phase II study to compare the efficacy and safety of weekly paclitaxel combined with carboplatin with those of the standard schedule Elderly patients age > or = 70 years with advanced NSCLC were randomly assigned to either the weekly arm { 70 mg/m 2 paclitaxel on days 1 8 and 15 and carboplatin [ area under the curve AUC = 6 ] on day 1 } or the standard arm [ 200 mg/m 2 paclitaxel and carboplatin AUC = 6 on day 1 ] The primary end point was the overall response rate ORR Eighty-two patients were enrolled The ORR and median progression-free survival were 55 % and 60 months for the weekly arm and 53 % and 56 months for the standard arm Grade 3/4 neutropenia and peripheral neuropathy were observed in 41 % and 0 % of the patients in the weekly arm and in 88 % and 25 % in the standard arm respectively This is the first randomized study that compares the platinum doublet designed specifically for the elderly Regarding the safety the weekly regimen was less toxic than the standard regimen and seems to be preferable for elderly patients with advanced NSCLC\",\n",
            "}\n",
            "13180\n",
            "{\n",
            "  \"id\" : \"10561342\",\n",
            "  \"contents\" : \"Because small-cell lung cancer is a rapidly proliferating tumor it was hypothesized that it may be more responsive to thoracic irradiation TI given twice-daily than once-daily This hypothesis was tested in a phase III trial Patients with limited-stage small-cell lung cancer were entered onto a phase III trial and all patients initially received three cycles of etoposide 130 mg/m 2 x 3 and cisplatin 30 mg/m 2 x 3 Subsequently patients who did not have progression to a distant site other than brain were randomized to twice-daily thoracic irradiation TDTI versus once-daily thoracic irradiation ODTI given concomitantly with two additional cycles of etoposide 100 mg/m 2 x 3 and cisplatin 30 mg/m 2 x 3 The irradiation doses were TDTI 48 Gy in 32 fractions with a 25-week break after the initial 24 Gy and ODTI 504 Gy in 28 fractions After thoracic irradiation the patients received a sixth cycle of etoposide/cisplatin followed by prophylactic cranial irradiation 30 Gy/15 fractions if they had a complete response Of 311 assessable patients enrolled in the trial 262 underwent randomization to TDTI or ODTI There were no differences between the two treatments with respect to local-only progression rates overall progression rates or overall survival The patients who received TDTI had greater esophagitis > or = grade 3 than those who received ODTI 123 % v 53 % P = 05 Although patients received thoracic irradiation encompassing the postchemotherapy volumes only seven of 90 local failures were out of the portal of irradiation When TI is delayed until the fourth cycle of chemotherapy TDTI does not result in improvement in local control or survival compared with ODTI\",\n",
            "}\n",
            "13181\n",
            "{\n",
            "  \"id\" : \"20022032\",\n",
            "  \"contents\" : \"Spaced education is a novel form of online education that harnesses the 2 psychology research findings of spacing and testing effects Spaced education is delivered by daily emails containing clinically relevant multiple choice questions To take advantage of the spacing effect the questions are repeated at fixed intervals for a fixed number of repetitions An adaptive spaced education system was developed to customize spacing intervals and the number of repetitions based on learner knowledge level To determine whether this system improves learning efficiency I performed a randomized trial to compare the learning efficiency of adaptive vs nonadaptive spaced education systems among surgery students at 2 medical schools A total of 62 year 3 students were randomized to identical course content in adaptive or nonadaptive spaced education formats The course consisted of 40 validated spaced education items on the 4 urology topics benign prostatic hyperplasia erectile dysfunction prostate cancer and prostate specific antigen screening The nonadaptive cohort received daily emails containing 2 questions with a linear review of the material 20 days after initial presentation The adaptive cohort received daily emails via an adaptive algorithm that limited the repetition of mastered content Each cohort completed a validated end of course test The adaptive cohort answered significantly fewer spaced education items than the nonadaptive cohort p = 0001 but achieved comparable end of course test scores p = 037 The adaptive algorithm increased learning efficiency by 38 % Adaptive spaced education boosts learning efficiency\",\n",
            "}\n",
            "13182\n",
            "{\n",
            "  \"id\" : \"25351455\",\n",
            "  \"contents\" : \"Breast cancer survivors who make preference-sensitive decisions about postmastectomy breast reconstruction often have large gaps in knowledge and undergo procedures that are misaligned with their treatment goals We evaluated the feasibility and effect of a pre-consultation educational group intervention on the decision-making process for breast reconstruction We conducted a pilot randomized controlled trial RCT where participants were randomly assigned to the intervention with routine education or routine education alone The outcomes evaluated were decisional conflict decision self-efficacy satisfaction with information perceived involvement in care and uptake of reconstruction following surgical consultation Trial feasibility and acceptability were evaluated and effect sizes were calculated to determine the primary outcome for the full-scale RCT Of the 41 patients enrolled recruitment rate was 72 % treatment fidelity was 98 % and retention rate was 95 % The Cohen s d effect size in reduction of decisional conflict was moderate to high for the intervention group compared to routine education 069 95 % CI = 002-1 42 while the effect sizes of increase in decision self-efficacy 005 95 % CI = -060 -071 and satisfaction with information 011 95 % CI = -053 -076 were small A higher proportion of patients receiving routine education signed informed consent to undergo breast reconstruction 14/20 or 70 % compared to the intervention group 8/21 or 38 % P = 006 A pre-consultation educational group intervention improves patients shared decision-making quality compared to routine preoperative patient education A full-scale definitive RCT is warranted based on high feasibility outcomes and the primary outcome for the main trial will be decisional conflict\",\n",
            "}\n",
            "13183\n",
            "{\n",
            "  \"id\" : \"10100592\",\n",
            "  \"contents\" : \"The antiemetic effect of granisetron injection at a dose of 40 microg/kg used in the treatment of nausea/vomiting induced by multidrug combined cancer chemotherapy excluding cisplatin in patients with tumors of hematopoietic organs was evaluated by comparing a 30-min infusion and a slow intravenous injection given over 30 sA two-group random-allocation comparative study was performed with the cooperation of multiple institutions using a central registration system In the treatment of acute clinical symptoms appetite was described as similar to that during good health by 611 % of patients 55/93 in the instillation group and by 473 % 44/93 in the slow injection group a significant advantage in the infusion group However no significant differences in the number of episodes of vomiting the severity of nausea or clinical efficacy were found In the final clinical evaluation and assessment of usefulness based on the subjective judgement of physicians throughout the entire therapeutic period no differences were discernible No side effects were reported for either method and there was no indication of a sex difference concerning efficacy However the efficacy in patients with an anemic tendency was slightly inferior The maintenance of appetite during the administration of anticancer drugs is very important to maintain patients daily activities and quality of life The present results support the usefulness of infusion of granisetron as an administration method during chemotherapy for malignant hemopathy\",\n",
            "}\n",
            "13184\n",
            "{\n",
            "  \"id\" : \"24603102\",\n",
            "  \"contents\" : \"We studied adjuvant daily sildenafil citrate during and after radiotherapy for prostate cancer for erectile function preservation We performed a randomized prospective trial of 279patients with localized prostate cancer treated with radiotherapy who received sildenafil citrate 50 mg daily or placebo 21 randomization Medication/placebo was initiated 3 days before treatment and continued daily for 6months Before therapy and 3 6 9 12 18 and 24 months after radiotherapy patients completed the IIEF questionnaire including the erectile function domain the I-PSS questionnaire and the RAND SF-36 All IIEF domains werescored At 12 months erectile function scores were better for sildenafil citrate than placebo p = 0018 73 % of patients on sildenafil citrate vs 50 % on placebo had mild/no erectile dysfunction p = 0024 and the sildenafil citrate arm had superior overall satisfaction p = 0027 and IIEF total scores p = 0043 At 24months erectile function and IIEF scores were no longer significantly better for sildenafil citrate p = 0172 and 009 respectively and yet overall satisfaction scores were higher p = 0033 Sexual desire scores in patients who received sildenafil citrate were higher at 24 months although they had completed drug therapy 18 months previously p = 0049 At 24 months 816 % of patients on sildenafil citrate and 560 % of those on placebo achieved functional erection with or without erectile dysfunction medication p = 0045 Daily sildenafil citrate during and after radiotherapy for prostate cancer was associated with improved overall sexual function compared with placebo for various sexual function domains To our knowledge this is the largestrandomized prospective controlled trial to show the usefulness of a phosphodiesterase-5 inhibitor as a rehabilitation strategy in patients with prostate cancer who received radiation therapy\",\n",
            "}\n",
            "13185\n",
            "{\n",
            "  \"id\" : \"23553796\",\n",
            "  \"contents\" : \"Radiotherapy RT in rectal cancer increases postoperative morbidity A suggested reason is RT-induced bone marrow depression resulting in impaired leucocyte counts The ongoing Stockholm III Trial randomizes patients with operable rectal cancers to short-course RT with immediate surgery SRT short-course RT with surgery delayed for 4-8 weeks SRT-delay and long-course RT with surgery delayed for 4-8 weeks LRT-delay This study examined differences between the randomization arms regarding leucocyte response and postoperative complications Patients randomized in the Stockholm III Trial between October 1998 and November 2010 were included Data were collected in a prospective register Additional data were obtained by retrospective review of clinical records Of 657 randomized patients 585 had data on leucocytes The SRT arm had the highest proportion of postoperative complications SRT 525 per cent SRT-delay 394 per cent LRT-delay 41 per cent P = 0010 There was no association between low preoperative leucocyte count and postoperative complications P = 0238 Irrespective of randomization arm patients with an impaired postoperative to preoperative leucocyte ratio had the highest rate of complications low ratio 566 per cent intermediate ratio 469 per cent high ratio 363 per cent P = 0010 The SRT arm had the highest proportion of low ratios SRT 489 per cent SRT-delay 228 per cent LRT-delay 22 per cent P < 0001 An impaired postoperative leucocyte response is associated with postoperative complications The highest risk is with immediate surgery following short-course radiotherapy NCT 00904813 http//wwwclinicaltrialsgov\",\n",
            "}\n",
            "13186\n",
            "{\n",
            "  \"id\" : \"24956453\",\n",
            "  \"contents\" : \"Patients undergoing breast cancer surgery frequently experience chronic postoperative pain The primary objective of this randomized study was to determine if thoracic paravertebral block TPVB reduced the incidence of chronic pain after a modified radical mastectomy MRM when compared with general anesthesia GA One hundred eighty women undergoing MRM were randomized to 1 of 3 study groups group 1 standardized GA group 2 GA with a single-injection TPVB and placebo paravertebral infusion and group 3 GA with a continuous TPVB Outcomes assessed postoperatively included acute postoperative pain and analgesic consumption and at 3 and 6 months the incidence and severity of chronic pain and physical and mental health-related quality of life HRQOL There was no significant difference in the incidence of chronic pain at 3 months P = 013 and 6 months P = 079 after the MRM between the study groups The relative risk of developing chronic pain P = 025 was also similar between the groups There was no difference in acute pain P = 022 or postoperative analgesic consumption P = 067 between the groups Nevertheless differences were observed in chronic pain-related secondary outcome variables The TPVB groups reported lower chronic pain scores P < 005 exhibited fewer symptoms and signs of chronic pain P 001 and also experienced better physical and mental HRQOL than did the GA group Chronic pain scores also decreased with time in all study groups P < 005 There is no significant difference in the incidence or relative risk of chronic pain at 3 and 6 months after an MRM when TPVB is used in conjunction with GA Nevertheless patients who receive a TPVB report less severe chronic pain exhibit fewer symptoms and signs of chronic pain and also experience better physical and mental HRQOL\",\n",
            "}\n",
            "13187\n",
            "{\n",
            "  \"id\" : \"20332140\",\n",
            "  \"contents\" : \"Customized chemotherapy is likely to improve outcome in patients with advanced non-small-cell lung cancer NSCLC Excision repair cross-complementation group 1 ERCC1 is a promising biomarker however current evidence is inadequate Impact of ERCC1 status was evaluated among patients participating in a large randomized chemotherapy trial Four hundred and forty-three patients with advanced NSCLC were enrolled in a phase III trial and were randomly allocated to triplet chemotherapy or standard doublet regimen Immunohistochemical evaluation for ERCC1 status was mainly carried out on bioptic material Two hundred and sixty-four 595 % patients had representative tissue samples for ERCC1 evaluation Median overall survival OS in the ERCC1-negative and ERCC1-positive population was 118 and 98 months respectively P = 0028 The median OS among patients with adenocarcinomas n = 122 was 152 and 83 months respectively P = 0007 Interaction analysis between ERCC1-negative status and adenocarcinomas yielded a hazard ratio of 064 for death P = 0002 Clinically applicable evaluation of ERCC1 status predicted cisplatin sensitivity in the largest randomized patient population with advanced NSCLC reported to date The predictive value can be ascribed to the adenocarcinomas emphasizing the relevance of ERCC1 expression in this subgroup\",\n",
            "}\n",
            "13188\n",
            "{\n",
            "  \"id\" : \"16754728\",\n",
            "  \"contents\" : \"Tamoxifen has been approved for breast cancer risk reduction in high-risk women but how raloxifene compares with tamoxifen is unknown To compare the differences in patient-reported outcomes quality of life [ QOL ] and symptoms in Study of Tamoxifen and Raloxifene STAR participants by treatment assignment STAR was a double-blind randomized phase 3 prevention trial designed to evaluate the relative efficacy of raloxifene vs tamoxifen in reducing the incidence of invasive breast cancer in high-risk postmenopausal women Between July 1 1999 and November 4 2004 19747 participants were enrolled at centers throughout North America with a median potential follow-up time of 46 years range 12-6 5 years Patient-reported symptoms were collected from all participants using a 36-item symptom checklist Quality of life was measured with the Medical Outcomes Study Short-Form Health Survey SF-36 the Center for Epidemiologic Studies-Depression CES-D and the Medical Outcomes Study Sexual Activity Questionnaire in a substudy of 1983 participants median potential follow-up 54 years range 46-6 0 years Questionnaires were administered before treatment every 6 months for 60 months and at 72 months Primary QOL end points were the SF-36 physical PCS and mental MCS component summaries Among women in the QOL analysis mean PCS MCS and CES-D scores worsened modestly over the study s 60 months with no significant difference between the tamoxifen n = 973 and raloxifene n = 1010 groups P > 2 Sexual function was slightly better for participants assigned to tamoxifen age-adjusted repeated measure odds ratio 122 % 95 % CI 101-1 46 Of the women in the symptom assessment analyses the 9769 in the raloxifene group reported greater mean symptom severity over 60 months of assessments than the 9743 in the tamoxifen group for musculoskeletal problems 115 vs 110 P = 002 dyspareunia 078 vs 068 P < 001 and weight gain 082 vs 076 P < 001 Women in the tamoxifen group reported greater mean symptom severity for gynecological problems 029 vs 019 P < 001 vasomotor symptoms 096 vs 085 P < 001 leg cramps 110 vs 091 P < 001 and bladder control symptoms 088 vs 073 P < 001 No significant differences existed between the tamoxifen and raloxifene groups in patient-reported outcomes for physical health mental health and depression although the tamoxifen group reported better sexual function Although mean symptom severity was low among these postmenopausal women those in the tamoxifen group reported more gynecological problems vasomotor symptoms leg cramps and bladder control problems whereas women in the raloxifene group reported more musculoskeletal problems dyspareunia and weight gain clinicaltrialsgov Identifier NCT00003906\",\n",
            "}\n",
            "13189\n",
            "{\n",
            "  \"id\" : \"11709742\",\n",
            "  \"contents\" : \"The German Adjuvant Breast Cancer Study Group GABG conducts trials of preoperative chemotherapy in patients with primary breast cancer using a combination of doxorubicin and docetaxel ADoc We conducted a parallel-grouped phase IIa-study with 42 patients with a conventionally dosed and a dose-dense ADoc-schedule 4 cycles of Doxorubicin 50 mg/m 2 Docetaxel 75 mg/m 2 i v day 1 q day 15 or 22 G-CSF day 3-15 only for the dose-dense schedule and a randomized phase IIb-study GEPARDO-Study with 250 patients with ADoc + / - Tamoxifen Biological factors were determined immunohistochemically on 197 core biopsies before treatment A comparison to a sequential AC-Doc regimen including 913 patients has been completed recently ADoc can be applicated on schedule in 93 % of all patients The dose-dense regimen shows a tendency to more toxicity but also to more efficacy The rate of complete pathological remissions pCR was 97 % No difference was found between chemo - and chemoendocrine treatment Clinically negative lymphnodes and a negative estrogen receptor status is predictive for a higher pCR-rate To date no differences in toxicity could be found between ADoc and AC-Doc The dose-dense ADoc regimen is well tolerated and highly effective as preoperative therapy of breast cancer\",\n",
            "}\n",
            "13190\n",
            "{\n",
            "  \"id\" : \"10076721\",\n",
            "  \"contents\" : \"Neoadjuvant chemotherapy improves overall survival and renders possible breast-conserving treatment in locally advanced breast cancer It was necessary for this method to be evaluated in operable breast tumors too large to be treated immediately by conserving surgery Initial results of this randomized trial were published in Annals of Oncology 1991 Women with T2 > 3 cm or T3 N0-1 M0 breast tumors were treated by either initial mastectomy followed by adjuvant chemotherapy or neoadjuvant chemotherapy followed by adjusted locoregional treatment Chemotherapy was the same in the two arms The prognostic and predictive factors of response to chemotherapy were analyzed Conserving treatments were performed in 63 % at the end of neoadjuvant chemotherapy and this rate had decreased to 45 % at the median follow-up of 124 months Survivals are identical in the two treatment groups Initial clinical tumor size < 40 mm IHC-ER < 10 % and Mib1 > 40 % are predictive of tumor response to chemotherapy by uni - and multivariate analyses For outcome prediction c-erb-B2 > 0 % is the independent prognostic factor for overall and metastasis-free survivals Breast-conserving therapy can be performed in more than half of all cases without alteration of survival despite a non-negligible rate of local recurrences\",\n",
            "}\n",
            "13191\n",
            "{\n",
            "  \"id\" : \"16043828\",\n",
            "  \"contents\" : \"Epidermal growth factor receptor EGFR mutations have been associated with tumor response to treatment with single-agent EGFR inhibitors in patients with relapsed non-small-cell lung cancer NSCLC The implications of EGFR mutations in patients treated with EGFR inhibitors plus first-line chemotherapy are unknown KRAS is frequently activated in NSCLC The relationship of KRAS mutations to outcome after EGFR inhibitor treatment has not been described Previously untreated patients with advanced NSCLC in the phase III TRIBUTE study who were randomly assigned to carboplatin and paclitaxel with erlotinib or placebo were assessed for survival response and time to progression TTP EGFR exons 18 through 21 and KRAS exon 2 were sequenced in tumors from 274 patients Outcomes were correlated with EGFR and KRAS mutations in retrospective subset analyses EGFR mutations were detected in 13 % of tumors and were associated with longer survival irrespective of treatment P < 001 Among erlotinib-treated patients EGFR mutations were associated with improved response rate P < 05 and there was a trend toward an erlotinib benefit on TTP P = 092 but not improved survival P = 96 KRAS mutations 21 % of tumors were associated with significantly decreased TTP and survival in erlotinib plus chemotherapy-treated patients EGFR mutations may be a positive prognostic factor for survival in advanced NSCLC patients treated with chemotherapy with or without erlotinib and may predict greater likelihood of response Patients with KRAS-mutant NSCLC showed poorer clinical outcomes when treated with erlotinib and chemotherapy Further studies are needed to confirm the findings of this retrospective subset analysis\",\n",
            "}\n",
            "13192\n",
            "{\n",
            "  \"id\" : \"17704418\",\n",
            "  \"contents\" : \"Older node-positive patients treated with newer adjuvant chemotherapy regimens have improvements in relapse-free and overall survival similar to younger patients We compared toxicity of older and younger patients in three randomized trials of adjuvant chemotherapy Toxicity data were available for 93 % of 6642 patients enrolled The three trials included Cancer and Leukemia Group B CALGB 8541 a comparison of cyclophosphamide doxorubicin and fluorouracil in three dose schedules CALGB 9344 cyclophosphamide and doxorubicin with or without paclitaxel and CALGB 9741 cyclophosphamide doxorubicin and paclitaxel every 2 versus every 3 weeks National Cancer Institute grade 3 to 5 toxicities were compared among age groups Seven percent of patients n = 458 were age 65 or older 3 % were 70 or older 38 % were 51 to 64 and 55 % were 50 or younger Twenty-four deaths 04 % were attributed to treatment seven 15 % of 486 in patients 65 or older 10 040 % of 2480 in patients who were 51 to 64 years and seven 019 % of 3676 occurred in patients younger than 50 In multivariate analysis older patients were significantly more likely to have grade 4 hematologic toxicity to have discontinued treatment for toxicity or to have died of acute myeloid leukemia/myelodysplastic syndrome There were no significant differences in grade 3 to 4 nonhematologic toxicity Healthy older patients who met the strict eligibility criteria for these trials had a higher rate of hematologic toxicity and treatment-related deaths than younger patients but no increase in nonhematologic toxicity Elderly patients treated with newer adjuvant chemotherapy regimens derive the same benefits from newer chemotherapy regimens as younger patients but should be cautioned about the increased risk of toxicity and treatment-related death\",\n",
            "}\n",
            "13193\n",
            "{\n",
            "  \"id\" : \"26169611\",\n",
            "  \"contents\" : \"Tivantinib a MET receptor tyrosine kinase inhibitor demonstrated increased anticancer activity in preclinical and early clinical studies when combined with erlotinib Our study aimed to confirm efficacy and safety of the combination in previously treated patients with non-small-cell lung cancer NSCLC Patients with advanced nonsquamous NSCLC previously treated with one to two systemic regimens including a platinum doublet were randomly assigned at a 11 ratio to receive erlotinib 150 mg daily plus oral tivantinib 360 mg twice daily E + T or erlotinib plus placebo E + P until disease progression Tumor specimens were evaluated for EGFR and KRAS mutations MET expression and MET gene amplification The primary end point was overall survival OS Secondary and exploratory objectives included progression-free survival PFS OS in molecular subgroups and safety The study enrolled 1048 patients and was discontinued for futility at the interim analysis OS did not improve with E + T versus E + P median OS 85 v 78 months respectively hazard ratio [ HR ] 098 95 % CI 084 to 115 P = 81 even though PFS increased median PFS 36 v 19 months HR 074 95 % CI 062 to 089 P < 001 Exploratory subgroup analyses suggested OS improvement in patients with high MET expression HR 070 95 % CI 049 to 101 Most common adverse events occurring with E + T versus E + P were rash 331 % v 373 % respectively diarrhea 346 % v 410 % asthenia or fatigue 435 % v 381 % and neutropenia grade 3 to 4 85 % v 08 % E + T was well tolerated and increased PFS but did not improve OS in the overall nonsquamous NSCLC population\",\n",
            "}\n",
            "13194\n",
            "{\n",
            "  \"id\" : \"20006459\",\n",
            "  \"contents\" : \"We examined how navigation defined as the assessment and alleviation of barriers to adequate health care influences patients perspectives on the quality of their cancer care We conducted post-study patient interviews from a randomized controlled trial usual care vs patient navigation services from cancer diagnosis through treatment completion Patients were recruited from 11 primary care hospital and community oncology practices in New York We interviewed patients about their expectations and experience of patient navigation or for non-navigated patients other sources of assistance Thirty-five patients newly diagnosed with breast or colorectal cancer Valued aspects of navigation included emotional support assistance with information needs and problem-solving and logistical coordination of cancer care Unmet cancer care needs expressed by patients randomized to usual care consisted of lack of assistance or support with childcare household responsibilities coordination of care and emotional support Cancer patients value navigation Instrumental benefits were the most important expectations for navigation from navigated and non-navigated patients Navigated patients received emotional support and assistance with information needs problem-solving and logistical aspects of cancer care coordination Navigation services may help improve cancer care outcomes important to patients by addressing fragmented confusing uncoordinated or inefficient care\",\n",
            "}\n",
            "13195\n",
            "{\n",
            "  \"id\" : \"21910336\",\n",
            "  \"contents\" : \"To explore the clinical value of Chinese medical intervention and treatment of high-risk human papilloma virus HR-HPV infection in patients of cervical cancer CC during radiotherapy RT Eighty CC patients of the Ia-IIb stage receiving primary RT were assigned to two groups RT and local intervention by Xunxi No 1 was given to patients in the test group for 20 days while patients in the control group were treated with RT alone Expression of high-risk HPV HR-HPV HPV16/18 infection was detected by in-situ hybridization ISH before and after treatment The 5-year disease free survival rate and pelvic lymph node metastasis rate with the lymph node diameter > 09 cm shown by CT in patients were observed After treatment the HR-HPV positive rate was lowered from 675 % 27/40 to 375 % 15/40 in the test group P < 005 while it was lowered from 725 % 29/40 to 650 % 26/40 in the control group P > 005 By follow-ups the 3-year disease free survival rate in the test group was better than that in the control group 33/40 vs 27/40 showing insignificant difference between the two groups P > 005 Significant difference was shown in the 5-year disease free survival rate and the pelvic lymph node metastasis rate 650 % vs 425 % 75 % vs 250 % between the two groups both P < 005 In early RT of CC combined application of Xunxi No 1 could obviously lower the HPV positive rate The 5-year disease free survival rate was superior to that in the control group with lower pelvic lymph node metastasis rate Xunxi No 1 had better clinical value in clinical application\",\n",
            "}\n",
            "13196\n",
            "{\n",
            "  \"id\" : \"17164376\",\n",
            "  \"contents\" : \"Both obesity and sex hormones are known risk factors for postmenopausal breast cancer Although adiposity and sex hormones have been studied in the past previous reports in postmenopausal women have not been conducted under carefully controlled dietary conditions In this study we investigated the usefulness of body mass index BMI as a sufficient adiposity measurement to assess associations with sex hormone levels This study was conducted as a cross-sectional analysis within the control segment 0 g alcohol group of a randomized crossover design in which 51 postmenopausal women consumed 0 control 15 one drink and 30 two drinks g alcohol ethanol / d for 8 weeks each as part of a controlled diet Dual-energy X-ray absorptiometry scans were administered to the women during the control 0 g alcohol segment and a blood sample was drawn at the end of that diet period for hormone analysis In multivariate analysis adjusted for age race family history of breast cancer parity and menarche < 12 years women who were overweight or obese had significantly higher serum concentrations of estradiol bioavailable estradiol estrone and estrone sulfate and lower sex hormone-binding globulin than normal weight women all P < 005 In models adjusted for BMI and the covariates above none of the dual-energy X-ray absorptiometry adiposity measures added further information all P > 010 for these five analytes beyond that of BMI alone In this population of postmenopausal women under carefully controlled dietary conditions we confirmed previous findings that higher levels of adiposity were associated with higher concentrations of estrogens and lower sex hormone-binding globulin and we found that the use of the epidemiology-friendly BMI seems sufficient to assess associations with these hormone levels\",\n",
            "}\n",
            "13197\n",
            "{\n",
            "  \"id\" : \"21347224\",\n",
            "  \"contents\" : \"Chronic HBV infects 350 million people causing cancer and liver failure We aimed to assess the safety and efficacy of plasmid DNA pSG2HBs vaccine followed by recombinant modified vaccinia virus Ankara MVAHBs encoding the surface antigen of HBV as therapy for chronic HBV A secondary goal was to characterize the immune responses Firstly 32 HBV e antigen negative eAg - participants were randomly assigned to one of four groups to receive vaccines alone lamivudine 3TC alone both or neither Later 16 eAg + volunteers in two groups received either 3TC alone or both 3TC and vaccines Finally 12 eAg - and 12 eAg + subjects were enrolled into higher-dose treatment groups Healthy but chronically HBV-infected males between the ages of 15-25 who lived in the western part of The Gambia were eligible Participants in some groups received 1 mg or 2 mg of pSG2HBs intramuscularly twice followed by 510 7 pfu or 1510 8 pfu of MVAHBs intradermally at 3-weekly intervals with or without concomitant 3TC for 11-14 weeks Intradermal rabies vaccine was administered to a negative control group Safety was assessed clinically and biochemically The primary measure of efficacy was a quantitative PCR assay of plasma HBV Immunity was assessed by IFN - ELISpot and intracellular cytokine staining Mild local and systemic adverse events were observed following the vaccines A small shiny scar was observed in some cases after MVAHBs There were no significant changes in AST or ALT HBeAg was lost in one participant in the higher-dose group As expected the 3TC therapy reduced viraemia levels during therapy but the prime-boost vaccine regimen did not reduce the viraemia The immune responses were variable The majority of IFN - was made by antigen non-specific CD16 + cells both CD3 + and CD3 - The vaccines were well tolerated but did not control HBV infection ISRCTN ISRCTN67270384\",\n",
            "}\n",
            "13198\n",
            "{\n",
            "  \"id\" : \"20209742\",\n",
            "  \"contents\" : \"According to recent census data 1216600 Canadians are of Chinese descent and over 80 % of Chinese Canadians are foreign born Approximately 10 % of Chinese immigrants are chronic carriers of hepatitis B compared with less than 05 % of the general population English as a second language ESL classes provide ready access for individuals with limited English proficiency who are not reached by English language health education materials and media campaigns We conducted a group-randomized trial to evaluate the effectiveness of a hepatitis B ESL educational curriculum for Chinese immigrants Five community-based organizations that provide ESL education in the greater Vancouver area participated in the study Forty-one ESL classes which included 325 Chinese students were randomly assigned to experimental or control status A follow-up survey conducted six months after randomization assessed knowledge about hepatitis B Generalized estimating equations were used to analyze the data Follow-up surveys were completed by 298 92 % of the students At follow-up experimental group students were significantly p < 005 more likely than control group students to know that immigrants have higher hepatitis B infection rates than people who were born in Canada hepatitis B can be spread during childbirth during sexual intercourse and by sharing razors hepatitis B is not spread by sharing eating utensils and hepatitis B infection can cause cirrhosis and liver cancer Our findings indicate that ESL curricula can have a positive impact on health knowledge among Chinese immigrants with limited English Future research should evaluate the effectiveness of ESL curricula for other immigrant groups as well as other health topics\",\n",
            "}\n",
            "13199\n",
            "{\n",
            "  \"id\" : \"25015203\",\n",
            "  \"contents\" : \"Mature data on tumor control and survival are presented from a randomized trial of the addition of a brachytherapy boost to long-course neoadjuvant chemoradiation therapy CRT for locally advanced rectal cancer Between March 2005 and November 2008 248 patients with T3-4N0-2M0 rectal cancer were prospectively randomized to either long-course preoperative CRT 504 Gy in 28 fractions per oral tegafur-uracil and L-leucovorin alone or the same CRT schedule plus a brachytherapy boost 10 Gy in 2 fractions The primary trial endpoint was pathologic complete response pCR at the time of surgery secondary endpoints included overall survival OS progression-free survival PFS and freedom from locoregional failure Results for the primary endpoint have previously been reported This analysis presents survival data for the 224 patients in the Danish part of the trial In all 221 patients 111 control arm 110 brachytherapy boost arm had data available for analysis with a median follow-up time of 54 years Despite a significant increase in tumor response at the time of surgery no differences in 5-year OS 706 % vs 636 % hazard ratio [ HR ] = 124 P = 34 and PFS 639 % vs 520 % HR = 122 P = 32 were observed Freedom from locoregional failure at 5 years were 939 % and 857 % HR = 260 P = 06 in the standard and in the brachytherapy arms respectively There was no difference in the prevalence of stoma Explorative analysis based on stratification for tumor regression grade and resection margin status indicated the presence of response migration Despite increased pathologic tumor regression at the time of surgery we observed no benefit on late outcome Improved tumor regression does not necessarily lead to a relevant clinical benefit when the neoadjuvant treatment is followed by high-quality surgery\",\n",
            "}\n",
            "13200\n",
            "{\n",
            "  \"id\" : \"10623705\",\n",
            "  \"contents\" : \"A randomized phase III clinical trial of adjuvant active specific immunotherapy ASI with an autologous tumor cell-bacillus Calmette-Gurin BCG vaccine was conducted to determine whether surgical resection plus ASI was more beneficial than resection alone in stage II and III colon cancer patients Patients n = 412 with colon cancer 297 with stage II disease 115 with stage III disease were randomly allocated to an observation arm or to a treatment arm in which they received three weekly intradermal vaccine injections of 10 7 irradiated autologous tumor cells beginning approximately 4 weeks after surgery The first two weekly injections also contained 10 7 BCG organisms Patients were observed for determination of time to recurrence and disease-free and overall survival This was a negative study in that after a 76-year median follow-up period there were no statistically significant differences in clinical outcomes between the treatment arms However there were disease-free survival P = 078 and overall survival P = 12 trends in favor of ASI when treatment compliance was evaluated ie patients who received the intended treatment had a delayed cutaneous hypersensitivity DCH response to the third vaccination induration > / = 5 mm Also the magnitude of the DCH response correlated with improved prognosis The 5-year survival proportion was 846 % for those with indurations greater than 10 mm compared with 450 % for those with indurations less than 5 mm When all randomized patients were evaluated no significant clinical benefit was seen with ASI in surgically resected colon cancer patients with stage II or III colon cancer However there was an indication that treatment compliance with effective immunization results in disease-free and overall survival benefits\",\n",
            "}\n",
            "13201\n",
            "{\n",
            "  \"id\" : \"19002689\",\n",
            "  \"contents\" : \"Orthotopic neobladder reconstruction has become a standard form of urinary diversion in many centers for patients undergoing radical cystectomy for bladder cancer There is still controversy about the best technique for construction of the neobladder and especially whether it is necessary to include an antireflux mechanism We designed a prospective randomized clinical trial comparing two forms of ileal neobladder the Studer pouch and the T-pouch The latter includes an extraserosal tunneled afferent limb which prevents reflux from the pouch to the kidneys The primary endpoint of the study is renal function and anatomy at 3 years following surgery with secondary endpoints including early and late postoperative complications renal infections and need for secondary procedures To date we have randomized 462 patients over approximately 6 years with a planned full enrollment of 550 patients Ten percent of patients have been withdrawn because they did not undergo the planned orthotopic diversion due to a positive urethral margin on frozen section We expect approximately 70 % of patients to be alive and available for follow-up at 3 years which will give us ample power to detect clinically meaningful differences in the outcome of these two diversions This trial has been feasible and randomization has been acceptable to most patients Long-term follow-up of the patients on this trial should be able to definitively answer the question of the importance of an antireflux mechanism in the orthotopic neobladders construction\",\n",
            "}\n",
            "13202\n",
            "{\n",
            "  \"id\" : \"24597866\",\n",
            "  \"contents\" : \"Radical prostatectomy reduces mortality among men with localized prostate cancer however important questions regarding long-term benefit remain Between 1989 and 1999 we randomly assigned 695 men with early prostate cancer to watchful waiting or radical prostatectomy and followed them through the end of 2012 The primary end points in the Scandinavian Prostate Cancer Group Study Number 4 SPCG-4 were death from any cause death from prostate cancer and the risk of metastases Secondary end points included the initiation of androgen-deprivation therapy During 232 years of follow-up 200 of 347 men in the surgery group and 247 of the 348 men in the watchful-waiting group died Of the deaths 63 in the surgery group and 99 in the watchful-waiting group were due to prostate cancer the relative risk was 056 95 % confidence interval [ CI ] 041 to 077 P = 0001 and the absolute difference was 110 percentage points 95 % CI 45 to 175 The number needed to treat to prevent one death was 8 One man died after surgery in the radical-prostatectomy group Androgen-deprivation therapy was used in fewer patients who underwent prostatectomy a difference of 250 percentage points 95 % CI 177 to 323 The benefit of surgery with respect to death from prostate cancer was largest in men younger than 65 years of age relative risk 045 and in those with intermediate-risk prostate cancer relative risk 038 However radical prostatectomy was associated with a reduced risk of metastases among older men relative risk 068 P = 004 Extended follow-up confirmed a substantial reduction in mortality after radical prostatectomy the number needed to treat to prevent one death continued to decrease when the treatment was modified according to age at diagnosis and tumor risk A large proportion of long-term survivors in the watchful-waiting group have not required any palliative treatment Funded by the Swedish Cancer Society and others\",\n",
            "}\n",
            "13203\n",
            "{\n",
            "  \"id\" : \"18349393\",\n",
            "  \"contents\" : \"This study was designed to compare fluorouracil leucovorin and oxaliplatin with fluorouracil leucovorin and cisplatin in patients with advanced gastric cancer Patients with previously untreated advanced adenocarcinoma of the stomach or esophagogastric junction were randomly assigned to receive either fluorouracil 2600 mg/m 2 via 24-hour infusion leucovorin 200 mg/m 2 and oxaliplatin 85 mg/m 2 FLO every 2 weeks or fluorouracil 2000 mg/m 2 via 24-hour infusion leucovorin 200 mg/m 2 weekly and cisplatin 50 mg/m 2 every 2 weeks FLP The primary end point was progression-free survival PFS Two hundred twenty patients median age 64 years metastatic 94 % were randomly assigned FLO was associated with significantly less any grade anemia 54 % v 72 % nausea 53 % v 70 % vomiting 31 % v 52 % alopecia 22 % v 39 % fatigue 19 % v 34 % renal toxicity 11 % v 34 % thromboembolic events 09 % v 78 % and serious adverse events related to the treatment 9 % v 19 % FLP was associated with significantly less peripheral neuropathy 22 % v 63 % There was a trend toward improved median PFS with FLO versus FLP 58 v 39 months respectively P = 077 and no significant difference in median overall survival 107 v 88 months respectively However in patients older than 65 years n = 94 treatment with FLO resulted in significantly superior response rates 413 % v 167 % P = 012 time to treatment failure 54 v 23 months P < 001 and PFS 60 v 31 month P = 029 and an improved OS 139 v 72 months as compared with FLP respectively FLO reduced toxicity as compared with FLP In older adult patients FLO also seemed to be associated with improved efficacy\",\n",
            "}\n",
            "13204\n",
            "{\n",
            "  \"id\" : \"24916837\",\n",
            "  \"contents\" : \"Studies suggest that both affective and cognitive processes are involved in the perception of vulnerability to cancer and that affect has an early influence in this assessment of risk We constructed a path model based on a conceptual framework of heuristic reasoning affect resemblance and availability coupled with cognitive processes involved in developing personal models of cancer causation From an eligible cohort of 16700 women in a managed care organization we randomly selected 2524 women at high elevated and average risk of ovarian cancer and administered a questionnaire to test our model response rate 763 % Path analysis delineated the relationships between personal and cognitive characteristics number of relatives with cancer age ideas about cancer causation perceived resemblance to an affected friend or relative and ovarian cancer knowledge and emotional constructs closeness to an affected relative or friend time spent processing the cancer experience and cancer worry on perceived risk of ovarian cancer Our final model fit the data well root mean square error of approximation RMSEA = 0028 comparative fit index CFI = 099 normed fit index NFI = 098 This final model 1 demonstrated the nature and direction of relationships between cognitive characteristics and perceived risk 2 showed that time spent processing the cancer experience was associated with cancer worry and 3 showed that cancer worry moderately influenced perceived risk Our results highlight the important role that family cancer experience has on cancer worry and shows how cancer experience translates into personal risk perceptions This understanding informs the discordance between medical or objective risk assessment and personal risk assessment Published in 2014 This article is a US Government work and is in the public domain in the USA\",\n",
            "}\n",
            "13205\n",
            "{\n",
            "  \"id\" : \"20546516\",\n",
            "  \"contents\" : \"Paravertebral block PVB is an effective alternative to general anesthesia for breast cancer surgery Continuous paravertebral block CPVB anesthesia may extend postoperative analgesia at home and improve quality of early postoperative recovery of breast cancer patients This double-blinded randomized trial was conducted to compare degree of pain nausea mood level of symptom distress and time to return to normal daily activity between PVB and PVB + CPVB in patients undergoing outpatient breast cancer surgery Between July 2003 and April 2008 we randomly assigned 94 73 evaluable patients in a 111 ratio with early breast cancer to single injection PVB followed by CPVB infusion of 01 % or 02 % ropivacaine vs placebo saline for 48 hours postoperatively for unilateral breast cancer surgery without reconstruction The primary study endpoint was the degree of pain nausea mood state level of symptom distress and recovery time Of the 468 patients assessed for eligibility 94 consented and 21 with incomplete data or follow-up were excluded leaving 73 subjects for analysis There was no clinically significant difference in degree of postoperative pain nausea mood state level of symptom distress or return to normal activity among the three study groups The current study does not support the routine use of continuous paravertebral catheter anesthesia in patients undergoing operative treatment for breast cancer\",\n",
            "}\n",
            "13206\n",
            "{\n",
            "  \"id\" : \"23780837\",\n",
            "  \"contents\" : \"Low high-density lipoprotein cholesterol HDL-C and type II diabetes are associated with an increased risk for cancer Patients with type II diabetes typically have low HDL-C however the association between HDL-C and cancer has not been examined in this population A total of 11140 patients with type II diabetes were followed for a median of 5 years Cox proportional hazard models were used to assess the association between baseline HDL-C and risk of cancer incidence and cancer death with adjustments made for potential confounders To explore the possibility of reverse causation analyses were repeated for the cancers occurring in the first and second halves of follow-up Six hundred and ninety-nine patients developed cancer with 48 % occurring within the first half of follow-up For every 04 mmol/L lower baseline HDL-C there was a 16 % higher risk of cancer [ HR 116 95 % confidence interval CI 106-1 28 P = 00008 ] and cancer death HR 116 95 % CI 101-1 32 P = 003 After adjustment for confounding the higher risk remained significant for cancer adjusted HR 110 95 % CI 100-1 22 P = 005 but not for cancer death adjusted HR 108 95 % CI 093-1 25 P = 031 The association was driven by cancers occurring within the first half of follow-up adjusted HR 122 95 % CI 105-1 41 P = 0008 as no significant association was found between HDL-C and cancer in the second half of follow-up Low HDL-C is associated with cancer risk in patients with type II diabetes However this association may be explained by confounding and reverse causation HDL-C is not a risk factor for cancer in type II diabetes\",\n",
            "}\n",
            "13207\n",
            "{\n",
            "  \"id\" : \"24644183\",\n",
            "  \"contents\" : \"Pain during bone marrow biopsy BMB under local anaesthesia LA is reported in 70 % of patients of whom 35 % rate the pain as severe Pain is experienced during both the biopsy and the marrow aspiration Many medical centres use conscious sedation involving benzodiazepines and/or opioids administered orally or intravenously for BMB analgesia Methoxyflurane MEOF is self-administered by a handheld device the Penthrox inhaler which is licensed in Australia for the relief of pain associated with short surgical procedures To evaluate the efficacy and safety of MEOF analgesia in patients with cancer undergoing BMB Patients received LA plus either MEOF or placebo The primary endpoint was worst pain intensity measured with the Numerical Rating Scale Anxiety was assessed with the State Trait Anxiety Inventory STAI-Y-1 Patients operators and the research nurse rated global medication performance using a 5-point Likert scale Forty-nine of the 50 patients randomised to MEOF and 48 of the 50 patients randomised to placebo effectively received the allocated intervention MeanSD worst pain overall was 490207 in MEOF group and 60224 in placebo group p = 0011 Worst pain during the aspiration was 3320 in MEOF group and 5024 in placebo group p < 0001 49 % of patients treated with MEOF rated the medication as very good or excellent compared with 165 % of the patients treated with placebo p = 0005 204 % of patients treated with MEOF had an adverse event AE compared with 42 % in the placebo arm p = 0028 All AEs were grade 1 MEOF was safe and performed better than placebo for analgesia in BMB procedures\",\n",
            "}\n",
            "13208\n",
            "{\n",
            "  \"id\" : \"25091056\",\n",
            "  \"contents\" : \"Preoperative nutrition is beneficial for malnourished cancer patients Yet there is little evidence whether or not it should be given to nonmalnourished patients The aim of this study was to assess the need to introduce preoperative nutritional support in patients without malnutrition at qualification for surgery This was a prospective two-arm randomized controlled open-label study Patients in interventional group received nutritional supplementation for 14 days before surgery while control group kept on to their everyday diet Each patient s nutritional status was assessed twice -- at qualification weight loss in 6 months laboratory parameters albumin total protein transferrin and total lymphocyte count and 1 day before surgery change in body weight and laboratory parameters After surgery all patients were followed up for 30 days for postoperative complications Fifty-four patients in interventional and 48 in control group were analyzed In postoperative period patients in control group suffered from significantly higher p < 0001 number of serious complications compared with patients receiving nutritional supplementation Moreover levels of all laboratory parameters declined significantly p < 0001 in these patients while in interventional arm were stable albumin and total protein or raised transferrin and total lymphocyte count Preoperative nutritional support should be introduced for nonmalnourished patients as it helps to maintain proper nutritional status and reduce number and severity of postoperative complications compared with patients without such support\",\n",
            "}\n",
            "13209\n",
            "{\n",
            "  \"id\" : \"25122437\",\n",
            "  \"contents\" : \"ATLAS compared bevacizumab plus erlotinib B+E with bevacizumab plus placebo B+P as maintenance therapy after first-line bevacizumab plus chemotherapy B+C for advanced non-small-cell lung cancer NSCLC Prespecified biomarkers were prospectively evaluated Tumor samples were analyzed for epidermal growth factor receptor EGFR expression immunohistochemistry [ IHC ] EGFR gene copy number fluorescence in-situ hybridization [ FISH ] EGFR mutations exon 19 deletions/L858R mutations and KRAS mutations exons 2/3 Progression-free survival PFS and overall survival OS were estimated Of 743 patients randomized to receive maintenance treatment after four cycles of B+C without progression 190 B+E and 177 B+P were evaluable for biomarker status Median PFS from randomization was 44 months B+E versus 37 months B+P hazard ratio [ HR ] 075 95 % confidence interval [ CI ] 057-0 99 which was numerically similar to the intent-to-treat PFS PFS benefit of B+E was observed across most biomarker subgroups EGFR IHC EGFR FISH and EGFR/KRAS mutation status were not predictive of outcome B+E - treated patients with EGFR mutation-positive NSCLC had longer PFS compared with B+P - treated patients HR 044 95 % CI 022-0 86 p = 00139 Patients with KRAS wild-type disease had significant PFS improvements with B+E compared with B+P HR 066 95 % CI 0485-0 914 p = 00105 No OS benefit of B+E was observed Patients with KRAS wild-type or EGFR mutation-positive NSCLC derived PFS benefits from B+E However EGFR IHC EGFR FISH and EGFR or KRAS mutation status were not strongly predictive of survival A larger sample size would be needed to confirm the initial trends observed in this study\",\n",
            "}\n",
            "13210\n",
            "{\n",
            "  \"id\" : \"16889324\",\n",
            "  \"contents\" : \"Women with breast cancer suffer from considerable stress related to the diagnosis surgery and medical treatment It is important to develop strategies to strengthen coping resources among these women Research in art therapy has shown outcomes such as an increase in self-esteem and cohesion significant improvement in global health and a decrease in anxiety and depression The aim of the present article was to describe the effects of an art therapy intervention program on coping resources in women with primary breast cancer In this article we report some of the results from a study including 41 women aged 37-69 years old with nonmetastatic primary breast cancer referred to the Department of Oncology at Ume University Hospital in Sweden for postoperative radiotherapy The women represented various socioeconomic backgrounds They were randomized to a study group n = 20 with individual art therapy for 1 h/week during postoperative radiotherapy or to a control group n = 21 The article focuses on changes in coping resources as measured by the Coping Resources Inventory CRI before and 2 and 6 months after the start of radiotherapy The study protocol was approved by the Ume University Ethical Committee at the Medical Faculty archive number 99-386 There was an overall increase in coping resources among women with breast cancer after taking part in the art therapy intervention Significant differences were seen between the study and control groups in the social domain on the second and third occasions Significant differences were also observed in the total score on the second occasion This study shows that individual art therapy provided by a trained art therapist in a clinical setting can give beneficial support to women with primary breast cancer undergoing radiotherapy as it can improve their coping resources\",\n",
            "}\n",
            "13211\n",
            "{\n",
            "  \"id\" : \"15764270\",\n",
            "  \"contents\" : \"Prostate cancer PC is a highly lethal neoplastic disease affecting the physical mental and social well-being of patients ie their quality of life QOL Patients suffering from metastatic PC are faced with serious decisions regarding treatment strategies Therefore QOL information has become a crucial element of decision making in this group of patients The first objective of this study was to describe QOL in a group of patients diagnosed with metastatic PC and skeletal metastases At the time of evaluation the patients had not received any treatment but were evaluated before entering a study of androgen-modulating therapy the Scandinavian Prostate Cancer Group study 5 The second objective was to identify demographic and disease-related factors affecting QOL A total of 917 patients with metastatic PC were evaluated using a well-described and validated questionnaire [ European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-C30 EORTC QLQ-C30 ] The characteristics of the PC were noted and simultaneously patients were evaluated with respect to use of analgesics pain and performance status using a scoring system Biochemical tests were performed when patients entered the study A multivariate regression analysis was performed to analyse the correlations between QOL scores patient demographics and disease-related data The patients reported QOL scores significantly lower than those in the background population Pain and fatigue were pronounced whereas dyspnoea insomnia loss of appetite constipation and diarrhoea were less prominent Patients with high tumour grades high PSPA scores the sum of the pain score the performance status and the use of analgesics and those using analgesics had significantly lower QOL scores than the other patients Patients with metastatic PC have reduced QOL Our findings are in line with those of other studies of QOL among patients with this disease as evaluated by means of the EORTC QLQ-C30 questionnaire Baseline data from studies like this provide important information when treatment modalities for PC are evaluated\",\n",
            "}\n",
            "13212\n",
            "{\n",
            "  \"id\" : \"20716619\",\n",
            "  \"contents\" : \"To evaluate a decision aid DA designed to promote informed decision making for prostate cancer screening Twelve work sites were randomly assigned to an intervention or nonintervention comparison condition Intervention sites received access to a computer-tailored DA at the workplace Male employees age 45 years and above n = 625 completed surveys at baseline and at 3-month follow-up documenting aspects of informed decision making Using an intention-to-treat analysis men in the intervention group were significantly more likely to have made a screening decision and to have improved knowledge without increased decisional conflict relative to men in the comparison group These changes were observed despite the fact that only 30 % of men in intervention sites used the DA Among DA users similar improvements were observed although the magnitudes of changes were substantially greater and significant improvements in decision self-efficacy were observed A DA offered in the workplace promoted decision making improved knowledge and increased decision self-efficacy among users without increasing decisional conflict However participation was suboptimal suggesting that better methods for engaging men in workplace interventions are needed IMPACT STATEMENT This trial shows the efficacy of a computer-tailored DA in promoting informed decisions about prostate cancer screening The DA was delivered through work sites thereby providing access to resources required to participate in informed decision making without requiring a medical appointment However participation rates were suboptimal and additional strategies for engaging men are needed\",\n",
            "}\n",
            "13213\n",
            "{\n",
            "  \"id\" : \"16257791\",\n",
            "  \"contents\" : \"Androgen deprivation is an established treatment regimen for disseminated prostate cancer however its role in patients with localised cancer is less clear We did a large randomised controlled trial to determine whether 3 months or 6 months of androgen deprivation given before and during radiotherapy improves outcomes for patients with locally advanced prostate cancer 818 men with locally advanced prostate cancer were randomly assigned to no androgen deprivation ie radiotherapy alone 66 Gy in 33 fractions of 2 Gy per day over 65-7 0 weeks to the prostate and seminal vesicles 3 months androgen deprivation with 36 mg goserelin given subcutaneously every month and 250 mg flutamide given orally three times a day starting 2 months before radiotherapy same regimen as control group or 6 months androgen deprivation with the same regimen starting 5 months before radiotherapy same regimen as control group Primary endpoints were time to local failure and prostate-cancer-specific survival secondary endpoints were distant failure disease-free survival and freedom from salvage treatment Analyses were done by intention to treat 802 98 % patients were eligible for analysis Median follow-up was 59 years range 01-8 5 Compared with patients assigned no androgen deprivation those assigned 3 months treatment had significantly improved local failure hazard ratio [ HR ] 056 [ 95 % CI 039-0 79 ] p = 0001 biochemical failure-free survival 070 [ 056-0 88 ] p = 0002 disease-free survival 065 [ 052-0 80 ] p = 00001 and freedom from salvage treatment 073 [ 056-0 96 ] p = 0025 6 months androgen deprivation significantly improved local failure 042 [ 028-0 62 ] p < 00001 biochemical failure-free survival 058 [ 046-0 74 ] p < 00001 disease-free survival 056 [ 045-0 69 ] p < 00001 freedom from salvage treatment 053 [ 040-0 71 ] p < 00001 distant failure 067 [ 045-0 99 ] p = 0046 and prostate-cancer-specific survival 056 [ 032-0 98 ] p = 004 compared with no androgen deprivation 6 months androgen deprivation given before and during radiotherapy improves the outlook of patients with locally advanced prostate cancer Further follow-up is needed to estimate precisely the size of survival benefits Increased radiation doses and additional periods of androgen deprivation might lead to further benefit\",\n",
            "}\n",
            "13214\n",
            "{\n",
            "  \"id\" : \"19531265\",\n",
            "  \"contents\" : \"The diagnosis and treatment of cancer is a major life stress such that approximately 35 % of patients experience persistent clinically significant distress and carers often experience even higher distress than patients This paper presents the design of a two arm randomised controlled trial with patients and carers who have elevated psychological distress comparing minimal contact self management vs an individualised tele-based cognitive behavioural intervention 140 patients and 140 carers per condition 560 participants in total will been recruited after being identified as high distress through caller screening at two community-based cancer helplines and randomised to 1 a single 30-minute telephone support and education session with a nurse counsellor with self management materials 2 a tele-based psychologist delivered five session individualised cognitive behavioural intervention Session components will include stress reduction problem-solving cognitive challenging and enhancing relationship support and will be delivered weekly Participants will be assessed at baseline and 3 6 and 12 months after recruitment Outcome measures include anxiety and depression cancer specific distress unmet psychological supportive care needs positive adjustment overall Quality of life The study will provide recommendations about the efficacy and potential economic value of minimal contact self management vs tele-based psychologist delivered cognitive behavioural intervention to facilitate better psychosocial adjustment and mental health for people with cancer and their carers ACTRN12609000301268\",\n",
            "}\n",
            "13215\n",
            "{\n",
            "  \"id\" : \"22766314\",\n",
            "  \"contents\" : \"Pemetrexed and docetaxel are established therapies in second line non-small cell lung cancer NSCLC Comparative data concerning the two agents in the designated settings however are lacking in Chinese patients who account for the largest lung cancer population in the world We designed and performed a multi-center randomized exploratory clinical trial of pemetrexed compared with docetaxel in second line chemotherapy in Chinese NSCLC patients Eligible patients with histological or cytological diagnosis of stage IIIB or IV NSCLC who were not suitable for curative therapy and had failed from prior first line chemotherapy regimen for at least 4 weeks were randomized to receive either pemetrexed 500 mg/m 2 intravenously day 1 with vitamin B12 folic acid and dexamethasone or docetaxel 75 mg/m 2 intravenously day 1 with dexamethasone Both regimens were implemented once every 21 days for 2 cycles This study was designed to be a non-inferiority trial that compared tumor response for overall response rate ORR between the two drugs as primary endpoint The secondary endpoints included disease control rate DCR Karnofsky performance status KPS scores and toxicities 260 patients were enrolled and randomly assigned to receive chemotherapy of either pemetrexed 132 patients or docetaxel 128 patients 106 patients in pemetrexed arm and 102 patients in docetaxel arm were evaluable for efficacy The efficacy of pemetrexed was equivalent to that of docetaxel in the second-line treatment for Chinese NSCLC ORR pemetrexed vs docetaxel = 94 % vs 49 p = 0285 DCR pemetrexed vs docetaxel = 672 % vs 696 % p = 0685 And pemetrexed seemed to slightly promote patients average KPS score when comparing with docetaxel although the difference was without statistical significance changes of average KPS scores pemetrexed vs docetaxel = 028 593 vs -167 857 p = 0149 Patients receiving pemetrexed experienced significantly lower incidences of grade 3/4 neutropenia 70 % vs 276 % p < 0001 and leucocytopenia 47 % vs 228 % p < 0001 than those who received docetaxel Also there were lower incidences of alopecia stomatitis and neural abnormality for patients receiving pemetrexed than those receiving docetaxel Incidence of serum glutamic oxaloacetic transaminase elevation however was higher in pemetrexed arm than in docetaxel arm 323 % vs 149 % p = 0013 In addition age 60 patients benefit from pemetrexed with equivalent efficacies yet much lower toxicities compared to docetaxel DCR pemetrexed vs docetaxel = 6667 % vs 8158 % p = 0146 grade 3/4 hematologic toxicities pemetrexed vs docetaxel = 1725 % vs 396 % p = 0016 Treatment with pemetrexed resulted in equivalent efficacy outcomes and better safety profiles compared with docetaxel in second-line therapy for advanced NSCLC in Chinese lung cancer population And age 60 patients may benefit from second-line single pemetrexed\",\n",
            "}\n",
            "13216\n",
            "{\n",
            "  \"id\" : \"17641543\",\n",
            "  \"contents\" : \"To study whether perioperative treatment with darbepoetin alfa DA improves physical performance following colorectal cancer surgery Patients admitted for planned colorectal cancer surgery were randomized to receive either weekly placebo or DA 300 or 150 microg depending on the hemoglobin Hb concentration Patients were assessed 10 days before as well as 7 and 30 days after surgery for work capacity postural sway muscle strength fatigue and quality of life QoL The primary outcome measure were the changes in patients physical performance from preoperative to postoperative day 7 Of 221 included patients 151 were evaluable Baseline characteristics were similar in the 2 groups Patients receiving DA had a significantly better working capacity on day 7 p = 003 and day 30 p = 003 compared with the placebo group There were no statistically significant differences between the 2 groups on days 7 or 30 for fatigue postural sway and QoL DA treatment significantly p < 001 reduced the decrease in Hb concentrations on day 7 and resulted in an earlier return p < 001 to the preoperative Hb concentration compared to placebo treatment Perioperative DA treatment improved postoperative work capacity and Hb concentrations but had no effect on postoperative fatigue postural sway QoL and muscle strength\",\n",
            "}\n",
            "13217\n",
            "{\n",
            "  \"id\" : \"23803886\",\n",
            "  \"contents\" : \"Two chemoprevention trials found that supplementation with - carotene increased the risk of lung cancer and overall mortality The biologic basis of these findings remains poorly understood The objective was to compare the on-study change in metabolomic profiles of men randomly assigned to receive or not receive - carotene supplements in the Alpha-Tocopherol Beta-Carotene Cancer Prevention ATBC Study The ATBC Study was a randomized double-blind placebo-controlled primary cancer prevention trial participants were Finnish male smokers assigned to 1 of 4 intervention groups 1 - tocopherol 2 - carotene 3 both or 4 placebo Fifty participants with both baseline and follow-up fasting serum samples were randomly selected from each of these groups Metabolomic profiling was conducted by mass spectrometry The association between change in each metabolite over time and trial assignment - carotene or no - carotene was estimated by linear regression We measured 489 metabolites and 17 changed significantly P < 005 in response to - carotene supplementation More of these 17 metabolites were of xenobiotic origin than would be expected by chance 9 of 60 or 15 % P = 000004 We also found a suggestive association with 15-anhydroglucitol-a marker of glycemic control = -0379 P = 00071 Male smokers supplemented with - carotene developed metabolomic profiles consistent with the induction of cytochrome P450 enzymes the primary metabolizers of xenobiotics in humans These findings may shed light on the increased mortality associated with - carotene supplementation in the ATBC Study and suggest the need to explore potential interactions between medication use and dietary supplements particularly among smokers This trial was registered at clinicaltrialsgov as NCT00342992\",\n",
            "}\n",
            "13218\n",
            "{\n",
            "  \"id\" : \"12600848\",\n",
            "  \"contents\" : \"Prospective studies suggested that substituting whole-grain products for refined-grain products lowers the risks of type 2 diabetes and cardiovascular disease CVD in women Although breakfast cereals are a major source of whole and refined grains little is known about their direct association with the risk of premature mortality We prospectively evaluated the association between whole - and refined-grain breakfast cereal intakes and total and CVD-specific mortality in a cohort of US men We examined 86190 US male physicians aged 40-84 y in 1982 who were free of known CVD and cancer at baseline During 55 y we documented 3114 deaths from all causes including 1381 due to CVD 488 myocardial infarctions and 146 strokes Whole-grain breakfast cereal intake was inversely associated with total and CVD-specific mortality independent of age body mass index smoking alcohol intake physical activity history of diabetes hypertension or high cholesterol and use of multivitamins Compared with men who rarely or never consumed whole-grain cereal men in the highest category of whole-grain cereal intake > or = 1 serving/d had multivariate-estimated relative risks of total and CVD-specific mortality of 083 95 % CI 073 094 P for trend < 0001 and 080 066 097 P for trend < 0001 respectively In contrast total and refined-grain breakfast cereal intakes were not significantly associated with total and CVD-specific mortality These findings persisted in analyses stratified by history of type 2 diabetes hypertension and high cholesterol Both total mortality and CVD-specific mortality were inversely associated with whole-grain but not refined-grain breakfast cereal intake These prospective data highlight the importance of distinguishing whole-grain from refined-grain cereals in the prevention of chronic diseases\",\n",
            "}\n",
            "13219\n",
            "{\n",
            "  \"id\" : \"22806415\",\n",
            "  \"contents\" : \"Patient-controlled epidural analgesia PCEA has not been widely used after gastrectomy although in other abdominal surgery it benefits patients more than patient-controlled intravenous analgesia PCIA We attempted to determine the effect of PCEA compared with PCIA on postoperative pain control and recovery after gastrectomy for gastric cancer A randomized controlled clinical trial that included patients undergoing D2 radical gastrectomy for gastric cancer was conducted for this study Patients were randomized to a morphine-bupivacaine PCEA group and a morphine PCIA group Postoperative outcomes such as pain fasting blood glucose FBG time to first passage of flatus complications and time staying in hospital after surgery were compared with an intention-to-treat analysis Between March 2010 and October 2010 67 patients were randomized and 60 were evaluated The PCEA group showed lower pain scores both at rest and on coughing after the operation P < 005 FBG after the operation was significantly lower in the PCEA group than that in the PCIA group P < 005 Time to first passage of flatus after surgery was shorter in the PCEA group P < 005 while there were no significant differences regarding the incidence of complications between the two groups in terms of the clinical records The length of hospital stay in the PCEA group was 107 17 days which was significantly shorter than that in the PCIA group 119 18 days P < 005 After gastrectomy for gastric cancer PCEA compared with PCIA offered safer pain relief with superior pain control and resulted in a lower stress response and a quicker return of bowel activity\",\n",
            "}\n",
            "13220\n",
            "{\n",
            "  \"id\" : \"22863642\",\n",
            "  \"contents\" : \"The purpose of this study was to assess whether CAM use affected breast cancer prognosis in those who did not receive systemic therapy Secondary data analysis of baseline/survey data from the Women s Healthy Eating and Living WHEL study 2562 breast cancer survivors participating in the study completed baseline assessments and a CAM use questionnaire Cox regression models were conducted to evaluate the use of CAM modalities and dietary supplements on time to an additional breast cancer event mean follow-up = 73 years A US-based multi-site randomized dietary trial Time to additional breast cancer events The women who did not receive any systemic treatment had a higher risk for time to additional breast cancer events HR = 19 95 % CI 132 273 and for all-cause mortality HR = 17 95 % CI 106 273 compared to those who had received systemic treatment Among 177 women who did not receive systemic treatment CAM use was not significantly related to additional breast cancer events There were no significant differences between high supplement users 3 formulations per day and low supplement users in either risk for additional breast cancer events The risk for an additional breast cancer event and/or death was higher for those who did not receive any systemic treatments the use of dietary supplements or CAM therapies did not change this risk This indicates that complementary and alternative therapies did not alter the outcome of breast cancer and should not be used in place of standard treatment\",\n",
            "}\n",
            "13221\n",
            "{\n",
            "  \"id\" : \"24889794\",\n",
            "  \"contents\" : \"Despite aggressive local therapy patients with locally advanced bladder cancer have a significant risk of distant metastases This study evaluated the role of neoadjuvant combination chemotherapy with gemcitabine/cisplatin GC in improving the outcome of this group of patients over radical cystectomy alone A total of 114 patients with newly diagnosed bladder cancer T3-4 N0-2 M0 were randomized to radical cystectomy alone or initial 3 cycles of GC then managed according to response Patients who achieved complete response completed 6 cycles of GC followed by local radiation therapy RT only If tumors were downstaged to T1 complete transurethral resection was done followed by 3 cycles of GC and then RT Patients with partial response underwent radical cystectomy followed by 3 cycles of GC Patients with stable disease or disease progression underwent radical cystectomy The overall response rate to GC was 551 % and complete response was achieved in 286 % The 3-year overall survival OS was 519 % versus 512 % in the chemotherapy and surgery arms respectively P = 399 The 3-year disease-free survival was 318 % in the chemotherapy arm and 451 % in the surgery arm P = 06 Bladder preservation was achieved in 225 % of patients in the neoadjuvant arm OS was 78 % in responding patients and 100 % in patients with complete response Neoadjuvant GC did not improve survival in locally advanced bladder cancer over radical cystectomy alone However bladder preservation was feasible and OS in responding patients was impressive Therefore predictive models to select patients are needed This is the largest prospective study of squamous cell carcinoma and transitional cell carcinoma using neoadjuvant GC\",\n",
            "}\n",
            "13222\n",
            "{\n",
            "  \"id\" : \"15459217\",\n",
            "  \"contents\" : \"To determine whether R115777 improves survival in patients with refractory advanced colorectal cancer CRC in a multicenter double-blind prospective randomized study Three hundred sixty-eight patients were randomly assigned to R115777 300 mg twice daily orally for 21 days every 28 days or placebo in a 21 ratio All patients received best supportive care The primary end point was overall survival secondary end points were progression free survival tumor response toxicity and quality of life The two treatment groups were well balanced for baseline demographics including previous chemotherapy for advanced CRC The median overall survival for R115777 was 174 days 95 % CI 157 to 198 days and 185 days 95 % CI 158 to 238 days for those patients receiving placebo P = 376 One patient achieved a partial response in the R115777 arm Stable disease > 3 months was observed in 243 % patients in the R115777 group compared to 128 % in the placebo arm This did not translate into a statistically significant increase in progression-free survival Overall treatment was well tolerated There was an increased incidence of reversible myelosuppression neutropenia thrombocytopenia rash and grade 1 to 2 diarrhea in the R115777 arm There was no statistically significant difference in quality of life between arms Single agent R115777 given at this dose and schedule has an acceptable toxicity profile but does not improve overall survival compared to best supportive care alone in refractory advanced CRC\",\n",
            "}\n",
            "13223\n",
            "{\n",
            "  \"id\" : \"15036854\",\n",
            "  \"contents\" : \"This study reanalysed the results of the Cs-137 low-dose-rate brachytherapy trials for stage I and II cervix carcinoma at the Christie Hospital Manchester UK in order to quantify the clinical outcome as a function of dose and to extract radiobiological parameter values by modelling the data for local control and morbidity Kaplan-Meier survival curves and Cox regression analyses were used to analyse the time to event data Linear-quadratic LQ analysis was also used in a mixture model incorporating a half-time for repair a time factor and a heterogeneity function between patients Full 5-year follow-up data were available for 339 patients receiving Cs-137 doses between 60 and 75 Gy delivered at 14-1 8 Gy/h and 178 patients receiving a Ra-226 dose of 75 Gy at 05 Gy/h using two insertions 7-10 days apart With the increased dose-rate a dose reduction between 20 and 25 % was required to achieve a similar morbidity rate This reduction had a detrimental effect on tumour control by about 15 % points Unexpectedly this loss in local control did not lead to a decrease in cancer-specific survival For both tumour control and complications a high alpha/beta and short half-time for repair best fitted the data suggesting that consequential late reactions may be responsible for much of the bowel and urinary morbidity after these short treatments The variability in response between patients was greater CV 40 % for morbidity than for tumour control CV 17 % probably reflecting the greater variation in dose at the target tissue There was no significant dependence on overall treatment time detected over the 7-10-day range of these treatments The therapeutic ratio was somewhat less for the higher dose-rate in agreement with radiobiological expectations although cancer-specific survival was inexplicably unchanged The LQ-parameter analysis suggests that high alpha/beta ratios and/or short repair half-times are applicable for both tumour and normal tissue responses in these treatments\",\n",
            "}\n",
            "13224\n",
            "{\n",
            "  \"id\" : \"16029638\",\n",
            "  \"contents\" : \"To evaluate the effects of 125 I seed implantation in sphincter preservation for treatment of low rectal cancer Seventy-six patients with low rectal cancer were randomly divided into 2 group group A 17 males and 13 females aged 485 + / - 24 receiving rectostomy and anal sphincter preservation and group B 24 males and 22 females aged 494 + / - 26 receiving modified TME and anal sphincter preservation combined with brachytherapy by 125 I seed implantation Two to four weeks after operation chemotherapy with 5-FU/CF were performed Follow-up was carried out 6 12 24 and 36 months after operation The local recurrence rates 6 12 24 and 36 months after operation were 0 % 111 % 143 % and 23 % respectively in the group A and all 0 % in the group B P < 005 for the rate 36 months later The survival rates 6 12 24 and 36 months after operation were 100 % 100 % 857 % and 767 % respectively in the group A and were 100 % 100 % 971 % and 93 % respectively in the group B P < 005 for the rate 36 months later The functions of defecation and erection were better in the group B and the symptom of pain was improved better in the group A too all P < 005 Safe simple and effective surgery with sphincter preservation combined with brachytherapy in low rectal cancer is one of the ideal methods for treatment of low rectal cancer\",\n",
            "}\n",
            "13225\n",
            "{\n",
            "  \"id\" : \"25534388\",\n",
            "  \"contents\" : \"To determine whether prolonged androgen suppression AS duration before radiotherapy improves survival and disease control in prostate cancer One thousand five hundred seventy-nine men with intermediate-risk prostate cancer were randomly assigned to 8 weeks of AS followed by radiotherapy with an additional 8 weeks of concurrent AS 16 weeks total or to 28 weeks of AS followed by radiotherapy with an additional 8 weeks of AS 36 weeks total The trial sought primarily to detect a 33 % reduction in the hazard of prostate cancer death in the 28-week assignment Time-to-event end points are reported for up to 10 years of follow-up There were no between-group differences in baseline characteristics of 1489 eligible patients with follow-up For the 8 - and 28-week assignments 10-year disease-specific survival rates were 95 % 95 % CI 933 % to 970 % and 96 % 95 % CI 946 % to 980 % hazard ratio [ HR ] 081 P = 45 respectively and 10-year overall survival rates were 66 % 95 % CI 620 % to 699 % and 67 % 95 % CI 630 % to 708 % HR 095 P = 62 respectively For the 8 - and 28-week assignments 10-year cumulative incidences of locoregional progression were 6 % 95 % CI 43 % to 80 % and 4 % 95 % CI 25 % to 57 % HR 065 P = 07 respectively 10-year distant metastasis cumulative incidences were 6 % 95 % CI 40 % to 77 % and 6 % 95 % CI 40 % to 76 % HR 107 P = 80 respectively and 10-year prostate-specific antigen-based recurrence cumulative incidences were 27 % 95 % CI 231 % to 298 % and 27 % 95 % CI 234 % to 303 % HR 097 P = 77 respectively Extending AS duration from 8 weeks to 28 weeks before radiotherapy did not improve outcomes A lower than expected prostate cancer death rate reduced ability to detect a between-group difference in disease-specific survival The schedule of 8 weeks of AS before radiotherapy plus 8 weeks of AS during radiotherapy remains a standard of care in intermediate-risk prostate cancer\",\n",
            "}\n",
            "13226\n",
            "{\n",
            "  \"id\" : \"16983112\",\n",
            "  \"contents\" : \"Exatecan mesylate is a hexacyclic water-soluble topoisomerase-1 inhibitor Exatecan has single-agent and combination activity with gemcitabine in advanced pancreatic cancer A multicenter randomized phase III trial comparing exatecan plus gemcitabine versus gemcitabine alone in advanced pancreatic cancer was conducted Eligibility criteria included Karnofsky performance status > or = 60 % locally advanced or metastatic pancreatic adenocarcinoma and no prior chemotherapy Radiation alone for locally advanced disease was permitted Patients were randomly assigned on a 11 basis For the exatecan plus gemcitabine arm exatecan 20 mg/m2 and gemcitabine 1000 mg/m2 were administered on days 1 and 8 every 3 weeks Gemcitabine alone was dosed at 1000 mg/m2 up to 7 weeks in the first cycle then once a week for the first 3 weeks of a 4-week cycle Tumor assessment was performed every 6 weeks The primary end point was overall survival An intent-to-treat analysis was used From August 2001 to January 2003 349 patients were randomly assigned 175 to exatecan plus gemcitabine and 174 to gemcitabine alone Twenty-four patients 69 % were not treated The median survival time was 67 months for exatecan plus gemcitabine and 62 months for gemcitabine alone P = 52 One complete response CR < 1 % and 11 partial responses PRs 63 % were observed in the exatecan plus gemcitabine treatment group and one CR < 1 % and eight PRs 46 % were observed in the gemcitabine-alone group Grade 3 and 4 toxicities were higher for the exatecan plus gemcitabine arm versus the gemcitabine alone arm neutropenia 30 % v 15 % and thrombocytopenia 15 % v 4 % Exatecan plus gemcitabine was not superior to gemcitabine alone with respect to overall survival in the first-line treatment of advanced pancreatic cancer\",\n",
            "}\n",
            "13227\n",
            "{\n",
            "  \"id\" : \"10701731\",\n",
            "  \"contents\" : \"To evaluate the influence of oral glutamine on radiation-induced oral mucositis in the radiotherapy of head and neck cancer From July 1997 through June 1998 17 patients with head and neck cancer receiving primary or adjuvant irradiation were randomized to either glutamine suspension 16 g in 240 ml normal saline n = 8 or placebo normal saline n = 9 arm Patients were instructed to swish the test solutions 30 ml four times per day All patients received half-mouth irradiation at least Patients were treated 18 Gy per fraction daily 5 days a week We evaluated the grading of oral mucositis daily fraction at each day of treatment until 45 Gy/25 fractions World Health Organization WHO step analgesic medication and body weight change were compared between the two arms The duration of objective oral mucositis > or = Grade 1 p = 00097 Grade 2 p = 00232 and Grade 3 p = 00168 was shorter in the glutamine arm Mean maximum grade of objective oral mucositis was less severe in the glutamine arm 16 vs 26 p = 00058 Glutamine did not reduce the duration and severity of subjective oral mucositis except for duration > or = Grade 3 p = 00386 In the analysis of mean maximum WHO step of analgesic medication there was no statistical difference p = 05374 between the two arms Mean body weight change was also not significantly different p = 08070 Oral glutamine may significantly reduce the duration and severity of objective oral mucositis during radiotherapy It may shorten the duration of > or = Grade 3 subjective mucositis\",\n",
            "}\n",
            "13228\n",
            "{\n",
            "  \"id\" : \"16394300\",\n",
            "  \"contents\" : \"Standard chemotherapy for newly diagnosed ovarian cancer is a platinum-taxane combination The Gynecologic Oncology Group conducted a randomized phase 3 trial that compared intravenous paclitaxel plus cisplatin with intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel in patients with stage III ovarian cancer We randomly assigned patients with stage III ovarian carcinoma or primary peritoneal carcinoma with no residual mass greater than 10 cm to receive 135 mg of intravenous paclitaxel per square meter of body-surface area over a 24-hour period followed by either 75 mg of intravenous cisplatin per square meter on day 2 intravenous-therapy group or 100 mg of intraperitoneal cisplatin per square meter on day 2 and 60 mg of intraperitoneal paclitaxel per square meter on day 8 intraperitoneal-therapy group Treatment was given every three weeks for six cycles Quality of life was assessed Of 429 patients who underwent randomization 415 were eligible Grade 3 and 4 pain fatigue and hematologic gastrointestinal metabolic and neurologic toxic effects were more common in the intraperitoneal-therapy group than in the intravenous-therapy group P < or = 0001 Only 42 percent of the patients in the intraperitoneal-therapy group completed six cycles of the assigned therapy but the median duration of progression-free survival in the intravenous-therapy and intraperitoneal-therapy groups was 183 and 238 months respectively P = 005 by the log-rank test The median duration of overall survival in the intravenous-therapy and intraperitoneal-therapy groups was 497 and 656 months respectively P = 003 by the log-rank test Quality of life was significantly worse in the intraperitoneal-therapy group before cycle 4 and three to six weeks after treatment but not one year after treatment As compared with intravenous paclitaxel plus cisplatin intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel improves survival in patients with optimally debulked stage III ovarian cancer\",\n",
            "}\n",
            "13229\n",
            "{\n",
            "  \"id\" : \"10855346\",\n",
            "  \"contents\" : \"The objective was to compare health related quality of life QOL in hormone receptor negative node-positive breast cancer patients receiving adjuvant chemotherapy to determine whether a more intensive chemotherapy regimen has an adverse effect upon QOL that is not balanced by improvements in disease control or survival Increased physical symptoms including fatigue and the inconvenience of the dose intensive 16-week regimen were expected to have a negative impact on QOL QOL was measured in 163 patients randomized to either a standard cyclophosphamide doxorubicin and 5-flurouracil CAF or a 16-week multidrug regimen using the Breast Chemotherapy Questionnaire BCQ The 30 item BCQ was self-administered prior to therapy during therapy and 4 months post treatment BCQ scores decreased worsened more during therapy on the 16-week regimen median change -14 than on CAF median change -08 p < 0001 By 4 months post treatment BCQ scores were higher than pre-treatment and equal in the two arms CAF 81 and 16 weeks 82 p = 06 Over a period of 48 months patients on the 16-week regimen averaged 14 fewer months of treatment with toxicity 40 more months without symptoms and 07 fewer months post recurrence compared to patients on the CAF regimen Given typical values for these health states the gain in Q-TWiST observed for the CAF regimen during treatment shifted to the 16-week regimen after 1 year with a gain of 20 to 24 months after 4 years The hypothesized negative impact of the dose intensive 16-week regimen was confirmed by the BCQ assessments However Q-TWiST analysis suggests a small gain for the 16-week regimen The later results should be interpreted with caution with the limited follow-up of 4 years\",\n",
            "}\n",
            "13230\n",
            "{\n",
            "  \"id\" : \"15226327\",\n",
            "  \"contents\" : \"To compare the overall survival OS of patients with advanced non-small-cell lung cancer NSCLC treated with docetaxel plus cisplatin DC or docetaxel D alone Chemotherapy-nave patients with advanced/metastatic NSCLC were randomly assigned to receive either DC n = 167 docetaxel 100 mg/m 2 on day 1 cisplatin 80 mg/m 2 on day 2 and recombinant human granulocyte colony-stimulating factor rhG-CSF 150 microg/m 2 / d on days 3 to 9 or D n = 152 100 mg/m 2 on day 1 without rhG-CSF every 3 weeks The overall response rates were 365 % for DC three complete responses and 58 partial responses and 217 % for D one complete response and 32 partial responses P = 004 The median OS was 105 months range 05 to 41 months and 80 months range 05 to 41 months for DC and D respectively P = 200 The 1 - and 2-year survival rates were 44 % and 19 % for DC and 43 % and 15 % for D respectively Median times to tumor progression were 40 and 25 months for DC and D respectively P = 580 Grade 2/3 anemia was significantly higher with DC than with D 33 % v 16 % P = 0001 Fifteen 9 % DC and 12 8 % D patients developed febrile neutropenia Grade 3/4 nausea/vomiting P = 0001 diarrhea P = 007 neurotoxicity P = 017 and nephroroxicity P = 006 were significantly more common with DC than with DThere were five treatment-related deaths in the DC group and one in the D P = 098 DC regimen resulted in a higher response rate but without improvement in median time to tumor progression or OS compared with D D could be a reasonable front-line chemotherapy for patients who can not tolerate cisplatin\",\n",
            "}\n",
            "13231\n",
            "{\n",
            "  \"id\" : \"17401004\",\n",
            "  \"contents\" : \"Uncontrolled studies suggest that chemoradiation has similar efficacy as surgery for esophageal cancer Therefore a randomized trial was carried out to compare in responders only chemoradiation alone with chemoradiation followed by surgery in patients with locally advanced tumors Eligible patients had operable T3N0-1M0 thoracic esophageal cancer Patients received two cycles of fluorouracil FU and cisplatin days 1 to 5 and 22 to 26 and either conventional 46 Gy in 45 weeks or split-course 15 Gy days 1 to 5 and 22 to 26 concomitant radiotherapy Patients with response and no contraindication to either treatment were randomly assigned to surgery arm A or continuation of chemoradiation arm B three cycles of FU/cisplatin and either conventional [ 20 Gy ] or split-course [ 15 Gy ] radiotherapy Chemoradiation was considered equivalent to surgery if the difference in 2-year survival rate was less than 10 % Of 444 eligible patients 259 were randomly assigned 230 patients 888 % had epidermoid cancer and 29 112 % had glandular carcinoma Two-year survival rate was 34 % in arm A versus 40 % in arm B hazard ratio for arm B v arm A = 090 adjusted P = 44 Median survival time was 177 months in arm A compared with 193 months in arm B Two-year local control rate was 664 % in arm A compared with 570 % in arm B and stents were less required in the surgery arm 5 % in arm A v 32 % in arm B P < 001 The 3-month mortality rate was 93 % in arm A compared with 08 % in arm B P = 002 Cumulative hospital stay was 68 days in arm A compared with 52 days in arm B P = 02 Our data suggest that in patients with locally advanced thoracic esophageal cancers especially epidermoid who respond to chemoradiation there is no benefit for the addition of surgery after chemoradiation compared with the continuation of additional chemoradiation\",\n",
            "}\n",
            "13232\n",
            "{\n",
            "  \"id\" : \"18843004\",\n",
            "  \"contents\" : \"The relatively high dietary intake of soy in Asian countries has been hypothesized to at least partly explain the lower breast cancer incidence patterns in these countries compared with the Western world The aim of the present study was to determine the effect of daily soy supplementation on mammographic density one of the strongest known risk factors for breast cancer A double-blind randomized controlled trial was conducted to compare the effects of soy protein intake containing 99 mg isoflavones daily with intake of milk protein placebo for the duration of 1 year Two hundred and two Dutch postmenopausal women ages 60 to 75 years were randomized Mammographic density was assessed using a quantitative computer-assisted method on digitized mammograms Equol producer status was assessed in plasma provided at the final visit soy group or after a 3-day challenge with soy after the trial was finished placebo group A total of 175 women completed the baseline visits and at least one follow-up visit and were included in the intention-to-treat analyses For 126 women both pre - and post-trial mammograms were available Mammographic density decreased in both study arms but the decrease did not differ significantly between intervention and placebo groups Equol producer status did not modify the results The results of this trial do not support the hypothesis that a diet high in soy protein among postmenopausal women decreases mammographic density\",\n",
            "}\n",
            "13233\n",
            "{\n",
            "  \"id\" : \"23980081\",\n",
            "  \"contents\" : \"Bisphosphonates prevent skeletal-related events in patients with metastatic breast cancer Their effect in early breast cancer is controversial Ibandronate is an orally and intravenously available amino-bisphosphonate with a favorable toxicity profile It therefore qualifies as potential agent for adjuvant use The GAIN German Adjuvant Intergroup Node-Positive study was an open-label randomized controlled phase III trial with a 2 2 factorial design Patients with node-positive early breast cancer were randomly assigned 11 to two different dose-dense chemotherapy regimens and 21 to ibandronate 50 mg per day orally for 2 years or observation In all 2640 patients and 728 events were estimated to be required to demonstrate an increase in disease-free survival DFS by ibandronate from 75 % to 795 % by using a two-sided = 05 and 1 - of 80 % We report here the efficacy analysis for ibandronate which was released by the independent data monitoring committee because the futility boundary was not crossed after 50 % of the required DFS events were observed Between June 2004 and August 2008 2015 patients were randomly assigned to ibandronate and 1008 to observation Patients randomly assigned to ibandronate showed no superior DFS or overall survival OS compared with patients randomly assigned to observation DFS hazard ratio 0945 95 % CI 0768 to 1161 P = 589 OS HR 1040 95 % CI 0763 to 1419 P = 803 DFS was numerically longer if ibandronate was used in patients younger than 40 years or older than 60 years compared with patients age 40 to 59 years test for interaction P = 093 Adjuvant treatment with oral ibandronate did not improve outcome of patients with high-risk early breast cancer who received dose-dense chemotherapy\",\n",
            "}\n",
            "13234\n",
            "{\n",
            "  \"id\" : \"24160264\",\n",
            "  \"contents\" : \"There is a need to establish clinically relevant thresholds anchors for identification of differences in health-related quality of life HRQoL and thereby provide stronger evidence regarding the HRQoL of childhood cancer survivors To investigate HRQoL in childhood cancer survivors with a standardised instrument and to establish thresholds for clinically significant differences by using qualitative interviews as anchors An additional aim was to investigate survivors HRQoL in relation to an age-matched comparison group without cancer experience Self-rated HRQoL KIDSCREEN-27 was assessed in a national cohort of survivors n = 63 aged 12-22 and a comparison group n = 257 aged 11-23 Findings from qualitative interview data were also used n = 61 three subgroups Feeling like anyone else Feeling almost like others Feeling different were identified based on survivors own perception of influence on daily life Effect size calculations based on means from the KIDSCREEN-27 dimensions were performed using the subgroups as anchors to indicate clinical importance Furthermore standard multiple regression analyses were performed Results Effect sizes between the subgroups Feeling like anyone else and Feeling almost like others and the group Feeling different were large for all dimensions 104-2 07 The multiple regression models showed that being a survivor was significantly associated with one of the dimensions School Environment where survivors scored higher HRQoL Furthermore female sex and older age 17-23 years significantly contributed to lower self-rated HRQoL Conclusion In clinical practice the KIDSCREEN-27 could be a useful screening tool to identify survivors of childhood cancer in need of extra support using KIDSCREEN dimension mean values of 45 or less as thresholds Larger scale studies are recommended to identify and test thresholds with regard to different age groups and time since diagnosis\",\n",
            "}\n",
            "13235\n",
            "{\n",
            "  \"id\" : \"25123116\",\n",
            "  \"contents\" : \"Bacillus Calmette-Gurin BCG is considered the most effective treatment to reduce recurrence and progression of non-muscle invasive bladder cancer NMIBC but can induce local side effects leading to treatment discontinuation or interruption Aim of this exploratory study is to investigate if the sequential administration of Hyaluronic acid HA may reduce local side effects of BCG 30 consecutive subjects undergoing BCG intravesical administration for high risk NMIBC were randomized to receive BCG only Group A or BCG and HA Group B A 1 to 10 Visual Analog Scale VAS for bladder pain International Prostate Symptom Score IPSS and number of micturitions per day were evaluated in the two groups before and after six weekly BCG instillations Patients were also evaluated at 3 and 6 months by means of cystostopy and urine cytology One out of 30 33 % patients in group A dropped out from the protocol for local side effects Mean VAS for pain was significantly lower in group B after BCG treatment 42 vs 58 p = 004 Post vs pre treatment differences in VAS for pain IPSS and number of daily micturitions were all significantly lower in group B Three patients in group A and 4 in group B presented with recurrent pathology at 6 month follow up These preliminary data suggest a possible role of HA in reducing BCG local side effects and could be used to design larger randomized controlled trials assessing safety and efficacy of sequential BCG and HA administration NCT02207608 ClinicalTrialsgov 01/08/2014 Policlinico Tor Vergata Ethics Committee resolution n 69-2011\",\n",
            "}\n",
            "13236\n",
            "{\n",
            "  \"id\" : \"25983022\",\n",
            "  \"contents\" : \"Hangeshashinto TJ-14 a Kampo medicine which reduces the level of prostaglandin E2 and affects the cyclooxygenase activity alleviates chemotherapy-induced oral mucositis COM We conducted a double-blind placebo-controlled randomized comparative trial to investigate whether TJ-14 prevents and controls COM in patients with colorectal cancer Ninety-three patients with colorectal cancer who developed moderate-to-severe COM WHO grade 1 during any cycle of chemotherapy using FOLFOX FOLFIRI and/or XELOX treatment were randomly assigned to receive either TJ-14 n = 46 or placebo n = 47 Patients received the administration of placebo or TJ-14 for 2weeks at the start of the next course of chemotherapy Patients were assessed three times per week for safety and for COM incidence and its severity using the WHO grading Ninety eligible patients TJ-14 43 placebo 47 per protocol set analysis were included in the analysis after the key-opening Although the incidence of grade 2 oral mucositis was lower for patients treated with TJ-14 compared to those treated with placebo there was no significant difference 488 vs 574 % p = 041 The median duration of grade 2 mucositis was 55 versus 105 days p = 0018 No difference in other treatment toxicity was observed between the two groups and patients exhibited high compliance in dosing administration The present study results did not meet the primary endpoint However TJ-14 demonstrated a significant effect in the treatment of grade 2 mucositis in patients with colorectal cancer compared to the placebo\",\n",
            "}\n",
            "13237\n",
            "{\n",
            "  \"id\" : \"17785082\",\n",
            "  \"contents\" : \"To evaluate the maximum tolerated dose and dose-limiting toxicity DLT of 10-hydroxy-camptothecin 10-HCPT in HFL regimen for the treatment of advanced colorectal cancer CRC 18 advanced CRC patients 13 males and 3 females aged 33 - 70 were randomly assigned to 6 groups to be treated with 10-HCPT 4 6 8 10 12 or 14 mg/m 2 and 5-fluoro-uracil 5-FU 425 mg/m 2 and leucovorin LV 20 mg/m 2 all administered intravenously on days 1 - 5 with 4 weeks as one cycle The efficacy and side-effect were evaluated There were two patients with grade IV myelosuppression in the 10 12 and 14 mg/m 2 groups each The most dose-associated adverse reactions were myelosuppression and GI dysfunction The DLT was myelosuppression and the maximum tolerable dose of 10-HCPT is 10 mg/m 2 on days 1 - 5 HFL regimen is well tolerated in the patients with advanced CRC The dosing regimen recommended in clinic trial is 8 mg/m 2\",\n",
            "}\n",
            "13238\n",
            "{\n",
            "  \"id\" : \"12921927\",\n",
            "  \"contents\" : \"Recruitment to randomized trials is often difficult but few studies have investigated interventions to improve recruitment In a randomized trial nested within a trial of treatments for localized prostate cancer we investigated the comparative effectiveness and cost-effectiveness of nurses and surgeons in recruiting patients Men with localized prostate cancer were randomized to see a nurse or urologic surgeon for an information appointment in which they were asked to consent to the ProtecT treatment trial comparing surgery radiotherapy and active monitoring Analysis was conducted by intention to treat using chi-square with 95 % confidence intervals for proportions and differences between groups An economic evaluation was performed using the duration of appointments and grade of recruitment staff Case-finding identified 167 men with localized prostate cancer One hundred fifty 90 % took part in the recruitment trial There was a 40 % difference between nurses and surgeons in recruitment rates 67 % nurses 71 % urologists 95 % CI -108 % to +188 % P = 60 Cost-minimization analysis showed that nurses spent longer times with patients but surgeon costs were higher and nurses often supported surgeon-led clinics Nurses were as effective and more cost-effective recruiters than urologic surgeons This suggests an increased role for nurses in recruiting patients to randomized trials\",\n",
            "}\n",
            "13239\n",
            "{\n",
            "  \"id\" : \"20855825\",\n",
            "  \"contents\" : \"We compared fulvestrant 500 mg regimen with the approved dose of fulvestrant 250 mg per month for treatment of postmenopausal women with estrogen receptor-positive advanced breast cancer who experienced progression after prior endocrine therapy Comparison of Faslodex in Recurrent or Metastatic Breast Cancer CONFIRM is a double-blind parallel-group multicenter phase III study Patients were randomly assigned to fulvestrant 500 mg 500 mg intramuscularly [ IM ] on day 0 then 500 mg IM on days 14 and 28 and every 28 days thereafter or 250 mg every 28 days Primary end point was progression-free survival PFS Secondary end points included objective response rate clinical benefit rate CBR duration of clinical benefit DoCB overall survival OS and quality of life QOL PFS was significantly longer for fulvestrant 500 mg n = 362 than 250 mg n = 374 hazard ratio [ HR ] = 080 95 % CI 068 to 094 P = 006 corresponding to a 20 % reduction in risk of progression Objective response rate was similar for fulvestrant 500 mg and 250 mg 91 % v 102 % respectively CBR was 456 % for fulvestrant 500 mg and 396 % for fulvestrant 250 mg DoCB and OS were 166 and 251 months respectively for the 500-mg group whereas DoCB and OS were 139 and 228 months respectively in the 250-mg group Fulvestrant 500 mg was well tolerated with no dose-dependent adverse events QOL was similar for both arms Fulvestrant 500 mg was associated with a statistically significant increase in PFS and not associated with increased toxicity corresponding to a clinically meaningful improvement in benefit versus risk compared with fulvestrant 250 mg\",\n",
            "}\n",
            "13240\n",
            "{\n",
            "  \"id\" : \"11333294\",\n",
            "  \"contents\" : \"Alcohol ingestion is associated with an increased risk of breast cancer in most epidemiologic studies Results however are heterogeneous at lower levels of alcohol intake and a biologic mechanism for the association has not been clearly identified To determine whether alcohol consumption by postmenopausal women elevates serum levels of hormones associated with an increased risk of breast cancer we performed a controlled feeding study Participants were 51 healthy postmenopausal women not using hormone replacement therapy Each participant rotated through three 8-week dietary periods in which she consumed 15 or 30 g of alcohol per day or an alcohol-free placebo beverage The order of assignment to the three alcohol levels was random During the dietary periods all food and beverages were supplied by the study and energy intake was adjusted to keep body weight constant Levels of estradiol estrone estrone sulfate testosterone androstenedione progesterone dehydroepiandrosterone DHEA DHEA sulfate DHEAS and androstenediol were measured by radioimmunoassays in serum collected at the end of each dietary period All statistical tests are two-sided When women consumed 15 or 30 g of alcohol per day respectively estrone sulfate concentrations increased by 75 % 95 % confidence interval [ CI ] = -03 % to 159 % P = 06 and 107 % 95 % CI = 27 % to 193 % P = 009 and DHEAS concentrations increased by 51 % 95 % CI = 14 % to 90 % P = 008 and 75 % 95 % CI = 37 % to 115 % P < 001 relative to levels when women consumed placebo None of the other hormones measured changed statistically significantly when women consumed alcohol Results suggest a possible mechanism by which consumption of one or two alcoholic drinks per day by postmenopausal women could increase their risk of breast cancer\",\n",
            "}\n",
            "13241\n",
            "{\n",
            "  \"id\" : \"12504395\",\n",
            "  \"contents\" : \"Results of observational studies suggest that hormone replacement therapy HRT could reduce the risk of coronary heart disease CHD but those of randomised trials do not indicate a lower risk in women who use oestrogen plus progestagen The aim of this study was to ascertain whether or not unopposed oestrogen reduces the risk of further cardiac events in postmenopausal women who survive a first myocardial infarction The study was a randomised blinded placebo controlled secondary prevention trial of postmenopausal women age 50-69 years n = 1017 who had survived a first myocardial infarction Individuals were recruited from 35 hospitals in England and Wales Women received either one tablet of oestradiol valerate 2 mg n = 513 or placebo n = 504 daily for 2 years Primary outcomes were reinfarction or cardiac death and all-cause mortality Analyses were by intention-to-treat Secondary outcomes were uterine bleeding endometrial cancer stroke or other embolic events and fractures Frequency of reinfarction or cardiac death did not differ between treatment groups at 24 months rate ratio 099 95 % CI 070-1 41 p = 097 Similarly the reduction in all-cause mortality between those who took oestrogen and those on placebo was not significant 079 050-1 27 p = 034 The relative risk of any death 056 023-1 33 and cardiac death 033 011-1 01 was lowest at 3 months post-recruitment Oestradiol valerate does not reduce the overall risk of further cardiac events in postmenopausal women who have survived a myocardial infarction\",\n",
            "}\n",
            "13242\n",
            "{\n",
            "  \"id\" : \"20080830\",\n",
            "  \"contents\" : \"To reduce side-effects of corticosteroid-containing antiemetic regimens tailoring antiemetic schedules to specific requirements of different patients could be of benefit We evaluated the possibility to reduce the total dose of corticosteroids when palonosetron a long-acting second-generation 5-hydroxytryptamine-3 5-HT 3 receptor antagonist is used Double-blind multicentre noninferiority study of chemotherapy-naive breast cancer patients receiving 025 mg palonosetron and 8 mg dexamethasone on day 1 randomly assigned to receive placebo n = 151 or 4 mg bid dexamethasone n = 149 on days 2 and 3 Primary end point was complete response CR rate no emesis no rescue medication in the overall days 1-5 period Secondary end points were CR rates in the acute day 1 and delayed days 2-5 periods rates of no emesis and no nausea and impact on daily functioning Functional Living Index-Emesis Noninferiority between the two treatments was demonstrated by similar CR rates P = 0487 in the overall period Most parameters showed that palonosetron and dexamethasone on day 1 only offer chemotherapy-induced nausea and vomiting protection similar to multiple-day dexamethasone administration In patients treated with a single injection of palonosetron on day 1 reducing dexamethasone is an option that is not associated with significant reduction in antiemetic control during the 5-day period or an impact on patient functioning\",\n",
            "}\n",
            "13243\n",
            "{\n",
            "  \"id\" : \"8839554\",\n",
            "  \"contents\" : \"Chemotherapy CT may induce acute mucosal injury to the stomach and duodenum but its prevention has been scarcely investigated One hundred and eighty-two cancer patients with normal stomach and duodenum or having fewer than 3 erosions selected to be treated with cyclophosphamide methotrexate and 5-fluorouracil CMF 77 breast carcinoma patients or 5-fluorouracil 5-FU 105 colon carcinoma patients were randomly assigned to prophylactic treatment with misoprostol 400 micrograms twice a day omeprazole 20 mg once a day or placebo 1 tablet twice a day Seven days after the end of the second source of CT all patients underwent control esophagogastroduodenoscopy Endoscopic findings were quantified on the basis of an arbitrary score 0 = normal 1 = less than 3 erosions 2 = 3-15 erosions 3 = more than 15 erosions or ulcer 4 = giant ulcer greatest dimension of more than 2 cm or multiple ulcers with cumulative greatest dimension exceeding 2 cm Mean score increased significantly in the placebo and misoprostol groups either after CMF P < 0001 and P < 005 respectively or after 5-FU P < 0001 for both whereas it did not in the omeprazole group Gastric and duodenal ulcers were significantly less frequent in patients receiving omeprazole than in those receiving placebo P < 005 after both CMF and 5-FU No significant difference was observed between placebo and misoprostol Omeprazole was significantly more effective than placebo and misoprostol in reducing the frequency and degree of the endoscopic worsening either after CMF or after 5-FU P < 005 for both CT regimens Epigastric pain and/or heartburn were significantly less frequent in patients receiving omeprazole than in those receiving placebo P < 001 or misoprostol P < 0001 The strong and prolonged inhibition of gastric acid production induced by omeprazole seems to be effective in preventing chemotherapy-induced gastroduodenal mucosal injury Further trials are necessary to verify whether such a prevention of endoscopically observed injury can translate into prevention of clinically significant injury\",\n",
            "}\n",
            "13244\n",
            "{\n",
            "  \"id\" : \"20032789\",\n",
            "  \"contents\" : \"Bevacizumab B improves survival of patients with metastatic nonsquamous non-small cell lung cancer Based on encouraging results from preclinical studies combining B with sunitinib S a phase II randomized open-label study Study Assessing the Blockade of both VEGF Receptor and ligand to enhance Efficacy in Lung was initiated to assess clinical outcomes of adding S to paclitaxel P / carboplatin C + B PCB for first-line treatment of locally advanced metastatic or recurrent nonsquamous non-small cell lung cancer Study enrollment was to occur in three phases In the first phase patients received PC + B 15 mg/kg every 3 weeks + / - S 25 mg daily 2 weeks on 1 week off If tolerated the second phase would include a third cohort receiving 375 mg SThe third phase would consist of PCB + / - highest tolerable dose SBetween March 2007 and January 2008 26 patients were randomized to receive PCB and 30 to PCB + S 25 mg Because of poor tolerability none of the patients were escalated to 375 mg S Median treatment duration was 103 weeks for PCB and 60 weeks for PCB + S Thirty-five percent of patients on PCB + S required S dose reduction 52 % required S treatment interruption and 59 % discontinued S because of adverse events most frequently hematologic events neutropenia thrombocytopenia and leukopenia and fatigue Patients receiving PCB + S required more B interruptions 38 % versus 19 % for PCB and discontinuation 52 % versus 35 % because of adverse events Survival data were limited by small sample sizes and limited treatment duration Overall survival was not mature at time of analysis median 66 months for PCB + S and not reached for PCB Two out of 25 efficacy-evaluable patients randomized to the PCB + S cohort had confirmed partial responses compared with 5 of 19 randomized to the PCB cohort The addition of S to PCB was not well tolerated because of toxicities This combination should not be studied further at these doses and schedules\",\n",
            "}\n",
            "13245\n",
            "{\n",
            "  \"id\" : \"19137506\",\n",
            "  \"contents\" : \"We investigated whether regular home visits to persons with newly diagnosed colorectal cancer influenced their overall survival and selected immune parameters A total of 249 Danish colorectal cancer patients undergoing abdominal surgery were randomly assigned to a control or an intervention group The intervention group received 10 home visits from a project nurse or a medical doctor during the first 2 years after discharge The home visits aimed at providing emotional support and information A subgroup of 55 patients provided blood samples 3 12 and 24 months after discharge for measurement of immune parameters Survival was assessed 65-9 5 years after the first operation A total of 148 patients died during follow-up The intervention was not significantly associated with survival p = 068 after adjustment for Dukes stage radicality of the operation age sex family social class and marital status Likewise no significant interactions were found between group and these covariates all p > or = 008 In the substudy of the possible effect of the intervention on immune parameters there were no differences between the two groups with respect to lymphocyte proliferation all p > or = 0078 or natural killer cell activity all p > or = 033 and no consistent effect on the number of specific subsets of cells phenotypes during follow-up The study failed to provide evidence that the psychosocial intervention provided as home visits significantly affected the prognosis or selected immune parameters of patients who had undergone surgery for colorectal cancer\",\n",
            "}\n",
            "13246\n",
            "{\n",
            "  \"id\" : \"10458255\",\n",
            "  \"contents\" : \"Pain and symptom management is an integral part of the clinical practice of oncology A number of guidelines have been developed to assist the clinician in optimizing comfort care We implemented clinical guidelines for cancer pain management in the community setting and evaluated whether these guidelines improved care Eighty-one cancer patients aged 37 to 76 years were enrolled onto a prospective longitudinal randomized controlled study from the outpatient clinic settings of 26 western Washington-area medical oncologists A multilevel treatment algorithm based on the Agency for Health Care Policy and Research Guidelines for Cancer Pain Management was compared with standard-practice control pain and symptom management therapies used by community oncologists The primary outcome of interest was pain Brief Pain Inventory secondary outcomes of interest were all other symptoms Memorial Symptom Assessment Scale and quality of life Functional Assessment of Cancer Therapy Scale Patients randomized to the pain algorithm group achieved a statistically significant reduction in usual pain intensity measured as slope scores when compared with standard community practice P < 02 Concurrent chemotherapy and patient adherence to treatment were significant mediators of worst pain There were no significant differences in other symptoms or quality of life between the two treatment groups This guideline implementation study supports the use of algorithmic decision making in the management of cancer pain These findings suggest that comprehensive pain assessment and evidence-based analgesic decision-making processes do enhance usual pain outcomes\",\n",
            "}\n",
            "13247\n",
            "{\n",
            "  \"id\" : \"10617707\",\n",
            "  \"contents\" : \"Anxiety and pain even in minor procedures are still great problems in pediatrics not least in pediatric oncology Conscious sedation is indicated when other means to overcome a child s fear fail The aim of this study was to investigate whether intranasal administration of midazolam given before insertion of a needle in a subcutaneously implanted central venous port could reduce anxiety discomfort pain and procedure problems Forty-three children with cancer participated in this randomized double-blind placebo-controlled crossover study in which nasal administration of midazolam spray 2 mg/kg body weight was compared with placebo Children parents and nurses completed a visual analog scale questionnaire to evaluate efficacy Parents and nurses reported reduced anxiety discomfort and procedure problems for children in the midazolam group and would prefer the same medication at next procedure They also reported pain reduction Children reported reduced anxiety and procedure problems but reduction of pain and discomfort was not significant No serious or unexpected side effects occurred Nasal discomfort was the most common side effect 17/38 approximately 45 % and the primary reason for dropouts 8/43 approximately 19 % Anxiety varied with age but not with gender When anxiety increased the differences between midazolam and placebo increased Nasal midazolam spray offers relief to children anxious about procedures such as insertion of a needle in a subcutaneously implanted intravenous port venous blood sampling venous cannulation etc Its use however may be limited by nasal discomfort in some patients for whom rectal and oral routes might be alternatives\",\n",
            "}\n",
            "13248\n",
            "{\n",
            "  \"id\" : \"14679383\",\n",
            "  \"contents\" : \"Isoflavones are estrogen-like plant compounds that may protect against cardiovascular disease and endocrine-responsive cancer Isoflavones may because of their ability to act as selective estrogen receptor modulators alter insulin-like growth factor IGF status The aim of this study was to assess the effect of 1-month isoflavone supplementation 86 mg/day red clover-derived isoflavones on IGF status Healthy pre - n = 16 and postmenopausal n = 7 women were invited to take part in a randomised placebo-controlled crossover study with a minimum 2-month washout period For premenopausal subjects the change in IGF-1 IGF-BP1 and IGF-BP3 assessed at different points of the menstrual cycle did not differ between isoflavone and placebo phase However the change in IGF-1 when examined pre - and post-supplementation was nonsignificantly reduced P = 006 on the isoflavone supplement compared to placebo For postmenopausal subjects the change in IGF-1 IGF-BP1 and IGFBP-3 concentrations over the supplementation period did not differ between isoflavone or placebo phase Isoflavones increased HDL in postmenopausal women compared to placebo P = 002 but did not alter either cholesterol or triacylglycerol concentrations and had no effect on antioxidant status This study shows that 1-month supplementation with red clover isoflavones has a positive effect on HDL cholesterol but at most a small effect on IGF status in premenopausal and no effect in postmenopausal subjects Further studies are required to ascertain the role these dietary compounds may have to play in breast cancer prevention\",\n",
            "}\n",
            "13249\n",
            "{\n",
            "  \"id\" : \"17823908\",\n",
            "  \"contents\" : \"The aim of this study was to compare the efficacy of single-agent weekly docetaxel with the combination of docetaxel and gemcitabine in elderly and/or poor performance status patients with advanced nonsmall cell lung cancer NSCLC Previously untreated patients with stage IIIB/IV NSCLC who were either > 65 years old or had an Eastern Cooperative Oncology Group ECOG performance status 2 were eligible Patients were randomized to receive weekly docetaxel 36 mg/m 2 Days 1 8 and 15 or docetaxel 30 mg/m 2 / gemcitabine 800 mg/m 2 Days 1 8 and 15 Both regimens were repeated on 28-day cycles for 6 cycles or until disease progression Three hundred fifty patients were randomized and 345 received treatment The median age of patients was 74 years 38 % were > 75 years old and 35 % had ECOG performance status 2 Intent-to-treat analysis showed median survivals of 55 months versus 51 months in the groups receiving docetaxel/gemcitabine versus weekly docetaxel respectively P = 65 There were no survival differences detected with docetaxel/gemcitabine versus weekly docetaxel in the 223 patients with good performance status 72 months vs 80 months respectively or in the 122 poor performance status patients 38 months vs 29 months respectively Median time-to-progression was longer in patients who received docetaxel/gemcitabine 48 months vs 29 months P = 004 Both regimens were generally well tolerated Treatment with docetaxel/gemcitabine produced a modest improvement in time-to-progression but had no impact on survival when compared with single-agent weekly docetaxel in this group of patients Results with both regimens were disappointing particularly in patients with poor performance status Improved treatment for these patients will require the introduction of novel well-tolerated targeted agents\",\n",
            "}\n",
            "13250\n",
            "{\n",
            "  \"id\" : \"18718725\",\n",
            "  \"contents\" : \"To compare the acute and late gastrointestinal GI and genitourinary GU toxicity in prostate cancer patients treated to a total dose of 78 Gy with either a three-conformal radiotherapy technique with a sequential boost SEQ or a simultaneous integrated boost using intensity-modulated radiotherapy SIB-IMRT A total of 78 prostate cancer patients participating in the randomized Dutch trial comparing 68 Gy and 78 Gy were the subject of this analysis They were all treated at the same institution to a total dose of 78 Gy The median follow-up was 76 and 56 months for the SEQ and SIB-IMRT groups respectively The primary endpoints were acute and late GI and GU toxicity A significantly lower incidence of acute Grade 2 or greater GI toxicity occurred in patients treated with SIB-IMRT compared with SEQ 20 % vs 61 % p = 0001 For acute GU toxicity and late GI and GU toxicity the incidence was lower after SIB-IMRT but these differences were not statistically significant No statistically significant difference were found in the 5-year freedom from biochemical failure rate Phoenix definition between the two groups 70 % for the SIB-IMRT group vs 61 % for the SEQ group p = 03 The same was true for the 5-year freedom from clinical failure rate 90 % vs 72 % p = 007 The results of our study have shown that SIB-IMRT reduced the toxicity without compromising the outcome in patients with localized prostate cancer treated to 78 Gy radiation\",\n",
            "}\n",
            "13251\n",
            "{\n",
            "  \"id\" : \"15821120\",\n",
            "  \"contents\" : \"This randomized phase III study compared the efficacy and safety of first-line gemcitabine versus epirubicin in the treatment of postmenopausal women with metastatic breast cancer MBC Patients aged > or = 60 years median 68 years with clinically measurable MBC received either gemcitabine 1200 mg/m 2 or epirubicin 35 mg/m 2 on days 1 8 and 15 of a 28-day cycle Of 410 patients entered 397 198 gemcitabine and 199 epirubicin were randomized and qualified for the time to progressive disease TTP and survival analyses Total cycles administered in 185 gemcitabine and 192 epirubicin patients respectively were 699 mean 35 range 0-12 and 917 mean 46 range 0-10 Epirubicin demonstrated statistically significant superiority in TTP 61 and 34 months P = 00001 overall survival 191 and 118 months P = 00004 and independently assessed response rate 403 % and 164 % in 186 and 183 evaluable patients P < 0001 For gemcitabine n = 190 and epirubicin n = 192 respectively common WHO grade 3/4 toxicities were neutropenia 253 % and 179 % and leukopenia 143 % and 193 % Of the 28 on-study deaths 17 gemcitabine 11 epirubicin three were considered possibly or probably related to treatment gemcitabine Postmenopausal women > or = 60 years of age with MBC tolerate chemotherapy well In this study epirubicin was superior to gemcitabine in the treatment of MBC in women age > or = 60 confirming that anthracyclines remain important drugs for first-line treatment of MBC\",\n",
            "}\n",
            "13252\n",
            "{\n",
            "  \"id\" : \"24638238\",\n",
            "  \"contents\" : \"The German Society of Radiation Oncology initiated a multicenter trial to evaluate core processes and subprocesses of radiotherapy by prospective evaluation of all important procedures in the most frequent malignancies treated by radiation therapy The aim of this analysis was to assess the required resources for interstitial high-dose-rate HDR and low-dose-rate LDR prostate brachytherapy BRT based on actual time measurements regarding allocation of personnel and room occupation needed for specific procedures Two radiotherapy centers community hospital of Offenbach am Main and community hospital of Eschweiler participated in this prospective study Working time of the different occupational groups and room occupancies for the workflow of prostate BRT were recorded and methodically assessed during a 3-month period For HDR and LDR BRT a total of 560 and 92 measurements respectively were documented The time needed for treatment preplanning was median 24min for HDR n = 112 measurements and 6min for LDR BRT n = 21 Catheter implantation with intraoperative HDR real-time planning n = 112 postimplantation HDR treatment planning n = 112 and remotely controlled HDR afterloading irradiation n = 112 required median 25 39 and 50min respectively For LDR real-time planning n = 39 and LDR treatment postplanning n = 32 the assessed median duration was 91 and 11min respectively Room occupancy and overall mean medical staff times were 194 and 910min respectively for HDR and 113 and 371min respectively for LDR BRT In this prospective analysis the resource requirements for the application of HDR and LDR BRT of prostate cancer were assessed methodically and are presented for first time\",\n",
            "}\n",
            "13253\n",
            "{\n",
            "  \"id\" : \"22882698\",\n",
            "  \"contents\" : \"Pemetrexed plus platinum has shown efficacy as a first-line treatment for advanced non-small cell lung cancer NSCLC but little is known about its efficacy and safety in East Asian patients We report the final analysis of overall survival OS from a multicentre randomized phase II trial in chemotherapy-naive Chinese patients with advanced NSCLC An additional meta-analysis was performed to systematically evaluate pemetrexed/platinum as first-line treatment for advanced NSCLC Eligible patients received up to six cycles of pemetrexed 500 mg/m 2 plus cisplatin 75 mg/m 2 day 1 or gemcitabine 1000 mg/m 2 days 1 and 8 plus cisplatin 75 mg/m 2 day 1 OS and toxicity were assessed A total of 254 patients were randomized and 251 were eligible for inclusion in the efficacy and safety analyses Median OS in the pemetrexed/cisplatin arm was 153 months compared with 169 months in the gemcitabine/cisplatin arm [ hazard ratio HR 109 95 % confidence interval CI 080-1 48 log-rank P = 04888 There was a trend towards improved survival in both arms Patients in the pemetrexed/cisplatin arm showed a lower incidence of drug-related grade 3 to 4 leukopenia and thrombocytopenia Meta-analysis showed that pemetrexed-platinum treatment was associated with 19 % longer survival among females HR 081 95 % CI 069-0 96 and 17 % longer survival among patients with non-squamous cell lung cancer HR 083 95 % CI 073-0 95 In Chinese patients with advanced NSCLC pemetrexed/cisplatin treatment resulted in comparable OS outcomes and was better tolerated than gemcitabine/cisplatin Meta-analysis supports the use of pemetrexed-platinum as first-line treatment for female patients and those with the non-squamous cell subtype of advanced NSCLC\",\n",
            "}\n",
            "13254\n",
            "{\n",
            "  \"id\" : \"24926548\",\n",
            "  \"contents\" : \"The phosphotidylinositol-3 kinase/serine-threonine kinase AKT / mammalian target of rapamycin signaling pathway is frequently altered in non-small-cell lung cancer NSCLC PX-866 is an oral irreversible pan-isoform inhibitor of phosphotidylinositol-3 kinase Preclinical models revealed synergy with docetaxel and a phase 1 trial demonstrated tolerability of this combination This randomized phase 2 study evaluated PX-866 combined with docetaxel in patients with advanced refractory NSCLC Patients with locally advanced recurrent or metastatic NSCLC who had received at least one and no more than two prior systemic treatment regimens were randomized 11 to a combination of docetaxel 75 mg/m intravenous every 21 days with or without PX-866 8 mg orally daily arms A and B respectively The primary end point was progression-free survival PFS Secondary end points included objective response rate overall survival OS toxicity and correlation of biomarker analyses with efficacy outcomes A total of 95 patients were enrolled Median PFS was 2 months in arm A and 29 months in arm B p = 065 Objective response rates were 6 % and 0 % in arms A and B respectively p = 04 There was no difference in OS between the two arms 70 versus 92 months p = 09 Grade 3 or higher adverse events were infrequent but more common in the combination arm with respect to diarrhea 7 % versus 2 % nausea 4 % versus 0 % and vomiting 7 % versus 0 % PIK3CA mutations or PTEN loss were infrequently observed The addition of PX-866 to docetaxel did not improve PFS response rate or OS in patients with advanced refractory NSCLC without molecular preselection\",\n",
            "}\n",
            "13255\n",
            "{\n",
            "  \"id\" : \"12718385\",\n",
            "  \"contents\" : \"This randomized trial was conducted to compare the efficacy and side effects of intravesical mitoxantrone instillation with those of doxorubicin in superficial bladder cancer following transurethral resection Sixty-three patients were randomized into mitoxantrone and doxorubicin groups Most of the patients enrolled were elderly people mean age 71 years The instilled doses of doxorubicin and mitoxantrone were 30 and 14 mg respectively Disease recurrence and side effects were compared using Fisher s exact test The interval to recurrence was shown by Kaplan-Meier survivorship curves and the log-rank test was used to compare the time to recurrence The median follow-up period was 36 months Thirty-three patients received mitoxantrone whereas 30 patients used doxorubicin The recurrence rate in the doxorubicin group was 30 % 95 % CI 198 % -388 % while it was 273 % 95 % CI 175 % -368 % in the mitoxantrone group The median recurrence-free survival in the mitoxantrone group and in the doxorubicin group was 22 and 20 months respectively p = 0580 Higher recurrence rates were found for Grade III and multiple primary tumors There was no significant difference in response rates p = 0784 The incidence of side effects was 20 % in the doxorubicin group and 212 % in the mitoxantrone group However the difference was not significant p > 099 The results revealed that the efficacy and side effects of mitoxantrone were similar to those of doxorubicin Especially for patients with pulmonary tuberculosis or aged patients with primary bladder tumors mitoxantrone and doxorubicin may be the tolerable and effective intravesical agents\",\n",
            "}\n",
            "13256\n",
            "{\n",
            "  \"id\" : \"12743146\",\n",
            "  \"contents\" : \"To determine whether fluoxetine improves overall quality of life QOL in advanced cancer patients with symptoms of depression revealed by a simple survey One hundred sixty-three patients with an advanced solid tumor and expected survival between 3 and 24 months were randomly assigned in a double-blinded fashion to receive either fluoxetine 20 mg daily or placebo for 12 weeks Patients were screened for at least minimal depressive symptoms and assessed every 3 to 6 weeks for QOL and depression Patients with recent exposure to antidepressants were excluded The groups were comparable at baseline in terms of age sex disease distribution performance status and level of depressive symptoms One hundred twenty-nine patients 79 % completed at least one follow-up assessment Analysis using generalized estimating equation modeling revealed that patients treated with fluoxetine exhibited a significant improvement in QOL as shown by the Functional Assessment of Cancer Therapy-General compared with patients given placebo P = 01 Specifically the level of depressive symptoms expressed was lower in patients treated with fluoxetine P = 0005 and the subgroup of patients showing higher levels of depressive symptoms on the two-question screening survey were the most likely to benefit from treatment In this mix of patients with advanced cancer who had symptoms of depression as determined by a two-question bedside survey use of fluoxetine was well tolerated overall QOL was improved and depressive symptoms were reduced\",\n",
            "}\n",
            "13257\n",
            "{\n",
            "  \"id\" : \"22364367\",\n",
            "  \"contents\" : \"Numerous technical modifications to radical prostatectomy have been proposed Such modifications are likely to lead to only slight improvements in outcomes Although small differences would be worthwhile an appropriately powered randomized trial would need to be very large and thus of doubtful feasibility given the expense complexity and regulatory burden of contemporary clinical trials We have proposed a novel methodology the clinically-integrated randomized trial which dramatically streamlines trial procedures in order to reduce the marginal cost of an additional patient towards zero We aimed to determine the feasibility of implementing such a trial for radical prostatectomy Patients undergoing radical prostatectomy as initial treatment for prostate cancer were randomized in a factorial design to involvement of the fascia during placement of the anastomotic sutures urethral irrigation both or neither Endpoint data were obtained from routine clinical documentation Accrual and compliance rates were monitored to determine the feasibility of the trial From a total of 260 eligible patients 154 59 % consented 56 patients declined to participate 20 were not approached on recommendation of the treating surgeon and 30 were not approached for logistical reasons Although recording by surgeons of the procedure used was incomplete ~ 80 % compliance with randomization was excellent when it was recorded with only 6 % of procedures inconsistent with allocation Outcomes data was received from 71 % of patients at one year This improved to 83 % as the trial progressed A clinically-integrated randomized trial was conducted at low cost with excellent accrual and acceptable compliance with treatment allocation and outcomes reporting This demonstrates the feasibility of the methodology Improved methods to ensure documentation of surgical procedures would be required before wider implementation ClinicalTrialsgov NCT00928850\",\n",
            "}\n",
            "13258\n",
            "{\n",
            "  \"id\" : \"18514303\",\n",
            "  \"contents\" : \"Axitinib AG-013736 is a potent and selective oral inhibitor of vascular endothelial growth factor receptors 1 2 and 3 which have an important role in pancreatic cancer The aim of this study was to assess the safety and efficacy of gemcitabine plus axitinib versus gemcitabine alone Between January and August 2006 103 patients with unresectable locally advanced or metastatic pancreatic cancer were randomly assigned in a two to one ratio to receive gemcitabine 1000 mg/m 2 plus axitinib 5 mg twice daily n = 69 or gemcitabine 1000 mg/m 2 alone n = 34 by a centralised registration system The primary endpoint was overall survival Analyses were done by intention to treat This trial is registered with ClinicalTrialsgov number NCT00219557 All randomised patients were included in the efficacy analyses Median overall survival was longer with gemcitabine plus axitinib than with gemcitabine alone 69 [ 95 % CI 53-10 1 ] months vs 56 [ 39-8 8 ] months The hazard ratio for survival with gemcitabine plus axitinib versus with gemcitabine alone adjusted for stratification factors was 071 95 % CI 044-1 13 The most common grade 3 or worse adverse events were fatigue 15 [ 22 % ] patients in the gemcitabine plus axitinib group vs one [ 3 % ] in the gemcitabine alone group abdominal pain eight [ 12 % ] vs five [ 16 % ] and asthenia eight [ 12 % ] vs one [ 3 % ] Gemcitabine plus axitinib showed a similar safety profile to gemcitabine alone the small non-statistically significant gain in overall survival needs to be assessed in a randomised phase III trial\",\n",
            "}\n",
            "13259\n",
            "{\n",
            "  \"id\" : \"18398095\",\n",
            "  \"contents\" : \"The dose intensity of chemotherapy can be increased to the highest possible level by early administration of multiple and sequential high-dose cycles supported by transfusion with peripheral blood progenitor cells PBPCs A randomized trial was performed to test the impact of such dose intensification on the long-term survival of patients with small cell lung cancer SCLC Patients who had limited or extensive SCLC with no more than two metastatic sites were randomly assigned to high-dose High n = 69 or standard-dose Std n = 71 chemotherapy with ifosfamide carboplatin and etoposide ICE High-ICE cycles were supported by transfusion with PBPCs that were collected after two cycles of treatment with epidoxorubicin at 150 mg/m 2 paclitaxel at 175 mg/m 2 and filgrastim The primary outcome was 3-year survival Comparisons between response rates and toxic effects within subgroups limited or extensive disease liver metastases or no liver metastases Eastern Cooperative Oncology Group performance status of 0 or 1 normal or abnormal lactate dehydrogenase levels were also performed Median relative dose intensity in the High-ICE arm was 293 % range = 174 % -392 % of that in the Std-ICE arm The 3-year survival rates were 18 % 95 % confidence interval [ CI ] = 10 % to 29 % and 19 % 95 % CI = 11 % to 30 % in the High-ICE and Std-ICE arms respectively No differences were observed between the High-ICE and Std-ICE arms in overall response n = 54 [ 78 % 95 % CI = 67 % to 87 % ] and n = 48 [ 68 % 95 % CI = 55 % to 78 % ] respectively or complete response n = 27 [ 39 % 95 % CI = 28 % to 52 % ] and n = 24 [ 34 % 95 % CI = 23 % to 46 % ] respectively Subgroup analyses showed no benefit for any outcome from High-ICE treatment Hematologic toxicity was substantial in the Std-ICE arm grade > or = 3 neutropenia n = 49 [ 70 % ] anemia n = 17 [ 25 % ] thrombopenia n = 17 [ 25 % ] and three patients 4 % died from toxicity High-ICE treatment was predictably associated with severe myelosuppression and five patients 8 % died from toxicity The long-term outcome of SCLC was not improved by raising the dose intensity of ICE chemotherapy by threefold\",\n",
            "}\n",
            "13260\n",
            "{\n",
            "  \"id\" : \"15924667\",\n",
            "  \"contents\" : \"To evaluate the effect of preoperative chemotherapy on bulky cervical cancer by internal iliac arterial infusion One hundred and eighty-six patients with bulky cervical cancer were randomly divided into two groups chemotherapy + radiotherapy group C + R group n = 105 and radiotherapy group R group n = 81 Patients in C + R group underwent internal iliac arterial infusion chemotherapy by using Seldinger technique internal iliac arterial or epigastric arterial catheterization Combined regimens were prescribed including cisplatin as the major drug Meanwhile 192Ir high-dose-rate intracavitary radiotherapy was performed with A point dose at 12 - 24 Gy/2 -4 times C + R group Patients in R group were only given radiotherapy Both groups of patients received radical hysterectomy two weeks after radiotherapy The tumor regression rate of C + R group was 971 % significantly higher than 790 % in R group P < 001 The effective rate for clinical Ib stage cancer in C + R group was 1000 % significantly higher than 783 % in R group P < 001 but for clinical IIa IIb stage cancers the effective rate between two groups had no obvious difference P > 005 Postoperative pathologic examinations showed the percentage of cervical tumor residue parauterine invasion pelvic lymph node metastasis in C + R group was lower than those of R group P < 001 The 2-year recurrent rate in R group 235 % was higher than that of C + R group 67 % P < 001 but 2-year survival rate between two groups had no obvious difference Internal iliac arterial infusion chemotherapy can effectively reduce tumor volume decrease lymph node and subclinical metastasis rates and postoperative recurrence rate it can also improve radical resectability of patients with stage IIb cervical cancer But the effect on long-term survival rate needs to be further evaluated through long-term follow-up of patients\",\n",
            "}\n",
            "13261\n",
            "{\n",
            "  \"id\" : \"10791849\",\n",
            "  \"contents\" : \"Thymidylate synthase TS is regarded as a parameter of 5-fluorouracil 5-FU chemosensitivity for colorectal carcinoma Recent researchers indicate that the chemosensitivity of 5-FU for colorectal carcinoma with low expression of TS is better than tumors with high expression of TS But the relation between TS expression and overall survival of curatively resected colorectal cancer patients has been less studied Specimens of curatively resected colon carcinoma from 148 patients were included in this study TS expression in the tumor was assessed by immunohistochemical staining technique and the patients were categorized into TS - + and TS - - groups First the relation between TS expression and survival of patients was examined Next for each group we compared survival between the chemotherapy - + and the chemotherapy - - subgroup Overall survival was significantly better in the TS - - group n = 107 than in the TS - + group n = 41 P = 0003 In the TS - - group there was little difference between the chemotherapy - + and the chemotherapy - - subgroup In the TS - + group the survival of the chemotherapy - + subgroup was significantly better than the chemotherapy - - subgroup P = 0439 TS itself may be a prognostic factor for colon carcinoma and 5-FU adjuvant chemotherapy may be appropriate for colon carcinoma with high expression of TS\",\n",
            "}\n",
            "13262\n",
            "{\n",
            "  \"id\" : \"22201654\",\n",
            "  \"contents\" : \"To test the effectiveness of two interventions compared to usual care in decreasing attitudinal barriers to cancer pain management decreasing pain intensity and improving functional status and quality of life QOL Randomized clinical trial Six outpatient oncology clinics three Veterans Affairs [ VA ] facilities one county hospital and one community-based practice in California and one VA clinic in New Jersey Sample 318 adults with various types of cancer-related pain Patients were randomly assigned to one of three groups control standardized education or coaching Patients in the education and coaching groups viewed a video and received a pamphlet on managing cancer pain In addition patients in the coaching group participated in four telephone sessions with an advanced practice nurse interventionist using motivational interviewing techniques to decrease attitudinal barriers to cancer pain management Questionnaires were completed at baseline and six weeks after the final telephone calls Analysis of covariance was used to evaluate for differences in study outcomes among the three groups Pain intensity pain relief pain interference attitudinal barriers functional status and QOL Attitudinal barrier scores did not change over time among groups Patients randomized to the coaching group reported significant improvement in their ratings of pain-related interference with function as well as general health vitality and mental health Although additional evaluation is needed coaching may be a useful strategy to help patients decrease attitudinal barriers toward cancer pain management and to better manage their cancer pain By using motivational interviewing techniques advanced practice oncology nurses can help patients develop an appropriate plan of care to decrease pain and other symptoms\",\n",
            "}\n",
            "13263\n",
            "{\n",
            "  \"id\" : \"21940785\",\n",
            "  \"contents\" : \"Hand-foot syndrome HFS is the most common adverse event induced by capecitabine Some clinicians think that HFS is a type of inflammation limited to the hands and feet and can be prevented with a COX-2 inhibitor celecoxib We designed a single-center prospective randomized clinical trial to test the hypothesis From August 2008 to December 2010 stage II and III colorectal cancer patients receiving capecitabine-based chemotherapy enrolled in the trial voluntarily All patients were divided randomly into two groups treated with or without celecoxib All adverse events were recorded Grade 1 and grade 2 HFS were more common in the capecitabine group than in the capecitabine/celecoxib group 746 % versus 574 % P = 0034 296 % versus 147 % P = 0035 The use of celecoxib P < 0001 P = 0003 and the level of dihydropyrimidine dehydrogenase P = 0048 P = 0014 affected the incidence of grade 1 and 2 HFS as determined by log-rank analysis Multivariate Cox proportional hazards regression analysis indicated that the use of celecoxib was the only factor that affected the incidence of grade 1 HFS [ Hazard Ratio HR 0556 P = 0001 ] and grade 2 HFS HR 0414 P = 0005 Celecoxib can be used effectively and safely to prevent capecitabine-related HFS\",\n",
            "}\n",
            "13264\n",
            "{\n",
            "  \"id\" : \"24124893\",\n",
            "  \"contents\" : \"Lung cancer is the leading cause of cancer death in North America and Western Europe Patients with lung cancer in general have reduced physical capacity functional capacity poor quality of life and increased levels of anxiety and depression Intervention studies indicate that physical training can address these issues However there is a lack of decisive evidence regarding the effect of physical exercise in patients with advanced lung cancer The aim of this study is to evaluate the effects of a twelve weeks twice weekly program consisting of supervised structured training in a group of advanced lung cancer patients cardiovascular and strength training relaxation A randomized controlled trial will test the effects of the exercise intervention in 216 patients with advanced lung cancer non-small cell lung cancer NSCLC stage IIIb-IV and small cell lung cancer SCLC extensive disease ED Primary outcome is maximal oxygen uptake VOpeak Secondary outcomes are muscle strength 1RM functional capacity 6MWD lung capacity Fev1 and patient reported outcome including anxiety depression HADS and quality of life HRQOL The present randomized controlled study will provide data on the effectiveness of a supervised exercise intervention in patients receiving systemic therapy for advanced lung cancer It is hoped that the intervention can improve physical capacity and functional level during rehabilitation of cancer patients with complex symptom burden and help them to maintain independent function for as long as possible http//ClinicalTrialsgov NCT01881906\",\n",
            "}\n",
            "13265\n",
            "{\n",
            "  \"id\" : \"24977700\",\n",
            "  \"contents\" : \"This study aimed to examine the acute effect of caffeine on exercise capacity exercise-related fatigue and functional performance in prostate cancer survivors In this randomized placebo-controlled double-blind crossover study 30 prostate cancer survivors age 703 77 yr body mass 805 130 kg mean SD consumed 604 016 mgkg -1 of anhydrous caffeine or a placebo 1 h before completing a battery of exercise capacity and functional performance tests Testing sessions were separated by 3-4 wk Immediate fatigue and perceived exertion were measured directly pre - and postexercise at both testing sessions Caffeine increased exercise capacity by 793 s +30 % P = 0010 however postexercise fatigue and perception of exertion were comparable with the placebo session P = 0632 and P = 0902 respectively Increases in isometric grip strength trended toward significance in both dominant +29 % P = 0053 and nondominant +21 % P = 0061 hands in the caffeine trial compared with placebo Caffeine ingestion did not result in improvements in performance for any of the remaining functional measures including the timed up-and-go test repeated chair stands 6-m fast walk and 6-m backward tandem walk Systolic blood pressure and HR were significantly increased P = 0006 and P = 0040 respectively upon completion of the testing battery when compared with placebo Consumption of caffeine 1 h before exercise induced improvements in exercise capacity and muscular strength in prostate cancer survivors However there was no change in exercise-related fatigue when compared with placebo despite reduction in timed performance of the 400-m walk Caffeine seems to enhance exercise tolerance through improved performance with no subsequent increase in fatigue or perception of exertion and may be an appropriate strategy to promote exercise participation in prostate cancer survivors\",\n",
            "}\n",
            "13266\n",
            "{\n",
            "  \"id\" : \"22726581\",\n",
            "  \"contents\" : \"This secondary analysis was performed to identify predictive factors for severe late radiotherapy RT - related toxicity after treatment with hyperfractionated RT + / - concomitant cisplatin in locally advanced head and neck cancer Patients were retrospectively analyzed from the previously reported randomized phase III trial SAKK 10/94 Severe late RT-related toxicity was defined as late RTOG grade 3 toxicity starting 3 months after end of RT and/or potential treatment-related death within 3 years of randomization Two hundred and thirteen randomized patients were analyzed 84 39 % experienced severe late RT-related toxicity With median follow-up of 97 years range 04-15 4 years median time to severe late RT-related toxicity was 96 years In the univariate Cox proportional hazards model the following variables were associated with severe late RT-related toxicity advanced N-classification p < 0001 technically unresectable disease p = 004 weight loss ratio p = 0003 supportive measures p = 0009 and severe acute dysphagia p = 0001 In the subsequent multivariate analysis all variables except use of supportive measures remained statistically significant Chemotherapy did not appear to affect severe late RT-related toxicity but advanced N-classification technically unresectable disease weight loss ratio and severe acute dysphagia were independent predictive factors for severe late RT-related toxicity\",\n",
            "}\n",
            "13267\n",
            "{\n",
            "  \"id\" : \"24743455\",\n",
            "  \"contents\" : \"Chronic lymphedema occurs frequently in breast cancer patients and is associated with significant morbidity and reduced quality-of-life In this pilot study the authors 1 addressed whether conducting a larger randomized controlled trial of aqua lymphatic therapy ALT would be feasible and 2 estimated the extent to which ALT combined with home-based exercise compared with home-based exercise alone would reduce arm disability in patients with breast cancer-related lymphedema Twenty-five women with breast cancer-related lymphedema were randomized to either ALT in addition to a home land-based exercise program ALT group n = 13 or to a home land-based exercise program alone control group n = 12 The participants were evaluated before and after a 12-wk intervention period composed of weekly pool exercise sessions Main outcome measures were arm volume arm disability pain and quality-of-life At follow-up there was no statistical difference between the control and ALT groups in any of the outcomes except for present pain intensity At the end of the study period there was no change in the lymphedematous limb volume in either group Grip strength was improved in both groups Only the ALT group showed a statistically significant difference with a reduction in pain intensity score and arm disability Furthermore quality-of-life significantly improved only in the ALT group Conducting a larger randomized controlled trial would be feasible In comparison with the beginning of the intervention the participants in the ALT group showed significant beneficial changes after 12 wks of treatment whereas the control group did not improve ALT did not make the lymphedema volume worse and therefore may serve as a safe alternative to land-based treatments of breast cancer-related lymphedema\",\n",
            "}\n",
            "13268\n",
            "{\n",
            "  \"id\" : \"24357105\",\n",
            "  \"contents\" : \"Brassica vegetable consumption may confer a protective effect against cancer possibly attributable to their glucosinolates Glucobrassicin is a predominant glucosinolate and is the precursor of indole-3-carbinol I3C a compound with anticancer effects However objective assessments of I3C uptake from Brassica vegetables have not been successful We conducted a randomized crossover trial to test whether 33 - diindolylmethane DIM a metabolite of I3C excreted in the urine after consumption of raw Brassica vegetables with divergent glucobrassicin concentrations is a marker of I3C uptake from such foods Twenty-five subjects were fed 50 g of either raw Jade Cross Brussels sprouts high glucobrassicin concentration or Blue Dynasty cabbage low glucobrassicin concentration once daily for 3 days All urine was collected for 24 hours after vegetable consumption each day After a washout period subjects crossed over to the alternate vegetable Urinary DIM was measured using a novel liquid chromatography-electrospray ionization-tandem mass spectrometry-selected reaction monitoring LC-ESI-MS/MS-SRM method with [ 2 H2 ] DIM as internal standard Urinary DIM was consistently and significantly higher after Brussels sprouts feeding than after cabbage feeding as evidenced by an average difference of 873 pmol/mg creatinine 95 % confidence interval 536-12 10 P = 000002 We have successfully quantified urinary DIM after uptake of I3C from food and demonstrated that differences in glucobrassicin exposure are reflected in urinary DIM levels Our LC-ESI-MS/MS-SRM method and the results of our study indicate urinary DIM is a measure of I3C uptake from Brassica vegetables a finding that can be utilized in prospective epidemiologic and chemoprevention studies\",\n",
            "}\n",
            "13269\n",
            "{\n",
            "  \"id\" : \"21724195\",\n",
            "  \"contents\" : \"Z4032 was a randomized study conducted by the American College of Surgeons Oncology Group comparing sublobar resection alone versus sublobar resection with brachytherapy for high-risk operable patients with non-small cell lung cancer NSCLC This evaluates early impact of adjuvant brachytherapy on pulmonary function tests dyspnea and perioperative 30-day respiratory complications in this impaired patient population Eligible patients with stage I NSCLC tumors 3 cm or smaller were randomly allocated to undergo sublobar resection with SRB group or without SR group brachytherapy Outcomes measured included the percentage predicted forced expiratory volume in 1 second FEV1 % percentage predicted carbon monoxide diffusion capacity DLCO % and dyspnea score per the University of California San Diego Shortness of Breath Questionnaire Pulmonary morbidity was assessed per the Common Terminology Criteria for Adverse Events version 30 Outcomes were measured at baseline and 3 months A 10 % change in pulmonary function test or 10-point change in dyspnea score was deemed clinically meaningful Z4032 permanently closed to patient accrual in January 2010 at 224 patients At 3-month follow-up pulmonary function data are currently available for 148 74 SR and 74 SRB patients described in this report There were no differences in baseline characteristics between arms In the SR arm 9 patients 12 % reported grade 3 respiratory adverse events compared with 12 16 % in the SRB arm P = 49 There was no significant change in percentage change in DLCO % or dyspnea score from baseline to 3 months within either arm In the case of FEV1 % percentage change from baseline to 3 months was significant within the SR arm P = 03 with patients reporting improvement in FEV1 % at month 3 Multivariable regression analysis adjusted for baseline values showed no significant impact of treatment arm tumor location upper vs other lobe or surgical approach video-assisted thoracoscopic surgery vs thoracotomy on 3-month FEV1 % DLCO % and dyspnea score There was no significant difference in incidence of clinically meaningful 10 % pulmonary function or 10-point dyspnea score change change between arms Twenty-two percent of patients with lower-lobe tumors and 9 % with upper-lobe tumors demonstrated 10 % decline in FEV1 % odds ratio 279 95 confidence interval 107-7 25 P = 04 Adjuvant intraoperative brachytherapy in conjunction with sublobar resection did not significantly worsen pulmonary function or dyspnea at 3 months in a high-risk population with NSCLC nor was it associated with increased perioperative pulmonary adverse events Lower-lobe resection was the only factor significantly associated with clinically meaningful decline in FEV1 %\",\n",
            "}\n",
            "13270\n",
            "{\n",
            "  \"id\" : \"1423088\",\n",
            "  \"contents\" : \"To evaluate the efficacy of annual mammography over and above annual physical examination of the breasts and the teaching of breast self-examination among women aged 50 to 59 on entry Individually randomized controlled trial Fifteen urban centres in Canada with expertise in the diagnosis and treatment of breast cancer Women with no history of breast cancer and no mammography in the previous 12 months were randomly assigned to undergo either annual mammography and physical examination MP group or annual physical examination only PO group The 39405 women enrolled from January 1980 through March 1985 were followed for a mean of 83 years Derived from the participants by initial and annual self-administered questionnaires from the screening examinations from the patients physicians from the provincial cancer registries and by record linkage to the Canadian National Mortality Data Base Expert panels evaluated histologic and death data Rates of referral from screening rates of detection of breast cancer from screening and from community care nodal status tumour size and rates of death from all causes and from breast cancer Over 85 % of the women in each group attended the screening sessions after screen 1 The characteristics of the women in the two groups were similar Compared with the Canadian population the participants were more likely to be married have fewer children have more education be in a professional occupation smoke less and have been born in North America The rate of screen-detected breast cancer on first examination was 720 per 1000 in the MP group and 345 per 1000 in the PO group more node-positive tumours were found in the MP group than in the PO group At subsequent screens the detection rates were a little less than half the rates at screen 1 During years 2 through 5 the ratios of observed to expected cases of invasive breast cancer were 128 in the MP group and 118 in the PO group Of the women with invasive breast cancer through to 7 years 217 in the MP group and 184 in the PO group had no node involvement 66 and 56 had one to three nodes involved 32 and 34 had four or more nodes involved and 55 and 46 had an unknown nodal status There were 38 deaths from breast cancer in the MP group and 39 in the PO group The ratio of the proportions of death from breast cancer in the MP group compared with those in the UC group was 097 95 % confidence interval 062 to 152 The survival rates were similar in the two groups Women whose cancer had been detected by mammography alone had the highest survival rate The study was internally valid and there was no evidence of randomization bias Screening with yearly mammography in addition to physical examination of the breasts detected considerably more node-negative small tumours than screening with physical examination alone but it had no impact on the rate of death from breast cancer up to 7 years follow-up from entry\",\n",
            "}\n",
            "13271\n",
            "{\n",
            "  \"id\" : \"25076161\",\n",
            "  \"contents\" : \"Identification of cancer or inflammatory bowel disease in the intestinal tract by PET/computed tomography CT imaging can be hampered by physiological uptake of F-fluorodeoxyglucose F-FDG in the normal colon Previous work has localized this F-FDG uptake to the intestinal lumen predominantly occupied by bacteria We sought to determine whether pretreatment with an antibiotic could reduce F-FDG uptake in the healthy colon Thirty patients undergoing restaging PET/CT for nongastrointestinal lymphoma were randomly selected to receive rifaximin 550 mg twice daily for 2 days before their scan post-rifaximin Their PET/CT images were compared with those from their prior study pre-rifaximin Cecal maximum standard uptake value SUVmax and overall colonic F-FDG uptake were compared between scans All PET/CT images were blindly scored by a radiologist The same comparison of sequential scans was also undertaken in 30 patients who did not receive antibiotics Thirty post-rifaximin scans were compared with 30 pre-rifaximin scans in the same patients SUVmax in the cecum was significantly lower in the patient s post-rifaximin scans than in their pre-rifaximin scans P = 0002 The percentage of scans with greater than grade 1 colonic F-FDG uptake was significantly lower in the post-rifaximin scans than in the pre-rifaximin scans P < 005 In contrast there was no significant difference in the paired sequential scans from control patients nor a reduction in the percentage of scans with greater than grade 1 colonic F-FDG uptake This pilot study shows that treatment with rifaximin for 2 days before PET/CT scanning can significantly reduce physiological F-FDG uptake in the normal colonic lumen\",\n",
            "}\n",
            "13272\n",
            "{\n",
            "  \"id\" : \"22699302\",\n",
            "  \"contents\" : \"Cachexia in cancer adversely affects patients perception of symptoms well-being and response to therapy and shortens survival Anamorelin an oral mimetic of ghrelin has been shown to increase body weight and anabolic hormone levels in healthy volunteers and is being investigated to treat cancer cachexia This multicenter double-blind placebo-controlled crossover study evaluated the effects of anamorelin in 16 patients with different cancers and cachexia Patients were randomly assigned to anamorelin 50 mg/day or placebo for 3 days A 3 - to 7-day washout period followed and then treatments were switched Assessments included body weight appetite food intake growth hormone GH levels patient-reported symptom assessments eg the Anderson Symptom Assessment Scale [ ASAS ] and also an inclusion criterion and safety Anamorelin significantly increased body weight compared with placebo 077 kg vs -033 kg Food intake increased compared with placebo but not significantly GH significantly increased at all time points 05-4 h postdose Insulin-like growth factor-1 IGF-1 significantly increased by 5409 ng/mL with anamorelin treatment compared with -356 ng/mL for placebo significant changes in insulin-like growth factor-binding protein 3 IGFBP-3 were 075 g/mL vs -019 g/mL respectively Patient-reported symptoms including appetite as measured by ASAS significantly improved with anamorelin 81 vs 10 for placebo Adverse events AEs in four patients were possibly or probably related to anamorelin hyperglycemia two patients nausea one patient and dizziness one patient Most AEs were mild no patients withdrew due to AEs Anamorelin showed significant metabolic clinical and patient-rated effects in cancer cachexia Further studies are warranted\",\n",
            "}\n",
            "13273\n",
            "{\n",
            "  \"id\" : \"22041444\",\n",
            "  \"contents\" : \"To evaluate the application of pathological diagnosis by rapid paraffin sections in the diagnosis and treatment of cervical diseases A total of 176 cases from our hospital between September 2009 and January 2010 with abnormal cervical cancer screening including abnormal cytology result and high-risk HPV continuous positive were randomly divided into 2 groups Eighty-seven cases of them whose biopsy were got by Belinson forceps under the direction of colposcopy with rapid paraffin sections by ultrasonic histopathological rapid processor and BT transparent agents were selected as group A while 89 cases with conventional paraffin sections were selected as group BThe production time and quality for paraffin sections were analyzed in the two groups Those diagnosed as cervical intraepithelial neoplasia CIN II or even worse and some special patients with CINI in the two groups received surgery including loop electrosurgical procedure LEEP cold knife conization CKC hysterectomy or radical hysterectomy Tissue obtained after surgery was sent for routine pathological examination If the results of postoperative routine pathological examination were inconsistent with the rapid or routine biopsy pathological examination the heavier results were regard as the final diagnoses The pathological results and diagnose accordance rates were recorded and compared between group A and group BThe quality of sections in two groups were all satisfied or basically satisfied to meet the diagnostic requirements There were statistically significant difference in average production time between group A and B 40 minutes vs 24 hours P < 005 Thirty patients in group A and 32 patients in group B received surgery The coincidence rate of biopsy pathological results and final diagnoses were 93 % 28/30 for group A and 91 % 29/32 for group B in which there were not statistically significant difference P > 005 Rapid paraffin sections technology is safe accurate and economical for rapid pathological diagnosis of cervical diseases which is worthy for being widely used in hospitals\",\n",
            "}\n",
            "13274\n",
            "{\n",
            "  \"id\" : \"11354285\",\n",
            "  \"contents\" : \"There is currently no proven chemotherapy regimen for hepatocellular carcinoma HCC The principal chemotherapeutic approach in most cases is infusion therapy into the hepatic arteries feeding the tumors However the clinical effects of chemotherapy are extremely poor Therefore in the present study we conducted a prospective randomized trial of the efficacy of oral administration of enteric-coated tegafur/uracil for advanced HCC From 1994 to 1999 a total of 56 consecutive patients with unresectable stage IV-A HCC were studied prospectively to examine the efficacy of enteric-coated tegafur/uracil in HCC and to determine the significant prognostic factors Twenty-eight patients were treated only with enteric-coated tegafur/uracil without other anticancer treatment Another 20 patients were given conservative management only The remaining eight patients withdrew from the study In the group treated only with enteric-coated tegafur/uracil the median survival time and 1 and 2 year survival rates were 1213 months and 553 and 369 % respectively In the control group the median survival time and 1 year survival rate were 620 months and 55 % respectively By both univariate analysis and multivariate analysis using Cox s proportional hazards model treatment with enteric-coated tegafur/uracil was shown to be the factor most significantly favoring a better prognosis Although the prognosis of most patients with stage IV-A HCC is poor administration of enteric-coated tegafur/uracil induces long-term survival and is an effective treatment for stage IV-A HCC\",\n",
            "}\n",
            "13275\n",
            "{\n",
            "  \"id\" : \"22000747\",\n",
            "  \"contents\" : \"Transforming growth factor-beta1 is related to adverse events in radiochemotherapy We investigated TGFB1 genetic variability in relation to quality of life-impairing acute organ toxicity QAOT of neoadjuvant radiochemotherapy under clinical trial conditions Two independent patient cohorts n = 88 and n = 75 diagnosed with International Union Against Cancer stage II/III rectal cancer received neoadjuvant radiation doses of 504 Gy combined with 5-fluorouracil-based chemotherapy Toxicity was monitored according to Common Terminology Criteria for Adverse Events QAOT was defined as a CTCAE grade 2 for at least one case of enteritis proctitis cystitis or dermatitis Nine germline polymorphisms covering the common genetic diversity in the TGFB1 gene were genotyped In both cohorts all patients carrying the TGFB1 Pro25 variant experienced QAOT positive predictive value of 100 % adjusted p = 00006 In a multivariate logistic regression model gender age body mass index type of chemotherapy or disease state had no significant impact on QAOT The TGFB1 Pro25 variant could be a relevant marker for individual treatment stratification and carriers may benefit from adaptive clinical care or specific radiation techniques\",\n",
            "}\n",
            "13276\n",
            "{\n",
            "  \"id\" : \"21519851\",\n",
            "  \"contents\" : \"To investigate cancer detection rates and percentage of tumour per core between real-time sonoelastography RTE targeted biopsy and lateralised tenfold random biopsy of the prostate in the primary and re-biopsy setting Patients undergoing primary or re-biopsy of the prostate were included Systematic RTE EUB 7500 Hitachi Medical Systems Tokio Japan was performed with the patient in the left lateral position A maximum of four RTE targeted biopsies of the peripheral zone were taken following by a lateralised tenfold biopsy done by a second investigator blinded to the RTE findings RTE targeted and random biopsy cylinders from corresponding areas were compared for percentage of tumour per core Chi-square test and Wilcoxon signed rank test were used to compare differences between different groups One hundred and thirty-nine patients were included 52 with primary biopsy 87 with re-biopsy Prostate cancer was found in 73 525 % patients Cancer detection rates per core were 232 % versus 92 % and 219 % versus 127 % for RTE targeted and random biopsies in the primary and re-biopsy setting which was statistically significant P < 005 The mean percentage of prostate cancer per core from corresponding areas was significantly higher in RTE targeted compared to random biopsy cores with 215 % versus 164 % P < 005 RTE targeted biopsy significantly increases cancer detection rates per core in comparison with random biopsy The difference is more pronounced in the primary biopsy setting RTE targeted biopsy cores are of improved diagnostic value due significantly higher percentages of cancer compared to random biopsy cores\",\n",
            "}\n",
            "13277\n",
            "{\n",
            "  \"id\" : \"16428497\",\n",
            "  \"contents\" : \"Pemetrexed is an antimetabolite that is structurally similar to methotrexate Because nonsteroidal anti-inflammatory drugs NSAID impair methotrexate clearance and increase its toxicity we evaluated the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in advanced cancer patients In two independent randomized crossover drug interaction studies cancer patients with a creatinine clearance CrCl > or = 60 mL/min received an NSAID aspirin or ibuprofen with either the first or the second dose of pemetrexed cycle 1 or 2 Pemetrexed 500 mg/m 2 was infused iv on day 1 of a 21-day cycle and all patients were supplemented with oral folic acid and im vitamin B 12 Aspirin 325 mg or ibuprofen 400 mg 2 x 200 mg was given orally every 6 hours starting 2 days before pemetrexed administration with the ninth and final dose taken 1 hour before infusion Pemetrexed pharmacokinetics with and without concomitant NSAID treatment were compared for cycles 1 and 2 Data from 27 patients in each study were evaluable for the analysis of pemetrexed pharmacokinetics Coadministration of aspirin did not alter pemetrexed pharmacokinetics however ibuprofen coadministration was associated with a 16 % reduction in clearance a 15 % increase in maximum plasma concentration and a 20 % increase in area under the plasma concentration versus time curve but no significant change in V ss compared with pemetrexed alone No febrile neutropenia occurred in any patient and no increase in pemetrexed-related toxicity was associated with NSAID administration Pemetrexed 500 mg/m 2 with vitamin supplementation is well tolerated and requires no dosage adjustment when coadministered with aspirin in patients with CrCl > or = 60 mL/min or ibuprofen in patients with CrCl > or = 80 mL/min\",\n",
            "}\n",
            "13278\n",
            "{\n",
            "  \"id\" : \"23244709\",\n",
            "  \"contents\" : \"This study investigated the impact of early tumor shrinkage ETS on progression-free - PFS and overall survival OS in patients with metastatic colorectal cancer mCRC treated within the AIO KRK 0104 trial as first-line therapy Moreover correlations of ETS with clinical characteristics and prognostic markers were evaluated In total 121 patients were included into this analysis Patients were treated with cetuximab combined with either CAPIRI or CAPOX ETS at six weeks was defined as a relative change of 20 % in the sum of the longest diameters of target lesions compared to baseline Survival times were compared between patients with ETS 20 % versus no-ETS ETS 20 % was observed in 59 % of all patients with KRAS wild-type tumors In these patients ETS 20 % was associated with higher overall response rate 82 % vs 19 % p < 0001 Also PFS 89 vs 47 months p < 0001 and OS 316 vs 158 months p = 0005 were significantly superior in ETS 20 % of patients compared to no-ETS In patients with KRAS mutant mCRC ETS 20 % neither had an effect on PFS nor OS Cetuximab-induced skin toxicity correlated with the occurrence of ETS 20 % p = 0002 In patients with KRAS wild-type tumors treated with cetuximab plus capecitabine-based chemotherapy ETS 20 % is an important predictor of favorable outcome\",\n",
            "}\n",
            "13279\n",
            "{\n",
            "  \"id\" : \"10664641\",\n",
            "  \"contents\" : \"Level of acuity and number of referrals for home health care have been escalating exponentially As referrals continue to increase health care organizations are encouraged to find more effective methods for providing high-quality patient care with cost savings To evaluate the use of remote video technology in the home health care setting as well as the quality use patient satisfaction and cost savings from this technology Quasi-experimental study conducted from May 1996 to October 1997 Home health department in the Sacramento Calif facility of a large health maintenance organization Newly referred patients diagnosed as having congestive heart failure chronic obstructive pulmonary disease cerebral vascular accident cancer diabetes anxiety or need for wound care were eligible for random assignment to intervention n = 102 or control n = 110 groups The control and intervention groups received routine home health care home visits and telephone contact The intervention group also had access to a remote video system that allowed nurses and patients to interact in real time The video system included peripheral equipment for assessing cardiopulmonary status Three quality indicators medication compliance knowledge of disease and ability for self-care extent of use of services degree of patient satisfaction as reported on a 3-part scale and direct and indirect costs of using the remote video technology No differences in the quality indicators patient satisfaction or use were seen Although the average direct cost for home health services was $ 1830 in the intervention group and $ 1167 in the control group the total mean costs of care excluding home health care costs were $ 1948 in the intervention group and $ 2674 in the control group Remote video technology in the home health care setting was shown to be effective well received by patients capable of maintaining quality of care and to have the potential for cost savings Patients seemed pleased with the equipment and the ability to access a home health care provider 24 hours a day Remote technology has the potential to effect cost savings when used to substitute some in-person visits and can also improve access to home health care staff for patients and caregivers This technology can thus be an asset for patients and providers\",\n",
            "}\n",
            "13280\n",
            "{\n",
            "  \"id\" : \"20621736\",\n",
            "  \"contents\" : \"Perceived burden of colorectal cancer CRC screening is an important determinant of participation in subsequent screening rounds and therefore crucial for the effectiveness of a screening programme This study determined differences in perceived burden and willingness to return for a second screening round among participants of a randomised population-based trial comparing a guaiac-based faecal occult blood test gFOBT a faecal immunochemical test FIT and flexible sigmoidoscopy FS screening A representative sample of the Dutch population aged 50-74years was randomised to be invited for gFOBT FIT and FS screening A random sample of participants of each group was asked to complete a questionnaire about test burden and willingness to return for CRC screening In total 402/481 84 % gFOBT 530/659 80 % FIT and 852/1124 76 % FS screenees returned the questionnaire The test was reported as burdensome by 25 % of gFOBT 14 % of FIT and 129 % of FS screenees comparing gFOBT versus FIT p = 005 versus FS p < 0001 In total 941 % of gFOBT 940 % of FIT and 838 % of FS screenees were willing to attend successive screening rounds comparing gFOBT versus FIT p = 084 versus FS p < 0001 Women reported more burden during FS screening than men 182 % versus 77 % p < 0001 FIT slightly outperforms gFOBT with a lower level of reported discomfort and overall burden Both FOBTs are better accepted than FS screening All three tests have a high level of acceptance which may affect uptake of subsequent screening rounds and should be taken into consideration before implementing a CRC screening programme\",\n",
            "}\n",
            "13281\n",
            "{\n",
            "  \"id\" : \"12174922\",\n",
            "  \"contents\" : \"The objective of this study was to evaluate the efficacy and tolerability of leuprorelin acetate in adjuvant treatment in comparison to standard chemotherapy with CMF in premenopausal estrogen-receptor-positive or unknown node-positive patients with early breast cancer The patients were randomly assigned to receive either 2 years of hormone ablation with leuprorelin acetate 1125 mg as a subcutaneous injection every three months or six courses of CMF cyclophosphamide 500 mg/m2 methotrexate 40 mg/m2 fluorouracil 600 mg/m2 days 1 and 8 q 4 weeks The primary study end-point was recurrence-free survival RFS after 2 years Secondary end-points included overall survival adverse events and hormonal suppression Between 1995 and 1999 a total of 589 patients with breast cancer were randomized to treatment with leuprorelin acetate or CMF The data of 227 patients were available for this first interim analysis One hundred and ten and 117 patients were assigned to leuprorelin acetate and chemotherapy respectively Both treatment arms were well balanced for baseline characteristics So far no difference between the groups has emerged with respect to recurrence-free or overall survivaL Suppression of serum estradiol levels and menstruation was less marked in the CMF-group compared to the leuprorelin arm The most common adverse events were low-grade hot flushes weight gain and increased sweating in the leuprorelin-treated patients and alopecia nausea and vomiting in the CMF-group According to these preliminary results ovarian suppression with leuprorelin acetate was as effective as standard chemotherapy for premenopausal women with hormone-sensitive node-positive early breast cancer\",\n",
            "}\n",
            "13282\n",
            "{\n",
            "  \"id\" : \"22105826\",\n",
            "  \"contents\" : \"Capecitabine is an active agent in the treatment of breast cancer It is not known whether integration of capecitabine into an adjuvant regimen that contains a taxane an anthracycline and cyclophosphamide improves outcome in early breast cancer Women with axillary node-positive or high-risk node-negative breast cancer were randomly assigned to receive either three cycles of docetaxel and capecitabine TX followed by three cycles of cyclophosphamide epirubicin and capecitabine CEX n = 753 or three cycles of docetaxel T followed by three cycles of cyclophosphamide epirubicin and fluorouracil CEF n = 747 The primary end point was recurrence-free survival RFS During a median follow-up time of 59 months 214 RFS events occurred local or distant recurrences or deaths TX/CEX n = 96 T/CEF n = 118 RFS was not significantly different between the groups hazard ratio [ HR ] 079 95 % CI 060 to 104 P = 087 5-year RFS 866 % for TX/CEX v 841 % for T/CEF Fifty-six patients assigned to TX/CEX died during the follow-up compared with 75 of patients assigned to T/CEF HR 073 95 % CI 052 to 104 P = 080 In exploratory analyses TX/CEX improved breast cancer-specific survival HR 064 95 % CI 044 to 095 P = 027 and RFS in women with triple-negative disease and in women who had more than three metastatic axillary lymph nodes at the time of diagnosis We detected little severe late toxicity Integration of capecitabine into a regimen that contains docetaxel epirubicin and cyclophosphamide did not improve RFS significantly compared with a similar regimen without capecitabine\",\n",
            "}\n",
            "13283\n",
            "{\n",
            "  \"id\" : \"22864881\",\n",
            "  \"contents\" : \"Robotic surgery was invented to overcome the demerits of laparoscopic technique However it is unclear whether robot-assisted colectomy RAC has significant clinical advantages over laparoscopically assisted colectomy LAC in treating colonic cancer The aim of this study was to compare the surgical outcomes of RAC versus LAC for right-sided colonic cancer Patients with right-sided colonic cancer were randomized to receive RAC or LAC The primary outcome measure was length of hospital stay Secondary outcomes were duration of operation morbidity postoperative pain hospital costs and pathological quality of the specimen Of 71 patients randomized 70 35 in each group were included in the analysis Hospital stay surgical complications postoperative pain score resection margin clearance and number of lymph nodes harvested were similar in both groups The duration of surgery was longer in the RAC group 195 versus 130 min P < 0001 No conversion to open surgery was needed in either group Overall hospital costs were significantly higher for RAC US $ 12235 versus $ 10320 P = 0013 the higher costs were attributed primarily to the costs of surgery including consumables Robotic-assisted laparoscopic right colectomy was feasible but provided no benefit to justify the greater cost NCT01042743 http//wwwclinicaltrialsgov\",\n",
            "}\n",
            "13284\n",
            "{\n",
            "  \"id\" : \"25421252\",\n",
            "  \"contents\" : \"Locally advanced rectal cancer LARC is a heterogeneous group of tumors where a risk-adapted therapeutic strategy is needed Short-course radiotherapy SCRT is a more convenient option for LARC patients than preoperative long-course RT plus capecitabine Histone-deacetylase inhibitors HDACi have shown activity in combination with RT and chemotherapy in the treatment of solid tumors Valproic acid VPA is an anti-epileptic drug with HDACi and anticancer activity In preclinical studies our group showed that the addition of HDACi including VPA to capecitabine produces synergistic antitumour effects by up-regulating thymidine phosphorylase TP the key enzyme converting capecitabine to 5-FU and by downregulating thymidylate synthase TS the 5-FU target Two parallel phase-1 studies will assess the safety of preoperative SCRT 5 fractions each of 5Gy on days 1 to 5 combined with a capecitabine alone increasing dose levels 500-825mg / m2/bid on days 1-21 or b capecitabine as above plus VPA oral daily day -14 to 21 with an intra-patient titration for a target serum level of 50-100 microg/ml followed by surgery 8weeks after the end of SCRT in low-moderate risk RC patients Also a randomized phase-2 study will be performed to explore whether the addition of VPA and/or capecitabine to preoperative SCRT might increase pathologic complete tumor regression TRG1 rate A sample size of 86 patients 21-22 / arm was calculated under the hypothesis that the addition of capecitabine or VPA to SCRT can improve the TRG1 rate from 5 % to 20 % with one-sided alpha = 010 and 80 % powerSeveral biomarkers will be evaluated comparing normal mucosa with tumor TP TS VEGF RAD51 XRCC1 Histones/proteins acetylation HDAC isoforms and on blood samples polymorphisms of DPD TS XRCC1 GSTP1 RAD51 and XRCC3 circulating endothelial and progenitors cells PBMCs-Histones/proteins acetylation Tumor metabolism will be measured by 18FDG-PET at baseline and 15days after the beginning of SCRT This project aims to improve the efficacy of preoperative treatment of LARC and to decrease the inconvenience and the cost of standard long-course RT Correlative studies could identify both prognostic and predictive biomarkers and could add new insight in the mechanism of interaction between VPA capecitabine and RTEudraCT Number 2012-002831-28 ClinicalTrialsgov number NCT01898104\",\n",
            "}\n",
            "13285\n",
            "{\n",
            "  \"id\" : \"12525526\",\n",
            "  \"contents\" : \"Prognosis of patients with advanced oral cavity cancer is worth improving Chemotherapy has been reported to be especially active in oral cavity tumors Here we repeat the results of a randomized multicenter trial enrolling patients with a resectable stage T2-T4 > 3 cm N0-N2 M0 untreated squamous cell carcinoma of the oral cavity Patients were randomly assigned to three cycles of cisplatin and fluorouracil followed by surgery chemotherapy arm or surgery alone control arm In both arms postoperative radiotherapy was reserved to high-risk patients and surgery was modulated depending on the tumor s closeness to the mandible Patients accrual was opened in 1989 and closed in 1999 It included 195 patients In the chemotherapy arm three toxic deaths were recorded No significant difference in overall survival was found Five-year overall survival was for both arms 55 % Postoperative radiotherapy was administered in 33 % of patients in the chemotherapy arm versus 46 % in the control arm A mandible resection was performed in 52 % of patients in the control arm versus 31 % in the chemotherapy arm The addition of primary chemotherapy to standard surgery was unable to improve survival However in this study primary chemotherapy seemed to play a role in reducing the number of patients who needed to undergo mandibulectomy and/or radiation therapy Variations in the criteria used to select patients for these treatment options may make it difficult to generalize these results but there appears to be room for using preoperative chemotherapy to spare destructive surgery or radiation therapy in patients with advanced resectable oral cavity cancer\",\n",
            "}\n",
            "13286\n",
            "{\n",
            "  \"id\" : \"8478672\",\n",
            "  \"contents\" : \"To provide a detailed description of rehabilitation problems of women considered to be low risk and at risk for psychosocial morbidity diagnosed with stage I and II breast cancer 1 month and 1 year after primary treatment A sample of 227 newly diagnosed breast cancer patients were systematically interviewed by a clinical social worker and classified for risk of psychosocial distress in the year after diagnosis They completed a battery of standardized instruments to assess quality of life QL rehabilitation needs and psychologic distress The primary QL instrument the Cancer Rehabilitation Evaluation System CARES provides a detailed listing of rehabilitation needs Descriptive CARES data are presented with comparisons between the two groups The at-risk women had significantly more problems with greater severity than the low-risk women in all areas physical psychosocial medical interaction sexual and marital While both groups showed improvement over the year following diagnosis the at-risk group had significantly more problems 1 year later Many physical problems subside but problems at the local surgical site psychologic distress communication with marital partners and negative body image are more persistent in the at-risk group 1 year later while half of both groups continue to have sexual dysfunction The detailed listing of problems provided by the CARES may be helpful to clinicians in their interactions with patients The need for preventive and early intervention for the at-risk patients is underscored\",\n",
            "}\n",
            "13287\n",
            "{\n",
            "  \"id\" : \"12149301\",\n",
            "  \"contents\" : \"Gemcitabine is generally considered to constitute first-line therapy for pancreatic cancer To determine whether the addition of fluorouracil 5-FU improves on the results from single-agent gemcitabine the Eastern Cooperative Oncology Group ECOG compared gemcitabine plus bolus 5-FU with gemcitabine alone for patients with advanced pancreatic carcinoma This trial involved patients with biopsy-proven advanced carcinoma of the pancreas not amenable to surgical resection Patients were randomized to receive either gemcitabine alone 1000 mg/m 2 / wk weekly for 3 weeks of every 4 or to receive gemcitabine 1000 mg/m 2 / wk followed by 5-FU 600 mg/m 2 / wk weekly on the same schedule The primary end point of the trial was survival with secondary end points of time to progression and response rate Of 327 patients enrolled over 18 months 322 were eligible Overall the median survival was 54 months for gemcitabine alone and 67 months for gemcitabine plus 5-FU P = 09 Progression-free survival for gemcitabine alone was 22 months compared with 34 months for gemcitabine plus 5-FU P = 022 Objective responses were uncommon and were observed in only 56 % of patients treated with gemcitabine and 69 % of patients treated with gemcitabine plus 5-FU Most toxicities were hematologic or gastrointestinal no significant differences were noted between the two treatment arms 5-FU administered in conjunction with gemcitabine did not improve the median survival of patients with advanced pancreatic carcinoma compared with single-agent gemcitabine Further studies with other combinations of gemcitabine and 5-FU are not compelling and clinical trial resources should address other combinations and novel agents\",\n",
            "}\n",
            "13288\n",
            "{\n",
            "  \"id\" : \"18089867\",\n",
            "  \"contents\" : \"This is one of a few studies that have explored the value of baseline symptoms and health-related quality of life HRQOL in predicting survival in patients with brain cancer Baseline HRQOL scores from the European Organisation for Research and Treatment of Cancer [ EORTC ] Quality of Life Questionnaire C30 and the EORTC Brain Cancer Module were examined in 247 patients with anaplastic oligodendrogliomas to determine the relationship with overall survival by using Cox proportional hazards regression models Refined techniques as the bootstrap resampling procedure and the computation of C indexes and R2 coefficients were used to explore the stability of the models as well as better assess the potential benefit of using HRQOL to predict survival in clinical practice and research Classical analysis controlled for major clinical prognostic factors selected emotional functioning P = 0016 communication deficit P = 0261 future uncertainty P = 0481 and weakness of legs P = 0001 as statistically significant prognostic factors of survival However several issues question the validity of these findings and no single model was found to be preferable over all others C indexes which estimate the probability of a model to correctly predict which patient among a randomly chosen pair of patients will survive longer and R2 coefficients which measure the proportion of variability explained by the model did not exhibit major improvement when adding selected or all HRQOL scores to clinical factors While classical techniques lead to positive results more refined analyses suggest that baseline HRQOL scores add relatively little to clinical factors to predict survival These results may have implications for future use of HRQOL as a prognostic factor for patients with cancer\",\n",
            "}\n",
            "13289\n",
            "{\n",
            "  \"id\" : \"11283130\",\n",
            "  \"contents\" : \"In retrospective studies total mesorectal excision TME surgery has been demonstrated to result in a reduction in the number of local recurrences of rectal cancer Reports on improved local control after preoperative hypofractionated radiotherapy have led to the introduction of a randomized multicenter trial to evaluate the effect of TME surgery with and without preoperative radiotherapy Treatment with preoperative radiotherapy might have an effect on the pathologic characteristics that determine staging of rectal cancer We investigated the occurrence of downstaging in rectal cancer patients treated with and without preoperative radiotherapy We analyzed the differences in tumor size number of examined lymph nodes tumor-node-metastasis stage and histopathologic features in 1321 patients entered onto a randomized trial The trial compared preoperative radiotherapy 5 x 5 Gy followed by TME surgery with TME surgery alone Patients who had an interval of more than 10 days between the start of radiotherapy and surgery were excluded from analysis Differences were observed in tumor size P < 001 and total number of examined lymph nodes P < 001 No difference in tumor or node classification was detected The irradiated group demonstrated more poorly differentiated tumors as well as more mucinous tumors In rectal cancer patients short-term preoperative radiotherapy with 5 x 5 Gy does not lead to downstaging if the interval between the start of radiotherapy and surgery does not exceed 10 days\",\n",
            "}\n",
            "13290\n",
            "{\n",
            "  \"id\" : \"11084571\",\n",
            "  \"contents\" : \"We assessed whether asymptomatic ovarian abnormalities detected on ultrasonography in postmenopausal women are precursors to ovarian cancer We compared the transvaginal ultrasonographic findings from the initial examination of 20000 postmenopausal women enrolled to date in an ongoing randomized trial of cancer screening with data on the established risk factors for ovarian cancer obtained from self-administered questionnaires We distinguished cysts with the suggestive characteristic s of a septum a solid component or an irregular or thick wall complex cysts from simple sonolucent cysts with none of those features High parity a strong ovarian cancer protective factor was negatively associated with complex cysts odds ratio for > or = 5 births vs no births 072 95 % confidence interval 053-0 97 but long-term oral contraceptive use another strong ovarian cancer protective factor was not associated with complex cysts odds ratio 096 95 % confidence interval 076-1 20 A family history of ovarian cancer or multiple breast cancers a strong risk factor for cancer was not associated with complex cysts odds ratio 099 95 % confidence interval 068-1 44 Other abnormalities found on ultrasonography including simple cysts bilateral cysts or all abnormalities combined also did not share the established risk factors for ovarian malignancy We did not identify any combination of features of abnormalities septum echogenicity size or papillary projections that manifested the cancer risk factor profile Although a very small proportion of the clinically silent ovarian abnormalities found on ultrasonography are determined to be ovarian cancers the remaining complex cysts and other clinically suspicious abnormalities do not appear to be the immediate precursors of ovarian cancer The eventual identification of such precursors will yield opportunities for earlier diagnosis screening of high-risk groups and better understanding of the cause of this often lethal malignancy\",\n",
            "}\n",
            "13291\n",
            "{\n",
            "  \"id\" : \"24247559\",\n",
            "  \"contents\" : \"It was the aim of this study to evaluate maintenance therapy with bevacizumab + capecitabine following induction with bevacizumab + capecitabine + oxaliplatin XELOX versus bevacizumab + XELOX until progression as first-line therapy in metastatic colorectal cancer mCRC Patients received either bevacizumab 75 mg/kg + XELOX capecitabine 1000 mg/m 2 twice daily on days 1-14 + oxaliplatin 130 mg/m 2 on day 1 every 3 weeks until disease progression arm A or the same doses of bevacizumab + XELOX for 6 cycles followed by bevacizumab + capecitabine until disease progression arm B The primary endpoint was progression-free survival PFS secondary endpoints included overall survival OS objective response rate ORR and safety One hundred and twenty-three patients were randomized Treatment compliance was similar in both groups Median PFS was significantly longer for arm B than for arm A 110 vs 83 months p = 0002 There was no significant difference between the two arms for ORR 667 vs 590 % p = 0861 or median OS 238 vs 202 months p = 0100 Tolerability was acceptable in both treatment arms the most frequent grade 3/4 treatment-related adverse events arm B vs arm A were fatigue 66 vs 161 % diarrhoea 33 vs 113 % anorexia 33 vs 113 % and neuropathy 16 vs 81 % Maintenance therapy with bevacizumab + capecitabine can be considered an appropriate option following induction bevacizumab + XELOX in patients with mCRC instead of continuation of bevacizumab + XELOX\",\n",
            "}\n",
            "13292\n",
            "{\n",
            "  \"id\" : \"11235682\",\n",
            "  \"contents\" : \"The optimal approach to the investigation of possible distant metastases in patients with apparently operable non-small cell lung cancer who do not have symptoms suggesting metastatic disease is controversial We conducted a randomized controlled trial in thoracic surgery services at mainly academic tertiary - and secondary-care general hospitals We recruited 634 patients with apparently operable suspected or proven non-small cell carcinoma of the lung without findings on history physical examination laboratory testing or imaging suggesting extrathoracic metastases Patients were randomly allocated to receive either mediastinoscopy and computed tomography of the chest and then depending on the results immediate thoracotomy or bone scintigraphy and computed tomographic scanning of the head liver and adrenal glands The relative risk of thoracotomy without cure the combination of open and closed thoracotomy incomplete resection and thoracotomy with subsequent recurrence in the full investigation group versus the limited investigation group was 080 95 % confidence interval [ CI ] 056 to 113 p = 020 Forty-three patients in the full investigation group and 61 patients in the limited investigation group underwent a thoracotomy but subsequently had recurrence relative risk 070 95 % CI 047 to 103 p = 007 Patients in the full investigation group were more likely to have avoided thoracotomy because of extrathoracic metastatic disease than those in the limited investigation group 22 patients versus 10 patients respectively relative risk 219 95 % CI 104 to 459 p value = 004 The total number of negative invasive tests was six in the full investigation group and one in the limited investigation group relative risk 61 95 % CI 072 to 510 p = 010 and the total number of invasive tests 11 versus six respectively relative risk 184 95 % CI 068 to 498 p = 023 The full investigation strategy cost $ 823 less per patient 95 % CIs 2482 to -725 Full investigation for metastatic disease in patients with non-small cell lung cancer without symptoms or signs of metastatic disease may reduce the number of thoracotomies without cure The higher the threshold for considering symptoms to suggest metastatic disease the more likely it is that investigation will spare patients futile thoracotomy\",\n",
            "}\n",
            "13293\n",
            "{\n",
            "  \"id\" : \"21208247\",\n",
            "  \"contents\" : \"Bone-cancer pain is a common and refractory cancer pain Opioids on their own do not control this type of pain well enough and co-analgesics are necessary Patients with bone metastasis-related pain at Numeric Rating Scale 4 were enrolled to this randomized placebo-controlled trial They had also received morphine or transdermal fentanyl patches for at least 1 week During the 3-day efficacy phase patients received placebo or 1-3 tablets of oxycodone/paracetamol 5/325 mg four times daily for 3 days All patients kept a daily pain diary The primary endpoint was the Pain Intensity Difference PID Secondary endpoints were cases of breakthrough pain and rescue morphine consumption Additional analyses included the Short Form-6 Dimensions SF-6D quality-of-life scale and a general impression GI of patient satisfaction with treatment at the end of the phase Of the 246 patients in the intent-to-treat set 894 % completed the 3-day efficacy phase PIDs were 09 and 03 in the oxycodone/paracetamol and placebo groups respectively on day 1 P < 0001 and 15 and 03 respectively on day 3 P < 0001 Thirty-eight patients in the treatment group and 58 in the placebo group suffered breakthrough pain on day 3 P < 0001 The SF-6D score decreased to 212 25 in the oxycodone/paracetamol group at the end of the phase P = 0001 In the oxycodone/paracetamol group 67 % rated GI as good very good or excellent Patients with bone-cancer pain already on opioids obtain clinically important additional pain-control with regular oxycodone/paracetamol dosing\",\n",
            "}\n",
            "13294\n",
            "{\n",
            "  \"id\" : \"10102019\",\n",
            "  \"contents\" : \"Prevention of central nervous system CNS leukemia by early introduction of therapy to this sanctuary site is an essential component of modern treatment strategy for acute lymphoblastic leukemia ALL However the optimal form of preventive CNS therapy remains debatable To address this issue we evaluated the efficacy of CNS preventive therapy for 572 children with ALL who achieved complete remission in the Children s Cancer and Leukemia Study Group CCLSG ALL874 1987-1990 and ALL911 1991-1993 studies They received risk-directed therapy based on age and leukocyte count In the ALL 874 study the non-high-risk low-risk [ LR ] + intermediate risk [ IR ] patients were randomly assigned to the conventional cranial irradiation CRT regimen L874A and I874A and the high-dose methotrexate HDMTX regimen without CRT L874B and I874B The former patients received 18-Gy CRT plus 3 doses of intrathecal it MTX and the latter patients received 3 courses of HDMTX at 2 g/m2 plus 13 doses of ITMTX L874B or 4 courses of HDMTX at 45 g/m2 plus 1 dose of ITMTX I874B The 7-year probabilities + / - SE of CNS relapse-free survival were 973 % + / - 26 % L874A n = 41 vs 903 % + / - 53 % L874B n = 39 P = 025 in the LR patients and 100 % I874A n = 55 vs 785 % + / - 65 % I874B n = 54 P = 0002 in the IR patients The corresponding disease-free survival DFS rates were 794 % + / - 65 % vs 744 % + / - 73 % P = 062 in the LR group and 633 % + / - 68 % vs 583 % + / - 72 % P = 066 in the IR group Thus the HDMTX regimen could not provide better protection of CNS relapse as compared with the CRT regimen although their overall efficacy was not significantly different In the ALL 911 study intensive systemic chemotherapy with extended i t injections of MTX plus cytarabine achieved a high CNS relapse-free survival 98 % + / - 19 % at 7 years and a favorable DFS 855 % + / - 5 % at 7 years in the IR patients The patients in the high-risk HR group in both ALL874 and ALL911 studies received the 18-Gy or 24-Gy CRT with intensive systemic chemotherapy Their 7-year probabilities of CNS relapse-free survival ranged from 88 % to 95 % among which the T-ALL patients had a risk of CNS leukemia which was 3-4 times higher compared with B-precursor ALL patients These results indicate that long-term intrathecal CNS prophylaxis as well as appropriate systemic therapy for the non-high-risk patients can provide protection against CNS relapse equivalent to that provided by cranial irradiation\",\n",
            "}\n",
            "13295\n",
            "{\n",
            "  \"id\" : \"15596193\",\n",
            "  \"contents\" : \"To investigate whether testosterone surges occur on repeat injections of 36 or 108 mg goserelin Zoladex depot and if so their extent Men with prostate cancer for whom hormonal therapy was indicated were randomized to open-label goserelin 36 mg every 28 days n = 129 or 108 mg every 84 days n = 118 for 48 weeks Serum testosterone and luteinizing hormone levels were measured before repeat injection on day 1 of each treatment cycle and then on days 4 and 8 Surges were defined in three ways type 1 simultaneous increase in both testosterone and luteinizing hormone to within the age-specific normal range type 2 increase in testosterone to within the age-specific normal range and type 3 elevation in testosterone from less than to greater than the castrate level greater than 185 ng/dL Most patients did not experience a testosterone surge Two patients 18 % in the 108-mg group had a type 1 surge after one repeat injection and two 16 % in the 36-mg group had a type 2 surge after one repeat injection Type 3 surges occurred after one or more repeat injections in 34 270 % and 20 177 % patients in the 36-mg and 108-mg groups respectively P = 0065 the mean surge + / - standard deviation was 112 ng/dL + / -135 and 173 ng/dL + / -246 respectively No patient with a testosterone surge had clinical symptoms of a tumor flare reaction The testosterone levels were consistently maintained within the castrate range 185 ng/dL or less in most 774 % patients receiving long-term 36 mg or 108 mg goserelin\",\n",
            "}\n",
            "13296\n",
            "{\n",
            "  \"id\" : \"12702522\",\n",
            "  \"contents\" : \"The purpose of this study was to determine the best tolerated and efficacious dose of vinorelbine given once or twice in 3-week cycles in combination with methotrexate and fluorouracil VMF Vinorelbine 40 mg/m 2 was given as follows 20 mg/m 2 on days 1 and 8 group 1 30 mg/m 2 on day 1 and 10 mg/m 2 on day 8 group 2 or 40 mg/m 2 on day 1 not exeeding 60 mg/m 2 group 3 The methotrexate dose was 40 mg/m 2 on day 1 and the fluorouracil dose 600 mg/m 2 on days 1 and 8 Thirty patients with evaluable metastases were randomly allocated to the groups first step The second step was to exclude the worst tolerated regimen and then to expand the study to 60 patients Thus group 1 had 26 patients group 2 had 24 patients and group 3 had 10 patients World Health Organization WHO grade 3 hematological toxicity occurred in 23 % 36 % and 50 % of patients and grade 4 in 39 % 32 % and 50 % of patients in groups 1 2 and 3 respectively grade 3 infections were observed in 15 % 9 % and 10 % of patients in groups 1 2 and 3 and grade 4 infections in 5 % and 10 % of patients in groups 2 and 3 respectively Nonhematological toxicity included a mild to moderate neurotoxicity manifesting as constipation abdominal colics and myalgia in the majority of patients One patient in group 3 had serious convulsions after vinorelbine administration she also developed neutropenic sepsis all symptoms were reversible No patient died from side-effects The objective response rates were 50 % 55 % and 44 % for groups 1 2 and 3 respectively Median time to progression was 7 10 and 8 months and median survival time was 26 23 and 16 months in groups 1 2 and 3 respectively VMF regimens where the vinorelbine dose 40 mg/m 2 is divided 20 + 20 mg/m 2 and 30 + 10 mg/m 2 between days 1 and 8 of a 3-week cycle are equally well tolerated and the efficacy is comparable to other modern first line regimens used in the treatment of metastatic breast cancer\",\n",
            "}\n",
            "13297\n",
            "{\n",
            "  \"id\" : \"21905162\",\n",
            "  \"contents\" : \"Patients with breast cancer experience unmet informational and psychosocial needs at the end of treatment A brief psychoeducational intervention delivered at this transition may help to address some of the challenges these women face The purpose of this study was to test the effectiveness of a single-session group psychoeducational intervention GBOT group compared with standard print material usual care In this randomized controlled trial 442 patients with breast cancer who were completing their adjuvant radiotherapy were recruited and randomized to receive either usual care which includes standard print material CRL group n = 226 or usual care and the GBOT group intervention INT group n = 216 Participants completed measures at baseline and again at 3 and 6 months post-intervention The INT group showed significant improvement in their knowledge regarding the re-entry transition period d = 031 and in their feelings of preparedness for re-entry d = 037 There were no differences between the groups over time on health-related distress or mood Results support the effectiveness of providing a single-session group psychoeducational intervention as a first-step approach to supportive care for women at the end of breast cancer treatment\",\n",
            "}\n",
            "13298\n",
            "{\n",
            "  \"id\" : \"11026949\",\n",
            "  \"contents\" : \"There is ample scope to devise forms of psychotherapy in consultation-liaison psychiatry including the newly evolving area of psycho-oncology To highlight the development of psychotherapy in psycho-oncology providing two illustrations We report on conceptual and clinical research in the context of oncology and palliative care focusing on a an approach for families at risk of maladaptive bereavement and b a group programme for women newly diagnosed with early-stage breast cancer We were able to introduce new forms of psychological treatment for specific clinical groups and anecdotal evidence points to useful benefits for participants Psychotherapists should grasp the opportunity to bring their skills to the medical arena but need to subject newly devised interventions to well-designed and methodologically rigorous research\",\n",
            "}\n",
            "13299\n",
            "{\n",
            "  \"id\" : \"18708192\",\n",
            "  \"contents\" : \"One-lung ventilation OLV during thoracoabdominal esophagectomy may induce an inflammatory response that can contribute to the induction and propagation of frequently occurring postoperative respiratory distress Markers of such a response might be detected in the pulmonary as well as in the systemic circulation Inflammation and tissue damage may be key pathogenetic pathways and we hypothesized that 1-lung ventilation may induce an inflammatory cascade reflected by markers for such a response Thirty patients with esophageal cancer were randomized to OLV n = 16 or 2-lung ventilation TLV n = 14 during the thoracic part of the operation Compounds involved in inflammation and coagulation were measured perioperatively and during the 1st 2nd 3rd and 10th postoperative dDuring the perioperative phase the proinflammatory cytokine interleukin-6 and thrombin measured as thrombin-antithrombin complexes started to increase Thrombin which can induce complement activation peaked at the end of surgery and interleukin-6 at the 1st to 2nd postoperative d but there were no differences between the OLV and TLV groups C3a and terminal complement complex TCC started to increase on the 2nd postoperative d and continued to do so for the rest of the study period The increase of TCC was significantly higher in the OLV group compared to the TLV group whereas C3a attained similar levels in the 2 groups OLV is associated with an augmented inflammatory response as reflected by the activation of the TCC This may induce pulmonary tissue damage and recruitment of inflammatory cells\",\n",
            "}\n",
            "13300\n",
            "{\n",
            "  \"id\" : \"24620386\",\n",
            "  \"contents\" : \"To observe the protective effect of Xuebijing injection pretreatment on hepatic ischemia reperfusion I/R injury and coagulopathy in liver cancer patients undergoing excision of hepatic cancer after occlusion of hepatic blood flow A prospective randomly controlled study was conducted Sixty patients with liver cancer classified as Child-Pugh class A undergoing hepatectomy in the Department of Hepatobiliary Surgery of Sun Yat-sen University Cancer Center from October 2011 to March 2013 were enrolled The patients were randomized into control group and Xuebijing group each patient received 100 mL Xuebijing injection added to 09 % saline as a preoperative treatment for 3 days Complete blood count coagulation function hepatic function serum pro-inflammatory cytokines and alpha-fetoprotein AFP levels were determined before and after operation Forty-five out of 60 patients were enrolled eventually with 23 patients in control group and 22 in Xuebijing group and among them 43 patients were positive for hepatitis B surface antigen HBsAg at admission Compared with those before operation the postoperative levels of alanine transaminase ALT aspartate transaminase AST and lactate dehydrogenase LDH in control and Xuebijing groups were significantly elevated prothrombin time PT and activated partial prothrombin time AfYIT were significantly prolonged and white blood cells WBC proportion of neutrophils N and C-reactive protein CRP were significantly increased P < 005 or P < 001 Although the above indexes in Xuebijing group after operation were lower than those in control group in different degrees [ ALT U/L 2131 804-796 6 vs 2658 156-882 3 AST UIL 1941 654-914 2 vs 2643 154-475 9 LDH lg U/L 569 072 vs 571 072 PT s 1524 216 vs 1441 133 AfYIT s 3151 704 vs 2947 490 WBC x 109/L 134 7 466 vs 1458 440 N 087 006 vs 087 004 CRP mg/L 4064 1693-189 59 vs 4564 165-349 40 J no statistical significance was found between the groups all P > 005 The preoperative levels of tumor necrosis factor-a TNF - a and interleukin-6 OL-6 were both less than 10 ng/L and the postoperative levels of TNF-a showed no significant change and IL-6 was increased to 48510 10400-837 50 ng/L and 19326 9510-385 20 ng/L in control and Xuebijing groups respectively P < 001 The serum high mobility group box-1 HMGB1 protein levels after operation were higher than those of preoperative in both groups both P < 001 but the postoperative HMGB1 in Xuebijing group were significantly lower than those in control group jLg / L 26873 556 vs 27712 292 P < 001 Acute physiology and chronic health evaluation ll APACHE ll score in Xuebijing group was significantly lower than that in control group 418 375 vs 453 234 t = 5328 P = 0027 and the first passage of flatus and defecation after operation in Xuebijing group were significantly earlier than those in control group [ exhaust time days 3 2-4 vs 3 2-4 U = -2023 P = 0043 defecation time days 4 2-6 vs 5 3-8 U = -2926 P = 0003 J However no difference was found between two groups in the postoperative and total hospital days Spearman rank correlation analysis showed there were positive correlations between hepatitis B virus HBV - DNA levels and preoperative ALT r = 0414 P = 0044 and AST r = 0405 P = 0024 in 33 HBV-DNA positive patients but there was no significant correlation between HBV - DNA levels or other preoperative liver function indicators Hepatic I/R injury and coagulopathy may occur in liver cancer patients undergoing resection of cancer with occlusion of hepatic blood flow Xuebijing injection may inhibit the release of serum pro-inflammatory cytokines thereby alleviate hepatic I/R injury and promote the recovery of intestinal function But it does not offer protective effect on coagulopathy\",\n",
            "}\n",
            "13301\n",
            "{\n",
            "  \"id\" : \"15802904\",\n",
            "  \"contents\" : \"The aim of our study was to investigate whether oral ambulatory nutrition of head and neck cancer patients using an omega3 fatty acid-enhanced diet low ratio omega6/omega3 fatty acids versus an arginine-enhanced diet could improve nutritional variables as well as clinical outcome postoperative infectious and wound complications A population of 73 ambulatory postsurgical patients with oral and laryngeal cancer were enrolled At discharge from hospital the postsurgical head and neck cancer patients were asked to consume two units per day of either a specially designed omega3 fatty acid-enhanced supplement group 1 or an arginine-enhanced supplement group 2 for a 12-week period No significant intergroup differences in the trend of the three serum proteins and lymphocytes were detected Differences were detected in weight group 1 655 + / - 115 kg vs 704 + / - 111 kg p < 005 with a significant increase in fat mass in group 1 154 + / - 66 vs 181 + / - 84 kg p < 005 and in tricipital skinfold The postoperative infectious complications were similar in both groups 0 in group 1 and 857 % in group 2 nonsignificant No local complications were detected in the surgical wound Gastrointestinal tolerance diarrhea and vomiting episodes of both formulas was good At the dose taken the omega3-enhanced formula improved fat mass and proteins in ambulatory postoperative head and neck cancer patients The arginine-enhanced formula improved proteins Further studies are required to examine the potential role of immune-enhanced supplements\",\n",
            "}\n",
            "13302\n",
            "{\n",
            "  \"id\" : \"9215819\",\n",
            "  \"contents\" : \"To determine the maximum-tolerated dose MTD of paclitaxel over 3 hours with a fixed dose of epirubicin to investigate the plasma pharmacokinetics of this combination and to evaluate the toxicity and the activity in previously untreated metastatic breast cancer patients Fifty patients with metastatic breast cancer measurable disease and normal left ventricular ejection fraction LVEF were eligible Epirubicin was administered as an intravenous IV bolus at the fixed dose of 90 mg/m2 before the infusion of paclitaxel over 3 hours The initial dose of paclitaxel was 135 mg/m2 and was increased by 20 mg/m2 in subsequent cohorts of six patients until dose-limiting toxicity DLT Plasma pharmacokinetics of paclitaxel and epirubicin was performed at cycle 1 in at least two patients per dose level of paclitaxel 175 up to 225 mg/m2 The DLT of this combination was febrile neutropenia in two of eight patients who received paclitaxel at 225 mg/m2 The mean peak plasma concentration of paclitaxel ranged between 51 and 62 micromol/L at doses of 175 to 225 mg/m2 The concentration of epirubicinol decreased from 473 + / - 94 to 379 + / - 75 ng/mL in patients treated with paclitaxel 175 and 225 mg/m2 The most relevant toxicity was grade 4 neutropenia 61 % of all courses The pharmacokinetic data of paclitaxel in particular the time above the threshold level of 005 micromol/L were not significantly related to myelosuppression Cardiac toxicity was mild three patients 6 % developed mild congestive heart failure that was responsive to therapy Among 49 assessable patients 41 responses 84 % 95 % confidence interval [ CI ] 70 % to 92 % were observed and nine 18 % of these were complete Our study demonstrates that 1 the MTD is epirubicin 90 mg/m2 and paclitaxel 200 mg/m2 2 no clear relationship exists between pharmacokinetic data of paclitaxel and myelosuppression while the increase in the dose of paclitaxel is associated with a reduction in epirubicinol plasma levels and 3 the association is feasible with low cardiotoxicity and has a high activity in metastatic breast cancer\",\n",
            "}\n",
            "13303\n",
            "{\n",
            "  \"id\" : \"16293867\",\n",
            "  \"contents\" : \"Ifosfamide carboplatin etoposide and vincristine alone and in combination are highly active against small-cell lung cancer SCLC This trial was designed to investigate whether survival could be improved by a regimen of all four drugs ICE-V compared with standard chemotherapy in patients with SCLC and good performance status and to assess the patients quality of life QL Patients were randomly assigned to receive six cycles of either ICE-V at 4-week intervals without dose reduction or standard chemotherapy administered according to local practice The recommended standard control regimens were cyclophosphamide doxorubicin and etoposide and cisplatin and etoposide A total of 402 patients were randomly assigned and 350 87 % patients have died Overall survival was longer in the ICE-V group hazard ratio 074 95 % CI 060 to 091 P = 0049 median survival was 156 months in the ICE-V group and 116 months in the control group and 2-year survival rates were 20 % and 11 % respectively There was no evidence that the relative survival benefit for ICE-V was less in extensive-stage than in limited-stage patients An increased rate of septicemia was reported in the ICE-V group 15 % v 7 % in the control group but this did not result in an increase in reported treatment-related deaths four patients [ 2 % ] in both groups The findings on QL were broadly similar in both groups with some benefit in favor of ICE-V Compared with standard chemotherapy the ICE-V regimen improves overall survival without QL penalties despite an increased but manageable level of toxicity\",\n",
            "}\n",
            "13304\n",
            "{\n",
            "  \"id\" : \"18024869\",\n",
            "  \"contents\" : \"This trial was conducted to determine the optimal duration of chemotherapy in Korean patients with advanced non-small-cell lung cancer NSCLC Patients with stages IIIB to IV NSCLC who had not progressed after two cycles of chemotherapy were randomly assigned to receive either four arm A or two arm B more cycles of third-generation platinum-doublet treatment Of the 452 enrolled patients 314 were randomly assigned to the groups One-year survival rates were 590 % in arm A and 624 % in arm B and the difference of 34 % 95 % CI -80 to 48 met the predefined criteria for noninferiority The median time to progression TTP however was 62 months 95 % CI 57 to 67 months in arm A and 46 months 95 % CI 44 to 48 months in arm B the difference of which is statistically significant P = 001 The frequencies of hematologic and nonhematologic toxicities were similar in the two arms This study confirms the noninferiority of overall survival with four cycles compared with six cycles of chemotherapy for the first-line treatment of advanced NSCLC and supports the current American Society of Clinical Oncology guidelines Notably patients receiving six cycles of chemotherapy compared with four cycles showed a favorable TTP suggesting that further investigation of the new strategies of maintenance therapy with less toxic agents after three to four cycles of induction chemotherapy might be warranted to improve survival with consideration of both ethnicity and pharmacogenomic signatures\",\n",
            "}\n",
            "13305\n",
            "{\n",
            "  \"id\" : \"19644973\",\n",
            "  \"contents\" : \"The laparoscopic treatment of rectal cancer is controversial This study compared surgical outcomes after laparoscopic and open approaches for mid and low rectal cancers Some 204 patients with mid and low rectal adenocarcinomas were allocated randomly to open 103 or laparoscopic 101 surgery The surgical team was the same for both procedures Most patients had stage II or III disease and received neoadjuvant therapy with oral capecitabine and 50-54 Gy external beam radiotherapy Sphincter-preserving surgery was performed in 786 and 762 per cent of patients in the open and laparoscopic groups respectively Blood loss was significantly greater for open surgery P < 0001 and operating time was significantly greater for laparoscopic surgery P = 0020 and return to diet and hospital stay were longer for open surgery Complication rates and involvement of circumferential and radial margins were similar for both procedures but the number of isolated lymph nodes was greater in the laparoscopic group mean 1363 versus 1157 P = 0026 There were no differences in local recurrence disease-free or overall survival Laparoscopic surgery for rectal cancer has a similar complication rate to open surgery with less blood loss rapid intestinal recovery shorter hospital stay and no compromise of oncological outcomes\",\n",
            "}\n",
            "13306\n",
            "{\n",
            "  \"id\" : \"23404211\",\n",
            "  \"contents\" : \"The addition of mTOR inhibitor everolimus EVE to exemestane EXE was evaluated in an international phase 3 study BOLERO-2 in patients with hormone-receptor-positive HR + breast cancer refractory to letrozole or anastrozole The safety and efficacy of anticancer treatments may be influenced by ethnicity Sekine et al in Br J Cancer 991757 -62 2008 Safety and efficacy results from Asian versus non-Asian patients in BOLERO-2 are reported Patients were randomized 21 to 10 mg/day EVE + EXE or placebo PBO + EXE Primary endpoint was progression-free survival PFS Secondary endpoints included overall survival response rate clinical benefit rate and safety Of 143 Asian patients 98 received EVE + EXE and 45 received PBO + EXE Treatment with EVE + EXE significantly improved median PFS versus PBO + EXE among Asian patients by 38 % HR = 062 95 % CI 041-0 94 Median PFS was also improved among non-Asian patients by 59 % HR = 041 95 % CI 033-0 50 Median PFS duration among EVE-treated Asian patients was 848 versus 414 months for PBO + EXE and 733 versus 283 months respectively in non-Asian patients The most common grade 3/4 adverse events stomatitis anemia elevated liver enzymes hyperglycemia and dyspnea occurred at similar frequencies in Asian and non-Asian patients Grade 1/2 interstitial lung disease occurred more frequently in Asian patients Quality of life was similar between treatment arms in Asian patients Adding EVE to EXE provided substantial clinical benefit in both Asian and non-Asian patients with similar safety profiles This combination represents an improvement in the management of postmenopausal women with HR + / HER2 - advanced breast cancer progressing on nonsteroidal aromatase inhibitors regardless of ethnicity\",\n",
            "}\n",
            "13307\n",
            "{\n",
            "  \"id\" : \"18532895\",\n",
            "  \"contents\" : \"Radiotherapy-induced xerostomia seriously reduces the quality of life QOL for patients with head and neck cancer This study aimed to investigate the effects of manual acupuncture on objective and subjective assessment of symptom changes in patients with cancer who have with radiation-induced xerostomia Twelve 12 patients with radiation-induced xerostomia were randomized into 2 groups real or sham acupuncture Acupuncture was conducted twice weekly for 6 weeks in a single-blind setting The effect was evaluated by measuring whole salivary flow rates stimulated and unstimulated and questionnaire-based assessment of subjective symptoms pre - and post-treatment 3 and 6 weeks after acupuncture treatment Both groups showed a slight increase in whole salivary flow rates with no significant difference between them However real acupuncture markedly increased unstimulated salivary flow rates and improved the score for dry mouth according to the xerostomia questionnaire by 233 points versus 033 in the controls Our results showed the significantly meaningful amelioration of the subjective sensation of xerostomia closely associated with QOL in patients with head and neck cancer treated with irradiation\",\n",
            "}\n",
            "13308\n",
            "{\n",
            "  \"id\" : \"21495025\",\n",
            "  \"contents\" : \"African American breast cancer survivors may be at high risk for reproductive health problems including menopause symptoms sexual dysfunction and distress about cancer-related infertility The authors partnered with Sisters Network Inc to create the Sisters Peer Counseling in Reproductive Issues After Treatment SPIRIT program a culturally sensitive intervention program that combined a written workbook and peer counseling Three hundred women were randomized to receive either the workbook plus 3 in-person sessions with a trained peer counselor or the workbook plus 30 minutes of telephone counseling to be initiated by the participant Questionnaires at baseline post-treatment and at 6-month and 12-month follow-up assessed emotional distress sexual function relationship satisfaction spirituality menopause symptoms and knowledge Satisfaction with the program and the use of medical care also were assessed Both groups of women improved significantly in knowledge decreased in distress and had decreased hot flashes Sexually active women had improved sexual function at 6-month follow-up but not at 1 year However peer counseling had little incremental benefit over the telephone counseling The SPIRIT program was rated very useful by 66 % of women Outcomes justify continued use of the workbook and further research to optimize the impact of peer counseling\",\n",
            "}\n",
            "13309\n",
            "{\n",
            "  \"id\" : \"24467669\",\n",
            "  \"contents\" : \"To determine if supervised exercise minimises treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy ADT This is the first study to date that has investigated the potential role of exercise in preventing ADT toxicity rather than recovering from established toxicities Sixty-three men scheduled to receive ADT were randomly assigned to a 3-month supervised exercise programme involving aerobic and resistance exercise sessions commenced within 10 days of their first ADT injection 32 men or usual care 31 men The primary outcome was body composition lean and fat mass Other study outcomes included bone mineral density physical function blood biomarkers of chronic disease risk and bone turnover general and prostate cancer-specific quality of life fatigue and psychological distress Outcomes were compared between groups using analysis of covariance adjusted for baseline values Compared to usual care a 3-month exercise programme preserved appendicular lean mass P = 0019 and prevented gains in whole body fat mass trunk fat mass and percentage fat with group differences of -14 kg P = 0001 -09 kg P = 0008 and -13 % P < 0001 respectively Significant between-group differences were also seen favouring the exercise group for cardiovascular fitness peak oxygen consumption 11 mL/kg/min P = 0004 muscular strength 40-25 9 kg P 0026 lower body function -11 s P < 0001 total cholesterol high-density lipoprotein-cholesterol ratio -052 P = 0028 sexual function 152 P = 0028 fatigue 31 P = 0042 psychological distress -22 P = 0045 social functioning 38 P = 0015 and mental health 36-3 8 P 0022 There were no significant group differences for any other outcomes Commencing a supervised exercise programme involving aerobic and resistance exercise when initiating ADT significantly reduced treatment toxicity while improving social functioning and mental health Concurrent prescription of supervised exercise when initiating ADT is therefore advised to minimise morbidity associated with severe hypogonadism\",\n",
            "}\n",
            "13310\n",
            "{\n",
            "  \"id\" : \"22524802\",\n",
            "  \"contents\" : \"Health risk appraisal is often utilized to modify individual s health behavior especially concerning disease prevention and web-based health risk appraisal services are being provided to the general public in Korea However little is known about the psychological effect of the health risk appraisal even though poorly communicated information by the web-based service may result in unintended adverse health outcomes This study was conducted to explore the psychological effect of health risk appraisal using epidemiological risk factor profile We conducted a randomized trial comparing risk factor list type health risk appraisal and risk score type health risk appraisal We studied 60 women aged 30 years and older who had no cancer Anxiety level was assessed using the Spielberger State-Trait Anxiety Inventory YZ The results of multivariate analysis showed that risk status was the independent predictors of increase of state anxiety after health risk appraisal intervention when age education health risk appraisal type numeracy state anxiety trait anxiety and health risk appraisal type by risk status interaction was adjusted Women who had higher risk status had an odd of having increased anxiety that was about 5 times greater than women who had lower risk status Our findings indicate that communicating the risk status by individual health risk appraisal service can induce psychological sequelae especially in women having higher risk status Hospitals institutes or medical schools that are operating or planning to operate the online health risk appraisal service should take side effects such as psychological sequelae into consideration\",\n",
            "}\n",
            "13311\n",
            "{\n",
            "  \"id\" : \"24279296\",\n",
            "  \"contents\" : \"In order to improve lung cancer survival in the UK a greater proportion of resectable cancers must be diagnosed It is likely that resectability rates would be increased by more timely diagnosis Aside from screening the only way of achieving this is to reduce the time to diagnosis in symptomatic cancers Currently lung cancers are mainly diagnosed by general practitioners GPs using the National Institute for Health and Clinical Excellence NICE guidelines for urgent referral for chest X-ray which recommend urgent imaging or referral for patients who have one of a number of chest symptoms for more than 3 weeks We are proposing to expand this recommendation to include one of a number of chest symptoms of any duration in higher-risk patients We intend to conduct a trial of imaging in these higher-risk patients and compare it with NICE guidelines to see if imaging improves stage at diagnosis and resection rates This trial would have to be large and consequently resource-intensive because most of these patients will not have lung cancer making optimal design crucial We are therefore conducting a pilot trial that will ascertain the feasibility of running a full trial and provide key information that will be required in order to design the full trial This trial will assess the feasibility and inform the design of a large UK-wide clinical trial of a change to the NICE guidelines for urgent referral for chest X-ray for suspected lung cancer It utilizes a combination of workshop health economic quality of life qualitative and quantitative methods in order to fully assess feasibility Clinicaltrialsgov NCT01344005\",\n",
            "}\n",
            "13312\n",
            "{\n",
            "  \"id\" : \"16118805\",\n",
            "  \"contents\" : \"The objective of this study was to compare the quality of life QOL after treatment among patients who had breast carcinoma with multiple positive lymph nodes The patients were randomized to receive either high-dose chemotherapy with autologous stem cell support HDC or intermediate-dose chemotherapy IDC in the adjuvant setting Two hundred forty-six patients with AJCC Stage IIA IIB or IIIA breast carcinoma who had > or = 10 positive lymph nodes and who were participants in Cancer and Leukemia Group B CALGB 9082 were enrolled in this companion study CALGB 9066 Patients were randomized to receive either high-dose cyclophosphamide carmustine and cisplatin CPA/cDDP/BCNU and autologous bone marrow transplantation the HDC arm or intermediate-dose CPA/cDDP/BCNU as consolidation to adjuvant chemotherapy the IDC arm QOL was assessed at baseline and at 3 months 12 months 24 months and 36 months using the Functional Living Index-Cancer FLIC the Psychosocial Adjustment to Illness Scale PAIS - Self Report and the McCorkle Symptom Distress Scale SDS At the 3-month assessment patients in the HDC arm demonstrated significant worsening of QOL compared with the IDC arm in terms of their physical well being FLIC P = 0023 social functioning FLIC P = 0026 PAIS P < 00001 symptom distress SDS P = 00002 and total QOL scores FLIC P = 0042 At 12 months the differences in QOL scores between the HDC arm and the IDC arm had resolved Patients who received more intensive adjuvant therapy experienced transient declines in QOL By 12 months after therapy QOL was comparable between the 2 arms regardless of therapy intensity and many QOL areas were improved from baseline\",\n",
            "}\n",
            "13313\n",
            "{\n",
            "  \"id\" : \"10197566\",\n",
            "  \"contents\" : \"Vitamin A supplementation is being used successfully to treat some forms of cancer and the degenerative eye disease retinitis pigmentosa The daily biological need for vitamin A is estimated to be 800 retinol equivalents RE / d 2667 IU/d for adult women and 1000 RE/d 3300 IU/d for adult men doses > or = 7500 RE > or = 25000 IU / d are considered potentially toxic over the long term We assessed the safety in adults of long-term vitamin A supplementation with doses above the daily biological need but < 7500 RE < 25000 IU / dAdults aged 18-54 y with retinitis pigmentosa but in generally good health n = 146 were supplemented with 4500 RE 15000 IU vitamin A/d for < or = 12 y group A and compared with a similar group n = 149 that received 23 RE 75 IU / d trace group Mean total consumption of vitamin A in group A was 5583 RE 18609 IU / d range 4911-7296 RE/d or 16369-24318 IU/d and that in the trace group was 1053 RE 3511 IU / d range 401-3192 RE/d or 1338-10638 IU/d Patients in group A showed an 8 % increase in mean serum retinol concentration at 5 y and an 18 % increase at 12 y P < 0001 no retinol value exceeded the upper normal limit 349 micromol/L or 100 microg/dL Mean serum retinyl esters were elevated approximately 17-fold at 5 y and remained relatively stable thereafter No clinical symptoms or signs of liver toxicity attributable to vitamin A excess were detected Prolonged daily consumption of < 7500 RE < 25000 IU vitamin A/d can be considered safe in this age group\",\n",
            "}\n",
            "13314\n",
            "{\n",
            "  \"id\" : \"15138463\",\n",
            "  \"contents\" : \"Although alcohol intake has been positively associated with breast cancer risk in epidemiologic studies a causal relationship has not been established and the mechanisms mediating this association are speculative Alcohol may act through altered status of folate and vitamin B 12 two vitamins required for DNA methylation and nucleotide synthesis and thus cell integrity Although the effects of heavy alcohol intake on folate and vitamin B 12 status have been well-documented few studies have addressed the effects of moderate alcohol intake in a controlled setting The objective of this study was to determine the effects of moderate alcohol intake on folate and vitamin B 12 status in healthy well-nourished postmenopausal women The study design was a randomized diet-controlled crossover intervention Postmenopausal women n = 53 received three 8-week alcohol treatments in random order 0 15 and 30 g/day Treatment periods were preceded by 2-5-week washout periods Blood collected at baseline and week 8 of each treatment period was analyzed for serum folate vitamin B 12 homocysteine HCY and methylmalonic acid MMA concentrations After adjusting for body mass index BMI a significant 5 % decrease was observed in mean serum vitamin B 12 concentrations from 0 to 30 g of alcohol/day 46145 + / -3026 vs 44025 + / -3024 pg/ml P = 003 Mean serum HCY concentrations tended to increase by 3 % from 0 to 30 g of alcohol/day 944 + / -037 vs 973 + / -037 micromol/l P = 005 Alcohol intake had no significant effects on serum folate or MMA concentrations Among healthy well-nourished postmenopausal women moderate alcohol intake may diminish vitamin B 12 status\",\n",
            "}\n",
            "13315\n",
            "{\n",
            "  \"id\" : \"21632509\",\n",
            "  \"contents\" : \"This phase III study examined efficacy of the synthetic Toll-like receptor 9-activating oligodeoxynucleotide PF-3512676 in combination with standard paclitaxel/carboplatin chemotherapy in patients with advanced non-small-cell lung cancer NSCLC Chemotherapy-naive patients with stage IIIB or IV NSCLC were randomly assigned 11 to receive up to six courses of paclitaxel/carboplatin intravenous paclitaxel 200 mg/m 2 and carboplatin at area under the [ concentration-time ] curve 6 on day 1 of a 3-week cycle alone control arm or in combination with 02 mg/kg subcutaneous PF-3512676 on days 8 and 15 investigational arm Primary end point was overall survival OS Baseline demographics were similar across arms N = 828 Most patients 88 % had stage IV disease Median OS and median progression-free survival PFS were similar OS investigational arm 100 months v control arm 98 months P = 56 PFS investigational arm 48 months v control arm 47 months P = 79 Most commonly reported PF-3512676-related adverse events AEs were mild-to-moderate local injection site reactions pyrexia and flu-like symptoms In the investigational arm grades 3 to 4 AEs including neutropenia thrombocytopenia and anemia were more frequent and more patients had one or more sepsis-related AEs versus controls 17 v 3 At first interim analysis the Data Safety Monitoring Committee recommended study discontinuation because of lack of incremental efficacy and more sepsis-related serious AEs in the PF-3512676 arm Administration of PF-3512676 but not chemotherapy was halted Addition of PF-3512676 to paclitaxel/carboplatin did not improve OS or PFS versus paclitaxel/carboplatin alone for first-line treatment of patients with advanced NSCLC but did increase toxicity This regimen can not be recommended for treating patients with advanced NSCLC\",\n",
            "}\n",
            "13316\n",
            "{\n",
            "  \"id\" : \"1727913\",\n",
            "  \"contents\" : \"To test potential protection by ICRF-187 against cumulative doxorubicin-dose-related cardiac toxicity we conducted a randomized clinical trial in 150 women with advanced breast cancer Patients received fluorouracil 5FU 500 mg/m2 doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 every 21 days intravenously IV control regimen 74 patients or the same regimen preceded by ICRF-187 1000 mg/m2 IV experimental regimen 76 patients We previously reported that ICRF-187 in this dose and schedule provides cardiac protection and does not substantially alter the noncardiac toxicity or antitumor efficacy of the control regimen In this updated analysis of the entire patient cohort we provide additional support for these findings and demonstrate that patients in the ICRF-187 group received more cycles median 11 and higher cumulative doses median 500 mg/m2 of doxorubicin than patients in the control group median nine cycles P less than 01 and 441 mg/m2 P less than 05 Twenty-six patients in the ICRF-187 group received doxorubicin doses of at least 700 mg/m2 and among them 11 patients received 1000 mg/m2 or more Only three patients in the control group received doxorubicin doses of 700 mg/m2 the maximum dose administered to one patient in this group was 950 mg/m2 ICRF-187 cardiac protection was demonstrated by difference in incidence of clinical congestive heart failure CHF two patients in the ICRF-187 group v 20 in the control group P less than 0001 and by differences in resting left ventricular ejection fraction LVEF determined by multigated radionuclide MUGA scan from baselines and that required patient removal from study five patients in the ICRF-187 group had a decrease in LVEF to less than 045 or a decrease from the baseline LVEF of 020 or more v 32 in the control group P less than 000001 Among the 30 patients who had an assessable endomyocardial biopsy at cumulative doxorubicin 450 mg/m2 none of 16 in the ICRF-187 group and six of 14 in the control group had a score of 2 P less than 05 ICRF-187 cardiac protection was observed in patients with and without prior chest-wall radiation or other risk factors for developing doxorubicin cardiac toxicity By protecting against cumulative doxorubicin-induced cardiac toxicity ICRF-187 permits significantly greater doses of doxorubicin to be administered to patients with greater safety\",\n",
            "}\n",
            "13317\n",
            "{\n",
            "  \"id\" : \"22335953\",\n",
            "  \"contents\" : \"To analyze the efficacy and quality of life and safety for paclitaxel and carboplatin TC and TC combined with endostar in the treatment of advanced non-small cell lung cancer NSCLC This is a prospective multicenter randomized double-blind placebo-controlled clinical study A total of 126 cases of untreated advanced NSCLC were enrolled in this study There were 63 patients in the TC control arm and TC combined endostar arm respectively All enrolled patients were continuously followed-up for disease progression and death The objective response rate ORR of TC combined with endostar arm was 393 % and that of TC control arm was 230 % P = 0078 The progression-free survival rates for TC combined with endostar arm and TC control arm were 783 % and 588 % respectively in 24 weeks P = 0017 The hazard ratio for the risk of disease progression was 035 95 % CI 013 to 090 P = 0030 The median time to progression TTP of the TC combined with endostar arm was 71 months and TC arm 63 months P > 005 The follow-up results showed that the median survival time mOS of the TC + Endostar arm was 176 months 95 % CI 134 to 217 months and the TC + placebo arm 158 months 95 % CI 94 to 229 months P > 005 The quality of life scores LCSS patient scale after treatment of the TC combined with endostar arm was improved and that of the TC group was improved after completion of two cycles and three cycles of treatment The quality of life scores compared with baseline after the completion of one cycle treatment was significantly improved for both the TC combined with endostar arm P = 0028 and and TC arm P = 0036 It Indicated that TC combined with endostar treatment improved the patient s quality of life in the early treatment The difference of adverse and serious adverse event rates between the two groups was not significant P > 005 Compared with TC alone treatmrnt TC combined with endostar treatment can reduce the risk of disease progression at early time 24 weeks increase the ORR and can be used as first-line treatment for advanced NSCLC The TC combined with endostar treatment has good safety and tolerability improves the quality of life and not increases serious adverse effects and toxicity for patients with advanced NSCLC\",\n",
            "}\n",
            "13318\n",
            "{\n",
            "  \"id\" : \"15082593\",\n",
            "  \"contents\" : \"Covered self-expandable metal stents EMS were recently developed to overcome tumour ingrowth in conventional EMS However supporting evidence for the efficacy of covered EMS is lacking We enrolled 112 patients with unresectable distal biliary malignancies They were randomly assigned to polyurethane covered n = 57 or original diamond stent n = 55 Stent occlusion occurred in eight patients 14 % after a mean of 304 days in the covered group and in 21 patients 38 % after a mean of 166 days in the uncovered group The incidence of covered EMS occlusion was significantly lower than that of uncovered EMS p = 00032 The cumulative stent patency of covered stents was significantly higher than that of uncovered stents p = 00066 No tumour ingrowth occurred in the covered group while it was observed in 15 patients in the uncovered group In subgroup analysis the cumulative patency of the covered EMS was significantly higher in pancreatic cancer p = 00363 and metastatic lymph nodes p = 00354 There was no significant difference in survival between the two groups Acute cholecystitis was observed in two of the covered group and in none of the uncovered group Mild pancreatitis occurred in five of the covered group and in one of the uncovered group Covered diamond stents successfully prevented tumour ingrowth and were significantly superior to uncovered stents for the treatment of patients with distal malignant biliary obstruction However careful attention must be paid to complications specific to covered self-expandable metal stents such as acute cholecystitis and pancreatitis\",\n",
            "}\n",
            "13319\n",
            "{\n",
            "  \"id\" : \"22232535\",\n",
            "  \"contents\" : \"To measure the effect of the adverse events within 35 days of transrectal ultrasound guided biopsy from the perspective of asymptomatic men having prostate specific antigen PSA testing to assess early attitude to re-biopsy to estimate healthcare resource use associated with adverse events due to biopsy and to develop a classification scheme for reporting adverse events after prostate biopsy Prospective cohort study Prostate Biopsy Effects ProBE nested within Prostate Testing for Cancer and Treatment ProtecT study Participants Between 1999 and 2008 227000 community dwelling men aged 50-69 years were identified at 352 practices and invited to counselling about PSA testing 111148 attended a nurse led clinic in the community and 10297 with PSA concentrations of 3-20 ng/mL were offered biopsy within ProtecT Between February 2006 and May 2008 1147/1753 65 % eligible men mean age 621 years mean PSA 54 ng/mL having 10 core transrectal ultrasound guided biopsy under antibiotic cover in the context of ProtecT were recruited to the ProBE study Purpose designed questionnaire administered at biopsy and 7 and 35 days after the procedure to measure frequency and effect of symptoms related to pain infection and bleeding patients attitude to repeat biopsy assessed immediately after biopsy and 7 days later participants healthcare resource use within 35 days of biopsy evaluated by questionnaire telephone follow-up and medical note review each man s adverse event profile graded according to symptoms and healthcare use Pain was reported by 429/984 436 % fever by 172/985 175 % haematuria by 642/976 658 % haematochezia by 356/967 368 % and haemoejaculate by 605/653 926 % men during the 35 days after biopsy Fewer men rated these symptoms as a major/moderate problem-71 / 977 73 % for pain 54/981 55 % for fever 59/958 62 % for haematuria 24/951 25 % for haematochezia and 172/646 266 % for haemoejaculate Immediately after biopsy 124/1142 109 % 95 % confidence interval 92 to 128 men reported that they would consider further biopsy a major or moderate problem seven days after biopsy this proportion had increased to 213/1085 196 % 174 % to 221 % A negative attitude to repeat biopsy was associated with unfavourable experience after the first biopsy particularly pain at biopsy odds ratio 82 P < 0001 and symptoms related to infection 79 P < 0001 and bleeding 42 P < 0001 differences were evident between centres P < 0001 119/1147 104 % 87 % to 123 % men reported consultation with a healthcare professional usually their general practitioner most commonly for infective symptoms Complete data for all index symptoms at all time points were available in 851 participants Symptoms and healthcare use could be used to grade these men as follows grade 0 no symptoms/contact 18 21 % 13 % to 33 % grade 1 minor problem/no contact 550 646 % 614 % to 678 % grade 2 moderate/major problem or contact 271 318 % 288 % to 351 % grade 3 hospital admission 12 14 % 08 % to 24 % and grade 4 death 0 Grade of adverse event was associated with an unfavourable attitude to repeat biopsy Kendall s - b ordinal by ordinal 029 P < 0001 This study with a high response rate of 89 % at 35 days in men undergoing biopsy in the context of a randomised controlled trial has shown that although prostate biopsy is well tolerated by most men it is associated with significant symptoms in a minority and affects attitudes to repeat biopsy and primary care resource use These findings will inform men who seek PSA testing for detection of prostate cancer and assist their physicians during counselling about the potential risks and effect of biopsy Variability in the adverse event profile between centres suggests that patients outcomes could be improved and healthcare use reduced with more effective administration of local anaesthetic and antibiotics Trial registration Current Controlled Trials ISRCTN20141297\",\n",
            "}\n",
            "13320\n",
            "{\n",
            "  \"id\" : \"20413076\",\n",
            "  \"contents\" : \"Immunization of girls against oncogenic human papillomavirus HPV types before sexual debut is important for cervical cancer prevention This phase III blinded randomized controlled trial in adolescent girls assessed safety of the HPV-16 / 18 AS04-adjuvanted vaccine Girls mean age 12 years in 12 countries received the HPV-16 / 18 L1 virus-like particle AS04-adjuvanted vaccine N = 1035 or hepatitis A virus vaccine as control N = 1032 at 0 1 and 6 months The primary objective was to compare the occurrence of serious adverse events SAEs between groups HPV-16 and HPV-18 antibody titers were assessed by enzyme-linked immunosorbent assay post-vaccination Up to study month 7 11 girls in the HPV-16 / 18 vaccine group reported 14 SAEs and 13 girls in the control group reported 15 SAEs The difference in SAE incidence between groups was 20 % 95 % CI -78 120 No SAE in the HPV-16 / 18 vaccine group was considered related to vaccination or led to withdrawal The incidence of solicited local and general symptoms up to 7 days post-vaccination was moderately higher with the HPV-16 / 18 vaccine than with control The incidence of unsolicited symptoms new onset of chronic diseases and medically significant conditions was similar between groups All girls seroconverted for both antigens after three doses of the HPV-16 / 18 vaccine geometric mean titers were 198820 and 82620 EU/mL for anti-HPV-16 and -18 antibodies respectively in initially seronegative girls The HPV-16 / 18 AS04-adjuvanted vaccine was generally well tolerated and immunogenic when administered to young adolescent females the primary target of organized vaccination programs\",\n",
            "}\n",
            "13321\n",
            "{\n",
            "  \"id\" : \"15226326\",\n",
            "  \"contents\" : \"This randomized multicenter phase III trial evaluated whether sequential doxorubicin and docetaxel A -- > T reduced hematological toxicity especially febrile neutropenia compared with concomitant AT administration as first-line chemotherapy in metastatic breast cancer MBC One hundred forty-four patients were randomly assigned to receive three cycles of doxorubicin 75 mg/m 2 every 21 days followed by three cycles of docetaxel 100 mg/m 2 every 21 days A -- > T or six cycles of the combination doxorubicin 50 mg/m 2 and docetaxel 75 mg/m 2 AT every 21 days Patients previously treated with anthracyclines received two cycles of doxorubicin followed by four cycles of docetaxel A -- > T or three cycles of AT followed by three cycles of docetaxel 100 mg/m 2 every 21 days Febrile neutropenia was less common in the A -- > T arm 293 % of patients 69 % of cycles compared with the AT arm 478 % of patients 148 % of cycles P = 02 and P = 0004 respectively Asthenia diarrhea and fever occurred more frequently in the AT arm The overall responses rates were 61 % in the A -- > T arm 95 % CI 50 % to 72 % and 51 % in the AT arm 95 % CI 39 % to 63 % The median duration of response was 87 months A -- > T and 76 months AT the median time to progression was 105 months A -- > T and 92 months AT the median overall survival was 223 months A -- > T and 218 months AT and no significant differences were found A -- > T significantly reduced febrile neutropenia compared with AT in MBC patients and maintains comparable antitumoral efficacy A -- > T represents a valid option for the treatment of MBC\",\n",
            "}\n",
            "13322\n",
            "{\n",
            "  \"id\" : \"12429158\",\n",
            "  \"contents\" : \"To compare the efficacy of bicalutamide monotherapy to maximal androgen blockade in advanced prostatic cancer Previously untreated patients with histologically proven stage C or D American Urological Association Staging System disease were randomly allocated to either bicalutamide B or goserelin plus flutamide G+F After disease progression patients treated with B were assigned to castration The primary endpoint for this trial was overall survival Prostate cancer-specific survival and progression were included among secondary endpoints In total 108 patients received B and 112 received G+F At a median follow-up time of 54 months range 1-89 151 patients progressed and 113 died There was no significant difference in the duration of either progression-free or overall survival Hazards of progression death and cancer-specific death corrected by disease stage tumor grade and baseline PSA level showed that patients initially assigned to B had a higher risk of progression but a comparable risk of death and cancer-specific death with the exception of patients with G3 tumors who had an increased risk of death In patients with well or moderately well differentiated tumors B monotherapy followed by castration may offer the same survival chance as maximal androgen deprivation In those patients it thus represents a reasonable choice that can avoid the side effects of androgen deprivation for considerable periods of time\",\n",
            "}\n",
            "13323\n",
            "{\n",
            "  \"id\" : \"8565696\",\n",
            "  \"contents\" : \"To compare the changes of serum levels and tissue receptor levels of estrogen and progesterone as well as histopathological changes following treatments of endometrial cancer with aminoglutethimide AG progesterone caproate or a combination of both Thirty-nine patients of endometrial cancer were treated with hydroxyprogesterone caproate AG or combination of both and their effects were compared It was observed that 1 the administration of AG gave a fall of estradiol and progesterone serum levels hydroxyprogesterone caproates therapy increased the level of progesterone and following the combination treatment higher progesterone and lower estradiol levels were found P < 005 2 treatments by AG as well as by combination therapy brought about a considerable fall of the positive rate of ER and PR in tissues P < 005 3 histological changes showed inhibition of cell growths in all three types of treatment secretory cells and decidual reaction were shown under the influence of hydroxyprogesterone caproates the changes in combination therapy mainly complied with those in AG treatment The results suggested that AG was effective in treating patients with endometrial cancer resulting in changes of endocrine environments and inhibition of cell growth by mechanism different from that of hydroxyprogesterone caproates\",\n",
            "}\n",
            "13324\n",
            "{\n",
            "  \"id\" : \"15087034\",\n",
            "  \"contents\" : \"Non-small cell lung cancer NSCLC is hyposensitive to the normal first and second-line chemotherapy regimens Camptothecin derivative is becoming a hot point in the treatment of advanced NSCLC The objective of this article was to evaluate the response toxicity and survival time of HMVP MVP and HVP regimens detail in below in the treatment of advanced NSCLC A total of 134 cases with advanced NSCLC was randomized into three groups HMVP group [ 46 patients hydroxycamptothecin HCPT 12 mg/m 2 from d1 to d5 mitomycin C MMC 6 mg/m 2 d1 vindesine VDS 25-3 mg/m 2 d1 and d8 cisplatin DDP 50 mg/m 2 d2 and d3 ] MVP group 44 patients MMC VDS and DDP were the same as HMVP group and HVP group 44 patients HCPT VDS DDP were the same as HMVP group The response rates were 3954 % 17/43 3557 % 15/42 and 2619 % 11/42 in HMVP MVP and HVP groups respectively no significant difference was detected among the three groups P > 005 No significant difference was detected in the median time of remission median survival time and 1 - 2-year survival rates among the three groups Moreover no significant difference was detected in grade III-IV leukopenia grade III-IV thrombocytopenia grade III-IV nausea and vomiting and grade III-IV constipation among the three groups The response rate of MVP regimen is slightly lower than that of HMVP regimen but HMVP regimen do not show obvious superiority It may increase toxicities such as leukopenia nausea/vomiting and constipation The response rate of HVP regimen is slightly lower than that of MVP regimen\",\n",
            "}\n",
            "13325\n",
            "{\n",
            "  \"id\" : \"8207189\",\n",
            "  \"contents\" : \"In many hospitals the only sterile precautions used during the insertion of a nontunneled central venous catheter are sterile gloves and small sterile drapes We investigated whether the use of maximal sterile barrier consisting of mask cap sterile gloves gown and large drape would lower the risk of acquiring catheter-related infections Prospective randomized trial A 500-bed cancer referral center We randomized patients to have their nontunneled central catheter inserted under maximal sterile barrier precautions or control precautions sterile gloves and small drape only All patients were followed for 3 months postinsertion or until the catheter was removed whichever came first Catheter-related infections were diagnosed by quantitative catheter cultures and/or simultaneous quantitative blood cultures The 176 patients whose catheters were inserted by using maximal sterile barrier precautions were comparable to the 167 control patients in underlying disease degree of immuno-suppression therapeutic interventions and catheter risk factors for infections duration and site of catheterization number of catheter lumen catheter insertion difficulty reason for catheter removal There were a total of four catheter infections in the test group and 12 in the control group P = 003 chi-square test The catheter-related septicemia rate was 63 times higher in the control group P = 006 Fisher s exact test Most 67 % of the catheter infections in the control group occurred during the first 2 months after insertion whereas 25 % of the catheter infections in the maximal sterile precautions group occurred during the same period P < 001 Fisher s exact test Cost-benefit analysis showed the use of such precautions to be highly cost-effective Maximal sterile barrier precautions during the insertion of nontunneled catheters reduce the risk of catheter infection This practice is cost-effective and is consistent with the practice of universal precautions during an invasive procedure\",\n",
            "}\n",
            "13326\n",
            "{\n",
            "  \"id\" : \"21575503\",\n",
            "  \"contents\" : \"To observe and compare the response rate and toxicity of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer Sixty-three patients with advanced gastric cancer were randomly divided into two groups The CPT-11 + CAP group consisted of 32 patients who received irinotecan plus capecitabine CPT-11 100 mg/m 2 was injected in 90 minutes on d 1 8 capecitabine 2000 mg/m 2 bid with the first dose in the evening of day 1 and last dose the morning of day 15 repeated for every 21 days The L-OHP + CAP group consisted of 31 patients who received oxaliplatin plus capecitabine oxaliplatin 100 mg/m 2 on day 1 capecitabine 2000 mg/m 2 bid with the first dose in the evening of day 1 and last dose the morning of day 15 repeated for every 21 days Two or more cycle chemotherapy was completed in each group In the CPT-11 + CAP group no patient achieved complete response and 13 patients achieved partia1 response The overall response rate was 406 % 13/32 and the median progression-free survival time was 63 months In the L-OHP + CAP group no patient achieved complete response and 12 patients achieved partial response The overall response rate was 387 % 12/31 and the median progression-free survival time was 61 months There was no significant difference between them P > 005 The most common toxicities were gastrointestinal reaction peripheral neuropathy and myelosuppression in the two groups Patients in CPT-11 + CAP group experienced more III/IV diarrhea 281 % / 32 % P = 0018 On the contrary the rate of III/IV neurotoxicity in the group B was higher 258 % / 31 % P = 0027 No chemotherapy-related death occurred The therapeutic effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer are good and comparable and their toxicities are tolerable\",\n",
            "}\n",
            "13327\n",
            "{\n",
            "  \"id\" : \"24718886\",\n",
            "  \"contents\" : \"The Panitumumab Randomized trial In combination with chemotherapy for Metastatic colorectal cancer to determine Efficacy PRIME demonstrated that panitumumab-FOLFOX4 significantly improved progression-free survival PFS versus FOLFOX4 as first-line treatment of wild-type WT KRAS metastatic colorectal cancer mCRC the primary end point of the study Patients were randomized 11 to panitumumab 60 mg/kg every 2 weeks + FOLFOX4 arm 1 or FOLFOX4 arm 2 This prespecified final descriptive analysis of efficacy and safety was planned for 30 months after the last patient was enrolled A total of 1183 patients were randomized Median PFS for WT KRAS mCRC was 100 months [ 95 % confidence interval CI 93-11 4 months ] for arm 1 and 86 months 95 % CI 75-9 5 months for arm 2 hazard ratio HR = 080 95 % CI 067-0 95 P = 001 Median overall survival OS for WT KRAS mCRC was 239 months 95 % CI 203-27 7 months for arm 1 and 197 months 95 % CI 176-22 7 months for arm 2 HR = 088 95 % CI 073-1 06 P = 017 68 % OS events An exploratory analysis of updated survival > 80 % OS events was carried out which demonstrated improvement in OS HR = 083 95 % CI 070-0 98 P = 003 for WT KRAS mCRC The adverse event profile was consistent with the primary analysis In WT KRAS mCRC PFS was improved objective response was higher and there was a trend toward improved OS with panitumumab-FOLFOX4 with significant improvement in OS observed in an updated analysis of survival in patients with WT KRAS mCRC treated with panitumumab + FOLFOX4 versus FOLFOX4 alone P = 003 These data support a positive benefit-risk profile for panitumumab-FOLFOX4 for patients with previously untreated WT KRAS mCRC KRAS testing is critical to select appropriate patients for treatment with panitumumab\",\n",
            "}\n",
            "13328\n",
            "{\n",
            "  \"id\" : \"15169798\",\n",
            "  \"contents\" : \"A phase II clinical trial was conducted to evaluate the feasibility and tolerability of a prime/boost vaccine strategy using vaccinia virus and fowlpox virus expressing human prostate-specific antigen PSA in patients with biochemical progression after local therapy for prostate cancer The induction of PSA-specific immunity was also evaluated A randomized clinical trial was conducted by the Eastern Cooperative Oncology group and 64 eligible patients were randomly assigned to receive four vaccinations with fowlpox-PSA rF-PSA three rF-PSA vaccines followed by one vaccinia-PSA rV-PSA vaccine or one rV-PSA vaccine followed by three rF-PSA vaccines The major end point was PSA response at 6 months and immune monitoring included measurements of anti-PSA and anti-vaccinia antibody titers and PSA-specific T-cell responses The prime/boost schedule was well tolerated with few adverse events Of the eligible patients 453 % of men remained free of PSA progression at 191 months and 781 % demonstrated clinical progression-free survival There was a trend favoring the treatment group that received a priming dose of rV-PSA Although no significant increases in anti-PSA antibody titers were detected 46 % of patients demonstrated an increase in PSA-reactive T-cells Therapy with poxviruses expressing PSA and delivered in a prime/boost regimen was feasible and associated with minimal toxicity in the cooperative group setting A significant proportion of men remained free of PSA and clinical progression after 19 months follow-up and nearly half demonstrated an increase in PSA-specific T-cell responses Phase III studies are needed to define the role of vaccination in men with prostate cancer or those who are at risk for the disease\",\n",
            "}\n",
            "13329\n",
            "{\n",
            "  \"id\" : \"24363523\",\n",
            "  \"contents\" : \"To evaluate the use of the Roux loop on the postoperative course in patients submitted for gastroenteroanastomosis GE Non-jaundiced patients n = 41 operated on in the Department of General and Transplant Surgery in Lodz between January 2010 and December 2011 were enrolled The tumor was considered unresectable when liver metastases or major vascular involvement were confirmed Patients were randomized to receive Roux n = 21 or conventional GE n = 20 on a prophylactic basis The mean time to nasogastric tube withdrawal in Roux GE group was shorter 14 075 vs 28 11 P < 0001 Time to starting oral liquids soft diet and regular diet were decreased 23 086 vs 345 119 P < 0001 33 073 vs 44 123 P < 0001 and 45 076 vs 56 142 P = 0002 respectively The Roux GE group had a lower use of prokinetics 10 mg thrice daily for 22 18 d vs 37 26 d P = 0044 total 62 49 mg vs 111 79 mg P = 0025 The mean hospitalization time following Roux GE was shorter 77 d vs 96 d P = 0006 Delayed gastric emptying DGE was confirmed in 20 % after conventional GE but in none of the patients following Roux GE Roux gastrojejunostomy during open abdomen exploration in patients with unresectable pancreatic cancer is easy to perform decreases the incidence of DGE and lowers hospitalization time\",\n",
            "}\n",
            "13330\n",
            "{\n",
            "  \"id\" : \"16219926\",\n",
            "  \"contents\" : \"Determine whether standard or high-dose chemotherapy leads to changes in fatigue hemoglobin Hb mental health muscle and joint pain and menopausal status from pre - to post-treatment and to evaluate whether fatigue is associated with these factors in disease-free breast cancer patients Eight hundred eighty-five patients were randomly assigned between two chemotherapy regimens both followed by radiotherapy and tamoxifen Fatigue was assessed using vitality scale score < or = 46 defined as fatigue poor mental health using mental health scale score < or = 56 defined as poor mental health both of Short-Form 36 muscle and joint pain with Rotterdam Symptom Checklist and Hb levels were assessed before and 1 2 and 3 years after chemotherapy Fatigue was reported in 20 % of 430 assessable patients 202 standard-dose 228 high-dose with at least a 3-year follow-up without change over time or difference between treatment arms Mean Hb levels were lower following high-dose chemotherapy Only 5 % of patients experienced fatigue and anemia Mental health score was the strongest fatigue predictor at all assessment moments Menopausal status had no effect on fatigue Linear mixed effect models showed that the higher the Hb level P = 0006 and mental health score P < 0001 the less fatigue was experienced Joint P < 0001 and muscle pain P = 0283 were associated with more fatigue In 3 years after treatment no significant differences in fatigue were found between standard and high-dose chemotherapy Fatigue did not change over time The strongest fatigue predictor was poor mental health\",\n",
            "}\n",
            "13331\n",
            "{\n",
            "  \"id\" : \"9093728\",\n",
            "  \"contents\" : \"5-HT3 antagonists are effective in reducing the acute nausea and vomiting caused by cancer chemotherapy However it is not clear whether continuing these agents beyond twenty four hours is useful in controlling emesis on days two to seven after chemotherapy Four hundred seven patients receiving moderately emetogenic chemotherapy who had been given dexamethasone 8 mg iv and either ondansetron 32 mg iv or dolasetron 24 mg/kg iv were randomized to continue either an oral form of their 5-HT3 antagonist ondansetron 8 mg bid or dolasetron 200 mg daily plus dexamethasone 8 mg po daily or dexamethasone alone for days two to seven Endpoints assessed by self-report were 1 complete control no vomiting no rescue medications no missing data of emesis 2 nausea severity and 3 quality-of-life as measured by the EORTC QLQ-C30 Continuation of 5-HT3 antagonists improved slightly but not significantly the complete control rate 47 % vs 41 % P = 024 one-sided after chemotherapy However mean nausea severity was significantly P = 0015 one sided reduced by 3 mm on a 10 cm scale on the combined arm Minimal differences in quality of life were observed The benefit of continuing 5-HT3 antagonists beyond 24 hours is modest and the merits of routine use in these circumstances debatable\",\n",
            "}\n",
            "13332\n",
            "{\n",
            "  \"id\" : \"8418243\",\n",
            "  \"contents\" : \"Osteolytic metastases often give rise to hypercalcemia fracture and bone pain and occur commonly in patients with recurrent breast cancer We assessed the bisphosphonate clodronate which has proven to be a useful treatment for hypercalcemia and may be a potent inhibitor of tumor-induced osteolysis for its effect on reducing the osseous complications of metastatic breast cancer We studied 173 patients with bone metastases due to breast cancer in a randomized double-blind placebo-controlled trial of oral clodronate 1600 mg/d 85 patients compared with an identical placebo 88 patients The patients in each wing were comparable in their clinical radiologic and biochemical characteristics at trial entry In patients who received clodronate there was a significant reduction compared with placebo in the total number of hypercalcemic episodes 28 v 52 P < 01 in the number of terminal hypercalcemic episodes seven v 17 P < 05 in the incidence of vertebral fractures 84 v 124 per 100 patient-years P < 025 and in the rate of vertebral deformity 168 v 252 per 100 patient-years P < 001 The combined rate of all morbid skeletal events was significantly reduced 2186 v 3048 per 100 patient-years P < 001 Trends were seen in favor of clodronate for nonvertebral fracture rates and radiotherapy requirements for bone pain particularly spinal pain No significant survival differences and no significant differences in side effects were observed between the two groups These findings indicate that oral clodronate has a beneficial effect on the skeletal morbidity associated with breast cancer and should be considered as antiosteolytic therapy in affected patients It deserves further investigation as an adjuvant therapy in operable breast cancer and in patients with nonosseous recurrence who are at high risk for bone metastases\",\n",
            "}\n",
            "13333\n",
            "{\n",
            "  \"id\" : \"12556062\",\n",
            "  \"contents\" : \"This study tested a breast cancer education intervention for African American women with poor screening histories Disparities in rates of later-stage disease and death may be related to lower screening rates due to behavioral eg knowledge gap and structural eg access barriers 94 African American women low-income poor screening histories were randomly assigned for an educational and on-site screening intervention or non-intervention status Primary care sites were used for educational purposes Three-month post-intervention mammography was assessed The intervention group had significantly higher screening rates than the non-intervention group The latter had a knowledge gap poor screening history cancer fears and insurance differences relative to the screened women Screening was predicted by behavioral rather than structural factors Since low-income African American women face behavioral and structural barriers to breast cancer screening an educational program that improves knowledge levels and is offered in primary care sites can effectively impact screening\",\n",
            "}\n",
            "13334\n",
            "{\n",
            "  \"id\" : \"19243946\",\n",
            "  \"contents\" : \"The relationship between nail and bone may be measurable thus making the fingernail a potentially valuable tool for assessing bone health for women receiving treatment for breast cancer In the BIG 1-98 Fingernail Pilot Substudy Bone Quality Test BQT scores of fingernails were measured at two assessment timepoints Thirteen eligible patients were enrolled into the substudy during their treatment with tamoxifen four patients or letrozole nine patients Two fingernails were tested and BQT scores averaged for two assessments six months apart BQT scores collected six months later second assessment significantly decreased compared with those at first collection p = 0007 regardless of treatment and prior fracture The reduction of BQT scores observed in the patients of our small exploratory study during exposure to bone-altering breast cancer treatments is an incentive for larger studies using this technique\",\n",
            "}\n",
            "13335\n",
            "{\n",
            "  \"id\" : \"24778046\",\n",
            "  \"contents\" : \"We report the results of a phase II trial of adding the anti-ascular endothelial growth factor VEGF bevacizumab to gemcitabine neoadjuvant chemotherapy for patients with borderline and unresectable non-metastatic pancreatic cancer Patients were assigned to one of the two treatment arms Both groups received 1000 mg/m 2 gemcitabine on days 1 8 and 15 of a 4-week cycle for a total of four cycles Group 1 received 5 mg/kg bevacizumab for six weeks three doses every second week starting at week 6 of gemcitabine therapy Group 2 received 5 mg/kg bevacizumab for 12 weeks six doses every second week starting at week 1 of gemcitabine therapy The objective of the present study was to assess the rate of complete radical resection and overall survival A total of 30 patients were enrolled 19 patients had unresectable and 11 patients had borderline-resectable pancreatic cancer Eleven patients 37 % underwent resection The median overall survival of patients who underwent tumor resection was 13 months 95 % confidence interval = 11-15 months In general adding bevacizumab to neoadjuvant gemcitabine does not improve outcomes for patients with locally advanced pancreatic cancer However in individual cases surgery is consequently possible and prolonged survival may be observed\",\n",
            "}\n",
            "13336\n",
            "{\n",
            "  \"id\" : \"18076918\",\n",
            "  \"contents\" : \"A prospective randomized controlled trial was done to evaluate whether oral administration of a preparation of the probiotic agent Lactobacillus casei Yakult Honsha Tokyo Japan could enhance the prevention of recurrence by intravesical instillation of epirubicin after transurethral resection for superficial bladder cancer Between August 1999 and December 2002 207 patients clinically diagnosed with superficial bladder cancer were included as study candidates and underwent transurethral resection followed by intravesical instillation of 30 mg epirubicin/30 ml saline twice during 1 week After histological confirmation of superficial bladder cancer they were again included as study participants with 102 randomized to receive treatment with 6 additional intravesical instillations of epirubicin during the 3-month period after transurethral resection epirubicin group and 100 randomized to intravesical chemotherapy on the same schedule as the epirubicin group plus oral administration of 3 gm Lactobacillus casei preparation per day for 1 year epirubicin plus Lactobacillus casei group Patients were evaluated for intravesical recurrence disease progression prognosis and adverse drug reactions The 3-year recurrence-free survival rate was significantly higher in the epirubicin plus Lactobacillus casei group than in the epirubicin group 746 % vs 599 % p = 00234 although neither progression-free nor overall survival differed between the groups The incidence of adverse drug reactions did not significantly differ between the groups and there were no serious adverse drug reactions Intravesical instillation of epirubicin plus oral administration of Lactobacillus casei preparation is a novel promising treatment for preventing recurrence after transurethral resection for superficial bladder cancer\",\n",
            "}\n",
            "13337\n",
            "{\n",
            "  \"id\" : \"19887581\",\n",
            "  \"contents\" : \"Circulating total cholesterol has been inversely associated with cancer risk however the role of reverse causation and the associations for high-density lipoprotein HDL cholesterol have not been fully characterized We examined the relationship between serum total and HDL cholesterol and risk of overall and site-specific cancers among 29093 men in the Alpha-Tocopherol Beta-Carotene Cancer Prevention ATBC Study cohort Fasting serum total and HDL cholesterol were assayed at baseline and 7545 incident cancers were identified during up to 18 years of follow-up Multivariable proportional hazards models were conducted to estimate relative risks RR Higher serum total cholesterol concentration was associated with decreased risk of cancer overall RR for comparing high versus low quintile 085 95 % confidence interval 079-0 91 P trend < 0001 > 2767 versus < 2039 mg/dL and the inverse association was particularly evident for cancers of the lung and liver These associations were no longer significant however when cases diagnosed during the first 9 years of follow-up were excluded Greater HDL cholesterol was also associated with decreased risk of cancer RR for high versus low quintile 089 95 % confidence interval 083-0 97 P trend = 001 > 553 versus < 362 mg/dL The inverse association of HDL cholesterol was evident for cancers of lung prostate liver and the hematopoietic system and the associations of HDL cholesterol with liver and lung cancers remained after excluding cases diagnosed within 12 years of study entry Our findings suggest that prior observations regarding serum total cholesterol and cancer are largely explained by reverse causation Although chance and reverse causation may explain some of the inverse HDL associations we can not rule out some etiologic role for this lipid fraction\",\n",
            "}\n",
            "13338\n",
            "{\n",
            "  \"id\" : \"15946977\",\n",
            "  \"contents\" : \"Vinorelbine is active and well tolerated against advanced breast cancer but there are no published efficacy studies in early breast cancer We have therefore carried out a randomised phase III neoadjuvant trial in operable breast cancer Patients with > or = 3 cm operable breast carcinoma were randomised to receive either vinorelbine 25 mg/m 2 on days 1 and 8 and epirubicin 60 mg/m 2 on day 1 3 weekly for six cycles VE or doxorubicin 60 mg/m 2 and cyclophosphamide 600 mg/m 2 iv on day 1 3 weekly for six cycles AC prior to standard local therapy and adjuvant endocrine therapy as appropriate A total of 451 patients were randomised Results for AC and VE respectively were overall clinical response 73 % and 74 % complete clinical remission 20 % and 24 % pathological complete remission 12 % and 12 % mastectomy rate 52 % and 55 % None of these differences were significant Dose reduction was required in 8 % for AC and 20 % for VE P < 0001 GSCF support not used Significantly more grade 3/4 toxicity for nausea vomiting and alopecia despite scalp cooling was seen for AC compared with VE but significantly less grade 3/4 thrombophlebitis and neuropathy Neoadjuvant VE is as effective as AC in early breast cancer and was better tolerated except for thrombophlebitis and neuropathy\",\n",
            "}\n",
            "13339\n",
            "{\n",
            "  \"id\" : \"19568773\",\n",
            "  \"contents\" : \"Aprepitant was shown previously to be effective for prevention of chemotherapy-induced nausea and vomiting CINV with moderately emetogenic chemotherapy MEC in breast cancer patients receiving an anthracycline and cyclophosphamide AC - based regimen This study assessed aprepitant in patients receiving a broad range of MEC regimens with a variety of tumor types This phase III randomized gender-stratified double-blind trial enrolled patients with confirmed malignancies nave to MEC or highly emetogenic chemotherapy who were scheduled to receive a single dose of at least one MEC agent Patients received an aprepitant triple-therapy regimen aprepitant ondansetron and dexamethasone or a control regimen ondansetron and dexamethasone administered orally Primary and key secondary efficacy endpoints were proportions of patients with no vomiting and complete response no vomiting and no rescue medication respectively during the 120 h post-chemotherapy Of 848 randomized patients 77 % were female and 52 % received non-AC-based antineoplastic regimens Significantly more patients in the aprepitant group achieved no vomiting and complete response regardless of whether they received AC or non-AC regimens in the 120 h after chemotherapy Overall the incidences of adverse events were generally similar in the aprepitant 628 % and control groups 672 % The aprepitant regimen provided superior efficacy in the treatment of CINV in a broad range of patients receiving MEC non-AC or AC in both no vomiting and complete response endpoints Aprepitant was generally well tolerated These results show the benefit of including aprepitant as part of the standard antiemetic regimen for cancer patients receiving MEC\",\n",
            "}\n",
            "13340\n",
            "{\n",
            "  \"id\" : \"26067687\",\n",
            "  \"contents\" : \"In preclinical work and retrospective population studies the anti-diabetic drug metformin has been associated with antineoplastic activity and decreased burden of many cancers including pancreatic cancer There is therefore interest in the hypothesis that this drug might be repurposed for indications in oncology We aimed to assess the efficacy of the addition of metformin to a standard systemic therapy in patients with advanced pancreatic cancer and provide the first report of a clinical trial with a survival endpoint of metformin for an oncological indication We did this double-blind randomised placebo-controlled phase 2 trial at four centres in the Netherlands Patients aged 18 years or older with advanced pancreatic cancer were randomly assigned 11 via a permutated computer-generated block allocation scheme block size of six to receive intravenous gemcitabine 1000 mg/m 2 on days 1 8 and 15 every 4 weeks and oral erlotinib 100mg once daily in combination with either oral metformin or placebo twice daily Metformin dose was escalated from 500 mg in the first week to 1000 mg twice daily in the second week Randomisation was stratified by hospital diabetes status and tumour stage The primary endpoint was overall survival at 6 months in the intention-to-treat population This trial is complete and is registered with ClinicalTrialsgov number NCT01210911 Between May 31 2010 and Jan 3 2014 we randomly assigned 121 patients to receive gemcitabine and erlotinib with either placebo n = 61 or metformin n = 60 Overall survival at 6 months was 639 % 95 % CI 519-759 in the placebo group and 567 % 441-692 in the metformin group p = 041 There was no difference in overall survival between groups median 76 months [ 95 % CI 61-91 ] vs 68 months [ 95 % CI 51-85 ] in the metformin group hazard ratio [ HR ] 1056 [ 95 % CI 072-155 ] log-rank p = 078 The most frequent grade 3-4 toxic effects were neutropenia 15 [ 25 % ] patients in placebo group vs 15 [ 25 % ] in metformin group skin rash six [ 10 % ] vs four [ 7 % ] diarrhoea three [ 5 % ] vs six [ 10 % ] and fatigue two [ 3 % ] vs six [ 10 % ] Addition of a conventional anti-diabetic dose of metformin does not improve outcome in patients with advanced pancreatic cancer treated with gemcitabine and erlotinib Future research should include studies of more potent biguanides and should focus on patients with hyperinsulinaemia and patients with tumours showing markers of sensitivity to energetic stress such as loss of function of AMP kinase a key regulator of cellular energy homoeostasis Academic Medical Centre Amsterdam and The Terry Fox Foundation Vancouver Canada\",\n",
            "}\n",
            "13341\n",
            "{\n",
            "  \"id\" : \"17566844\",\n",
            "  \"contents\" : \"It has been reported that a docetaxel-carboplatin combination as first-line chemotherapy for ovarian cancer showed a level of progression-free survival similar to that of paclitaxel-carboplatin while reducing neurotoxicity and improving quality of life We investigated the recommended doses of docetaxel-carboplatin in Japanese patients with ovarian cancer and conducted a comparative study of docetaxel-carboplatin versus paclitaxel-carboplatin Thirty-nine patients with ovarian cancer were enrolled in this study and 38 patients were evaluated We conducted a dose-escalation study using a docetaxel dose of 70 mg/m 2 and carboplatin AUC 5 and 6 In the comparative study patients received either docetaxel 70 mg/m 2 and carboplatin AUC 5 or paclitaxel 175 mg/m 2 and carboplatin AUC 5 Progression-free survival survival rate at 2 years response rate toxicity and quality of life were investigated In the dose-finding study we determined the recommended doses as docetaxel 70 mg/m 2 and carboplatin AUC 5 In the comparative study the two arms showed similar progression-free survival Grade 4 neutropenia occurred more frequently in the docetaxel-carboplatin group 846 % than in the paclitaxel-carboplatin group 438 % while sensory neurotoxicity was less frequent in the docetaxel-carboplatin group 538 % than in the paclitaxel-carboplatin 688 % group There were significant differences in the quality-of-life data in favor of docetaxel-carboplatin We determined the recommended doses of docetaxel-carboplatin for Japanese patients with ovarian cancer to be docetaxel 70 mg/m 2 and carboplatin AUC 5 In the comparative study we suggest that the docetaxel-carboplatin combination is effective and well tolerated as first-line chemotherapy for Japanese patients with ovarian cancer\",\n",
            "}\n",
            "13342\n",
            "{\n",
            "  \"id\" : \"24447519\",\n",
            "  \"contents\" : \"Renal transplantation is the best treatment for kidney failure in terms of length and quality of life and cost-effectiveness However most transplants fail after 10 to 12 years consigning patients back onto dialysis Damage by the immune system accounts for approximately 50 % of failing transplants and it is possible to identify patients at risk by screening for the presence of antibodies against human leukocyte antigens However it is not clear how best to treat patients with antibodies This trial will test a combined screening and treatment protocol in renal transplant recipients Recipients > 1 year post-transplantation aged 18 to 70 with an estimated glomerular filtration rate > 30 mL/min will be randomly allocated to blinded or unblinded screening arms before being screened for the presence of antibodies In the unblinded arm test results will be revealed Those with antibodies will have biomarker-led care consisting of a change in their anti-rejection drugs to prednisone tacrolimus and mycophenolate mofetil In the blinded arm screening results will be double blinded and all recruits will remain on current therapy standard care In both arms those without antibodies will be retested every 8 months for 3 years The primary outcome is the 3-year kidney failure rate for the antibody-positive recruits as measured by initiation of long-term dialysis or re-transplantation predicted to be approximately 20 % in the standard care group but < 10 % in biomarker-led care The secondary outcomes include the rate of transplant dysfunction incidence of infection cancer and diabetes mellitus an analysis of adherence with medication and a health economic analysis of the combined screening and treatment protocol Blood samples will be collected and stored every 4 months and will form the basis of separately funded studies to identify new biomarkers associated with the outcomes We have evidence that the biomarker-led care regime will be effective at preventing graft dysfunction and expect this to feed through to graft survival This trial will confirm the benefit of routine screening and lead to a greater understanding of how to keep kidney transplants working longer Current Controlled Trials ISRCTN46157828\",\n",
            "}\n",
            "13343\n",
            "{\n",
            "  \"id\" : \"21108675\",\n",
            "  \"contents\" : \"To describe and compare changes in quality of life in two groups of patients with breast cancer and to identify factors predicting negative changes in quality of life within six months Women with breast cancer suffer from various treatment side-effects from psychological and social symptoms as well as decreased quality of life creating a need for support that may persist throughout the breast cancer experience This six-month longitudinal study involved a sample of 164 women who were quasi-randomized between intervention n = 85 and control groups n = 79 after breast cancer surgery Intervention group received support and education via telephone one week after the breast cancer surgery and face-to-face support six months after the surgery Quality of life was estimated one week and six months after breast cancer surgery using the Quality of Life Index-Cancer Version QLI-CV and the European Organisation for Research and Treatment of Cancer Breast Cancer-Specific Quality of Life questionnaire EORTC QLQ-BR23 Data were analysed statistically using descriptive statistics and non-parametric tests Factors predicting negative changes in quality of life within six months were investigated using logistic regression models with the enter method Significant group difference in the magnitude of changes within six months was found in future outlook Logistic regression analyses revealed six significant predictors of negative changes in quality of life within six months education employment status having underaged children chemotherapy radiotherapy and hormonal therapy The results of this study underline the importance of identifying quality of life changes in patients with breast cancer and paying attention to those women with difficulties in adapting to being a cancer survivor The findings of this study provide evidence which may help to create appropriate supportive interventions for both acute and long-term settings\",\n",
            "}\n",
            "13344\n",
            "{\n",
            "  \"id\" : \"17403076\",\n",
            "  \"contents\" : \"With conventional methods of endoscopic mucosal resection for early gastric cancer EGC proton pump inhibitors PPIs and H2-receptor antagonists H2RAs have a similar effect on preventing bleeding from artificial ulcers An objective of this study is to investigate whether a stronger acid suppressant ie PPI more effectively prevents bleeding after the recent advanced technique of endoscopic submucosal dissection ESD for EGC This was a prospective randomized controlled trial performed in a referral cancer center A total of 143 patients with EGC who underwent ESD were randomly assigned to the treatment groups They received either rabeprazole 20 mg PPI group or cimetidine 800 mg H2RA group on the day before ESD and continued for 8 wk The primary end point was the incidence of bleeding that was defined as hematemesis or melena that required endoscopic hemostasis and decreased the hemoglobin count by more than 2 g/dL In baseline data the endoscopists who performed the ESD were significantly different between the groups Finally 66 of 73 patients in the PPI group and 64 of 70 in the H2RA group were analyzed Bleeding occurred in four patients in the PPI group and 11 in the H2RA group P = 0057 Multivariate analysis revealed that treatment with the PPI significantly reduced the risk of bleeding adjusted hazard ratio 047 95 % confidence interval 022-0 92 P = 0028 One delayed perforation was experienced in the H2RA group PPI therapy more effectively prevented delayed bleeding from the ulcer created after ESD than did H2RA treatment\",\n",
            "}\n",
            "13345\n",
            "{\n",
            "  \"id\" : \"15769967\",\n",
            "  \"contents\" : \"Experimental and epidemiological data suggest that vitamin E supplementation may prevent cancer and cardiovascular events Clinical trials have generally failed to confirm benefits possibly due to their relatively short duration To evaluate whether long-term supplementation with vitamin E decreases the risk of cancer cancer death and major cardiovascular events A randomized double-blind placebo-controlled international trial the initial Heart Outcomes Prevention Evaluation [ HOPE ] trial conducted between December 21 1993 and April 15 1999 of patients at least 55 years old with vascular disease or diabetes mellitus was extended HOPE-The Ongoing Outcomes [ HOPE-TOO ] between April 16 1999 and May 26 2003 Of the initial 267 HOPE centers that had enrolled 9541 patients 174 centers participated in the HOPE-TOO trial Of 7030 patients enrolled at these centers 916 were deceased at the beginning of the extension 1382 refused participation 3994 continued to take the study intervention and 738 agreed to passive follow-up Median duration of follow-up was 70 years Daily dose of natural source vitamin E 400 IU or matching placebo Primary outcomes included cancer incidence cancer deaths and major cardiovascular events myocardial infarction stroke and cardiovascular death Secondary outcomes included heart failure unstable angina and revascularizations Among all HOPE patients there were no significant differences in the primary analysis for cancer incidence there were 552 patients 116 % in the vitamin E group vs 586 123 % in the placebo group relative risk [ RR ] 094 95 % confidence interval [ CI ] 084-1 06 P = 30 for cancer deaths 156 33 % vs 178 37 % respectively RR 088 95 % CI 071-1 09 P = 24 and for major cardiovascular events 1022 215 % vs 985 206 % respectively RR 104 95 % CI 096-1 14 P = 34 Patients in the vitamin E group had a higher risk of heart failure RR 113 95 % CI 101-1 26 P = 03 and hospitalization for heart failure RR 121 95 % CI 100-1 47 P = 045 Similarly among patients enrolled at the centers participating in the HOPE-TOO trial there were no differences in cancer incidence cancer deaths and major cardiovascular events but higher rates of heart failure and hospitalizations for heart failure In patients with vascular disease or diabetes mellitus long-term vitamin E supplementation does not prevent cancer or major cardiovascular events and may increase the risk for heart failure\",\n",
            "}\n",
            "13346\n",
            "{\n",
            "  \"id\" : \"20339140\",\n",
            "  \"contents\" : \"In anorectal cancer patients an acute side effect of chemoradiotherapy is gastrointestinal toxicity which often impedes treatment delivery Based on previous trials octreotide acetate is widely recommended for the control of chemotherapy-induced diarrhea However the effectiveness of octreotide in preventing or controlling radiation - and chemoradiation-induced diarrhea is not known A randomized double-blinded placebo-controlled trial was designed to determine the efficacy of long-acting octreotide acetate LAO in preventing the onset of acute diarrhea in patients undergoing chemoradiation therapy for rectal or anal cancer Between 4 and 7 days before the start of radiation therapy patients received a 30-mg dose of LAO 109 patients or placebo 106 patients via intramuscular injection A second dose was given on day 22 + / -3 days of radiation treatment A total of 215 patients were included in the final analysis The primary endpoint was the incidence of grade 2-4 acute diarrhea secondary endpoints included treatment compliance medical resource utilization patient-reported bowel function and quality of life QoL Statistical tests were one - or two-sided as specified After a median follow-up time of 964 months incidence rates of grades 2-4 acute diarrhea were similar in both groups 49 % placebo vs 44 % LAO P = 21 No statistically significant treatment differences in chemotherapy or radiation delivery medical resource utilization patient-reported bowel function or QoL were observed In this study the prophylactic use of LAO did not prevent the incidence or reduce the severity of diarrhea and had no notable impact on patient-reported bowel function or QoL\",\n",
            "}\n",
            "13347\n",
            "{\n",
            "  \"id\" : \"10811678\",\n",
            "  \"contents\" : \"To determine whether the addition of rifampin to a quinolone-based antibacterial prophylactic regimen in patients undergoing high-dose chemotherapy HDC with peripheral-blood stem-cell transplantation PBSCT decreases the incidence of neutropenia and fever Gram-positive bacteremia and infection-related morbidity Patients with solid tumors undergoing HDC with PBSCT were randomized to receive prophylactic antibiotics with either ciprofloxacin 500 mg orally every 8 hours or the same ciprofloxacin regimen with rifampin 300 mg orally every 12 hours Prophylaxis was started 48 hours before stem-cell reinfusion Patients were monitored to document the occurrence of neutropenia and fever incidence and cause of bacterial infection time to onset and duration of fever requirement for intravenous antimicrobials and length of hospital admission Sixty-five patients were randomized to receive ciprofloxacin and 65 to receive ciprofloxacin plus rifampin and from these groups 62 and 61 were assessable respectively The proportion of patients who developed neutropenia and fever was 87 % in the group treated with ciprofloxacin and 78 % in the group treated with ciprofloxacin and rifampin P = 25 Although there was a trend toward a reduction in the overall incidence of bacteremia 12 v 4 patients and Gram-positive bacteremia 8 v 2 patients with the addition of rifampin none of these comparisons was statistically significant P = 05 and P = 09 respectively The results of this study which demonstrate that rifampin does not improve ciprofloxacin antibacterial prophylaxis in cancer patients undergoing HDC with PBSCT support but that it does increase the occurrence of undesirable side effects do not support the routine use of rifampin in this setting\",\n",
            "}\n",
            "13348\n",
            "{\n",
            "  \"id\" : \"24585721\",\n",
            "  \"contents\" : \"The role of zoledronic acid ZA when added to the neoadjuvant treatment of breast cancer BC in enhancing the clinical and pathological response of tumors is unclear The effect of ZA on the antitumor effect of neoadjuvant chemotherapy has not prospectively been studied before NEOZOTAC is a national multicenter randomized study comparing the efficacy of TAC docetaxel adriamycin and cyclophosphamide iv followed by granulocyte colony-stimulating factor on day 2 with or without ZA 4 mg iv q 3 weeks inpatients withstage II/III HER2-negative BC We present data on the pathological complete response pCR in breast and axilla on clinical response using MRI and toxicity Post hoc subgroup analyses were undertaken to address the predictive value of menopausal status Addition of ZA to chemotherapy did not improve pCR rates 132 % for TAC+ZA versus 133 % for TAC Postmenopausal women N = 96 had a numerical benefit from ZA treatment pCR 140 % for TAC+ZA versus 87 % for TAC P = 042 Clinical objective response did not differ between treatment arms 729 % versus 737 % There was no difference in grade III/IV toxicity between treatment arms Addition of ZA to neoadjuvant chemotherapy did not improve pathological or clinical response to chemotherapy Further investigations are warranted in postmenopausal women with BC since this subgroup might benefit from ZA treatment\",\n",
            "}\n",
            "13349\n",
            "{\n",
            "  \"id\" : \"17624475\",\n",
            "  \"contents\" : \"Lung cancer has the highest mortality-rate per cancer with an overall 5-year survival < 15 % Several non-randomized studies pointed out the high sensitivity of low dose computed tomography LDCT to detect early stage lung cancer In France Depiscan a pilot RCT of LDCT versus chest X-ray CXR started on October 2002 to determine the feasibility of enrollment by general practitioners GPs investigations and diagnostic procedures by university hospital radiologists and multidisciplinary teams data management by centralized clinical research assistants and anticipate the future management of a large national trial GPs and occupational physicians OPs selected and enrolled 1000 subjects in 1 year Eligible subjects were asymptomatic males or females aged 50-75 years with a current or former cigarette smoking history of > / = 15 cigarettes per day for at least 20 years former smokers having quit < 15 years prior to enrollment Based to randomization annual LDCT or CXR screenings were planned at baseline and annually for 2 years Between October 2002 and December 2004 765 subjects were enrolled by 89 out of the 232 participating GPs and OPs Complete clinical and imaging baseline data were available for 621 individuals out of the 765 enrolled due to 144 noncompliant subjects who withdrew their consent At least one nodule was detected in 152 out of 336 subjects 452 % in the LDCT screening versus 21 out of 285 subjects 74 % in the CXR screening arm Eight lung cancers were detected in the LDCT arm and one in the CXR arm This pilot trial allows estimating that non-calcified nodules are 10 [ 636-17 07 ] times more often detected from LDCT than from CXR However enrollment by GPs was more difficult than expected with 41 % active investigators and a high rate 19 % of noncompliant patients This experience speaks to the need for a high level of GPs formation and a large coordinated clinical research team in such a trial 02526\",\n",
            "}\n",
            "13350\n",
            "{\n",
            "  \"id\" : \"24638015\",\n",
            "  \"contents\" : \"This randomized phase III trial was conducted to confirm noninferiority of amrubicin plus cisplatin AP compared with irinotecan plus cisplatin IP in terms of overall survival OS in chemotherapy-naive patients with extensive-disease ED small-cell lung cancer SCLC Chemotherapy-naive patients with ED-SCLC were randomly assigned to receive IP composed of irinotecan 60 mg/m 2 on days 1 8 and 15 and cisplatin 60 mg/m 2 on day 1 every 4 weeks or AP composed of amrubicin 40 mg/m 2 on days 1 2 and 3 and cisplatin 60 mg/m 2 on day 1 every 3 weeks A total of 284 patients were randomly assigned to IP n = 142 and AP n = 142 arms The point estimate of OS hazard ratio HR for AP to IP in the second interim analysis exceeded the noninferior margin HR 131 resulting in early publication because of futility In updated analysis median survival time was 177 IP versus 150 months AP HR 143 95 % CI 110 to 185 median progression-free survival was 56 IP versus 51 months AP HR 142 95 % CI 116 to 173 and response rate was 723 % IP versus 779 % AP P = 33 Adverse events observed in IP and AP arms were grade 4 neutropenia 225 % v 793 % grade 3 to 4 febrile neutropenia 106 % v 321 % and grade 3 to 4 diarrhea 77 % v 14 % AP proved inferior to IP in this trial perhaps because the efficacy of amrubicin as a salvage therapy was differentially beneficial to IP IP remains the standard treatment for extensive-stage SCLC in Japan\",\n",
            "}\n",
            "13351\n",
            "{\n",
            "  \"id\" : \"22410862\",\n",
            "  \"contents\" : \"This study evaluated the acute effect of massage and compression components of lymphoedema treatment in women with and without arm lymphoedema secondary to breast cancer from a single treatment session Women with n = 15 and without n = 15 lymphoedema underwent a single session of lymphatic massage Following the session women were randomised to receive or not receive a compression sleeve Measurements were taken prior to during and following the massage as well as 30 min after completion of the massage Bioimpedance spectrometry BIS was used to measure changes in extracellular fluid volume of all limbs as well as 10-cm segments within the upper limbs perometry was used to measure changes in total upper limb volume as well as 10-cm segments within the limb There were no significant changes after massage with or without compression The median and interquartile range BIS ratios unaffected affected for the whole upper limb for women with lymphoedema changed from 1152 1053 to 1422 to 1192 1045 to 1410 after massage while the control group changed from 1024 0998 to 1047 to 1041 0982 to 107 The median change in both the BIS ratio and the total arm volume measured with perometry from prior to the massage to following 30-min rest changed < 2 % irrespective of whether women used a compression garment and whether women presented with or without lymphoedema Examination of 10-cm segments within the arm also revealed no significant change in BIS ratio from one segment to the next Massage alone or the application of compression after a single session of lymphatic massage was ineffective for reducing lymphoedema\",\n",
            "}\n",
            "13352\n",
            "{\n",
            "  \"id\" : \"12721239\",\n",
            "  \"contents\" : \"To determine the effects of exercise training on cardiopulmonary function and quality of life QOL in postmenopausal breast cancer survivors who had completed surgery radiotherapy and/or chemotherapy with or without current hormone therapy use Fifty-three postmenopausal breast cancer survivors were randomly assigned to an exercise n = 25 or control n = 28 group The exercise group trained on cycle ergometers three times per week for 15 weeks at a power output that elicited the ventilatory equivalent for carbon dioxide The control group did not train The primary outcomes were changes in peak oxygen consumption and overall QOL from baseline to postintervention Peak oxygen consumption was assessed by a graded exercise test using gas exchange analysis Overall QOL was assessed by the Functional Assessment of Cancer Therapy-Breast scale Fifty-two participants completed the trial The exercise group completed 984 % of the exercise sessions Baseline values for peak oxygen consumption P = 254 and overall QOL P = 286 did not differ between groups Peak oxygen consumption increased by 024 L/min in the exercise group whereas it decreased by 005 L/min in the control group mean difference 029 L/min 95 % confidence interval [ CI ] 018 to 040 P < 001 Overall QOL increased by 91 points in the exercise group compared with 03 points in the control group mean difference 88 points 95 % CI 36 to 140 P = 001 Pearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL r = 045 P < 01 Exercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors\",\n",
            "}\n",
            "13353\n",
            "{\n",
            "  \"id\" : \"17968163\",\n",
            "  \"contents\" : \"The role of adjuvant chemoradiation in pancreatic cancer remains unclear This report presents the long-term follow-up results of EORTC trial 40891 which assessed the role of chemoradiation in resectable pancreatic cancer Two hundred eighteen patients were randomized after resection of the primary tumor Eligible patients had T1-2 N0-N1a M0 pancreatic cancer or T1-3 N0-N1a M0 periampullary cancers all histologic proven Patients in the treatment group n = 110 underwent postoperative chemoradiation 40 Gy plus 5-FU Patients in the control group n = 108 had no further adjuvant treatment After a median follow-up of 117 years 173 deaths 79 % have been reported The overall survival did not differ between the 2 treatment groups Chemoradiation treatment vsdeath rate ratio 091 95 % CI 068-1 23 P value 054 The 10-year overall survival was 18 % in the whole population of patients 8 % in the pancreatic head cancer group and 29 % in the periampullary cancer group These results confirm the previous short-term analysis indicating no benefit of adjuvant chemoradiation over observation in patients with resected pancreatic cancer or periampullary cancer Patients with pancreatic cancer may survive more than 10 years Only 1 of 31 cases recurred after year 7\",\n",
            "}\n",
            "13354\n",
            "{\n",
            "  \"id\" : \"21509444\",\n",
            "  \"contents\" : \"Type 2 diabetes has been associated with an increased risk of cancer This study examines the effect of more vs less intensive glucose control on the risk of cancer in patients with type 2 diabetes All 11140 participants from the Action in Diabetes and Vascular Disease Preterax and Diamicron-MR Controlled Evaluation ADVANCE trial ClinicalTrialsgov NCT00145925 were studied Cancer incidence and cancer mortality was compared in groups randomised to intensive or standard glucose control Information on events during follow-up was obtained from serious adverse event reports and death certificates HRs 95 % CI were calculated for all cancers all solid cancers cancer deaths and site-specific cancers After a median follow-up of 5 years 363 and 337 cancer events were reported in the intensive and standard control groups respectively incidence 139 / 100 person-years [ PY ] and 128 / 100 PY HR 108 [ 95 % CI 093-1 26 ] The incidences of all solid cancers and cancer deaths were 125 / 100 PY and 055 / 100 PY in the intensive group and 115 / 100 PY and 063 / 100 PY in the standard group HR 109 [ 95 % CI 093127 ] for solid cancers and 088 [ 071110 ] for cancer death [ corrected ] Across all the major organ systems studied no significant differences in the cancer incidences were observed in the intensive and standard control groups More intensive glucose control achieved with a regimen that included greater use of gliclazide insulin metformin and other agents did not affect the risk of cancer events or death in patients with type 2 diabetes\",\n",
            "}\n",
            "13355\n",
            "{\n",
            "  \"id\" : \"17520385\",\n",
            "  \"contents\" : \"To assess the advantage and disadvantage of laparoscopic abdomino-perineal resection and open abdominoperineal resection for low rectal cancer Patients with low rectal cancer collected from July 2003 to April 2006 were randomly divided into laparoscopic abdominoperineal resection group 37 cases and open abdominoperineal resection group 37 cases Operation time number of lymph node removed intra-operative blood loss time to pass flatus time to ambulate time to discharge complications early recurrence and economical cost were compared between the 2 groups All patients were performed successfully For the first 10 patients operation time of laparoscopic group was significantly longer than that of open group but there was no significant difference between the 2 groups Intra-operative blood loss of laparoscopic group was significantly less than that of open group but it was reverse for the first 10 patients There was no significant difference in time to pass flatus between the 2 groups Time to ambulate in laparoscopic group was significantly earlier than that in open group There was no significant difference in time to discharge between the 2 groups but it was earlier for perineum closure in laparoscopic group Relative complications of laparoscopic group including pulmonary infection abdominal wound infection or split were significantly less than those of open group There was no significant difference in number of lymph nodes removed early recurrence between the 2 groups Operation cost of laparoscopic group was significantly higher than that of open group but there was no significant difference Advantages of laparoscopic abdominoperineal resection were characterized for not only minimal invasion and good cosmetic outcome but also less blood loss complications and earlier postoperative recovery The operation time total costs and oncological clearance of laparoscopic abdominoperineal resection patients were comparable with those of open procedure patients\",\n",
            "}\n",
            "13356\n",
            "{\n",
            "  \"id\" : \"20052732\",\n",
            "  \"contents\" : \"Colorectal cancer CRC is the second leading cause of cancer death in the United States CRC incidence and mortality rates are higher among blacks than among whites and screening rates are lower in blacks than in whites For the current study the authors tested 3 interventions that were intended to increase the rate of CRC screening among African Americans The following interventions were chosen to address evidence gaps in the Centers for Disease Control and Prevention s Guide to Community Preventive Services one-on-one education group education and reducing out-of-pocket costs Three hundred sixty-nine African-American men and women aged > or = 50 years were enrolled in this randomized controlled community intervention trial The main outcome measures were postintervention increase in CRC knowledge and obtaining a screening test within 6 months There was substantial attrition Two hundred fifty-seven participants completed the intervention and were available for follow-up 3 months to 6 months later Among completers there were significant increases in knowledge in both educational cohorts but in neither of the other 2 cohorts By the 6-month follow-up 177 % 11 of 62 participants of the Control cohort reported having undergone screening compared with 339 % 22 of 65 participants of the Group Education cohort P = 039 Screening rate increases in the other 2 cohorts were not statistically significant The current results indicated that group education could increase CRC cancer screening rates among African Americans The screening rate of < 35 % in a group of individuals who participated in an educational program through multiple sessions over a period of several weeks indicated that there still are barriers to overcome\",\n",
            "}\n",
            "13357\n",
            "{\n",
            "  \"id\" : \"22353804\",\n",
            "  \"contents\" : \"High-level microsatellite instability MSI-H has been reported as a prognostic marker in colon cancer We here analysed the prognostic significance of MSI and mutations of the Beta2-Microglobulin B2M gene which occur in about 30 % of MSI-H colon cancer in the cohort of the prospective FOGT-4 Forschungsruppe Onkologie Gastrointestinale Tumoren FOGT trial Microsatellite instability status was determined using standard protocols NCI/ICG-HNPCC panel and CAT25 in 223 colon cancer lesions Beta2-Microglobulin mutation status was evaluated by exon-wise sequencing in all MSI-H lesions Patients with MSI-H n = 34 colon cancer presented with a significantly lower risk of relapse after 12 months of follow-up compared with MSS n = 189 colon cancer patients 5 year time to relapse MSI-H 082 vs MSS 066 P = 003 No significant difference in overall survival was detected Beta2-Microglobulin mutations were identified in 10 294 % out of 34 MSI-H colon cancers and were associated with a complete absence of disease relapse or tumour-related death events P = 009 The risk of late disease relapse was significantly lower in patients with MSI-H compared with MSS colon cancer Moreover B2M mutations may contribute to the favourable outcome of MSI-H colon cancer patients and should therefore be evaluated as a potential prognostic marker in future clinical trials\",\n",
            "}\n",
            "13358\n",
            "{\n",
            "  \"id\" : \"17805064\",\n",
            "  \"contents\" : \"The tyrosine kinase KIT has variable expression in small-cell lung cancer SCLC and may be a prognostic factor Imatinib targets KIT expression providing rationale for studying its role in combination with chemotherapy in SCLC in a multicenter phase II trial Patients with untreated extensive-stage SCLC received carboplatin area under the concentration-time curve of 4 on day 1 irinotecan 60 mg/m2 on days 1 8 and 15 and imatinib 600 mg/day Treatment cycles were 28 days Patients remained on imatinib until progressive disease or significant toxicity Between September 2002 and May 2004 68 patients were enrolled in this multicenter trial Median age was 60 years range 37-81 The objective response rate was 66 % 95 % confidence interval 54 % -76 % Median progression-free survival was 54 months 95 % CI 43-6 0 months Median overall survival was 84 months 95 % CI 63-10 5 months Thirty-five percent of patients were alive at 1 year Grade 3/4 hematologic toxicity included neutropenia 43 % anemia 16 % and thrombocytopenia 9 % Grade 3 nonhematologic toxicity included diarrhea 19 % fatigue 24 % and nausea 26 % Forty-eight of 56 patients 86 % with available tumor specimens had KIT expression detected KIT expression did not appear to correlate with progression-free survival or overall survival in a retrospective analysis Irinotecan carboplatin and imatinib is a safe and generally well-tolerated regimen in patients with SCLC However the addition of imatinib did not improve results from those expected with chemotherapy alone\",\n",
            "}\n",
            "13359\n",
            "{\n",
            "  \"id\" : \"15860850\",\n",
            "  \"contents\" : \"To describe the natural history of nonmetastatic prostate cancer and rising prostate-specific antigen PSA despite androgen deprivation therapy The 201 patients in this report were the placebo control group from an aborted randomized controlled trial to evaluate the effects of zoledronic acid on time to first bone metastasis in men with prostate cancer no bone metastases and rising PSA despite androgen deprivation therapy Relationships between baseline covariates and clinical outcomes were assessed by Cox proportional hazard analyses Covariates in the model were baseline PSA Gleason sum history of bilateral orchiectomies regional lymph node metastases at diagnosis prior prostatectomy time from androgen deprivation therapy to random assignment time from diagnosis to random assignment and PSA velocity At 2 years 33 % of patients had developed bone metastases Median bone metastasis-free survival was 30 months Median time to first bone metastases and overall survival were not reached Baseline PSA level greater than 10 ng/mL relative risk 318 95 % CI 174 to 580 P < 001 and PSA velocity 434 for each 001 increase in PSA velocity 95 % CI 230 to 821 P < 001 independently predicted shorter time to first bone metastasis Baseline PSA and PSA velocity also independently predicted overall survival and metastasis-free survival Other covariates did not consistently predict clinical outcomes Men with nonmetastatic prostate cancer and rising PSA despite androgen deprivation therapy have a relatively indolent natural history Baseline PSA and PSA velocity independently predict time to first bone metastasis and survival\",\n",
            "}\n",
            "13360\n",
            "{\n",
            "  \"id\" : \"22100906\",\n",
            "  \"contents\" : \"Annualised figures show an up to 7-fold higher incidence of vascular thromboembolism VTE in patients with advanced pancreatic cancer APC compared to other common malignancies Concurrent VTE has been shown to confer a worse overall prognosis in APC One hundred and twenty three APC patients were randomised to receive either gemcitabine 1000 mg/m 2 or the same with weight-adjusted dalteparin WAD for 12 weeks Primary end-point was the reduction of all-type VTE during the study period NCT00462852 ISRCTN 76464767 The incidence of all-type VTE during the WAD treatment period < 100 days from randomisation was reduced from 23 % to 34 % p = 0002 with a risk ratio RR of 0145 95 % confidence interval CI 0035-0 612 and an 85 % risk reduction All-type VTE throughout the whole follow-up period was reduced from 28 % to 12 % p = 0039 RR = 0419 95 % CI 0187-0 935 and a 58 % risk reduction Lethal VTE < 100 days was seen only in the control arm 83 % compared to 0 % p = 0057 RR = 0092 95 % CI 0005-1 635 Weight adjusted dalteparin used as primary prophylaxis for 12 weeks is safe and produces a highly significant reduction of all-type VTE during the prophylaxis period The benefit is maintained after dalteparin withdrawal although decreases with time\",\n",
            "}\n",
            "13361\n",
            "{\n",
            "  \"id\" : \"16607678\",\n",
            "  \"contents\" : \"Preservation or removal of the spleen during total gastrectomy for proximal gastric cancer is a matter of debate A randomized clinical trial included patients with gastric adenocarcinoma who underwent total gastrectomy either with 104 patients or without 103 splenectomy Postoperative outcome in the two groups was compared including morbidity mortality and survival Gastrectomy combined with splenectomy tended to be associated with slightly higher morbidity and mortality rates a slightly greater incidence of lymph node metastasis at the splenic hilum and along the splenic artery and marginally better survival but there were no statistically significant differences between the groups Splenectomy had no impact on survival in patients with metastatic lymph nodes at the hilum of the spleen or in those with metastatic lymph nodes along the splenic artery These results do not support the use of prophylactic splenectomy to remove macroscopically negative lymph nodes near the spleen in patients undergoing total gastrectomy for proximal gastric cancer\",\n",
            "}\n",
            "13362\n",
            "{\n",
            "  \"id\" : \"10584133\",\n",
            "  \"contents\" : \"Parenchymal impairment of salivary glands following high-dose radioiodine treatment is a well-known side effect in general caused by free radicals Therefore the radioprotective effect of the radical scavenger amifostine was evaluated prospectively in patients receiving high-dose radioiodine treatment Parenchymal function was assessed by quantitative salivary gland scintigraphy performed in 50 patients with differentiated thyroid cancer prior to and 3 months after high-dose radioiodine treatment with either 3 GBq 131I n = 21 or 6 GBq 131I n = 29 in a double-blinded placebo-controlled study Twenty-five patients treated with 500 mg/m2 amifostine intravenously prior to high-dose radioiodine treatment were compared to 25 control patients receiving physiological saline solution Xerostomia was graded according to WHO-criteria In 25 control patients high-dose radioiodine treatment significantly p < 0001 reduced parenchymal function of parotid and submandibular glands by 402 + / - 141 % and 399 + / - 153 % respectively Nine out of these 25 patients developed Grade I and 2 Grade II xerostomia In contrast in 25 amifostine-treated patients there was no significant p = 0691 decrease in parenchymal function following high-dose radioiodine treatment and xerostomia did not occur in any of them Parenchymal damage of salivary glands induced by high-dose radioiodine treatment can be significantly reduced by amifostine which may improve quality of life of patients with differentiated thyroid cancer\",\n",
            "}\n",
            "13363\n",
            "{\n",
            "  \"id\" : \"17389293\",\n",
            "  \"contents\" : \"Screening mammography is recommended for early detection of breast cancer but screening rates remain suboptimal A primary care portal for a large academic primary practice was developed for all preventive services Another Web-based system PRECARES [ PREventive CAre REminder System ] was developed for appointment secretaries to manage proactive breast cancer screening Female patients aged 40 to 75 years were randomly assigned to a control group usual care and an intervention group For the intervention group 2 monthly letters inviting patients to undergo mammography were sent starting 3 months before they were due for annual screening followed by a telephone call to nonresponding patients A subgroup of women employees was further randomized to receive a reminder by either US mail or e-mail Of the total eligible population of 6665 women identified as having consented to participate in research 3339 were randomly assigned to the control group and 3326 to the intervention group The screening rate for annual mammography was 643 % for the intervention group and 553 % for the control group P < 001 There were no significant differences between the 2 groups for any of the other adult preventive services For the employee subgroup the screening rate was 575 % for the control group 681 % for the US mail group and 722 % for the e-mail group intervention vs control P < 001 e-mail vs US mail P = 24 The breast cancer screening rate improved significantly with the practice redesign of having appointment secretaries proactively manage breast cancer screening needs\",\n",
            "}\n",
            "13364\n",
            "{\n",
            "  \"id\" : \"11597539\",\n",
            "  \"contents\" : \"To characterize the role of demographic and clinical parameters in the measurements of prostate-specific antigen PSA free PSA fPSA and percent free PSA % fPSA This was a cohort study of volunteers to a randomized screening trial A central laboratory determined PSA and fPSA for the Prostate Lung Colorectal and Ovarian PLCO Cancer Screening Trial A baseline evaluation of free and total PSA was done for 7183 white black Asian Hispanic and other male volunteers aged 55 to 74 years Comparisons were made across racial and ethnic groups and across a set of clinical parameters from a baseline questionnaire The median levels of serum PSA were less than 21 ng/mL in each age-race grouping of the study participants The levels of free and total PSA were higher in black n = 868 12 % participants than in white n = 4995 70 % and Asian n = 849 118 % participants Individuals who identified themselves as ethnically Hispanic n = 339 47 % had median PSA levels higher than whites who were not Hispanic The free and total PSA levels increased with age particularly among men 70 to 74 years old However the % fPSA levels showed less variation among the four racial groups or by age The free and total PSA levels were higher among those who had a history of benign prostatic disease Demographic age and race/ethnicity and clinical history of benign prostatic disease variables had a moderate effect on the measures of PSA and fPSA and very little effect on % fPSA\",\n",
            "}\n",
            "13365\n",
            "{\n",
            "  \"id\" : \"24888818\",\n",
            "  \"contents\" : \"Increased circulating tumor cells CTCs five or more CTCs per 75 mL of whole blood are associated with poor prognosis in metastatic breast cancer MBC A randomized trial of patients with persistent increase in CTCs tested whether changing chemotherapy after one cycle of first-line chemotherapy would improve the primary outcome of overall survival OS Patients with MBC who did not have increased CTCs at baseline remained on initial therapy until progression arm A Patients with initially increased CTCs that decreased after 21 days of therapy remained on initial therapy arm B Patients with persistently increased CTCs after 21 days of therapy were randomly assigned to continue initial therapy arm C1 or change to an alternative chemotherapy arm C2 Of 595 eligible and evaluable patients 276 46 % did not have increased CTCs arm A Of those with initially increased CTCs 31 10 % were not retested 165 were assigned to arm B and 123 were randomly assigned to arm C1 or C2 No difference in median OS was observed between arm C1 and C2 107 and 125 months respectively P = 98 CTCs were strongly prognostic Median OS for arms A B and C C1 and C2 combined were 35 months 23 months and 13 months respectively P < 001 This study confirms the prognostic significance of CTCs in patients with MBC receiving first-line chemotherapy For patients with persistently increased CTCs after 21 days of first-line chemotherapy early switching to an alternate cytotoxic therapy was not effective in prolonging OS For this population there is a need for more effective treatment than standard chemotherapy\",\n",
            "}\n",
            "13366\n",
            "{\n",
            "  \"id\" : \"14965832\",\n",
            "  \"contents\" : \"To evaluate the effects of the two conformal radiotherapy modalities in the treatment of locally advanced pancreatic carcinoma From October 1998 to June 2001 67 patients with locally advanced pancreatic carcinoma received conformal radiotherapy CRT Vacuum cushions were applied to immobilize the patients before contrast CT scans the treatment plans were simulated by three-dimensional treatment planning system The patients were randomized into group A to receive a total dose of 45-54 Gy given in 8-12 fractions completed in 18-27 d and group B with a total dose of 45-54 Gy in 15-18 fractions within 20-25 dThe partial and complete pain relief rates of the two groups were 959 % and 816 % respectively one month after the completion of the radiotherapy with a median survival of 125 months The response rates of the patients and the 2-year overall survival rates in group A were 818 % and 516 % respectively and were 353 % and 121 % in group BThe low-dose fractionated CRT was superior than accelerated CRT For patients with unresectable pancreatic cancer receiving low-dose fractionated CRT a high dose targeted at the tumor can be given in a fraction and the normal surrounding tissues are exposed to low-dose radiation to achieve good therapeutic effect with minimized adverse effects on normal tissues in relation to the exposure\",\n",
            "}\n",
            "13367\n",
            "{\n",
            "  \"id\" : \"11942978\",\n",
            "  \"contents\" : \"To evaluate in a prospective study the effects and results of maintenance therapy with bacille Calmette-Gurin BCG in treating patients with high-risk superficial bladder cancer In all 155 patients were enrolled in a randomized study of transurethral resection alone 53 or combined with intravesical BCG 102 as a treatment for superficial bladder cancer BCG was administered for six consecutive weeks followed by three weekly instillations in months 3 6 12 18 24 30 and 36 after resection Recurrence progression prognostic factors and side-effects were assessed and analysed After a median range follow-up of 23 6-42 months 83 of the 102 patients treated with BCG 81 % were disease-free compared with 24 of the 53 treated with resection alone 45 % There was also a significant difference in tumour progression and time to progression between the trial arms The disease progressed in eight patients 8 % treated with BCG and in 12 23 % of those treated by resection alone Independent risk factors for progression were DNA ploidy status and stage Only the completion of treatment was predictive of outcome risk of recurrence for patients treated with BCG Maintenance BCG therapy was better than resection alone in reducing the incidence of recurrence and progression in patients with high-risk superficial bladder cancer\",\n",
            "}\n",
            "13368\n",
            "{\n",
            "  \"id\" : \"23375640\",\n",
            "  \"contents\" : \"The main aim of this exploratory study was to assess whether salivary - amylase sAA and salivary cortisol levels would be positively modulated by sleep-focused mind-body interventions in female and male cancer survivors We conducted a randomized controlled trial in which 57 cancer survivors with self-reported sleep disturbance received either a Sleep Hygiene Education SHE n = 18 control or one of two experimental mind-body interventions namely Mind-Body Bridging MBB n = 19 or Mindfulness Meditation MM n = 20 Interventions were three sessions each conducted once per week for three consecutive weeks Saliva cortisol and sAA were measured at baseline and 1 week after the last session Participants also completed a sleep scale at the same time points when saliva was collected for biomarker measurement Our study revealed that at post-intervention assessment mean sAA levels upon awakening Waking sample declined in MBB compared with that of SHE Mean Waking cortisol levels did not differ among treatment groups but declined slightly in SHE Self-reported sleep improved across the three interventions at Post-assessment with largest improvements in the MBB intervention In this exploratory study sleep focused mind-body intervention MBB attenuated Waking sAA levels suggesting positive influences of a mind-body intervention on sympathetic activity in cancer survivors with sleep disturbance\",\n",
            "}\n",
            "13369\n",
            "{\n",
            "  \"id\" : \"21088920\",\n",
            "  \"contents\" : \"We examined the presence and correlates of Black/White racial disparities in adherence to guidelines for colorectal cancer screening CRCS The sample included 328 Black and 1827 White patients age 50-75 from 24 VA medical facilities who responded to a mailed survey with phone follow-up response rate 73 % for Blacks and 89 % for Whites CRCS adherence and race were obtained through surveys and supplemented with administrative data Logistic regressions estimated the contribution of demographic health cognitive and environmental factors to racial disparities in adherence to CRCS guidelines In unadjusted analyses Blacks had slightly lower rates of adherence to CRCS guidelines than Whites 72 % versus 77 % p < 005 This racial disparity in CRCS adherence was explained by race differences in demographic health and environmental factors but not by cognitive factors Tests for interactions revealed that the association of race with adherence varied significantly across levels of income education and marital status In particular among those who were married with higher levels of education CRCS adherence was significantly higher for Whites whereas among those who were unmarried with low levels of education adherence was significantly higher for Blacks We found that disparities in CRCS are greatly attenuated in the VA system and both Whites and Blacks have substantially higher rates of CRCS than the national average These results point to the success of the VA at implementing CRCS system-wide Our findings also suggest additional initiatives may be needed for unmarried low income white men and higher income black men\",\n",
            "}\n",
            "13370\n",
            "{\n",
            "  \"id\" : \"15256239\",\n",
            "  \"contents\" : \"Gastric cancer in Western countries is often diagnosed in an advanced stage and prognosis is poor We performed a randomised trial with pre-operative FAMTX vs surgery alone in order to evaluate the effect of pre-operative chemotherapy on resectability and survival Patients with proven adenocarcinoma of the stomach were randomised to receive four courses of chemotherapy using 5-Fluorouracil doxorubicin and methotrexate FAMTX prior to surgery or to undergo surgery alone Fifty-nine patients were randomised 29 patients were allocated to the FAMTX regimen prior to surgery and 30 patients had surgery alone Resectability rates were equal for both groups Complete or partial response was registered in 32 % of the FAMTX group With a median follow-up of 83 months the median survival since randomisation is 18 months in the FAMTX group vs 30 months in the surgery alone group p = 017 This trial could not show a beneficial effect of pre-operative FAMTX Until large randomised studies prove otherwise adequate surgery without delay is the best treatment for operable gastric cancer\",\n",
            "}\n",
            "13371\n",
            "{\n",
            "  \"id\" : \"18089866\",\n",
            "  \"contents\" : \"Little is known about the health-related quality of life HRQOL of patients treated for anaplastic oligodendrogliomas The impact of combined procarbazine CCNU lomustine and vincristine PCV chemotherapy after radiotherapy RT compared with RT alone on HRQOL in the randomized European Organisation for Research and Treatment of Cancer EORTC 26951 trial was studied Adult patients with anaplastic oligodendrogliomas received RT alone or RT plus PCV chemotherapy HRQOL was assessed with the EORTC Quality of Life Questionnaire C30 and Brain Cancer Module Seven prespecified HRQOL end points were selected We hypothesized that chemotherapy would impair HRQOL during treatment but that there would be a similar HRQOL between treatment arms once off treatment Assessments were performed at randomization at the end of RT and then every 3 to 6 months until progression A total of 368 patients were randomly assigned to one of the two arms overall 58 % were male and the median age was 49 years Compliance with HRQOL was 78 % at baseline and dropped to 55 % to 72 % up to 25 years post-RT Baseline scores demonstrated considerable impairments in HRQOL for both treatment groups The longitudinal analysis showed a significant increase in nausea/vomiting in the RT plus PCV chemotherapy arm during and shortly after chemotherapy Because of a difference in baseline scores for fatigue and physical functioning the differences between treatment arms during PCV did not reach significance The nonselected scales of appetite loss and drowsiness demonstrated significant differences between treatment arms during chemotherapy in favor of the RT arm The long-term results showed no difference between arms The major impact of PCV on HRQOL is on nausea/vomiting loss of appetite and drowsiness during and shortly after treatment There are no long-term effects of PCV chemotherapy\",\n",
            "}\n",
            "13372\n",
            "{\n",
            "  \"id\" : \"10506598\",\n",
            "  \"contents\" : \"To determine whether the neurotoxicity of paclitaxel 250 mg/m 2 given over 3 hours every 3 weeks could be reduced by pretreatment with amifostine 910 mg/m 2 Secondary objectives included comparing myelosuppression myalgias and response rates of the two groups Forty women with metastatic breast cancer were randomized to receive either paclitaxel alone arm 1 or paclitaxel preceded by amifostine arm 2 All were assessable for toxicity and 37 were assessable for response At baseline and after each cycle all patients completed questionnaires for neurologic symptoms and had standardized neurologic examinations including objective assessments of power and vibration sense In addition standard follow-up assessments for other toxicities and tumor response were undertaken Changes from baseline after courses 1 2 and 3 were assessed The sample size was sufficient to detect a 50 % improvement in the expected determination in sensory change There were no differences observed in any of the measures of neurotoxicity Other toxicity was similar in arms 1 and 2 including hair loss 95 % v 90 % neurosensory changes 100 % v 100 % fatigue/lethargy 85 % v 90 % myalgia 95 % v 90 % and grade 4 neutropenia 47 % v 60 % Nausea vomiting dizziness hypotension and sneezing were more common in the amifostine arm Response rates 222 % v 368 % and paclitaxel pharmacokinetics were not significantly different There was no protection from paclitaxel-related neurotoxicity or hematologic toxicity in this study These results suggest that the mechanism of action of paclitaxel-related toxic effects is not amenable to the cytoprotective action of amifostine\",\n",
            "}\n",
            "13373\n",
            "{\n",
            "  \"id\" : \"18303031\",\n",
            "  \"contents\" : \"The objective of this study was to assess the performance of three staging systems [ Okuda Cancer of the Liver Italian Program CLIP and Barcelona Clinic Liver Cancer group BCLC ] for predicting survival in patients with hepatocellular carcinoma HCC and to explore how to improve prognostic classification among French patients with HCC whose main etiology is alcoholic cirrhosis We have pooled two randomized clinical trials in palliative condition from the Fdration Francophone de Cancerologie Digestive They had included 416 and 122 patients Performances of Okuda CLIP and BCLC scores have been compared using Akaike information criterion discriminatory ability Harrell s C and the Royston s D statistics monotonicity of gradients and predictive accuracy Schemper statistics Vs To explore how to improve classifications univariate and multivariate Cox model analyses were carried out The pooled database included 538 patients The median survival was 53 months 95 % confidence interval 46-6 2 For all statistics CLIP staging system had a better prognostic ability Performances of all staging systems were rather disappointing World Health Organization performance status WHO PS for CLIP or alpha-fetoprotein for BCLC allowed a significant improvement of prognostic information Our results indicate that CLIP staging seems to be most adapted to palliative setting and that it could be better by associating WHO PS\",\n",
            "}\n",
            "13374\n",
            "{\n",
            "  \"id\" : \"18181314\",\n",
            "  \"contents\" : \"Seroma is a common complication after mastectomy Most postoperative seroma occur at the axilla Many previous studies had tried to reduce seroma formation after mastectomy by multimodalities Closing the dead space gave a good result for many previous retrospective studies but limited number of randomized control study To reduce postoperative seroma by closing the axillary space as a randomized control study and to evaluate the incidence of seroma formation at the axilla as a prospective randomized control trial in axillary space closure by suturing a skin flap to the underlying chest wall after MRM Total consecutive 16 patients who were diagnosed with breast cancer at Rajavithi Hospital by pathologic examination from May 2005 to May 2006 and signed informed consent was obtained in the present study All patients were randomized after mastectomy before wound closure into the control group or study group In the control group the wound was closed conventionally In the study group axillary space was closed by suturing the skin flap to the underlying muscle 3 points at mid axillary line Patients characteristics and operative related factors were recorded and compared between the two groups All patients received ultrasonographic examination at axilla two weeks after discharge There were eight patients in the control group and eight patients in the study group The patients characteristic and tumor characteristics were recorded and compared There was no statistical significance of BMI tumor size and hormonal status between the two groups In the study group the patients age was significantly higher There was no statistical significance of seroma thickness at the axilla between control group and study group 177 + / - 100 vs 100 + / - 022 p = 0067 There was no statistically significant difference of seroma thickness at the axilla between the two groups Further study with a larger sample size is required\",\n",
            "}\n",
            "13375\n",
            "{\n",
            "  \"id\" : \"24977342\",\n",
            "  \"contents\" : \"Short-term advantages to laparoscopic surgery are well described This study compared medium - to long-term outcomes of a randomized clinical trial comparing laparoscopic and open colonic resection for cancer The case notes of patients included in the LAFA study perioperative strategy in colonic surgery LAparoscopy and/or FAst track multimodal management versus standard care were reviewed 2-5years after randomization for incisional hernia adhesional small bowel obstruction SBO overall survival cancer recurrence and quality of life QoL The laparoscopic and open groups were compared irrespective of fast-track or standard perioperative care Data on incisional hernias SBO survival and recurrence were available for 399 of 400 patients 208 laparoscopic and 191 open resections These outcomes were corrected for duration of follow-up Median follow-up was 34 iqr 26-44 years Multivariable regression analysis showed that open resection was a risk factor for incisional hernia odds ratio OR 244 95 per cent confidence interval ci 112 to 526 P = 0022 and SBO OR 370 107 to 1250 P = 0039 There were no differences in overall survival hazard ratio 110 95 per cent ci 067 to 180 P = 0730 or in cumulative incidence of recurrence P = 0514 between the laparoscopic and open groups There were no measured differences in QoL in 281 respondents P > 0350 for all scales Laparoscopic colonic surgery led to fewer incisional hernia and adhesional SBO events NTR222 http//wwwtrialregisternl\",\n",
            "}\n",
            "13376\n",
            "{\n",
            "  \"id\" : \"8602180\",\n",
            "  \"contents\" : \"Lung cancer and cardiovascular disease are major causes of death in the United States It has been proposed that carotenoids and retinoids are agents that may prevent these disorders We conducted a multicenter randomized double-blind placebo-controlled primary prevention trial -- the Beta Carotene and Retinol Efficacy Trial -- involving a total of 18314 smokers former smokers and workers exposed to asbestos The effects of a combination of 30 mg of beta carotene per day and 25000 IU of retinol vitamin A in the form of retinyl palmitate per day on the primary end point the incidence of lung cancer were compared with those of placebo A total of 388 new cases of lung cancer were diagnosed during the 73135 person-years of follow-up mean length of follow-up 40 years The active-treatment group had a relative risk of lung cancer of 128 95 percent confidence interval 104 to 157 P = 002 as compared with the placebo group There were no statistically significant differences in the risks of other types of cancer In the active-treatment group the relative risk of death from any cause was 117 95 percent confidence interval 103 to 133 of death from lung cancer 146 95 percent confidence interval 107 to 200 and of death from cardiovascular disease 126 95 percent confidence interval 099 to 161 On the basis of these findings the randomized trial was stopped 21 months earlier than planned follow-up will continue for another 5 years After an average of four years of supplementation the combination of beta carotene and vitamin A had no benefit and may have had an adverse effect on the incidence of lung cancer and on the risk of death from lung cancer cardiovascular disease and any cause in smokers and workers exposed to asbestos\",\n",
            "}\n",
            "13377\n",
            "{\n",
            "  \"id\" : \"21699587\",\n",
            "  \"contents\" : \"Perioperative oral supplementation has been shown to reduce post-operative complications However the use of preoperative standard oral supplements in a cohort of colorectal cancer patients has not been evaluated The present study examined whether preoperative supplements are beneficial in this group In a randomised controlled trial patients were assigned to receive 400 mL of oral supplement and dietary advice or dietary advice alone Primary outcome was the number of post-operative complications One hundred and twenty-five patients were recruited 59 randomised to the intervention group and 66 to the control group and nine were excluded In the intervention group 24 44 % patients had a complication compared to 26 42 % in the control group P = 0780 In the intervention and control groups there were eight 15 % and 16 25 % surgical site infections respectively P = 0140 and seven 13 % and 11 17 % chest infections respectively P = 0470 Subgroup analysis for hypothesis generation included 83 71 % weight-losing patients where there was a significant reduction in surgical site infections using the Buzby definition P = 0034 although this was not the case for the Centre for Disease Control definition P = 0052 There was no evidence that preoperative supplements were beneficial in reducing the number of complications although there may be some benefit for surgical site infections in selected weight-losing preoperative patients\",\n",
            "}\n",
            "13378\n",
            "{\n",
            "  \"id\" : \"23564803\",\n",
            "  \"contents\" : \"The aim of the present study was to examine the impact of obesity and physical activity on the health and wellbeing of patients with breast cancer shortly after the adjuvant treatments A total of 537 women aged 35 to 68 years with newly-diagnosed breast cancer were enrolled into the exercise intervention study The physical activity physical performance 2-km walking test cardiovascular risk factors quality of life EORTC-QoL-C30 co-morbidities and body-mass index BMI were measured after the adjuvant treatments Overall 191 39 % patients were overweight BMI = 25-30 and 85 17 % obese BMI 30 Physical activity and performance p < 0001 and p < 0001 QoL p < 0001 and high density lipoprotein HDL - cholesterol decreased p < 0001 whereas age p = 0009 co-morbidities p < 0001 hypertension p = 0011 metabolic syndrome p < 0001 low density lipoprotein LDL - cholesterol p = 00043 triglycerides p < 0001 glucose p < 0001 and insulin p < 0001 increased linearly with BMI Higher waist circumference p = 00011 triglyceride p = 0020 insulin p = 00098 rate of metabolic syndrome p = 0028 and lower HDL-cholesterol p = 0012 and QoL p < 0001 were associated with low physical activity Physical activity and BMI were the most important determinants of physical performance p < 0001 and p < 0001 respectively Obesity and a sedentary lifestyle are related to poor physical performance increased risk of cardiovascular diseases and impaired QoL leading to a vicious circle which impairs patients physical health and QoL\",\n",
            "}\n",
            "13379\n",
            "{\n",
            "  \"id\" : \"23328996\",\n",
            "  \"contents\" : \"This study explored whether docetaxel/cisplatin and radiotherapy TP-R increases overall survival OS and recurrence-free survival RFS compared to single-agent cisplatin and radiotherapy C-R in patients with high-risk early-stage cervical cancer post surgery Patients with clinical stage IB and IIA carcinoma of the cervix initially treated with radical hysterectomy and pelvic lymphadenectomy and who had positive pelvic lymph nodes and/or positive margins and/or the diameter of the primary tumor 4 cm and/or depth of interstitial infiltration 1/2 and/or lymphovascular space invasion were eligible for this study Patients were randomized to receive C-R or TP-R Radiotherapy in both groups was external radiation 46-54 Gy followed by high-dose rate brachytherapy 12-24 Gy Patients were given cisplatin 40 mg/m 2 every week for five cycles C-R group or docetaxel 30 mg/m 2 and cisplatin 30 mg/m 2 every week for five cycles TP-R group Between 2003 and 2008 320 patients were entered onto the study Final analyses included 285 patients One hundred and forty patients comprised the C-R group and 145 were in the TP-R group The 5-year OS were 743 % in the C-R group and 828 % in the TP-R group The hazard ratio HR for death was 065 in the TP-R group 95 % CI 039-1 09 P = 0098 The RFS were 693 % in the C-R group and 793 % in the TP-R group and the HR for recurrence was 064 in the TP-R group 95 % CI 040-1 03 P = 0061 Recurrence rates were similar in both groups 27 in the C-R group and 18 in the TP-R group P = 0112 The seriousness of late side effects was similar in the two groups with a higher rate of reversible hematological effects in the TP-R group Compared with single-agent cisplatin and radiotherapy docetaxel/cisplatin in combination with radiotherapy does not increase OS but has the trend of increasing RFS in patients with high-risk early-stage cervical cancer However docetaxel/cisplatin in combination with radiotherapy is associated with a higher incidence of side effects this effect was reversible and the incidence of late side effects was similar in the two treatment groups\",\n",
            "}\n",
            "13380\n",
            "{\n",
            "  \"id\" : \"8357293\",\n",
            "  \"contents\" : \"We evaluated recurrence and survival for 68 patients with malignant melanoma who participated in a 6-week structured psychiatric group intervention 5 to 6 years earlier shortly after their diagnosis and initial surgical treatment We also explored the role of several factors as possible predictors of outcome This was a randomized controlled experimental study The Cox proportion hazards regression model was used to quantify the relationship between treatment and the outcomes adjusted by the covariates age sex Breslow depth tumor site baseline Profile of Mood States Total Mood Disturbance baseline active-behavioral coping baseline natural killer cell activity and treatment [ ie group intervention ] The stepwise procedure was used for covariate selection For control patients there was a trend for recurrence 13/34 and a statistically significant greater rate of death 10/34 than for experimental patients 7/34 and 3/34 respectively We found that being male and having a greater Breslow depth predicted greater recurrence and poorer survival Analysis of multiple covariates found that only Breslow depth and treatment ie group intervention were significant Adjusting for Breslow depth treatment effect remained significant Finally baseline affective distress and baseline coping were significant psychobehavioral predictors for recurrence and survival Surprisingly higher levels of baseline distress as well as baseline coping and enhancement of active-behavioral coping over time were predictive of lower rates of recurrence and death Psychiatric interventions that enhance effective coping and reduce affective distress appear to have beneficial effects on survival but are not proposed as an alternative or independent treatment for cancer or any other illness or disease However the exact nature of this relationship warrants further investigation\",\n",
            "}\n",
            "13381\n",
            "{\n",
            "  \"id\" : \"25336193\",\n",
            "  \"contents\" : \"The single most distressing symptom for patients with advanced esophageal cancer is dysphagia Amongst the more effective treatments for relief of dysphagia is insertion of a self-expanding metal stent SEMS It is possible that the addition of a palliative dose of external beam radiotherapy may prolong the relief of dysphagia and provide additional survival benefit The ROCS trial will assess the effect of adding palliative radiotherapy after esophageal stent insertion The study is a randomized multicenter phase III trial with an internal pilot phase comparing stent alone versus stent plus palliative radiotherapy in patients with incurable esophageal cancer Eligible participants are those with advanced esophageal cancer who are in need of stent insertion for primary management of dysphagia Radiotherapy will be administered as 20 Gray Gy in five fractions over one week or 30 Gy in 10 fractions over two weeks within four weeks of stent insertion The internal pilot will assess rates and methods of recruitment pre-agreed criteria will determine progression to the main trial In total 496 patients will be randomized in a 11 ratio with follow up until death The primary outcome is time to progression of patient-reported dysphagia Secondary outcomes include survival toxicity health resource utilization and quality of life An embedded qualitative study will explore the feasibility of patient recruitment by examining patients motivations for involvement and their experiences of consent and recruitment including reasons for not consenting It will also explore patients experiences of each trial arm The ROCS study will be a challenging trial studying palliation in patients with a poor prognosis The internal pilot design will optimize methods for recruitment and data collection to ensure that the main trial is completed on time As a pragmatic trial study strengths include collection of all follow-up data in the usual place of care and a focus on patient-reported rather than disease-orientated outcomes Exploration of patient experience and health economic analyses will be integral to the assessment of benefit for patients and the NHS The trial was registered with Current Controlled Trials registration number ISRCTN12376468 on 10 July 2012\",\n",
            "}\n",
            "13382\n",
            "{\n",
            "  \"id\" : \"18443351\",\n",
            "  \"contents\" : \"To determine the effect of elevated serum TIMP-1 on the response of patients with metastatic breast cancer to an aromatase inhibitor versus tamoxifen Five hundred twenty-two patients estrogen receptor-positive metastatic breast cancer were randomly assigned to receive first-line hormone therapy with letrozole or tamoxifen Serum tissue inhibitor of metalloproteinases-1 TIMP-1 levels were measured using an enzyme-linked immunosorbent assay Pretreatment serum TIMP-1 was elevated in 120 23 % of 522 patients Patients with elevated serum TIMP-1 had a significantly reduced objective response rate 192 % v 306 % odds ratio 054 P = 01 duration of response median 155 v 262 months P = 001 time to treatment progression TTP median 45 v 92 months HR 178 P = 0001 time to treatment failure median 35 v 90 months HR 177 P = 0001 and overall survival median 203 v 358 months HR 177 P = 0001 compared with patients with normal pretreatment TIMP-1 levels Letrozole was superior to tamoxifen in both the normal serum TIMP-1 group median TTP 118 v 86 months P = 003 and in the elevated serum TIMP-1 group median 61 v 32 months P = 03 In multivariate analysis elevated serum TIMP-1 remained an independent predictor of both shorter TTP HR 146 P = 002 and survival HR 144 P = 002 as did serum HER-2 Combined analysis of both serum TIMP-1 and HER-2 / neu conferred additional ability to predict significantly different clinical outcomes compared to using either biomarker alone Patients with elevated pretreatment serum TIMP-1 had a significantly reduced response and survival Serum TIMP-1 was an independent predictive and prognostic factor Blockade of TIMP-1 and HER-2 / neu activity may be beneficial in a subset of patients with breast cancer\",\n",
            "}\n",
            "13383\n",
            "{\n",
            "  \"id\" : \"25243960\",\n",
            "  \"contents\" : \"To evaluate the efficacy of Fuzhenghuayu capsule for the prevention of oesophageal variceal bleeding in patients with liver cirrhosis A multicentre randomized placebo-controlled trial was conducted A total of 181 liver cirrhosis patients were enrolled in the study and randomly assigned to different groups according to the level of oesophageal variceal bleeding Patients with light oesophageal varices received Fuzhenghuayu capsule or a placebo Patients with medium to heavy oesophageal varices received either Fuzhenghuayu capsule alone Fuzhenghuayu capsule plus propranolol or propranolol plus a placebo Patients with a history of oesophageal variceal bleeding received either Fuzhenghuayu capsule plus propranolol propranolol alone or a placebo For all patients the treatment lasted 2 years The primary end point of the study was oesophageal variceal bleeding The secondary end points were liver cancer death by any cause and liver transplantation Risk of bleeding and survival were statistically assessed The median follow-up time was 50 months The patients with small oesophageal varices who were treated with Fuzhenghuayu capsule showed a significantly higher cumulative probability of bleeding than their counterparts treated with the placebo 34 % vs 237 % x = 4829 P = 0028 The patients with medium to heavy oesophageal varices and no history of oesophageal variceal bleeding who were treated with Fuzhenghuayu capsule plus propranolol showed a remarkably higher cumulative probability of bleeding than their counterparts treated with propranolol alone 152 % vs 436 % x = 6166 P = 0013 There were no significant differences between the patients treated with Fuzhenghuayu capsule alone and those treated with propranolol alone P = 0147 or the patients treated with Fuzhenghuayu capsule plus propranolol and those treated with Fuzhenghuayu capsule alone P = 0147 The patients with history of oesophageal variceal bleeding who were treated with Fuzhenghuayu capsule showed significantly higher cumulative probability of bleeding and median time of bleeding than their counterparts treated with propranolol alone 440 % vs 242 % and 4000 1792 months vs 700 235 months x = 4433 P = 0035 There were no significant differences in the cumulative probability of liver cancer and survival among all of the groups Fuzhenghuayu capsule can decrease the cumulative probability of bleeding in cirrhotic patients with light oesophageal varices For cirrhosis patients with a history of oesophageal variceal bleeding the combination of Fuzhenghuayu capsule plus propranolol can decrease the cumulative probability of bleeding with median or heavy varices\",\n",
            "}\n",
            "13384\n",
            "{\n",
            "  \"id\" : \"25607608\",\n",
            "  \"contents\" : \"One in 4 men in the United States aged > 50 years will have an osteoporosis-related fracture Fewer data are available on osteoporosis treatment in men than in women The purpose of this study was to evaluate denosumab therapy in men with low bone mineral density BMD This was a phase 3 study with 2 treatment periods a previously reported 12-month double-blind placebo-controlled phase and a 12-month open-label phase This was a multicenter study conducted in North America and Europe A total of 228 men entered the open-label phase and 219 completed the study Men from the original denosumab long-term and placebo crossover groups received 60 mg of denosumab sc every 6 months BMD serum collagen type I C-telopeptide and safety were measured During the open-label phase continued BMD increases occurred with long-term denosumab treatment 22 % lumbar spine 09 % total hip 13 % femoral neck 13 % trochanter and 02 % 1/3 radius resulting in cumulative 24-month gains from baseline of 80 % 34 % 34 % 46 % and 07 % respectively all P < 01 The crossover group showed BMD gains after 12 months of denosumab treatment similar to those of the long-term denosumab group during the first treatment year Significant reductions in serum collagen type I C-teleopeptide were observed after denosumab administration Adverse event rates were similar between groups and no new safety signals were identified In men with low BMD denosumab treatment for a second year continued to increase BMD maintained reductions in bone resorption and was well tolerated BMD increased in men initiating denosumab during the second year These effects were similar to those previously seen in postmenopausal women with osteoporosis and in men with prostate cancer receiving androgen deprivation therapy\",\n",
            "}\n",
            "13385\n",
            "{\n",
            "  \"id\" : \"15717937\",\n",
            "  \"contents\" : \"To compare whether treatment with self-expanding metal stents SEMS is more cost-effective than treatment with conventional modalities in patients with inoperable oesophageal cancer Quality of life effects were also considered A multicentre pragmatic randomised controlled trial with health economic analysis Seven NHS hospitals selected to represent a cross-section of UK hospitals in terms of facilities and staffing All patients attending the centres with oesophageal cancer deemed unsuitable for surgery were assessed for inclusion in the main trial 217 patients were randomised A health state utilities substudy was also performed in 71 patients who had previously received curative surgery for oesophageal cancer Eligible patients were randomised to one of four treatment groups within two study arms Assessments were performed at enrolment 1 week following treatment and thereafter at 6-weekly intervals until death with prospective data collection on complications and survival Structured interviews to elicit patient preferences to health states and treatments were performed in a substudy Dysphagia grade and quality of life were examined at 6 weeks Survival resources consumed from randomisation to death and quality-adjusted life-years were also considered There was no difference in cost or effectiveness between SEMS and non-SEMS therapies and 18-mm SEMS had equal effectiveness to but less associated pain than 24-mm SEMS Rigid intubation was associated with a worse quality of swallowing and increased late morbidity Bipolar electrocoagulation and ethanol tumour necrosis were poor in primary palliation A survival advantage was found for non-stent therapies but there was a significant delay to treatment The length of stay accounts for the majority of the cost to the NHS Patients were found to have distinct individual treatment preferences It was suggested that rigid tubes and 24-mm SEMS should no longer be recommended and bipolar electrocoagulation and ethanol tumour necrosis should not be used for primary palliation The choice in palliation would between non-stent and 18-mm SEMS treatments with non-stent therapies being made more available and accessible to reduce delay A multidisciplinary team approach to palliation is also suggested A randomised controlled clinical trial of 18-mm SEMS versus non-stent therapies with survival and quality of life end-points would be helpful as would an audit of palliative patient admissions to determine the reasons and need for inpatient hospital care with a view to implementing cycle-associated change to reduce inpatient stay A study of delays in palliative radiotherapy treatment is also suggested with a view to implementing cycle-associated change to reduce waiting time\",\n",
            "}\n",
            "13386\n",
            "{\n",
            "  \"id\" : \"24357423\",\n",
            "  \"contents\" : \"Incisional hernias in old stoma wounds occur in one-third of former stoma patients and pose a significant clinical problem Parastomal hernias can be prevented by prophylactic mesh placement however no trial results are available for incisional hernia prevention after stoma reversal In this feasibility study we explore the safety of placing an intraperitoneal mesh to prevent incisional herniation after temporary stoma reversal Ten patients who underwent a low anterior resection with a deviating double-loop stoma for rectal cancer received an intraperitoneal parastomal mesh at the time of stoma formation At stoma reversal laparoscopy was performed and adhesions were scored After reversal the mesh defect was closed Mesh and stoma complications were closely monitored Incisional herniation was assessed at the 2-year follow-up after stoma reversal using ultrasonography No infections occurred after mesh placement After a median of 6 months stomas were reversed Laparoscopy could be performed in seven patients all patients had adhesions median of 25 % of mesh surface In three patients the bowel was involved one required a laparotomy for bowel mobilization during stoma reversal No adhesion-related morbidity was noted at any time Except for one superficial wound infection after stoma reversal no infectious complications were observed After a median follow-up of 26 months no incisional herniations were demonstrated Prophylactic mesh placement in temporary stoma formations seems safe and feasible and prevents incisional herniation 2 years after stoma reversal\",\n",
            "}\n",
            "13387\n",
            "{\n",
            "  \"id\" : \"21131631\",\n",
            "  \"contents\" : \"Characteristic pancreatic duct changes on endoscopic retrograde pancreatography ERP have been described in autoimmune pancreatitis AIP The performance characteristics of ERP to diagnose AIP were determined The study was done in two phases In phase I 21 physicians from four centres in Asia Europe and the USA unaware of the clinical data or diagnoses reviewed 40 preselected ERPs of patients with AIP n = 20 chronic pancreatitis n = 10 and pancreatic cancer n = 10 Physicians noted the presence or absence of key pancreatographic features and ranked the diagnostic possibilities For phase II a teaching module was created based on features found most useful in the diagnosis of AIP by the four best performing physicians in phase IAfter a washout period of 3 months all physicians reviewed the teaching module and reanalysed the same set of ERPs unaware of their performance in phase IIn phase I the sensitivity specificity and interobserver agreement of ERP alone to diagnose AIP were 44 92 and 023 respectively The four key features of AIP identified in phase I were i long > 1/3 the length of the pancreatic duct stricture ii lack of upstream dilatation from the stricture < 5 mm iii multiple strictures and iv side branches arising from a strictured segment In phase II the sensitivity 71 % of ERP significantly improved p < 005 without a significant decline in specificity 83 % p > 005 the interobserver agreement was fair 040 The ability to diagnose AIP based on ERP features alone is limited but can be improved with knowledge of some key features\",\n",
            "}\n",
            "13388\n",
            "{\n",
            "  \"id\" : \"7531432\",\n",
            "  \"contents\" : \"Selection of patients for a clinical trial is affected by awareness of the existence of the trial interest in the study question and clinical practices and views of the clinicians To investigate the selectivity that may have occurred at Peter MacCallum Cancer Institute PMCI during the ANZ Lymphoma Group trial of MACOP-B vs CHOP in non-Hodgkin s lymphoma NHL NHL patients at PMCI in the study period were assessed against the trial s eligibility criteria Comparisons were made between eligible except for consent non-trial patients and all patients actually randomised into the trial Of 497 patients presenting during the trial period 320 64 % did not meet the specified eligibility criteria 102 21 % were unsuitable on other grounds age and medical and 75 15 % were eligible Of those eligible 43 57 % were entered into the trial and 32 43 % were not Four non-trial patients had inappropriate application of eligibility criteria and 13 unknown reason Eligible non-trial patients were similar to trial patients in most patient and tumour characteristics and overall survival Significantly more non-trial patients had higher stage disease p = 002 More non-trial patients had lower grade histology but this was not significant Physician selectivity occurred with respect to patient entry but trial and non-trial patients were similar in most characteristics Eligibility criteria should specify that patients can withstand all trial drugs and patient availability for treatment and follow-up PMCI trial accural could have been up to 33 % greater These results suggest the trial accrual period could have been 25 % shorter Patient entry into this trial by PMCI clinicians compared favourably with other centres\",\n",
            "}\n",
            "13389\n",
            "{\n",
            "  \"id\" : \"24093978\",\n",
            "  \"contents\" : \"Breast pain and non-discrete breast nodularity are common in women We did a randomized double-blind placebocontrolled trial of oral ormeloxifene 30 mg a selective oestrogen receptor modulator SERM or placebo twice a week for 3 months in 20-50-year-old women with breast pain with or without lumpiness Women with a discrete benign lump or cancer were excluded from the study Serial assessments of pain on a visual analogue scale and nodularity grade on a 5-point ordinal Lucknow-Cardiff scale were done A total of 151 patients were randomly allocated to two interventions using a block size of 4 Of the 151 patients 121 active 57 placebo 64 were available for efficacy analysis The mean pain level showed a systematic downward trend over five visits F = 10523 p < 00001 that significantly reduced in the active group compared to that in the placebo group F = 1866 p < 00001 The patterns of variation in pain over time for the individual groups differ from the overall mean pattern for the two groups and thus from one another F = 4443 p < 00001 Cumulative frequencies of breast nodularity grades during successive visits showed significant improvement p = 0001 compared to placebo at the end of the third month The effect of the active drug persisted till the completion 6 months of treatment p < 0001 At the last visit 933 % of women in the active group had grade 2 or lower nodularity as compared to 711 % in the placebo group Oligomenorrhoea alone was reported by 12 patients Ormeloxifene showed significant efficacy for treating breast pain and nodularity\",\n",
            "}\n",
            "13390\n",
            "{\n",
            "  \"id\" : \"20570559\",\n",
            "  \"contents\" : \"Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor VEGFR epidermal growth factor receptor EGFR and rearranged during transfection RET tyrosine kinases In a randomised phase 2 study in patients with previously treated non-small-cell lung cancer NSCLC adding vandetanib 100 mg to docetaxel significantly improved progression-free survival PFS compared with docetaxel alone including a longer PFS in women These results supported investigation of the combination in this larger definitive phase 3 trial ZODIAC Between May 2006 and April 2008 patients with locally advanced or metastatic stage IIIB-IV NSCLC after progression following first-line chemotherapy were randomly assigned 11 through a third-party interactive voice system to receive vandetanib 100 mg/day plus docetaxel 75 mg/m 2 intravenously every 21 days maximum six cycles or placebo plus docetaxel The primary objective was comparison of PFS between the two groups in the intention-to-treat population Women were a coprimary analysis population This study has been completed and is registered with ClinicalTrialsgov number NCT00312377 1391 patients received vandetanib plus docetaxel n = 694 [ 197 women ] or placebo plus docetaxel n = 697 [ 224 women ] Vandetanib plus docetaxel led to a significant improvement in PFS versus placebo plus docetaxel hazard ratio [ HR ] 079 9758 % CI 070-0 90 p < 00001 median PFS was 40 months in the vandetanib group versus 32 months in placebo group A similar improvement in PFS with vandetanib plus docetaxel versus placebo plus docetaxel was seen in women HR 079 062-1 00 p = 0024 median PFS was 46 months in the vandetanib group versus 42 months in the placebo group Among grade 3 or higher adverse events rash 63/689 [ 9 % ] vs 7/690 [ 1 % ] neutropenia 199/689 [ 29 % ] vs 164/690 [ 24 % ] leukopenia 99/689 [ 14 % ] vs 77/690 [ 11 % ] and febrile neutropenia 61/689 [ 9 % ] vs 48/690 [ 7 % ] were more common with vandetanib plus docetaxel than with placebo plus docetaxel The most common serious adverse event was febrile neutropenia 46/689 [ 7 % ] in the vandetanib group vs 38/690 [ 6 % ] in the placebo group The addition of vandetanib to docetaxel provides a significant improvement in PFS in patients with advanced NSCLC after progression following first-line therapy\",\n",
            "}\n",
            "13391\n",
            "{\n",
            "  \"id\" : \"21358087\",\n",
            "  \"contents\" : \"Head and neck cancer is the leading cause of male mortality due to cancer in India Surgery radiation alone or in combination has been the backbone of treatment strategies Chemo-radiation has emerged as the standard of care in most types of head and neck cancer This strategy has the advantage of maintaining both structure and functions albeit with increased acute and delayed side effects Radiation with hyperthermia can achieve the same objective without additional toxicities A total of 56 patients were randomized to radiation therapy RT alone or RT-hyperthermia RT-HT arm Twenty-six patients were included in RT alone arm and 28 patients in the RT-HT arm Both groups were evenly matched for age sex and stage Patients in both the arms received radiation to a dose of 66-70 Gy in 65-7 weeks Patients in the study group received weekly HT HT was started after impedance matching to last for 30 minutes Complete response was seen in 424 % of RT alone group compare to 786 % in the HT group The difference was statistically significant < 005 Kaplan-Meir analysis of survival also showed a significant improvement in favor of RT-HT No dose limiting thermal burns and excessive mucosal or thermal toxicity were recorded Radiofrequency RF based heating and radical radiation of head and neck cancers is better than in RT alone group HT should be considered as a valid option wherever the facility for HT is available This report should infuse greater confidence in radiation Oncologists to practice HT as an adjuvant treatment modality\",\n",
            "}\n",
            "13392\n",
            "{\n",
            "  \"id\" : \"23299383\",\n",
            "  \"contents\" : \"To summarize the ongoing prevention of Alzheimer s disease AD by vitamin E and selenium PREADViSE trial as an ancillary study to SELECT a large prostate cancer prevention trial and to present the blinded results of the first year as an exposure study PREADViSE was designed as a double blind randomized controlled trial RCT SELECT terminated after median of 55 years of exposure to supplements due to a futility analysis Both trials then converted into an exposure study In the randomized component PREADViSE enrolled 7547 men age 62 or older 60 if African American Once the trial terminated 4246 of these men volunteered for the exposure study Demographics were similar for both groups with exposure volunteers having baseline mean age 673 52 years 153 24 years of education 98 % African Americans and 220 % reporting a family history of dementia In the RCT men were randomly assigned to either daily doses of 400 IU of vitamin E or placebo and 200 g of selenium or placebo using a 2x2 factorial structure In the RCT participants completed the memory impairment screen MIS and if they failed underwent a longer screening based on an expanded Consortium to Establish a Registry in AD [ CERAD ] battery CERAD failure resulted in visits to their clinician for medical examination with records of these examinations forwarded to the PREADViSE center for further review In the exposure study men are contacted by telephone and complete the telephone version of the memory impairment screen MIS-T screen If they fail the MIS-T a modified telephone interview of cognitive status TICS-M exam is given A failed TICS-M exam also leads to a visit to their clinician for an in-depth examination and forwarding of records for a centralized consensus diagnosis by expert clinicians A subgroup of the men who pass the MIS-T also take the TICS-M exam for validation purposes While this ancillary trial was open to all 427 SELECT clinical sites only 130 300 % of the sites chose to participate in PREADViSE Staff turnover at the sites presented challenges when training persons unfamiliar with cognitive testing procedures to conduct the memory screens In the RCT few participants 16 % failed the MIS screen and among those who passed this screen a significant practice effect was encountered In the exposure study 3581 men were reached by phone in year 1 157 % could not be reached after 5 calls and of those contacted 60 % refused the screen even after consenting to the procedures at their clinical site Most notable is that the failure rate for the MIS-T increased fourfold to 72 % Of the 257 men who took the TICS-M 840 % failed and were asked to contact their physicians for a more detailed memory assessment and approximately half of these had some form of dementia or cognitive impairment Several of these dementia cases are not AD Partnering with SELECT led to an AD prevention trial conducted at a very reasonable cost by taking advantage of the experience and efficient clinical trial management found in a cancer cooperative group Southwest Oncology Group or SWOG Once unblinded the RCT and exposure study data have the potential to yield new information on long term exposure to antioxidant supplements under controlled conditions\",\n",
            "}\n",
            "13393\n",
            "{\n",
            "  \"id\" : \"24892815\",\n",
            "  \"contents\" : \"Treatment of patients with prostate cancer has evolved considerably in the last decade especially in terms of minimization of the negative impacts on erectile function and continence to ensure good quality of life for treated patients New surgical devices such as dissectors and hemostatic scalpels allow precise definition of the surgical field with finer dissection of the anatomic structures with subsequent reductions in operative times and better oncologic and functional outcomes Although monopolar scissors MS are still widely used radiofrequency RF and ultrasound US scalpels have been introduced recently in laparoscopic radical prostatectomy LRP Despite the widespread use of these scalpels however few studies have compared these devices in terms of oncologic and functional outcomes after radical prostatectomy The present study aimed to prospectively assess the impact of MS RF and US scalpels on margin status at apex and recovery of urinary continence and erectile function in patients undergoing extraperitoneal LRP A total of 150 men were prospectively enrolled between September 2009 and April 2013 and postoperatively evaluated for continence and clinical factors There were no differences in terms of operative times P = 09433 blood loss P = 09681 apical margin positivity P = 03965 or postoperative hospital stay P = 09257 among the groups Moreover no differences in the functional outcome scores as evaluated by the International Consultation on Incontinence self-administered Questionnaire at 1 3 and 6 months postsurgery were observed Our study represents the first evaluation of continence recovery in LRP with respect to different devices used for prostatic apex dissection We found that the oncologic functional and operative outcomes were similar between these different devices during LRP with no scalpel demonstrating superiority in continence recovery\",\n",
            "}\n",
            "13394\n",
            "{\n",
            "  \"id\" : \"23391814\",\n",
            "  \"contents\" : \"A phase 3 Radiation Therapy Oncology Group RTOG study subset analysis demonstrated improved overall survival OS with the addition of stereotactic radiosurgery SRS to whole brain radiation therapy WBRT in non-small cell lung cancer NSCLC patients with 1 to 3 brain metastases Because temozolomide TMZ and erlotinib ETN cross the blood-brain barrier and have documented activity in NSCLC a phase 3 study was designed to test whether these drugs would improve the OS associated with WBRT + SRS NSCLC patients with 1 to 3 brain metastases were randomized to receive WBRT 25 Gy 15 to 375 Gy and SRS alone versus WBRT + SRS + TMZ 75 mg/m 2 / day 21 days or ETN 150 mg/day ETN 150 mg/day or TMZ 150-200 mg/m 2 / day 5 days/month could be continued for as long as 6 months after WBRT + SRS The primary endpoint was OS After 126 patients were enrolled the study closed because of accrual limitations The median survival times MST for WBRT + SRS WBRT + SRS + TMZ and WBRT + SRS + ETN were qualitatively different 134 63 and 61 months respectively although the differences were not statistically significant Time to central nervous system progression and performance status at 6 months were better in the WBRT + SRS arm Grade 3 to 5 toxicity was 11 % 41 % and 49 % in arms 1 2 and 3 respectively P < 001 The addition of TMZ or ETN to WBRT + SRS in NSCLC patients with 1 to 3 brain metastases did not improve survival and possibly had a deleterious effect Because the analysis is underpowered these data suggest but do not prove that increased toxicity was the cause of inferior survival in the drug arms\",\n",
            "}\n",
            "13395\n",
            "{\n",
            "  \"id\" : \"22005471\",\n",
            "  \"contents\" : \"This study compared survival without toxicity in patients with advanced nonsquamous non-small cell lung cancer who were treated with first-line pemetrexed/carboplatin or docetaxel/carboplatin This multicenter open-label parallel-group phase 3 trial comprised patients randomized 11 to pemetrexed/carboplatin n = 128 or docetaxel/carboplatin n = 132 Patients received treatment on day 1 of each 21-day cycle maximum of six cycles Treatment included carboplatin area under the curve = 5 mg/ml min and pemetrexed 500 mg/m 2 or docetaxel 75 mg/m 2 The primary outcome measure survival without treatment-emergent grade 3/4 toxicity was defined as the time from randomization to the first treatment-emergent grade 3/4 adverse event or death and was analyzed using a log-rank test The analysis population included 106 patients in the pemetrexed/carboplatin Pem/Carb group and 105 patients in the docetaxel/carboplatin Doc/Carb group Survival without treatment-emergent grade 3/4 toxicity was significantly longer in the Pem/Carb versus the Doc/Carb group log-rank p < 0001 median survival without treatment-emergent grade 3/4 toxicity 32 versus 07 months adjusted hazard ratio = 045 [ 95 % confidence interval 034-0 61 ] Overall survival was similar in the Pem/Carb versus the Doc/Carb group log-rank p = 0934 median survival 149 versus 147 months adjusted hazard ratio = 093 [ 95 % confidence interval 066-1 32 ] Compared with the Doc/Carb group fewer patients in the Pem/Carb group experienced grade 3/4 drug-related treatment-emergent neutropenia leukopenia or febrile neutropenia and more patients experienced anemia and thrombocytopenia There were three study drug-related deaths during treatment in each group The favorable benefit-to-risk profile of pemetrexed/carboplatin suggests that pemetrexed/carboplatin is an appropriate first-line treatment option for chemonave patients with advanced nonsquamous non-small cell lung cancer\",\n",
            "}\n",
            "13396\n",
            "{\n",
            "  \"id\" : \"16093971\",\n",
            "  \"contents\" : \"We determined if improved tumor detection using hexaminolevulinate HAL fluorescence cystoscopy could lead to improved treatment in patients with bladder cancer A total of 146 patients with known or suspected bladder cancer were assessed in this open comparative within patient controlled phase III study Patients received intravesical HAL for 1 hour and were assessed with standard white light cystoscopy and blue light fluorescence cystoscopy All lesions were mapped onto a bladder chart and biopsies were taken from suspicious areas for assessment by an independent pathologist An independent urologist blinded to the detection method used recommended treatment plans based on biopsy results and medical history according to European Association of Urology bladder cancer guidelines Any differences in recommended treatment plans arising from the 2 cystoscopy methods were recorded HAL imaging improved overall tumor detection Of all tumors 96 % were detected with HAL imaging compared with 77 % using standard cystoscopy This difference was particularly noticeable for dysplasia 93 % vs 48 % carcinoma in situ 95 % vs 68 % and superficial papillary tumors 96 % vs 85 % As a result of improved detection additional postoperative procedures were recommended in 15 patients 10 % and more extensive treatment was done intraoperatively in a further 10 Overall 17 % of patients received more appropriate treatment at the time of the study following blue light fluorescence cystoscopy that is 22 % or 1 of 5 if patients without tumors were excluded HAL imaging is more effective than standard white light cystoscopy for detecting bladder tumors and lesions This leads to improved treatment in a significant number of patients p < 00001\",\n",
            "}\n",
            "13397\n",
            "{\n",
            "  \"id\" : \"17763372\",\n",
            "  \"contents\" : \"Data from randomized controlled trials of zoledronic acid were retrospectively analyzed to assess the effect of pathologic fractures on survival in patients with malignant bone disease A Cox regression model was used to estimate the effect of fractures time-dependent variable on survival in patients with stage III multiple myeloma or bone metastases from solid tumors enrolled in 3 large trials Patients were randomized to receive zoledronic acid pamidronate or placebo every 3-4 weeks for up to 24 months prostate cancer breast cancer and multiple myeloma or up to 21 months lung and other solid tumors A total of 3049 patients with multiple myeloma n = 513 breast n = 1130 prostate n = 640 or lung cancer or other solid tumors n = 766 were included in this analysis Patients with multiple myeloma had the highest fracture incidence 43 % followed by breast 35 % prostate 19 % and lung cancer 17 % In all tumor types except lung pathologic fracture was associated with a significant increase in risk of death and breast cancer patients had the greatest increased risk After adjustment for baseline characteristics including performance status and prior skeletal complications breast cancer patients who developed a pathologic fracture on study had a significant 32 % increased risk of death relative to patients without a fracture hazard ratio = 132 P < 01 patients with multiple myeloma or prostate cancer had a > 20 % increased risk of death These results suggest that fractures are associated with increased risk of death in patients with malignant bone disease Therefore preventing fractures is an important goal of therapy\",\n",
            "}\n",
            "13398\n",
            "{\n",
            "  \"id\" : \"24486592\",\n",
            "  \"contents\" : \"Approximately 30 % higher grade premalignant oral intraepithelial neoplasia OIN lesions will progress to oral cancer Although surgery is the OIN treatment mainstay many OIN lesions recur which is highly problematic for both surgeons and patients This clinical trial assessed the chemopreventive efficacy of a natural product-based bioadhesive gel on OIN lesions This placebo-controlled multicenter study investigated the effects of topical application of bioadhesive gels that contained either 10 % w/w freeze-dried black raspberries BRB or an identical formulation devoid of BRB placebo to biopsy-confirmed OIN lesions 05 g qid 12 weeks Baseline evaluative parameters size histologic grade LOH events were comparable in the randomly assigned BRB n = 22 and placebo n = 18 gel cohorts Evaluative parameters were histologic grade clinical size and LOH Topical application of the BRB gel to OIN lesions resulted in statistically significant reductions in lesional sizes histologic grades and LOH events In contrast placebo gel lesions demonstrated a significant increase in lesional size and no significant effects on histologic grade or LOH events Collectively these data strongly support BRB s chemopreventive impact A cohort of very BRB-responsive patients as demonstrated by high therapeutic efficacy was identified Corresponding protein profiling studies which demonstrated higher pretreatment levels of BRB metabolic and keratinocyte differentiation enzymes in BRB-responsive lesions reinforce the importance of local metabolism and differentiation competency Results from this trial substantiate the LOH reductions identified in the pilot BRB gel study and extend therapeutic effects to significant improvements in histologic grade and lesional size\",\n",
            "}\n",
            "13399\n",
            "{\n",
            "  \"id\" : \"9738579\",\n",
            "  \"contents\" : \"The randomized multicenter trial of continuous hyperfractionated accelerated radiotherapy CHART versus conventional radiotherapy for patients with non-small-cell lung cancer NSCLC showed a significant survival benefit to CHART 29 % v 20 % at 2 years P = 004 However an assessment of the effect on physical and psychologic symptoms is vital to balance the costs and benefits of the two treatments A total of 356 patients in the United Kingdom completed the Rotterdam Symptom Checklist RSCL and the Hospital Anxiety and Depression Scale HADS at 10 time points The principal aim of the analyses was to keep the methods simple so as to allow the presentation and interpretation of the results to be as clear as possible This was achieved by 1 considering individual symptoms rather than symptom subscales or domains 2 assessing short-term effects up to 3 months and long-term effects at 1 and 2 years separately and 3 for the short-term analyses a splitting the data randomly into an exploratory data set and a confirmatory data set and b using two different methods of analysis a subject-specific approach which used the area under the curve AUC as a summary measure and a group-based method which plotted the percent of patients with moderate or severe symptoms over time The results indicate that apart from CHART causing transient pain on swallowing and heartburn there was little difference between the regimens in the short or long-term Combining the results of the patient-assessed symptom comparisons with the clinical results indicates that CHART confers a major benefit without serious morbidity\",\n",
            "}\n",
            "13400\n",
            "{\n",
            "  \"id\" : \"10547465\",\n",
            "  \"contents\" : \"A systematic retrospective study of the largest randomized trial of induction chemotherapy and radiation for advanced laryngeal cancer was undertaken to determine whether specific tumor or biologic factors were predictive of chemotherapy response organ preservation or survival The variables analyzed included clinical and histologic factors immunohistochemical expression of proliferating cell nuclear antigen and p53 and adjusted DNA index measurements Variables were evaluated for correlation with outcomes of tumor response organ preservation and survival Multivariate analysis revealed that the best predictor of complete response to induction chemotherapy was low T class The full multivariate model for predicting larynx preservation in patients treated with induction chemotherapy plus radiation shows that T class p53 overexpression and elevated proliferating cell nuclear antigen index were independent predictors of successful organ preservation These predictive markers should be included in future clinical trials of advanced laryngeal cancer to determine their usefulness prospectively\",\n",
            "}\n",
            "13401\n",
            "{\n",
            "  \"id\" : \"18155056\",\n",
            "  \"contents\" : \"Surgical stress and general anesthesia suppress immune function Preemptive epidural analgesia can affect the perioperative immune responses and influence cancer management Forty women undergoing elective laparoscopic radical hysterectomy for cervical cancer were allocated to this prospective randomized double-blind trial Before inducing anesthesia 2 mg morphine dissolved in 15 mL of 1 % lidocaine preemptive group or the same volume of normal saline control group was administered into the epidural space through a prepared catheter in a double-blind manner using sealed syringes After peritoneal closure the other drugs in the remaining sealed syringe were administered in the reverse manner All patients were then administered lidocaine plus morphine over a 72-hour period using a patient-controlled epidural analgesia pump The interleukin-6 levels in both groups increased significantly after surgery These elevations were significantly less pronounced in the preemptive group than in the control group The interleukin-2 level in both groups decreased significantly after surgery Seventy-two hours after surgery the interleukin-2 level returned to its baseline value in the preemptive group but not in the control group The number of lymphocytes in both groups decreased significantly after surgery The pain scores at 6 and 12 hours after surgery in the preemptive group were significantly lower than in the control group Preemptive epidural analgesia is a reasonable approach for potentially controlling perioperative immune function and preventing postoperative pain in patients undergoing cancer surgery\",\n",
            "}\n",
            "13402\n",
            "{\n",
            "  \"id\" : \"18504252\",\n",
            "  \"contents\" : \"The purpose of this study was to determine in limited small-cell lung cancer if locoregional irradiation concurrently with induction chemotherapy with cisplatin and etoposide prolongs survival when cisplatin is given daily as a radiosensitiser Two-hundred and four eligible patients were randomised between standard radiosensitised induction chemoradiotherapy arm A with cisplatin 90 mg/m 2 day 1 plus etoposide and daily radiosensitised induction chemoradiotherapy arm B with cisplatin 6 mg/m 2 / day plus etoposide Chemotherapy and chest irradiation 3990 Gy in 15 fractions > 3 weeks both started on day 1 There was no difference in survival between both arms with respective median 2 and 5 years of 155 months 35 % and 18 % in arm A and 170 months 38 % and 21 % in arm B P = 050 Performance status and T status were identified as independent prognostic factors for survival In terms of local control rate there was a statistical trend in favour of arm A with 2 % only local relapse versus 10 % in arm B Daily cisplatin radiosensitisation was associated with more oesophagitis and thrombopenia but less nephrotoxicity Induction chemoradiotherapy resulted in both arms in good long-term survival comparable to the best reported results and without improvement by daily cisplatin administration\",\n",
            "}\n",
            "13403\n",
            "{\n",
            "  \"id\" : \"21777283\",\n",
            "  \"contents\" : \"For colonoscopic examinations the narrow-band imaging NBI system is more convenient and timesaving than magnifying chromoendoscopy MCE However the time-saving aspects of NBI techniques have not been assessed The present study compared interpretation times between NBI and MCE techniques in distinguishing between neoplastic and non-neoplastic small colorectal lesions Between January and March 2010 693 consecutive patients who underwent colonoscopy at the National Cancer Center Hospital Tokyo Japan were enrolled When the first lesion was detected by conventional white-light observation the patient was randomly assigned to undergo a sequence of NBI and MCE observations group A NBI-MCE group B MCE-NBI The time to diagnosis with each modality NBI from changing to NBI until diagnosis MCE from the start of indigo carmine solution spraying until diagnosis was recorded by an independent observer The sensitivity specificity and diagnostic accuracy of the first modality used in each group NBI or MCE were assessed by referring to the histopathological data Seventy-one patients with 137 lesions were randomized to group A and 80 patients with 163 lesions to group BThe median interpretation times were 12 s interquartile range [ IQR ] 7-19 s in group A and 17 s IQR 12-24 s in group B the difference being significant P < 0001 No significant differences were observed between NBI and MCE in terms of sensitivity specificity and diagnostic accuracy NBI reduces the interpretation times for distinguishing between neoplastic and non-neoplastic small lesions during colonoscopies without loss of diagnostic accuracy\",\n",
            "}\n",
            "13404\n",
            "{\n",
            "  \"id\" : \"19418107\",\n",
            "  \"contents\" : \"Individuals with a sibling who has had colorectal cancer diagnosed before age 61 are at increased risk for colorectal cancer and may derive particular benefit from screening Tailored interventions may increase participation in appropriate colorectal cancer screening This study evaluated the efficacy of two tailored interventions and a generic print intervention Participant siblings N = 412 who were not up-to-date with colorectal cancer screening were randomly assigned to receive either a generic print pamphlet a tailored print pamphlet or a tailored print pamphlet and tailored counseling call Colorectal cancer screening 6 months after the baseline interview was the outcome measure Results indicated that colorectal cancer screening adherence increased among intermediate risk siblings enrolled in all three intervention groups Participants in both tailored intervention groups reported having colorectal cancer screening at significantly higher rates than participants in the generic print group The increase in colorectal cancer screening in the tailored print and counseling call group was not significantly higher than that achieved by the tailored print alone Decisional balance partially mediated treatment effects Tailored behavioral interventions are effective methods for increasing screening adherence but telephone counseling did not add significantly to treatment effects\",\n",
            "}\n",
            "13405\n",
            "{\n",
            "  \"id\" : \"21900849\",\n",
            "  \"contents\" : \"Preliminary data suggest that flaxseed a rich source of dietary lignans may be a potentially effective treatment of hot flashes A phase III randomized placebo controlled trial was conducted to evaluate the efficacy of flaxseed in reducing hot flashes Postmenopausal women with or without breast cancer were randomly assigned to a flaxseed bar providing 410 mg of lignans for 6 weeks versus a placebo bar Participants completed daily prospective hot flash diaries during the baseline week and then ate one study bar per day for 6 weeks while recording their daily hot flashes The intraparticipant difference in hot flash activity between baseline and the last treatment week was the primary endpoint Adverse effects were evaluated through a self-report and the Common Terminology Criteria assessment A total of 188 women were enrolled in this trial The mean hot flash score was reduced 49 in the flaxseed group and 35 in the placebo group P = 029 In both groups slightly more than a third of the women received a 50 % reduction in their hot flash score Only one adverse effect was significantly different between groups grade 1 pruritus which was more common in the placebo group 8 % vs 1 % Both groups reported abdominal distension flatulence diarrhea and nausea Adherence and ability to detect treatment assignment did not differ between groups The results of this trial do not support the use of 410 mg of lignans for the reduction of hot flashes The bars were fairly well tolerated with both groups reporting gastrointestinal effects probably due to the fiber content\",\n",
            "}\n",
            "13406\n",
            "{\n",
            "  \"id\" : \"23861293\",\n",
            "  \"contents\" : \"Women with breast cancer have decreased levels of melatonin or its metabolite in plasma and/or urine We measured serum melatonin urinary 6-sulfatoxymelatonin catecholamines and cortisol in 141 sedentary young female participants in a clinical trial comparing 150 min/wk aerobic exercise for 4 months to no-exercise controls Demographics health surveys body composition sleep quality fitness levels and blood and urine samples were obtained at baseline and 16 weeks There were no differences between groups at baseline in demographics exercise sleep habits or study hormones There were also no significant differences between groups in any of the hormones at 16 weeks Sixteen weeks of exercise had minimal effects on melatonin secretion of young women There is convincing evidence that exercise protects against breast cancer but this does not appear to occur through changes in melatonin secretion\",\n",
            "}\n",
            "13407\n",
            "{\n",
            "  \"id\" : \"9261520\",\n",
            "  \"contents\" : \"This randomised study was designed to determine the response rate survival and toxicity of single-agent gemcitabine and cisplatin-etoposide in chemo-nave patients with locally advanced or metastatic non-small-cell lung cancer Gemcitabine 1000 mg/m2 was given as a 30 min intravenous infusion on days 1 8 15 of a 28-day cycle cisplatin 100 mg/m2 on day 1 and etoposide 100 mg/m2 on days 1 following cisplatin 2 and 3 Major eligibility criteria included histologically confirmed non-small-cell lung cancer measurable disease Zubrod PS 0-2 no prior chemotherapy no prior radiation of the measured lesion and no CNS metastases 146 patients were enrolled 71 patients on gemcitabine and 75 patients on cisplatin-etoposide Patient characteristics were well matched across both arms Sixty-six gemcitabine patients and 72 cisplatin-etoposide patients were evaluable Partial responses were seen in 12 gemcitabine patients 182 % 95 % CI 98-30 and 11 cisplatin-etoposide patients 153 % 95 % CI 79-25 7 Early indications show no statistical differences between the two treatments with respect to time to disease progression or survival Haematological and laboratory toxicity were moderate and manageable However hospitalisation because of neutropenic fever was required for 6 8 % cisplatin-etoposide patients but not for any gemcitabine patients Non-haematological toxicity was more pronounced with significant differences in nausea and vomiting grade 3 and 4 11 % gemcitabine vs 29 % cisplatin-etoposide despite the allowance for 5-HT3 antiemetics during the first cycle of cisplatin-etoposide and alopecia grade 3 and 43 % gemcitabine vs 62 % cisplatin-etoposide In this randomised study single-agent gemcitabine was at least as active but better tolerated than the combination cisplatin-etoposide\",\n",
            "}\n",
            "13408\n",
            "{\n",
            "  \"id\" : \"11790211\",\n",
            "  \"contents\" : \"Laparoscopic-assisted colectomy LAC has emerged as the preferred minimally invasive surgical strategy for diseases of the colon The safety and efficacy of LAC for colon cancer are unknown and the nature and magnitude of any quality-of-life QOL benefit resulting from LAC for colon cancer is also unknown To compare short-term QOL outcomes after LAC vs open colectomy for colon cancer Multicenter randomized controlled trial Clinical Outcomes of Surgical Therapy [ COST ] Between September 1994 and February 1999 37 of 48 centers provided data for the QOL component of the trial for 449 consecutive patients with clinically resectable colon cancer Scores on the Symptoms Distress Scale SDS Quality of Life Index and a single-item global rating scale at 2 days 2 weeks and 2 months postoperative duration of postoperative in-hospital analgesic use and length of stay Of 449 patients 428 provided QOL data In an intention-to-treat analysis comparing SDS pain intensity SDS summary QOL Index summary and global rating scale scores at each time point the only statistically significant difference observed between groups was the global rating scale score for 2 weeks postsurgery The mean median global rating scale scores for 2 weeks postsurgery were 769 80 for LAC vs 744 75 for open colectomy P = 009 While in the hospital patients assigned to LAC required fewer days of both parenteral analgesics compared with patients assigned to open colectomy mean [ median ] 32 [ 3 ] vs 40 [ 4 ] days P < 001 and oral analgesics mean [ median ] 19 [ 1 ] vs 22 [ 2 ] days P = 03 Only minimal short-term QOL benefits were found with LAC for colon cancer compared with standard open colectomy Until ongoing trials establish that LAC is as effective as open colectomy in preventing recurrence and death from colon cancer this procedure should not be offered to patients with colon cancer\",\n",
            "}\n",
            "13409\n",
            "{\n",
            "  \"id\" : \"8368227\",\n",
            "  \"contents\" : \"To determine the efficacy dose-response relationship and safety of 30 60 and 90 mg of a single intravenous dose of an aminobisphosphonate pamidronate APD for the treatment of moderate to severe hypercalcemia of malignancy Patients with histologically proven cancer and a corrected serum calcium level of at least 120 mg/dL after 48 hours of normal saline hydration were enrolled in a double-blind multicenter randomized clinical trial Pamidronate in 30 - 60 - or 90-mg doses was administered as a single 24-hour infusion Serum calcium corrected for albumin urine hydroxyproline and calcium excretion and serum parathyroid hormone PTH 1-84 were determined before and after pamidronate therapy Thirty-two men and 18 women entered the study A dose-response relationship for normalization of corrected serum calcium was seen after pamidronate administration Corrected serum calcium normalized in 40 % of patients who received 30 mg in 61 % of patients who received 60 mg and in 100 % of patients who received 90 mg of pamidronate The decline in the serum calcium level was associated with decreased osteoclastic skeletal resorption evidenced by a decrease in urine calcium and hydroxyproline excretion Among those with a normalized corrected serum calcium level the mean median duration of normalization of the corrected serum calcium value was 92 4 133 5 and 108 6 days in the 30 - 60 - and 90-mg treatment groups respectively The response of hypercalcemia to pamidronate was not significantly influenced by the presence of skeletal metastases PTH 1-84 suppressed in patients on entry into this study increased to a greater extent in those patients with osteolytic skeletal metastases compared with those with humoral hypercalcemia of malignancy Clinical improvement including improved mental status and decreased anorexia accompanied the decline in the corrected serum calcium level in all three treatment groups Side effects included low-grade fever asymptomatic hypocalcemia hypomagnesemia and hypophosphatemia A single-dose infusion of 60 to 90 mg of pamidronate was highly effective and well tolerated and normalized corrected serum calcium in nearly all patients 61 % to 100 % with hypercalcemia of malignancy\",\n",
            "}\n",
            "13410\n",
            "{\n",
            "  \"id\" : \"9390536\",\n",
            "  \"contents\" : \"The B-20 study of the National Surgical Adjuvant Breast and Bowel Project NSABP was conducted to determine whether chemotherapy plus tamoxifen would be of greater benefit than tamoxifen alone in the treatment of patients with axillary lymph node-negative estrogen receptor-positive breast cancer Eligible patients n = 2306 were randomly assigned to one of three treatment groups following surgery A total of 771 patients with follow-up data received tamoxifen alone 767 received methotrexate fluorouracil and tamoxifen MFT and 768 received cyclophosphamide methotrexate fluorouracil and tamoxifen CMFT The Kaplan-Meier method was used to estimate disease-free survival distant disease-free survival and survival Reported P values are two-sided Through 5 years of follow-up chemotherapy plus tamoxifen resulted in significantly better disease-free survival than tamoxifen alone 90 % for MFT versus 85 % for tamoxifen [ P = 01 ] 89 % for CMFT versus 85 % for tamoxifen [ P = 001 ] A similar benefit was observed in both distant disease-free survival 92 % for MFT versus 87 % for tamoxifen [ P = 008 ] 91 % for CMFT versus 87 % for tamoxifen [ P = 006 ] and survival 97 % for MFT versus 94 % for tamoxifen [ P = 05 ] 96 % for CMFT versus 94 % for tamoxifen [ P = 03 ] Compared with tamoxifen alone MFT and CMFT reduced the risk of ipsilateral breast tumor recurrence after lumpectomy and the risk of recurrence at other local regional and distant sites Risk of treatment failure was reduced after both types of chemotherapy regardless of tumor size tumor estrogen or progesterone receptor level or patient age however the reduction was greatest in patients aged 49 years or less No subgroup of patients evaluated in this study failed to benefit from chemotherapy Findings from this and other NSABP studies indicate that patients with breast cancer who meet NSABP protocol criteria regardless of age lymph node status tumor size or estrogen receptor status are candidates for chemotherapy\",\n",
            "}\n",
            "13411\n",
            "{\n",
            "  \"id\" : \"26275735\",\n",
            "  \"contents\" : \"One of the standard options in the treatment of stage IIIA/N2 non-small-cell lung cancer is neoadjuvant chemotherapy and surgery We did a randomised trial to investigate whether the addition of neoadjuvant radiotherapy improves outcomes We enrolled patients in 23 centres in Switzerland Germany and Serbia Eligible patients had pathologically proven stage IIIA/N2 non-small-cell lung cancer and were randomly assigned to treatment groups in a 11 ratio Those in the chemoradiotherapy group received three cycles of neoadjuvant chemotherapy 100 mg/m 2 cisplatin and 85 mg/m 2 docetaxel followed by radiotherapy with 44 Gy in 22 fractions over 3 weeks and those in the control group received neoadjuvant chemotherapy alone All patients were scheduled to undergo surgery Randomisation was stratified by centre mediastinal bulk less than 5 cm vs 5 cm or more and weight loss 5 % or more vs less than 5 % in the previous 6 months The primary endpoint was event-free survival Analyses were done by intention to treat This trial is registered with ClinicalTrialsgov number NCT00030771 From 2001 to 2012 232 patients were enrolled of whom 117 were allocated to the chemoradiotherapy group and 115 to the chemotherapy group Median event-free survival was similar in the two groups at 128 months 95 % CI 97-229 in the chemoradiotherapy group and 116 months 84-152 in the chemotherapy group p = 067 Median overall survival was 371 months 95 % CI 226-500 with radiotherapy compared with 262 months 199-521 in the control group Chemotherapy-related toxic effects were reported in most patients but 91 % of patients completed three cycles of chemotherapy Radiotherapy-induced grade 3 dysphagia was seen in seven 7 % patients Three patients died in the control group within 30 days after surgery Radiotherapy did not add any benefit to induction chemotherapy followed by surgery We suggest that one definitive local treatment modality combined with neoadjuvant chemotherapy is adequate to treat resectable stage IIIA/N2 non-small-cell lung cancer Swiss State Secretariat for Education Research and Innovation SERI Swiss Cancer League and Sanofi\",\n",
            "}\n",
            "13412\n",
            "{\n",
            "  \"id\" : \"18258332\",\n",
            "  \"contents\" : \"We sought to identify relationship and partner-related moderating variables that influence the effectiveness of both a couples and a solo learning intervention designed to increase skin self-examination behavior in a sample of patients at risk for developing melanoma Patients received a brief intervention designed to teach skin self-examination skills and were randomly assigned into either a solo learning condition where the intervention was administered to the patient alone n = 65 or a couple learning condition where the intervention was administered to the patient and patient s spouse or cohabiting partner n = 65 The main outcome measure was skin self-examination self-efficacy which is the strongest mediator of skin self-examination The relationship moderator variables measured were quality of relationship partner motivation and ability to assist in implementation of the intervention When quality of the marital/partner relationship was high the beneficial effects provided by the partner being included in the skin self-examination skills training were the highest and patients exhibited higher self-efficacy Similar effects were observed for those with partners who were motivated to implement the intervention and for those with partners high in ability to provide support Study limitations include the need to evaluate whether the effects can be sustained long term and the exclusion of patients with melanoma without partners The amount of beneficial effects gained by the patient from the skin self-examination intervention was influenced by marital/partner relationships Clinicians may need to consider these relationship and partner characteristics when communicating to patients about skin cancer screening\",\n",
            "}\n",
            "13413\n",
            "{\n",
            "  \"id\" : \"16360449\",\n",
            "  \"contents\" : \"To evaluate the effects of prostatic massage on the serum complexed PSA cPSA concentration in various prostatic diseases A total of 51 men who presented to our outpatient clinic for the first time with symptoms of lower urinary outflow obstruction were included in this study Blood samples were obtained from each patient before and 30 minutes after prostatic massage Total PSA tPSA free PSA fPSA and cPSA levels were measured using a chemiluminescent enzyme immunoassay After prostatic massage the tPSA and fPSA levels and fPSA/tPSA ratio increased significantly P < 00001 and the increase in cPSA was minimal but statistically significant P = 0047 In patients with prostate cancer no significant increase occurred in the mean forms of PSA tPSA cPSA and fPSA/tPSA ratio except for fPSA after prostatic massage We observed a greater increase in all PSA forms in the chronic prostatitis group In this study prostatic massage increased serum cPSA concentration but to a lesser extent than tPSA and fPSA\",\n",
            "}\n",
            "13414\n",
            "{\n",
            "  \"id\" : \"9445122\",\n",
            "  \"contents\" : \"To evaluate the effectiveness of lymphadenectomy in the treatment of non-small cell lung cancer NSCLC The extent of lymphadenectomy in the treatment of NSCLC is still a matter of controversy Although some centers perform mediastinal lymph node sampling LS with resection of only suspicious lymph nodes others recommend a radical systematic mediastinal lymphadenectomy LA to improve survival and to achieve a better staging In a controlled prospective randomized clinical trial the effects of LA on recurrence rates and survival were analyzed comparing LS and LA in 169 patients with operable NSCLC After a median follow-up of 47 months LA did not improve survival in the overall group of patients hazard ratio 078 95 % confidence interval 047-1 24 Although recurrences rates tended to be reduced among patients who underwent LA these decreases were not statistically significant hazard ratio 082 95 % confidence interval 054-1 27 However analysis of subgroups of patients according to histopathologic lymph node staging revealed that LA appears to prolong relapse-free survival p = 0037 with a borderline effect on overall survival p = 0058 in patients with limited lymph node involvement pN1 disease or pN2 disease with involvement of only one lymph node level in patients with pN0 disease no survival benefit was observed Radical systematic mediastinal lymphadenectomy does not influence disease-free or overall survival in patients with NSCLC and without overt lymph node involvement However a small subgroup of patients with limited mediastinal lymph node metastases might benefit from a systematic lymphadenectomy\",\n",
            "}\n",
            "13415\n",
            "{\n",
            "  \"id\" : \"24687921\",\n",
            "  \"contents\" : \"In a recent phase II study of onartuzumab MetMAb patients whose non-small cell lung cancer NSCLC tissue scored as positive for MET protein by immunohistochemistry IHC experienced a significant benefit with onartuzumab plus erlotinib O+E versus erlotinib We describe development and validation of a standardized MET IHC assay and retrospectively evaluate multiple biomarkers as predictors of patient benefit Biomarkers related to MET and/or EGF receptor EGFR signaling were measured by IHC FISH quantitative reverse transcription PCR mutation detection techniques and ELISA A positive correlation between IHC Western blotting and MET mRNA expression was observed in NSCLC cell lines/tissues An IHC scoring system of MET expression taking proportional and intensity-based thresholds into consideration was applied in an analysis of the phase II study and resulted in the best differentiation of outcomes Further analyses revealed a nonsignificant overall survival OS improvement with O+E in patients with high MET copy number mean5 copies/cell by FISH however benefit was maintained in MET IHC-positive / MET FISH-negative patients HR 037 P = 001 MET EGFR amphiregulin epiregulin or HGF mRNA expression did not predict a significant benefit with onartuzumab a nonsignificant OS improvement was observed in patients with high tumor MET mRNA levels HR 059 P = 023 Patients with low baseline plasma hepatocyte growth factor HGF exhibited an HR for OS of 0519 P = 009 in favor of onartuzumab treatment MET IHC remains the most robust predictor of OS and progression-free survival benefit from O+E relative to all examined exploratory markers\",\n",
            "}\n",
            "13416\n",
            "{\n",
            "  \"id\" : \"15036850\",\n",
            "  \"contents\" : \"The optimal treatment position for patients receiving radical radiation therapy for prostate cancer has been a source of controversy To resolve this issue we conducted a randomized trial to evaluate the effects of supine and prone positioning on organ motion positioning errors and dose to critical organs during escalated dose conformal irradiation for localized prostate cancer and patient and therapist satisfaction with setup technique Twenty eight patients were randomized to commence treatment immobilized in the supine or prone position and were subsequently changed to the alternate positioning for the latter half of their treatment Patients underwent CT simulation and conformal radiotherapy planning and treatment in both positions The clinical target volume encompassed the prostate gland Alternate day lateral port films were compared to corresponding simulator radiographs to measure the isocentre positioning errors IPE Prostate motion PM and total positioning error TPE were measured from the same films by the displacements of three implanted fiducial markers Dose volume histograms DVHs for the two treatment positions were compared at the 95 80 and 50 % dose D % levels The patients and radiation therapists completed weekly questionnaires regarding patient comfort and ease of setup Seven patients who started in the supine position subsequently refused prone position and received their whole treatment supine Small bowel in the treatment volume not present in the supine position prevented one patient from being treated prone PM in anterior posterior direction was statistically significantly less in the supine position P < 005 There was no significant difference in superior inferior PM for the two treatment positions No statistically significant difference between supine and prone positioning was observed in isocentre positioning error IPE or total positioning error TPE due to a policy of daily pre-treatment correction However more pre-treatment corrections were required for patients in the prone position The DVH analysis demonstrated larger volumes of the bladder wall rectal wall and small bowel within the D95 D80 and D50 % when comparing the planning target volumes PTVs actually treated for prone positioning When the prone PTV was expanded to account for the greater PM encountered in that position a statistically significant difference P < 0007 was observed in favour of the supine position at all dose levels In the prone position four patients had small bowel within the 60 Gray Gy isodose and in the supine position no patients had small bowel in the 60 or 38Gy volumes Supine position was significantly more comfortable for the patients and setup was significantly easier for the radiation therapists The median patient comfort score was 079 Standard deviation SD 003 supine and 045 SD 005 prone P < 0001 The therapist convenience of setup was 080 SD 0016 supine and 054 SD 0025 prone P < 0005 No statistically significant difference was seen for the other parameters studied We demonstrated significantly less PM in the supine treatment position There was no difference for either treatment position in IPE or TPE however more pre-treatment corrections were required in the prone position Prone position required a larger PTV with resulting increased dose to critical organs There were statistically significant improvements at all dose levels for small bowel rectal wall and bladder wall doses in the supine position once corrections were made for differences in organ motion Linear analogue scores of patient comfort and radiation therapist convenience demonstrated statistically significant improvement in favour of the supine position Supine positioning has been adopted as the standard for conformal prostatic irradiation at our centre\",\n",
            "}\n",
            "13417\n",
            "{\n",
            "  \"id\" : \"21733143\",\n",
            "  \"contents\" : \"Weight loss in patients with cancer is common and associated with a poorer survival and quality of life Benefits from nutritional interventions are unclear The present study assessed the effect of dietary advice and/or oral nutritional supplements on survival nutritional endpoints and quality of life in patients with weight loss receiving palliative chemotherapy for gastrointestinal and non-small cell lung cancers or mesothelioma Participants were randomly assigned to receive no intervention dietary advice a nutritional supplement or dietary advice plus supplement before the start of chemotherapy Patients were followed for 1 year Survival nutritional status and quality of life were assessed In total 256 men and 102 women median age 66 years range 24-88 years with gastrointestinal n = 277 and lung n = 81 cancers were recruited Median range follow-up was 6 0-49 months One-year survival was 386 % 95 % confidence interval 333-43 9 No differences in survival weight or quality of life between groups were seen Patients surviving beyond 26 weeks experienced significant weight gain from baseline to 12 weeks although this was independent of nutritional intervention Simple nutritional interventions did not improve clinical or nutritional outcomes or quality of life Weight gain predicted a longer survival but occurred independently of nutritional intervention\",\n",
            "}\n",
            "13418\n",
            "{\n",
            "  \"id\" : \"17267326\",\n",
            "  \"contents\" : \"Tamoxifen preserves bone in postmenopausal women but non-steroidal aromatase inhibitors accelerate bone loss and increase fracture risk We aimed to study the effect on bone health in a subgroup of women included in the Intergroup Exemestane Study IES a large randomised trial that compared the switch to the steroidal aromatase inhibitor exemestane with continuation of tamoxifen in the adjuvant treatment of postmenopausal breast cancer Results were analysed from 206 evaluable patients from the IES in which postmenopausal women with histologically confirmed and completely resected unilateral breast cancer that was oestrogen-receptor positive or of unknown status who were disease-free after 2-3 years of treatment with tamoxifen were randomised to continue oral tamoxifen 20 mg/day or switch to oral exemestane 25 mg/day to complete a total of 5 years of adjuvant endocrine therapy The primary endpoint was change in bone-mineral density BMD assessed by dual energy X-ray absorptiometry Changes in biochemical markers of bone turnover were also analysed in this substudy and the incidence of fractures in the entire study reported The IES is registered on the Current Controlled Trials website Within 6 months of switching to exemestane BMD was lowered by 0051 g/cm 3 27 % 95 % CI 20-3 4 p < 00001 at the lumbar spine and 0025 g/cm 3 14 % 08-1 9 p < 00001 at the hip compared with baseline BMD decreases were only 10 % 04-1 7 p = 0002 and 08 % 03-1 4 p = 0003 in year 2 at the lumbar spine and hip respectively No patient with BMD in the normal range at trial entry developed osteoporosis Bone resorption and formation markers increased at all time points in women receiving exemestane p < 0001 With a median follow-up in all IES participants n = 4274 of 58 months 162 7 % and 115 5 % patients in the exemestane and tamoxifen groups respectively had fractures odds ratio 145 [ 113-1 87 ] p = 0003 These results indicate that the increase in survival shown previously with the IES switch strategy is achieved at the expense of some detriment to skeletal health so the risk-benefit ratio to women needs to be individually assessed\",\n",
            "}\n",
            "13419\n",
            "{\n",
            "  \"id\" : \"19189349\",\n",
            "  \"contents\" : \"Primary surgery followed by platinum-taxane based chemotherapy has been the standard therapy in advanced ovarian cancer However the prognostic role of complete and so-called optimal and suboptimal debulking and its interaction with biological factors has not been not fully defined Exploratory analysis was conducted of 3 prospective randomized trials AGO-OVAR 3 5 and 7 investigating platinum-taxane based chemotherapy regimens in advanced ovarian cancer conducted between 1995 and 2002 A total of 3126 patients were analyzed Approximately one-third each fulfilled criteria for complete resection group A small residual tumor burden of 1-10 mm group B or macroscopic residual disease exceeding 1 cm in diameter group C Multivariate analysis showed improved progression-free and overall survival for group A with complete resection compared with groups B or C P < 0001 The impact of so-called optimal debulking as in group B showed a smaller prognostic impact compared with group C Further independent prognostic factors for overall survival were age performance status grade FIGO stage and histology namely the mucinous subtype An interaction between residual tumor and some biologic factors was demonstrated The goal of primary surgery should be complete resection The prognostic impact of tumor biology seemed to be partially overruled by residual tumor and further evaluation of biologic factors should stratify for residual tumor\",\n",
            "}\n",
            "13420\n",
            "{\n",
            "  \"id\" : \"23315099\",\n",
            "  \"contents\" : \"CA 19-9 is the only established tumor marker in pancreatic cancer PC the prognostic role of other serum markers like CEA CRP LDH or bilirubin has not yet been defined We pooled pre-treatment data on CA 19-9 CEA CRP LDH and bilirubin levels from two German multicenter randomized phase II trials together with prospective patient data from one high-volume German Cancer Center Marker levels were assessed locally before the start of palliative first-line therapy for advanced PC and serially during treatment for CA 19-9 only Clinical and biomarker data overall 12 variables were correlated with the efficacy endpoints time-to-progression TTP and overall survival OS by using uni - and multivariate Cox models Data from 291 patients were included in this pooled analysis 253 patients 87 % received treatment within prospective clinical trials Median TTP in the study cohort was 51 months and median OS 90 months In univariate analysis pre-treatment CA 19-9 HR 155 LDH HR 204 and CEA HR 189 levels were significantly associated with TTP Regarding OS baseline CA 19-9 HR 146 LDH HR 207 CRP HR 169 and bilirubin HR 162 were significant prognostic factors Within multivariate analyses pre-treatment log [ CA 19-9 ] as continuous variable for TTP and log [ bilirubin ] as well as log [ CRP ] for OS had an independent prognostic value A CA 19-9 decline of 25 % during the first two chemotherapy cycles was predictive for TTP and OS independent of the applied CA 19-9 assay Baseline CA 19-9 and CA 19-9 kinetics during first-line chemotherapy are prognostic in advanced PC Besides that finding other serum markers like CRP LDH and bilirubin can also provide prognostic information on TTP and OS\",\n",
            "}\n",
            "13421\n",
            "{\n",
            "  \"id\" : \"24003005\",\n",
            "  \"contents\" : \"Early psychosocial screening may guide interventions and ameliorate the adverse psychosocial effects of childhood cancer The revised psychosocial assessment tool provides risk information - Universal typical distress Targeted additional specific distress and Clinical severe distress - about the child with cancer and his or her family This pilot study investigated the benefits of providing a summary of family psychosocial risk information to the medical team treating the newly diagnosed child Experimental Group EG We conducted a pilot randomized control trial with a sample of 67 parents comparing the EG to the control group CG on parental perception of family psychosocial difficulties revised psychosocial assessment tool risk levels child behavior behavior assessment scale for children-2 pediatric quality of life PedsQL and parental anxiety state-anxiety scale of the state-trait anxiety inventory 2-4weeks after diagnosis Time 1 and 6months later Time 2 Compared to the CG participants in the EG had significantly reduced targeted and clinical risk p < 0001 and improved pain related PedsQL at Time 2 p < 005 Scores for PedsQL total and nearly all subscales improved over time in both groups p < 005 to p < 0001 No changes in behavior scores were noted Preliminary findings suggest that providing a summary of the Psychosocial Assessment Tool to the treating team shortly after diagnosis may help reduce family wide psychosocial risk 6months later and improve quality of life related to pain for children who are undergoing treatment for cancer\",\n",
            "}\n",
            "13422\n",
            "{\n",
            "  \"id\" : \"21794114\",\n",
            "  \"contents\" : \"MANTICORE 101 - Breast Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research is a randomized trial to determine if conventional heart failure pharmacotherapy angiotensin converting enzyme inhibitor or beta-blocker can prevent trastuzumab-mediated left ventricular remodeling measured with cardiac MRI among patients with HER2 + early breast cancer One hundred and fifty-nine patients with histologically confirmed HER2 + breast cancer will be enrolled in a parallel 3-arm randomized placebo controlled double-blind design After baseline assessments participants will be randomized in a 111 ratio to an angiotensin-converting enzyme inhibitor perindopril beta-blocker bisoprolol or placebo Participants will receive drug or placebo for 1 year beginning 7 days before trastuzumab therapy Dosages for all groups will be systematically up-titrated as tolerated at 1 week intervals for a total of 3 weeks The primary objective of this randomized clinical trial is to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2 + early breast cancer as measured by 12 month change in left ventricular end-diastolic volume using cardiac MRI Secondary objectives include 1 determine the evolution of left ventricular remodeling on cardiac MRI in patients with HER2 + early breast cancer 2 understand the mechanism of trastuzumab mediated cardiac toxicity by assessing for the presence of myocardial injury and apoptosis on serum biomarkers and cardiac MRI and 3 correlate cardiac biomarkers of myocyte injury and extra-cellular matrix remodeling with left ventricular remodeling on cardiac MRI in patients with HER2 + early breast cancer Cardiac toxicity as a result of cancer therapies is now recognized as a significant health problem of increasing prevalence To our knowledge MANTICORE will be the first randomized trial testing proven heart failure pharmacotherapy in the prevention of trastuzumab-mediated cardiotoxicity We expect the findings of this trial to provide important evidence in the development of guidelines for preventive therapy ClinicalTrialsgov NCT01016886\",\n",
            "}\n",
            "13423\n",
            "{\n",
            "  \"id\" : \"25624432\",\n",
            "  \"contents\" : \"Progression-free survival PFS in metastatic castration-resistant prostate cancer mCRPC trials has been inconsistently defined and poorly associated with overall survival OS A reproducible quantitative definition of radiographic PFS rPFS was tested for association with a coprimary end point of OS in a randomized trial of abiraterone in patients with mCRPC rPFS was defined as two new lesions on an 8-week bone scan plus two additional lesions on a confirmatory scan two new confirmed lesions on any scan 12 weeks after random assignment and/or progression in nodes or viscera on cross-sectional imaging or death rPFS was assessed by independent review at 15 % of deaths and by investigator review at 15 % and 40 % of deaths rPFS and OS association was evaluated by Spearman s correlation A total of 1088 patients were randomly assigned to abiraterone plus prednisone or prednisone alone At first interim analysis the hazard ratio HR by independent review was 043 95 % CI 035 to 052 P < 001 abiraterone plus prednisone median rPFS not estimable prednisone median rPFS 83 months Similar HRs were obtained by investigator review at the first two interim analyses HR 049 95 % CI 041 to 060 P < 001 and HR 053 95 % CI 045 to 062 P < 001 respectively validating the imaging data assay used Spearman s correlation coefficient between rPFS and OS was 072 rPFS was highly consistent and highly associated with OS providing initial prospective evidence on further developing rPFS as an intermediate end point in mCRPC trials\",\n",
            "}\n",
            "13424\n",
            "{\n",
            "  \"id\" : \"11369909\",\n",
            "  \"contents\" : \"Skin cancer is the most common form of cancer in the United States and one of the most preventable Prevention programs for children at outdoor recreation sites may influence not only the youth but the staff or caregivers as well By teaching children about sun protection staff may also change their sun protection behaviors We report on the impact of a childhood skin cancer prevention program SunSmart on staff at outdoor recreation sites where a child-focused intervention was conducted The intervention included staff training on-site activities delivered by staff distribution of sunscreen and the promotion of sun-safe environments It was hypothesized that by teaching children about sun protection staff would change their sun protection behaviors A randomized trial at 14 recreation sites n = 176 staff in Hawaii tested the efficacy of education only and education plus environmental changes compared with a control condition Results showed significant positive changes in knowledge sun protection habits norms and sun protection policies The education plus environment group was not superior to education alone Changes in staff behavior and attitudes are important for their own health as positive role models and for the dissemination of skin cancer control programs\",\n",
            "}\n",
            "13425\n",
            "{\n",
            "  \"id\" : \"21911313\",\n",
            "  \"contents\" : \"The goal of this study was to assess the effect of oral cryotherapy on the development of oral mucositis related to infusion of 5-fluorouracil 5-FU with leucovorin This study a randomized controlled trial with random assignments to the experimental and control groups was conducted with cancer patients The study included 60 patients 30 patients in the study group were instructed to hold ice cubes in their mouth shortly before during and shortly after infusion of 5-FU with leucovorin the 30 patients in the control group received routine care Oral mucositis in the patients was evaluated at 7 14 and 21 days after chemotherapy For analysis of data chi-square Fisher s tests were used p < 005 was accepted as statistically significant In the majority of patients receiving cryotherapy oral mucositis was not observed Grade 0 at 7 and 14 days Similarly incidence of Grades 1 2 and 3 oral mucositis in the experimental group was quite a bit lower when compared to the control group p < 005 On day 21 no statistically significant difference between the experimental and control groups was determined based on the development of oral mucositis p > 005 We found that oral cryotherapy has a significant contribution to the protection of oral health by reducing mucositis score according to the WHO mucositis scale especially on the 7th and 14th days Nurses awareness of how cryotherapy can affect patients and options for resolving problems will enable them to provide a higher standard of individualized care\",\n",
            "}\n",
            "13426\n",
            "{\n",
            "  \"id\" : \"17085656\",\n",
            "  \"contents\" : \"The combination of radiotherapy and good quality surgery reduces local recurrence rate for rectal cancer patients This study assesses the prognostic value of both intrinsic and radiotherapy-induced apoptosis and evaluates the relevance of radiotherapy for outcome of rectal cancer patients Tumor samples 1198 were available from the Dutch Total Mesorectal Excision trial in which rectal cancer patients were treated with standardized surgery and randomized for preoperative short-term radiotherapy or not Tumor samples were obtained at time of surgery Tissue microarrays were constructed and stained with the active caspase-specific M30 antibody to determine the amount of apoptotic epithelial tumor cells Nonirradiated patients with a negative circumferential margin displaying lower than median levels of apoptosis developed more local recurrences 105 % versus 61 % P = 006 and more rapidly after surgery than patients with high intrinsic apoptosis in their tumors median time to recurrence 130 versus 213 months P = 004 In multivariate analysis intrinsic apoptosis was an independent predictor for the development of local recurrences hazard ratio 20 P = 005 Radiotherapy increased apoptosis level 11 versus 23 apoptotic cells/mm2 tumor epithelium P < 0001 but this apoptosis did not influence patients prognosis Rectal cancer patients with low intrinsic apoptosis will benefit from radiotherapy with respect to the development of local recurrences Because apoptosis is an inherent characteristic of tumors patients who do not need radiotherapy may be selected based on the apoptotic index of the primary tumor\",\n",
            "}\n",
            "13427\n",
            "{\n",
            "  \"id\" : \"16990670\",\n",
            "  \"contents\" : \"To retrospectively determine if the use of a computer-aided detection CAD system can improve the performance of single reading of screening mammograms to match that of double reading in the United Kingdom Local research ethics committee approval was obtained informed consent was not required This study included a sample of 10 267 mammograms obtained in women aged 50 years or older who underwent routine screening at one of two breast screening centers in 1996 Mammograms that were double read in 1996 were randomly allocated to be re-read by eight different radiologists using CAD The cancer detection and recall rates from double reading and single reading with CAD were compared Statistical significance and confidence intervals were calculated with the McNemar test to account for the matched nature of the data Single reading with CAD led to a cancer detection rate that was significantly P = 02 higher than that achieved with double reading 65 % more cancers were detected by means of single reading with CAD than by means of double reading However the recall rate was higher for single reading with CAD than for double reading 86 % vs 65 % respectively P < 001 This was equivalent to relative increases of 15 % and 32 % in the cancer detection and recall rates respectively Single reading with CAD leads to an improved cancer detection rate and an increased recall rate\",\n",
            "}\n",
            "13428\n",
            "{\n",
            "  \"id\" : \"19704064\",\n",
            "  \"contents\" : \"To assess whether six courses of paclitaxel are effective as consolidation treatment in patients with advanced epithelial ovarian cancer who are in complete response after first-line paclitaxel/platinum-based chemotherapy Patients with stages IIb to IV disease in clinical or pathologic complete response after six courses of paclitaxel/platinum-based chemotherapy were randomly allocated to either observation ie control or six courses of paclitaxel 175 mg/m 2 every 3 weeks ie maintenance Two hundred patients were randomly assigned from March 1999 to July 2006 Because of the low accrual rate an unplanned interim analysis of futility according to the Bayesian approach was performed Grade 2 or greater motor neurotoxicity and sensory neurotoxicity were reported in 113 % and 280 % of the paclitaxel-arm patients respectively After a median follow-up of 435 months 107 patients 53 % had experienced relapse and 48 patients 24 % had died Two-year progression-free survival rates were 54 % 95 % CI 43 % to 64 % and 59 % 95 % CI 49 % to 69 % P = not significant in the control and maintenance arms respectively Corresponding 2-year overall survival rates were 90 % 95 % CI 84 % to 97 % and 87 % 95 % CI 80 % to 94 % P = not significant respectively The Cox model showed that residual disease after initial surgery macroscopic v no macroscopic residuum hazard ratio [ HR ] 191 95 % CI 121 to 303 and stage IIIc to IV v others HR 310 95 % CI 113 to 848 were independent prognostic factors for progression-free survival whereas the treatment arm maintenance v control had no prognostic relevance A consolidation treatment with six cycles of paclitaxel does not prolong progression-free survival or overall survival in patients in complete response after first-line paclitaxel/platinum-based regimens\",\n",
            "}\n",
            "13429\n",
            "{\n",
            "  \"id\" : \"20421817\",\n",
            "  \"contents\" : \"To compare the response rates and safety profiles of two investigational chemotherapies that were delivered concurrently with whole-brain radiotherapy in a population of patients with chemonaive non-small cell lung cancer Eligible patients included those presenting with brain metastases belonging to the Recursive Partitioning Analysis of prognostic factors from the Radiation Therapy Oncology groups II or III who were not able to undergo surgery or stereotactic radiotherapy Other main eligibility criteria were age < 75 years and Eastern Cooperative Oncology Group performance status = 0 to 2 The study design was as follows all patients received whole-brain radiotherapy in three split courses of 18 gy/10 fractions They were randomly 11 assigned to regimen A consisting of a triplet cisplatin-vinorelbine-ifosfomide or to regimen B consisting of high-dose single-drug ifosfamide In both groups chemotherapy was delivered on a 4-week cycle for three courses Each course was delivered concurrently with radiotherapy Brain and other tumor lesion assessments were performed in both groups at the end of the three courses RECIST Neurologic symptoms were evaluated quantitatively at each step of the treatment program All analyses were carried out in an intention to treat basis and statistical tests were two sided Seventy patients were randomly allocated into groups A n = 37 and B n = 33 With regards to the whole lesions overall response rates did not significantly differ between the groups group A 459 % group B 333 % chi 2 p = 028 When brain-target lesions were separately analyzed respective response rates were 595 % and 485 % chi 2 p = 0053 Febrile neutropenia was more frequently observed in the former group n = 19 5429 % than in the latter n = 12 3636 % p = 013 and a similar difference was also observed regarding documented infections Red blood cell transfusions and readmission for antibiotic infusions significantly affected more patients in group A than in group BThe longitudinal evaluation of neurologic symptoms by means of Generalized Estimating Equation slightly improved during the treatment program and there was no difference between the groups Median overall survival did not significantly differ between the two groups months [ 95 % confidence interval ] 85 [ 64-10 8 ] and 57 [ 46-11 9 ] in groups A B respectively p = 082 In the Cox model a high neuron-specific enolase serum level was the only significant prognostic determinant Both regimens were active and induced a high rate of response particularly for brain-target lesions Myelotoxicity jeopardizes the acceptability of both regimens Despite such an aggressive approach none of the regimens suggested a putative overall improvement of outcome in this poor prognosis presentation of metastatic non-small cell lung cancer The search for alternative therapies to chemotherapy such as targeted therapy is urgently warranted in this setting\",\n",
            "}\n",
            "13430\n",
            "{\n",
            "  \"id\" : \"24642620\",\n",
            "  \"contents\" : \"Our previous laboratory and clinical data suggested that one mechanism underlying the development of platinum resistance in ovarian cancer is the acquisition of DNA methylation We therefore tested the hypothesis that the DNA hypomethylating agent 5-aza-2 - deoxycytodine decitabine can reverse resistance to carboplatin in women with relapsed ovarian cancer Patients progressing 6-12 months after previous platinum therapy were randomised to decitabine on day 1 and carboplatin AUC 6 on day 8 every 28 days or carboplatin alone The primary objective was response rate in patients with methylated hMLH1 tumour DNA in plasma After a pre-defined interim analysis the study closed due to lack of efficacy and poor treatment deliverability in 15 patients treated with the combination Responses by GCIG criteria were 9 out of 14 vs 3 out of 15 and by RECIST were 6 out of 13 vs 1 out of 12 for carboplatin and carboplatin/decitabine respectively Grade 3/4 neutropenia was more common with the combination 60 % vs 154 % as was G2/3 carboplatin hypersensitivity 47 % vs 21 % With this schedule the addition of decitabine appears to reduce rather than increase the efficacy of carboplatin in partially platinum-sensitive ovarian cancer and is difficult to deliver Patient-selection strategies different schedules and other demethylating agents should be considered in future combination studies\",\n",
            "}\n",
            "13431\n",
            "{\n",
            "  \"id\" : \"15721417\",\n",
            "  \"contents\" : \"To retrospectively analyze data from a previously reported randomized trial of either pelvic radiation RT or RT + chemotherapy CT in patients undergoing radical hysterectomy and pelvic lymphadenectomy with positive pelvic lymph nodes parametrial involvement or surgical margins to explore associations between RT + CT and to investigate histopathologic and clinical factors which might be predictive of recurrence Histopathologic sections from biopsies and hysterectomies and clinical data were reviewed from patients with stage IA2 IB or IIA cervical cancer treated with RT or RT + CT cisplatin 70 mg/m2 plus fluorouracil 1000 mg/m2 every 3 weeks for four cycles A univariate analysis was performed because the relatively small sample size limited the interpretation of a multivariate analysis Of the 268 enrolled women 243 RT = 116 RT + CT = 127 were evaluable The beneficial effect of adjuvant CT was not strongly associated with patient age histological type or tumor grade The prognostic significance of histological type tumor size number of positive nodes and parametrial extension in the RT group was less apparent when CT was added The absolute improvement in 5-year survival for adjuvant CT in patients with tumors < or = 2 cm was only 5 % 77 % versus 82 % while for those with tumors > 2 cm it was 19 % 58 % versus 77 % Similarly the absolute 5-year survival benefit was less evident among patients with one nodal metastasis 79 % versus 83 % than when at least two nodes were positive 55 % versus 75 % In this exploratory hypothesis-generating analysis adding CT to RT after radical hysterectomy appears to provide a smaller absolute benefit when only one node is positive or when the tumor size is < 2 cm Further study of the role of CT after radical hysterectomy in patients with a low risk of recurrence may be warranted\",\n",
            "}\n",
            "13432\n",
            "{\n",
            "  \"id\" : \"1997835\",\n",
            "  \"contents\" : \"Radiation therapy as an adjunct to surgery for rectal cancer has been shown to reduce local recurrence but has not improved survival In a previous study combined radiation and chemotherapy improved survival significantly as compared with surgery alone but not as compared with adjuvant radiation which many regard as standard therapy We designed a combination regimen to optimize the contribution of chemotherapy decrease recurrence and improve survival as compared with adjuvant radiation alone Two hundred four patients with rectal carcinoma that was either deeply invasive or metastatic to regional lymph nodes were randomly assigned to postoperative radiation alone 4500 to 5040 cGy or to radiation plus fluorouracil which was both preceded and followed by a cycle of systemic therapy with fluorouracil plus semustine methyl-CCNU After a median follow-up of more than seven years the combined therapy had reduced the recurrence of rectal cancer by 34 percent P = 00016 95 percent confidence interval 12 to 50 percent Initial local recurrence was reduced by 46 percent P = 0036 95 percent confidence interval 2 to 70 percent and distant metastasis by 37 percent P = 0011 95 percent confidence interval 9 to 57 percent In addition combined therapy reduced the rate of cancer-related deaths by 36 percent P = 00071 95 percent confidence interval 14 to 53 percent and the overall death rate by 29 percent P = 0025 95 percent confidence interval 7 to 45 percent Its acute toxic effects included nausea vomiting diarrhea leukopenia and thrombocytopenia These effects were seldom severe Severe delayed treatment-related reactions usually small-bowel obstruction requiring surgery occurred in 67 percent of all patients receiving radiation and the frequencies of these complications were comparable in both treatment groups The combination of postoperative local therapy with radiation plus fluorouracil and systemic therapy with a fluorouracil-based regimen significantly and substantively improves the results of therapy for rectal carcinoma with a poor prognosis as compared with postoperative radiation alone\",\n",
            "}\n",
            "13433\n",
            "{\n",
            "  \"id\" : \"17507633\",\n",
            "  \"contents\" : \"To evaluate the cardiovascular risk profile of a subset of patients with early-stage breast cancer treated with adjuvant taxane-anthracycline-containing chemotherapy and/or trastuzumab Herceptin Twenty-six patients with breast cancer mean 20 months postchemotherapy and 10 healthy age-matched women were studied We measured 14 metabolic and vascular established cardiovascular disease CVD risk factors body mass index cardiorespiratory fitness and left ventricular systolic function All assessments were done within a 14-day period Cardiac abnormalities were suggested by left ventricular ejection fraction LVEF < 50 % in 8 % of patients LVEF remained > 10 % below pretreatment values in 38 % whereas 50 % presented with resting sinus tachycardia Brain natriuretic peptide was significantly elevated in 40 % of patients and was correlated with LVEF r = -072 P = or < 0001 For the majority of CVD risk factors similar proportions of patients and controls 35-60 % were classified as undesirable A significantly higher proportion of patients were classified with low cardiorespiratory fitness 46 % versus 0 % P < 001 being overweight/obese 72 % versus 50 % P < 005 and having resting sinus tachycardia 50 % versus 0 % P < 001 compared with controls Cardiorespiratory fitness and body mass index were correlated with CVD risk factors r = -064 to 063 P < 005 r = -063 to 067 P < 005 respectively Exploratory analyses revealed several differences between CVD risk factors based on chemotherapy regimen Breast cancer survivors treated with adjuvant chemotherapy are at a higher risk of developing late-occurring CVD than age-matched controls due to direct and indirect treatment-related toxicity\",\n",
            "}\n",
            "13434\n",
            "{\n",
            "  \"id\" : \"20421153\",\n",
            "  \"contents\" : \"To assess the impact of dose escalation of radiotherapy on quality of life QoL in prostate cancer patients Three hundred prostate cancer patients participating in the Dutch randomized trial CKTO 69-10 comparing 68 Gy with 78 Gy were the subject of this analysis These patients filled out the SF-36 QoL questionnaire before radiotherapy baseline and 6 12 24 and 36 months thereafter Changes in QoL over time of 10 points were considered clinically relevant Repeated-measures regression analyses were applied to estimate and test the QoL changes over time the differences between the two arms and for association with a number of covariates At 3-year follow-up the summary score physical health was 732 for the 68-Gy arm vs 716 for the 78-Gy arm p = 081 and the summary score mental health was 767 for the 68-Gy arm vs 761 for the 78-Gy arm p = 097 Statistically significant p < 001 deterioration in QoL scores over time was registered in both arms in six scales The deterioration over time was more pronounced in the high-dose arm for most scales However clinically relevant deterioration > 10 points was seen for only two scales None of the tested covariates were significantly correlated with QoL scores Dose escalation did not result in significant deterioration of QoL in prostate cancer patients In both randomization arms statistically significant decreases in QoL scores over time were seen in six scales The deterioration of QoL was more pronounced in the physical than in the mental health domain and in some scales more in the high - than in the low-dose arm but the differences between arms were not statistically significant\",\n",
            "}\n",
            "13435\n",
            "{\n",
            "  \"id\" : \"12648685\",\n",
            "  \"contents\" : \"Axillary lymph node dissection for staging and local control of nodal disease is an integral part of breast cancer therapy Lymphorrea is a serious and disabling complication of axillary lymphadenectomy but no effective therapy is currently available Octreotide is a hormone with general antisecretory effects that has been used to control lymphorrhea in thoracic duct injury and after radical neck dissection The aim of the study we describe in this article was to determine whether octreotide has a role in the treatment of post axillary lymphadenectomy lymphorrhea This is a prospective randomized controlled trial Two hundred sixty-one consecutive patients with various stages of breast cancer who underwent axillary lymph node dissection were randomized and followed for 7 years The treatment group received 01 mg octreotide subcutaneously three times a day for 5 days starting on the first postoperative day while the control group received no treatment Of the 261 patients undergoing axillary node dissection 136 were assigned to the control group and 125 composed the treatment group The control group and the treatment group were evaluated for amount and duration of lymphorrhea as well as inflammatory and infectious complications In the control group the mean quantity + / - standard deviation of lymphorrhea was 946 + / - 19 cc per day and the average duration was 167 + / - 30 days In comparison the mean quantity of lymphorrhea in the treatment group was 654 + / - 211 cc p < 00001 per day and the average duration was 71 + / - 29 days p < 00001 We did not find an important difference in the number of infectious complication or hematomas formation between the study groups Octreotide can be used successfully for the treatment of post-axillary dissection lymphorrea and potentially in the prevention of post-axillary lymph node dissection lymphosarcoma since the amount and duration of lymphorrhea in this setting are known to be important risk factors for its development Potentially octreotide might be used in similar situations where lymphorrhea is detrimental such as peripheral vascular surgery and regional lymph node dissection for melanoma\",\n",
            "}\n",
            "13436\n",
            "{\n",
            "  \"id\" : \"15634526\",\n",
            "  \"contents\" : \"To explore high effective and low toxic chemotherapeutic regimens in the treatment of non-small-cell lung cancer NSCLC A total of 126 patients with advanced NSCLC Stage III IV were randomly divided into two groups high dose impulsion chemotherapy group HDIC group and low dose density chemotherapy group LDDC group with 54 patients in HDIC group who received paclitaxel 135-175 mg/m2 on day 1 DDP 80-100 mg/m2 on day 1 and BCNU 125 mg given for brain metastasis on days 1-3 in a 4-6 weeks cycle Seventy-two patients in LDDC group were given paclitaxel 60-80 mg/m2 on day 1 DDP 40-80 mg/m2 on day 1 repeated weekly and BCNU 125 mg given for brain metastasis with an interval of 2 weeks in a 4-6 weeks cycle Antiemetic agent and fluid were administered routinely in HDIC group whereas LDDC group was given antiemetic agent only Of 157 courses in HDIC group an average of 29 courses per patient CR 3 PR 23 SD 17 and PD 11 were observed The effective remission rate was 481 % the median effective remission period was 45 months and the 1-year survival rate was 463 % Of 184 courses in LDDC group an average of 26 courses per patient CR 9 PR 30 SD 24 and PD 9 were observed The effective remission rate was 542 % the median effective remission period was 6 months and the 1-year survival rate was 569 % The effective remission rate and the 1-year survival rate were higher in HDIC group than those in LDDC group but there was no statistical difference between the two groups P > 005 Severe toxicity was higher in HDIC group than in LDDC group Two patients in HDIC group died of treatment-related complications 37 % Quality of life was better in LDDC group 708 % than in HDIC group 519 % When comparing with high dose impulsion low dose density regimen of paclitaxel plus cisplatin is more effective and better tolerated with improvement of quality of patients life in the treatment of NSCLC due to its low dose and short interval duration\",\n",
            "}\n",
            "13437\n",
            "{\n",
            "  \"id\" : \"23362174\",\n",
            "  \"contents\" : \"The use of pressor drugs after microsurgical free tissue transfer remains controversial because of potential vasoconstrictor effects on the free flap Noninvasive monitoring of free flaps with laser Doppler flowmetry may provide further information regarding the local regulation of blood flow in the flap tissues during pressor infusions This study evaluated the effects of four commonly used pressor agents Twenty four patients 25 data sets undergoing head and neck cancer resection and free flap reconstruction were recruited Epinephrine norepinephrine dopexamine and dobutamine were infused in a random order at four infusion rates after surgery with free flap and control area deltoid region laser Doppler skin blood flow monitoring Frequency analysis of the Doppler waveform was performed utilizing the time period immediately before the first drug infusion for each patient as baseline At baseline there was less power at the 0002-0 6 Hz frequency in the flap compared with control tissue consistent with surgical denervation At maximum epinephrine infusion rates the control of blood flow moved toward ie proportion of power increased in the lower frequencies as smooth muscle mediated myogenic control began to dominate blood flow an effect most marked with norepinephrine Dobutamine and dopexamine had little effect on control of blood flow Denervation of free flap tissue is demonstrable using spectral analysis of laser Doppler blood flow signals With norepinephrine the control of blood flow shifts toward low frequency vasomotion where blood flow depends mostly on average blood pressure making it potentially the most suitable agent following free tissue transfer\",\n",
            "}\n",
            "13438\n",
            "{\n",
            "  \"id\" : \"19242921\",\n",
            "  \"contents\" : \"Evidence of the benefits of exercise for those treated for cancer has led to exercise interventions for this population Some have questioned whether cancer patients offered a home-based intervention adhere to the exercise prescribed We examined exercise adherence in a randomized controlled trial of a 12-week home-based exercise trial for breast cancer patients Three adherence outcomes were examined minutes of exercise participation/week number of steps taken during planned exercise/week and whether the participant met her weekly exercise goal Predictors of adherence eg demographic and medical variables Transtheoretical Model variables history of exercise were examined Findings indicate that participants significantly increased their minutes of exercise and steps taken during planned exercise from Week 1 to 12 The percentage of participants achieving exercise goals was highest in the first few weeks Exercise self-efficacy significantly predicted each adherence outcome Baseline PA predicted mean exercise session steps over the 12 weeks Adherence to a home-based exercise intervention for breast cancer patients changes over time and may be related to baseline levels of exercise self-efficacy\",\n",
            "}\n",
            "13439\n",
            "{\n",
            "  \"id\" : \"22502704\",\n",
            "  \"contents\" : \"Caveolin-1 CAV-1 encoding the structural component of cellular caveolae is a suggested tumor suppressor gene involved in cell signalling Aberrant promoter methylation of CAV-1 is associated with inactivation of expression We previously observed CAV-1 mutations in breast cancers and therefore devised this study to examine the hypermethylation status of the promoter region of CAV-1 with reference to breast cancer progression and development Hypermethylation status of CAV-1 was analyzed by methylation specific PCR Loss of expression of the CAV-1 gene was further evaluated by semi-quantitative rt-PCR 28/130 215 % breast cancer cases showed promoter hypermethylation with reduced CAV-1 expression levels when compared with adjacent normal breast tissue CAV-1 gene hypermethylation was significantly related to menopausal status histopathological grade and age The rationale of our study is that CAV-1 gene is transcriptionally repressed in breast cancer cells due to hypermethylation Our results reveal that promoter hypermethylation and loss of expression of the CAV-1 gene is an important alternative mechanism for inactivation of CAV-1 leading to complete gene silencing\",\n",
            "}\n",
            "13440\n",
            "{\n",
            "  \"id\" : \"20850152\",\n",
            "  \"contents\" : \"We assessed the impact that improved detection of nonmuscle invasive bladder cancer with hexaminolevulinate fluorescence cystoscopy may have on early recurrence rates This prospective randomized study enrolled 814 patients suspected of having bladder cancer at increased risk for recurrence All patients underwent white light cystoscopy and mapping of lesions followed by transurethral resection of the bladder when indicated Patients in the fluorescence group also received intravesical hexaminolevulinate solution at least 1 hour before cystoscopy to induce fluorescence of cancerous lesions and underwent additional inspection with blue light before and after transurethral resection of the bladder Adjuvant intravesical therapy was based on risk Followup cystoscopy at 3 6 and 9 months was conducted with white light Detection was performed as a within patient comparison in the fluorescence group In this group 286 patients had at least 1 Ta or T1 tumor intent to treat In 47 patients 16 % at least 1 of the tumors was seen only with fluorescence p = 0001 During the 9-month followup intent to treat there was tumor recurrence in 128 of 271 patients 47 % in the fluorescence group and 157 of 280 56 % in the white light group p = 0026 The relative reduction in recurrence rate was 16 % Hexaminolevulinate fluorescence cystoscopy significantly improves the detection of Ta and T1 lesions and significantly reduces the rate of tumor recurrence at 9 months\",\n",
            "}\n",
            "13441\n",
            "{\n",
            "  \"id\" : \"22704366\",\n",
            "  \"contents\" : \"Metastatic disease is a major morbidity of prostate cancer PCa Its prevention is an important goal To assess the effect of screening for PCa on the incidence of metastatic disease in a randomized trial Data were available for 76813 men aged 55-69 yr coming from four centers of the European Randomized Study of Screening for Prostate Cancer ERSPC The presence of metastatic disease was evaluated by imaging or by prostate-specific antigen PSA values > 100 ng/ml at diagnosis and during follow-up Regular screening based on serum PSA measurements was offered to 36270 men randomized to the screening arm while no screening was provided to the 40543 men in the control arm The Nelson-Aalen technique and Poisson regression were used to calculate cumulative incidence and rate ratios of M + disease After a median follow-up of 12 yr 666 men with M + PCa were detected 256 in the screening arm and 410 in the control arm resulting in cumulative incidence of 067 % and 086 % per 1000 men respectively p < 0001 This finding translated into a relative reduction of 30 % hazard ratio [ HR ] 070 95 % confidence interval [ CI ] 060-0 82 p = 0001 in the intention-to-screen analysis and a 42 % p = 00001 reduction for men who were actually screened An absolute risk reduction of metastatic disease of 31 per 1000 men randomized 031 % was found A large discrepancy was seen when comparing the rates of M + detected at diagnosis and all M + cases that emerged during the total follow-up period a 50 % reduction HR 050 95 % CI 041-0 62 versus the 30 % reduction The main limitation is incomplete explanation of the lack of an effect of screening during follow-up PSA screening significantly reduces the risk of developing metastatic PCa However despite earlier diagnosis with screening certain men still progress and develop metastases The ERSPC trial is registered under number ISRCTN49127736\",\n",
            "}\n",
            "13442\n",
            "{\n",
            "  \"id\" : \"16111583\",\n",
            "  \"contents\" : \"To compare the rectal and prostatic radiation doses for a prospective series of 503 patients 44 of whom developed persistent rectal bleeding and 2 of whom developed rectal-prostatic fistulas The 503 patients were randomized and treated by implantation with 125I vs 103Pd alone n = 290 or to 103Pd with 20 Gy vs 44 Gy supplemental external beam radiotherapy n = 213 and treated at the Puget Sound Veterans Affairs Medical Center n = 227 Schiffler Cancer Center n = 242 or University of Washington n = 34 Patients were treated between September 1998 and October 2001 and had a minimum of 24 months of follow-up The patient groups were treated concurrently Treatment-related morbidity was monitored by mailed questionnaires using standard American Urological Association and Radiation Therapy Oncology Group criteria at 1 3 6 12 18 and 24 months Patients who reported Grade 1 or greater Radiation Therapy Oncology Group rectal morbidity were interviewed by telephone to clarify details regarding their rectal bleeding Those who reported persistent bleeding lasting for > 1 month were included as having Grade 2 toxicity Three of the patients with rectal bleeding required a colostomy two of whom developed a fistula No patient was lost to follow-up The rectal doses were defined as the rectal volume in cubic centimeters that received > 50 % 100 % 200 % or 300 % of the prescription dose The rectum was considered as a solid structure defined by the outer wall without attempting to differentiate the inner wall or contents Persistent rectal bleeding occurred in 44 of the 502 patients 32 of whom 73 % underwent confirmatory endoscopy In univariate analysis multiple parameters were associated with late rectal bleeding including all rectal brachytherapy indexes In multivariate analysis however only the rectal volume that received > 100 % of the dose was significantly predictive of bleeding Rectal fistulas occurred in 2 patients 04 % both of whom had received moderate rectal radiation doses and extensive intervention for rectal bleeding Partly on the basis of data from others and data presented here we believe that the incidence of rectal fistulas can be much lower than in our series High rectal radiation doses should be avoided a priori to minimize the likelihood of rectal bleeding and hence the likelihood that invasive procedures will be performed\",\n",
            "}\n",
            "13443\n",
            "{\n",
            "  \"id\" : \"24101048\",\n",
            "  \"contents\" : \"Radiation Therapy Oncology Group trial 0525 tested whether dose-intensifying temozolomide versus standard chemoradiotherapy improves overall survival OS or progression-free survival PFS in newly diagnosed glioblastoma Tests of neurocognitive function NCF and symptoms using the MD Anderson Symptom Inventory-Brain Tumor module MDASI-BT and of quality of life European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire [ EORTC QLQ ] - C30/BN20 examined the net clinical benefit NCB of therapy NCF tests Hopkins Verbal Learning Test-Revised Trail Making Test and Controlled Oral Word Association MDASI-BT and EORTC QLQ-C30 / BN20 were completed in a subset of patients Multivariate Cox proportional hazard regression modeling determined the prognostic value of baseline and early change from baseline to cycle 1 for OS and PFS Two-sample proportional test statistic was used to evaluate differences between treatments dose-dense v standard-dose on NCB measures from baseline to cycle 4 in stable patients Overall 182 patients participated in the study Baseline NCF tests and the physical functioning quality of life scale were associated with OS and PFS Baseline to cycle 1 in all NCB components were associated with OS and PFS There was greater deterioration in the dose-dense arm from baseline to cycle 4 in the Global Health and Motor Function subscales EORTC QLQ-C30 / BN20 as well as in overall symptom burden overall symptom interference and activity-related symptom interference subscales MDASI-BT There were no between-arm differences in NCF Longitudinal collection of NCB measures is feasible in cooperative group studies and provides an added dimension to standard outcome measures Greater adverse symptom burden and functional interference as well as decreased global health and motor function were observed in patients randomly assigned to the dose-dense arm Baseline and early change in NCB measures were associated with decreased rates of survival\",\n",
            "}\n",
            "13444\n",
            "{\n",
            "  \"id\" : \"21188380\",\n",
            "  \"contents\" : \"To evaluate the efficacy and safety of preoperative radiotherapy with capecitabine and mitomycin C in patients with locally advanced rectal cancer A prospective open-label non-randomized phase II study was performed on 49 patients with locally advanced rectal cancer Preoperative radiotherapy was conducted on linear accelerators 15 or 18MV with a tumor dose of 45Gy in 25 fractions over 5weeks combined with mitomycin C 7mg/m 2 on days 1 and 29 and oral capecitabine 825mg/m 2 twice daily on days 1-35 Surgery was performed 5-6weeks after the end of chemoradiation The primary study endpoint was histopathological complete regression rate pCR Dworak grade 4 Disease stage at diagnosis was T3 in 34 patients 69 % and T4 in 15 patients 31 % Positive lymph nodes were diagnosed in 28 patients 57 % Toxicity all grades was documented in 35 patients 71 % Grade 3 toxicities were radiation dermatitis 25 % diarrhea 2 % neutropenia 2 % and granulocytopenia 2 % No patient experienced grade 4 toxicity A pCR was seen in 8 16 % 95 % CI 9-29 % patients a major response was noted in 24 49 % patients and a minor response in 14 29 % patients R0 resection was performed in 46 patients 939 % and R1 in 3 patients 61 % Histopathological tumor downstaging was documented in 26 patients 53 % One-year disease-free survival was 933 % and 1-year survival was 977 % Preoperative chemoradiation with capecitabine and mitomycin C appeared to be effective with low toxicity in patients with locally advanced rectal cancer\",\n",
            "}\n",
            "13445\n",
            "{\n",
            "  \"id\" : \"23104212\",\n",
            "  \"contents\" : \"The prognostic potential of individual clinical and molecular parameters in stage II/III colon cancer has been investigated but a thorough multivariable assessment of their relative impact is missing Tumors from patients N = 1404 in the PETACC3 adjuvant chemotherapy trial were examined for BRAF and KRAS mutations microsatellite instability MSI chromosome 18q loss of heterozygosity 18qLOH and SMAD4 expression Their importance in predicting relapse-free survival RFS and overall survival OS was assessed by Kaplan-Meier analyses Cox regression models and recursive partitioning trees All statistical tests were two-sided MSI-high status and SMAD4 focal loss of expression were identified as independent prognostic factors with better RFS hazard ratio [ HR ] of recurrence = 054 95 % CI = 037 to 081 P = 003 and OS HR of death = 043 95 % CI = 027 to 070 P = 001 for MSI-high status and worse RFS HR = 147 95 % CI = 119 to 181 P < 001 and OS HR = 158 95 % CI = 123 to 201 P < 001 for SMAD4 loss 18qLOH did not have any prognostic value in RFS or OS Recursive partitioning identified refinements of TNM into new clinically interesting prognostic subgroups Notably T3N1 tumors with MSI-high status and retained SMAD4 expression had outcomes similar to stage II disease Concomitant assessment of molecular and clinical markers in multivariable analysis is essential to confirm or refute their independent prognostic value Including molecular markers with independent prognostic value might allow more accurate prediction of prognosis than TNM staging alone\",\n",
            "}\n",
            "13446\n",
            "{\n",
            "  \"id\" : \"8971064\",\n",
            "  \"contents\" : \"To determine whether a nutritional supplement of selenium will decrease the incidence of cancer A multicenter double-blind randomized placebo-controlled cancer prevention trial Seven dermatology clinics in the eastern United States A total of 1312 patients mean age 63 years range 18-80 years with a history of basal cell or squamous cell carcinomas of the skin were randomized from 1983 through 1991 Patients were treated for a mean SD of 45 28 years and had a total follow-up of 64 20 years Oral administration of 200 microg of selenium per day or placebo The primary end points for the trial were the incidences of basal and squamous cell carcinomas of the skin The secondary end points established in 1990 were all-cause mortality and total cancer mortality total cancer incidence and the incidences of lung prostate and colorectal cancers After a total follow-up of 8271 person-years selenium treatment did not significantly affect the incidence of basal cell or squamous cell skin cancer There were 377 new cases of basal cell skin cancer among patients in the selenium group and 350 cases among the control group relative risk [ RR ] 110 95 % confidence interval [ CI ] 095-1 28 and 218 new squamous cell skin cancers in the selenium group and 190 cases among the controls RR 114 95 % CI 093-1 39 Analysis of secondary end points revealed that compared with controls patients treated with selenium had a nonsignificant reduction in all-cause mortality 108 deaths in the selenium group and 129 deaths in the control group [ RR 083 95 % CI 063-1 08 ] and significant reductions in total cancer mortality 29 deaths in the selenium treatment group and 57 deaths in controls [ RR 050 95 % CI 031-0 80 ] total cancer incidence 77 cancers in the selenium group and 119 in controls [ RR 063 95 % CI 047-0 85 ] and incidences of lung colorectal and prostate cancers Primarily because of the apparent reductions in total cancer mortality and total cancer incidence in the selenium group the blinded phase of the trial was stopped early No cases of selenium toxicity occurred Selenium treatment did not protect against development of basal or squamous cell carcinomas of the skin However results from secondary end-point analyses support the hypothesis that supplemental selenium may reduce the incidence of and mortality from carcinomas of several sites These effects of selenium require confirmation in an independent trial of appropriate design before new public health recommendations regarding selenium supplementation can be made\",\n",
            "}\n",
            "13447\n",
            "{\n",
            "  \"id\" : \"25560809\",\n",
            "  \"contents\" : \"To report pre-specified and exploratory results on the effect of different surgical approaches on erectile function EF after nerve-sparing radical prostatectomy nsRP obtained from the multicentre randomised double-blind double-dummy REACTT trial of tadalafil once a day [ OaD ] or on-demand [ pro-re-nata PRN ] vs placebo Patients aged < 68years with normal preoperative EF who underwent nsRP for localised prostate cancer Gleason 7 prostate-specific antigen [ PSA ] < 10ng/mL were randomised after nsRP 111 to 9-month double-blind treatment with tadalafil 5mg OaD tadalafil 20mg PRN or placebo followed by 6-week drug-free washout and 3-month open-label OaD treatment all patients Recovery of EF was defined as an International Index of Erectile Function IIEF - EF domain score of 22 and normal orgasmic function was defined based on IIEF Question 10 Both parameters were analysed at the end of washout using logistic regression including terms for treatment country visit visit-by-treatment interaction age group nerve-sparing score perfect = 2 non-perfect > 2 and surgical approach open surgery robot-assisted laparoscopy conventional laparoscopy other Time to EF recovery was analysed post hoc with a Cox proportional-hazards model including terms for treatment age-group country surgical approach and surgery-by-treatment interaction Of 422 patients treated 189 underwent open surgery 115 robot-assisted laparoscopy 88 conventional laparoscopy and 30 surgery classified as other The odds of achieving EF recovery at the end of drug-free washout were about twice as high for the robot-assisted laparoscopy group compared with the open surgery group odds ratio 242 95 % confidence interval [ CI ] 124 472 P = 0029 Patients who underwent robot-assisted laparoscopy were significantly more likely to recover during double-blind treatment compared with patients who underwent open surgery hazard ratio 192 95 % CI 117 315 P = 0010 No favourable effect of conventional laparoscopy compared with open surgery could be seen These results may provide further insights into the role of surgery on EF recovery after nsRP However the trial was not designed for these analyses and further prospective studies are needed\",\n",
            "}\n",
            "13448\n",
            "{\n",
            "  \"id\" : \"11597802\",\n",
            "  \"contents\" : \"Acute rectal complications occur in the majority of patients receiving external-beam radiotherapy for carcinoma of the prostate Sucralfate has been proposed to reduce radiation-induced mucosal injury by forming a protective barrier on ulcer bases binding local growth factors and stimulating angiogenesis However there is conflicting clinical evidence as to whether sucralfate taken prophylactically during radiotherapy can ameliorate the symptoms of acute radiation proctitis A double-blind randomized trial was conducted at four Radiation Oncology Departments in Sydney Australia between February 1995 and June 1997 A total of 338 patients with clinically localized prostate cancer receiving small volume radiotherapy of whom 335 were evaluable were randomized to receive either 3 g of oral sucralfate suspension or placebo twice a day during radiotherapy Patients kept a daily record of their bowel symptoms and were graded according to the RTOG/EORTC acute toxicity criteria One hundred sixty-four patients received sucralfate and 171 received placebo Both groups were well balanced with regard to patient tumor treatment factors and baseline symptoms except that the placebo group had a significantly more liquid baseline stool consistency score p = 0004 Patients kept a daily diary of symptoms during radiotherapy After adjusting for baseline values there was no significant difference between the two groups with regard to stool frequency p = 041 consistency p = 020 flatus p = 025 mucus p = 054 and pain p = 073 However there was more bleeding in the sucralfate group with 64 % of patients noticing rectal bleeding compared with 47 % in the placebo group p = 0001 There was no significant difference between the two groups with respect to RTOG/EORTC acute toxicity p = 088 sucralfate 13 % 44 % 43 % and placebo 15 % 44 % 40 % for grade 0 1 and 2 respectively This study suggests that oral sucralfate taken prophylactically during radiotherapy does not ameliorate the symptoms of acute radiation proctitis and may increase acute bleeding The cause of the increased bleeding in the sucralfate group is unclear As the pathogenesis of acute and late reactions are different late follow-up which includes sigmoidoscopic evaluation is currently being performed on this cohort of patients\",\n",
            "}\n",
            "13449\n",
            "{\n",
            "  \"id\" : \"11118461\",\n",
            "  \"contents\" : \"Subcutaneous recombinant interleukin-2 rIL-2 and recombinant interferon alfa-2a rIFNalpha-2a have been used extensively in the treatment of metastatic renal cancer Most results coming from noncontrolled phase II trials showed inconsistent rates of response More recently the addition of fluorouracil FU was proposed to improve the efficacy of these regimens The role of a subcutaneous combination of rIL-2 and rIFNalpha-2a with or without FU was investigated Patients were randomly assigned to receive a combination of rIL-2 and rIFNalpha-2a at weeks 1 3 5 and 7 or the same combination together with a continuous infusion of FU at weeks 1 and 5 The major end points of this multicenter randomized trial were progression-free survival response rate and toxicity Overall survival was a secondary end point Tumor responses were reviewed by an independent committee Analysis of the results was performed on an intention-to-treat basis One hundred thirty-one patients were enrolled There was no difference in toxicity between the arms and no toxic death was observed One partial response was observed in arm A and five in arm B Progression-free survival did not differ between the arms and rates at 1 year were 12 % and 15 % in arms A and B respectively No statistically significant differences were detected in any end point The subcutaneous combination of rIL-2 and rIFNalpha-2a with or without FU does not benefit patients with metastatic renal carcinoma Neither of these regimens can be recommended as standard treatment The results of the subcutaneous cytokine regimen seem disappointing\",\n",
            "}\n",
            "13450\n",
            "{\n",
            "  \"id\" : \"16022917\",\n",
            "  \"contents\" : \"The objective of this trial was to compare two vinorelbine-based doublets with carboplatin CBDCA-VC or with gemcitabine VG in patients with stage IIIB-IV non-small cell lung cancer NSCLC A total of 316 patients with advanced NSCLC previously untreated were randomized to either vinorelbine 30 mg/m 2 D1 8 with carboplatin AUC 5 D1 VC or vinorelbine 25mg/m 2 with gemcitabine VG 1000 mg/m 2 both given D1 8 every 3 weeks The primary endpoint was response rate with secondary parameters being survival OS progression-free survival PFS tolerance and clinical benefit The median number of cycles was four in each arm with a total of 1268 cycles The objective response OR on intent-to-treat was 208 % in VC and 28 % in VG p = 015 Median PFS was 39 months in VC and 44 months mo in VG p = 018 Median survival was significantly longer p = 001 for VG with 115 mo compared to 86 mo in VC with 1 year survival at 489 and 344 % respectively Tolerance was better in the VG arm as compared to the VC patients Four toxic deaths were recorded in the VC group Clinical benefit response rate was 324 % compared to 409 % in 111 and 110 evaluable patients in VC and VG respectively VG compared to VC resulted in a similar overall response rate favourable median survival and a better toxicity profile For non-cisplatin-based chemotherapy VG is a useful alternative\",\n",
            "}\n",
            "13451\n",
            "{\n",
            "  \"id\" : \"17998547\",\n",
            "  \"contents\" : \"To identify factors that condition or moderate the impact of a previously described set of interventions on psychological and physical adjustment after diagnosis and treatment for early-stage breast cancer Younger women age < 51 years N = 252 with early-stage breast cancer within 2 months of having completed active nonhormonal adjuvant therapy were randomly assigned to a three-arm clinical trial consisting of a control arm an education arm and a nutrition arm Primary end points assessed before random assignment and 4 and 13 months later included mental functioning physical functioning and depressive symptoms Four types of moderator variables were identified including two sets reflecting psychosocial resources specifically personality factors and factors related to the person s social environment a set reflecting demographic variables and a set reflecting treatment and disease variables including comorbidities Psychosocial factors were more likely to moderate treatment effects than were demographic and disease-related factors but the moderating effects of these psychosocial factors were limited to patients receiving the nutrition intervention Patients with lower psychosocial resources benefited from the nutrition intervention whereas patients with a greater amount of psychosocial resources did not Future trials of this type should stratify by or select for the moderating variables identified here ie dispositional pessimism unmitigated communion and negative social interaction to establish more firmly their role in responses to psychosocial interventions Effort should also be made to collect data to inform the delivery of interventions to those who might benefit the most\",\n",
            "}\n",
            "13452\n",
            "{\n",
            "  \"id\" : \"20434400\",\n",
            "  \"contents\" : \"The optimum treatment for high-risk soft-tissue sarcoma STS in adults is unclear Regional hyperthermia concentrates the action of chemotherapy within the heated tumour region Phase 2 studies have shown that chemotherapy with regional hyperthermia improves local control compared with chemotherapy alone We designed a parallel-group randomised controlled trial to assess the safety and efficacy of regional hyperthermia with chemotherapy Patients were recruited to the trial between July 21 1997 and November 30 2006 at nine centres in Europe and North America Patients with localised high-risk STS > or = 5 cm Fdration Nationale des Centres de Lutte Contre le Cancer [ FNCLCC ] grade 2 or 3 deep to the fascia were randomly assigned to receive either neo-adjuvant chemotherapy consisting of etoposide ifosfamide and doxorubicin EIA alone or combined with regional hyperthermia EIA plus regional hyperthermia in addition to local therapy Local progression-free survival LPFS was the primary endpoint Efficacy analyses were done by intention to treat This trial is registered with ClinicalTrialsgov number NCT 00003052 341 patients were enrolled with 169 randomly assigned to EIA plus regional hyperthermia and 172 to EIA alone All patients were included in the analysis of the primary endpoint and 332 patients who received at least one cycle of chemotherapy were included in the safety analysis After a median follow-up of 34 months IQR 20-67 132 patients had local progression 56 EIA plus regional hyperthermia vs 76 EIA Patients were more likely to experience local progression or death in the EIA-alone group compared with the EIA plus regional hyperthermia group relative hazard [ RH ] 058 95 % CI 041-0 83 p = 0003 with an absolute difference in LPFS at 2 years of 15 % 95 % CI 6-26 76 % EIA plus regional hyperthermia vs 61 % EIA For disease-free survival the relative hazard was 070 95 % CI 054-0 92 p = 0011 for EIA plus regional hyperthermia compared with EIA alone The treatment response rate in the group that received regional hyperthermia was 288 % compared with 127 % in the group who received chemotherapy alone p = 0002 In a pre-specified per-protocol analysis of patients who completed EIA plus regional hyperthermia induction therapy compared with those who completed EIA alone overall survival was better in the combined therapy group HR 066 95 % CI 045-0 98 p = 0038 Leucopenia grade 3 or 4 was more frequent in the EIA plus regional hyperthermia group compared with the EIA-alone group 128 of 165 vs 106 of 167 p = 0005 Hyperthermia-related adverse events were pain bolus pressure and skin burn which were mild to moderate in 66 405 % 43 264 % and 29 patients 178 % and severe in seven 43 % eight 49 % and one patient 06 % respectively Two deaths were attributable to treatment in the combined treatment group and one death was attributable to treatment in the EIA-alone group To our knowledge this is the first randomised phase 3 trial to show that regional hyperthermia increases the benefit of chemotherapy Adding regional hyperthermia to chemotherapy is a new effective treatment strategy for patients with high-risk STS including STS with an abdominal or retroperitoneal location Deutsche Krebshilfe Helmholtz Association HGF European Organisation of Research and Treatment of Cancer EORTC European Society for Hyperthermic Oncology ESHO and US National Institute of Health NIH\",\n",
            "}\n",
            "13453\n",
            "{\n",
            "  \"id\" : \"24616307\",\n",
            "  \"contents\" : \"This study aimed to determine whether feeding back patient-reported outcomes PROs to providers and families of children with advanced cancer improves symptom distress and health-related quality of life HRQoL This study was a parallel multicentered pilot randomized controlled trial At most once per week children age 2 years old with advanced cancer or their parent completed the computer-based Pediatric Quality of Life and Evaluation of Symptoms Technology PediQUEST survey consisting of age - and respondent-adapted versions of the Memorial Symptom Assessment Scale MSAS Pediatric Quality of Life Inventory 40 Generic Core Scales PedsQL4 0 and an overall Sickness question In the intervention group n = 51 oncologists and families received printed reports summarizing PROs e-mails were sent to oncologists and subspecialists when predetermined scores were exceeded No feedback was provided in the control group n = 53 Primary outcomes included linear trends of MSAS PedsQL4 0 total and subscale scores and Sickness scores during 20 weeks of follow-up along with child parent and provider satisfaction with PediQUEST feedback Feedback did not significantly affect average MSAS PedsQL4 0 or Sickness score trends Post hoc subgroup analyses among children age 8 years who survived 20 weeks showed that feedback improved PedsQL4 0 emotional +81 95 % CI 18 to 144 and Sickness -82 95 % CI -142 to -22 scores PediQUEST reports were valued by children parents and providers and contributed at least sometimes to physician initiation of a psychosocial consult 56 % Although routine feedback of PROs did not significantly affect the child s symptoms or HRQoL changes were in expected directions and improvements observed in emotional HRQoL through exploratory analyses were encouraging Importantly children parents and providers value PRO feedback\",\n",
            "}\n",
            "13454\n",
            "{\n",
            "  \"id\" : \"12813842\",\n",
            "  \"contents\" : \"To examine uptake rates for screening sigmoidoscopy and whether offering prior consultation about sigmoidoscopic screening improves the uptake rate Patients between 505-60 5 years of age registered with one practice were identified and offered screening sigmoidoscopy Patients were randomly allocated to one of two groups The first group was sent an invitation to have screening sigmoidoscopy along with an explanatory leaflet The second group was sent the same invitation and leaflet but with an added option to discuss the test in the first instance with their general practitioner Response rates regarding reply to initial invitation and subsequent attendance for screening in the two groups were measured Urban General Practice Dundee Scotland UK The overall uptake rate was low at 24 % Significantly fewer people in the second group ie those with the option to discuss first replied to the initial invitation Assessing those who did reply there was no difference between the two groups in numbers who thereafter went on to attend for screening Only two percent of people took up the offer to find out more about the test from their general practitioner The offer of flexible sigmoidoscopy as a screening test for colorectal cancer generates little interest in this population at present and compliance rates are low The offer of prior consultation about the procedure with a patient s own general practitioner is not sufficient to generate interest These results highlight potential difficulties with the introduction of a mass screening program\",\n",
            "}\n",
            "13455\n",
            "{\n",
            "  \"id\" : \"9287967\",\n",
            "  \"contents\" : \"Octreotide was shown to inhibit the growth of colon cancer and to reduce serum concentrations of tumor growth factors such as insulin-like growth factor I IGF-I and epidermal growth factor EGF in vitro and in animal models Effects of octreotide on tumor cell kinetics and serum concentration of IGF-I and EGF in patients with colorectal cancer were evaluated Seventy-five patients with colorectal cancer were randomized to receive octreotide 200 micrograms daily in the 2 weeks before surgery or the usual medications Samples of tumor tissue were taken at endoscopy and at surgery [ 3H ] Thymidine labeling index and flow cytometry were used to assess the S-phase fraction In octreotide-treated patients plasma levels of IGF-I EGF and growth hormone were assessed before and after treatment There was a statistically significant reduction in the mean percentage of the S-phase fraction as a result of octreotide treatment measured by both [ 3H ] thymidine labeling index P = 0001 and flow cytometry P = 0001 No reduction in the percentage of the S-phase fraction was observed in the control group patients Serum values of IGF-I were significantly reduced by octreotide whereas EGF and growth hormone levels were not affected Octreotide reduces the proliferative activity of tumor cells and the serum IGF-I levels in patients with colorectal cancer This activity may have a role in the treatment of colorectal cancer\",\n",
            "}\n",
            "13456\n",
            "{\n",
            "  \"id\" : \"10974381\",\n",
            "  \"contents\" : \"A randomized controlled trial was designed to evaluate the clinical and quality of life QL outcomes of patients receiving endobronchial brachytherapy EBT or external beam radiotherapy XRT as a primary palliative treatment in advanced lung cancer Ninety-nine patients presenting de novo with lung cancer were randomized to receive EBT or XRT Eleven key symptoms or clinical signs were assessed by clinicians and patient ratings using self-assessment questionnaires were obtained at the same time The primary endpoints were a comparison of EBT and XRT for symptom relief and acute and late side-effects palliation and their effect on patients functional status and patient-rated QL outcomes A secondary objective was a comparison of clinician assessments with patient self-reported symptoms Both treatments produced good levels of symptom relief They were better for XRT at the expense of more acute morbidity Late side-effects were similar The functional status of patients was well maintained and changed similarly with time in both groups XRT gave a better duration of palliation Twenty-eight percent of XRT patients required EBT at a median time of 304 days whereas 51 % of EBT patients subsequently had XRT at a median of 125 days There was a significant modest gain in median survival with initial XRT 287 vs 250 days When clinician and patient assessments were compared doctors were found to underestimate the severity of breathlessness anorexia tiredness and nausea Fractionated XRT is preferred to EBT as an initial treatment in better performance patients because it provides better overall and more sustained palliation with fewer retreatments and a modest gain in survival time QL assessment is required in the evaluation of palliative treatments because clinicians frequently underestimate the incidence and severity of key symptoms\",\n",
            "}\n",
            "13457\n",
            "{\n",
            "  \"id\" : \"12479110\",\n",
            "  \"contents\" : \"Morphine is a widely used analgesic in management of postoperative pain with well documented analgesic properties and side effects Tramadol a new synthetic mu-opioid receptor agonist little is known about its efficacy and side effects when administered in epidural for pain relief The aim of this study is to compare the efficacy and side effects of tramadol morphine versus their combination for postoperative analgesia One hundred and twenty patients undergoing abdominal cancer surgery were assigned to one of three groups randomly tramadol group Group T n = 40 morphine group Group M n = 40 and combination of tramadol and morphine group group T + M n = 40 for postoperative analgesia In group T 12 mg/kg tramadol and 0125 % bupivacaine 100 ml were used for 48 h postoperative analgesia In group M 012 mg/kg morphine and 0125 % bupivacaine 100 ml and in group T + M 6 mg/kg tramadol 012 mg/kg morphine and 0125 % Bupivacaine 100 ml were used for postoperative analgesia Efficacy was assessed by comparing visual analogue scale VAS Bruggman comfort score BCS global satisfaction score GSS at several time points over 48 hours Possile adverse events were recorded There is no significant difference among three groups in VAS but in group T there are more patients whose VAS > 5 score than those in group M and group T + M BCS GSS in group T + M are lower than that in group T and group MThe occurrence rate of nausea and vomiting in group T + M are lower than that in group MThe efficacy of tramadol in epidural postoperative analgesia is similar to that of morphine but varied from patient to patient so the dose of tramadol should be individualized Combination of tramadol and morphine can provide effective analgesia for postoperative pain and cause little adverse effect especially reduce the occurrence rate of nausea and vomiting\",\n",
            "}\n",
            "13458\n",
            "{\n",
            "  \"id\" : \"20087643\",\n",
            "  \"contents\" : \"Many cancer patients continue to smoke post diagnosis yet there have been few smoking cessation trials for this population Depression which is prevalent among cancer patients may be a barrier to cessation This double-blind placebo-controlled trial randomized 246 cancer patients to 9 weeks of placebo or bupropion stratifying by pre-treatment depression symptoms In addition all patients received transdermal nicotine and behavioral counseling Primary outcomes were 7-day point-prevalence abstinence biochemically confirmed at the end of treatment Week 12 and at 6 months post quit day Week 27 Additional outcomes included withdrawal affect quality of life compliance and side effects There was no main effect of bupropion vs placebo on abstinence Odds Ratio [ OR ] = 136 95 % CI 038-4 81 p = 64 Patients with depression symptoms reported significantly lower abstinence rates vs patients without depression symptoms OR = 14 95 % CI 002-0 80 p = 03 Bupropion increased abstinence rates vs placebo more for participants with depression vs those without depression symptoms For patients with depression symptoms bupropion reduced withdrawal symptoms and improved quality of life vs placebo For patients with depression symptoms bupropion increases abstinence rates lowers withdrawal and increases quality of life However abstinence rates among patients with depression symptoms were low vs patients without depression symptoms who exhibited similar abstinence rates when treated with bupropion or transdermal nicotine and counseling alone These results can guide future smoking cessation intervention studies with cancer patients\",\n",
            "}\n",
            "13459\n",
            "{\n",
            "  \"id\" : \"23980044\",\n",
            "  \"contents\" : \"To investigate the effects of intermittent pneumatic compression IPC on coagulation function deep venous hemodynamics and prevention of deep venous thrombosis DVT of lower limbs in patients after rectal cancer resection A total of 120 patients undergoing rectal cancer resection were randomly divided into non-IPC group control group n = 60 and IPC group n = 60 The control group received routine treatment after resection and the IPC group received IPC based on the routine treatments Prothrombin time PT activated partial thromboplastin time APTT fibrinogen FIB international normalized ratio INR and volume of D-dimer D-D were detected before operation and 1 - 3 - 5 - and 7-day after operation Meanwhile blood flow velocity and caliber of external iliac vein femoral vein and popliteal vein were examined by color Doppler ultrasound then the average blood flow velocity and blood flow volume were calculated Incidence of lower limb DVT was 133 % 8/60 and 17 % 1/60 in control group and IPC group respectively with significant difference P < 005 The differences in PT APTT and INR were not significant P > 005 at 1-day after operation as compared to the preoperative level while FIB and D-D both increased P < 005 all presented no significant difference among the two groups P > 005 PT shortened gradually P < 005 APTT and INR did not change significantly P > 005 FIB and D-D increased gradually P < 005 and no significant differences were found between the two groups at the same time point all P > 005 All the above parameters in the control group were significantly lower than those in IPC group all P < 005 IPC can improve hemodynamics indexes of deep veins of lower limb in patients after rectal cancer operation and prevent the lower limb DVT IPC is a safe simple and convenient physical therapy\",\n",
            "}\n",
            "13460\n",
            "{\n",
            "  \"id\" : \"16630670\",\n",
            "  \"contents\" : \"Gemcitabine is one of the most active drugs against non-small-cell lung cancer NSCLC Preclinical data suggested that gemcitabine efficacy could be improved by increasing the dose or by increasing the infusion duration This study has been designed in order to explore two different approaches of gemcitabine dose intensification in patients with advanced NSCLC A total of 121 chemonaive patients with locally advanced or metastatic NSCLC not suitable for a platinum-based chemotherapy were randomly allocated to chemotherapy with gemcitabine 1500 mg/m2 on days 1 and 8 every 3 weeks by standard 30 min intravenous infusion arm A or gemcitabine 10 mg/m2/min for 150 min on days 1 and 8 every 3 weeks by intravenous infusion at fixed dose rate arm B One hundred and seventeen patients were fully analyzed No difference in response rate 161 % versus 99 % p = 028 median time to disease progression 4 months versus 45 months p = 034 median survival 98 months in both arms and 1-year survival 426 % versus 390 % p = 098 was detected in arms A and B respectively No treatment-related deaths occurred Main hematological toxicities were grade 3-4 neutropenia observed in 179 % of patients in group A and in 492 % of individuals in group B p = 00002 The incidence of febrile neutropenia was 33 % in arm A and 0 % in arm B p = 017 Grade 3-4 thrombocytopenia was more frequently observed in arm B patients 99 % versus 18 % p = 0057 Non-hematological toxicity was similar in both arms and consisted in grade 1-2 gastrointestinal toxicity observed in 482 % of patients in arm A and 410 % in arm BIntensification of standard doses or prolonged infusion schedule did not result in efficacy improvement Gemcitabine infusion duration does not warrant further investigation in patients with advanced NSCLC\",\n",
            "}\n",
            "13461\n",
            "{\n",
            "  \"id\" : \"24716835\",\n",
            "  \"contents\" : \"To evaluate the efficacy and safety of oral lubiprostone for relieving symptoms of opioid-induced constipation OIC in patients with chronic noncancer pain Prospective randomized double-blind placebo-controlled trial Seventy-nine US and Canadian centers Patients aged 18 years with OIC defined as < 3 spontaneous bowel movements SBMs per week Patients received lubiprostone 24 mcg or placebo twice daily for 12 weeks The primary endpoint was change from baseline in SBM frequency at week 8 Among randomized patients N = 418 lubiprostone N = 210 placebo N = 208 most completed the study lubiprostone 671 % placebo 697 % The safety and efficacy intent-to-treat populations included 414 lubiprostone N = 208 placebo N = 206 and 413 lubiprostone N = 209 placebo N = 204 patients respectively The mean standard deviation age was 504 109 years most patients were female 644 % and white 777 % Changes from baseline in SBM frequency rates were significantly higher at week 8 P = 0005 and overall P = 0004 in patients treated with lubiprostone compared with placebo Pairwise comparisons showed significantly greater overall improvement for abdominal discomfort P = 0047 straining P < 0001 constipation severity P = 0007 and stool consistency P < 0001 with lubiprostone compared with placebo Moreover patients rated the effectiveness of lubiprostone as significantly P < 005 better than placebo for 11 of 12 weeks The most common treatment-related adverse events AEs with lubiprostone and placebo were nausea 168 % vs 58 % respectively diarrhea 96 % vs 29 % and abdominal distention 82 % vs 24 % No lubiprostone-related serious AEs occurred Lubiprostone effectively relieved OIC and associated signs and symptoms and was well tolerated in patients with chronic noncancer pain http//clinicaltrialsgov/ct2/show/NCT00595946\",\n",
            "}\n",
            "13462\n",
            "{\n",
            "  \"id\" : \"17239942\",\n",
            "  \"contents\" : \"Aim of this study to improve the detection rate of parametrial sentinel nodes in patients with early cervical cancer by using a new dosage of blue dye in a randomized trial Standard labelling volume of 4 ml Patent Blue was compared to 2 ml Patent Blue diluted with 8 ml NaCl 09 % in 60 patients using a randomized protocol Tc-99 was not applied in any patient All patients underwent open lymphadenectomy In each arm 30 patients were enrolled Overall detection rate of sentinel nodes was 933 % Both groups did not differ with regard to patient s age BMI tumor stage number of lymph nodes harvested number of sentinel nodes detected and detection rate Significantly more patients with parametrial sentinel nodes were detected in the diluted protocol 370 % vs 103 % which is due to the lateral part of the cardinal ligament 296 % vs 69 % In our study overall detection of sentinel nodes using a dye was high The diluted solution of Patent Blue led to a higher detection rate of parametrial sentinel nodes These findings might help explain the discrepancy between the high reported rate of parametrial lymph nodes in anatomical studies compared with the low rates in clinical sentinel series\",\n",
            "}\n",
            "13463\n",
            "{\n",
            "  \"id\" : \"23612465\",\n",
            "  \"contents\" : \"Recruitment and nodule management are critical issues of lung cancer screening with low-dose computed tomography LDCT We report subjects compliance and results of LDCT screening and management protocol in the active arm of the ITALUNG trial Three thousand two hundred six smokers or former smokers invited by mail were randomized to receive four annual LDCT n = 1613 or usual care n = 1593 Management protocol included follow-up LDCT 2 - [ 18F ] fluoro-2-deoxy-D glucose positron emission tomography FDG-PET and CT-guided fine-needle aspiration biopsy FNAB One thousand four hundred six subjects 87 % underwent baseline LDCT and 1263 79 % completed four screening rounds LDCT was positive in 303 % of the subjects at baseline and 158 % subsequently Twenty-one lung tumors in 20 subjects 15 % detection were found at baseline and 20 lung tumors in 18 subjects 05 % detection in subsequent screening rounds Ten of 18 prevalent 55 % and 13 of 17 incident 76 % non-small-cell cancers were in stage I Interval growth enabled diagnosis of lung cancer in 16 subjects 42 % but at least one follow-up LDCT was obtained in 741 subjects 527 % over the screening period FDG-PET obtained in 65 % of subjects had 84 % sensitivity and 90 % specificity for malignant lesions FNAB obtained in 24 % of subjects showed 90 % sensitivity and 88 % specificity Positivity of both FDG-PET and FNAB invariably predicted malignancy Surgery for benign lesions was performed on four subjects 10 % of procedures but followed protocol violations on three subjects High-risk subjects recruited by mail who entered LDCT screening showed a high and stable compliance Efficacy of screening is however weakened by low detection rate and specificity Adhesion to management protocol might lessen surgery for benign lesions\",\n",
            "}\n",
            "13464\n",
            "{\n",
            "  \"id\" : \"22446022\",\n",
            "  \"contents\" : \"The CRYSTAL and OPUS randomised clinical trials demonstrated that adding cetuximab to first-line chemotherapy in patients with KRAS wild-type metastatic colorectal cancer mCRC significantly improved treatment outcome compared with chemotherapy alone The objective of this pooled analysis was to further investigate these findings in patients with KRAS wild-type tumours using extended survival data and following an enhancement in the ascertainment rate of KRAS and BRAF tumour mutation status from these studies Pooled individual patient data from each study were analysed for overall survival OS progression-free survival PFS and best overall response rate ORR in patients evaluable for KRAS and BRAF mutation status Treatment arms were compared according to mutation status using log-rank and Cochran-Mantel-Haenszel tests In 845 patients with KRAS wild-type tumours adding cetuximab to chemotherapy led to a significant improvement in OS hazard ratio [ HR ] 081 p = 00062 PFS HR 066 p < 0001 and ORR odds ratio 216 p < 00001 BRAF mutations were detected in 70/800 evaluable tumours No significant differences were found in outcome between the treatment groups in these patients Prognosis was worse in each treatment arm for patients with BRAF tumour mutations compared with those with BRAF wild-type tumours Analysis of pooled data from the CRYSTAL and OPUS studies confirms the consistency of the benefit obtained across all efficacy end-points from adding cetuximab to first-line chemotherapy in patients with KRAS wild-type mCRC BRAF mutation does not appear to be a predictive biomarker in this setting but is a marker of poor prognosis\",\n",
            "}\n",
            "13465\n",
            "{\n",
            "  \"id\" : \"20713879\",\n",
            "  \"contents\" : \"To evaluate the safety and efficacy of IMC-A12 a human monoclonal antibody mAb that blocks insulin-like growth factor receptor-1 IGF-1R as monotherapy or in combination with cetuximab in patients with metastatic refractory anti-epidermal growth factor receptor EGFR mAb colorectal cancer A randomized phase II study was performed in which patients in arm A received IMC-A12 10 mg/kg intravenously IV every 2 weeks while patients in arm B received this same dose of IMC-A12 plus cetuximab 500 mg/m 2 IV every 2 weeks Subsequently arm C same combination treatment as arm B was added to include patients who had disease control on a prior anti-EGFR mAb and wild-type KRAS tumors Archived pretreatment tumor tissue was obtained when possible for KRAS PIK3CA and BRAF genotyping and immunohistochemistry was obtained for pAKT as well as IGF-1R Overall 64 patients were treated median age 61 years range 40 to 84 years 23 patients in arm A 21 in arm B and 20 in arm C No antitumor activity was seen in the 23 patients treated with IMC-A12 monotherapy Of the 21 patients randomly assigned to IMC-A12 plus cetuximab one patient with KRAS wild type achieved a partial response with disease control lasting 65 months Arm C all patients with KRAS wild type however showed no additional antitumor activity Serious adverse events thought possibly related to IMC-A12 included a grade 2 infusion-related reaction 2 % one of 64 patients thrombocytopenia 2 % one of 64 patients grade 3 hyperglycemia 2 % one of 64 patients and grade 1 pyrexia 2 % one of 64 patients IMC-A12 alone or in combination with cetuximab was insufficient to warrant additional study in patients with colorectal cancer refractory to EGFR inhibitors\",\n",
            "}\n",
            "13466\n",
            "{\n",
            "  \"id\" : \"10561192\",\n",
            "  \"contents\" : \"To compare the toxicity and effects on hematologic recovery and circulating progenitor cell mobilization of three cytokine regimens administered after high-dose cyclophosphamide HD-CTX 6 g/m 2 given as the first step of a high-dose sequential chemotherapy Forty-eight patients with breast cancer or non-Hodgkin s lymphoma were randomized to receive granulocyte colony-stimulating factor G-CSF alone arm 1 granulocyte-macrophage colony-stimulating factor GM-CSF alone arm 2 or sequential interleukin-3 IL-3 and GM-CSF arm 3 Cytokines were administered as a single daily subcutaneous injection at a dose of 5 to 6 microg/kg/d Progenitor cells were evaluated in peripheral blood as well as in apheretic product as both CD34 + cells and granulocyte-macrophage colony-forming units CFU-GM Neutrophil recovery was faster in arm 1 as compared with arms 2 and 3 P < 0001 no significant differences were observed between arms 2 and 3 In arm 3 a moderate acceleration of platelet recovery was observed but it was statistically significant only as compared with arm 1 P = 028 The peak of CD34 + cells was hastened in a median of 2 days in arm 1 compared with arms 2 and 3 P = 0002 whereas the median peak value of CD34 + cells and CFU-GM was similar in the three patient groups Administration of IL-3 and GM-CSF resulted in more significant toxicity requiring pharmacologic treatment in 90 % of patients The three cytokine regimens administered after HD-CTX are comparably effective in reducing hematologic toxicity and mobilizing the hematopoietic progenitor cells G-CSF accelerates leukocyte recovery and progenitor mobilization Although G-CSF-treated patients have somewhat slower platelet recovery they definitely have fewer side effects\",\n",
            "}\n",
            "13467\n",
            "{\n",
            "  \"id\" : \"22251615\",\n",
            "  \"contents\" : \"The Livial Intervention Following Breast Cancer Efficacy Recurrence and Tolerability Endpoints LIBERATE Clinical http//Trialsgov number NCT00408863 a randomized placebo-controlled double-blind trial that demonstrated that tibolone Livial a tissue-selective hormone-replacement therapy HRT increased breast cancer BC recurrence HR 140 95 % CI 114 to 170 P = 0001 A subgroup of women was entered into a study of bone mineral density BMD Women with surgically excised primary BC T1-3 N0-2 M-0 within the last 5 years complaining of vasomotor symptoms were assigned to tibolone 25 mg daily or placebo treatment for a maximum of 5 years The BMD substudy enrolled 763 patients using dual-energy X-ray absorptiometry DXA scanning at baseline and at 2 years In the bone substudy 699 of 763 women were eligible 345 allocated to tibolone and 354 to placebo After undergoing DXA scans 300 43 % women had normal BMD 317 45 % osteopenia and 82 117 % osteoporosis Low body-mass index P < 0001 Asian race P < 0001 and late age at menarche P < 004 predicted low bone mass at baseline Tibolone increased BMD by 32 % at the lumbar spine and 29 % at the hip compared with placebo both P < 0001 The majority of fractures 55 % occurred in osteopenic patients Women with normal BMD had increased recurrence with tibolone 22 156 % of 141 compared with placebo 11 69 % of 159 P = 0016 whereas no increased BC recurrence was seen in women with low BMD 15 74 % of 204 taking tibolone versus 13 67 % of 195 taking placebo Tibolone is contraindicated after BC treatment as it increases BMD and BC recurrence Risk of BC recurrence was elevated in BC women with normal BMD compared with low who took tibolone\",\n",
            "}\n",
            "13468\n",
            "{\n",
            "  \"id\" : \"10750206\",\n",
            "  \"contents\" : \"The burden of cancer care in general practice is increasing Patient-held records may facilitate effective coordinated care but no randomised controlled trials of their use in cancer care have been conducted and concerns about possible negative effects remain To evaluate the use of a supplementary patient-held record in cancer care Six hundred and fifty radiotherapy outpatients with any form of cancer were randomised either to hold a supplementary record or to receive normal care It was explained to record holders that the supplementary record was intended to improve communication with health professionals and act as an aide memoire After three months patients satisfaction with communication and with participation in their own care were assessed Global health status emotional functioning and cognitive functioning were measured using the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire There were no significant differences between groups in any of the outcome measures Patients in both groups expressed a high level of satisfaction with communication and participation in their care Mean SD scores in the intervention and control groups were global health status 668 242 and 653 237 emotional functioning 750 246 and 774 228 cognitive functioning 845 210 and 840 213 A supplementary patient-held record for radiotherapy outpatients appears to have no effect on satisfaction with communication participation in care or quality of life\",\n",
            "}\n",
            "13469\n",
            "{\n",
            "  \"id\" : \"26045340\",\n",
            "  \"contents\" : \"Necitumumab is a second-generation recombinant human immunoglobulin G1 EGFR antibody In this study we aimed to compare treatment with necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone in patients with previously untreated stage IV squamous non-small-cell lung cancer We did this open-label randomised phase 3 study at 184 investigative sites in 26 countries Patients aged 18 years or older with histologically or cytologically confirmed stage IV squamous non-small-cell lung cancer with an Eastern Cooperative Oncology Group ECOG performance status of 0-2 and adequate organ function and who had not received previous chemotherapy for their disease were eligible for inclusion Enrolled patients were randomly assigned centrally 11 to a maximum of six 3-week cycles of gemcitabine and cisplastin chemotherapy with or without necitumumab according to a block randomisation scheme block size of four by a telephone-based interactive voice response system or interactive web response system Chemotherapy was gemcitabine 1250 mg/m 2 administered intravenously over 30 min on days 1 and 8 of a 3-week cycle and cisplatin 75 mg/m 2 administered intravenously over 120 min on day 1 of a 3-week cycle Necitumumab 800 mg administered intravenously over a minimum of 50 min on days 1 and 8 was continued after the end of chemotherapy until disease progression or intolerable toxic side-effects occurred Randomisation was stratified by ECOG performance status and geographical region Neither physicians nor patients were masked to group assignment because of the expected occurrence of acne-like rash -- a class effect of EGFR antibodies -- that would have unmasked most patients and investigators to treatment The primary endpoint was overall survival analysed by intention to treat We report the final clinical analysis This study is registered with ClinicalTrialsgov number NCT00981058 Between Jan 7 2010 and Feb 22 2012 we enrolled 1093 patients and randomly assigned them to receive necitumumab plus gemcitabine and cisplatin n = 545 or gemcitabine and cisplatin n = 548 Overall survival was significantly longer in the necitumumab plus gemcitabine and cisplatin group than in the gemcitabine and cisplatin alone group median 115 months [ 95 % CI 104-126 ] vs 99 months [ 89-111 ] stratified hazard ratio 084 [ 95 % CI 074-096 p = 001 ] In the necitumumab plus gemcitabine and cisplatin group the number of patients with at least one grade 3 or worse adverse event was higher 388 [ 72 % ] of 538 patients than in the gemcitabine and cisplatin group 333 [ 62 % ] of 541 as was the incidence of serious adverse events 257 [ 48 % ] of 538 patients vs 203 [ 38 % ] of 541 More patients in the necitumumab plus gemcitabine and cisplatin group had grade 3-4 hypomagnesaemia 47 [ 9 % ] of 538 patients in the necitumumab plus gemcitabine and cisplatin group vs six [ 1 % ] of 541 in the gemcitabine and cisplatin group and grade 3 rash 20 [ 4 % ] vs one [ < 1 % ] Including events related to disease progression adverse events with an outcome of death were reported for 66 12 % of 538 patients in the necitumumab plus gemcitabine and cisplatin group and 57 11 % of 541 patients in the gemcitabine and cisplatin group these were deemed to be related to study drugs in 15 3 % and ten 2 % patients respectively Overall we found that the safety profile of necitumumab plus gemcitabine and cisplatin was acceptable and in line with expectations Our findings show that the addition of necitumumab to gemcitabine and cisplatin chemotherapy improves overall survival in patients with advanced squamous non-small-cell lung cancer and represents a new first-line treatment option for this disease Eli Lilly and Company\",\n",
            "}\n",
            "13470\n",
            "{\n",
            "  \"id\" : \"22578920\",\n",
            "  \"contents\" : \"To prospectively test the hypothesis that end-fire transrectal ultrasound prostate biopsy probes have greater cancer detection rates than side-fire probes Retrospective studies have suggested that such probes might have greater cancer detection rates The present prospective randomized multicenter trial aimed to compare the prostate cancer detection rates of the end-fire versus side-fire probe configuration during transrectal ultrasound-guided 12-core prostate biopsy Patients were randomized according to age prostate-specific antigen level and prostate volume An interim analysis was planned after the inclusion of 300 patients At the interim analysis after the inclusion of 297 patients no differences were found in the mean prostate-specific antigen level P = 412 mean age P = 519 mean prostate volume P = 730 and positive digital rectal examination findings P = 295 The prostate cancer detection rate did not differ between the end-fire and side-fire probe 343 % vs 344 % P = 972 On multivariate analysis suspicious digital rectal examination findings relative risk 8185 P < 001 prostate-specific antigen level relative risk 1051 P = 041 and prostate volume relative risk 0973 P < 001 but not probe configuration relative risk 0942 P = 831 were independent predictive factors for the detection of prostate cancer The interim analysis committee suggested that because no difference of 5 absolute percent was achieved after 300 patients no additional recruitment was necessary Therefore the study was terminated early The results of the present study have shown that the transrectal ultrasound probe configuration does not affect the prostate cancer detection rate during transrectal ultrasound-guided prostate biopsy\",\n",
            "}\n",
            "13471\n",
            "{\n",
            "  \"id\" : \"19236277\",\n",
            "  \"contents\" : \"We evaluated the impact of a quadrivalent human papillomavirus HPV vaccine on infection and cervical disease related to 10 nonvaccine HPV types 31 33 35 39 45 51 52 56 58 and 59 associated with > 20 % of cervical cancers The population evaluated included HPV-naive women and women with preexisting HPV infection and/or HPV-related disease at enrollment Phase 3 efficacy studies enrolled 17622 women aged 16-26 years Subjects underwent cervicovaginal sampling and Pap testing on day 1 and then at 6-12-month intervals for up to 4 years HPV typing was performed on samples from enrollment and follow-up visits including samples obtained for diagnosis or treatment of HPV-related disease All subjects who received 1 dose and returned for follow-up were included Vaccination reduced the rate of HPV-31 / 33/45/52 / 58 infection by 177 % 95 % confidence interval [ CI ] 51 % to 287 % and of cervical intraepithelial neoplasia CIN 1-3 or adenocarcinoma in situ AIS by 188 % 95 % CI 74 % to 289 % Vaccination also reduced the rate of HPV-31 / 58/59-related CIN1-3 / AIS by 260 % 95 % CI 67 % to 414 % 281 % 95 % CI 53 % to 456 % and 376 % 95 % CI 60 % to 591 % respectively Although a modest reduction in HPV-31 / 33/45/52 / 58-related CIN2 or worse was observed the estimated reduction was not statistically significant These cross-protection results complement the vaccine s prophylactic efficacy against disease associated with HPV-6 -11 -16 and -18 Long-term monitoring of vaccinated populations are needed to fully ascertain the population-based impact and public health significance of these findings ClinicalTrialsgov identifiers NCT00092521 NCT00092534 and NCT00092482\",\n",
            "}\n",
            "13472\n",
            "{\n",
            "  \"id\" : \"21123311\",\n",
            "  \"contents\" : \"A post hoc analysis of Asian men in the REDUCE study was conducted to investigate whether the outcomes were in line with those of the overall population REDUCE was a 4-year international multicenter randomized double-blind placebo-controlled parallel-group study Inclusion criteria were men between 50 and 75 years of age a serum prostate-specific antigen level of 25-10 0 ng/ml 50-60 years or 30-10 0 ng/ml > 60 years and a single negative prostate biopsy 6-12 cores within 6 months before enrollment The primary endpoint was biopsy-detectable prostate cancer This post hoc analysis included subjects who were recorded as Asian A total of 134 Asians including 57 Japanese were randomized to the study treatment During the study period the incidence of prostate cancer in the placebo and dutasteride groups was 196 % 11/56 and 93 % 5/54 respectively relative risk reduction 54 % 95 % confidence intervals -27 to 83 % P = 012 in the Asian subpopulation Fewer tumors with the Gleason scores of 7-10 and 8-10 were detected among dutasteride-treated men Although the incidences of drug-related sexual adverse events were higher in the dutasteride group only in rare occasions did they lead to drug discontinuation The incidence of prostate cancer in the dutasteride group was lower than that in the placebo group although the difference was not significant These results paralleled those for the overall population and support the value of dutasteride for prostate cancer risk reduction in Asian men with an increased risk of prostate cancer\",\n",
            "}\n",
            "13473\n",
            "{\n",
            "  \"id\" : \"21299153\",\n",
            "  \"contents\" : \"This prospective randomized study compared the patency and effective drainage rate of two stents with different materials but similar design in the palliation of inoperable malignant biliary obstruction A total of 49 patients 26 women mean age 7255 + / - 1075 years range 48-91 years with obstructive jaundice due to inoperable malignant stricture of the distal common bile duct without previous drainage procedure were randomly assigned to receive 10F Double Layer DLS n = 24 or 10F Tannenbaum TAN n = 25 biliary plastic stent The diagnosis included pancreatic cancer n = 33 cholangiocarcinoma n = 8 ampullary cancer n = 7 and metastatic lymphadenopathy n = 1 The duration of stent patency the effective drainage and the adverse events were analyzed Stent placement was successful in all patients with minor complications The overall median patency rates between the two groups did not differ 1075 days for DLS group vs 101 days for TAN group p = 0066 Effective drainage rate at the end of second week was 958 % for DLS group and 96 % for TAN group p = 100 Proximal stent migration occurred in one patient with TAN stent The present study demonstrated that both DLS and TAN stents are comparable in terms of placement overall stent patency and complications\",\n",
            "}\n",
            "13474\n",
            "{\n",
            "  \"id\" : \"20727735\",\n",
            "  \"contents\" : \"Statins have for long been considered to play a potential role in anticancer treatment based upon their ability to inhibit the mevalonate synthesis pathway This randomised phase II trial compared the efficacy and safety of pravastatin added to epirubicin cisplatin and capecitabine ECC versus ECC+P in patients with advanced gastric carcinoma Patients were randomised to receive up to six cycles of 3-weekly ECC with or without pravastatin 40 mg once daily from day 1 of the first cycle until day 21 of the last cycle Primary end-point was progression-free rate at 6 months PFR 6 months Secondary end-points were response rate RR progression-free survival PFS overall survival OS and safety For early termination in case of futility a two-stage design was applied P 0 = 50 % P 1 = 70 % = 005 = 010 Thirty patients were enrolled PFR 6 months was 6/14 patients 428 % in the ECC+P arm and 7/15 patients 467 % in the control arm and therefore the study was terminated after the first stage In the ECC and ECC+P arm RR was 7/15 467 % and 5/15 333 % median PFS was 5 and 6 months and median OS was 6 and 8 months respectively Toxicity data showed no significant differences although there was a trend towards more gastrointestinal side-effects such as diarrhoea and stomatitis in the ECC+P arm In this randomised phase II trial the addition of pravastatin to ECC did not improve outcome in patients with advanced gastric cancer Therefore further testing of this combination in a randomised phase III trial can not be recommended\",\n",
            "}\n",
            "13475\n",
            "{\n",
            "  \"id\" : \"10562681\",\n",
            "  \"contents\" : \"Either modified type III radical neck dissection MRND or lateral neck dissections LNDs are considered valid treatments for patients with laryngeal carcinoma with clinically negative neck findings N0 The object of this prospective study was to compare complications neck recurrences and survival results of elective MRND and LND on the management of laryngeal cancer patients Patients and Methods This prospective randomized study began in 1990 and patient accrual was closed on December 1993 A total of 132 patients was included in the trial All patients had previously untreated T2-T4 N0 M0 supraglottic or transglottic squamous cell carcinoma No significant imbalance was found between groups with respect to demographic clinical pathologic and other therapeutic variables Seventy-one patients were given MRNDs 13 bilateral and 61 were given LNDs 18 bilateral The false-negative rate was 26 % and most positive nodes were sited at levels II and III Complications and period of hospitalization were similar in both groups There were 6 ipsilateral neck recurrences 4 in the MRND group and 2 in the LND group The 5-year actuarial survival calculated by Kaplan-Meier method was 723 % in the MRND group and 624 % in the LND group log-rank test p = 312 The rate of false-negative nodes in supraglottic and transglottic carcinomas was 26 % and most positive nodes were at levels II and III The rates of 5-year overall survival neck recurrences and complications were similar in both groups These results confirm the efficacy of lateral neck dissection in the elective treatment of the neck in patients with supraglottic and transglottic carcinomas\",\n",
            "}\n",
            "13476\n",
            "{\n",
            "  \"id\" : \"21335509\",\n",
            "  \"contents\" : \"Lung cancer and tuberculosis cause significant morbidity and mortality worldwide Tuberculosis may increase lung cancer risk through substantial and prolonged pulmonary inflammation However prospective data on tuberculosis and lung cancer risk are limited Our study included 29133 Finnish male smokers followed prospectively in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study 1985-2005 Lung cancers were identified through linkage with the Finnish Cancer Registry and hospital-treated tuberculosis cases were ascertained from the National Hospital Discharge Register We assessed the association between tuberculosis and lung cancer risk with proportional hazards regression models adjusting for age and cigarette smoking Forty-four lung cancer cases occurred among 273 men with tuberculosis incidence rate = 1786 per 100000 person-years Tuberculosis was associated with a two-fold elevation in lung cancer risk HR = 197 95 % CI = 146-2 65 with significant associations observed for both incident HR = 205 95 % CI = 142-2 96 and prevalent tuberculosis HR = 182 95 % CI = 109-3 02 Lung cancer risk was greatest in the 2-year window after tuberculosis diagnosis HR = 501 95 % CI = 296-8 48 but remained elevated at longer latencies HR = 153 95 % CI = 107-2 20 Though tuberculosis was associated with an increased risk of squamous cell carcinoma HR = 371 adenocarcinoma HR = 171 small cell carcinoma HR = 172 and lung cancer of other HR = 123 and unknown histologies HR = 135 only the association for squamous cell carcinoma was statistically significant Tuberculosis is associated with increased lung cancer risk in male smokers Our results add to the growing body of evidence implicating chronic inflammation and pulmonary scarring in the etiology of lung cancer\",\n",
            "}\n",
            "13477\n",
            "{\n",
            "  \"id\" : \"9051085\",\n",
            "  \"contents\" : \"Several studies suggest that perioperative blood transfusion is a major independent risk factor for postoperative bacterial infections Transfusion-induced immunosuppression is thought to mediate this effect In a randomized clinical trial comprising 697 patients with colorectal cancer the relationship between two types of red cell components buffy coat-depleted packed red cells and white cell-reduced [ filtered ] packed red cells and postoperative bacterial infections was analyzed Both types of red cells appeared to be associated with a greater incidence of postoperative infection than was no transfusion 39 vs 24 % p < 001 A dose-response relationship could be demonstrated the corrected relative risk was 16 for 1 to 3 units of red cells and 36 for more than 3 units Multivariate analyses identified the transfusion of red cells and tumor location as the only significant independent risk factors for postoperative bacterial infection Because allogeneic white cells plasma microaggregates citrate and platelets could be ruled out as risk factors for transfusion-associated postoperative infections it is hypothesized that the transfusion of red cells is a potentially detrimental factor that transiently impairs the clearance of bacteria by phagocytic cells\",\n",
            "}\n",
            "13478\n",
            "{\n",
            "  \"id\" : \"24708851\",\n",
            "  \"contents\" : \"Physical therapy treatment of patients with lymphedema includes treatment based on the principles of Complete Decongestive Therapy CDT CDT consists of the following components skin care manual lymphatic drainage bandaging and exercises The scientific evidence regarding what type of treatment is most effective is sparse The objective of this study is to investigate whether CDT is equally effective if it includes manual lymphatic drainage or not in the treatment of arm lymphedema among patients with breast cancer A randomized single-blind equivalence trial A total of 160 breast cancer patients with arm lymphedema will be recruited from 3 hospitals and randomized into one of two treatment groups A Complete Decongestive Therapy including manual drainage or B Complete Decongestive Therapy without manual lymphatic drainage The intervention period will be approximately 4 weeks followed by a 6 month follow-up period 7 months from baseline Primary outcome variable the percentage volume reduction of lymphedema % from baseline to 7 months Secondary outcome variables Differences from baseline to week 4 and from week 4 to month 7 in circumference of the arm cm body weight kg patient sensation of heaviness scale range 0-10 patient sensation of tension scale range 0-10 and quality of life EQ-5D-5 L-questionnaire All measurements are standardized and will be performed before randomization after 4 weeks and after 7 months This randomized controlled study seeks to provide data on an effective treatment for patients with breast cancer related arm lymphedema and which at the same time causes minimal patient inconvenience ClinicalTrialsgov Identifier NCT02015897\",\n",
            "}\n",
            "13479\n",
            "{\n",
            "  \"id\" : \"19150955\",\n",
            "  \"contents\" : \"Colorectal cancer CRC is biologically a heterogeneous disease which may affect response to drug therapy We investigated the correlation of genome-wide DNA copy number profiles of primary tumors with response to systemic chemotherapy in advanced CRC DNA was isolated from formaldehyde-fixed paraffin-embedded primary tumors of 32 patients with advanced CRC which were selected based on either a good response n = 16 or a poor response n = 16 to first-line combination therapy with capecitabine and irinotecan High-resolution DNA copy number profiles were obtained by means of 30 K oligonucleotide-based array comparative genomic hybridization aCGH Unsupervised hierarchical cluster analysis of the aCGH data revealed two clusters of 19 and 13 tumors respectively and cluster membership showed a significant correlation with response status P < 003 The nonresponders had fewer chromosomal alterations compared with the responders in particular less losses were found P < 003 Most prominent differences between the two groups were losses of regions 18p1132-q11 2 P < 002 and 18q121-q23 P < 003 which were more frequently observed in responders Differences in DNA copy number profiles of primary CRCs are associated with response to systemic combination chemotherapy with capecitabine and irinotecan Responders overall had more chromosomal alterations especially loss of chromosome 18\",\n",
            "}\n",
            "13480\n",
            "{\n",
            "  \"id\" : \"17714128\",\n",
            "  \"contents\" : \"Regular thorough skin self-examination TSSE has potential for detecting melanoma early and reducing melanoma mortality We sought to model factors associated with skin self-examination SSE and test whether efficacy and attitudes about SSE mediated these relationships The Check-It-Out project is a randomized trial of an intervention to encourage TSSE 2126 participants were recruited from the practices of primary care physicians Correlates predicting baseline TSSE included demographic variables skin cancer risk physician advice to examine skin and appropriate conditions for conducting SSE availability of partner to assist with self-examination availability of a wall mirror and use of contact lenses/glasses Those who were given physician advice had a wall mirror and had a partner available were more likely to perform TSSE We identified the factors associated with concurrent TSSE practices Further research is needed to determine if these same factors predict future behaviour Our findings may not be applicable in geographical areas other than our recruitment area Primary care providers can recommend SSE and provide materials to increase ability to recognize skin problems Providing instructions and aids for conducting TSSE may increase self-efficacy\",\n",
            "}\n",
            "13481\n",
            "{\n",
            "  \"id\" : \"21067912\",\n",
            "  \"contents\" : \"Peripheral sensory neurotoxicity is a frequent and potentially debilitating side effect of oxaliplatin treatment Calcium and magnesium Ca/Mg infusions are frequently used to prevent this toxicity However concerns about a negative impact of Ca/Mg infusions on outcome have been raised We retrospectively assessed the effect of Ca/Mg infusions on the incidence of neurotoxicity and on clinical outcome in advanced colorectal cancer ACC patients treated in the phase III CAIRO2 study Seven hundred and fifty five previously untreated ACC patients were randomised between treatment with capecitabine oxaliplatin and bevacizumab or the same combination with the addition of cetuximab Patients were retrospectively divided into two groups patients in the Ca/Mg + group received Ca/Mg at least during their first treatment cycle and patients in the Ca/Mg - group did not Seven hundred and thirty two patients were evaluable for this analysis The Ca/Mg + group consisted of 551 patients the Ca/Mg - group consisted of 181 patients The incidence of all grade neurotoxicity in the Ca/Mg + group and the Ca/Mg - group was 85 % and 92 % respectively p = 002 and the incidence of grade 2 neurotoxicity was 40 % and 45 % respectively p = 022 The median PFS in the Ca/Mg + versus Ca/Mg - group was 101 versus 107 months p = 092 the median OS was 198 versus 207 months p = 010 and the response rate was 431 % versus 50 % p = 011 respectively In this largest retrospective analysis to date we observed that Ca/Mg infusions significantly reduced all grade oxaliplatin-related neurotoxicity Ca/Mg infusions did not affect the clinical efficacy of treatment\",\n",
            "}\n",
            "13482\n",
            "{\n",
            "  \"id\" : \"10458212\",\n",
            "  \"contents\" : \"We conducted a randomized trial to compare gemcitabine-cisplatin with etoposide-cisplatin in the treatment of patients with advanced non-small-cell lung cancer NSCLC The primary end point of the comparison was response rate A total of 135 chemotherapy-naive patients with advanced NSCLC were randomized to receive either gemcitabine 1250 mg/m2 intravenously IV days 1 and 8 or etoposide 100 mg/m2 IV days 1 to 3 along with cisplatin 100 mg/m2 IV day 1 Both treatments were administered in 21-day cycles One hundred thirty-three patients were included in the intent-to-treat analysis of response The response rate externally validated for patients given gemcitabine-cisplatin was superior to that for patients given etoposide-cisplatin 406 % v 219 % P = 02 This superior response rate was associated with a significant delay in time to disease progression 69 months v 43 months P = 01 without an impairment in quality of life QOL There was no statistically significant difference in survival time between both arms 87 months for gemcitabine-cisplatin v 72 months for etoposide-cisplatin P = 18 The overall toxicity profile for both combinations of drugs was similar Nausea and vomiting were reported more frequently in the gemcitabine arm than in the etoposide arm However the difference was not significant Gemcitabine-cisplatin produced less grade 3 alopecia 13 % v 51 % and less grade 4 neutropenia 28 % v 56 % but more grade 3 and 4 thrombocytopenia 56 % v 13 % than did etoposide-cisplatin However there were no thrombocytopenia-related complications in the gemcitabine arm Compared with etoposide-cisplatin gemcitabine-cisplatin provides a significantly higher response rate and a delay in disease progression without impairing QOL in patients with advanced NSCLC\",\n",
            "}\n",
            "13483\n",
            "{\n",
            "  \"id\" : \"22162577\",\n",
            "  \"contents\" : \"Adipokines are linked to obesity and insulin sensitivity and have recently been related to breast cancer risk and prognosis We investigated the associations of plasma leptin and adiponectin with mammographic density and disease status and assessed their prognostic effect on recurrence-free survival in premenopausal women at risk for breast cancer We measured circulating lipids insulin-like growth factor 1 glucose insulin and insulin sensitivity calculated by homeostasis model assessment [ HOMA ] index leptin adiponectin and leptin-to-adiponectin ratio in 235 premenopausal women with pT1mic/pT1a breast cancer n = 21 intraepithelial neoplasia n = 160 or 5-year Gail risk of 13 % or greater n = 54 who participated in a 2 2 trial of low-dose tamoxifen fenretinide both agents or placebo over a 2-year period At baseline adiponectin levels were directly associated with mammographic density and HDL cholesterol and negatively associated with leptin leptin-to-adiponectin ratio body mass index BMI and HOMA index Median adiponectin levels were lower in affected than in unaffected women P = 006 After a median of 72 years and total of 57 breast neoplastic events there was a 12 % reduction in the risk of breast neoplastic events per unit increase of adiponectin adjusted hazard ratio 088 95 % CI 081 to 096 P = 03 There was no interaction between treatment and adiponectin levels Low adiponectin levels are associated with a history of prior intraepithelial neoplasia or pT1mic/pT1a breast cancer and higher risk of second breast neoplastic events in premenopausal women The associations are independent of BMI mammographic density and treatment Our findings support the role of adiponectin as a potential target for premenopausal breast cancer prevention and treatment\",\n",
            "}\n",
            "13484\n",
            "{\n",
            "  \"id\" : \"11689582\",\n",
            "  \"contents\" : \"We investigated tumor - and patient-related features that might influence the response to perioperative chemotherapy PeCT compared with no adjuvant therapy for patients with node-negative breast cancer A total of 1275 patients were randomized to either no adjuvant treatment 427 patients or PeCT 848 patients The following variables thought to have prognostic significance were evaluated grade tumor size estrogen ER and progesterone receptor PgR content absent low 1 to 9 fmol/mg cytosol protein or positive > or = 10 fmol/mg cytosol protein c-erbB-2 overexpression menopausal status and age Cox proportional hazards regression models were used to assess the relative influence of these factors to predict the effect of PeCT on disease-free survival DFS Median follow-up was 135 years The 10-year DFS percentage for 692 premenopausal patients did not significantly differ between the PeCT and no-adjuvant-treatment groups 61 % and 59 % respectively relative risk [ RR ] 095 95 % confidence interval [ CI ] 075 to 120 P = 70 No predictive factors were identified For 583 postmenopausal patients 10-year DFS percentages for the groups were 63 % and 58 % respectively RR 075 95 % CI 058 to 093 P = 03 The absence of expression of ER PgR or both ER and PgR was the most important factor predicting improved outcome with PeCT among postmenopausal patients The 10-year DFS percentages were 85 % and 53 % for the steroid hormone receptor-absent cohort of treated and untreated patients respectively RR 018 95 % CI 006 to 049 P = 0009 The role of PeCT should be explored for patients whose primary tumors do not express steroid hormone receptors because it is likely that early initiation of treatment is exclusively relevant for such patients\",\n",
            "}\n",
            "13485\n",
            "{\n",
            "  \"id\" : \"15262126\",\n",
            "  \"contents\" : \"To evaluate response rates progression-free survival PFS overall survival OS and toxicity of two high-dose chemotherapy regimens with stem cell rescue used to treat patients with recurrent or persistent stage III/IV ovarian cancer with the goal of taking one forward into a Phase III comparison with conventional therapy Patients under 65 with clinically or pathologically persistent disease after initial chemotherapy or those relapsing > 6 months after a complete remission CR were randomized to CMC carboplatin 1500 mg/m 2 mitoxantrone 75 mg/m 2 and cyclophosphamide 120 mg/kg ] or CTC [ cisplatin 165 mg/m 2 thiotepa 600 mg/m 2 and cyclophosphamide 5625 mg/m 2 ] with stem cell rescue Of 67 randomized the 32 and 26 eligible in the CMC and CTC arms were matched including age median 49 maximum tumor diameter and disease status at transplant Low-risk disease maximum diameter disease < or = 05 cm and platinum sensitivity was demonstrated in only approximately one-half of the patients There were two treatment-related deaths in each arm The median PFS was 13 and 8 months respectively for the CMC and CTC arms The median OS was 29 and 22 months for the CMC and CTC arms In a multivariate analysis of PFS normal CA125 at transplant and CR to primary therapy were significant for OS normal CA125 and platinum sensitivity were significant The CMC regimen was the superior regimen However few patients were long-term progression-free survivors A clinical CR to primary therapy and a normal CA125 seen in a minority of patients were requirements for a favorable outcome\",\n",
            "}\n",
            "13486\n",
            "{\n",
            "  \"id\" : \"14508838\",\n",
            "  \"contents\" : \"It has been hypothesized that people in lower socioeconomic groups have worse outcomes because they present with advanced-stage cancers or receive inadequate treatment The authors investigated this hypothesis by using education level as a proxy for socioeconomic status in patients treated on Radiation Therapy Oncology Group RTOG Protocol 90-03 RTOG 90-03 was a Phase III randomized trial investigating four different radiation fractionation schedules in the treatment of locally advanced head and neck carcinomas Overall survival and locoregional control rates were analyzed by education level as measured by patient response on the demographic form at study entry A significant difference was observed in the distribution of patients by education level between the standard fractionated radiation treatment arm and the hyperfractionated radiation treatment arm More patients in the standard fractionated treatment arm had a higher education level P = 0018 Patients attending college had highly and significantly better overall survival and locoregional control than the other groups combined P = 00056 and P = 0025 respectively from Cox proportional hazards models stratified by assigned treatment with educational level T classification N classification Karnofsky performance status primary site and race Multivariate analysis revealed that education level was significant for predicting both overall survival and locoregional control when comparing attended college/technical school compared with all other education levels Patients attending college or technical school had improved overall survival and locoregional control These differences can not be explained by differences in tumor stage or treatment Poorer overall health or lack of support systems contributing to these results needs to be investigated further\",\n",
            "}\n",
            "13487\n",
            "{\n",
            "  \"id\" : \"19690306\",\n",
            "  \"contents\" : \"There are few randomized controlled trials on the effectiveness of palliative care interventions to improve the care of patients with advanced cancer To determine the effect of a nursing-led intervention on quality of life symptom intensity mood and resource use in patients with advanced cancer Randomized controlled trial conducted from November 2003 through May 2008 of 322 patients with advanced cancer in a rural National Cancer Institute-designated comprehensive cancer center in New Hampshire and affiliated outreach clinics and a VA medical center in Vermont A multicomponent psychoeducational intervention Project ENABLE [ Educate Nurture Advise Before Life Ends ] conducted by advanced practice nurses consisting of 4 weekly educational sessions and monthly follow-up sessions until death or study completion n = 161 vs usual care n = 161 Quality of life was measured by the Functional Assessment of Chronic Illness Therapy for Palliative Care score range 0-184 Symptom intensity was measured by the Edmonton Symptom Assessment Scale score range 0-900 Mood was measured by the Center for Epidemiological Studies Depression Scale range 0-60 These measures were assessed at baseline 1 month and every 3 months until death or study completion Intensity of service was measured as the number of days in the hospital and in the intensive care unit ICU and the number of emergency department visits recorded in the electronic medical record A total of 322 participants with cancer of the gastrointestinal tract 41 % 67 in the usual care group vs 66 in the intervention group lung 36 % 58 vs 59 genitourinary tract 12 % 20 vs 19 and breast 10 % 16 vs 17 were randomized The estimated treatment effects intervention minus usual care for all participants were a mean SE of 46 2 for quality of life P = 02 -278 15 for symptom intensity P = 06 and -18 081 for depressed mood P = 02 The estimated treatment effects in participants who died during the study were a mean SE of 86 36 for quality of life P = 02 -242 205 for symptom intensity P = 24 and -27 12 for depressed mood P = 03 Intensity of service did not differ between the 2 groups Compared with participants receiving usual oncology care those receiving a nurse-led palliative care-focused intervention addressing physical psychosocial and care coordination provided concurrently with oncology care had higher scores for quality of life and mood but did not have improvements in symptom intensity scores or reduced days in the hospital or ICU or emergency department visits clinicaltrialsgov Identifier NCT00253383\",\n",
            "}\n",
            "13488\n",
            "{\n",
            "  \"id\" : \"20186830\",\n",
            "  \"contents\" : \"The Danish Breast Cancer Cooperative Group DBCG 77B trial examined the relative efficacy of levamisole single-agent oral cyclophosphamide and the classic combination of cyclophosphamide methotrexate and 5-fluorouracil CMF against no adjuvant systemic therapy in high-risk breast cancer patients The authors report the results from that trial after a potential follow-up of 25 years Between 1977 and 1983 1146 premenopausal patients who had tumors > 5 cm or positive axillary lymph nodes were assigned randomly to 1 of 4 options no systemic therapy levamisole 5 mg weekly for 48 weeks the levamisole arm oral cyclophosphamide 130 mg/m 2 on Days 1 through 14 every 4 weeks for 12 cycles the C arm or oral cyclophosphamide 80 mg/m 2 on Days 1 through 14 plus methotrexate 30 mg/m 2 and fluorouracil 500 mg/m 2 intravenously on Days 1 and 8 every 4 weeks for 12 cycles the CMF arm The 10-year invasive disease-free survival IDFS rate was 386 % in the control arm compared with 555 % in the C arm 488 % in the CMF arm and 352 % in the levamisole arm Compared with the control arm the hazard ratio for an IDFS event was 062 in the C arm P = 001 and 070 in the CMF arm P = 01 The hazard ratio for death was 070 in both the C arm P = 02 and the CMF arm P = 02 at 10 years and the overall survival OS benefit was maintained during 25 years of follow-up No significant differences were observed in IDFS or OS between the C arm and the CMF arm or between the levamisole arm and the control arm Compared with controls both cyclophosphamide and CMF significantly improved disease-free survival and OS and the benefits persisted for at least 25 years in premenopausal patients who had high-risk breast cancer\",\n",
            "}\n",
            "13489\n",
            "{\n",
            "  \"id\" : \"19433686\",\n",
            "  \"contents\" : \"Interferon IFN - based adjuvant therapy in melanoma is associated with significant side effects which necessitates evaluation of health-related quality of life HRQOL Our trial examined the HRQOL effects of adjuvant pegylated IFN-alpha-2b PEG-IFN-alpha-2b versus observation in patients with stage III melanoma A total of 1256 patients with stage III melanoma were randomly assigned after full lymphadenectomy to receive either observation n = 629 or PEG-IFN-alpha-2b n = 627 induction 6 micrograms/kg/wk [ DOSAGE ERROR CORRECTED ] for 8 weeks then maintenance 3 micrograms/kg/wk [ DOSAGE ERROR CORRECTED ] for an intended total duration of 5 years The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 was used to assess HRQOL At 38 years of median follow-up for the primary end point recurrence-free survival RFS risk was reduced by 18 % hazard rate = 082 P = 01 in the PEG-IFN-alpha-2b arm compared with observation Significant and clinically meaningful differences occurred with the PEG-IFN-alpha-2b treatment arm compared with the observation group showing decreased global HRQOL at month 3 -116 points 99 % CI -82 to -150 and year 2 -105 points 99 % CI -66 to -144 Many of the other scales showed statistically significant differences between scores when comparing the two arms From a clinical point of view important differences were found for five scales two functioning scales social and role functioning and three symptom scales appetite loss fatigue and dyspnea with the PEG-IFN-alpha-2b arm being most impaired PEG-IFN-alpha-2b leads to a significant and sustained improvement in RFS There is an expected negative effect on global HRQOL and selected symptoms when patients undergo PEG-IFN-alpha-2b treatment\",\n",
            "}\n",
            "13490\n",
            "{\n",
            "  \"id\" : \"21324954\",\n",
            "  \"contents\" : \"We aimed to determine the smallest changes in health-related quality of life HRQoL scores in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 30 and the Brain Cancer Module QLQ-BN20 which could be considered as clinically meaningful in brain cancer patients World Health Organisation performance status PS and mini-mental state examination MMSE were used as clinical anchors appropriate to related subscales to determine the minimal clinically important differences MCIDs in HRQoL change scores range 0-100 in the QLQ-C30 and QLQ-BN20 A threshold of 02 standard deviation SD small effect was used to exclude anchor-based MCID estimates considered too small to inform interpretation Based on PS our findings support the following integer estimates of the MCID for improvement and deterioration respectively physical 6 9 role 14 12 and cognitive functioning 8 8 global health status 7 4 * fatigue 12 9 and motor dysfunction 4 * 5 Anchoring with MMSE cognitive functioning MCID estimates for improvement and deterioration were 11 2 * and for communication deficit were 9 7 Estimates with asterisks were < 02 SD and were excluded from our MCID range of 5-14 These estimates can help clinicians evaluate changes in HRQoL over time assess the value of a health care intervention and can be useful in determining sample sizes in designing future clinical trials\",\n",
            "}\n",
            "13491\n",
            "{\n",
            "  \"id\" : \"17614245\",\n",
            "  \"contents\" : \"To compare physical morbidity and health-related quality of life HRQOL in breast cancer patients who received standard axillary dissection ALND or sentinel lymph node biopsy SLNB followed by axillary dissection only in the case of sentinel-node positivity within a randomised clinical trial Patients with early breast cancer < or = 3cm and clinically negative axilla were randomly allocated to ALND or SLNB All patients underwent physical examination every 6 months in order to assess any arm-related symptoms A subset of patients completed the SF-36 quality of life questionnaire and the Psychological General Well Being Index PGWBI before randomisation at 6 and 12 months after surgery and yearly thereafter Results of the first 24 months are reported Six-hundred and seventy-seven patients were available for analysis 341 patients randomised to the ALND group and 336 to the SLNB group Six months after surgery the SLNB group had significantly less lymph-oedema movement restrictions pain and numbness with respect to the ALND group Lymph-oedema was also significantly reduced at 12 months and numbness remained significantly less frequent in the SLNB arm at all time points Three-hundred and ten patients participated in the HRQOL assessment The mean scores of the PGWB questionnaire general index and anxiety domain were significantly better in the SLNB group than in the ALND group but the difference ceased to be significant at 24 months The SLNB is associated with reduced arm morbidity without evidence of a negative impact on psychological well being While waiting for long-term results of ongoing randomised clinical trials the SLNB may be proposed for early stage breast cancer patients after adequate information on the expected advantages and the possible risks\",\n",
            "}\n",
            "13492\n",
            "{\n",
            "  \"id\" : \"19887582\",\n",
            "  \"contents\" : \"Several prospective studies suggest that use of cholesterol-lowering statin drugs is inversely associated with advanced stage and possibly high-grade prostate cancer One study reported that men with low cholesterol had a lower risk of high-grade prostate cancer Given these findings we investigated the association between low serum cholesterol and prostate cancer risk in the Prostate Cancer Prevention Trial We conducted a cohort study of 5586 men ages > or = 55 years who were randomized to the placebo arm of the Prostate Cancer Prevention Trial between 1993 and 1996 Serum cholesterol was measured enzymatically at entry By the end of follow-up 1251 prostate cancer cases were confirmed We used logistic regression to calculate the multivariable odds ratio OR of total and Gleason 2 to 6 n = 993 7 n = 199 and 8 to 10 n = 59 prostate cancer comparing low serum normal < 200 mg/dL to high-serum borderline and elevated cholesterol > or = 200 mg/dL cholesterol Men with low cholesterol had a lower risk of Gleason 8 to 10 prostate cancer [ OR 041 95 % confidence interval CI 022-0 77 ] than men with high cholesterol No association was present for prostate cancer overall OR 097 95 % CI 085-1 11 Gleason 2 to 6 disease OR 103 95 % CI 089-1 18 or Gleason 7 disease OR 093 95 % CI 069-1 24 These prospective results support that men with low cholesterol have a reduced risk of high-grade prostate cancer These and other contemporary data that suggest that cholesterol metabolism should be investigated further in the etiology of prostate cancer\",\n",
            "}\n",
            "13493\n",
            "{\n",
            "  \"id\" : \"1307881\",\n",
            "  \"contents\" : \"To assess the accuracy of room-temperature thermodilution cardiac output measurements from the right ventricular port In addition waveform patterns were evaluated to determine the actual location of the right ventricular port Central venous port cardiac output measurements were compared with right ventricular port cardiac output measurements using the same right-heart catheter The general intensive care unit of Memorial Sloan-Kettering Cancer Center Thirty-seven critically ill cancer patients with 38 different right-heart catheters were evaluated Four injections of 10 mL normal saline at room temperature were made through each port the results of the last three injections were averaged Cardiac output determinations from both ports were completed in less than 10 minutes The order of port injection was random No difference was noted between cardiac output determinations from the two ports in a paired t test Of 38 right-heart catheters 17 were in the right ventricle and the other 21 in the right atrium A comparison of ports in the 17 right ventricle catheters showed no difference with a significant P < 01 R2 = 096 correlation Thermodilution cardiac output measurements using 10 mL normal saline at room temperature can be determined accurately using the right ventricular port if the central venous port becomes nonfunctional\",\n",
            "}\n",
            "13494\n",
            "{\n",
            "  \"id\" : \"23228988\",\n",
            "  \"contents\" : \"Glioblastoma GBM is one of the worst cancers in terms of prognosis Standard therapy consists of resection with concomitant chemoradiotherapy Resistance to nimustine hydrochloride ACNU an alkylating agent has been linked to methylguanine DNA methyltransferase MGMT Daily administration of procarbazine PCZ has been reported to decrease MGMT activity This study investigated the efficacy of ACNU + PCZ compared to ACNU alone for GBM and anaplastic astrocytoma AA Patients 20-69 years who had newly diagnosed AA and GBM were randomly assigned to receive radiotherapy with ACNU alone or with ACNU + PCZ The primary endpoint was overall survival OS This was designed as a phase II/III trial with a total sample size of 310 patients and was registered as UMIN-CTR C000000108 After 111 patients from 19 centers in Japan were enrolled this study was terminated early because temozolomide was newly approved in Japan The median OS and median progression-free survival PFS with ACNU alone n = 55 or ACNU + PCZ n = 56 in the intention-to-treat population were 274 and 224 months p = 075 and 86 and 69 months respectively The median OS and median PFS of the GBM subgroup treated with ACNU alone n = 40 or ACNU + PCZ n = 41 were 190 and 195 months and 62 and 63 months respectively Grade 3/4 hematologic adverse events occurred in more than 40 % of patients in both arms and 27 % of patients discontinued treatment because of adverse events The addition of PCZ to ACNU was not beneficial in comparison with ACNU alone for patients with newly diagnosed AA and GBM\",\n",
            "}\n",
            "13495\n",
            "{\n",
            "  \"id\" : \"22049088\",\n",
            "  \"contents\" : \"One of the expected benefits of sharing trial results with participants is that it may enhance trust in medical researchers TMRs In a prospective study on a sample of clinical trial participants we investigated the effect on the participants TMRs of providing final trial results to participants via the Internet Participants in the FNCLCC-PACS04 trial ClinicalTrialsgov Identifier NCT00054587 were surveyed on average 6 years after enrollment when the trial results were available In the current study they were randomized to receive experimental group or not to receive control group a letter informing them that the results of the trial could be consulted on a specific website TMRs was measured before randomization and 6 months later using mailed self-administered questionnaires The response rate was 93 % N = 107 TMRs remained unchanged in the control group mean effect size = -006 95 % confidence interval CI -028 to 017 p = 0617 but decreased in the experimental group -030 95 % CI -053 to -006 p = 0015 However the difference between the two effect sizes was not statistically significant p = 0144 The results obtained here on the disclosure of final trial results to breast cancer patients via the Internet can not be generalized to all situations involving the disclosure of phase III randomized controlled trial results Transparency is an ethical research requirement but it may not enhance participants TMRs\",\n",
            "}\n",
            "13496\n",
            "{\n",
            "  \"id\" : \"8626113\",\n",
            "  \"contents\" : \"To compare the clinical efficacy of adjuvant chemotherapy a lone vs chemotherapy plus whole pelvic radiation therapy RT on recurrence rates patterns of recurrence and survival of patients post-RH-PLND for cervical cancer at high risk for recurrence Prospective multicenter randomized Phase III trial Patients with Stage IB-IIA cervical cancer undergoing RH-PLND were eligible Risk factors include deep cervical invasion tumor > or = 4 cm parametrial involvement nonsquamous histology and/or pelvic lymph node metastasis Chemotherapy consisted of cisplatin and bleomycin alone or in combination with whole pelvic RT Survival was determined by Kaplan-Meier estimate Eighty-nine patients were entered from 1987 to 1994 Seventy-five patients had a Stage IB cancer and 14 patients had Stage IIA Twenty-five patients had > or = 3 risk factors Forty-four patients received chemotherapy alone vs 45 patients treated with chemotherapy and RT Nineteen patients had recurrences and 16 patients have died Nine of 44 20 % patients receiving chemo alone recurred compared to 10/45 22 % patients receiving chemo and RT P = ns Patterns of recurrence were statistically similar between the two treatment arms even among the subgroup of patients with > or = 3 risk factors Both regimens were well tolerated CT + RT did not prove a superior adjuvant therapy for patients at high risk of recurrence after RH-PLND for early cervical cancer in this limited trial Recurrence rates and patterns of recurrences local regional or distant were not influenced by the addition of RT\",\n",
            "}\n",
            "13497\n",
            "{\n",
            "  \"id\" : \"12011126\",\n",
            "  \"contents\" : \"To investigate the effect of recombinant human erythropoietin epoetin beta on anemia transfusion need and quality of life QOL in severely anemic patients with low-grade non-Hodgkin s lymphoma NHL chronic lymphocytic leukemia CLL or multiple myeloma MM Transfusion-dependent patients with NHL n = 106 CLL n = 126 or MM n = 117 and a low serum erythropoietin concentration were randomized to receive epoetin beta 150 IU/kg or placebo subcutaneously three times a week for 16 weeks Primary efficacy criteria were transfusion-free and transfusion - and severe anemia-free survival hemoglobin [ Hb ] > 85 g/dL between weeks 5 to 16 Response was defined as an increase in Hb > or = 2 g/dL with elimination of transfusion need QOL was assessed by the Functional Assessment of Cancer Therapy scale Transfusion-free P = 0012 survival and transfusion - and severe anemia-free survival P = 0001 were significantly greater in the epoetin beta group versus placebo Wald chi 2 test giving a relative risk reduction of 43 % and 51 % respectively The response rate was 67 % and 27 % in the epoetin beta versus the placebo group respectively P < 0001 After 12 and 16 weeks of treatment QOL significantly improved in the epoetin beta group compared with placebo P < 05 this improvement correlated with an increase in Hb concentration > or = 2 g/dL A target Hb that could be generally recommended could not be identified Many severely anemic and transfusion-dependent patients with advanced MM NHL and CLL and a low performance status benefited from epoetin therapy with elimination of severe anemia and transfusion need and improvement in QOL\",\n",
            "}\n",
            "13498\n",
            "{\n",
            "  \"id\" : \"18165618\",\n",
            "  \"contents\" : \"There is a misconception that elderly cancer patients can not tolerate standard doses of chemotherapy because of the frequency and severity of myelosuppressive complications The reactive use of colony-stimulating factors ie in response to severe neutropenia commonly observed in this setting contributes to the frequency and severity of these complications This study evaluated the incidence of febrile neutropenia and related events in elderly cancer patients receiving pegfilgrastim beginning with cycle 1 proactive in comparison with pegfilgrastim initiated after cycle 1 at the physician s discretion reactive Patients > or = 65 years of age with either solid tumors or non-Hodgkin s lymphoma NHL were randomly assigned to receive pegfilgrastim either proactively or reactively The primary endpoint was the proportion of patients experiencing febrile neutropenia There were 852 patients enrolled median age 72 years Proactive pegfilgrastim use resulted in a significantly lower incidence of febrile neutropenia for both solid tumor and NHL patients compared with reactive use Proactive pegfilgrastim use also led to fewer hospitalizations resulting from neutropenia and febrile neutropenia by approximately 50 % Antibiotic use was lower for solid tumor patients receiving proactive pegfilgrastim and equivalent in the two NHL groups This is the largest randomized prospective trial evaluating growth factor support in typical elderly cancer patients Proactive pegfilgrastim use effectively produced a lower incidence of febrile neutropenia and related events in elderly patients with either solid tumors or NHL receiving an array of mild to moderately neutropenic chemotherapy regimens Pegfilgrastim should be used proactively in elderly cancer patients to support the optimal delivery of standard chemotherapy\",\n",
            "}\n",
            "13499\n",
            "{\n",
            "  \"id\" : \"21502557\",\n",
            "  \"contents\" : \"This article presents the long-term results of the international multicenter randomized trial that investigated the use of neoadjuvant cisplatin methotrexate and vinblastine CMV chemotherapy in patients with muscle-invasive urothelial cancer of the bladder treated by cystectomy and/or radiotherapy Nine hundred seventy-six patients were recruited between 1989 and 1995 and median follow-up is now 80 years This was a randomized phase III trial of either no neoadjuvant chemotherapy or three cycles of CMV The previously reported possible survival advantage of CMV is now statistically significant at the 5 % level Results show a statistically significant 16 % reduction in the risk of death hazard ratio 084 95 % CI 072 to 099 P = 037 corresponding to an increase in 10-year survival from 30 % to 36 % after CMV We conclude that CMV chemotherapy improves outcome as first-line adjunctive treatment for invasive bladder cancer Two large randomized trials by the Medical Research Council/European Organisation for Research and Treatment of Cancer and Southwest Oncology Group have confirmed a statistically significant and clinically relevant survival benefit and neoadjuvant chemotherapy followed by definitive local therapy should be viewed as state of the art as compared with cystectomy or radiotherapy alone for deeply invasive bladder cancer\",\n",
            "}\n",
            "13500\n",
            "{\n",
            "  \"id\" : \"15639693\",\n",
            "  \"contents\" : \"Buprenorphine a potent opioid analgesic has been available in parenteral and oral or sublingual SL formulations for > 25 years In 2001 the buprenorphine transdermal delivery system TES was introduced at 3 release rates 35 525 and 70 microg/h for the treatment of chronic cancer and noncancer pain This study compared the analgesic efficacy and tolerability of buprenorphine TES at a release rate of 35 microg/h with those of buprenorphine SL and placebo in patients with severe or very severe chronic cancer or noncancer pain This multicenter double-blind placebo-controlled parallel-group trial was 1 of 3 Phase III studies involved in the clinical development of buprenorphine TDS It comprised a 6-day open-label run-in phase in which patients received buprenorphine SL 08 to 16 mg/d as needed and a double-blind phase in which patients were randomized to receive 3 sequential patches containing buprenorphine TES 35 microg/h or placebo each lasting 72 hours Rescue analgesia consisting of buprenorphine SL 02-mg tablets was available as needed throughout the double-blind phase The main outcome measures were 1 the number of buprenorphine SL tablets required in addition to buprenorphine TES during the double-blind phase compared with the placebo group and compared with the buprenorphine SL requirement during the run-in phase and 2 patients assessments of pain intensity pain relief and duration of sleep uninterrupted by pain in the double-blind phase compared with the run-in phase Adverse events were documented throughout the study One hundred thirty-seven patients were included in the double-blind phase 90 buprenorphine TES 47 placebo The buprenorphine TES group included 47 men and 43 women mean [ SD ] age 560 [ 121 ] years and the placebo group included 23 men and 24 women mean age 557 [ 129 ] years Forty-five patients had cancer-related pain and 92 had noncancer-related pain The 2 treatment groups were comparable with respect to sex distribution age height and body weight Patients receiving buprenorphine TES significantly reduced their consumption of buprenorphine SL tablets in the double-blind phase compared with patients receiving placebo reduction of 06 [ 04 ] mg vs 04 [ 04 ] mg P = 003 The relationship between the buprenorphine SL dose in the run-in phase and the number of buprenorphine SL tablets required in the double-blind phase was dose dependent in the active-treatment group only Patients assessments of pain intensity and pain relief suggested better analgesia with buprenorphine TES than with placebo although the differences did not reach statistical significance The proportion of patients who reported sleeping for > 6 hours uninterrupted by pain in the double-blind phase compared with the run-in phase increased by 64 % in the buprenorphine TDS group 356 % vs 292 % respectively compared with a decrease of 59 % in the placebo group 404 % vs 463 % no statistical analysis of sleep duration data was performed Buprenorphine TDS was well tolerated with adverse events generally similar to those associated with other opioids The incidence of systemic adverse events in the double-blind phase was similar in the 2 treatment groups 289 % buprenorphine TDS 276 % placebo with the most common adverse events being nausea dizziness and vomiting After patch removal skin reactions mainly mild or moderate pruritus and erythema were seen in 356 % of the buprenorphine TDS group and 255 % of the placebo group In the population studied buprenorphine TDS provided adequate pain relief as well as improvements in pain intensity and duration of pain-free sleep It may be considered a therapeutic option for the treatment of moderate to severe chronic pain\",\n",
            "}\n",
            "13501\n",
            "{\n",
            "  \"id\" : \"23233710\",\n",
            "  \"contents\" : \"Advanced follicular lymphomas FL are considered incurable with conventional chemotherapy and there is no consensus on the best treatment approach Southwest Oncology Group SWOG and Cancer and Leukemia Group B compared the safety and efficacy of two immunochemotherapy regimens for FL in a phase III randomized intergroup protocol SWOG S0016 that enrolled 554 patients with previously untreated advanced-stage FL between March 1 2001 and September 15 2008 Patients were eligible for the study if they had advanced-stage bulky stage II III or IV evaluable FL of any grade 1 2 or 3 and had not received previous therapy In one arm of the study patients received six cycles of cyclophosphamide doxorubicin vincristine and prednisone CHOP chemotherapy at 3-week intervals with six doses of rituximab CHOP-R In another arm of the study patients received six cycles of CHOP followed by consolidation with tositumomab/iodine I-131 tositumomab radioimmunotherapy RIT After a median follow-up period of 49 years the 2-year estimate of progression-free survival PFS was 76 % on the CHOP-R arm and 80 % on the CHOP-RIT arm P = 11 The 2-year estimate of overall survival OS was 97 % on the CHOP-R arm and 93 % on the CHOP-RIT arm P = 08 There was no evidence of a significant improvement in PFS comparing CHOP-RIT with CHOP-R However PFS and OS were outstanding on both arms of the study Future studies are needed to determine the potential benefits of combining CHOP-R induction chemotherapy with RIT consolidation and/or extended rituximab maintenance therapy\",\n",
            "}\n",
            "13502\n",
            "{\n",
            "  \"id\" : \"21919119\",\n",
            "  \"contents\" : \"We evaluated the effect of Emotionally Focused Therapy EFT [ intervention INT ] modified for the advanced cancer population versus standard care [ control CTL ] on marital functioning and psychosocial outcomes among distressed couples EFT examines the ways couples process patterns of interaction facilitating change Forty-two patients with metastatic cancer and their caregivers were assigned randomly to receive eight sessions of EFT delivered by one EFT-trained psychologist or standard care provided by multidisciplinary clinicians Partners completed measures of marital functioning depression hopelessness empathic caregiving patient and caregiver burden caregiver before randomization at baseline T0 post-intervention T1 and 3-month post-intervention T2 Data were analyzed using three-way analyses of covariance main effects were treatment patient status and sex Multilevel modeling was also employed At T1 INT group led to significant improvement in marital functioning p 00001 and patients experience of caregiver empathic care p = 002 versus CTL group Effect sizes for these differences were in the large range d = 100 In both groups patients showed a marginally higher mean score for marital functioning compared with caregivers [ INT M = 563 standard deviation SD = 46 vs M = 543 SD = 45 CTL group M = 434 SD = 103 vs M = 424 SD = 68 respectively ] At T2 results were maintained The effectiveness of and adherence to the EFT couple intervention for patients facing advanced cancer were demonstrated in this study Larger randomized control trials are needed to confirm these findings Qualitative studies may help to further understand the mechanism by which such an intervention may act\",\n",
            "}\n",
            "13503\n",
            "{\n",
            "  \"id\" : \"9439150\",\n",
            "  \"contents\" : \"To determine the effectiveness and toxicity when levamisole was added to the adjuvant combination chemotherapy in patients with operable gastric cancer After en bloc resection of gastric cancer without gross or microscopic evidence of residual disease from April 1991 to December 1992 100 patients were randomized to 6 months of 5-fluorouracil 1000 mg/m2/day administered as continuous infusion for 5 days cisplatin 60 mg/m2/day as intravenous infusion for 1 day with or without levamisole 50 mg every eight hours PO for a period of three days every 2 weeks for 6 months This chemotherapy treatment was begun within 2 to 4 weeks after the surgery The chemotherapy consisted of discrete 5-day courses administered at 4-weeks intervals All 100 patients are assessable The fifty patients were assigned to each treatment group There was no statistical difference and no bias in the distribution of characteristics of the 100 evaluable patients between the two groups A total of 274 courses of treatment were given in the levamisole group and 260 courses of treatment in non-levamisole group Eleven patients in each group did not finish planned 6 courses of treatment mainly due to non-compliance At median follow up of 39 months 32 patients relapsed 19 in the levamisole group and 13 in the non-levamisole group p = 0284 Twenty five patients died of relapsed diseases 15 in the levamisole group and 10 in the non-levamisole group The levamisole group tended to show more risk of overall death rate and recurrence than the non-levamisole group However this result was not statistically significant at 3 years The treatment was well tolerated in both treatment groups The grade 2-3 toxicities were nausea / vomiting levamisole non-levamisole group 317 % 293 % of treatment courses respectively diarrhea 76 % 84 % mucositis 116 % 123 % and leukopenia 98 % 96 % Levamisole had negative effects on disease-free survival and overall survival when added to adjuvant combination chemotherapy of cisplatin and 5-fluorouracil in patients with operable gastric cancer Both treatment arms were generally well tolerated and the toxicity profile was similar with or without levamisole\",\n",
            "}\n",
            "13504\n",
            "{\n",
            "  \"id\" : \"23132548\",\n",
            "  \"contents\" : \"Laparoscopic resection is used widely in the management of colorectal cancer however the data on long-term outcomes particularly those related to rectal cancer are limited The results of long-term follow-up of the UK Medical Research Council trial of laparoscopically assisted versus open surgery for colorectal cancer are presented A total of 794 patients from 27 UK centres were randomized to laparoscopic or open surgery in a 21 ratio between 1996 and 2002 Long-term follow-up data were analysed to determine differences in survival outcomes and recurrences for intention-to-treat and actual treatment groups Median follow-up of all patients was 629 interquartile range 229 - 928 months There were no statistically significant differences between open and laparoscopic groups in overall survival 783 95 per cent confidence interval ci 658 to 1066 versus 827 691 to 948 months respectively P = 0780 and disease-free survival DFS 895 671 to 1217 versus 770 633 to 940 months P = 0589 In colonic cancer intraoperative conversions to open surgery were associated with worse overall survival hazard ratio HR 228 95 per cent ci 147 to 353 P < 0001 and DFS HR 220 131 to 367 P = 0007 In terms of recurrence no significant differences were observed by randomized procedure However at 10 years right colonic cancers showed an increased propensity for local recurrence compared with left colonic cancers 147 versus 52 per cent difference 95 95 per cent ci 23 to 166 per cent P = 0019 Long-term results continue to support the use of laparoscopic surgery for both colonic and rectal cancer\",\n",
            "}\n",
            "13505\n",
            "{\n",
            "  \"id\" : \"24504222\",\n",
            "  \"contents\" : \"This study aims to investigate and evaluate the efficacy and safety of early enteral nutrition EN in maintaining and improving the postoperative nutritional status in patients undergoing esophagectomy A randomized controlled clinical trial was conducted in 120 adult patients with esophageal cancer and undergoing esophagectomy Patients were randomly divided into two groups receiving either EN N = 64 or parenteral nutrition PN N = 56 postoperatively The nutritional intake was isonitrogenic and isocalorie for both groups Nutritional status was evaluated preoperatively as well as on postoperative day I and day 8 Daily nitrogen balance was measured and 7-day cumulative nitrogen balance was calculated The levels of serum markers including d-lactate diamine oxidase DAO and endotoxin were determined on 1st 4th and 8th postoperative day for analyzing intestinal barrier function Postoperative infection rate and the incidence of nutrition support-related complications were examined The concentrations of serum albumin and prealbumin in patients of EN group were significantly higher than those in PN group and the concentrations of blood glucose - GT AKP TB and DB were significantly lower compared to those in the PN group P < 005 Both daily nitrogen balance and cumulative nitrogen balance of EN group were better than those of PN group since postoperative day III The serum levels of d-lactate DAO and endotoxin of EN group were significantly lower than those of PN group on postoperative day VIII P < 001 The incidence of postoperative infections in blood lung and intestinal tract in EN group was lower compared to PN group P < 005 No severe complications associated with nutritional support occurred in EN group The time to flatus passage in EN group was significantly shorter and the cost of nutritional support was significantly less compared to PN group P < 005 Postoperative early enteral nutrition was safe and feasible for patients undergoing esophagectomy Compared to PN EN more efficiently ameliorated postoperational nutritional status of the patients undergoing esophagectomy played an important role in restoring intestinal barrier function postoperatively reduced the incidence of postoperative infection and decreased the cost of hospital stay\",\n",
            "}\n",
            "13506\n",
            "{\n",
            "  \"id\" : \"21212421\",\n",
            "  \"contents\" : \"Quality of life QOL is markedly impaired in patients with anemia diabetes mellitus and chronic kidney disease Limited data exist regarding the effect of anemia treatment on patient perceptions The objectives were to determine the longitudinal impact of anemia treatment on quality of life in patients with diabetes and chronic kidney disease and to determine the predictors of baseline and change in QOL In a large double blind study patients with type 2 diabetes mellitus nondialysis chronic kidney disease estimated GFR 20 to 60 ml/min per 173 m 2 and anemia hemoglobin 104 g/dl were randomized to darbepoetin alfa or placebo QOL was measured with Functional Assessment of Cancer Therapy-Fatigue Short Form-36 and EuroQol scores over 97 weeks Patients randomized to darbepoetin alfa reported significant improvements compared with placebo patients in Functional Assessment of Cancer Therapy-Fatigue and EuroQol scores visual analog scores persisting through 97 weeks No consistent differences in Short Form-36 were noted Consistent predictors of worse change scores include lower activity level older age pulmonary disease and duration of diabetes Interim stroke had a substantial negative impact on fatigue and physical function Darbepoetin alfa confers a consistent but small improvement in fatigue and overall quality of life but not in other domains These modest QOL benefits must be considered in the context of neutral overall effect and increased risk of stroke in a small proportion of patients Patient s QOL and potential treatment risk should be considered in any treatment decision\",\n",
            "}\n",
            "13507\n",
            "{\n",
            "  \"id\" : \"24810181\",\n",
            "  \"contents\" : \"The primary objectives of this study were to evaluate the effect of food on the oral bioavailability and to evaluate the effect of diurnal variation on the pharmacokinetics of linifanib a novel tyrosine kinase TK inhibitor selective for vascular endothelial growth factor VEGF and platelet-derived growth factor PDGF receptors in patients with advanced solid tumors Adverse events were monitored This was a phase 1 open-label randomized crossover study Thirty-four patients received dosing regimens to evaluate linifanib pharmacokinetic parameters under fasting and non-fasting conditions and with morning or evening dosing Adverse events AEs were assessed according to National Cancer Institute Common Terminology Criteria for AEs Version 30 The administration with food had a negligible effect on the AUC of linifanib but the Cmax of linifanib was decreased by 40 % compared to the fasting condition Evening dosing after a 2-h fast had a negligible effect on AUC however the dose-normalized Cmax of linifanib after evening dosing was 64 % of that after morning dosing following a 10-h fast Common Grade 3/4 AEs were fatigue 24 % hypertension 21 % and palmar-plantar erythrodysaesthesia syndrome 15 % Dosing with food or in the evening has a significant effect on the oral bioavailability of linifanib that should be taken into consideration when designing future clinical studies The pattern of adverse advents reported in this study is similar to that seen in other studies of linifanib and other agents in the VEGF/PDGF TK receptor inhibitor class\",\n",
            "}\n",
            "13508\n",
            "{\n",
            "  \"id\" : \"23632052\",\n",
            "  \"contents\" : \"Paravertebral blocks PVBs have been introduced as an alternative to general anesthesia for breast cancer surgeries The addition of clonidine as an adjuvant in PVBs may enhance quality and duration of analgesia and significantly reduce the consumption of analgesics after breast surgery In this prospective randomized double-blind study we assessed the significance of adding clonidine to the anesthetic mixture for women undergoing mastectomy Sixty patients were randomized equally into 2 groups both of which received PVB block either with or without clonidine Analgesic consumption was noted up to 2 weeks after the operation A visual analog scale was used to assess pain postoperatively during the hospital stay and a numeric rating scale was used when patients were discharged Analgesic consumption was significantly lower in the clonidine group 48 hours postoperatively with 95 % confidence interval CI for the difference -695 % to -66 % Pain scores at rest showed significant reduction in the clonidine group during the period from 24 to 72 hours postoperatively with 95 % CI for the ratios of 2 means 109-3 61 204-9 04 and 254-16 55 respectively with shoulder movement at 24 48 and 72 hours postoperatively 95 % CI for the ratio of 2 means 110-3 15 132-6 38 and 133-8 42 respectively The time needed to resume daily activity was shorter in the clonidine group compared with the control group with 95 % CI for the ratio of 2 means 114-1 62 The addition of clonidine enhanced the analgesic efficacy of PVB up to 3 days postoperatively for patients undergoing breast surgery\",\n",
            "}\n",
            "13509\n",
            "{\n",
            "  \"id\" : \"18001802\",\n",
            "  \"contents\" : \"We evaluated the effects of toremifene on bone mineral density a surrogate for fracture risk in men receiving androgen deprivation therapy for prostate cancer In an ongoing multicenter phase 3 fracture prevention study 1392 men 50 years or older with prostate cancer receiving androgen deprivation therapy were randomized to 80 mg toremifene per day or placebo Bone mineral density of the lumbar spine total hip and femoral neck was assessed using dual energy x-ray absorptiometry In this planned interim analysis of the first 197 subjects we compared bone mineral density changes from baseline to month 12 between the placebo and toremifene groups Compared with the placebo group men in the toremifene group had significant increases in bone mineral density at each evaluated skeletal site Lumbar spine bone mineral density decreased 07 % in the placebo group and increased 16 % in the toremifene group between group comparison p < 0001 Total hip bone mineral density decreased 13 % in the placebo group and increased 07 % in the toremifene group p = 0001 Femoral neck bone mineral density decreased 13 % in the placebo group and increased 02 % in the toremifene group p = 0009 Between group differences in the change in bone mineral density from baseline to month 12 were 23 % 20 % and 15 % for the lumbar spine total hip and femoral neck respectively Toremifene significantly increased hip and spine bone mineral density in men receiving androgen deprivation therapy for prostate cancer The effect of toremifene on the fracture risk is being assessed in the ongoing randomized controlled trial\",\n",
            "}\n",
            "13510\n",
            "{\n",
            "  \"id\" : \"19919878\",\n",
            "  \"contents\" : \"Enoxaparin sodium enoxaparin is used worldwide for the prevention of venous thromboembolism VTE Registration trials of enoxaparin have been conducted primarily in Caucasian populations and its preventive use in Japanese patients has yet to be established To address this we evaluated the efficacy and safety of postoperative enoxaparin in Japanese patients undergoing surgery for abdominal cancer This multicenter open-label study randomized 151 Japanese patients undergoing curative surgery for abdominal cancer to enoxaparin 20mg twice daily for 14 days started 24-36 hours after surgery n = 113 or intermittent pneumatic compression IPC as a reference n = 38 IPC was performed at least once in both groups between randomization and surgery The primary efficacy endpoint was the incidence of VTE in the modified intention-to-treat mITT population The primary safety outcome was the incidence of any bleeding during treatment and follow-up Incidence of VTE was 12 % 95 % CI 003-6 53 % 1/83 patients in the enoxaparin group and 194 % 95 % CI 745-37 47 % 6/31 patients in the IPC group In the safety population 10/109 patients in the enoxaparin group 92 % 95 % CI 449-16 23 % and 3/38 patients in the IPC group 79 % 95 % CI 166-21 38 % experienced a bleeding event There were no cases of fatal bleeding or bleeding into any critical organ These favorable efficacy and safety data support the use of enoxaparin 20mg twice daily for 14 days started 24-36 hours after surgery in Japanese patients undergoing abdominal or pelvic cancer surgery\",\n",
            "}\n",
            "13511\n",
            "{\n",
            "  \"id\" : \"18794541\",\n",
            "  \"contents\" : \"Adjuvant systemic chemotherapy administered after surgical resection of colorectal cancer metastases may reduce the risk of recurrence and improve survival but its benefit has never been demonstrated Two phase III trials Fdration Francophone de Cancrologie Digestive [ FFCD ] Trial 9002 and the European Organisation for Research and Treatment of Cancer/National Cancer Institute of Canada Clinical Trials Group/Gruppo Italiano di Valutazione Interventi in Oncologia [ ENG ] trial used a similar design and showed a trend favoring adjuvant chemotherapy but both had to close prematurely because of slow accrual thus lacking the statistical power to demonstrate the predefined difference in survival We report here a pooled analysis based on individual data from these two trials After complete resection of colorectal liver or lung metastases patients were randomly assigned to chemotherapy CT arm fluorouracil [ FU ] 400 mg/m 2 administered intravenously [ IV ] once daily plus dl-leucovorin 200 mg/m 2 [ FFCD ] x 5 days or FU 370 mg/m 2 plus l-leucovorin 100 mg/m 2 IV x 5 days [ ENG ] for six cycles at 28-day intervals or to surgery alone S arm A total of 278 patients CT n = 138 S n = 140 were included in the pooled analysis Median progression-free survival was 279 months in the CT arm as compared with 188 months in the S arm hazard ratio = 132 95 % CI 100 to 176 P = 058 Median overall survival was 622 months in the CT arm compared with 473 months in the S arm hazard ratio = 132 95 % CI 095 to 182 P = 095 Adjuvant chemotherapy was independently associated with both progression-free survival and overall survival in multivariable analysis This pooled analysis shows a marginal statistical significance in favor of adjuvant chemotherapy with an FU bolus-based regimen after complete resection of colorectal cancer metastases\",\n",
            "}\n",
            "13512\n",
            "{\n",
            "  \"id\" : \"20499107\",\n",
            "  \"contents\" : \"We examined quality of life in spouses of men in the Post-Adjuvant Androgen Deprivation trial after radical prostatectomy Men at high risk of prostate cancer recurrence were randomized to receive androgen deprivation therapy or observation Forty-three couples completed telephone interviews every 6 months for 2 years assessing women s mood disturbance mental and physical health and sexual function and bother as well as men s symptoms and sociodemographic and marital variables We used linear mixed modeling to explore relationships between wives quality of life and time treatment group and men s symptoms Women s mental health functioning improved over time p < 005 Furthermore women with husbands in the observation group had worse mood disturbance p = 001 and poorer mental health p = 002 than women with husbands in treatment Men s symptoms were associated with worse physical health in wives p = 002 Women also reported worse sexual function at 18 and 24 months compared with baseline p = 002 but ratings of sexual bother were unrelated to time treatment and symptoms These exploratory results are consistent with research demonstrating that spousal cancer-related distress decreases over time Treatment group differences suggest that an examination of caregiving in the context of uncertainty is warranted Also the physical burden of caregiving may intensify when men have more symptoms To inform interventions future studies should clarify how treatment and symptoms influence wives distress by examining expectations and communication\",\n",
            "}\n",
            "13513\n",
            "{\n",
            "  \"id\" : \"23065023\",\n",
            "  \"contents\" : \"Patients who undergo polypectomy are at increased risk of adenoma recurrence The preventive potential of vitamins A C and E and selenium supplementation represent an interesting opportunity for colorectal cancer prevention To assess the efficacy of a combination of these micronutrients in reducing the incidence of recurrent adenomas in subjects on post-polypectomy endoscopic follow-up a double-blind placebo-controlled randomized trial was started in Italy in 1988 A total of 411 patients were randomized to receive either an active compound 200 g selenium 30 mg zinc 2 mg vitamin A 180 mg vitamin C 30 mg vitamin E or a placebo daily for 5 years Of them 330 had follow-up colonoscopy 164 in the intervention and 166 in the placebo group After a median follow-up of 4 years range 1-15 years 100 patients had recurrence 38 in the intervention and 62 in the placebo arm The 15-year cumulative incidence of recurrence was 483 % in the intervention and 645 % in the placebo arm HR = 059 log-rank P = 0009 A 39 % reduction of the risk of recurrence was observed in the intervention compared to the placebo group adjusted HR = 061 95 % CI 041-0 92 the risk reduction was similar for small tubular adjusted HR = 061 95 % CI 037-0 99 and advanced adenomas adjusted HR = 050 95 % CI 024-1 01 Our study showed a statistically significant effect of antioxidant supplementation on adenoma recurrence Further clinical trials are needed to address the role of antioxidants in subgroups of subjects at increased risk for colorectal cancer\",\n",
            "}\n",
            "13514\n",
            "{\n",
            "  \"id\" : \"12713981\",\n",
            "  \"contents\" : \"The aim of this study was to determine the rates of local control and survival after relapse in patients with stage I endometrial cancer treated in the multicenter randomized PORTEC trial The PORTEC trial included 715 patients with stage 1 endometrial cancer either grade 1 or 2 with deep > 50 % myometrial invasion or grade 2 or 3 with < 50 % invasion In all cases an abdominal hysterectomy was performed without lymphadenectomy After surgery patients were randomized to receive pelvic RT 46 Gy or no further treatment The analysis was done by intention-to-treat A total of 714 patients were evaluated At a median follow-up of 73 months 8-year actuarial locoregional recurrence rates were 4 % in the RT group and 15 % in the control group P < 00001 The 8-year actuarial overall survival rates were 71 RT group and 77 % control group P = 018 Eight-year rates of distant metastases were 10 and 6 % P = 020 The majority of the locoregional relapses were located in the vagina mainly in the vaginal vault Of the 39 patients with isolated vaginal relapse 35 87 % were treated with curative intent usually with external RT and brachytherapy and surgery in some A complete remission CR was obtained in 31 of the 35 patients 89 % and 24 patients 77 % were still in CR after further follow-up Five patients subsequently developed distant metastases and 2 had a second vaginal recurrence The 3-year survival after first relapse was 51 % for patients in the control group and 19 % in the RT group P = 0004 The 3-year survival after vaginal relapse was 73 % in contrast to 8 and 14 % after pelvic and distant relapse P < 0001 At 5 years the survival after vaginal relapse was 65 % in the control group compared to 43 % in the RT group Survival after relapse was significantly better in the patient group without previous RT Treatment for vaginal relapse was effective with 89 % CR and 65 % 5-year survival in the control group while there was no difference in survival between patients with pelvic relapse and those with distant metastases As pelvic RT was shown to improve locoregional control significantly but without a survival benefit its use should be limited to those patients at sufficiently high risk 15 % or over for recurrence in order to maximize local control and relapse-free survival\",\n",
            "}\n",
            "13515\n",
            "{\n",
            "  \"id\" : \"20479407\",\n",
            "  \"contents\" : \"We tested the hypothesis that Akt-Ser473 phosphorylation pAkt predicts benefit from the sequential addition of paclitaxel to adjuvant doxorubicin plus cyclophosphamide AC chemotherapy in patients with node-positive breast cancer participating in the National Surgical Adjuvant Breast and Bowel Project NSABP B-28 trial Primary tumors from the NSABP B-28 trial tissue microarray were available from 1581 of 3060 patients who were randomly assigned to receive either four cycles of AC alone or followed by four cycles of paclitaxel Immunohistochemistry and quantitative analysis of pAkt were performed at the National Cancer Institute blinded to clinical outcome Association between pAkt and clinical outcome was assessed using multivariate Cox modeling adjusting for age tumor size number of positive nodes tumor grade estrogen receptor status and human epidermal growth factor receptor 2 status With a median follow-up of 91 years there were no differences in disease-free survival adjusted hazard ratio [ HR ] 102 P = 81 or overall survival HR 097 P = 80 with and without receiving paclitaxel among 975 patients with pAkt-negative tumors In 606 patients with pAkt-positive tumors the sequential addition of paclitaxel resulted in a 26 % improvement in disease-free survival HR 074 P = 02 or a 20 % improvement in overall survival HR 080 P = 17 pAkt significantly predicts disease-free benefit from the sequential addition of paclitaxel to AC chemotherapy in patients with node-positive breast cancer Patients with pAkt-negative breast tumors do not appear to benefit from the addition of paclitaxel\",\n",
            "}\n",
            "13516\n",
            "{\n",
            "  \"id\" : \"10824073\",\n",
            "  \"contents\" : \"The prevention of delayed nausea and vomiting caused by moderately emetogenic chemotherapy for cancer has not been studied systematically We enrolled patients who were scheduled to receive chemotherapy for the first time in a double-blind randomized multicenter study All the patients received ondansetron combined with dexamethasone for prophylaxis against emesis that might occur within 24 hours after the start of chemotherapy acute emesis They were then divided into two groups patients who did not have either vomiting or moderate-to-severe nausea the low-risk group and patients who had one or both the high-risk group Patients in the low-risk group were then randomly assigned to one of the following regimens given on days 2 through 5 after the start of chemotherapy oral placebo 4 mg of dexamethasone given orally twice daily or 8 mg of ondansetron in combination with 4 mg of dexamethasone given orally twice daily Patients in the high-risk group were randomly assigned to receive oral dexamethasone alone or in combination with ondansetron at the same doses as those used in the low-risk group Among the 618 patients in the low-risk group there was a complete absence of both delayed vomiting and moderate-to-severe nausea in 918 percent of those who received ondansetron combined with dexamethasone 874 percent of those who received dexamethasone alone and 768 percent of those who received placebo The proportions of patients who were protected by dexamethasone combined with ondansetron or by dexamethasone alone were significantly greater than the proportion protected by placebo P < 0001 and P < 002 respectively Of the 87 patients in the high-risk group complete protection was achieved in 409 percent of those treated with ondansetron and dexamethasone and in 233 percent treated with dexamethasone alone P not significant The best way to prevent delayed nausea and vomiting in patients receiving moderately emetogenic chemotherapy is to control these complications within the first 24 hours after the start of chemotherapy Dexamethasone alone provides adequate protection against delayed emesis in patients at low risk those who have not had acute emesis\",\n",
            "}\n",
            "13517\n",
            "{\n",
            "  \"id\" : \"25827291\",\n",
            "  \"contents\" : \"A recent randomized trial demonstrated that concurrent chemoradiotherapy CCRT with weekly cisplatin and gemcitabine followed by two adjuvant cycles of cisplatin and gemcitabine improved survival for advanced cervical cancer patients An Asian Gynecologic Oncology Group AGOG study was designed to determine whether only adding gemcitabine in the chemoradiation phase without adjuvant chemotherapy could improve survival Between March 2009 and March 2013 74 eligible patients with International Federation of Obstetrics and Gynecology stage III/IVA cervical cancer or stage I/II with positive pelvic/para-aortic nodal metastasis were enrolled Thirty-seven patients were randomized to arm C weekly cisplatin 40mg/m 2 and 37 patients were randomized to arm CG weekly cisplatin 40mg/m 2 and gemcitabine 125mg/m 2 for six cycles Six eligible patients were excluded before the beginning of treatment An interim analysis showed superimposable progression-free PFS and overall survival OS a decision of closing accrual was made A 3-year PFS was similar in both arms arm C 651 % vs arm CG 710 % p = 071 and a 3-year OS was 741 % in arm C vs 859 % in arm CG p = 089 but crossed over at 5years Grade 2-4 hematological toxicities including neutropenia p = 0028 and thrombocytopenia p = 0001 were more frequent in arm CG than arm CDespite limitation in power it suggests that only adding gemcitabine at the CCRT phase does not provide substantially superior results but treatment toxicities could increase Further studies are required to determine the role of post-CCRT adjuvant chemotherapy in advanced cervical cancer\",\n",
            "}\n",
            "13518\n",
            "{\n",
            "  \"id\" : \"24171516\",\n",
            "  \"contents\" : \"The efficacy of autologous stem-cell transplantation during the first remission in patients with diffuse aggressive non-Hodgkin s lymphoma classified as high-intermediate risk or high risk on the International Prognostic Index remains controversial and is untested in the rituximab era We treated 397 patients who had disease with an age-adjusted classification of high risk or high-intermediate risk with five cycles of cyclophosphamide doxorubicin vincristine and prednisone CHOP or CHOP plus rituximab Patients with a response were randomly assigned to receive three additional cycles of induction chemotherapy control group or one additional cycle of induction chemotherapy followed by autologous stem-cell transplantation transplantation group The primary efficacy end points were 2-year progression-free survival and overall survival Of 370 induction-eligible patients 253 were randomly assigned to the transplantation group 125 or the control group 128 Forty-six patients in the transplantation group and 68 in the control group had disease progression or died with 2-year progression-free survival rates of 69 and 55 % respectively hazard ratio in the control group vs the transplantation group 172 95 % confidence interval [ CI ] 118 to 251 P = 0005 Thirty-seven patients in the transplantation group and 47 in the control group died with 2-year overall survival rates of 74 and 71 % respectively hazard ratio 126 95 % CI 082 to 194 P = 030 Exploratory analyses showed a differential treatment effect according to risk level for both progression-free survival P = 004 for interaction and overall survival P = 001 for interaction Among high-risk patients the 2-year overall survival rate was 82 % in the transplantation group and 64 % in the control group Early autologous stem-cell transplantation improved progression-free survival among patients with high-intermediate-risk or high-risk disease who had a response to induction therapy Overall survival after transplantation was not improved probably because of the effectiveness of salvage transplantation Funded by the National Cancer Institute Department of Health and Human Services and others SWOG-9704 ClinicalTrialsgov number NCT00004031\",\n",
            "}\n",
            "13519\n",
            "{\n",
            "  \"id\" : \"19196674\",\n",
            "  \"contents\" : \"Following the release of the 2002 report of the Women s Health Initiative WHI trial of estrogen plus progestin the use of menopausal hormone therapy in the United States decreased substantially Subsequently the incidence of breast cancer also dropped suggesting a cause-and-effect relation between hormone treatment and breast cancer However the cause of this decrease remains controversial We analyzed the results of the WHI randomized clinical trial -- in which one study group received 0625 mg of conjugated equine estrogens plus 25 mg of medroxyprogesterone acetate daily and another group received placebo -- and examined temporal trends in breast-cancer diagnoses in the WHI observational-study cohort Risk factors for breast cancer frequency of mammography and time-specific incidence of breast cancer were assessed in relation to combined hormone use In the clinical trial there were fewer breast-cancer diagnoses in the group receiving estrogen plus progestin than in the placebo group in the initial 2 years of the study but the number of diagnoses increased over the course of the 56-year intervention period The elevated risk decreased rapidly after both groups stopped taking the study pills despite a similar frequency of mammography In the observational study the incidence of breast cancer was initially about two times as high in the group receiving menopausal hormones as in the placebo group but this difference in incidence decreased rapidly in about 2 years coinciding with year-to-year reductions in combined hormone use During this period differences in the frequency of mammography between the two groups were unchanged The increased risk of breast cancer associated with the use of estrogen plus progestin declined markedly soon after discontinuation of combined hormone therapy and was unrelated to changes in frequency of mammography\",\n",
            "}\n",
            "13520\n",
            "{\n",
            "  \"id\" : \"19281324\",\n",
            "  \"contents\" : \"Few lifestyle intervention programs address the needs of financially disadvantaged low literacy populations The overall goal of the Illinois WISEWOMAN Program IWP was to design such a program and test its effectiveness in reducing cardiovascular disease CVD risk specifically physical activity and nutrition factors The purpose of this paper is to describe the IWP study design and methods development of the evidence-based curriculum appropriate for a low socioeconomic status SES population and baseline characteristics of IWP participants The Cooper Institute in collaboration with the Illinois Department of Public Health and the University of Illinois at Chicago adapted evidence-based interventions for financially disadvantaged low literacy populations The study used a randomized two-group experimental design In total 1021 women were recruited from the Illinois Breast and Cervical Cancer Program which serves uninsured and underinsured women aged 40-64 at or below 200 % of poverty The women were randomized to either a minimum intervention MI or an enhanced intervention EI group Both groups received CVD risk factor screening and educational materials Additionally the EI group received a 12-week lifestyle intervention Baseline comparisons show equivalent groups IWP participants had a higher prevalence of obesity and smoking than similar national samples IWP addressed many of the cultural and implementation barriers in programs that seek to improve the health of financially disadvantaged low literacy populations Because of the high burden of disease the unique study population and the sound design we anticipate that our future results will contribute to the translation literature which has largely ignored significant health disparities\",\n",
            "}\n",
            "13521\n",
            "{\n",
            "  \"id\" : \"21479690\",\n",
            "  \"contents\" : \"The intraoperative epidural analgesia EA has the potential to reduce stress response to surgical trauma which induces a transient immunoactivation that has a negative impact on the outcome This study investigates the effect of intraoperative EA versus intravenous analgesia IA on the immune function A total of 35 consecutive patients candidated to undergo major surgery for colon cancer were randomly assigned to intraoperative EA n = 18 or IA n = 17 Blood samples for TNF - IFN - IL-1 IL-2 IL-4 IL-6 IL-10 IL-12 and GM-CSF were obtained before surgery T pre 3 h T 3h and 24 h T 24h after skin incision Data on postoperative complications were prospectively collected and analyzed In the EA group IL-4 increased from T pre to T 3h and from T 3h to T 24h IL-10 increased from T pre to T 3h and persisted unmodified thereafter At all time-points IL-4 and IL-10 serum levels were significantly higher than those in the IA group Conversely in the IA group IL-4 and IL-10 serum levels did not change while all other cytokines levels were significantly higher compared with the EA group In particular IL-6 progressively reached a 7-fold increase of its basal value at T 24h Complications were significantly more common in IA patients 13 of 17 compared with EA patients 7 of 18 P = 024 Our results indicate that in cancer patients undergoing major elective colon surgery the EA attenuates the surgery-induced proinflammatory response and the typical postoperative transient immunosuppression and seems associated with a reduced rate of postoperative complications compared with IA\",\n",
            "}\n",
            "13522\n",
            "{\n",
            "  \"id\" : \"17592295\",\n",
            "  \"contents\" : \"This study was performed to identify tumor - and patient-related risk factors for distal rectal cancer in patients treated with an abdominoperineal resection APR associated with positive circumferential resection margin CRM local recurrence LR and overall survival OS The introduction of total mesorectal excision TME has improved the outcome of patients with rectal cancer However survival of patients treated with an APR improved less than of those treated with low anterior resections LAR Besides an APR is associated with a higher LR rate Patients were selected from the TME trial which is a randomized multicenter trial studying the effects of preoperative radiotherapy RT in 1861 patients Of the Dutch patients 455 underwent an APR Location of the bulk of the tumor was scored with surgery pathology or other reports CRM was available from pathology reports A positive CRM was found in 296 % of all patients 44 % for anterior 21 % for lateral 23 % for posterior and 17 % for semi circular tumor location P < 00001 In a multivariate analysis T-stage N-stage and tumor location were independent risk factors for CRM If a partial resection of the vaginal wall was performed in women 478 % of patients still had a positive CRM T-stage N-stage and CRM were risk factors for LR and age T-stage N-stage CRM and distance of the inferior tumor margin to the anal verge for OS Age T-stage N-stage CRM distance of the tumor to the anal verge and tumor location were independent risk factors for adverse outcome in patients treated with an APR for low rectal cancer Anterior location specifically in women more often requires downstaging and/or more extended resection to obtain free margins\",\n",
            "}\n",
            "13523\n",
            "{\n",
            "  \"id\" : \"12824959\",\n",
            "  \"contents\" : \"Malignant pleural effusion is a common problem in advanced cancers contributing to the poor quality of life in this group of patients The aim of the study was to assess the efficiency of talc powder and doxycycline in pleurodesis in patients with malignant pleural effusion in comparable conditions Of 52 patients screened 33 entered the trial They were randomized to the talc group n = 18 and the doxycycline group n = 15 Both groups were comparable with regard to age sex and the most important variables influencing effectiveness of the procedure ie primary malignancy and stage of metastatic involvement of the pleura Efficiency of pleurodesis was prospectively assessed The analysis of short-term effectiveness of pleurodesis in the first 33 patients has shown a highly significant difference in favor of talc powder p = 0009 this difference was the reason for terminating the randomization Further observation has revealed in the doxycycline group an increasing number of patients with fluid reaccumulation as time went by this was not observed in the talc group A statistical analysis of the long-term effectiveness of both agents studied has shown a more significant difference in favor of the talc powder p = 000003 Talc powder is superior to doxycycline in achieving pleurodesis in patients with malignant pleural effusion in both short - and long-term observations\",\n",
            "}\n",
            "13524\n",
            "{\n",
            "  \"id\" : \"24257551\",\n",
            "  \"contents\" : \"A significant number of ovarian borderline tumors BOTs and metastatic nonovarian primaries are erroneously diagnosed as ovarian carcinomas If BOTs are misdiagnosed as cancer patients may not only experience nonbeneficial morbidity but may have to cope with an incorrect diagnosis of cancer for the rest of their lives In cases of metastatic disease mistaken for an ovarian primary more adequate therapeutic modalities may be withheld from some patients Finally clinical trials may be biased through unintended disregard of histological inclusion criteria Patients were recruited for central pathology review according to a translational subprotocol of a prospectively randomized phase 3 study led by the Arbeitsgemeinschaft Gynaekologische Onkologie AGO Study Group All original slides were requested and a specialized central pathology review was performed by experienced gynecopathologists In cases of clinically relevant diagnostic discrepancies the pathologist responsible for the original diagnosis was contacted If a given discrepancy could not be resolved a panel of experts was involved for clarification Four hundred fifty-four patients with an original diagnosis of ovarian tubal or peritoneal epithelial carcinoma were recruited In 68 % 31 patients a major diagnostic discrepancy of clinical relevance was found Most frequently 15 patients serous BOT had been misdiagnosed as invasive cancer Ovarian metastases constituted the second most frequent misdiagnosis 13 patients Minor discrepancies not affecting patient treatment were found in 282 % 128 patients Specialized central pathology review could help to avoid overtreatment of patients with BOT and inappropriate treatment of patients with ovarian metastases The implementation of a specialized case review process may translate into enhanced patient safety in clinical trials of ovarian carcinomas Furthermore central pathology review may increase the rigor and ultimately the transferability of clinical research into practice and should therefore become a standard procedure in study protocols evaluating new therapies\",\n",
            "}\n",
            "13525\n",
            "{\n",
            "  \"id\" : \"21945310\",\n",
            "  \"contents\" : \"A phase II clinical trial compared docetaxel in combination with carboplatin to sequential single agent docetaxel followed by carboplatin for treatment of recurrent platinum-sensitive ovarian peritoneal or tubal cancer This manuscript reports prospectively collected health-related quality of life HRQL Participants were randomized to either weekly docetaxel 30 mg/m 2 / days 1 and 8 and carboplatin AUC 6/day 1 every 3 weeks cDC or docetaxel 30 mg/m 2 / days 1 and 8 repeated every 3 weeks for 6 cycles followed by carboplatin AUC 6/day 1 every 3 weeks for 6 cycles or until disease progression sDC The primary HRQL endpoint was the trial outcome index TOI score of the Functional Assessment of Cancer Therapy-Ovarian FACT-O instrument and was assessed as an intent-to-treat analysis The secondary HRQL endpoints included the FACT-O total score the FACT-General and several domain scores of the FACT-O instrument physical well-being PWB social/family well-being SWB emotional well-being EWB functional well-being FWB and the ovarian cancer specific OCS module The FACT-O was administered at randomization prior to each of 6 cycles of treatment and at study endpoint One hundred forty-eight participants were randomized to each group Sequential docetaxel followed by carboplatin sDC was associated with significant improvements in the FACT-O TOI p = 0013 FACT-O total score p = 0033 and OCS p = 0029 compared to the combination docetaxel and carboplatin group cDC Sequential single agent docetaxel followed by carboplatin is associated with improved HRQL when compared to cDC The improved progression-free survival observed with cDC should be weighed against lower quality of life during treatment\",\n",
            "}\n",
            "13526\n",
            "{\n",
            "  \"id\" : \"10984871\",\n",
            "  \"contents\" : \"The bedside wellness system BSW is effective for decreasing stress and improving mental well-being and should help relieve the side effects and mental disorders of patients during cancer chemotherapy The study was a randomized clinical trial After giving informed consent patients were randomly assigned to the BSW intervention or control groups The patients were given the Hospital Anxiety and Depression Scale HADS test before the trial to evaluate their emotional baseline The Cancer Fatigue Scale which was developed at our institute and face visual analog scale were used to measure the emotional state and subjective feelings before and after the trial The degree of emesis was measured using a visual analogue scale after the experience We set up the system in a room in the outpatient clinic of the National Cancer Center New Hospital Building The decreases in the fatigue score and emesis score 3-5 days after chemotherapy were statistically significant both p < 005 and carry-over effects were detected BSW intervention therapy is an effective way to treat fatigue and emesis This virtual reality system is a new therapeutic method that can be used in palliative medicine\",\n",
            "}\n",
            "13527\n",
            "{\n",
            "  \"id\" : \"19531212\",\n",
            "  \"contents\" : \"New third-generation aromatase inhibitors AIs have proven comparable or superior to the anti-estrogen tamoxifen for treatment of estrogen receptor ER and/or progesterone receptor PR positive breast cancer AIs suppress total body and intratumoral estrogen levels It is unclear whether in situ carcinoma cell aromatization is the primary source of estrogen production for tumor growth and whether the aromatase expression is predictive of response to endocrine therapy Due to methodological difficulties in the determination of the aromatase protein COX-2 an enzyme involved in the synthesis of aromatase has been suggested as a surrogate marker for aromatase expression Primary tumor material was retrospectively collected from 88 patients who participated in a randomized clinical trial comparing the AI letrozole to the anti-estrogen tamoxifen for first-line treatment of advanced breast cancer Semi-quantitative immunohistochemical IHC analysis was performed for ER PR COX-2 and aromatase using Tissue Microarrays TMAs Aromatase was also analyzed using whole sections WS Kappa analysis was applied to compare association of protein expression levels Univariate Wilcoxon analysis and the Cox-analysis were performed to evaluate time to progression TTP in relation to marker expression Aromatase expression was associated with ER but not with PR or COX-2 expression in carcinoma cells Measurements of aromatase in WS were not comparable to results from TMAs Expression of COX-2 and aromatase did not predict response to endocrine therapy Aromatase in combination with high PR expression may select letrozole treated patients with a longer TTP TMAs are not suitable for IHC analysis of in situ aromatase expression and we did not find COX-2 expression in carcinoma cells to be a surrogate marker for aromatase In situ aromatase expression in tumor cells is associated with ER expression and may thus point towards good prognosis Aromatase expression in cancer cells is not predictive of response to endocrine therapy indicating that in situ estrogen synthesis may not be the major source of intratumoral estrogen However aromatase expression in combination with high PR expression may select letrozole treated patients with longer TTP Sub-study of trial P025 for advanced breast cancer\",\n",
            "}\n",
            "13528\n",
            "{\n",
            "  \"id\" : \"12927310\",\n",
            "  \"contents\" : \"A traditional asiatic phytoestrogen-rich diet is associated with a lower incidence of estrogen-dependent cancers and clinical consequences of postmenopausal estrogen deficiency First Wilcox in 1990 showed an increase of the vaginal cell maturation with phytoestrogens on postmenopausal women but this has not been confirmed in some subsequent studies In this study we analyzed the effects of a 6-month soy-rich diet on the vaginal epithelium of asymptomatic postmenopausal women in a randomized clinical trial 187 women were recruited for the study and divided into three groups a phytoestrogen rich diet group a hormonal replacement group and a control group A vaginal sample for hormonal cytology was taken before and at the end of the study and sent unnamed to a cytologist The karyopycnotic index KI increased significantly in the diet group and in the HRT group but not in the control group The maturation value MV had an identical trend to the KI We conclude that a soy rich diet is efficacious in increasing the maturation indices of vaginal cells This effect could be a useful marker of the efficacy of a dietary intervention with phytoestrogen rich foods and should be considered during preventive interventions against menopausal effects and vaginal atrophy\",\n",
            "}\n",
            "13529\n",
            "{\n",
            "  \"id\" : \"23127215\",\n",
            "  \"contents\" : \"Soluble fiber and the physical state of fruits/vegetables affect plasma - carotene concentrations however most of this research was conducted in laboratory-based settings These analyses investigated the relationship between soluble fiber and juiced versus whole fruits/vegetables to plasma - carotene concentrations in a free-living population This cross-sectional analysis used 12-month follow-up data from the Women s Healthy Eating & Living Study 1995-2006 a study to improve diet in breast cancer survivors in the Western United States The dietary nutrients considered in this analysis included intake of soluble fiber g - carotene from fruit/vegetable juice mg and - carotene from whole fruits/vegetables mg A linear regression model was used to assess the relationship of the variables to plasma - carotene concentrations Out of 3088 women enrolled in the Women s Healthy Eating & Living Study 2397 women had complete data mean age = 54 The final model accounted for approximately 49 % of the explained variance in plasma - carotene concentrations Fruit/vegetable juice had the largest positive relation to plasma - carotene concentrations standardized parameter estimate = 023 p < 001 followed by whole fruits/vegetables standardized parameter estimate = 009 p < 001 Soluble fiber may inhibit - carotene absorption therefore consumption of juice may increase plasma - carotene concentrations more than whole fruits/vegetables in free-living populations\",\n",
            "}\n",
            "13530\n",
            "{\n",
            "  \"id\" : \"24906437\",\n",
            "  \"contents\" : \"The effectiveness and tolerability of tapentadol extended release ER a centrally acting analgesic with - opioid receptor agonist and norepinephrine noradrenaline reuptake inhibitor activities have been demonstrated in patients with chronic pain including those switching directly from prior opioid therapy The objective of the current study was to evaluate the effectiveness and safety of conversion to oral tapentadol ER 50-250 mg twice daily from previous around-the-clock strong opioid therapy in patients with moderate to severe chronic malignant tumor-related cancer pain that was well-controlled This randomized open-label phase III study which was conducted in Japan included a 1 - to 2-week screening period on previous opioid and an 8-week open-label treatment period Eligible patients who were taking a strong opioid analgesic and had a mean pain intensity score < 4 during the 3 days prior to randomization adequate pain control on previous strong opioid were randomized 11 to receive twice-daily treatment with tapentadol ER 100-500 mg/day or morphine sustained release SR 20-140 mg/day reference for assay sensitivity Initial doses were estimated based on the conversion ratio of tapentadol ER oxycodone morphine fentanyl = 1023003 The primary effectiveness endpoint was the proportion of patients who maintained pain control [ change from baseline in mean pain intensity 11-point numerical rating scale less than +15 for 3 consecutive days and no more than two doses of rescue medication per day for 3 consecutive days during the first week of open-label treatment In the tapentadol ER group n = 50 840 % of patients 42/50 95 % CI 7089-92 83 maintained pain control during Week 1 On the Patient Global Impression of Change 21 % 1/48 21 % 1/48 229 % 11/48 and 500 % 24/48 of patients in the tapentadol ER group reported that their overall condition was very much improved much improved minimally improved and not changed respectively at Week 1 compared with 0 % 107 % 3/28 286 % 8/28 and 536 % 15/28 reporting these ratings at Week 8 The sensitivity of effectiveness analyses was validated based on results using morphine SR 980 % 49/50 95 % CI 8935-99 95 of patients in the morphine SR group maintained pain control after 1 week of treatment The overall safety profile was similar to that demonstrated in previous studies tapentadol ER was associated with a lower incidence of gastrointestinal treatment-emergent adverse events than morphine SR [ 380 % 19/50 vs 540 % 27/50 ] including constipation [ 120 % 6/50 vs 200 % 10/50 ] and vomiting [ 60 % 3/50 vs 260 % 13/50 ] Overall results indicate that conversion from previous strong opioids to tapentadol ER 50-250 mg twice daily was successful and resulted in safe and effective pain control with improved gastrointestinal tolerability versus morphine SR in patients with moderate to severe cancer-related pain that was well-controlled on their previous opioid\",\n",
            "}\n",
            "13531\n",
            "{\n",
            "  \"id\" : \"16896884\",\n",
            "  \"contents\" : \"Castration therapy adjuvant to radiotherapy can significantly improve overall survival compared with radiotherapy alone in patients with locally advanced prostate cancer Although many of the adverse effects of castration therapy are manageable they can have a detrimental effect on quality of life Here we evaluate the efficacy and tolerability of the non-castration-based therapy bicalutamide Casodex 150 mg adjuvant to radiotherapy in patients with T1-4 M0 any n prostate cancer The subset of patients within the early prostate cancer EPC program who received radiotherapy with curative intent n = 1370 were included in the analysis These patients were randomized to receive oral bicalutamide 150 mg once daily n = 699 or placebo n = 671 The median follow-up for patients included in this analysis was 72 years In patients with locally advanced disease n = 305 bicalutamide adjuvant to radiotherapy significantly improved progression-free survival PFS reducing the risk of objective progression by 44 % compared with radiotherapy alone [ hazard ratio HR 056 95 % confidence interval CI 040 078 P < 0001 Prostate-specific antigen PSA - PFS reducing the risk of PSA progression by 59 % compared with radiotherapy alone HR 041 95 % CI 030 055 P < 0001 Overall survival reducing the risk of death by 35 % compared with radiotherapy alone HR 065 95 % CI 044 095 P = 003 This significant overall survival benefit for bicalutamide was driven by a lower risk of prostate cancer-related deaths 161 vs 243 % respectively There was no significant difference in PFS or overall survival in patients with localized disease n = 1065 In patients with locally advanced disease bicalutamide 150 mg adjuvant to radiotherapy demonstrates significant clinical benefits in terms of overall survival PFS and PSA-PFS compared with radiotherapy alone The overall survival benefit in these patients is consistent with prior studies evaluating castration-based therapies adjuvant to radiotherapy Bolla et al in Lancet 360103 -108 2002 Pilepich et al in Int J Radiat Oncol Biol Phys 611285 -1290 2005 In addition the clinical benefit of bicalutamide 150 mg in locally advanced patients but not in those with localized disease is consistent with the overall results from the EPC program McLeod et al BJU Int 97247 -254 2006 Given the quality-of-life advantages of bicalutamide relative to castration bicalutamide 150 mg adjuvant to radiotherapy is an attractive alternative for men with locally advanced prostate cancer\",\n",
            "}\n",
            "13532\n",
            "{\n",
            "  \"id\" : \"15911864\",\n",
            "  \"contents\" : \"To prospectively assess the impact of treatment with cisplatin alone or in combination with topotecan CT on quality of life QOL in patients with advanced or recurrent cervical cancer and to explore the prognostic value of baseline QOL scores Patients entered on Gynecologic Oncology Group GOG Protocol 179 were expected to complete QOL assessments at four time points using Functional Assessment of Cancer Therapy-General FACT-G Cervix subscale Cx subscale FACT/GOG-Neurotoxicity subscale NTX subscale Brief Pain Inventory BPI and UNISCALE UNI Adjusting for patient age baseline scores and effects of time we longitudinally examined treatment effect on QOL during and after chemotherapy Among patients randomly allocated to receive cisplatin n = 146 or CT n = 147 there were no statistically significant differences in QOL up to 9 months after randomization despite more hematologic toxicity in the combination arm QOL assessments were completed at rates of 98 % 85 % 68 % and 59 % respectively for the four time points with similar rates and reasons for nonparticipation between regimens Baseline FACT-G P = 0016 and BPI P = 0001 scores were significantly associated with patient age older patients had better QOL and less pain Baseline UNI was positively correlated with FACT-G r = 066 P < 001 and Cx subscale r = 029 P < 001 and negatively related to BPI r = -041 P < 0001 Baseline FACT-Cx FACT-G + Cx subscale was associated with survival Despite increased toxicity CT did not significantly reduce patient QOL when compared with cisplatin alone Patient-reported QOL measures may be an important prognostic tool in advanced cervix cancer\",\n",
            "}\n",
            "13533\n",
            "{\n",
            "  \"id\" : \"19047288\",\n",
            "  \"contents\" : \"Prophylactic cranial irradiation PCI in patients with extensive-disease small-cell lung cancer ED-SCLC leads to significantly fewer symptomatic brain metastases and improved survival Detailed effects of PCI on health-related quality of life HRQOL are reported here Patients age 18 to 75 years WHO < or = 2 with ED-SCLC and any response to chemotherapy were randomly assigned to either observation or PCI Health-related quality of life HRQOL and patient-reported symptoms were secondary end points The European Organisation for the Research and Treatment of Cancer core HRQOL tool Quality of Life Questionnaire C30 and brain module Quality of Life Questionnaire Brain Cancer Module were used to collect self-reported patient data Six HRQOL scales were selected as primary HRQOL end points global health status hair loss fatigue and role cognitive and emotional functioning Assessments were performed at random assignment 6 weeks 3 months and then 3-monthly up to 1 year and 6-monthly thereafter Compliance with the HRQOL assessment was 937 % at baseline and dropped to 60 % at 6 weeks Short-term results up to 3 months showed that there was a negative impact of PCI on selected HRQOL scales The largest mean difference between the two arms was observed for fatigue and hair loss The impact of PCI on global health status as well as on functioning scores was more limited For global health status the observed mean difference was eight points on a scale 0 to 100 at 6 weeks P = 018 and 3 months P = 055 PCI should be offered to all responding ED SCLC patients Patients should be informed of the potential adverse effects from PCI Clinicians should be alert to these monitor their patients and offer appropriate support clinical and psychosocial care\",\n",
            "}\n",
            "13534\n",
            "{\n",
            "  \"id\" : \"14521639\",\n",
            "  \"contents\" : \"Little is known about the relative advantages of video versus internet-based decision aids to facilitate shared medical decision making This study compared internet and video patient education modalities for men considering the prostate specific antigen PSA test Two hundred and twenty-six men aged 50 years or older and scheduled to complete a physical examination at an HMO Health Appraisal Clinic were randomly assigned to access a website N = 114 or view a 23-minute videotape in the clinic N = 112 prior to deciding whether they wanted to be screened for prostate cancer There were no between-groups differences in participants ratings of convenience effort or satisfaction following exposure to the decision aid Participants assigned to the video group were more likely to review the materials than individuals assigned to the internet group 982 % vs 535 % Participants in the video group showed significantly greater increases in PSA knowledge and were more likely to decline the PSA test than individuals assigned to the internet group However participants in the internet group who reviewed the entire online presentation showed similar increases in PSA knowledge as video participants Only 5 % of all participants visited other websites to inform themselves about the PSA test Overall the video was significantly more effective than the Internet in educating participants about benefits and risks of PSA screening\",\n",
            "}\n",
            "13535\n",
            "{\n",
            "  \"id\" : \"25377592\",\n",
            "  \"contents\" : \"Trastuzumab Herceptin is a humanized monoclonal antibody targeting the human epidermal growth factor receptor 2 HER2 and is used in the treatment of HER2-overexpressing breast and gastric cancer FTMB is being developed as a biosimilar of trastuzumab In this combined dose-escalation and bioequivalence study of parallel design the pharmacokinetic profile of FTMB was compared with Herceptin Healthy male volunteers received single doses of 05 15 30 or 60 mg/kg FTMB or placebo in consecutive dose-escalation cohorts to assess the safety profile Thereafter the 6 mg/kg cohort was expanded to establish bioequivalence between FTMB Test and Herceptin Reference based on an acceptance interval of 800-125 0 % In total 118 subjects were enrolled in the study The mean area under the concentration-time curve from time zero to infinity AUC was 1609 gday/mL Test and 1330 gday/mL Reference The log-transformed geometric mean Test/Reference T/R ratio for AUC was 896 % 90 % confidence interval [ CI ] 851-94 4 demonstrating bioequivalence For the secondary endpoint the maximum concentration observed Cmax the geometric mean T/R ratio was 894 % 90 % CI 834-95 9 Non-linear target-mediated pharmacokinetics were also observed Adverse events other than the documented side effects of Herceptin fever influenza-like illness and fatigue did not occur No signs of cardiotoxicity were observed This bioequivalence study with a trastuzumab biosimilar in healthy male volunteers demonstrated bioequivalence of FTMB with Herceptin FTMB was well tolerated in doses up to 6 mg/kg Non-linear target elimination was also observed in the pharmacokinetic profile of trastuzumab\",\n",
            "}\n",
            "13536\n",
            "{\n",
            "  \"id\" : \"24169176\",\n",
            "  \"contents\" : \"To evaluate outcomes of isolated hepatic perfusion IHP on isolated liver metastases LMs Isolated unresectable LMs are often the main determinant of overall survival OS for colorectal cancer CRC and other solid malignancies We hypothesized that IHP can be performed safely and yield impressive responses for a variety of solid tumor pathology using different perfusion agents Retrospective review of a prospectively collected database of patients undergoing IHP for unresectable solid tumor LM Between 2003 and 2012 IHP was completed in 91 patients Primary tumor pathology was CRC = 54 non-CRC = 37 ocular/cutaneous melanoma = 32 cholangiocarcinoma = 3 appendiceal = 1 and breast = 1 IHP employed Melphalan n = 69 CRC = 32 non-CRC = 37 Oxaliplatin n = 10 CRC or Oxaliplatin + 5FU n = 12 CRC Hepatic arterial infusion HAI pumps were placed in all CRC patients There were 3 33 % perioperative deaths Response rates for CRC melanoma and cholangiocarcinoma were 682 % 571 % and 100 % respectively Response rates for CRC patients using 5FU + Oxaliplatin Oxaliplatin or Melphalan were 833 % 667 % and 609 % respectively Median OS for the CRC patients from IHP date was 23 months 95 % confidence interval 15-28 months On univariate analysis receipt of HAI-FUDR floxuridine within 1 year of IHP was the only factor associated with improved OS P = 0043 in CRC patients IHP results in excellent response rates for patients with unresectable liver metastasis from solid tumors Improved local control for CRC patients undergoing IHP-HAI may improve survival\",\n",
            "}\n",
            "13537\n",
            "{\n",
            "  \"id\" : \"23000116\",\n",
            "  \"contents\" : \"The prostate component of the Prostate Lung Colorectal and Ovarian PLCO randomized screening trial demonstrated no mortality effect of screening Here we analyze prostate cancer specific survival in PLCO and its relation to screening 76693 men aged 55-74 were randomized to usual care n = 38350 or intervention n = 38343 Intervention arm men received annual prostate-specific antigen 6 years and digital rectal exam 4 years Men were followed for cancer diagnosis and mortality through 13 years Medical record abstractors confirmed prostate cancer diagnoses stage and grade Prostate-specific survival in PLCO cases was analyzed using Kaplan-Meier analysis and proportional hazards modeling We utilized data from the Surveillance Epidemiology and End Results SEER program to compute expected survival in PLCO and compared this to observed There was no significant difference in prostate-specific survival rates between arms 10 year survival rates were 947 % intervention n = 4250 cases versus 935 % usual care n = 3815 cases Within the intervention arm cases never screened in PLCO had lower 10 year survival rates 82 % than screen detected or interval following a negative screen cases both around 955 % The ratio of observed to expected 10 year prostate-specific death 1-survival rates was 059 95 % CI 051-0 68 for all PLCO cases 066 95 % CI 051-0 81 for Gleason 5-7 cases and 107 95 % CI 087-1 3 for Gleason 8-10 cases Prostate cancer specific survival in PLCO was comparable across arms and significantly better than expected based on nationwide population data How much of the better survival is due to a healthy volunteer effect and to lead-time and overdiagnosis biases is not readily determinable\",\n",
            "}\n",
            "13538\n",
            "{\n",
            "  \"id\" : \"21167327\",\n",
            "  \"contents\" : \"Nasojejunal tube NJT decompression is routinely used for intestinal drainage after total gastrectomy It is supposed that it would protect anastomosis but since the stomach should be completely removed today its efficacy is under question On the other hand the tube leads to the discomfort of patients and aspiration disorders or nasopharyngial ulceration The aim of this study was to evaluate the efficacy and necessity of the nasojejunal tube decompression after gastrectomy In this interventional study 50 gastric cancer patients who underwent gastrectomy in Ghaem and Omid hospitals which are affiliated with the Mashhad University of Medical Sciences from 2001 to 2008 were enrolled The patients were randomly divided into two groups of with NJT 25 cases and without NJT 25 cases The rate of complications hospital stay duration and the time of beginning their diet were evaluated The two groups were similar in age sex state of the disease bleeding volume and length of removed esophagus There was no significant difference between these two groups considering the initial passing of gas the beginning of their diet and hospital stay duration But the incidence of sore throat nasal discomfort speech disorders and patients dissatisfation were higher in the group with NJT It seems that patients without NJT were more comfortable and satisfied after total gastrectomy Thus there is no need for the insertion of the NJT after gastrectomy\",\n",
            "}\n",
            "13539\n",
            "{\n",
            "  \"id\" : \"24768938\",\n",
            "  \"contents\" : \"The primary goal of Phase II clinical trials is to understand better a treatment s safety and efficacy to inform a Phase III go/no-go decision Many Phase II designs have been proposed incorporating randomization interim analyses adaptation and patient selection The Phase II design with an option for direct assignment ie stop randomization and assign all patients to the experimental arm based on a single interim analysis IA at 50 % accrual was recently proposed [ An et al 2012 ] We discuss this design in the context of existing designs and extend it from a single-IA to a two-IA design We compared the statistical properties and clinical relevance of the direct assignment design with two IA DAD-2 versus a balanced randomized design with two IA BRD-2 and a direct assignment design with one IA DAD-1 over a range of response rate ratios 20-3 0 The DAD-2 has minimal loss in power < 22 % and minimal increase in T1ER < 16 % compared to a BRD-2 As many as 80 % more patients were treated with experimental vs control in the DAD-2 than with the BRD-2 experimental vs control ratio 18 vs 10 and as many as 64 % more in the DAD-2 than with the DAD-1 18 vs 11 We illustrate the DAD-2 using a case study in lung cancer In the spectrum of Phase II designs the direct assignment design especially with two IA provides a middle ground with desirable statistical properties and likely appeal to both clinicians and patients\",\n",
            "}\n",
            "13540\n",
            "{\n",
            "  \"id\" : \"24447434\",\n",
            "  \"contents\" : \"Activation of the phosphatidylinositol-3-kinase PI3K and/or mitogen-activated protein kinase MAPK pathways results in anti-estrogen resistance in vitro but a biomarker with clinical validity to predict intrinsic resistance has not been identified In metastatic breast cancer patients with previous exposure to endocrine therapy the addition of a mammalian target of rapamycine mTOR inhibitor has been shown to be beneficial Whether or not patients on adjuvant endocrine treatment might benefit from these drugs is currently unclear A biomarker that predicts intrinsic resistance could potentially be used as companion diagnostic in this setting We tested the clinical validity of different downstream-activated proteins in the PI3K and/or MAPK pathways to predict intrinsic tamoxifen resistance in postmenopausal primary breast cancer patients We recollected primary tumor tissue from patients who participated in a randomized trial of adjuvant tamoxifen 1-3 years versus observation After constructing a tissue micro-array cores from 563 estrogen receptor positive were immunostained for p-AKT Thr308 p-AKT Ser473 p-mTOR p-p706SK and p-ERK1 / 2 Cox proportional hazard models for recurrence free interval were used to assess hazard ratios and interactions between these markers and tamoxifen treatment efficacy Interactions were identified between tamoxifen and p-AKT Thr308 p-mTOR p-p70S6K and p-ERK1 / 2 Applying a conservative level of significance p-p70S6K remained significantly associated with tamoxifen resistance Patients with p-p70S6K negative tumors derived significant benefit from tamoxifen HR 024 P < 00001 while patients whose tumor did express p-p70S6K did not HR = 102 P = 095 P for interaction 0004 In systemically untreated breast cancer patients p-p70S6K was associated with a decreased risk for recurrence Patients whose tumor expresses p-p70S6K as a marker of downstream PI3K and/or MAPK pathway activation have a favorable prognosis but do not benefit from adjuvant tamoxifen A potential benefit from inhibitors of the PI3K/Akt/mTOR pathway in these patients needs to be further explored\",\n",
            "}\n",
            "13541\n",
            "{\n",
            "  \"id\" : \"17876013\",\n",
            "  \"contents\" : \"We evaluated the safety and efficacy of concurrent administration of two monoclonal antibodies cetuximab and bevacizumab in patients with metastatic colorectal cancer This was a randomized phase II study in patients with irinotecan-refractory colorectal cancer All patients were nave to both bevacizumab and cetuximab Patients in arm A received irinotecan at the same dose and schedule as last received before study entry plus cetuximab 400 mg/m2 loading dose then weekly cetuximab 250 mg/m2 plus bevacizumab 5 mg/kg administered every other week Patients in arm B received the same cetuximab and bevacizumab as those in arm A but without irinotecan Forty-three patients received cetuximab bevacizumab and irinotecan CBI and 40 patients received cetuximab and bevacizumab alone CB Toxicities were as would have been expected from the single agents For the CBI arm time to tumor progression TTP was 73 months and the response rate was 37 % for the CB arm TTP was 49 months and the response rate was 20 % The overall survival for the CBI arm was 145 months and the overall survival for the CB-alone arm was 114 months Cetuximab and bevacizumab can be administered concurrently with a toxicity pattern that seems to be similar to that which would be expected from the two agents alone This combination plus irinotecan also seems to be feasible The activity seen with the addition of bevacizumab to cetuximab or to cetuximab plus irinotecan seems to be favorable when compared with historical controls of cetuximab or cetuximab/irinotecan in patients who are nave to bevacizumab\",\n",
            "}\n",
            "13542\n",
            "{\n",
            "  \"id\" : \"23033982\",\n",
            "  \"contents\" : \"Mistletoe Viscum album L extracts are widely used in complementary cancer therapy Aim of this study was to evaluate safety and efficacy of a standardized mistletoe extract abnobaVISCUM Quercus aVQ in patients with gastric cancer 32 operated gastric cancer patients stage Ib or II who were waiting for oral chemotherapy with the 5-FU prodrug doxifluridine were randomized 11 to receive additional therapy with aVQ or no additional therapy aVQ was injected subcutaneously three times per week from postoperative day 7 to week 24 in increasing doses EORTC QLQ-C30 and - STO22 Quality of Life questionnaire differential blood count liver function tests various cytokine levels tumor necrosis factor TNF - alpha interleukin IL -2 CD 16 + / CD56 + and CD 19 + lymphocytes were analyzed at baseline and 8 16 and 24 weeks later Global health status p < 001 leukocyte - and eosinophil counts p 001 increased significantly in the treatment group compared to the control group Diarrhea was less frequently reported 7 % vs 50 % p = 0014 in the intervention group There was no significant treatment effect on levels of TNF-alpha IL-2 CD16 + / CD56 + and CD 19 + lymphocytes and liver function tests measured by ANOVA Additional treatment with aVQ is safe and was associated with improved QoL of gastric cancer patients ClinicalTrialsGov Registration number NCT01401075\",\n",
            "}\n",
            "13543\n",
            "{\n",
            "  \"id\" : \"25247897\",\n",
            "  \"contents\" : \"Caudal analgesia has been prolonged by the addition of various adjuvants Dexmedetomidine is a highly selective alpha-2 agonist with sedative and analgesic properties To investigate the effect of addition of dexmedetomidine to 025 % bupivacaine for caudal analgesia in children undergoing major abdominal cancer surgery A randomized double-blind trial Academic medical center Forty pediatric patients aged 3 - 12 years weighting 10 - 40 kg and of American Society of Anesthesiologists ASA physical status I and II scheduled for major abdominal cancer surgeries under general anesthesia combined with caudal analgesia were enrolled They were randomly allocated into 2 groups Group I BD n = 20 received 1 mL/kg bupivacaine 025 % with dexmedetomidine 1 g/kg and group II B n = 20 received 1 mL/kg bupivacaine 025 % Heart rate HR mean arterial pressure MAP and oxygen saturation SPO2 were recorded for 120 minutes Pain was assessed immediately postoperative and at hours 2 4 6 12 18 and 24 of postoperative period by Face Legs Activity Cry and Consolability FLACC score Time to first request for analgesia and total analgesic consumption in the first 24 hours were recorded The level of sedation was recorded using Ramsay s sedation scale [ Intravenous acetaminophen 15mg/kg perfalgan Squibb ] Adverse effects were recorded and treated There was significant reduction in FLACC score in group BD at 2 4 6 and 12 hours postoperatively compared to group BAt the eighteenth and twenty-fourth hour there was no significant difference Time of the first rescue analgesic requirement was significantly prolonged in group BD compared to group BThe mean total consumption of rescue analgesia in the 24 hours of the postoperative period was significantly decreased in group BD 40500 21503 mg when compared with group B 81035 20093 mg This study is limited by its small sample size Addition of dexmedetomidine 1 g/kg to caudal bupivacaine 025 % 1 mL/kg in pediatric major abdominal cancer surgeries achieved significant postoperative pain relief for up to 19 hours with less use of postoperative analgesics and prolonged duration of arousable sedation Hemodynamic changes were statistically significant yet of no clinical significance\",\n",
            "}\n",
            "13544\n",
            "{\n",
            "  \"id\" : \"20565953\",\n",
            "  \"contents\" : \"The aims of this study were to investigate whether drug sequence docetaxel followed by anthracyclines or the drugs in reverse order affects changes in the maximal standard uptake volume SUVmax on [ 18F ] fluorodeoxyglucose positron emission tomography FDG-PET during neoadjuvant chemotherapy in women with locally advanced breast cancer Women were randomly assigned to receive either drug sequence and FDG-PET scans were taken at baseline after four cycles and after eight cycles of chemotherapy Tumour response to chemotherapy was evaluated based on histology from a surgical specimen collected upon completion of chemotherapy Sixty women were enrolled into the study Thirty-one received docetaxel followed by anthracyclines Arm A and 29 received drugs in the reverse order Arm B Most women 83 % had ductal carcinoma and 10 women 17 % had lobular or lobular/ductal carcinoma All but one tumour were downstaged during therapy Overall there was no significant difference in response between the two drug regimens However women in Arm B who achieved complete pathological response had mean FDG-PET SUVmax reduction of 877 % after four cycles in contrast to those who had no or minor pathological response These women recorded mean SUVmax reductions of only 27 % P < 001 Women in Arm A showed no significant difference in SUVmax response according to pathological response Sensitivity specificity accuracy and positive and negative predictive values were highest in women in Arm BOur results show that SUVmax uptake by breast tumours during chemotherapy can be dependent on the drugs used Care must be taken when interpreting FDG-PET in settings where patients receive varied drug protocols\",\n",
            "}\n",
            "13545\n",
            "{\n",
            "  \"id\" : \"23702642\",\n",
            "  \"contents\" : \"A sound understanding of the benefits of different treatment options and their health-related quality of life HRQoL impacts is required for optimal breast cancer care A cross-sectional cohort study was conducted to determine the prevalence and severity of persistent functional decrements and symptoms and identify demographic clinical and treatment variables associated with poorer outcomes Four hundred English-speaking women treated for ductal carcinoma-in-situ or stage I to III breast cancer between 1999 and 2009 at least 12months after surgery and currently disease free were randomly selected and invited to complete 1 the Breast Cancer Treatment Outcome Scale and 2 the EORTC core Quality of Life Questionnaire version 3 The response rate was 8560 % Many participants reported moderate to severe decrements in a number of HRQoL domains including functional well-being 15 % cosmetic status 32 % and overall quality of life 21 % There were significant associations p < 05 between younger age and poorer HRQoL but none between time since surgery and morbidity p > 05 Different treatments were associated with different HRQoL impacts Poorer functional status was predicted by axillary dissection p = 011 and adjuvant radiotherapy was a significant predictor of breast-specific pain p < 05 Many breast cancer survivors report long-term morbidity that is unaffected by time since surgery The significant associations between the extent of locoregional therapies and poorer HRQoL outcomes emphasize the importance of the safe tailoring of these treatments\",\n",
            "}\n",
            "13546\n",
            "{\n",
            "  \"id\" : \"18048820\",\n",
            "  \"contents\" : \"To evaluate the ability of either oral minocycline topical tazarotene or both to reduce or prevent cetuximab-related acneiform rash when administered starting on day 1 of cetuximab therapy Metastatic colorectal cancer patients preparing to initiate cetuximab were randomly assigned to receive daily oral minocycline or placebo and to receive topical tazarotene application to either left or right side of the face Both therapies were administered for 8 weeks Forty-eight eligible patients were randomly assigned to minocycline n = 24 or placebo n = 24 Total facial lesion counts were significantly lower in patients receiving minocycline at weeks 1 through 4 At week 4 a lower proportion of patients in the minocycline arm reported moderate to severe itch than in the placebo arm 20 % v 50 % P = 05 Facial photographs obtained at week 4 were reviewed for rash global severity Patients in the minocycline arm trended toward lower frequency of moderate to severe rash than patients receiving placebo 20 % v 42 % P = 13 The differences in total facial lesion counts and subjectively assessed itch were diminished by week 8 Cetuximab treatment was interrupted because of grade 3 skin rash in four patients in the placebo arm and none in the minocycline arm There was no observed clinical benefit to tazarotene application Tazarotene treatment was associated with significant irritation causing its discontinuation in one third of patients Prophylaxis with oral minocycline may be useful in decreasing the severity of the acneiform rash during the first month of cetuximab treatment Topical tazarotene is not recommended for management of cetuximab-related rash\",\n",
            "}\n",
            "13547\n",
            "{\n",
            "  \"id\" : \"26164096\",\n",
            "  \"contents\" : \"Before this study started the standard postoperative chemotherapy regimen for stage II-III Wilms tumour pretreated with chemotherapy was to include doxorubicin However avoidance of doxorubicin-related cardiotoxicity effects is important to improve long-term outcomes for childhood cancers that have excellent prognosis We aimed to assess whether doxorubicin can be omitted safely from chemotherapy for stage II-III histological intermediate-risk Wilms tumour when a newly defined high-risk blastemal subtype was excluded from randomisation For this international multicentre open-label non-inferiority phase 3 randomised SIOP WT 2001 trial we recruited children aged 6 months to 18 years at the time of diagnosis of a primary renal tumour from 251 hospitals in 26 countries who had received 4 weeks of preoperative chemotherapy with vincristine and actinomycin D Children with stage II-III intermediate-risk Wilms tumours assessed after delayed nephrectomy were randomly assigned 11 by a minimisation technique to receive vincristine 15 mg/m 2 at weeks 1-8 11 12 14 15 17 18 20 21 23 24 26 and 27 plus actinomycin D 45 g/kg every 3 weeks from week 2 either with five doses of doxorubicin 50 mg/m 2 given every 6 weeks from week 2 standard treatment or without doxorubicin experimental treatment The primary endpoint was non-inferiority of event-free survival at 2 years analysed by intention to treat and a margin of 10 % Assessment of safety and adverse events included systematic monitoring of hepatic toxicity and cardiotoxicity This trial is registered with EudraCT number 2007-004591-39 and is closed to new participants Between Nov 1 2001 and Dec 16 2009 we recruited 583 patients 341 with stage II and 242 with stage III tumours and randomly assigned 291 children to treatment including doxorubicin and 292 children to treatment excluding doxorubicin Median follow-up was 608 months IQR 408-798 2 year event-free survival was 926 % 95 % CI 896-957 for treatment including doxorubicin and 882 % 845-921 for treatment excluding doxorubicin a difference of 44 % 95 % CI 04-93 that did not exceed the predefined 10 % margin 5 year overall survival was 965 % 943-988 for treatment including doxorubicin and 958 % 933-984 for treatment excluding doxorubicin Four children died from a treatment-related toxic effect one < 1 % of 291 receiving treatment including doxorubicin died of sepsis three 1 % of 292 receiving treatment excluding doxorubicin died of varicella metabolic seizure and sepsis during treatment for relapse 17 patients 3 % had hepatic veno-occlusive disease Cardiotoxic effects were reported in 15 5 % of 291 children receiving treatment including doxorubicin 12 children receiving treatment including doxorubicin and ten children receiving treatment excluding doxorubicin died with the remaining deaths from tumour recurrence Doxorubicin does not need to be included in treatment of stage II-III intermediate risk Wilms tumour when the histological response to preoperative chemotherapy is incorporated into the risk stratification See Acknowledgments for funders\",\n",
            "}\n",
            "13548\n",
            "{\n",
            "  \"id\" : \"9457819\",\n",
            "  \"contents\" : \"To investigate whether thoracic spinal cord dose of 504 Gy given via 12 Gy bid fractionation carries a risk of developing radiation myelitis during studies using hyperfractionated radiation therapy HFX RT with and without concurrent chemotherapy CHT Of 300 patients with Stage III nonsmall-cell lung cancer NSCLC who were treated on two consecutive Phase III studies 158 patients received 504 Gy to a portion of their spinal cord and survived > 1 year after the beginning of the therapy None of these 158 patients developed thoracic radiation myelitis Therefore influence of potentially contributing factors on the occurrence of radiation myelitis such as interfraction interval or those unproven yet such as cord length or administration of concurrent CHT was not possible to investigate Given the continuing interest in HFX RT and encouraging results obtained in studies in lung cancer further investigation is needed to get more informations about risks of developing thoracic radiation myelitis with this cord dose\",\n",
            "}\n",
            "13549\n",
            "{\n",
            "  \"id\" : \"23394492\",\n",
            "  \"contents\" : \"Since the definition of different histologic subtypes of urothelial carcinomas by the World Health Organization WHO 2004 classification description of molecular features and clinical behavior of these variants has gained more attention We reviewed 205 tumor samples of patients with locally advanced bladder cancer mainly treated within the randomized AUO-AB05 / 95 trial with radical cystectomy and adjuvant cisplatin-based chemotherapy for histologic subtypes 178 UC 18 plasmacytoid PUC and 9 micropapillary MPC carcinomas of the bladder were identified Kaplan Meier analysis and backward multivariate Cox s proportional hazards regression analysis were performed to compare overall survival between the three histologic subtypes Patients suffering from PUC have the worst clinical outcome regarding overall survival compared to conventional UC and MPC of the bladder that in turn seem have to best clinical outcome 274 months 626 months and 642 months respectively p = 0013 by Kaplan Meier analysis Backward multivariate Coxs proportional hazards regression analysis adjusted to relevant clinicopathological parameters showed a hazard ratio of 32 p = 0045 for PUC in contrast to patients suffering from MPC Histopathological diagnosis of rare variants of urothelial carcinoma can identify patients with poor prognosis\",\n",
            "}\n",
            "13550\n",
            "{\n",
            "  \"id\" : \"17180286\",\n",
            "  \"contents\" : \"Endoscopic ultrasonography EUS is an integrated part of the pretherapeutic evaluation program for patients with upper gastrointestinal GI tract cancer Whether the clinical impact of EUS differs between surgeons from different countries is unknown The same applies to the potential clinical influence of EUS misinterpretations The aim of this study was to evaluate the interobserver agreement on predefined treatment strategies between surgeons from four different countries with and without EUS and to evaluate the clinical consequences of EUS misinterpretations One hundred patients with upper GI tract cancer were randomly selected from all upper GI tract cancer patients treated at Odense University Hospital between 1997 and 2000 Based on patient records and EUS database results a case story was created with and without the EUS result for each patient Four surgeons were asked to select the relevant treatment strategy in each case at first without knowledge of the EUS and thereafter with the EUS result available Interobserver agreement and impact of EUS misinterpretations were evaluated using the actual final treatment of each patient as reference Three of four or all four surgeons agreed on the same treatment strategy for nearly 60 % of the patients with and without the EUS results Treatment decisions were changed in 34 % based on the EUS results and the majority of these changes were toward nonsurgical and palliative treatments 85 % Interobserver agreement was relatively low but overall EUS increased kappa values from 016 poor to 033 fair thus indicating increased overall agreement after the EUS results were available EUS conclusion regarding stage or resectability was wrong in 17 % of the cases but only one serious event would have been the clinical result of EUS misinterpretations Despite being used in different ways by different surgeons EUS did change patient management in one third of the cases The impact of EUS misinterpretations seemed very low and this study confirmed one of the strongest clinical possibilities of EUS ie the ability to detect nonresectable cases EUS is an important imaging modality for oncosurgeons from different countries\",\n",
            "}\n",
            "13551\n",
            "{\n",
            "  \"id\" : \"14630678\",\n",
            "  \"contents\" : \"Oral capecitabine achieves a superior response rate with an improved safety profile compared with bolus 5-fluorouracil-leucovorin 5-FU/LV as first-line treatment for patients with metastatic colorectal cancer We report here the results of a large phase III trial investigating adjuvant oral capecitabine compared with 5-FU/LV Mayo Clinic regimen in Dukes C colon cancer Patients aged 18-75 years with resected Dukes C colon carcinoma were randomized to receive 24 weeks of treatment with either oral capecitabine 1250 mg/m 2 twice daily days 1-14 every 21 days n = 993 or iv bolus 5-FU 425 mg/m 2 with iv leucovorin 20 mg/m 2 on days 1-5 repeated every 28 days n = 974 Patients receiving capecitabine experienced significantly P < 0001 less diarrhea stomatitis nausea/vomiting alopecia and neutropenia but more hand-foot syndrome than those receiving 5-FU/LV Fewer patients receiving capecitabine experienced grade 3 or 4 neutropenia febrile neutropenia/sepsis and stomatitis P < 0001 although more experienced grade 3 hand-foot syndrome than those treated with 5-FU/LV P < 0001 Capecitabine demonstrates a similar favorable safety profile in patients aged < 65 years or > or = 65 years old Based on its improved safety profile capecitabine has the potential to replace 5-FU/LV as standard adjuvant treatment for patients with colon cancer Efficacy results are expected to be available in Keywords Adjuvant treatment capecitabine chemotherapy colorectal cancer\",\n",
            "}\n",
            "13552\n",
            "{\n",
            "  \"id\" : \"22781292\",\n",
            "  \"contents\" : \"Recombinant human endostatin rh-Endostatin a protein modified by an additional nine-amino acid sequence to the N-terminal of endostatin is a novel antiangiogenesis drug developed in China The preclinical data suggested that it can inhibit proliferation and migration not only in endothelial cells but also in some types of tumor cells Theoretically antiangiogenesis drugs should also be effective in the therapy of other solid tumors including breast cancer Here a prospective randomized controlled phase II trial of combining rh-Endostatin and neoadjuvant chemotherapy was performed to evaluate its efficacy and safety profiles in patients with breast cancer A total of 68 patients with pathologically confirmed breast cancer were randomly assigned to receive the neoadjuvant DE regimen docetaxel 75 mg/m 2 d1 epirubicin 75 mg/m 2 d1 every 3 weeks with or without rh-Endostatin 75 mg/m 2 d1-d14 Surgical resection was performed after 3 cycles of neoadjuvant treatment The primary end-points were objective response rate ORR and pathological complete response rate PCRR while the secondary end-points quality of life QOL and toxicity Among all of them 64 were assessable for efficacy and 68 for toxicity The ORRs were 909 % 30/33 and 677 % 21/31 in the combination and control groups respectively P = 0021 The stratification analysis showed that rh-Endostatin was more effective in the treatment of pre-menopausal and Eastern Cooperative Oncology Group ECOG = 0 patients P < 005 The PCRRs were 152 % 5/33 and 65 % 2/31 in the combination and control groups respectively P = 0428 No significant difference was identified in QOL score and side effects P > 005 Compared with DE regimen alone the combination of rh-Endostatin with DE chemotherapy may achieve a higher ORR with no increased toxicity in breast cancer patients Thus it can be utilized safely and effectively in the neoadjuvant treatment of breast cancer\",\n",
            "}\n",
            "13553\n",
            "{\n",
            "  \"id\" : \"22246148\",\n",
            "  \"contents\" : \"Prostate cancer is the most common cancer affecting men in the United States Management options for localized disease exist yet an evidence-based criterion standard for treatment still has to emerge Although 5-year survival rates approach 98 % all treatment options carry the possibility for significant side effects such as erectile dysfunction and urinary incontinence It is therefore recommended that patients be actively involved in the treatment decision process We have developed an Internet/CD-ROM-based multimedia Prostate Interactive Educational System PIES to enhance patients treatment decision making PIES virtually mirrors a health center to provide patients with information about prostate cancer and its treatment through an intuitive interface using videos animations graphics and texts 1 To examine the acceptability and feasibility of the PIES intervention and to report preliminary outcomes of the program in a pilot trial among patients with a new prostate cancer diagnosis and 2 to explore the potential impact of tailoring PIES treatment information to participants information-seeking styles on study outcomes Participants n = 72 were patients with newly diagnosed localized prostate cancer who had not made a treatment decision Patients were randomly assigned to 3 experimental conditions 1 control condition providing information through standard National Cancer Institute brochures 26 % and PIES 2 with tailoring 43 % and 3 without tailoring to a patient s information-seeking style 31 % Questionnaires were administrated before t1 and immediately after the intervention t2 Measurements include evaluation and acceptability of the PIES intervention monitoring/blunting information-seeking style psychological distress and decision-related variables eg decisional confidence feeling informed about prostate cancer and treatment and treatment preference The PIES program was well accepted by patients and did not interfere with the clinical routine About 79 % of eligible patients 72/91 completed the pre - and post-PIES intervention assessments Patients in the PIES groups compared with those in the control condition were significantly more likely to report higher levels of confidence in their treatment choices higher levels of helpfulness of the information they received in making a treatment decision and that the information they received was emotionally reassuring Patients in the PIES groups compared with those in the control condition were significantly less likely to need more information about treatment options were less anxious about their treatment choices and thought the information they received was clear P < 05 Tailoring PIES information to information-seeking style was not related to decision-making variables This pilot study confirms that the implementation of PIES within a clinical practice is feasible and acceptable to patients with a recent diagnosis of prostate cancer PIES improved key decision-making process variables and reduced the emotional impact of a difficult medical decision\",\n",
            "}\n",
            "13554\n",
            "{\n",
            "  \"id\" : \"8059021\",\n",
            "  \"contents\" : \"To test whether the administration of calcium channel antagonists such as verapamil V on the day before during and for 24-36 h after an important abdominal intervention can lower the onset of acute renal failure ARF mostly in renal-risk patients such as the aged Randomized nonblinded study Three surgical care university departments and two intensive care units of the same hospital S Anna Ferrara Italy Thirty-five elderly patients 61-83 years old entered the study 18 of them were given V 17 were not treated and were considered as controls The two study groups were overlapping as regards age renal risk and surgical challenge The patients who underwent ARF 5 in the treated group 7 among the controls were rejected from the study V was given on the eve of surgery at a dose of 80 mg/8 h per os and then through slow infusion 5 mg/4 -6 h during the next intra - and postoperative 24-36 h Abdominal surgery was performed owing to gastric cancer 8 cases colorectal neoplasia 10 cases gallstone disease 4 cases subrenal aortic aneurysm 6 cases and iliofemoral obstructive arteriopathy 7 cases Serum creatinine SCr was assessed to test renal function 24-h urinary levels of brush-border enzymes gamma glutamyl transferase or gGT lysosomal enzymes N-acetyl-beta-D-glucosaminidase or NAG and beta 2-microglobulin or beta 2M were determined at T0 on the eve of surgery T1 first and second day after and T2 7th and 8th day after to demonstrate possible tubule cell damage In the evaluated patients 13 treated with V and 10 untreated a the 24-h urinary levels of gGt and NAG persisted unchanged throughout the study in the treated patients whereas in the controls the same indices exhibited significant p < 001 increases at T1 and T2 b the 24-h urinary levels of beta 2M showed significant p < 001 increases in both groups from T0 to T1 however at T2 these values tended to return to normal ranges in the treated patients whereas they continued to be elevated in the untreated group As regards the patients who underwent postoperative ARF in the treated group urine output was significantly larger p < 001 at T1 and p < 0001 at T2 SCr was significantly p < 005 lower and the renal function recovered earlier within 10 + / - 3 vs 22 + / - 9 days than in the controls The administration of calcium channel antagonists to renal-risk patients during surgery and immediately before and after it has failed to prevent the onset of postoperative ARF Nevertheless this procedure has been shown to somehow reduce surgery-mediated lesions of the tubule cells as demonstrated by the finding of elevated urinary enzymes only in the untreated group\",\n",
            "}\n",
            "13555\n",
            "{\n",
            "  \"id\" : \"22682806\",\n",
            "  \"contents\" : \"Radiation Therapy Oncology Group RTOG trial 9704 was the largest randomized trial to use adjuvant chemoradiation therapy for patients with pancreatic cancer This report analyzes 5-year survival by serum level of tumor marker CA 19-9 of 90 vs > 90 U/mL and compares results to the those of the CONKO-001 trial CA 19-9 expression was analyzed as a dichotomized variable 90 vs > 90 U/mL Cox proportional hazard models were used to identify the impact of the CA 19-9 value on overall survival OS Actuarial estimates of OS were calculated using the Kaplan-Meier method Both univariate hazard ratio [ HR ] = 32 95 % confidence interval [ CI ] 23-4 3 P < 0001 and multivariate HR = 31 95 % CI 22-4 2 P < 0001 analyses demonstrated a statistically significant decrease in OS for CA 19-9 serum level of 90 U/mL For patients in the gemcitabine Gem treatment arm with CA 19-9 < 90 U/mL median survival was 21 months For patients with CA 19-9 90 U/mL this number dropped to 10 months In patients with pancreatic head tumors in the Gem treatment arm with RT quality assurance per protocol and CA 19-9 of < 90 U/mL median survival and 5-year rate were 24 months and 34 % In comparison the median survival and 5-year OS rate for patients in the Gem arm of the CONKO trial were 22 months and 21 % This analysis demonstrates that patients with postresection CA 19-9 values 90 U/mL had a significantly worse survival Patients with pancreatic head tumors treated with Gem with CA 19-9 serum level of < 90 U/mL and per protocol RT had favorable survival compared to that seen in the CONKO trial CA 19-9 is a stratification factor for the current RTOG adjuvant pancreas trial 0848\",\n",
            "}\n",
            "13556\n",
            "{\n",
            "  \"id\" : \"10202164\",\n",
            "  \"contents\" : \"We compared the effect of radiotherapy to a pelvic and para-aortic field with that of pelvic radiation and concurrent chemotherapy with fluorouracil and cisplatin in women with advanced cervical cancer Between 1990 and 1997 403 women with advanced cervical cancer confined to the pelvis stages IIB through IVA or stage IB or IIa with a tumor diameter of at least 5 cm or involvement of pelvic lymph nodes were randomly assigned to receive either 45 Gy of radiation to the pelvis and para-aortic lymph nodes or 45 Gy of radiation to the pelvis alone plus two cycles of fluorouracil and cisplatin days 1 through 5 and days 22 through 26 of radiation Patients were then to receive one or two applications of low-dose-rate intracavitary radiation with a third cycle of chemotherapy planned for the second intracavitary procedure in the combined-therapy group Of the 403 eligible patients 193 in each group could be evaluated The median duration of follow-up was 43 months Estimated cumulative rates of survival at five years were 73 percent among patients treated with radiotherapy and chemotherapy and 58 percent among patients treated with radiotherapy alone P = 0004 Cumulative rates of disease-free survival at five years were 67 percent among patients in the combined-therapy group and 40 percent among patients in the radiotherapy group P < 0001 The rates of both distant metastases P < 0001 and locoregional recurrences P < 0001 were significantly higher among patients treated with radiotherapy alone The seriousness of side effects was similar in the two groups with a higher rate of reversible hematologic effects in the combined-therapy group The addition of chemotherapy with fluorouracil and cisplatin to treatment with external-beam and intracavitary radiation significantly improved survival among women with locally advanced cervical cancer\",\n",
            "}\n",
            "13557\n",
            "{\n",
            "  \"id\" : \"19194127\",\n",
            "  \"contents\" : \"The combination of carboplatin and etoposide CE is one of the most effective regimens in the treatment of small-cell lung cancer SCLC The aim of this study was to investigate whether dose-intensified CE with the supplementation of granulocyte-colony-stimulating factor G-CSF is more effective than conventional CE in terms of survival with acceptable toxicity In a 2-arm multicentric prospective open label study adult patients with SCLC in extensive disease stage were randomized either to conventional CE carboplatin AUC 5 on day 1 IV and etoposide 140 mg/m IV on days 1-3 q28 days or to dose-intensified therapy carboplatin AUC 5 on day 1 IV and etoposide 190 mg/m days 1-3 IV with lenograstim 263 microg subcutaneously on days 4-13 q21 days Primary end point was overall survival secondary endpoints were toxicity quality of life and disease-free survival Seventy-nine patients were included Thirty-seven received conventional CE and 42 received the dose-intensified regimen Median survival in the conventional group and the dose-intensified group were 112 months [ confidence interval CI 91-15 2 ] and 117 months CI 88-14 7 respectively Progression-free survival was 67 CI 58-7 5 and 74 months CI 62-9 0 respectively There was no statistically significant difference between these groups Grade 3/4 neutropenia occurred in 694 % in the conventional arm versus 375 % in the dose-intensified group P = 0009 Dose-intense CE with GM-CSF support can be administered safely but does not prolong overall or progression-free survival compared with standard therapy\",\n",
            "}\n",
            "13558\n",
            "{\n",
            "  \"id\" : \"23893421\",\n",
            "  \"contents\" : \"The objective of this study is to determine whether the inclusion of a psychooncological statement PO-statement in the discharge summary enhances patient-physician communication about psychosocial issues across the inpatient and outpatient sector A total of 1416 cancer patients were randomly assigned to the intervention with PO-statement in the discharge summary or control group discharge summary without PO-statement Shortly before discharge from the hospital T1 patients from the intervention group were screened for psychosocial distress Based on the electronic clinical documentation system screening results were subsequently integrated into the discharge summary which automatically generated a PO-statement To determine the effect of the PO-statement patients as well as their primary care physicians n = 596 were asked during follow-up care T2 whether psychosocial distress was discussed during the last consultation Including a PO-statement in the discharge summary did not result in more frequent discussions about psychosocial issues compared with the control group from the patients and physicians perspectives Instead discussions about psychosocial well-being were significantly associated with women of the patient p = < 0001 and the physician p = 0011 medical discipline gynecologists p = 0002 cancer diagnosis gynecological cancer p = 0002 metastases p = < 0001 professional training of patients none p = 0026 and psychosocial qualification of physicians p = 0018 Written information on psychosocial distress in the discharge summary alone does not affect communication\",\n",
            "}\n",
            "13559\n",
            "{\n",
            "  \"id\" : \"8143995\",\n",
            "  \"contents\" : \"Colon cancer is one of the major health problems in industrialized countries and its incidence appears to be increasing Surgical resectability is the most important prognostic determinant although despite apparently curative surgery recurrent tumors are common Metastatic disease can not be cured and thus there is a need for better adjuvant therapies Two hundred and thirty-nine patients with surgically resected colon cancer in Dukes stage B2 or C were randomly assigned to chemotherapy or observation alone to determine whether adjuvant chemotherapy could effectively reduce the rate of cancer recurrence One hundred and twenty-one patients in stage B2 and 118 patients in stage C were enrolled in the study Adjuvant treatment consisted of folinic acid 200 mg/m2 intravenously plus 5-fluorouracil 400 mg/m2 intravenously on days 1-5 every 4 weeks for 12 cycles In stage B2 no significant difference between the adjuvant arm and the observation arm was noted In stage C adjuvant chemotherapy produced an advantage over observation in terms of a reduction in cancer recurrence rate with prolongation of a disease-free interval P = 00016 and an improvement in overall survival P = 00025 This study shows that folinic acid plus 5-fluorouracil adjuvant chemotherapy is effective in patients with surgically resected Dukes stage C colon carcinoma\",\n",
            "}\n",
            "13560\n",
            "{\n",
            "  \"id\" : \"18347904\",\n",
            "  \"contents\" : \"The 5 A Day for Better Health community studies demonstrated in randomized trials the efficacy of population-based strategies to increase fruit and vegetable consumption in diverse geographic areas and settings Mediation analysis can help to elucidate the theoretical basis of changing dietary habits This is important for informing more powerful cancer prevention and control interventions to achieve broad public health impact Five sites that focused on adults were included in mediation analyses to determine whether theoretically derived constructs assessed at baseline and follow-up contributed to explaining change in fruit and vegetable F&V consumption These variables were knowledge self-efficacy and autonomy/responsibility Stage of change also was considered as a potential moderating variable Self-efficacy and knowledge of the 5 A Day recommendation increased in those who received the interventions and were positively associated with higher F&V Mediation of intervention effect was demonstrated for these variables Autonomy/responsibility did not meet the criteria for mediation There was no evidence of differential effect of mediators according to baseline stage The present study findings provide strong support for mediation of F&V consumption by two variables self-efficacy and knowledge The authors discuss the findings in relation to study limitations and future research directions\",\n",
            "}\n",
            "13561\n",
            "{\n",
            "  \"id\" : \"23104210\",\n",
            "  \"contents\" : \"The impact of lung cancer screening on smoking behavior is unclear The aims of this ancillary study of the Prostate Lung Colorectal and Ovarian Cancer Screening Trial were to produce risk prediction models to identify individuals at risk of relapse or continued smoking and to evaluate whether cancer-screening variables affect long-term smoking outcomes Participants completed a baseline questionnaire at trial enrollment and a supplemental questionnaire 4-14 years after enrollment which assessed several cancer-related variables including family history of cancer comorbidities and tobacco use Multivariable logistic regression models were used to predict smoking status at completion of the supplemental questionnaire The models predictive performances were evaluated by assessing discrimination via the receiver operator characteristic area under the curve ROC AUC and calibration Models were internally validated using bootstrap methods Of the 31 & emsp14 694 former smokers on the baseline questionnaire 1042 33 % had relapsed ie reported being a current smoker on the supplemental questionnaire Of the 6807 current smokers on the baseline questionnaire 4439 652 % reported continued smoking on the supplemental questionnaire Relapse was associated with multiple demographic medical and tobacco-related characteristics This model had a bootstrap median ROC AUC of 0862 95 % confidence interval [ CI ] = 0858 to 0866 and a calibration slope of 1004 95 % CI = 0978 to 1029 indicating excellent discrimination and calibration Predictors of continued smoking also included multiple demographic medical and tobacco-related characteristics This model had an ROC AUC of 0611 95 % CI = 0605 to 0614 and a slope of 1006 95 % CI = 0962 to 1041 indicating modest discrimination Neither the trial arm nor the lung-screening result was statistically significantly associated with smoking outcomes These models if validated externally may have public health utility in identifying individuals at risk for adverse smoking outcomes who may benefit from relapse prevention and smoking cessation interventions\",\n",
            "}\n",
            "13562\n",
            "{\n",
            "  \"id\" : \"18172173\",\n",
            "  \"contents\" : \"We evaluated capecitabine an oral fluoropyrimidine and oxaliplatin a platinum compound as alternatives to infused fluorouracil and cisplatin respectively for untreated advanced esophagogastric cancer In a two-by-two design we randomly assigned 1002 patients to receive triplet therapy with epirubicin and cisplatin plus either fluorouracil ECF or capecitabine ECX or triplet therapy with epirubicin and oxaliplatin plus either fluorouracil EOF or capecitabine EOX The primary end point was noninferiority in overall survival for the triplet therapies containing capecitabine as compared with fluorouracil and for those containing oxaliplatin as compared with cisplatin For the capecitabine-fluorouracil comparison the hazard ratio for death in the capecitabine group was 086 95 % confidence interval [ CI ] 080 to 099 for the oxaliplatin-cisplatin comparison the hazard ratio for the oxaliplatin group was 092 95 % CI 080 to 110 The upper limit of the confidence intervals for both hazard ratios excluded the predefined noninferiority margin of 123 Median survival times in the ECF ECX EOF and EOX groups were 99 months 99 months 93 months and 112 months respectively survival rates at 1 year were 377 % 408 % 404 % and 468 % respectively In the secondary analysis overall survival was longer with EOX than with ECF with a hazard ratio for death of 080 in the EOX group 95 % CI 066 to 097 P = 002 Progression-free survival and response rates did not differ significantly among the regimens Toxic effects of capecitabine and fluorouracil were similar As compared with cisplatin oxaliplatin was associated with lower incidences of grade 3 or 4 neutropenia alopecia renal toxicity and thromboembolism but with slightly higher incidences of grade 3 or 4 diarrhea and neuropathy Capecitabine and oxaliplatin are as effective as fluorouracil and cisplatin respectively in patients with previously untreated esophagogastric cancer Current Controlled Trials number ISRCTN51678883 [ controlled-trials com ]\",\n",
            "}\n",
            "13563\n",
            "{\n",
            "  \"id\" : \"23195993\",\n",
            "  \"contents\" : \"Occupational exposure to nickel Ni is associated with an increased risk of lung and nasal cancers Ni compounds exhibit weak mutagenic activity alter the cell s epigenetic homeostasis and activate signaling pathways However changes in gene expression associated with Ni exposure have only been investigated in vitro This study was conducted in a Chinese population to determine whether occupational exposure to Ni was associated with differential gene expression profiles in the peripheral blood mononuclear cells PBMC of Ni-refinery workers when compared with referents Eight Ni-refinery workers and ten referents were selected PBMC RNA was extracted and gene expression profiling was conducted using Affymetrix exon arrays Differentially expressed genes DEG between both groups were identified in a global analysis There were a total of 2756 DEGs in the Ni-refinery workers relative to the referents [ false discovery rate FDR adjusted P < 005 ] with 770 upregulated genes and 1986 downregulated genes DNA repair and epigenetic genes were significantly overrepresented P < 00002 among the DEGs Of 31 DNA repair genes 29 were repressed in the Ni-refinery workers and 2 were overexpressed Of the 16 epigenetic genes 12 were repressed in the Ni-refinery workers and 4 were overexpressed The results of this study indicate that occupational exposure to Ni is associated with alterations in gene expression profiles in PBMCs of subjects Gene expression may be useful in identifying patterns of deregulation that precede clinical identification of Ni-induced cancers\",\n",
            "}\n",
            "13564\n",
            "{\n",
            "  \"id\" : \"9457389\",\n",
            "  \"contents\" : \"This article reviews the currently available data on phase II and III trials regarding the efficacy of recombinant interleukin-2 rIL-2 - based regimens in the treatment of stage IV melanoma and discusses the rationale and outcome of past and currently ongoing rIL-2-based chemo-immunotherapy phase III trials conducted by the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group In the first EORTC-MCG phase III trial stage IV melanoma patients were stratified on the basis of serum lactate dehydrogenase levels and tumor burden and randomized to receive rIL-2 decrescendo regimen plus interferon-alpha IFN-alpha plus or minus cisplatin In the second trial which is still ongoing patients are being randomized to receive dacarbazine plus cisplatin plus IFN-alpha plus or minus rIL-2 These studies are designed to address the relative impact of cisplatin and rIL-2 respectively on response and survival The addition of cisplatin to immunotherapy rIL-2 plus IFN-alpha doubled the response rate from 18 % to 35 % but had no impact on survival The second trial is still ongoing and no data is available yet on the contribution of rIL-2 to response and survival Review of the literature and the outcome of our first trial indicate that the addition of single-agent cisplatin or polychemotherapy regimens to immunotherapy with rIL-2 and/or IFN-alpha can dramatically improve response rates However what impact if any these regimens have on overall survival is not known at this time We could not demonstrate a survival benefit in the cisplatin-containing arm in spite of the increased response rate Chemotherapy may yield only short-term responses whereas immunotherapy appears to yield durable complete responses in a subset of patients Further randomized phase III studies are needed to identify the essential components in combination regimens and to determine whether the toxicity associated with these regimens is outweighed by potential cure or a significant survival benefit\",\n",
            "}\n",
            "13565\n",
            "{\n",
            "  \"id\" : \"9747866\",\n",
            "  \"contents\" : \"We have previously reported that high expression of the erbB-2 gene also known as HER-2 / neu and ERBB2 in breast cancer is associated with patient response to dose-intensive treatment with cyclophosphamide doxorubicin Adriamycin and 5-flurouracil CAF on the basis of short-term follow-up of 397 patients set A with axillary lymph node-positive tumors who were enrolled in Cancer and Leukemia Group B CALGB protocol 8541 To validate those findings we conducted immunohistochemical analyses of erbB-2 and p53 protein expression in an additional cohort of 595 patients set B from CALGB 8541 as well as a molecular analysis of erbB-2 gene amplification in tumors from all patients sets A and B Marker data were compared with clinical histologic treatment and outcome data Updated analyses of data from set A median follow-up 104 years showed an even stronger interaction between erbB-2 expression and CAF dose by use of either immunohistochemical or molecular data A similar interaction between erbB-2 expression and CAF dose was observed in all 992 patients analyzed as a single group However for set B alone median follow-up 82 years results varied with the method of statistical analysis By use of a proportional hazards model the erbB-2 expression-CAF dose interaction was not significant for all patients However in the subgroups of patients randomly assigned to the high - or the moderate-dose arms significance was achieved When patient data were adjusted for differences by use of a prognostic index to balance an apparent failure of randomization in the low-dose arm the erbB-2 expression-CAF dose interaction was significant in all patients from the validation set B as well An interaction was also observed between p53 immunopositivity and CAF dose The hypothesis that patients whose breast tumors exhibit high erbB-2 expression benefit from dose-intensive CAF should be further validated before clinical implementation Interactions between erbB-2 expression p53 expression and CAF dose underscore the complexities of predictive markers where multiple interactions may confound the outcome\",\n",
            "}\n",
            "13566\n",
            "{\n",
            "  \"id\" : \"24379010\",\n",
            "  \"contents\" : \"Olive oil-based lipid emulsion LE and medium chain triglyceride/long chain triglyceride MCT/LCT emulsion are both LEs with low -6 polyunsaturated fat acids PUFAs content However which one of these LEs is associated with a lower infection risk in patients receiving parenteral nutrition PN remains unclear The aim of the study was to compare the effects of the two LEs in PN in esophageal cancer patients undergoing surgery Patients with resectable esophageal carcinoma were recruited and allocated randomly to two groups The test group was given enteral nutrition EN with PN containing olive oil-based LE after tumor resection for 7 days and the patients in the control group were supported by EN with MCT/LCT emulsion-based PN after surgery for the same time period Immunological markers and inflammatory indicators were tested and perioperative clinical outcomes were determined The trial was registered in the Chinese Clinical Trial Register number ChiCTR-TRC-13003562 94 Patients were recruited and grouped olive oil-based LE n = 46 and MCT/LCT n = 48 matched for sex age body mass index histological type TNM stage and nutrition risk screening NRS 2002 score There were no differences in perioperative fever > 38 C infectious complications length of hospital stay > 14 days length of critical care stay > 2 days time for oral food intake and in-hospital mortality between the two groups The test group showed a higher increase in IgG level compared with the MCT/LCT group p = 0028 There was no difference in other immunological markers and inflammatory indicators between the two groups PN containing olive oil-based or MCT/LCT LEs had similar effects on perioperative outcome cell-mediated immune function and inflammatory response in esophageal cancer patients who had undergone surgery and were receiving EN\",\n",
            "}\n",
            "13567\n",
            "{\n",
            "  \"id\" : \"11117247\",\n",
            "  \"contents\" : \"Glycerol is a low molecular weight solute MW 92 D that can be used as an osmotic agent in continuous ambulatory peritoneal dialysis CAPD Due to its low molecular weight the osmotic gradient disappears rapidly Despite the higher osmolality at the beginning of a dwell ultrafiltration has been found to be lower for glycerol compared to glucose MW 180 D when equimolar concentrations are used Previous studies have shown glycerol to be safe for long-term use but some discrepancies have been reported in small solute transport and protein loss To assess permeability characteristics for a 14 % glycerol dialysis solution compared to 136 % glucose Two standardized peritoneal permeability analyses SPA one using 14 % glycerol and the other using 136 % glucose in random order were performed within a span of 2 weeks in 10 stable CAPD patients The length of the study dwell was 4 hours Fluid kinetics and solute transport were calculated and signs of cell damage were compared for the two solutions Peritoneal dialysis unit in the Academic Medical Center Amsterdam Median values for the 14 % glycerol SPA were as follows net ultrafiltration 251 mL which was higher than that for 136 % glucose 12 mL p < 001 transcapillary ultrafiltration rate 212 mL/min which was higher than that for glucose 152 mL/min p = 001 and effective lymphatic absorption rate 101 mL/min which was not different from the glucose-based solution Calculation of peritoneal reflection coefficients for glycerol and glucose showed lower values for glycerol compared to glucose 003 vs 004 calculated with both the convection and the diffusion models A marked dip in dialysate-to-plasma ratio for sodium was seen in the 14 % glycerol exchange suggesting uncoupled water transport through water channels Mass transfer area coefficients for urea creatinine and urate were similar for both solutions Also clearances of the macromolecules beta2-microglobulin albumin IgG and alpha2-macroglobulin were not different for the two osmotic agents The median absorption was higher for glycerol 71 % compared to 49 % for glucose p < 001 as could be expected from the lower molecular weight The use of a 14 % glycerol solution during a 4-hour dwell caused a small but significant median rise in plasma glycerol from 022 mmol/L to 045 mmol/L p = 002 Dialysate cancer antigen 125 and lactate dehydrogenase LDH concentrations during the dwell were not different for both solutions These findings show that glycerol is an effective osmotic agent that can replace glucose in short dwells and show no acute mesothelial damage The higher net ultrafiltration obtained with 14 % glycerol can be explained by the higher initial net osmotic pressure gradient This was seen especially in the first hour of the dwell Thereafter the osmotic gradient diminished as a result of absorption The dip in dialysate-to-plasma ratio for sodium seen in the glycerol dwell can also be explained by this high initial osmotic pressure gradient implying that the effect of glycerol as an osmotic agent is more dependent on intact water channels than is glucose\",\n",
            "}\n",
            "13568\n",
            "{\n",
            "  \"id\" : \"16146257\",\n",
            "  \"contents\" : \"Breast cancer is the 2nd most common tumors in Thai women Until now oncologic breast surgeries are typically performed by general anesthesia GA However GA can not provide adequate postoperative pain control and routine use of parenteral opioids aggravate postoperative sedation nausea emesis impaired oxygenation and depressed ventilation Thoracic epidural anesthesia TEA is one of the regional anesthetic techniques that can be done by using a low dose of local anesthetic in combination with ipsilateral brachial plexus block BPB for axillary node dissection TEA can provide a better pain relief without potential paralysis of respiratory muscle and sedation Fifty ASA PS I-III patients undergoing MRM were randomly assigned to two study groups of 25 patients each In the TEA group an epidural catheter was inserted at T4 to T5 and 10-15 ml of 02 % ropivacaine was injected then interscalene BPB was done with 8 ml of 02 % ropivacaine Anesthesia was maintained with 5-10 ml of 02 % ropivacaine per hour GA was induced with 1 microg/kg of fentanyl followed by 15-2 mg/kg of propofol and was maintained with sevoflurane and 70 % N2O in oxygen The authors evaluated the adequacy of anesthesia surgical condition postanesthetic recovery postanesthetic analgesia and patients satisfaction The demographic data was similar in both groups The number of patients immediately arrived at PACU with a sedation score of 1 was significantly greater in TEA group p = 0003 while the number of patients with an Aldrete score of 10 was greater but not statistically significant p = 025 The verbal rating scale and analgesic requirement were significantly lower in the TEA group p < 0001 and p = 0002 respectively Patients satisfaction was greater with TEA than with GA p = 0014 Surgical condition was similar in both groups The present study shows that TEA combined with BPB by using a low dose of 02 % ropivacaine is a safe and reliable alternative technique for MRM It can provide not only effective anesthesia but also better postoperative pain relief faster anesthetic recovery and greater patient satisfaction than those of the GA technique\",\n",
            "}\n",
            "13569\n",
            "{\n",
            "  \"id\" : \"8656444\",\n",
            "  \"contents\" : \"Tamoxifen is an anti-estrogen with proven efficacy and low toxicity in the treatment of breast cancer However tamoxifen has been shown to exert a number of nonhormonal as well as hormonal effects One nonhormonal effect of tamoxifen is the induction of transforming growth factor-beta TGF-beta secretion TGF-beta has been implicated in the pathogenesis of radiation-induced fibrosis We investigated the development of lung fibrosis in breast cancer patients who were treated after mastectomy with radiotherapy with or without simultaneous adjuvant treatment with tamoxifen Data from 196 women were included in the analysis Eighty-four women were postmenopausal patients who participated in a randomized trial testing tamoxifen as an adjuvant to postmastectomy radiotherapy The radiotherapy technique employed an 8-MV photon field covering the axillary and the infraclavicular and supraclavicular regions of the affected side of the chest the chest wall was treated with an abutted electron field Optical density changes in pretreatment and post-treatment chest x-ray films were used to monitor the development of lung fibrosis lung reactions were assessed in the photon-irradiated field only Logistic regression analysis was used to explore relationships between radiation dose and the development of lung fibrosis in patients either receiving or not receiving tamoxifen All P values are from two-sided tests Among the 84 women who participated in the randomized trial of radiotherapy plus tamoxifen n = 38 versus radiotherapy alone n = 46 there was a significant association between tamoxifen treatment and the incidence of marked lung fibrosis relative risk = 20 95 % confidence interval [ CI ] = 12-3 5 P = 01 When logistic regression analysis was used to evaluate data from all 196 patients a highly significant relationship was found between the incidence of lung fibrosis and total radiation dose P = 0005 In the full analysis an increased risk of marked lung fibrosis was found again for patients who received tamoxifen simultaneously with radiotherapy with patients receiving radiotherapy alone as the referent odds ratio = 29 95 % CI = 13-6 3 P = 007 Patient age and menopausal status did not significantly influence the results Tamoxifen treatment during postmastectomy radiotherapy enhances the risk of radiation-induced lung fibrosis In view of pre-existing data we hypothesize that tamoxifen mediates the enhancement of radiation-induced lung fibrosis through the induction of TGF-beta secretion If this hypothesis is correct new strategies might be devised for preventing or reducing radiation-induced fibrosis Because we studied a relatively small portion of the irradiated lung we can not recommend changes in current therapeutic measures however we strongly encourage additional studies of lung fibrosis in patients receiving tamoxifen and radiotherapy\",\n",
            "}\n",
            "13570\n",
            "{\n",
            "  \"id\" : \"24231454\",\n",
            "  \"contents\" : \"Somatic mutations in PIK3CA phosphatidylinositol-4 5 - bisphosphonate 3-kinase [ PI3K ] catalytic subunit alpha gene activate the PI3K-AKT signaling pathway and contribute to pathogenesis of various malignancies including colorectal cancer We examined associations of PIK3CA oncogene mutation with relapse survival and treatment efficacy in 627 stage III colon carcinoma case subjects within a randomized adjuvant chemotherapy trial 5-fluorouracil and leucovorin [ FU/LV ] vs irinotecan [ CPT11 ] fluorouracil and leucovorin [ IFL ] Cancer and Leukemia Group B 89803 [ Alliance ] We detected PIK3CA mutation in exons 9 and 20 by polymerase chain reaction and pyrosequencing Cox proportional hazards model was used to assess prognostic and predictive role of PIK3CA mutation adjusting for clinical features and status of routine standard molecular pathology features including KRAS and BRAF mutations and microsatellite instability mismatch repair deficiency All statistical tests were two-sided Compared with PIK3CA wild-type cases overall status of PIK3CA mutation positivity or the presence of PIK3CA mutation in either exon 9 or 20 alone was not statistically significantly associated with recurrence-free disease-free or overall survival log-rank P > 70 P > 40 in multivariable regression models There was no statistically significant interaction between PIK3CA and KRAS or BRAF mutation status in survival analysis P interaction > 18 PIK3CA mutation status did not appear to predict better or worse response to IFL therapy compared with FU/LV therapy P interaction > 16 Overall tumor PIK3CA mutation status is not associated with stage III colon cancer prognosis PIK3CA mutation does not appear to serve as a predictive tumor molecular biomarker for response to irinotecan-based adjuvant chemotherapy\",\n",
            "}\n",
            "13571\n",
            "{\n",
            "  \"id\" : \"25937522\",\n",
            "  \"contents\" : \"The OPUS study demonstrated that addition of cetuximab to 5-fluorouracil folinic acid and oxaliplatin FOLFOX4 significantly improved objective response and progression-free survival PFS in the first-line treatment of patients with KRAS exon 2 wild-type metastatic colorectal cancer mCRC In patients with KRAS exon 2 mutations a detrimental effect was seen upon addition of cetuximab to FOLFOX4 The current study reports outcomes in subgroups defined by extended RAS testing Samples from OPUS study KRAS exon 2 wild-type tumours were reanalysed for other RAS mutations in four additional KRAS codons exons 3-4 and six NRAS codons exons 2-4 using BEAMing A cutoff of 5 % mutant/wild-type sequences was selected to define RAS status we also report an analysis using a cutoff based on the technical lower limit for mutation identification 01 % Other RAS mutations were detected in 31/118 26 % evaluable patients In the extended analysis of RAS wild-type tumours n = 87 objective response was significantly improved by addition of cetuximab to FOLFOX4 58 % versus 29 % odds ratio 333 [ 95 % confidence interval 136-8 17 ] P = 00084 although limited by population size there also appeared to be trends favouring the cetuximab arm in terms of PFS and overall survival in the RAS wild-type group compared with the RAS evaluable group There was no evidence that patients with other RAS mutations benefited from cetuximab but small numbers precluded precise estimations of treatment effects In the combined population of patients with any RAS mutation KRAS exon 2 or other RAS a clear detrimental effect was associated with addition of cetuximab to FOLFOX4 Patients with RAS-mutant mCRC as defined by mutations in KRAS and NRAS exons 2-4 derive no benefit and may be harmed by the addition of cetuximab to FOLFOX4 Restricting cetuximab administration to patients with RAS wild-type tumours will further tailor therapy to maximise benefit\",\n",
            "}\n",
            "13572\n",
            "{\n",
            "  \"id\" : \"21546875\",\n",
            "  \"contents\" : \"Bethanechol chloride is considered as a treatment in patients with high postvoid residual urine PVR It enhances detrusor muscle contraction resulting in higher maximum flow rate higher detrusor pressure at maximum flow and lower PVR The efficacy of this agent in patients after radical hysterectomy is unclear We aim to evaluate the efficacy of bethanechol chloride compared with placebo for the prevention of bladder dysfunction after type III radical hysterectomy Gynecologic cancer patients who underwent type III radical hysterectomy were randomized by computer-generated schedule to assign patients in a 11 ratio into 2 groups The treatment group received bethanechol chloride Ucholine 20 mg 3 times a day on the third to seventh postoperative day and the control group received placebo Patients and physicians were masked to treatment allocation The primary end point was the rate of urethral catheter removal at 1 week postoperatively If PVR was more than 30 % of voided volume the urethral catheter was reinserted and medication would be continued but not for more than 1 month This study was registered as ISRCTN92687416 There were 31 patients in each group without significant difference in baseline characteristics Twenty-one patients 677 % in the treatment group and 12 patients 387 % in the control group had the urethral catheter removed at 1 week postoperatively P = 004 Median duration of urethral catheterization was shorter in the treatment group 7 and 14 days P = 003 However the PVR and the incidence of urinary tract infection at 1 month postoperatively were not significantly different Nine patients 29 % in the treatment group had adverse events such as nausea abdominal distension and abdominal cramping which was higher than the control group 1 patient 32 % P = 001 However no patients required any medical treatments Bethanechol chloride decreases the duration of urethral catheterization in patients who underwent type III radical hysterectomy with manageable adverse events\",\n",
            "}\n",
            "13573\n",
            "{\n",
            "  \"id\" : \"22531635\",\n",
            "  \"contents\" : \"In the BIG 1-98 trial objective cognitive function improved in postmenopausal women 1 year after cessation of adjuvant endocrine therapy for breast cancer This report evaluates changes in subjective cognitive function SCF One hundred postmenopausal women randomised to receive 5 years of adjuvant tamoxifen letrozole or a sequence of the two completed self-reported measures on SCF psychological distress fatigue and quality of life during the fifth year of trial treatment year 5 and 1 year after treatment completion year 6 Changes between years 5 and 6 were evaluated using the Wilcoxon signed-rank test Subjective cognitive function and its correlates were explored Subjective cognitive function and the other patient-reported outcomes did not change significantly after cessation of endocrine therapy with the exception of improvement for hot flushes P = 00005 No difference in changes was found between women taking tamoxifen or letrozole Subjective cognitive function was the only psychosocial outcome with a substantial correlation between year 5 and 6 Spearman s R = 080 Correlations between SCF and the other patient-reported outcomes were generally low Improved objective cognitive function but not SCF occur following cessation of adjuvant endocrine therapy in the BIG 1-98 trial The substantial correlation of SCF scores over time may represent a stable attribute\",\n",
            "}\n",
            "13574\n",
            "{\n",
            "  \"id\" : \"25377520\",\n",
            "  \"contents\" : \"Denmark has inferior cancer survival rates compared with many European countries The main reason for this is suggested to be late diagnosis at advanced cancer stages Cancer diagnostic work-up begins in general practice in 85 % of all cancer cases Thus general practitioners GPs play a key role in the diagnostic process The latest Danish Cancer Plan included continuing medical education CME on early cancer diagnosis in general practice to improve early diagnosis This dual aims of this protocol are first to describe the conceptualisation operationalisation and implementation of the CME and second to describe the study design and outcomes chosen to evaluate the effects of the CME The intervention is a CME in early cancer diagnosis targeting individual GPs It was developed by a step-wise approach Barriers for early cancer diagnosis at GP level were identified systematically and analysed using the behaviour system involving capability opportunity and motivation described by Michie et al The study will be designed as a geographical cluster randomised stepped wedge study The study population counts 836 GPs from 417 general practices in the Central Denmark Region geographically divided into eight clusters GPs from each cluster will be invited to a CME meeting at a certain date three weeks apart The primary outcomes will be primary care interval and GP referral rate on cancer suspicion Data will be obtained from national registries GP-completed forms on patients referred to cancer fast-track pathways and GP-completed online questionnaires before and after the intervention To our knowledge this will be the first study to measure the effect of a theory-based CME in early cancer diagnosis at three levels GP knowledge and attitude GP activity and patient outcomes The achieved knowledge will contribute to the understanding of whether and how general practice s ability to perform cancer diagnosis may be improved Registered as NCT02069470 on ClinicalTrialsgov\",\n",
            "}\n",
            "13575\n",
            "{\n",
            "  \"id\" : \"25740979\",\n",
            "  \"contents\" : \"Metformin may improve metabolic factors insulin glucose leptin highly sensitive C-reactive protein [ hs-CRP ] associated with poor breast cancer outcomes The NCIC Clinical Trials Group NCIC CTG MA 32 investigates effects of metformin vs placebo on invasive disease-free survival and other outcomes in early breast cancer Maintaining blinding of investigators to outcomes we conducted a planned Data Safety Monitoring Committee-approved analysis of the effect of metformin vs placebo on weight and metabolic factors at six months including examination of interactions with baseline body mass index BMI and insulin in the first 492 patients with paired blood samples Eligible nondiabetic subjects with T1-3 N0-3 M0 breast cancer who had completed surgery and neo adjuvant chemotherapy if given provided fasting plasma samples at random assignment and at six months Glucose was measured locally blood was aliquoted frozen and stored at -80 C Paired plasma aliquots were analyzed for insulin hs-CRP and leptin Spearman correlation coefficients were calculated and comparisons analyzed using Wilcoxon signed rank test All statistical tests were two-sided Mean age was 52195 years in the metformin group and 526 98 years in the placebo group Arms were balanced for estrogen/progesterone receptor BMI prior neo adjuvant chemotherapy and stage At six months decreases in weight and blood variables were statistically significantly greater in the metformin arm vs placebo in univariate analyses weight -30 % glucose -38 % insulin -111 % homeostasis model assessment -171 % leptin -202 % hs-CRP -67 % all P values were less than or equal to 03 There was no statistically significant interaction of change in these variables with baseline BMI or insulin Metformin statistically significantly improved weight insulin glucose leptin and CRP at six months Effects did not vary by baseline BMI or fasting insulin\",\n",
            "}\n",
            "13576\n",
            "{\n",
            "  \"id\" : \"23462922\",\n",
            "  \"contents\" : \"Smoking tobacco preparations in a water pipe hookah is widespread in many places of the world and is perceived by many as relatively safe We investigated biomarkers of toxicant exposure with water pipe compared with cigarette smoking We conducted a crossover study to assess daily nicotine and carcinogen exposure with water pipe and cigarette smoking in 13 people who were experienced in using both products When smoking an average of 3 water pipe sessions compared with smoking 11 cigarettes per day cpd water pipe use was associated with a significantly lower intake of nicotine greater exposure to carbon monoxide CO and a different pattern of carcinogen exposure compared with cigarette smoking with greater exposure to benzene and high molecular weight polycyclic aromatic hydrocarbon PAH but less exposure to tobacco-specific nitrosamines 13-butadiene acrolein acrylonitrile propylene oxide ethylene oxide and low molecular weight PAHs A different pattern of carcinogen exposure might result in a different cancer risk profile between cigarette and water pipe smoking Of particular concern is the risk of leukemia related to high levels of benzene exposure with water pipe use Smoking tobacco in water pipes has gained popularity in the United States and around the world Many believe that water pipe smoking is not addictive and less harmful than cigarette smoking We provide data on toxicant exposure that will help guide regulation and public education regarding water pipe health risk\",\n",
            "}\n",
            "13577\n",
            "{\n",
            "  \"id\" : \"25348000\",\n",
            "  \"contents\" : \"CALGB 40302 sought to determine whether lapatinib would improve progression-free survival PFS among women with hormone receptor-positive metastatic breast cancer treated with fulvestrant Eligible women had estrogen receptor-positive and/or progesterone receptor-positive tumors regardless of human epidermal growth factor receptor 2 HER2 status and prior aromatase inhibitor treatment Patients received fulvestrant 500 mg intramuscularly on day 1 followed by 250 mg on days 15 and 28 and every 4 weeks thereafter and either lapatinib 1500 mg or placebo daily The study planned to accrue 324 patients and was powered for a 50 % improvement in PFS with lapatinib from 5 to 75 months At the third planned interim analysis the futility boundary was crossed and the data and safety monitoring board recommend study closure having accrued 295 patients At the final analysis there was no difference in PFS hazard ratio [ HR ] of placebo to lapatinib 104 95 % CI 082 to 133 P = 37 median PFS was 47 months for fulvestrant plus lapatinib versus 38 months for fulvestrant plus placebo There was no difference in overall survival OS HR 091 95 % CI 068 to 121 P = 25 For HER2-normal tumors median PFS did not differ by treatment arm 41 v 38 months For HER2-positive tumors lapatinib was associated with longer median PFS 59 v 33 months but the differential treatment effect by HER2 status was not significant P = 53 The most frequent toxicities were diarrhea fatigue and rash associated with lapatinib Adding lapatinib to fulvestrant does not improve PFS or OS in advanced ER-positive breast cancer and is more toxic\",\n",
            "}\n",
            "13578\n",
            "{\n",
            "  \"id\" : \"15110307\",\n",
            "  \"contents\" : \"Brachytherapy for prostate cancer with permanent low-dose-rate seeds has been shown to be an effective treatment for early stage prostate cancer Due to the rapid falloff of dose accurate seed placement is critical for optimal dosimetry One approach to achieve optimal dosimetry is the use of seeds embedded in suture material Seeds embedded in suture may not move after implantation as much as loose seeds This would improve implant dosimetry To evaluate this hypothesis a formal study was conducted in which half the gland was implanted with seeds embedded in suture and half with loose seeds Final dosimetry is compared between both halves of the prostate Patients entered this Investigational Review Board approved prospective trial after completion of informed consent At time of implant the side of the gland to be implanted with loose as opposed to suture embedded seeds was randomly assigned The patients then underwent intraoperative preplanned implantation None of the preplans directed seed locations outside the prostate Both the seeds embedded in suture and the loose seeds were implanted using needles with stylettes At 4-6 weeks post implant seed location was determined with CT Both sides of the gland on CT were contoured and used for final dosimetric calculations A cost function analysis was used to determine individual seed position deviation from intended to actual seed location Eight patients were enrolled in the study A total of 549 seeds were implanted 240 seeds embedded in suture and 309 loose seeds Prostate volumes ranged from 240-45 5 cc with a mean of 386 cc The average radial deviation of the loose seeds from planned position was determined to be 31 mm compared with the average radial deviation of the suture embedded seeds of 37 mm There was no improvement in the final dosimetry when suture embedded seeds where used The D90 and V100 values for the half of the prostate implanted with suture embedded seeds were 71-140 mean 921 and 802-99 5 mean 896 respectively for the half of the prostate implanted with loose seeds All D90 V100 values are % of prescription dose Seeds embedded in suture material do not lead to superior precision in seed deposition when compared with loose seeds when implanted inside the prostate\",\n",
            "}\n",
            "13579\n",
            "{\n",
            "  \"id\" : \"20675951\",\n",
            "  \"contents\" : \"Colorectal cancer CRC is the third cause of cancer deaths for African Americans 1 increase CRC knowledge 2 decrease cancer fatalism and 3 increase colonoscopy screening for CRC among African Americans in North Carolina Churches and community-based organizations were randomized into intervention and control groups The intervention group received a 90-minute culturally targeted educational program on colorectal health Pre-test and post-test questionnaires were completed by both groups A total of 539 African American men and women 50 years of age and older participated in this study The intervention group had a significantly greater proportion of those receiving a colonoscopy within three months after the educational session than the control group In the intervention group CRC knowledge significantly increased and cancer fatalism attitudes significantly decreased A culturally targeted faith/community-based educational intervention can increase CRC knowledge decrease cancer fatalism and increase screening for CRC among African Americans\",\n",
            "}\n",
            "13580\n",
            "{\n",
            "  \"id\" : \"11875329\",\n",
            "  \"contents\" : \"The prolonged use of estrogen therapy is associated with a slightly increased risk of breast cancer Alternative therapies that are effective in the prevention of menopause having associated morbidities but no unwanted effects are of primary interest in the pharmacologic research The aim of this study was to evaluate the effect of two alternative to estrogens drugs the selective estrogen receptor modulator raloxifene and the tissue-specific tibolone on the mammographic appearance of the breast The study group comprised 131 postmenopausal women aged 41 to 67 years The women were at least 2 years postmenopausal free of climacteric symptoms and at the time of entry to the study had not had therapy for at least 9 months Women with risk factors for osteoporosis or cardiovascular disease were allocated either to tibolone n = 56 or raloxifene n = 48 therapy Women with no risk factors and women who either did not qualify for or denied treatment n = 27 served as controls The study duration was 12 months Women received a baseline mammogram before commencing therapy and a repeat mammogram at the end of the study period Mammogram findings were classified according to the modified Wolfe criteria by two expert radiologists No difference was identified between groups with respect to baseline characteristics associated with breast cancer risk Similarly no difference was detected between groups concerning the modified Wolfe classification of baseline mammographic findings In the tibolone group 107 % of the women showed an increase in breast density in the 12-month reevaluation The respective figure in the raloxifene group was 63 % whereas no woman in the control group showed an increase in breast density Differences in the increase in breast density between groups did not however reach statistical significance Accordingly 107 % of women in the tibolone group and 188 % of women in the raloxifene group exhibited involutionary changes in the repeat mammogram whereas 259 % of women in the control group revealed a decrease in breast density in the 12-month examination The percentages were not significantly different between groups Breast density as shown by mammography was stable in a majority of patients and changed in a minority of cases for both tibolone and raloxifene In most patients these drugs are not likely to interfere with mammogram interpretation Larger long-term studies are needed to confirm the impact of prolonged tibolone or raloxifene administration on mammography\",\n",
            "}\n",
            "13581\n",
            "{\n",
            "  \"id\" : \"7595698\",\n",
            "  \"contents\" : \"We evaluated cognitive sequelae of treatment for childhood acute lymphoblastic leukemia ALL CNS therapy consisted of cranial irradiation CRT or no radiation Children were also randomized to single intravenous high-dose methotrexate HD-MTX or conventional-dose methotrexate CD-MTX during induction and all patients received intrathecal IT and systemic continuation chemotherapy Sixty-six patients treated for ALL on Dana-Farber Cancer Institute protocol 87-01 were evaluated by standardized cognitive and achievement tests These children had been assigned at diagnosis to a standard-risk SR or high-risk HR group and received no CRT or 18 Gy CRT respectively All patients were randomized to receive MTX during remission induction either as CD-MTX 40 mg/m2 or HD-MTX 4 g/m2 with leucovorin rescue There was no difference in cognitive outcomes between radiated and unirradiated patients P > 4 However the HD-MTX/CRT combination was associated with decreased intelligence quotient IQ estimate 93 points for girls only P < 08 A specific deficit in verbal coding and memory was documented for all patients P < 0001 We conclude the following 1 18 Gy CRT per se was not an independent toxic agent for cognitive outcome 2 HD-MTX during induction was associated with IQ decline in girls but only when it was followed by CRT and 3 impairment of verbal memory and coding was a consistent finding that was independent of CRT which implicates some component of chemotherapy possibly prednisone as a CNS toxin\",\n",
            "}\n",
            "13582\n",
            "{\n",
            "  \"id\" : \"9508204\",\n",
            "  \"contents\" : \"Postoperative infections are a frequent source of preventable morbidity and mortality in the oncologic population Granulocyte-macrophage colony-stimulating factor GM-CSF is a potent modulator of immune effector cells in vitro and in vivo This study was conducted to determine whether GM-CSF when administered perioperatively could reduce the incidence of surgical infections in cancer patients This was a prospective randomized placebo-controlled multicenter study Cancer patients at high risk of infectious surgical morbidity were randomized to receive GM-CSF 125 microg/m2 per day or placebo subcutaneously for 8 days beginning 3 days preoperatively Routine antibiotic prophylaxis was administered to all patients Three hundred ninety-nine patients were enrolled with 198 randomized to receive GM-CSF Twenty-one percent of patients experienced infections during the first 2 weeks postoperatively and there was no difference in infection rate between the study groups The most common sites of infection were respiratory tract 53 % and surgical wound 25 % The duration of operation and American Society of Anesthesiology ASA physical status classification were the most significant predictors of infection in multivariate analysis GM-CSF was well tolerated and was not associated with fever The eligibility criteria for this study were successful at defining a patient subgroup at high risk for postoperative infections At an immunomodulatory dose of 125 microg/m2 per day GM-CSF was safe and well tolerated but did not reduce the incidence of postoperative infections in this high-risk oncologic population Infectious morbidity in surgical oncology remains an important subject for continued clinical investigation\",\n",
            "}\n",
            "13583\n",
            "{\n",
            "  \"id\" : \"12072043\",\n",
            "  \"contents\" : \"We have shown previously that oestrogens attenuate cardiovascular and hormonal responses to stress in perimenopausal women The cardiovascular role of oestrogens in men is uncertain despite preliminary evidence that endogenous oestrogens produced by aromatization of androgenic precursors are of physiological importance hypogonadal men have very low levels of circulating oestrogen We therefore studied the haemodynamic and hormonal responses to a standardized laboratory mental stress test in 12 men mean age 689 + / - 26 SEM years rendered hypogonadal as a result of treatment for prostatic cancer before and after 8 weeks of oestrogen supplementation oestradiol valerate 1 mg daily n = 7 or placebo n = 5 The stress was administered as a standard mental arithmetic test of 10 minutes duration Blood pressure cortisol and ACTH were measured at baseline and following 5 minutes and 10 minutes of stress and ACTH again at 25 minutes on both days Noradrenaline and adrenaline responses to mental stress as well as changes in total body and forearm spillover of noradrenaline and noradrenaline clearance were also measured Oestrogen supplementation was well tolerated with minimal adverse effects Mean oestradiol levels increased from < 30 pmol/l to 308 + / - 65 pmol/l after oestrogen treatment Oestradiol significantly attenuated the mental stress-induced increase in both systolic and diastolic blood pressures Oestradiol also attenuated mental stress-induced increases in ACTH cortisol and adrenaline but did not influence either total body or forearm spillover of noradrenaline Responses to stress were unchanged after administration of placebo We conclude that oestrogen supplementation in men rendered hypogonadal as a result of treatment for prostate cancer is well tolerated and significantly attenuates blood pressure and hormonal responses to psychological stress These findings suggest the need for further studies to examine a possible clinical role for oestrogen treatment in hypogonadal men\",\n",
            "}\n",
            "13584\n",
            "{\n",
            "  \"id\" : \"25467927\",\n",
            "  \"contents\" : \"No reference second-line treatment of small-cell lung cancer is available The aim of the present phase II randomized trial Groupe Franais de Pneumo-Cancrologie 0501 was to compare in patients with progressive small-cell lung cancer after first-line platinum-based chemotherapy oral multidrug chemotherapy lomustine cyclophosphamide etoposide and intravenous therapy with cyclophosphamide doxorubicin and vincristine CAV in terms of efficacy and tolerance The primary endpoint was overall survival The secondary endpoints were progression-free survival response rate and tolerance The study randomized 131 patients 767 % male median age 61 81 years 855 % with a performance status of 0-1 65 to oral therapy and 66 to the CAV arm No statistically significant differences were found in the baseline patient characteristics The OS and PFS was 61 and 3 months for the oral arm and 58 and 31 months for the CAV arm respectively The control disease rate was 616 % and 455 % in oral and CAV arms respectively No unexpected adverse events occurred and no statistically significant difference was found between the 2 arms in terms of toxicity grade 4 hematologic adverse events in 323 % and 318 % of patients in the oral and CAV arms respectively Compared with CAV oral therapy in this setting appears as feasible as but not superior to the efficacy in the CAV arm\",\n",
            "}\n",
            "13585\n",
            "{\n",
            "  \"id\" : \"18044772\",\n",
            "  \"contents\" : \"Topical antifungal treatments are recommended but rarely used as first-line therapy for oropharyngeal candidiasis OPC in patients with cancer Miconazole Lauriad 50-mg mucoadhesive buccal tablet MBT Loramyc reportedly delivered rapid and prolonged effective concentrations of miconazole in the mouth The objective of the current study was to compare MBT with miconazole 500-mg oral gel MOG in patients with head and neck cancer Two hundred eighty-two patients with head and neck cancer received a 14-day treatment of either single-dose MBT or MOG administered in 4 divided doses The primary endpoint was clinical success at Day 14 and secondary endpoints included clinical success at Day 7 clinical cure improvement in clinical symptoms mycologic cure recurrence rate and safety The success rate was statistically not inferior P < 0001 in the MBT population to the rate observed in the MOG group 56 % vs 49 % respectively P < 0001 After adjustment for the extent of lesions and salivary secretions a trend toward superiority was observed in favor of MBT P = 13 particularly among patients with multiple lesions P = 013 Results for secondary endpoints were comparable to those observed for the primary endpoint Compliance with MBT was excellent and > 80 % of patients completed treatment Both treatments were safe The success rate of MBT Loramyc was significantly not inferior to that of MOG in the treatment of cancer patients with OPC and after adjusting for prognostic variables it was more effective than MOG MBT was well tolerated and thus may be recommended as first-line treatment in cancer patients who have OPC as an alternative to systemic antifungal agents Society\",\n",
            "}\n",
            "13586\n",
            "{\n",
            "  \"id\" : \"10543669\",\n",
            "  \"contents\" : \"Radiotherapy in addition to systemic treatment after mastectomy prolongs survival in high-risk breast-cancer patients However adjuvant radiotherapy has a potential association with ischaemic heart disease We assessed morbidity and mortality from ischaemic heart disease in patients treated with postmastectomy radiotherapy Between 1982 and 1990 we randomly assigned 3083 women at high risk of breast cancer after mastectomy adjuvant systemic treatment with n = 1538 or without n = 1545 radiotherapy An anterior photon field was used against the periclavicular region and the axilla The chest wall was treated through two anterior shaped electron fields one including the internal mammary nodes The intended dose was 48-50 Gy in 22-25 fractions at four to five fractions per week We obtained information on morbidity and mortality of ischaemic heart disease over a median of 10 years Analysis was by intention to treat More women in the no-radiotherapy group than in the radiotherapy group died of breast cancer 799 [ 525 % ] vs 674 [ 442 % ] whereas similar proportions of each group died from ischaemic heart disease 13 [ 09 % ] vs 12 [ 08 % ] The relative hazard of morbidity from ischaemic heart disease among patients in the radiotherapy compared with the no-radiotherapy group was 086 95 % CI 06-1 3 and that for death from ischaemic heart disease was 084 04-1 8 The hazard rate of morbidity from ischaemic heart disease in the radiotherapy group compared with the no-radiotherapy group did not increase with time from treatment Postmastectomy radiotherapy with this regimen does not increase the actuarial risk of ischaemic heart disease after 12 years\",\n",
            "}\n",
            "13587\n",
            "{\n",
            "  \"id\" : \"21112791\",\n",
            "  \"contents\" : \"Evaluation of the accuracy of palpation CT scan and Martnez-Gimeno Score System in the assessment of neck nodes metastasis in squamous cell carcinoma of the oral cavity This is a prospective triple blind study performed in 40 consecutive patients with squamous cell carcinoma of the oral cavity 40 consecutive patients suffering primary oral squamous cell carcinoma without any treatment before surgery palpation or CT Scan 40 % of the cases showed metastasis in pathological study Sensitivity was 100 % 94 % and 75 % for MGSS 13 CT scan and palpation respectively Specificity was 83 % 38 % and 25-50 % for palpation CT scan and MGSS 13-17 respectively Negative predictive result values were 100 % 90 % and 83 % for MGSS 13 CT Scan and palpation The logistic regression analysis showed an independent predictor factor for palpation p = 0001 and MGSS p = 001 The combination of MGSS and clinical palpation allowed a new design for evaluating neck metastasis in oral cancer This method establishes 3 different groups at risk 3 of very low < 2 % 2 of low risk 18-27 % and 1 of high risk 85 % MGSS predicts metastasis better than CT scan and palpation Combination of MGSS and palpation improves the prediction of metastasis\",\n",
            "}\n",
            "13588\n",
            "{\n",
            "  \"id\" : \"17264781\",\n",
            "  \"contents\" : \"In thyroidectomized patients increased levels of thyroid stimulating hormone TSH are necessary to maximize I uptake Traditionally this has been achieved by withdrawing L-thyroxine L-T4 for 4-6 weeks inducing hypothyroidism in patients The availability of a genetically engineered version of the recombinant human TSH rh-TSH provides an alternative tool to enhance the TSH serum level without inducing hypothyroidism In this paper the I remnant and red-marrow doses calculated in differentiated thyroid cancer DTC patients pre-treated with rh-TSH are compared to those calculated in patients in hypothyroidism induced by L-T4 withdrawal Forty-six DTC patients submitted to I ablative therapy were randomly divided in group A pre-treated with rh-TSH and group B treated after L-T4 withdrawal for 30 days The red-marrow absorbed dose per unit administered activity and the remnant cumulated activity per unit administered activity were calculated for both groups The red-marrow dose in 17 rh-TSH treated patients is 006 + / -002 mGyMBq that in 14 hypothyroid patients is 009 + / -003 mGyMBq two-tailed unpaired t-test P = 0003 The remnant cumulated activity per unit administered activity in 10 rh-TSH treated patients is 09 + / -08 h that calculated in 21 hypothyroid patients is 155 + / -105 h two-tailed unpaired t-test P = 0063 This last result is mainly due to the difference between the maximum uptake U in rh-TSH U = 001 + / -001 and hypothyroid patients U = 003 + / -002 two-tailed unpaired t-test P = 0019 The rh-TSH pre-treated patients seem to have a lower uptake compared to those in hypothyroidism induced by L-T4 withdrawal On the other hand their red-marrow absorbed dose seems to be lower\",\n",
            "}\n",
            "13589\n",
            "{\n",
            "  \"id\" : \"14627758\",\n",
            "  \"contents\" : \"Obese breast cancer survivors are a unique population for weight loss counseling because both obesity and a diagnosis of breast cancer can increase the risk of depression In this pilot study weight loss maintenance was examined in obese breast cancer survivors with relationship to psychiatric diagnosis Forty-eight subjects were enrolled The intervention which used individualized counseling for diet and exercise lasted 24 months After a 6-month period of no contact with study subjects a follow-up body weight was obtained at 30 months The nine subjects who dropped out of the study before 12 months all failed to complete a structured psychiatric interview Of the remaining 39 subjects 9 had major depressive disorder and 10 had a definable psychiatric disorder of lesser severity such as adjustment disorder Subjects with any type of psychiatric diagnosis displayed significantly less weight loss at the 12-month time-point than those with no diagnosis 63 % vs 126 % loss of baseline weight respectively At the 30-month follow-up visit subjects with any psychiatric disorder had a mean weight loss of 12 % of baseline weight compared with 78 % weight loss in subjects with no diagnosis These results suggest that the presence of psychiatric disorders can interfere with weight loss Therefore recognition and treatment of psychiatric disorders may be important in attempts at weight reduction and this will be especially important in populations such as cancer survivors who seem to have higher rates of depression and other disorders than the general population\",\n",
            "}\n",
            "13590\n",
            "{\n",
            "  \"id\" : \"19249153\",\n",
            "  \"contents\" : \"Few randomised studies have compared intermittent hormonal therapy IHT with continuous therapy for the treatment of advanced prostate cancer PCa To determine whether intermittent therapy is associated with a shorter time to progression 766 patients with locally advanced or metastatic PCa received a 3-mo induction treatment The 626 patients whose prostate-specific antigen PSA level decreased to < 4 ng/ml or to 80 % below the initial value were randomised Patients received cyproterone acetate CPA 200mg for 2 wk and then monthly depot injections of a luteinising hormone-releasing hormone LHRH analogue plus 200mg of CPA daily during induction Patients randomised to the intermittent arm ceased treatment while those randomised to the continuous arm received 200mg of CPA daily plus an LHRH analogue Primary outcome measurement was time to subjective or objective progression Secondary outcomes were survival and quality of life QoL Time off therapy in the intermittent arm was also recorded 127 patients from the intermittent arm and 107 patients from the continuous arm progressed with a hazard ratio HR of 081 95 % confidence interval [ CI ] 063-1 05 p = 011 There was no difference in survival with an HR of 099 95 % CI 080-1 23 and 170 deaths in the intermittent arm and 169 deaths in the continuous arm The greater number of cancer deaths in the intermittent treatment arm 106 vs 84 was balanced by a greater number of cardiovascular deaths in the continuous arm 52 vs 41 Side-effects were more pronounced in the continuous arm Men treated with intermittent therapy reported better sexual function Median time off therapy for the intermittent patients was 52 wk 95 % CI 394-65 7 IHT should be considered for use in routine practice because it is associated with no reduction in survival no clinically meaningful impairment in QoL better sexual activity and considerable economic benefit to the individual and the community\",\n",
            "}\n",
            "13591\n",
            "{\n",
            "  \"id\" : \"19032132\",\n",
            "  \"contents\" : \"Opioid therapy is frequently associated with treatment-limiting constipation Naloxone is an opioid antagonist with low oral systemic bioavailability This Phase III clinical trial assessed the safety and efficacy of an oral fixed-ratio combination of oxycodone prolonged-release PR and naloxone PR compared with oxycodone PR in relieving opioid-induced constipation This double-blind multicenter trial was conducted in specialist and primary care centers in four European countries in an out-patients setting The study included 322 adult patients with moderate-to-severe noncancer pain requiring opioid therapy in a range of > or = 20 mg/day and < or = 50 mg/day oxycodone Following a run-in phase patients were randomized to receive oxycodone PR/naloxone PR or oxycodone PR for 12 weeks The primary outcome was improvement in constipation as measured using the Bowel Function Index BFI Secondary/exploratory assessments focused on pain intensity and additional bowel parameters NCT00412152 A significant improvement in BFI scores occurred with oxycodone PR/naloxone PR compared with oxycodone PR after 4 weeks of double-blind treatment -269 vs -94 respectively p < 00001 observed after only 1 week of treatment and continued until study end A significant increase in the number of complete spontaneous bowel movements and decrease in laxative use were also reported This improvement in bowel function was achieved without compromising the analgesic efficacy of the oxycodone component pain intensity remained constant throughout the study The incidence of adverse events was comparable in both groups and consistent with those expected of opioid analgesics As the study was limited to a dose range of up to 50 mg oxycodone equivalent per day further research on higher doses would be recommended The fixed-ratio combination of oxycodone PR/naloxone PR is superior to oxycodone PR alone offering patients effective analgesia while significantly improving opioid-induced constipation\",\n",
            "}\n",
            "13592\n",
            "{\n",
            "  \"id\" : \"11323510\",\n",
            "  \"contents\" : \"To evaluate the clinical utility of frozen section in patients with follicular neoplasms of the thyroid in a randomized prospective trial The finding of a follicular neoplasm on fine-needle aspiration prompts many surgeons to perform intraoperative frozen section during thyroid lobectomy However the focal distribution of key diagnostic features of malignancy contributes to a high rate of noninformative frozen sections The series comprised 68 consecutive patients with a solitary thyroid nodule in whom fine-needle aspiration showed a follicular neoplasm Patients were excluded for bilateral or nodal disease extrathyroidal extension or a definitive fine-needle aspiration diagnosis Final pathologic findings were compared with frozen sections and cost analyses were performed Sixty-one patients met the inclusion criteria Twenty-nine were randomized to the frozen-section group and 32 to the non-frozen-section group In the non-frozen-section group one patient was excluded when gross examination of the specimen was suggestive of malignancy and a directed frozen section was diagnostic of follicular carcinoma Frozen-section analysis rendered a definitive diagnosis of malignancy in 1 of 29 34 % patients who then underwent a one-stage total thyroidectomy In the remaining 28 patients frozen section showed a follicular or Hrthle cell neoplasm Permanent histology demonstrated well-differentiated thyroid cancer in 6 of these 28 patients 21 % Of the 31 patients in the non-frozen-section group 3 10 % showed well-differentiated thyroid carcinoma on permanent histology Complications were limited to one transient unilateral vocal cord dysfunction All but one patient had a 1-day hospital stay There were no significant differences between the groups in surgical time or total hospital charges however the charge per informative frozen section was approximately $ 12470 For the vast majority of patients 964 % with follicular neoplasms of the thyroid frozen section is neither informative nor cost-effective\",\n",
            "}\n",
            "13593\n",
            "{\n",
            "  \"id\" : \"22100213\",\n",
            "  \"contents\" : \"To compare the results of continuous epidural bupivacaine analgesia with and without hydromorphone to continuous paravertebral analgesia with bupivcaine in patients with post-thoracotomy pain A prospective randomized double-blinded trial A teaching hospital Patients at a tertiary care teaching hospital undergoing throracotomy for lung cancer Subjects were assigned randomly to receive a continuous thoracic epidural or paravertebral infusion Patients in the epidural group were randomized to receive either bupivacaine alone or in combination with hydromorphone Visual analog scores as well as incentive spirometery results were obtained before and after thoracotomy Seventy-five consecutive patients presenting for thoracotomy were enrolled in this institutional review board-approved study On the morning of surgery subjects were randomized to either an epidural group receiving bupvicaine with and without hydromorphone or a paravertebral catheter-infused bupvicaine Postoperative visual analog scores and incentive spirometry data were measured in the postanesthesia care unit the evening of the first operative day and daily thereafter until postoperative day 4 Analgesia on all postoperative days was superior in the thoracic epidural group receiving bupivacaine plus hydromorphone Analgesia was similar in the epidural and continuous paravertebral groups receiving bupivacaine alone No significant improvement was noted by combining the continuous infusion of bupivacaine via the paravertebral and epidural routes Incentive spirometry goals were best achieved in the epidural bupivacaine and hydromorphone group and equal in the group receiving bupivacaine alone either via epidural or continuous paravertebral infusion The current study provided data that fill gaps in the current literature in 3 important areas First this study found that thoracic epidural analgesia TEA with bupivacaine and a hydrophilic opioid hydromorphone may provide enhanced analgesia over TEA or continuous paravertebral infusion CPI with bupivacaine alone Second in the bupivacaine-alone group the increased basal rates required to achieve analgesia resulted in hypotension more frequently than in the bupivacaine/hydromorphone combination group underscoring the benefit of the synergistic activity Finally in agreement with previous retrospective studies the current data suggest that CPI of local anesthetic appears to provide acceptable analgesia for post-thoracotomy pain\",\n",
            "}\n",
            "13594\n",
            "{\n",
            "  \"id\" : \"14767287\",\n",
            "  \"contents\" : \"We evaluated the benefits and sequencing of androgen suppression AS administered with external beam radiation therapy EBRT in T2-T3 prostate cancers Between 1990 and 1999 481 patients were entered in 2 successive prospective randomized studies including 161 in the study 1 and 325 in study 2 Eligible patients had clinical stages T2-T3 prostate cancer In the first study L-101 subjects were randomly allocated among EBRT alone group 1 EBRT preceded by 3 months of AS group 2 and neoadjuvant concomitant and adjuvant AS for a total of 10 months group 3 In the second study L-200 we analyzed neoadjuvant and concomitant AS total 5 months vs neoadjuvant concomitant and short course adjuvant total 10 months AS with EBRT In each study we used a total AS a luteinizing hormone-releasing hormone agonist plus an antiandrogen and a standard dose of radiation therapy at that time Patient characteristics were well balanced in regard to age stage prostate specific antigen and Gleason score No biochemical evidence of disease BNED was defined as an end point according to the Vancouver rule In the study 1 at a median followup of 5 years 7-year biochemical-free survival rates were 42 % 66 % and 69 % in groups 1 to 3 respectively BNED was significantly different between groups 1 and 2 p = 0009 and between groups 1 and 3 p = 0003 but not between groups 2 and 3 p = 06 Multivariate analysis using a Cox proportional hazards model showed an HR of 61 for Gleason score p = 0001 14 for PSA p = 0002 05 for group 1 vs group 2 p = 001 and 035 for group 1 vs group 3 p = 0008 In study 2 BNED at 4 years was 65 % There was no significant difference between arms 1 and 2 p = 055 The analysis of study 1 shows a benefit of using a short course of neoadjuvant AS with EBRT vs EBRT alone for localized T2-T3 prostate cancers Moreover in each study adding a short course of adjuvant AS after neoadjuvant 1 provided no more advantage in these patients\",\n",
            "}\n",
            "13595\n",
            "{\n",
            "  \"id\" : \"19033146\",\n",
            "  \"contents\" : \"Although many smokers seek Internet-based cessation assistance few studies have experimentally evaluated long-term cessation rates among cigarette smokers who receive Internet assistance in quitting The purpose of this study is to describe long-term smoking cessation rates associated with 6 different Internet-based cessation services and the variation among them to test the hypothesis that interactive and tailored Internet services yield higher long-term quit rates than more static Web-posted assistance and to explore the possible effects of level of site utilization and a self-reported indicator of depression on long-term cessation rates In 2004-05 a link was placed on the American Cancer Society ACS website for smokers who wanted help in quitting via the Internet The link led smokers to the QuitLink study website where they could answer eligibility questions provide informed consent and complete the baseline survey Enrolled participants were randomly assigned to receive emailed access to one of five tailored interactive sites provided by cooperating research partners or to a targeted minimally interactive ACS site with text photographs and graphics providing stage-based quitting advice and peer modeling 6451 of the visitors met eligibility requirements and completed consent procedures and the baseline survey All of these smokers were randomly assigned to one of the six experimental groups Follow-up surveys done online and via telephone interviews at approximately 13 months after randomization yielded 2468 respondents 38 % and found no significant overall quit rate differences among those assigned to the different websites P = 15 At baseline 1961 participants 30 % reported an indicator of depression Post hoc analyses found that this group had significantly lower 13-month quit rates than those who did not report the indicator all enrolled 8 % vs 12 % P < 001 followed only 25 % vs 31 % P = 003 When the 4490 participants 70 % who did not report an indicator of depression at baseline were separated for analysis the more interactive tailored sites as a whole were associated with higher quitting rates than the less interactive ACS site 13 % vs 10 % P = 04 among 4490 enrolled and 32 % vs 26 % P = 06 among 1798 followed These findings show that Internet assistance is attractive and potentially cost-effective and suggest that tailored interactive websites may help cigarette smokers who do not report an indicator of depression at baseline to quit and maintain cessation\",\n",
            "}\n",
            "13596\n",
            "{\n",
            "  \"id\" : \"18611212\",\n",
            "  \"contents\" : \"Sun-induced skin damage which increases skin cancer risk is initiated in early life and promoted through later sun exposure patterns If sun safety determinants are well understood and addressed during the school years skin cancer incidence might be reduced This study tested psychosocial influences on youth s sun safety and assessed their strength within and across gender and ethnicity in a sample of 1782 middle school students Predictors included sunburn and skin cancer knowledge tanning attitudes peer norms and barriers regarding sun exposure and were assessed with a self-administered validated questionnaire The hypothesized relationships were tested with structural equation models and confirmed with multilevel regression Across gender and ethnicity knowledge emerged as an important sun safety predictor with both direct and indirect effects mediated through tanning attitudes The relationship with barriers did not reach statistical significance within any of the subgroups possibly due to measurement limitations An indirect effect of peer norms on sun safety mediated through tanning attitudes was confirmed only among girls Also an indication that peer norms operate differently within the ethnic groups was found since this predictor had a statistically significantly stronger relationship with sun safety among non-Hispanics Youth s sun safety is a multifactorial practice partially determined by ethnicity - and gender-based standards In order to ensure health-promoting school environments needed are multicomponent programs where peer norms and knowledge are salient and where sun safety is addressed individually and together with other health risk behaviors\",\n",
            "}\n",
            "13597\n",
            "{\n",
            "  \"id\" : \"12607634\",\n",
            "  \"contents\" : \"Despite three decades of debate no conclusion has been reached concerning the effectiveness of postoperative radiotherapy for resected esophageal carcinoma From 1986 through 1997 a prospective randomized study was carried out with 495 patients in an attempt to define the value of this therapeutic modality A total of 495 patients with esophageal cancer who had undergone radical resection were randomized by the envelope method into a surgery-alone group S of 275 patients and a surgery plus radiotherapy group S + R of 220 patients Radiation treatment was started 3 to 4 weeks after the operation The portals encompassed the entire mediastinum and bilateral supraclavicular areas A midplane dose of 50 to 60 Gy in 25 to 30 fractions was delivered over 5 to 6 weeks The overall 5-year survival rate was 317 % for the S group and 413 % p = 04474 for the S + R group The 5-year survival rates of patients who were lymph node positive were 147 % and 292 % p = 00698 respectively Five-year survival rates of stage III patients were 131 % and 351 % p = 00027 respectively Postoperative prophylactic radiotherapy improved the 5-year survival rate in esophageal cancer patients with positive lymph node metastases and in patients with stage III disease compared with similar patients who did not receive radiation therapy These results were almost significant for patients with positive lymph node metastases and highly significant for patients with stage III disease\",\n",
            "}\n",
            "13598\n",
            "{\n",
            "  \"id\" : \"11870177\",\n",
            "  \"contents\" : \"To compare four cycles of therapy versus continuous therapy to determine the optimal duration of chemotherapy in advanced non-small-cell lung cancer NSCLC Stage IIIB/IV NSCLC patients were randomized to arm A four cycles of carboplatin at an area under the curve of 6 and paclitaxel 200 mg/m 2 every 21 days or arm B continuous treatment with carboplatin/paclitaxel until progression At progression all patients on both arms were to receive second-line weekly paclitaxel at 80 mg/m 2 / wk The primary end points were survival and quality of life QOL Two hundred thirty patients were randomized Fifty-seven percent of arm A patients completed four courses of therapy In the 116 arm B patients the median number of cycles delivered was four range zero to 19 cycles Forty-two percent received five or more cycles 18 % received eight or more cycles Overall response rates were 22 % and 24 % for arms A and B respectively P = 80 Median survival time and 1-year survival rates were 66 months and 28 % for arm A and 85 months and 34 % for arm B respectively log-rank P = 63 Rates of hematologic and nonhematologic toxicity were similar between the two arms except for neuropathy The rate of grade 2 to 4 neuropathy increased from 199 % 95 % confidence interval [ CI ] 136 % to 262 % at cycle 4 to 43 % 95 % CI 286 % to 574 % at cycle 8 There were no differences in QOL Only 45 % of patients received second-line therapy 42 % in arm A v 47 % in arm B P = 42 This study shows no overall benefit in survival response rates or QOL to continuing treatment with carboplatin/paclitaxel beyond four cycles in advanced NSCLC\",\n",
            "}\n",
            "13599\n",
            "{\n",
            "  \"id\" : \"20831683\",\n",
            "  \"contents\" : \"Pegylated liposomal doxorubicin PLD is a formulation of doxorubicin encapsulated with polyethylene glycol-coated liposomes which has prolonged circulation time and unique toxicity profile This study deals with the pharmacokinetics and its relation to toxicity in Chinese patients with breast tumours Twenty-two Chinese female patients with breast tumours were received two PLD products in single dose of 50 mg/m2 with a randomized two-period and cross-over design Blood was sampled immediately before and at 15 30 60 min 117 2 5 13 25 49 73 97 121 145 and 241 h after the PLD infusion The plasma level of doxorubicin was determined with LC-MS The pharmacokinetics of PLD was best described by a one-compartment linear structural model with a long elimination T 1/2 64 h a slow clearance 0025 L/h/m2 and a small volume of distribution 2310 L/m2 The main toxicities were neutropenia 22/44 nausea 22/44 vomiting 8/44 and pigmentation 4/44 The nausea and neutropenia were positively correlated with AUC while negatively correlated with Cl P < 005 The study confirms the different pharmacokinetic and toxicity profiles of PLD compared with non-liposomal doxorubicin The pharmacokinetic profiles in Chinese patients with breast tumours is different from those reported for European patients with metastatic breast cancer The correlation between toxicities neutropenia grade and nausea and two of the pharmacokinetic parameters AUC and Cl may be useful for guiding the dosing of the agent\",\n",
            "}\n",
            "13600\n",
            "{\n",
            "  \"id\" : \"8996340\",\n",
            "  \"contents\" : \"We examined the efficacy of a 12-week prophylactic course of bacillus Calmette-Guerin BCG on superficial bladder cancer From August 1992 until July 1994 70 evaluable patients 41 to 80 years old mean age 685 with high risk transitional cell carcinoma of the bladder were prospectively randomized to a 12-week prophylactic course of BCG group 2 versus a traditional 6-week course group 1 Mean followup was 28 months A 70 % tumor-free rate 21 patients and mean interval of 129 months to recurrence were achieved in group 2 compared to 55 % 22 patients and 123 months respectively in group 1 Group 2 patients had an overall longer disease-free survival although no statistical significance was achieved A subgroup of patients with stage Ta cancer in whom at least 1 tumor was resected 12 month before treatment showed the most benefit from long-term prophylactic treatment in terms of disease-free survival Side effects were only slightly more prominent in group 2 rendering the longer course fairly acceptable Our findings suggest a difference for better overall results with the 12-week course of BCG However a larger number of patients are needed to demonstrate a statistically significant difference between the 2 groups\",\n",
            "}\n",
            "13601\n",
            "{\n",
            "  \"id\" : \"7580659\",\n",
            "  \"contents\" : \"To determine effectiveness and adverse effects of anticonvulsant drugs in management of pain Systematic review of randomised controlled trials of anticonvulsants for acute chronic or cancer pain identified by using Medline by hand searching by searching reference lists and by contacting investigators Between 1966 and February 1994 37 reports were found 20 reports of four anticonvulsants were eligible Numbers needed to treat were calculated for effectiveness adverse effects and drug related withdrawal from study The only placebo controlled study in acute pain found no analgesic effect of sodium valproate For treating trigeminal neuralgia carbamazepine had a combined number needed to treat of 26 for effectiveness 34 for adverse effects and 24 for severe effects withdrawal from study For treating diabetic neuropathy anticonvulsants had a combined number needed to treat of 25 for effectiveness 31 for adverse effects and 20 for severe effects For migraine prophylaxis anticonvulsants had a combined number needed to treat of 16 for effectiveness 24 for adverse effects and 39 for severe effects Phenytoin had no effect on the irritable bowel syndrome and carbamazepine had little effect on pain after stroke Clonazepam was effective in one study for temporomandibular joint dysfunction No study compared one anticonvulsant with another Anticonvulsants were effective for trigeminal neuralgia and diabetic neuropathy and for migraine prophylaxis Minor adverse effects occurred as often as benefit\",\n",
            "}\n",
            "13602\n",
            "{\n",
            "  \"id\" : \"12488303\",\n",
            "  \"contents\" : \"Docetaxel Taxotere is a potent anticancer agent with proven efficacy as first-line therapy in non-small-cell lung cancer NSCLC The aim of this large randomised multicentre phase III study was to evaluate docetaxel in the neoadjuvant pre-operative setting Patients with stage IIIA or locally treatable IIIB NSCLC were randomly assigned to receive neoadjuvant docetaxel n = 134 or no chemotherapy n = 140 before surgery/curative-intention radiotherapy Patients received up to three 3-weekly cycles of docetaxel 100 mg/m 2 as 1-h intravenous infusions Median survival was 148 months in the docetaxel group and 126 months in the control group Median times to disease progression were 90 months docetaxel arm and 76 months control arm There were three complete responses and 25 partial responses in patients treated with docetaxel who were evaluable for response n = 101 Docetaxel was well-tolerated 103 patients 77 % received all three planned cycles The major toxicity was grade 4 neutropenia 69 patients 55 % and neutropenic fever eight patients 6 % Radiotherapy was well-tolerated after docetaxel administration Neoadjuvant docetaxel is generally well-tolerated and shows a promising trend towards longer survival in patients with NSCLC\",\n",
            "}\n",
            "13603\n",
            "{\n",
            "  \"id\" : \"9170575\",\n",
            "  \"contents\" : \"In a recent study by the Casodex Combination Study Group USA patients in a flutamide 750 mg/day plus LH-RH agonist group showed a high treatment failure rate mainly due to flutamide-induced diarrhea and hepatotoxicity Our current study was conducted to determine the optimal dose of flutamide for use in this type of combination therapy In a randomized multicenter study 30 patients hormone untreated stage C or D were divided into 2 groups flutamide 250 mg 125 mg x 2 14 patients and flutamide 375 mg 125 mg x 3 16 patients and each dose combined with either goserelin acetate 36 mg every 4 weeks or leuprolide acetate 375 mg every 4 weeks Goserelin and leuprolide were administered to patients in a 11 ratio Flutamide monotherapy at a daily dose of 375 mg was determined to be the optimal dose in Japan in our previous phase II study The endpoints of this pilot study were the objective response and adverse events during the 12-week treatment The objective response rate was 833 % in the flutamide 250 mg group and 857 % in the flutamide 175 mg group according to the Japanese response criteria for prostate cancer Elevated PSA levels fell to within the normal range in 833 % of the patients in the former group and in 933 % of the patients in the latter group One patient administered 250 mg of flutamide experienced diarrhea while the serum GOT and/or GPT were elevated in 3 patients administered 250 mg of flutamide and 4 patients administered 375 mg of flutamide Based on the findings of this pilot study of maximal androgen-depletion therapy for advanced prostate cancer 375 mg/day of flutamide is recommended in combination with an LH-RH agonist Assessment of the effects of our recommended regimen on longer term survival quality of life and antiandrogen withdrawal syndrome of patients treated requires additional patients and time for follow-up\",\n",
            "}\n",
            "13604\n",
            "{\n",
            "  \"id\" : \"22253296\",\n",
            "  \"contents\" : \"Calcium and vitamin D may be inversely related to breast cancer risk in part by affecting mammographic density However results from previous mostly cross-sectional studies have been mixed and there have been few randomized clinical trials of the effect of calcium and vitamin D supplementation on change in mammographic density We assessed the effect of one year of supplementation on mammographic density in 330 postmenopausal women enrolled in the Women s Health Initiative hormone therapy HT and calcium and vitamin D CaD trials Women were randomized to receive 1000 mg/d of elemental calcium carbonate plus 400 IU/d of vitamin D 3 or placebo After approximately one year mammographic density decreased 2 % in the CaD supplementation group and increased 1 % in the placebo group ratio of means = 097 95 % CI = 081-1 17 Results suggested potential interaction by HT use P = 008 Among women randomized to HT placebo the ratio of mean density comparing CaD supplementation and placebo groups was 082 95 % CI = 061-1 11 vs 116 95 % CI = 092-1 45 in women randomized to active HT In sensitivity analyses limited to women taking 80 % of study supplements ratios were 067 95 % CI = 041-1 07 in women not assigned to HT and 107 95 % CI = 079-1 47 women assigned to HT We observed no overall effect of vitamin D and calcium supplementation on mammographic density after one year Potential interaction between these nutrients and estrogen as related to mammographic density warrants further study\",\n",
            "}\n",
            "13605\n",
            "{\n",
            "  \"id\" : \"23000202\",\n",
            "  \"contents\" : \"Docetaxel clearance appears increased in men who are castrated Neutropenia in cycle 1 may be a pharmacodynamic marker for docetaxel which may enable tailored dosing in metastatic castration-resistant prostate cancer mCRPC The association of cycle 1 neutropenia with overall survival OS was examined post hoc in a randomized phase II trial of 221 men with mCRPC who received docetaxel-prednisone combined with placebo or AT-101 bcl-2 inhibitor weekly blood cell counts were performed during the first cycle Patients from both arms were combined because no outcome and toxicity differences were observed OS was calculated from randomization by the Kaplan-Meier method and Cox proportional hazards regression models were used to estimate the association with OS The difference in OS between men with day 8 grade 3 neutropenia and those with grade 2 neutropenia was significant after adjusting for trial stratification factors pain and performance status hazard ratio [ HR ] 064 2P = 048 Results were similar for logarithmic neutrophil counts adjusted for the risk group based on anemia visceral metastasis progression by bone scan and pain HR 118 2P = 07 for stratification factors HR 120 2P = 052 or both HR 120 2P = 046 Men with grade 3 neutropenia and 30 % prostate-specific antigen level decline by day 90 had improved OS compared with men exhibiting neither HR 051 2P = 014 For patients with mCRPC who received docetaxel grade 3 neutropenia on day 8 was prognostic for improved OS which suggests its utility as a pharmacodynamic marker in this hypothesis-generating analysis Exploration of dose escalation of docetaxel to attain grade 3 neutropenia on day 8 may be warranted\",\n",
            "}\n",
            "13606\n",
            "{\n",
            "  \"id\" : \"12867220\",\n",
            "  \"contents\" : \"The aim of this study was to describe the pharmacokinetics of 3 different single doses of fulvestrant-a new estrogen receptor ER antagonist that downregulates the ER with no known agonist effects-administered as a prolonged-release IM formulation Pharmacokinetic data were obtained in a randomized partially blinded placebo-controlled parallel-group Phase I/II multicenter trial involving postmenopausal women with primary breast cancer clinical stages T1-T3 with tumors that were ER positive or of unknown ER status awaiting curative-intent surgery Patients received either IM fulvestrant 50 125 or 250 mg oral tamoxifen 20 mg once daily or oral placebo once daily Treatment started 2 to 3 weeks before surgery and blood was taken at various times up to 12 weeks after fulvestrant administration to assess pharmacokinetic variables A total of 200 patients entered the trial of whom 58 took part in the pharmacokinetic analysis 50 mg n = 20 125 mg n = 16 250 mg n = 22 Following single IM injections of fulvestrant the median time to maximum concentration was 698 698 and 696 days in the 50 - 125 - and 250-mg dose groups respectively with an overall range of 2 to 19 days The plasma concentration-time profiles were primarily controlled by the rate of absorption from the injection site post-peak plasma concentrations declined over time and were measurable up to 84 days after administration of fulvestrant 125 and 250 mg Plasma concentrations at 28 days were 2 - to 5-fold lower than the maximum value Plasma concentration data for the 250-mg dose were best described by a 2-compartment pharmacokinetic model with an apparent terminal phase half-life of approximately 49 days beginning approximately 3 weeks after administration Mean area under the plasma concentration-time curve for days 0 through 28 AUC 0-28 was proportional for fulvestrant 50 125 and 250 mg For a doubling of the dose an analysis of covariance model of the pharmacokinetic data projected an estimated increase in AUC 0-28 of a factor of 184 95 % CI 167 to 204 The IM formulation of fulvestrant used in this study had predictable dose-linear pharmacokinetics The prolonged-release properties of this formulation suggested that it may be well suited for the once-monthly dosing schedule intended for clinical use\",\n",
            "}\n",
            "13607\n",
            "{\n",
            "  \"id\" : \"20356944\",\n",
            "  \"contents\" : \"The Age trial was a randomized controlled trial to study the effect on breast cancer mortality of invitation to annual mammography from age 40 to 41 Uptake of invitation to screening mammography in UK women aged below 50 is of interest particularly in the light of the recent announcement that the national breast screening programme will begin inviting women from age 47 The trial took place in 23 National Health Service breast screening units in England Wales and Scotland between 1991 and 2004 Data on invitation and attendance during 13 years of trial fieldwork were analysed The participants were 53884 women in the intervention arm of the Age trial who were randomized to receive annual invitation to mammography from age 40 or 41 up to age 48 The trial is registered as an International Standard Randomised Controlled Trial number ISRCTN24647151 Uptake of invitation to routine screening was 68 % at first round and 69 % at subsequent rounds A total of 43709 women in the intervention arm 81 % attended at least one routine screen and 23262 43 % attended at least seven screens 31392 women attended 75 % or more of all routine invitations they were offered Previous trial attendance was a predictor of subsequent uptake attendance was inversely related to Townsend deprivation score Uptake in this trial was comparable with that in the UK screening programme for women aged over 50 There was an inverse relationship between deprivation level and the number of screens attended\",\n",
            "}\n",
            "13608\n",
            "{\n",
            "  \"id\" : \"22727623\",\n",
            "  \"contents\" : \"The aim of this study was to describe the impact of a tailored Web-based educational program designed to reduce excessive screening mammography recall Radiologists enrolled in one of four mammography registries in the United States were invited to take part and were randomly assigned to receive the intervention or to serve as controls The controls were offered the intervention at the end of the study and data collection included an assessment of their clinical practice as well The intervention provided each radiologist with individual audit data for his or her sensitivity specificity recall rate positive predictive value and cancer detection rate compared to national benchmarks and peer comparisons for the same measures profiled breast cancer risk in each radiologist s respective patient populations to illustrate how low breast cancer risk is in population-based settings and evaluated the possible impact of medical malpractice concerns on recall rates Participants recall rates from actual practice were evaluated for three time periods the 9 months before the intervention was delivered to the intervention group baseline period the 9 months between the intervention and control groups T1 and the 9 months after completion of the intervention by the controls T2 Logistic regression models examining the probability that a mammogram was recalled included indication of intervention versus control and time period baseline T1 and T2 Interactions between the groups and time period were also included to determine if the association between time period and the probability of a positive result differed across groups Thirty-one radiologists who completed the continuing medical education intervention were included in the adjusted model comparing radiologists in the intervention group n = 22 to radiologists who completed the intervention in the control group n = 9 At T1 the intervention group had 12 % higher odds of positive mammographic results compared to the controls after controlling for baseline odds ratio 112 95 % confidence interval 100-1 27 P = 0569 At T2 a similar association was found but it was not statistically significant odds ratio 110 95 % confidence interval 096 to 125 No associations were found among radiologists in the control group when comparing those who completed the continuing medical education intervention n = 9 to those who did not n = 10 In addition no associations were found between time period and recall rate among radiologists who set realistic goals This study resulted in a null effect which may indicate that a single 1-hour intervention is not adequate to change excessive recall among radiologists who undertook the intervention being tested\",\n",
            "}\n",
            "13609\n",
            "{\n",
            "  \"id\" : \"15816467\",\n",
            "  \"contents\" : \"Cimetidine CIM seems to have positive effects on the immune systems of cancer patients This study was conducted to investigate the effects of perioperative administration of CIM on the peripheral blood lymphocytes natural killer NK cells and tumor infiltrating lymphocytes TIL in patients with gastrointestinal GI cancer Forty-nine GI cancer patients were randomized into a treatment group which took CIM in the perioperative period and a control group which did not take the drug The treatment was initiated 7 days d before operation and continued until 10 d after surgery At baseline examination before operation on the 2nd and the 10th postoperative d peripheral blood T lymphocytes helper T cells T suppressor cells and NK cells were measured by immunocytochemical method The surgical specimens were examined for TIL response and immunohistochemical study was performed to measure the proportion of T and B lymphocytes in the TIL population In comparison with normal controls both the treatment and the control groups had decreased T cells helper T cells and NK cells at baseline In the control group total T cells helper T cells and NK cells declined progressively with the disease course and the decreases became more profound after operation From the baseline to the 2nd postoperative d the proportion of total T cells helper T cells and NK cells went down from 605 + / -46 to 562 + / -38 percent from 334 + / -37 to 281 + / -34 percent and from 150 + / -28 to 142 + / -22 percent respectively On the other hand there were significant improvements in these parameters after CIM treatment On the 10th postoperative d the treatment group had significantly higher percentages of total T cells helper T cells and NK cells than control group Moreover CIM treatment also boosted the TIL response as was reflected by findings that 68 % 17/25 of the patients in the treatment group had significant TIL responses and only 25 % 6/24 of the cases had discernible TIL response Perioperative application of CIM to GI cancer patients could help restore the diminished cellular immunity boost TIL responses to tumor\",\n",
            "}\n",
            "13610\n",
            "{\n",
            "  \"id\" : \"12551829\",\n",
            "  \"contents\" : \"Upper extremity thrombosis is a major complication of central venous catheters implanted for chemotherapy in cancer patients Vitamin K antagonists and low-molecular-weight heparins have been recommended in this setting but their relative benefit-to-risk ratios have never been compared A prospective randomized open parallel-group multicenter trial was performed comparing the antithrombotic efficacy and safety of warfarin and the low-molecular-weight heparin nadroparin in cancer patients who had undergone central venous catheter implantation Warfarin was given orally at a fixed daily dose of 1 mg and nadroparin was injected subcutaneously at a fixed daily dose of 2850 IU for 90 days or until venographically-confirmed thrombosis occurred The primary efficacy outcome was the occurrence of upper extremity thrombosis confirmed by venography performed 90 days after insertion of the catheter or earlier if symptoms of thrombosis had appeared Safety end-points were bleeding and thrombocytopenia Fifty-nine patients were included in the study A total of 21 and 24 patients in the nadroparin and warfarin groups respectively were evaluable for primary efficacy Six out of the 21 patients in the nadroparin group 286 % and 4 out of the 24 patients in the warfarin group 167 % had venographically-documented upper extremity thrombosis at day 90 p = 048 Safety was satisfactory and similar with both treatments Warfarin at a fixed very low dose and nadroparin at a fixed prophylactic dose had comparable benefit-to-risk ratios in the prevention of thrombosis associated with central venous catheters in cancer patients\",\n",
            "}\n",
            "13611\n",
            "{\n",
            "  \"id\" : \"15051778\",\n",
            "  \"contents\" : \"Recombinant human erythropoietin rHuEPO is the standard of care for patients with chemotherapy-related anemia Intravenous IV iron improves hemoglobin Hb response and decreases dosage requirements in patients with anemia of kidney disease but its effect has not been studied in randomized trials in cancer patients This prospective multicenter open-label randomized trial enrolled 157 patients with chemotherapy-related anemia Hb < or = 105 g/L serum ferritin < or = 450 pmol/L or < or = 675 pmol/L with transferrin saturation < or = 19 % receiving subcutaneously rHuEPO 40000 U once weekly to 1 no-iron 2 oral iron 325 mg twice daily 3 iron dextran repeated 100mg IV bolus or 4 iron dextran total dose infusion TDI Hb and quality of life QOL were measured at baseline and throughout All groups showed Hb P < 0001 increases from baseline Mean Hb increases for both IV iron groups were greater P < 02 than for no-iron and oral iron groups The percentage of patients with hematopoietic responses was higher P < 01 in both IV iron groups each case 68 % compared with no-iron 25 % and oral iron 36 % groups IV iron groups showed increases in energy activity and overall QOL from baseline compared with a decrease in energy and activity for no-iron group and no change in activity or overall QOL for oral iron group rHuEPO increases Hb levels and improves QOL in patients with chemotherapy-related anemia Magnitude of Hb increase and QOL improvement is significantly greater if IV iron is added\",\n",
            "}\n",
            "13612\n",
            "{\n",
            "  \"id\" : \"11115157\",\n",
            "  \"contents\" : \"To record the profile of toxic effects of polyethylene glycol-coated liposomal doxorubicin hydrochloride Doxil to the skin and to evaluate whether the long circulation pattern and enhanced accumulation of liposomes in specific skin sites will result in any unique presentations Patients were accrued in the frame of dose-range-finding studies that examine the toxic effects and antitumor activity of Doxil therapy in metastatic breast and prostate cancers All patients receiving Doxil were instructed to report any skin eruption or discomfort Skin examination was performed on a regular basis at every cycle of Doxil therapy and after specific complaints Outpatient day care unit of the oncology institute of a secondary-referral medical center Sixty patients 45 women and 15 men A basic severity scale of I through IV was adopted for toxic effects to the skin based on National Cancer Institute common toxicity criteria The following 4 patterns of skin eruptions were encountered hand-foot syndrome n = 24 diffuse follicular rash n = 6 intertrigolike eruption n = 5 and new formation of melanotic macules n = 3 Another major toxic effect of Doxil was stomatitis which was found to be the dose-limiting factor for the maximal single dose Alopecia and extravasation injuries did not occur The profile of toxic effects of Doxil to the skin reflects its unique pharmacokinetics and tissue distribution These skin reactions vary significantly from those associated with doxorubicin in non-liposome-encapsulated form\",\n",
            "}\n",
            "13613\n",
            "{\n",
            "  \"id\" : \"23338230\",\n",
            "  \"contents\" : \"Previous studies have not defined the role of telemonitoring with educational tools in outpatients with advanced cancers We tested the effectiveness of standardized education and telemonitoring for improving pain distress anxiety depression quality of life QoL and performance in outpatients with advanced cancers A total of 108 patients were randomly assigned to receive pain education alone control arm or pain education plus telemonitoring experimental arm Nursing specialists provided video-assisted educational material in both arms and daily telemonitoring for the first week in the experimental arm Assessment was performed at baseline and 1 week and included evaluations of pain Brief Pain Inventory BPI distress Distress Thermometer DT anxiety and depression Hospital Anxiety and Depression Scale HADS QoL QLQ-C30 and a Karnofsky score Overall n = 108 pain intensity was significantly improved at 1 week including worst pain 73 to 57 P < 001 and average pain 46 to 38 P < 001 Additionally anxiety HADS score11 75 % to 56 % P < 001 depression HADS score11 73 % to 51 % P < 001 QoL fatigue and insomnia and the Karnofsky score 32 to 66 P < 001 were also significantly improved at 1 week However the level of distress did not improve The telemonitoring plus standardized education group showed more significant improvement in portion of pain > 4 on VAS scale 35 % vs 19 % P = 002 Standardized pain education using nursing specialists is an efficient way to improve not only pain itself but also anxiety depression performance and QoL The addition of telemonitoring helps to improve pain management in the outpatient setting\",\n",
            "}\n",
            "13614\n",
            "{\n",
            "  \"id\" : \"17031805\",\n",
            "  \"contents\" : \"Erythrocyte changes from aerobic exercise training were examined during radiation treatment of breast cancer Twenty sedentary females with breast carcinoma who were ages 35 to 65 years were randomized to aerobic exercise AE of walking for 20 to 45 minutes 3 to 5 times per week at 50 % to 70 % of measured maximum heart rates or to placebo stretching PS activities 3 to 5 days per week during 7 weeks of radiation treatment Measures were obtained 1 week before and after the radiation regimen Serum blood analyses through complete blood counts measured red blood cell counts RBC hematocrit HCT and hemoglobin HB Peak aerobic capacity peak VO 2 was measured by exercise testing with oxygen uptake analysis to assess training A Wilcoxon Mann-Whitney U test examined changes between groups P < or = 05 for significance AE peak VO 2 increased by 63 % P = 001 and PS decreased by 46 % P = 083 RBC increased in AE from 410 to 421 million cells/microL and declined in PS from 430 to 419 million cells/microL the between-group differences were significant P = 014 HCT increased in AE from 380 % to 388 % and declined in PS from 3740 % to 3650 % the between-group differences were significant P = 046 HB increased in AE from 123 to 124 g/dL and declined in PS from 1225 to 1177 g/dL the between-group differences were significant P = 009 The results of the current study suggest that moderate intensity aerobic exercise appears to maintain erythrocyte levels during radiation treatment of breast cancer compared with the declines observed in nontraining individuals These findings suggest a safe economical method to improve fitness and maintain erythrocytes in women during radiation treatment of breast cancer\",\n",
            "}\n",
            "13615\n",
            "{\n",
            "  \"id\" : \"25582112\",\n",
            "  \"contents\" : \"Image-enhanced endoscopy such as narrow band imaging and the Storz Professional Image Enhancement System have been increasingly used in patients with suspect lesions of the larynx and hypopharynx during preoperative and intraoperative assessment In the present study a contact endoscope was coupled with the systems of image-enhanced endoscopy as to precisely distinguish the peculiar neoangiogenetic changes in inflammation and precancerous and cancerous lesions of the larynx and hypopharynx We performed a single-blind study with this original approach of a series of 44 patients with different lesions of the larynx and hypopharynx We observed five obvious vascular patterns matching the diagnosis in 41 patients out of 44 with accuracy in the differential diagnosis between normal tissue and hyperplasia versus mild dysplasia and carcinoma of 976 % Enhanced contact endoscopy allows for predicting histologic changes of laryngeal and hypopharyngeal lesions from inflammation to cancer on based on fine evaluation of the neoangiogenetic changes of the chorion This innovative procedure can be considered an important tool during diagnosis treatment and follow-up of patients with precancer and cancer of the larynx and hypopharynx\",\n",
            "}\n",
            "13616\n",
            "{\n",
            "  \"id\" : \"7854929\",\n",
            "  \"contents\" : \"To determine whether infusion method influences the quality of platelets transfused Linked in vitro and in vivo study Quasi-experimental design for in vitro and cross-over design with balanced randomization for in vivo Pediatric cancer center in the midsouthern United States Pheresed/pooled platelet units in vitro n = 12 In vivo convenience sample of 26 children ages 2-19 years with cancer and thrombocytopenia who required platelet transfusion Two infusion pumps IMED 980 and Gemini IMED Corp San Diego CA versus gravity flow for in vitro platelet infusion Gemini infusion pump versus gravity flow for in vivo platelet transfusion Platelet count morphology score and corrected count increment No significant differences noted in platelet count or morphology score among or across the three infusion methods in vitro No significant differences noted between the two infusion methods in platelet count or corrected count increment in vivo Although limited to a specific patient population setting and infusion device findings revealed that the pump was clinically acceptable because it did not negatively affect platelet recovery Replication of this study with other infusion devices is recommended Study findings validate the current nursing procedure for the administration of platelets at the study setting Use of infusion pumps for platelet transfusions is time-efficient and energy-efficient for nurses because the pumps offer a well-controlled infusion rate accurate volume measurement and an alarm system for monitoring the infusion\",\n",
            "}\n",
            "13617\n",
            "{\n",
            "  \"id\" : \"22420471\",\n",
            "  \"contents\" : \"Tumor infiltrating lymphocytes may indicate an immune response to cancer development but their significance remains controversial in breast cancer We conducted this study to assess CD8 + cytotoxic T lymphocyte infiltration in a large cohort of invasive early stage breast cancers and to evaluate its prognostic effect in different breast cancer intrinsic subtypes Immunohistochemistry for CD8 staining was performed on tissue microarrays from 3992 breast cancer patients CD8 + tumor infiltrating lymphocytes were counted as intratumoral when in direct contact with tumor cells and as stromal in adjacent locations Kaplan-Meier functions and Cox proportional hazards regression models were applied to examine the associations between tumor infiltrating lymphocytes and breast cancer specific survival Among 3403 cases for which immunohistochemical results were obtained CD8 + tumor infiltrating lymphocytes were identified in an intratumoral pattern in 32 % and stromal pattern in 61 % of the cases In the whole cohort the presence of intratumoral tumor-infiltrating lymphocytes was significantly correlated with young age high grade estrogen receptor negativity human epidermal growth factor receptor-2 positivity and core basal intrinsic subtype and was associated with superior breast cancer specific survival Multivariate analysis indicated that the favorable prognostic effect of CD8 + tumor infiltrating lymphocytes was significant only in the core basal intrinsic subgroup Hazard ratio HR = 035 95 % CI = 023-0 54 No association with improved survival was present in those triple negative breast cancers that lack expression of basal markers HR = 099 95 % CI = 048-2 04 nor in the other intrinsic subtypes CD8 + tumor infiltrating lymphocytes are an independent prognostic factor associated with better patient survival in basal-like breast cancer but not in non-basal triple negative breast cancers nor in other intrinsic molecular subtypes\",\n",
            "}\n",
            "13618\n",
            "{\n",
            "  \"id\" : \"11977638\",\n",
            "  \"contents\" : \"To evaluate Amifostin s effect on protecting kidney from cisplatinum DDP injury and its adverse reactions and safety 193 Patients were divided into two groups randomly 102 in group A treatment group and 91 in group B control group Indexes such as blood routine blood calcium liver function blood urea nitrogen BUN cretinine C and urinary N-acetyl-beta-D-glucosaminidase NAG / C and micro-albumin MAB/C were monitored at different intervals before or after treatment In the two courses of treatment in both groups the deviation D values of MAB/C before treatment and on D2 in group A were lower than those in grop B P < 005 so were those before treatment and on D4 D6 D10 and D14 P < 001 The D-values of NAG/C before treatment and on D4 D6 D10 and D14 in the first course of group A were obviously lower than those on the corresponding days in group B P < 001 so were those before treatment and on D2 D4 D6 D10 and D14 in the second course P < 001 The reduction of MAB/C and NAG/C by Amifostin in group A demonstrates that Amifostin is able to effectively protect the renal function regardless of the type of tumor In contrast with group B Amifostin in group A shows no protection for tumor in lung cancer and ovarian cancer The main side effects of Amifostin are mild hypotension nausea vomiting and hypocalcemia in some patients\",\n",
            "}\n",
            "13619\n",
            "{\n",
            "  \"id\" : \"12074329\",\n",
            "  \"contents\" : \"The Eastern Cooperative Oncology Group conducted a randomized phase II trial to determine the objective response rates toxicities and overall survival and to assess effects on quality of life for two combination regimens in patients with advanced gastric cancer All patients had biopsy-proven untreated metastatic gastric cancer with measurable disease The FHIG arm employed infusional fluorouracil F 26 g/m2 given intravenously over 24 hours once perweek for 6 weeks infusional hydroxyurea H 43 g/m2 given intravenously over 24 hours once per week for 6 weeks and interferon-alpha-2a 1 9 MU given subcutaneously three times per week once per week for 6 weeks The AD arm employed doxorubicin A 50 mg/m2 and docetaxel D 75 mg/m2 both given intravenously every 21 days Quality of life was measured by the FACT-Fatigue scale and a novel questionnaire assessing interferon-mediated fatigue Twenty-nine patients were enrolled 23 were eligible and evaluable Twelve were enrolled on FHIG and 11 on AD The major grade > or = 3 toxicities were neuromotor 46 % in patients receiving FHIG and granulocytopenia 91 % in those receiving AD There were two fatalities in the AD arm There was one partial responder on FHIG 83 % and none on AD The median survival was 66 months for FHIG and 101 months for AD Quality-of-life analysis did not show substantial cumulative fatigue in patients treated with FHIG Neither regimen demonstrated enough activity to serve as a platform for the development of further clinical regimens against gastric carcinoma A subset of patients receiving interferon was able to tolerate therapy without deterioration in quality of life\",\n",
            "}\n",
            "13620\n",
            "{\n",
            "  \"id\" : \"11062381\",\n",
            "  \"contents\" : \"Neoadjuvant hormonal therapy NHT has been used for more than a decade for prostate cancer but the results of clinical trials are only now becoming available and the value of the treatment is not yet clear The authors reviewed the results of the European randomized trials to increase our understanding of the role of this treatment We report the results of 402 patients with prostate cancer 220 clinical stage T 2 and 182 clinical T 3 tumor of whom 192 were randomly assigned to NHT using an LHRH analog goserelin plus flutamide for a period of 3 months NHT and 210 underwent radical prostatectomy only RP Pathologic downstaging occurred in 15 % and 7 % of the NHT and the RP group respectively P < 001 Fifty of the 189 patients in the NHT group 26 % and 68 of the 209 patients in the RP group 33 % developed disease progression as determined by rising serum prostate specific antigen PSA concentration Regarding local disease progression the advantage for the use of NHT approached but did not reach statistical significance 18 of 189 patients 10 % in the NHT group and 33 of 209 patients 16 % in the RP group P = 007 Although there was a trend in favor of the NHT group with respect to the number of patients with PSA progression and the number with local disease progression it did not reach statistical significance These results may be attributable to a true lack of benefit of adjuvant hormonal ablation or to a lack of statistical power to demonstrate a difference in a subset of patients who might benefit from this therapy\",\n",
            "}\n",
            "13621\n",
            "{\n",
            "  \"id\" : \"17476865\",\n",
            "  \"contents\" : \"Nonalcoholic fatty liver disease NAFLD is a chronic condition that can progress to cirrhosis and hepatocellular cancer The most progressive form of NAFLD is nonalcoholic steatohepatitis NASH Currently the only method to diagnose NASH is with a liver biopsy however sampling error may limit diagnostic accuracy We investigated the discordance of paired liver biopsies in individuals undergoing gastric bypass Two liver biopsies composite size of > or = 25 mm and > or = 8 portal tracts PTs were obtained from the left lobe in 31 subjects Group 1 included specimens at least 15 mm in length with > or = 4 PTs compared to a second biopsy of at least 10 mm and > or = 4 PTs Group 2 The mean specimen size number of PTs for group 1 was 204 + / - 42 mm 117 + / - 55 PTs and group 2 was 161 + / - 53 mm 82 + / - 41 PTs Prevalence of NASH was 26 % in Group 1 and 32 % in Group 2 Sampling discordance was greatest for portal fibrosis 26 % followed by zone 3 fibrosis 13 % and ballooning degeneration 3 % The negative predictive values from Group 1 liver biopsies for NASH and portal fibrosis were only 83 % and 67 % respectively The results demonstrate that significant sampling variability exists in class 2 and 3 obese individuals undergoing screening liver biopsies for NAFLD The degree and histopathological discordance is dependent upon zonal location and types of injury Nevertheless a 25-mm biopsy specimen without zone 3 cellular ballooning or fibrosis appears adequate to exclude the diagnosis of NASH\",\n",
            "}\n",
            "13622\n",
            "{\n",
            "  \"id\" : \"23045575\",\n",
            "  \"contents\" : \"The purpose of our study was to evaluate the effect of cognitive behavioral therapy CBT physical exercise PE and of these two interventions combined CBT/PE on menopausal symptoms primary outcome body image sexual functioning psychological well-being and health-related quality of life secondary outcomes in patients with breast cancer experiencing treatment-induced menopause Patients with breast cancer reporting treatment-induced menopausal symptoms N = 422 were randomly assigned to CBT n = 109 PE n = 104 CBT/PE n = 106 or to a waiting list control group n = 103 Self-report questionnaires were completed at baseline 12 weeks and 6 months Multilevel procedures were used to compare the intervention groups with the control group over time Compared with the control group the intervention groups had a significant decrease in levels of endocrine symptoms Functional Assessment of Cancer Therapy-Endocrine Symptoms P < 001 effect size 031-0 52 and urinary symptoms Bristol Female Lower Urinary Tract Symptoms Questionnaire P = 002 effect size 029-0 33 and they showed an improvement in physical functioning 36-Item Short Form Health Survey physical functioning subscale P = 002 effect size 037-0 46 The groups that included CBT also showed a significant decrease in the perceived burden of hot flashes and night sweats problem rating scale of the Hot Flush Rating Scale P < 001 effect size 039-0 56 and an increase in sexual activity Sexual Activity Questionnaire habit subscale P = 027 effect size 065 Most of these effects were observed at both the 12-week and 6-month follow-ups CBT and PE can have salutary effects on endocrine symptoms and to a lesser degree on sexuality and physical functioning of patients with breast cancer experiencing treatment-induced menopause Future work is needed to improve the design and the planning of these interventions to improve program adherence\",\n",
            "}\n",
            "13623\n",
            "{\n",
            "  \"id\" : \"9579008\",\n",
            "  \"contents\" : \"This study identifies factors associated with employee intention to participate in a company-sponsored program of continuous screening for colorectal cancer Automobile industry pattern and model makers who had been offered screening for over a decade were included in the study Data were collected at the outset of a randomized trial of screening and nutrition interventions A baseline survey was mailed to 4490 white men without a history of colorectal cancer This mailing generated complete responses from 2693 60 % individuals Survey data obtained for these men including measures of cognitive and psychological representations related to colorectal screening social influence and intention to screen were supplemented by background information gathered from employment records of these men Workplace screening services were documented via a survey of plant health care professionals Fifty-eight percent of respondents reported a high level of intention to screen Multivariate analyses showed that intention to screen was positively associated with employee past participation in screening belief in the salience and coherence of screening belief in screening efficacy perceived self-efficacy belief that polyp removal prevents colorectal cancer perceived personal susceptibility to colorectal cancer or polyps receptivity to family member support for screening and workplace scheduling of screening examinations Factors associated with intention to screen may contribute to participation in continuous screening programs Research is needed to assess the impact of interventions that facilitate appointment scheduling provide tailored education about screening and encourage lay support\",\n",
            "}\n",
            "13624\n",
            "{\n",
            "  \"id\" : \"19243603\",\n",
            "  \"contents\" : \"To examine the effects of a 6 month lifestyle intervention on quality of life depression self-efficacy and eating behavior changes in overweight and obese endometrial cancer survivors Early stage endometrial cancer survivors were randomized to intervention n = 23 or usual care n = 22 groups Chi-square Student s t-test and repeated measures analysis of variance were used in intent-to-treat analyses Outcomes were also examined according to weight loss Morbidly obese patients had significantly lower self-efficacy specifically when feeling physical discomfort There was a significant improvement for self-efficacy related to social pressure p = 03 and restraint p = 02 in the LI group There was a significant difference for emotional well-being quality of life p = 02 self-efficacy related to negative emotions p < 01 food availability p = 03 and physical discomfort p = 01 in women who lost weight as compared to women who gained weight Improvement in restraint was also reported in women who lost weight p < 01 This pilot lifestyle intervention had no effect on quality of life or depression but did improve self-efficacy and some eating behaviors http//wwwclinicaltrialsgov NCT00420979\",\n",
            "}\n",
            "13625\n",
            "{\n",
            "  \"id\" : \"21992464\",\n",
            "  \"contents\" : \"Activation of beta-catenin is a hallmark of hepatoblastoma HB and appears to play a crucial role in its pathogenesis While aberrant accumulation of the beta-catenin is a common event in HB mutations or deletions in CTNNB1 beta-catenin gene do not always account for the high frequency of protein expression In this study we have investigated alternative activation of beta-catenin by HGF/c-Met signaling in a large cohort of 98 HB patients enrolled in the SIOPEL-3 clinical trial We performed immunohistochemistry using antibodies to total beta-catenin and tyrosine654-phosphorylated beta-catenin which is a good surrogate marker of HGF/c-Met activation CTNNB1 mutation analysis was also carried out on all samples We also investigated beta-catenin pathway activation in two liver cancer cell lines HuH-6 and HuH-7 Aberrant beta-catenin expression was seen in the cytoplasm and/or nucleus of 87 % of tumour samples Our results also revealed a large subset of HB 83 % with cytoplasmic expression of tyrosine654-phosphorylated beta-catenin and 30 % showing additional nuclear accumulation Sequence analysis revealed mutations in 15 % of our cohort Statistical analysis showed an association between nuclear expression of c-Met-activated beta-catenin and wild type CTNNB1 P-value = 0015 Analysis of total beta-catenin and Y654-beta-catenin in response to HGF activation in the cell lines mirrors that observed in our HB tumour cohort We identified a significant subset of hepatoblastoma patients for whom targeting of the c-Met pathway may be a treatment option and also demonstrate distinct mechanisms of beta-catenin activation in HB\",\n",
            "}\n",
            "13626\n",
            "{\n",
            "  \"id\" : \"25225952\",\n",
            "  \"contents\" : \"Fostering patients sense of meaning is an essential task for palliative care clinicians Few studies have reported the effects on nurses of a short-term training program aimed at improving skills to relieve feelings of meaninglessness in terminally ill cancer patients The primary aim of this study was to determine the impact on nurses of a novel two-day education program focusing on care that addresses patients feelings of meaninglessness Measured were impacts on nurses confidence self-reported practice attitudes toward caring for such patients burnout meaning of life and knowledge This study was a randomized controlled trial using the waiting list control Intervention consisted of a two-day interactive education program A total of 76 nurses randomly allocated to two groups completed the study Outcome measures included confidence scale self-reported practice scale scales of nursing attitudes toward caring for patients who experience feelings of meaningless willingness to help positive appraisal helplessness nurse-perceived value of being and nurse-perceived value of patients inner power Maslach burnout scale Functional Assessment of Chronic Illness Therapy-Spiritual and knowledge scale There were significant intervention effects in nurse-reported confidence and nurse-perceived value of patients inner power Nurse-reported helplessness showed marginally significant improvement after intervention p = 0067 No significant intervention effects were observed in the self-reported practice scale attitudes toward caring for patients willingness to help positive appraisal and nurse-perceived value of being burnout scale meaning of life and knowledge score The percentages of nurses who evaluated this program as useful or very useful were 95 % understanding the conceptual framework and 85 % helping to learn how to provide care for patients feeling meaninglessness in clinical practice This short-term educational intervention had a significant beneficial effect on nurses confidence and modest effects on attitudes\",\n",
            "}\n",
            "13627\n",
            "{\n",
            "  \"id\" : \"17122760\",\n",
            "  \"contents\" : \"The primary objective of the study was to compare the effect of laparoscopic-assisted LPS versus open surgery LPT for colorectal cancer on postoperative morbidity The secondary objectives were to evaluate immune response and intestinal wall oxygen perfusion A total of 610 patients with colorectal cancer were randomly assigned to receive colon resection by either LPS n = 306 or LPT n = 304 Four surgical staff members not involved in the study recorded postoperative complications up to 30 days after the operation Immune response was evaluated by measuring lymphocytic proliferation after challenge with Candida albicans and phytohemoagglutinin before at 3 and 15 days after the operation Intestinal wall oxygen perfusion was continuously monitored using a probe The conversion rate was 46 % in the LPS group Morbidity was 186 % in the LPS group and 345 % in the LPT group P < 00005 Infections developed in 91 % of LPS-treated patients and in 202 % of LPT-treated patients P < 00005 The mean length of stay was 97 + / -26 days in the LPS group and 122 + / -42 days in the LPT group P < 00001 In both groups lymphocytic proliferation was low at 3 days postoperative but returned to normal range at 15 days only in the LPS group Interoperative intestinal oxygen perfusion values were higher in the LPS group Laparoscopic colorectal surgery reduced both postoperative morbidity and length of stay Lymphocytic proliferation and intestinal wall oxygen perfusion were higher in patients who underwent laparoscopic-assisted surgery\",\n",
            "}\n",
            "13628\n",
            "{\n",
            "  \"id\" : \"23759326\",\n",
            "  \"contents\" : \"Evidence from randomized trials on the effects of screening for prostate cancer PCa on disease-specific mortality accumulates slowly with increasing follow-up To assess data on PCa-specific mortality in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer ERSPC trial A randomized controlled trial with randomization after signed written informed consent efficacy trial In the period 1993-1999 a total of 42 376 men aged 54-74 yr were randomized to a screening arm S-arm n = 21 210 with screening every 4 yr applying a total prostate-specific antigen [ PSA ] level cut-off 30 ng/ml as biopsy indication or a control arm C-arm n = 21 166 no intervention Number of PCas detected per arm depicted by predefined time periods and prognostic groups PCa-specific mortality analyses using Poisson regression in age group 55-74 yr at randomization and separately in the predefined age group of 55-69 yr After a median follow-up of 128 yr 19 765 men 942 % were screened at least once and 2674 PCas were detected of which 561 [ 210 % ] were interval PCas In the C-arm 1430 PCas were detected resulting in an excess incidence of 59 PCas per 1000 men randomized 61 PCas per 1000 in age group 55-69 yr Thirty-two percent of all men randomized have died PCa-specific mortality relative-risk RR reductions of 200 % overall age 55-74 yr p = 0042 and 316 % age 55-69 yr p = 0004 were found A 141 % increase was found in men aged 70-74 yr not statistically significant Absolute PCa mortality was 18 per 1000 men randomized 26 per 1000 men randomized in age group 55-69 yr The number needed to invite and number needed to manage were 565 and 33 respectively for age group 55-74 yr and 392 and 24 respectively for age group 65-69 yr Given the slow natural history of the disease follow-up might be too short Systematic PSA-based screening reduced PCa-specific mortality by 32 % in the age range of 55-69 yr The roughly twofold higher incidence in the S-arm underlines the importance of tools to better identify those men who would benefit from screening\",\n",
            "}\n",
            "13629\n",
            "{\n",
            "  \"id\" : \"23714670\",\n",
            "  \"contents\" : \"To evaluate the cardioprotective effects of dexrazoxane DEX on breast cancer patients who received anthracycline-containing chemotherapy A total of 122 breast cancer patients after operation were randomly divided into two groups The experimental group of 61 cases treated with EPI plus DEX DEX EPI = 101 as adjuvant chemotherapy regimen and the control group of 61 cases treated with EPI but without DEX All patients received four cycles of adjuvant chemotherapy and their changes of specific cardiac functional status and hematology status before and after chemotherapy as well as non-cardiac toxicity were observed and analyzed Brain natriuretic peptide BNP before chemotherapy and after four cycles of chemotherapy in the control group was 10678 452 10 -6 g/ml and 18719 871 10 -6 g/ml respectively with a significant difference between them P < 005 It in the experimental group was 10234 876 10 -6 g/ml and 10529 721 10 -6 g/ml respectively without a significant difference P > 005 Cardiac troponin T cTnT before chemotherapy and after four cycles of chemotherapy in the control group was 1255 273 10 -3 g/ml and 3105 710 10 -3 g/ml respectively with a significant difference between them P < 005 It in the experimental group was 1270 215 10 -3 g/ml and 1365 782 10 -3 g/ml respectively without a significant difference P > 005 The hart rate HR before chemotherapy and after four cycles of chemotherapy in the control group was 7532 714 bpm and 8960 921 bpm respectively with a significant difference P < 005 It in the experimental group was 7860 629 bpm and 8310 756 bpm respectively without a significant difference P > 005 The left ventricular ejection fraction LVEF before chemotherapy and after four cycles of chemotherapy in the control group was 6523 782 % and 5521 723 % respectively with a significant difference between them P < 005 It in the experimental group was 6412 625 % and 596 472 % respectively without a significant difference P > 005 The absolute neutrophil count before chemotherapy and after four cycles of chemotherapy in the control group was 395 136 10 9 / L and 350 152 10 9 / L respectively without a significant difference P > 005 It in the experimental group was 496 141 10 9 / L and 310 126 10 9 / L respectively with a significant difference P < 005 The incidence of grade I-IV bone marrow suppression in the experimental group was 213 % 164 % 246 % and 49 % respectively It in the control group was 164 % 115 % 98 % and 55 % respectively with a significant difference P < 005 Cardiac toxicity after anthracycline treatment in breast cancer patients may be significantly reduced by DEX without increase of non-cardiac and and non-hematologic toxicity DEX combined with anthracycline increases the risk of bone marrow suppression therefore peripheral blood picture should be monitored or routine bone marrow support may be needed\",\n",
            "}\n",
            "13630\n",
            "{\n",
            "  \"id\" : \"7844607\",\n",
            "  \"contents\" : \"Pelvic radiation is standard treatment for women with stage IIb to IVa cervical cancer but treatment results are disappointing particularly for women with bulky tumors We investigated the role of primary chemotherapy followed by pelvic radiotherapy in a randomized trial Two hundred sixty patients with stage IIb and IVa cervical cancer received either standard pelvic radiotherapy or primary chemotherapy with cisplatin 60 mg/m2 and epirubicin 110 mg/m2 administered at 3-week intervals for three cycles followed by pelvic radiotherapy Ninety-nine patients have relapsed with a median follow-up duration of 13 years in 62 patients the first site of progressive disease was the pelvis Patients who received primary chemotherapy had a significantly higher pelvic failure rate than those who received radiotherapy alone P < 003 Seventy-six patients have died and those who received primary chemotherapy had significantly inferior survival compared with those who received radiotherapy alone P = 02 Tumor response following chemotherapy was observed in 63 % After radiotherapy tumor response occurred in 72 % of those who received combined modality treatment compared with 92 % of those who received radiotherapy alone Primary chemotherapy with epirubicin and cisplatin although resulting in tumor response in a significant proportion of patients is accompanied by an inferior local control rate and survival compared with standard pelvic radiotherapy alone\",\n",
            "}\n",
            "13631\n",
            "{\n",
            "  \"id\" : \"23241439\",\n",
            "  \"contents\" : \"Over recent years a number of novel therapies have shown promise in advanced renal cell carcinoma RCC Internationally the standard of care of first-line therapy is sunitinib after a clear survival benefit was demonstrated over interferon - Convention dictates that sunitinib is continued until evidence of disease progression assuming tolerability although there is no evidence that this approach is superior to intermittent periods of treatment The purpose of the STAR trial is to compare the standard treatment strategy conventional continuation strategy CCS with a novel drug free interval strategy DFIS which includes planned treatment breaks The STAR trial is an NIHR HTA-funded UK pragmatic randomised phase II/III clinical trial in the first-line treatment of advanced RCC Participants will be randomised 11 to either a sunitinib CCS or a DFIS The overall aim of the trial is to determine whether a DFIS is non-inferior in terms of 2-year overall survival OS and quality adjusted life years QALY averaged over treatment and follow up compared to a CCS The QALY primary endpoint was selected to assess whether any detriment in terms of OS could be balanced with improvements in quality of life QoL This is a complex trial with a number of design challenges and to address these issues a feasibility stage is incorporated into the trial design Predetermined recruitment stage A and efficacy stage B intermediary endpoints must be met to allow continuation to the overall phase III trial stage C An integral qualitative patient preference and understanding study will occur alongside the feasibility stage to investigate patients feelings regarding participation or non-participation in the trial The optimal duration of continuing sunitinib in advanced RCC is unknown Novel targeted therapies do not always have the same constraints to treatment duration as standard chemotherapeutic agents and currently there are no randomised data comparing different treatment durations Incorporating planned treatment breaks has the potential to improve QoL and cost effectiveness hopefully without significant detriment on OS as has been demonstrated in other cancer types with other treatments Controlled-trials com ISRCTN 06473203\",\n",
            "}\n",
            "13632\n",
            "{\n",
            "  \"id\" : \"16782921\",\n",
            "  \"contents\" : \"Palliation of bone pain can be achieved in men with androgen-independent prostate cancer treated with docetaxel and estramustine DE or mitoxantrone and prednisone MP While Southwest Oncology Group trial 99-16 demonstrated a survival improvement of DE over MP the study also was designed to compare the palliation of disease-related symptoms Pain palliation and global quality of life QOL were the two primary patient-reported outcomes Pain was measured with the Present Pain Intensity scale of the McGill Pain Questionnaire-Short Form The European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire C30 QLQ-C30 and its Prostate Cancer Module PR25 measured QOL and symptom status Pain and analgesic use were measured at random assignment every cycle for eight cycles and 1 year from random assignment the QLQ-C30 and the PR25 were administered at random assignment before cycle four week 10 and cycle eight month 6 and at 1 year In addition to the primary intent-to-treat missing at random analysis sensitivity analyses were performed to assess robustness of global QOL conclusions under alternative informative missing data assumptions Six hundred seventy four eligible patients received DE n = 338 or MP n = 336 In an intention-to-treat analysis median overall survival was 175 months for the DE arm and 156 months for the MP arm P = 02 There were no statistically significant differences in pain palliation between the treatment arms The sensitivity analyses showed a consistent lack of statistically significant global QOL differences for the two arms DE had superior clinical efficacy overall survival time-to-progression and prostate-specific antigen declines with similar global QOL and pain palliation in the MP arm\",\n",
            "}\n",
            "13633\n",
            "{\n",
            "  \"id\" : \"15947595\",\n",
            "  \"contents\" : \"This report provides a comparison of characteristics detected in the screening and control arms of the European Randomized study of Screening for Prostate Cancer section Rotterdam Between December 1993 and January 1999 35148 men 55 to 74 years old were randomized to European Randomized study of Screening for Prostate Cancer Rotterdam including 17635 in the screening arm and 17513 in the control arm Prostate specific antigen testing digital rectal examination transrectal ultrasound and sextant biopsies were offered to all participants in the screening arm according to 2 algorithms All screening detected cancers and cancers found in the control arm were evaluated at the same cutoff point that is January 1 2003 To identify prostate cancer cases in the control arm yearly linkage was performed with the Rotterdam Cancer Registry database Followup information was collected by chart review By January 1 2003 1269 cancers were detected in the screening arm and 336 were detected in the control arm A shift to more favorable clinical stages and histological grades on biopsy was seen in the screening arm of the trial T1C and T2 cancers were 58 and 62 times more often diagnosed respectively in the screening arm than in the control arm of the trial Only 46 % of control arm cancers were found through opportunistic screening Although a favorable shift in prognostic factors was seen for the screening arm of the trial these results do not provide evidence that prostate cancer screening has an effect on prostate cancer mortality\",\n",
            "}\n",
            "13634\n",
            "{\n",
            "  \"id\" : \"19268686\",\n",
            "  \"contents\" : \"Tetrodotoxin TTX is a neurotoxin found in puffer fish and other marine animals New clinical studies suggest that low-dose TTX can safely relieve severe treatment-resistant cancer pain The therapeutic potential of TTX in addiction is supported by studies in laboratory animals The purpose of this double-blind placebo-controlled study was to assess the effect of a single intramuscular dose of TTX on cue-induced craving and anxiety in abstinent heroin addicts Forty-five abstinent heroin addicts were randomly assigned to three treatment groups placebo 5 microg TTX or 10 microg TTX Participants were exposed to a neutral video or a heroin-related video Craving anxiety blood pressure and heart rate were measured pre - and post-exposure Heroin-related cues increased both craving and anxiety and had no effect on blood pressure and heart rate A single dose of TTX dose-dependently attenuated the increases in craving and anxiety while having no effect on blood pressure or heart rate The results suggest that low-dose TTX is acutely effective in reducing cue-induced increases in heroin craving and associated anxiety\",\n",
            "}\n",
            "13635\n",
            "{\n",
            "  \"id\" : \"21046504\",\n",
            "  \"contents\" : \"We conducted this randomized trial to compare the LigaSure Vessel Sealing System with conventional methods in gastrointestinal carcinoma surgery at five specialty cancer hospitals Patients with resectable stomach or colorectal cancers were randomized to the LigaSure n = 100 or conventional surgery n = 74 groups according to sealed envelopes The operative data were compared There were no significant differences in operating times blood loss postoperative complications or hospital stay However at the hospital where most of the procedures took place the LigaSure was associated with a shorter operating time 173 43 min for gastric carcinoma and 157 43 min for colorectal carcinoma vs 211 55 min and 202 55 min for conventional surgery P = 00046 and P = 00200 respectively and less blood loss 300 196 ml and 150 133 ml respectively vs 453 387 ml and 382 444 ml P = 00482 and P = 00465 respectively The LigaSure is safe for both gastric and colorectal cancer surgery with extended lymph node dissection Used effectively the device appears to reduce operating times and blood loss although this requires confirmation in a larger series\",\n",
            "}\n",
            "13636\n",
            "{\n",
            "  \"id\" : \"20144231\",\n",
            "  \"contents\" : \"The purpose of the work reported here is to test reliable molecular profiles using routinely processed formalin-fixed paraffin-embedded FFPE tissues from participants of the clinical trial BIG 1-98 with a median follow-up of 60 months RNA from fresh frozen FF and FFPE tumor samples of 82 patients were used for quality control and independent FFPE tissues of 342 postmenopausal participants of BIG 1-98 with ER-positive cancer were analyzed by measuring prospectively selected genes and computing scores representing the functions of the estrogen receptor eight genes ER_8 the progesterone receptor five genes PGR_5 Her2 two genes HER2_2 and proliferation ten genes PRO_10 by quantitative reverse transcription PCR qRT-PCR on TaqMan Low Density Arrays Molecular scores were computed for each category and ER_8 PGR_5 HER2_2 and PRO_10 scores were combined into a RISK_25 score Pearson correlation coefficients between FF - and FFPE-derived scores were at least 094 and high concordance was observed between molecular scores and immunohistochemical data The HER2_2 PGR_5 PRO_10 and RISK_25 scores were significant predictors of disease free-survival DFS in univariate Cox proportional hazard regression PRO_10 and RISK_25 scores predicted DFS in patients with histological grade II breast cancer and in lymph node positive disease The PRO_10 and PGR_5 scores were independent predictors of DFS in multivariate Cox regression models incorporating clinical risk indicators PRO_10 outperformed Ki-67 labeling index in multivariate Cox proportional hazard analyses Scores representing the endocrine responsiveness and proliferation status of breast cancers were developed from gene expression analyses based on RNA derived from FFPE tissues The validation of the molecular scores with tumor samples of participants of the BIG 1-98 trial demonstrates that such scores can serve as independent prognostic factors to estimate disease free survival DFS in postmenopausal patients with estrogen receptor positive breast cancer\",\n",
            "}\n",
            "13637\n",
            "{\n",
            "  \"id\" : \"23151431\",\n",
            "  \"contents\" : \"Adjuvant androgen suppression and bisphosphonates with escalating doses of radiotherapy might improve efficacy outcomes in men with locally advanced prostate cancer In this study we investigated whether these treatments had a detrimental effect on patient-reported-outcome PRO scores We undertook a phase 3 trial with a 22 factorial design in 23 centres in Australia and New Zealand in men with non-metastatic adenocarcinoma of the prostate stage T2b-4 or T2a Gleason score 7 and baseline prostate-specific antigen concentration [ PSA ] 10 g/L and without previous lymph node or systemic metastases or comorbidities that could reduce life expectancy to less than 5 years The men were randomly assigned in a 1111 ratio to 6 months of neoadjuvant short-term androgen suppression STAS with leuprorelin 225 mg every 3 months intramuscularly or an additional 12 months intermediate-term androgen suppression [ ITAS ] of leuprorelin with or without 18 months of zoledronic acid 4 mg every 3 months intravenously Study drug administration commenced at randomisation after which radiotherapy started within the fifth month in all groups Treatment allocation was open-label and computer-generated randomisation stratified by centre baseline concentrations of PSA clinical stage of the tumour Gleason score and use of a brachytherapy boost was done by use of the minimisation technique PRO scores were calculated from European Organization for Research and Treatment of Cancer quality-of-life and prostate-specific quality-of-life module questionnaires and compared with multiple regression models at baseline and end of radiotherapy and 18 months and 36 months according to group and radiation dose The trial is ongoing and the primary endpoint prostate-cancer-specific mortality will be reported in 2014 This study is the final report of PRO scores a secondary endpoint Analysis was by intention to treat This trial is registered with ClinicalTrialsgov number NCT00193856 1071 men were randomly assigned to STAS n = 268 STAS plus zoledronic acid n = 268 ITAS n = 268 and ITAS plus zoledronic acid n = 267 At the end of radiotherapy significant detrimental changes in PRO scores p < 001 occurred in all groups There were no significant differences in global health status between groups at any timepoint At 18 months PROs that were significantly worse in the ITAS groups when compared with STAS were hormone-treatment-related symptoms HTRS STAS 1020 [ 95 % CI 866-1175 ] ITAS 1736 [ 1363-2108 ] p < 001 and ITAS plus zoledronic acid 1914 [ 1543-2285 ] p < 001 sexual activity STAS 2638 [ 2350-2927 ] ITAS 1440 [ 744-2136 ] p < 001 and ITAS plus zoledronic acid 1634 [ 939-2328 ] p < 001 social function STAS 9031 [ 8789-9273 ] ITAS 8735 [ 8152-9318 ] p = 009 and ITAS plus zoledronic acid 8366 [ 7785-8948 ] p < 001 fatigue STAS 1705 [ 1458-1951 ] ITAS 2452 [ 1858-3046 ] p < 001 and ITAS plus zoledronic acid 2426 [ 1833-3018 ] p < 001 and financial problems STAS 339 [ 129-548 ] ITAS 897 [ 392-1402 ] p < 001 and ITAS plus zoledronic acid 892 [ 389-1396 ] p < 001 With the exception of HTRS in which marginal differences remained persisting significant differences disappeared by 36 months Other factors associated with significant detrimental changes in PRO scores were a brachytherapy boost incomplete testosterone and haemoglobin recoveries age and smoking Compared with 6 months of androgen suppression 18 months of androgen suppression causes additional detrimental changes at the 18 month follow-up in some PRO scores but not in global quality-of-life scores However with the exception of HTRS these differences resolved by 36 months The use of zoledronic acid every 3 months over 18 months does not result in additional detrimental changes but the use of a brachytherapy boost to achieve radiation dose escalation in the prostate can adversely affect emotional function and financial problems National Health and Medical Research Council of Australia Novartis Pharmaceuticals Australia Abbott Pharmaceuticals Australia New Zealand Health Research Council New Zealand Cancer Society University of Newcastle Australia Hunter Medical Research Institute Calvary Mater Radiation Oncology Fund and Maitland Cancer Appeal\",\n",
            "}\n",
            "13638\n",
            "{\n",
            "  \"id\" : \"23436087\",\n",
            "  \"contents\" : \"Cancer gastrectomy seems to benefit type 2 diabetes however results are conflicting In a prospective protocol including retrospective information the aim was assessment of changes in glucose profile in patients with both normal and deranged preoperative glucose homeostasis Patients N = 164 with curative subtotal or total Roux-en-Y gastrectomy for gastric cancer n = 92 or Roux-en-Y gastric bypass for morbid obesity RYGB n = 72 were preoperatively classified into diabetes including prediabetes and control group Postoperative diabetes outcome was stratified as responsive or refractory and results in controls were correspondingly defined as stable or new-onset diabetes NOD according to fasting blood glucose and HbA1c Dietary intake and biochemical profile was documented Statistical methods included analysis of variance multivariate logistic regression and propensity score matching according to postoperative weight loss Age of cancer cases was 679 115 years 565 % males initial body mass index BMI 247 37 current BMI 226 38 kg/m 2 and follow-up 1021 510 months whereas in bariatric individuals age was 514 101 years 153 % males initial BMI 567 122 current BMI 348 81 kg/m 2 and follow-up 1041 297 months Refractory disease corresponded to 625 % cancer versus 235 % bariatric P = 0019 whereas NOD represented 692 versus 238 % respectively P = 0016 Weight loss BMI was associated with diabetes response in cancer patients but not with NOD No difference between subtotal and total gastrectomy was detected Divergent outcomes refractory vs responsive were confirmed in BMI-similar propensity-matched cancer gastrectomy patients with preoperative diabetes consistent with weight-dependent and - independent benefits Diabetes response was confirmed however with more refractory cases than in bariatric controls whereas high proportions of NOD occurred Such dichotomous pattern seems unusual albeit consistent with previous studies\",\n",
            "}\n",
            "13639\n",
            "{\n",
            "  \"id\" : \"24909376\",\n",
            "  \"contents\" : \"Patient information in cancer clinical trial is challenging The value of audio-recording interventions for patients considering participating in clinical trials is unclear The primary aim of this randomized study was to investigate effects of audio-recorded information on knowledge and understanding in patients considering participation in a clinical trial Patients scheduled for information about a phases 2 or 3 trial by one of the 13 participating oncologists at the Department of Oncology during the study period 2008-2013 were eligible The intervention consisted of an audio-recording on compact disc CD of the information at the medical consultation in which the patients were informed about a trial Knowledge and understanding was measured by the questionnaire Quality of Informed Consent A total of 130 patients were randomized 70 % of the calculated sample size n = 186 Sixty-seven patients were randomized to the intervention In total 101 patients 78 % completed questionnaires No statistical significant differences were found between the groups with respect to knowledge and understanding The level of knowledge was relatively high with the exceptions of the risks associated with and the unproven nature of the trial Overall patients who declined participation scored statistically significant lower on knowledge The present study was underpowered and the results should therefore be interpreted with caution Still 130 patients were included with a response rate of 78 % A CD including the oral information about a clinical trial did not show any effects on knowledge or understanding However the levels of knowledge were high possible due to the high levels of education in the study group Information on risks associated with the trial is still an area for improvement\",\n",
            "}\n",
            "13640\n",
            "{\n",
            "  \"id\" : \"16815535\",\n",
            "  \"contents\" : \"To determine if smoking a known risk factor for a number of cancers including cervical cancer is associated with poor prognosis in patients with locally advanced cervical carcinoma treated with chemoradiation Patients with primary previously untreated histologically confirmed stage II-B III-B or IV-A cervical carcinoma participated in a Gynecologic Oncology Group GOG phase III study GOG 165 and were randomly allocated to receive radiation plus either cisplatin or 5-fluorouracil Smoking behavior was ascertained using an administered questionnaire and by quantifying urine cotinine concentration Disease progression was defined as a > or = 50 % increase in the cross product of the existing tumor compared with previous assessments Patients were followed until death Of 328 enrolled patients 12 were ineligible one was inevaluable for reported smoking status and 40 others were inevaluable for cotinine-derived smoking status Among evaluable patients 133 42 % were reported smokers and 111 40 % were cotinine-derived smokers The kappa for agreement between the groups was 0872 P < 001 Compared with non-smokers median survival was 15 months shorter for reported smokers and 20 months shorter for cotinine-derived smokers P < 001 After adjusting for covariates a significant increase in the risk of death but not disease progression was observed for reported smokers hazard ratio [ HR ] 151 95 % confidence interval [ CI ] 101-2 27 P = 004 and cotinine-derived smokers HR 157 95 % CI 103-2 38 P = 004 Smoking predicts worse overall survival in women with locally advanced cervical carcinoma treated with chemoradiation\",\n",
            "}\n",
            "13641\n",
            "{\n",
            "  \"id\" : \"19742335\",\n",
            "  \"contents\" : \"To investigate the clinical significance of resection of the pancreatic capsule and anterior layer of transverse mesocolon in radical gastrectomy Between January 2007 and July 2008 a total of 213 gastric cancer patients enrolled in the study These patients were randomly assigned into two groups 105 in group R and 108 in group N Only in group R were the pancreatic capsule and anterior layer of transverse mesocolon resected during radical gastrectomy The pancreatic capsule and anterior layer of transverse mesocolon were histologically analyzed for metastasis The data including blood loss during operations number of dissected lymph nodes and postoperative complications were analyzed in both groups There were no significant differences between the two groups in blood loss during operation and postoperative complications but the differences in operation time and number of dissected lymph nodes between the two groups were significant Metastases to the pancreatic capsule and/or anterior layer of transverse mesocolon were diagnosed in nine 86 % patients of group RThe metastases to the pancreatic capsule and/or anterior layer of transverse mesocolon were found to be associated with tumor invasion depth anterior or posterior gastric wall clinical staging and perigastric lymph node metastasis extent P < 005 but not with age gender tumor location size Borrmann type and pathological classification P > 005 Resection of pancreatic capsule and anterior layer of transverse mesocolon in group R does not increase postoperative complications in comparison with group NThe resection is beneficial to the patients with advanced gastric cancer staging relatively late because of potential metastasis to pancreatic capsule and anterior layer of transverse mesocolon\",\n",
            "}\n",
            "13642\n",
            "{\n",
            "  \"id\" : \"15994264\",\n",
            "  \"contents\" : \"A large multicentre randomised trial the Big Lung Trial which in part compared supportive care with or without cisplatin-based chemotherapy in patients with advanced non-small cell lung cancer provided an opportunity to evaluate the impact on the UK National Health Service of the costs incurred with the use of chemotherapy This costing study was based on the retrospective collection of resource use data from hospital records Case notes from 194 patients 98 chemotherapy + supportive care C 96 supportive care alone NoC were inspected in eight centres recruiting the largest numbers of patients into the Big Lung Trial Quantities were multiplied by fixed unit costs to calculate a total cost for each patient The main outcome measure was the total cost incurred by the use of secondary care resources including investigations chemotherapy radiotherapy surgical procedures inpatient days outpatient attendances and hospice inpatient care in the two groups Patients randomised to receive cisplatin-based chemotherapy had an average of 34 more inpatient bed days than the mean of 119 days for patients randomised to supportive care alone and more outpatient attendances NoC patients were more likely to have received palliative radiotherapy The mean total cost for C patients was 5355 sterling pound compared with 3595 sterling pound for the NoC group difference 760 sterling pound 95 % CI 781 sterling pound to 2742 sterling pound When split the cost in the C group associated with the administration of chemotherapy was 1233 sterling pound and non-chemotherapy costs were 4122 sterling pound The additional cost of chemotherapy was not offset by a reduction in subsequent costs as the non-chemotherapy costs were similar so the survival benefit of about 10 weeks observed in the C group was achieved with the cost of chemotherapy administration\",\n",
            "}\n",
            "13643\n",
            "{\n",
            "  \"id\" : \"8709374\",\n",
            "  \"contents\" : \"A randomized multicenter trial was done to compare transurethral resection only to transurethral resection plus adjuvant mitomycin C and bacillus Calmette Guerin BCG instillation for treatment of superficial bladder cancer stage pTa/1 grades 1 to 3 except primary stage pTa grade 1 Included in the study were 337 patients with superficial stage pTa/1 grades 1 to 3 bladder cancer except primary stage pTa grade 1 tumors One group underwent transurethral resection alone Mitomycin C 20 mg / 50 ml sodium chloride was given every 2 weeks during year 1 and once a month during year 2 BCG 120 mg/50 ml sodium chloride was instilled once a week for 6 weeks and once a month for 4 months At a median followup of 202 months a decrease in recurrence rate was noted for both drug instillations compared to transurethral resection only The relative risk of recurrence was 0508 after mitomycin C and 0618 after BCG instillation compared to transurethral resection alone There was no significant difference between the mitomycin C and BCG instillations The progression rate was comparable in all 3 therapy groups with an estimated common progression rate of 422 % per year Side effects occurred most frequently during or after BCG instillation most often consisting of cystitis One patient required cystectomy because of ulcerating cystitis and a prostatic abscess subsequent to unsuccessful tuberculostatic therapy There were no systemic complications Our study showed a positive effect of adjuvant chemotherapy and immunotherapy on decreasing tumor recurrence rate No influence was observed concerning progression rate which was low overall\",\n",
            "}\n",
            "13644\n",
            "{\n",
            "  \"id\" : \"12114419\",\n",
            "  \"contents\" : \"Because treatment of metastatic colon cancer is noncurative new treatments are needed This trial evaluated the antitumor effects of two targeted anticancer agents a ISIS 3521 an antisense inhibitor of the protein kinase C alpha and b ISIS 5132 an antisense inhibitor of c-raf kinase in patients untreated previously with recurrent or metastatic colorectal carcinoma All patients had colorectal adenocarcinoma with measurable disease and no prior chemotherapy for metastatic disease Patients were randomized to receive either ISIS 3521 or ISIS 5132 at a dose of 2 mg/kg/day as a continuous iv infusion 21 of 28 days Cycles were repeated as long as progression was not seen and doses of both agents were modified according to toxic effects A two-arm study design was used with each study arm considered independently Steady-state blood levels of both antisense molecules were measured on days 8 15 and 22 of the first cycle of therapy Thirty-seven eligible patients were enrolled and 32 were evaluable for response 17 receiving ISIS 3521 and 15 receiving ISIS 5132 No responses were noted Four of the patients receiving ISIS 3521 had stable disease and 5 patients receiving ISIS 5132 were stable Neither ISIS 5132 nor ISIS 3521given in the dose and schedule studied induced objective responses in untreated colorectal cancer patients\",\n",
            "}\n",
            "13645\n",
            "{\n",
            "  \"id\" : \"11136842\",\n",
            "  \"contents\" : \"High mammographic density is associated with increased breast cancer risk Previous studies have shown that estrogens increase breast density on mammograms but the effect on mammographic density of selective estrogen receptor modulators such as raloxifene is unknown We assessed changes in mammographic density among women receiving placebo raloxifene or conjugated equine estrogens in an osteoporosis prevention trial In a 5-year multicenter double-blind randomized placebo-controlled osteoporosis prevention trial healthy postmenopausal women who had undergone hysterectomy less than 15 years before the study and had no history of breast cancer received placebo raloxifene at one of two doses or conjugated estrogens ERT Women from English-speaking investigative sites who had baseline and 2-year craniocaudal mammograms with comparable positioning n = 168 were eligible for this analysis Changes in mammographic density were determined by digital scanning and computer-assisted segmentation of mammograms and were analyzed with the use of analysis of variance All statistical tests were two-sided Among the four treatment groups after 2 years on study the mean breast density craniocaudal view was statistically significantly greater in the ERT group than it was in the other three groups P < 001 for all three comparisons Within treatment groups the mean breast density from baseline to 2 years decreased statistically significantly in women receiving the placebo or either the higher or lower raloxifene dose P = 0003 P = 0002 and P < 0001 respectively and showed a nonstatistically significant increase in women receiving ERT In an osteoporosis prevention trial raloxifene did not increase breast density after 2 years of treatment Raloxifene administration should not interfere with and could even enhance mammographic detection of new breast cancers\",\n",
            "}\n",
            "13646\n",
            "{\n",
            "  \"id\" : \"16126738\",\n",
            "  \"contents\" : \"Studies of women who had adjuvant chemotherapy for early breast cancer 10-20 years ago showed that many judged small benefits sufficient to make it worthwhile Indications regimens and supportive care have changed We sought the preferences of contemporary women who received similar chemotherapy Ninety-seven consecutive consenting women who completed adjuvant chemotherapy for early breast cancer 3-34 months previously were interviewed Preferences were elicited with a structured scripted interview using the trade-off method Women were presented with four hypothetical scenarios based on known life expectancies 5 and 15 years and survival rates 65 % and 85 % at 5 years without adjuvant chemotherapy Improvements of an additional year in life expectancy or 3 % in survival rates were judged sufficient to make adjuvant chemotherapy worthwhile by 68-84 % of women Half the women judged 1 day or 01 % sufficient to make adjuvant chemotherapy worthwhile Recollections of better well-being during adjuvant chemotherapy having dependants and having a friend or relative who died from cancer were independently associated with judging smaller benefits sufficient to make adjuvant chemotherapy worthwhile all P < 005 Preferences were highly variable but the benefits judged sufficient to make adjuvant chemotherapy worthwhile were even smaller than those found in previous studies Preferences were influenced by factors other than direct benefits and harms of chemotherapy\",\n",
            "}\n",
            "13647\n",
            "{\n",
            "  \"id\" : \"22467404\",\n",
            "  \"contents\" : \"The sentinel node SN concept has brought numerous advantages to women with breast cancer Sparing axillary node anatomy and physiology may enhance the cosmetic results of breast cancer conservative surgery either owing to less breast edema or to a better tolerance to the effects of surgery and radiotherapy Our aim was to compare the cosmetic outcome of two randomized groups of patients on a subjective and objective basis A consecutive series of breast cancer patients n = 60 submitted to partial mastectomy plus axillary dissection or partial mastectomy plus SN biopsy included in a randomized trial was photographed Photos were analysed in three ways by seven different observers according to seven features from poor to excellent two observers estimated the percentage of breast retraction assessment pBRA or by the BCCTcore 10 software The panel subjective analysis showed a benefit in terms of the skin colour for the patients submitted to SN biopsy only This group of patients did not show any advantage in terms of pBRA estimates even after the complex BCCTcore appraisal The sentinel node concept is not associated with improvements in the aesthetic outcome of breast cancer conservative treatment\",\n",
            "}\n",
            "13648\n",
            "{\n",
            "  \"id\" : \"21149659\",\n",
            "  \"contents\" : \"To evaluate docetaxel or vinorelbine both with trastuzumab as first-line therapy of human epidermal growth factor receptor 2-positive advanced breast cancer Patients naive to chemotherapy for advanced disease were randomly assigned to docetaxel 100 mg/m 2 day 1 or vinorelbine 30 to 35 mg/m 2 on days 1 and 8 both combined with trastuzumab 8-mg/kg loading dose and 6-mg/kg maintenance dose on day 1 every 3 weeks The primary end point was time to progression TTP A total of 143 patients were randomly allocated to docetaxel and 141 patients were assigned to vinorelbine The median TTP for docetaxel and vinorelbine respectively was 124 months versus 153 months hazard ratio [ HR ] = 094 95 % CI 071 to 125 P = 67 median overall survival was 357 months versus 388 months HR = 101 95 % CI 071 to 142 P = 98 and the 1-year survival rate was 88 % in both arms Median time to treatment failure for study chemotherapy was 56 months versus 77 months HR = 050 95 % CI 038 to 064 P < 0001 The investigator-assessed overall response rate among 241 patients with measurable disease were 593 % in both arms More patients in the docetaxel arm discontinued therapy due to toxicity P < 001 Significantly more treatment-related grade 3 to 4 febrile neutropenia 360 % v 101 % leucopenia 403 % v 210 % infection 251 % v 130 % fever 43 % v 0 % neuropathy 309 % v 36 % nail changes 79 % v 07 % and edema 65 % v 0 % were reported with docetaxel The study failed to demonstrate superiority of any drug in terms of efficacy but the vinorelbine combination had significantly fewer adverse effects and should be considered as an alternative first-line option\",\n",
            "}\n",
            "13649\n",
            "{\n",
            "  \"id\" : \"14599971\",\n",
            "  \"contents\" : \"To evaluate the effect of tamoxifen TAM combined with a somatostatin analogue octretide OCT on advanced liver cancer and whether tamoxifen combined with OCT is superior to regular chemotherapeutic agents 5-Fu and mitomycin C MMC Thirty-nine patients with inoperable liver cancer were randomly subdivided into TAM+OCT group n = 24 and regular chemotherapeutic group n = 15 They received treatment for three months respectively Blood cell count liver function immunologic function blood alpha-FP was regularly measured Liver lump and extrahepatic metastasis were examined by CT The patients were followed up after treatment and conducted survival analysis In the TAM+OCT group complete response is 4 patients partial response is 7 patients no change is 9 patients and progressive disease is 4 patients blood level of ALT and AST had no noticeable change IgE and IgG increased P < 001 and alpha-FP lowered P < 005 In regular chemotherapeutic group no change is 4 patients and progressive disease is 11 patients There was conspicuous statistical difference in the two groups The accumulative survival rates of 6 months 1 year and 2 years were 957 % vs 412 % P < 001 637 % vs 211 % P < 001 254 % vs 0 P < 001 respectively Medium survival time was 128 months in TAM+OCT group and 55 months in chemotherapeutic group TAM+OCT excerts reliable therapeutic effect on patients with inoperable ER + hepatocellular cancer It is superior to 5-Fu and MMC in increasing the survival rate prolonging survival time and reducing side-effects\",\n",
            "}\n",
            "13650\n",
            "{\n",
            "  \"id\" : \"24698346\",\n",
            "  \"contents\" : \"Observational studies suggest that moderate intakes of retinol and increased circulating retinol levels may increase fracture risk Easy access to supplements combined with an aging population makes this a potentially important association The aim of this study was to investigate plasma retinol and total carotene concentrations in relation to fracture risk after long-term supplementation with retinol and/or beta-carotene in 998 adults between 1990 and 2007 Participants were 663 men and 335 women in a cancer prevention program who were initially randomized to a retinol 75 mg RE/d or beta-carotene 30 mg/d supplement between 1990 and 1996 After 1996 all participants received the retinol supplement only Plasma retinol and total carotene medication use and various lifestyle factors were measured at annual clinic visits Fractures were identified by self-report in 2007 The risk for any fracture or osteoporotic fracture was modeled using Cox proportional hazard models Over a median follow-up of 78 y 123 participants with plasma samples reported an incident fracture Although plasma retinol concentrations were markedly higher than those reported in observational studies no association was observed between plasma retinol and risk for any fracture hazard ratio [ HR ] 086 mol/L 95 % confidence interval [ CI ] 065-1 14 or osteoporotic fracture HR 097 mol/L 95 % CI 066-1 43 A lower risk for any fracture was suggested with increasing plasma total carotenes HR 085 mol/L 95 % CI 071-1 01 This study does not support earlier reports of an increased fracture risk associated with increased plasma retinol concentration The potential for carotenes to prevent fractures deserves further investigation\",\n",
            "}\n",
            "13651\n",
            "{\n",
            "  \"id\" : \"11369066\",\n",
            "  \"contents\" : \"Radiation-induced dermatitis is a very common side effect of radiation therapy and may necessitate interruption of the therapy There is a substantial lack of evidence-based treatments for this condition The aim of this study was to investigate the effect of mometasone furoate cream MMF on radiation dermatitis in a prospective double-blind randomized study The study comprised 49 patients with node-negative breast cancer They were operated on with sector resection and scheduled for postoperative radiotherapy using photons with identical radiation qualities and dosage to the breast parenchyma The patients were randomized to receive either MMF or emollient cream The cream was applied on the irradiated skin twice a week from the start of radiotherapy until the 12th fraction 24 Gy and thereafter once daily until 3 weeks after completion of radiation Both groups additionally received non-blinded emollient cream daily The intensity of the acute radiation dermatitis was evaluated on a weekly basis regarding erythema and pigmentation using a reflectance spectrophotometer together with visual scoring of the skin reactions MMF in combination with emollient cream treatment significantly decreased acute radiation dermatitis P = 00033 compared with emollient cream alone There was no significant difference in pigmentation between the two groups Adding MMF a potent topical corticosteroid to an emollient cream is statistically significantly more effective than emollient cream alone in reducing acute radiation dermatitis\",\n",
            "}\n",
            "13652\n",
            "{\n",
            "  \"id\" : \"10334534\",\n",
            "  \"contents\" : \"To determine whether estrogen replacement therapy ERT alters the development of new or recurrent breast cancer in women previously treated for localized breast cancer Potential participants n = 319 in a trial of ERT after breast cancer were observed prospectively for at least 2 years whether they enrolled onto the randomized trial or not Of 319 women 39 were given estrogen and 280 were not given hormones Tumor size number of lymph nodes estrogen receptors menopausal status at diagnosis and disease-free interval at the initiation of the observation period were comparable for the trial participants n = 62 versus nonparticipants n = 257 and for women on ERT n = 39 versus controls n = 280 Cancer events were ascertained for both groups Patient and disease characteristics were comparable for the trial participants versus nonparticipants as well as for the women on ERT versus the controls One patient in the ERT group developed a new lobular estrogen receptor-positive breast cancer 72 months after the diagnosis of a ductal estrogen receptor-negative breast cancer and 27 months after initiation of ERT In the control group there were 20 cancer events 14 patients developed new or recurrent breast cancer at a median time of 1395 months after diagnosis and six patients developed other cancers at a median time of 122 months ERT does not seem to increase breast cancer events in this subset of patients previously treated for localized breast cancer Results of randomized trials are needed before any changes in current standards of care can be proposed\",\n",
            "}\n",
            "13653\n",
            "{\n",
            "  \"id\" : \"23341531\",\n",
            "  \"contents\" : \"TNFerade biologic is a novel means of delivering tumor necrosis factor alpha to tumor cells by gene transfer We herein report final results of the largest randomized phase III trial performed to date among patients with locally advanced pancreatic cancer LAPC and the first to test gene transfer against this malignancy In all 304 patients were randomly assigned 21 to standard of care plus TNFerade SOC + TNFerade versus standard of care alone SOC SOC consisted of 504 Gy in 28 fractions with concurrent fluorouracil 200 mg/m 2 per day continuous infusion TNFerade was injected intratumorally before the first fraction of radiotherapy each week at a dose of 4 10 11 particle units by using either a percutaneous transabdominal or an endoscopic ultrasound approach Four weeks after chemoradiotherapy patients began gemcitabine 1000 mg/m 2 intravenously with or without erlotinib 100 to 150 mg per day orally until progression or toxicity The analysis included 187 patients randomly assigned to SOC + TNFerade and 90 to SOC by using a modified intention-to-treat approach Median follow-up was 91 months range 01 to 505 months Median survival was 100 months for patients in both the SOC + TNFerade and SOC arms hazard ratio [ HR ] 090 95 % CI 066 to 122 P = 26 Median progression-free survival PFS was 68 months for SOC + TNFerade versus 70 months for SOC HR 096 95 % CI 069 to 132 P = 51 Among patients treated on the SOC + TNFerade arm multivariate analysis showed that TNFerade injection by an endoscopic ultrasound-guided transgastric/transduodenal approach rather than a percutaneous transabdominal approach was a risk factor for inferior PFS HR 208 95 % CI 106 to 406 P = 032 The patients in the SOC + TNFerade arm experienced more grade 1 to 2 fever and chills than those in the SOC arm P < 001 but both arms had similar rates of grade 3 to 4 toxicities all P > 05 SOC + TNFerade is safe but not effective for prolonging survival in patients with LAPC\",\n",
            "}\n",
            "13654\n",
            "{\n",
            "  \"id\" : \"7522527\",\n",
            "  \"contents\" : \"The EORTC Head and Neck Cancer Cooperative Group conducted a randomized comparison of cisplatin methotrexate bleomycin and vincristine CABO versus cisplatin and 5-fluorouracil CF versus cisplatin C in chemotherapy naive patients with recurrent or metastatic squamous cell carcinoma of the head and neck The primary objectives of this study were to investigate whether the CF regimen was in anyway superior to the CABO regimen and to detect any superiority of these two combinations over cisplatin alone Three hundred eighty-two patients were randomized to one of three treatments 1 methotrexate 40 mg/m2 days 1 and 15 bleomycin 10 mg and vincristine 2 mg days 1 8 and 15 cisplatin 50 mg/m2 day 4 repeated every 21 days 2 cisplatin 100 mg/m2 and 5-FU 1 g/m2 x 4 repeated every 21 days and 3 cisplatin 50 mg/m2 days 1 and 8 repeated every 28 days After 3 cycles all responding and stable disease patients in the three arms of the study continued with cisplatin alone The overall response rates to CABO 34 % and CF 31 % were superior to C 15 % p < 0001 p = 0003 respectively In addition complete response rate to CABO 95 % was superior to that of C 25 % p = 002 and also superior to that of CF 17 % p = 001 Response was associated with performance status and prior treatment but by multivariate analysis treatment type was the important determinant of response p = 00006 Although CABO and CF were superior to C with respect to time to progression within the first 6 to 8 months after randomization there was no overall difference in progression-free survival or survival between the three arms of the study Both hematologic and non-hematologic toxicity were worse in the combination chemotherapy arms We conclude that the CF regimen has no advantage over the CABO regimen which in fact showed a higher complete response rate Both combinations showed improved response rates but also more toxicity and no improvement in overall survival in comparison with cisplatin alone\",\n",
            "}\n",
            "13655\n",
            "{\n",
            "  \"id\" : \"7619749\",\n",
            "  \"contents\" : \"Cisplatin-based chemotherapy is generally considered the most active treatment for advanced non-small-cell lung cancer The combination of cisplatin and etoposide had for some time been the standard treatment at our center Of the other active regimens cisplatin in combination with mitomycin-C vindesine or ifosfamide MVP or MIC showed the highest response rates We decided to perform a comparative trial of the three best regimens in order to define a possible standard regimen in advanced NSCLC From May 1989 to April 1992 393 consecutive previously untreated NSCLC patients stages IIIB and IV were randomized to receive either cisplatin 120 mg/sqm day 1 + etoposide 100 mg/sqm days 1-3 every 3 weeks PE or cisplatin 120 mg/sqm every 4 weeks + mitomycin-C 8 mg/sqm days 1-29-71 + vindesine 3 mg/sqm days 1-8-15-22 MVP or cisplatin 120 mg/sqm day 1 + mitomycin-C 6 mg/sqm day 1 + ifosfamide 3 mg/sqm day 2 every 3 weeks MIC Of these 382 were evaluable for survival and 360 for response Response rates were statistically higher for both MIC 40 % and MVP 36 % than for the PE arm 23 % Survival estimates analyzed by the log-rank test showed a significant benefit p < 004 for patients treated with three-drug regimens MVP MIC as compared to those in the PE arm The main toxicity was myelosuppression thrombocytopenia WHO grade 3-4 was worse in the MIC arm nephrotoxicity grade 3-4 was also more frequent in the MIC arm A three-drug cisplatin-based regimen MVP MIC should be considered as reference treatment in NSCLC\",\n",
            "}\n",
            "13656\n",
            "{\n",
            "  \"id\" : \"22072307\",\n",
            "  \"contents\" : \"The aim of this randomized clinical trial was to evaluate the efficacy and safety of combination cDC and sequential sDC weekly docetaxel and carboplatin in women with recurrent platinum-sensitive epithelial ovarian cancer EOC Participants were randomized to either weekly docetaxel 30 mg/m 2 on days 1 and 8 and carboplatin area under the curve AUC = 6 on day 1 every 3 weeks or docetaxel 30 mg/m 2 on days 1 and 8 every 3 weeks for 6 cycles followed by carboplatin AUC = 6 on day 1 every 3 weeks for 6 cycles or until disease progression The primary endpoint was measurable progression-free survival PFS Between January 2004 and March 2007 150 participants were enrolled The response rate was 554 % and 432 % for those treated with cDC and sDC respectively The median PFS was 137 months 95 % confidence interval [ CI ] 99-16 8 for cDC and 84 months 95 % CI 71-11 0 for sDC On the basis of an exploratory analysis patients treated with sDC were at a 62 % increased risk of disease progression compared to those treated with cDC hazard ratio = 162 95 % CI 108-2 45 P = 02 The median overall survival time was similar in both groups 332 and 301 months P = 2 The incidence of grade 2 or 3 neurotoxicity and grade 3 or 4 neutropenia was higher with cDC than with sDC 117 % vs 85 % 368 % vs 113 % The sDC group demonstrated significant improvements in the Functional Assessment for Cancer Therapy-Ovarian Quality of Life Trial Outcome Index scores compared with the combination cohort P = 013 Both cDC and sDC regimens have activity in recurrent platinum-sensitive EOC with acceptable toxicity profiles The cDC regimen may provide a PFS advantage over sDC\",\n",
            "}\n",
            "13657\n",
            "{\n",
            "  \"id\" : \"10691066\",\n",
            "  \"contents\" : \"To assess the balance of benefits and risks of supplementation with beta-carotene vitamin E vitamin C and multivitamins on cancer cardiovascular CVD and eye diseases Physicians Health Study II PHS II is a randomized double-blind placebo-controlled trial enrolling 15000 willing and eligible physicians aged 55 years and older PHS II will utilize a 2 x 2 x 2 x 2 factorial design to test alternate day beta-carotene alternate day vitamin E daily vitamin C and a daily multivitamin in the prevention of total and prostate cancer CVD and the age-related eye diseases cataract and macular degeneration PRIOR The final results of the recently completed Physicians Health Study I PHS I a randomized double-blind placebo-controlled trial in 22071 healthy US male physicians indicated that beta-carotene supplementation 50 mg on alternate days had no significant benefit or harm on cancer or CVD during more than 12 years of treatment and follow-up In regards to cancer there were possible benefits on total and prostate cancer in those with low baseline levels assigned to beta-carotene a finding compatible with the Chinese Cancer Prevention Study for combined treatment with beta-carotene vitamin E and selenium in a poorly nourished population Further with respect to CVD there were apparent benefits of beta-carotene supplementation on subsequent vascular events among a small subgroup of 333 men with prior angina or revascularization The currently available data from randomized trials of primary prevention are sparse and inconsistent for vitamin E and non-existent for vitamin C and multivitamins For eye diseases namely cataract and age-related macular degeneration there are no completed large-scale randomized trials of antioxidant vitamins PHS II is unique in several respects PHS II is the only primary prevention trial in apparently healthy men testing the balance of benefits and risks of vitamin E on cancer and CVD In addition PHS II is the only primary prevention trial in apparently healthy men to test the balance of benefits and risks of vitamin C multivitamins as well as any single antioxidant vitamin alone and in combination on cancer CVD and eye diseases Finally PHS II is the only trial testing a priori the hypotheses that beta-carotene and vitamin E may reduce the risks of prostate cancer Thus PHS II will add unique as well as importantly relevant and complementary information to the totality of evidence from other completed and ongoing large-scale randomized trials on the balance of benefits and risks of beta-carotene vitamin E vitamin C and multivitamins alone and in combination on prevention of cancer CVD and eye diseases\",\n",
            "}\n",
            "13658\n",
            "{\n",
            "  \"id\" : \"15075997\",\n",
            "  \"contents\" : \"Stent clogging is a major limitation in the palliative treatment of malignant biliary obstruction Preliminary studies suggested improved duration of patency of a Tannenbaum design stent with a stainless steel mesh and an inner Teflon coating TTC We compared the patency of a TTC stent with a conventional polyethylene PE stent in a prospective randomized trial Between February 1998 and September 1998 we included 60 patients with distal malignant bile duct obstruction Diagnosis included carcinoma of the pancreas n = 57 and ampullary cancer n = 3 There were 29 men and 31 women with a median age of 77 years Stent diameter 10 Fr and length 11 cm were similar but both stent design and material were different a Tannenbaum design stent with a stainless steel mesh and an inner Teflon coating and an Amsterdam-type PE stent Sixty patients were evaluated 30 in the TTC group and 30 in the PE group Early complications occurred in two patients in each group Stent dysfunction occurred in 18 of TTC stents and 12 of PE stents Median stent patency was 102 days for TTC and 142 days for PE stents P = 041 Median survival did not differ significantly for both treatment groups TTC 121 days PE 105 days Stent migration in all cases proximal into the common bile duct occurred in four patients in the TTC group versus zero in the PE group P = 0038 This study did not confirm improved patency of Tannenbaum-type Teflon-coated stents Proximal migration prompts for additional design modifications\",\n",
            "}\n",
            "13659\n",
            "{\n",
            "  \"id\" : \"9075745\",\n",
            "  \"contents\" : \"National Surgical Adjuvant Breast and Bowel Project Protocol R-03 was designed to determine the worth of preoperative chemotherapy and radiation therapy in the management of operable rectal cancer Thus far 116 patients of an eventual 900 with primary operable rectal cancer have been randomized to receive multimodality therapy to begin preoperatively 59 patients or identical therapy beginning after curative surgery 57 All patients received seven cycles of 5-fluorouracil FU / leucovorin LV chemotherapy Cycles 1 and 4 through 7 used a high-dose weekly FU regimen In Cycles 2 and 3 FU and low-dose LV chemotherapy was given during the first and fifth week of radiation therapy 5040 cGy The preoperative arm Group 1 received the first three cycles of chemotherapy and all radiation therapy before surgery The postoperative arm Group 2 received all radiation and chemotherapy after surgery Primary study end points included disease-free survival and survival Secondary end points included local recurrence primary tumor response to combination therapy tumor downstaging and sphincter preservation Overall treatment-related toxicity was similar in both groups Although seven preoperative patients had events after randomization that precluded surgery eight events occurred during an equivalent follow-up period in the postoperative group No patient was deemed inoperable because of progressive local disease Sphincter-saving surgery was intended in 31 percent of Group 1 patients and 33 percent of Group 2 patients at the time of randomization Such surgery was actually performed in 50 percent of the preoperatively treated patients and 33 percent of the postoperatively treated patients The use of protective colostomy in patients undergoing sphincter-sparing surgery and the development of perioperative complications in all surgical patients were similar in both groups There was evidence of tumor downstaging in evaluable patients undergoing preoperative therapy with 8 percent of Group 1 patients having had a pathologic complete response These data do suggest that the preoperative chemotherapy and radiation therapy regimen used are at least as safe and tolerable as standard postoperative treatment There is presently a trend to tumor downstaging and sphincter preservation in the preoperative arm Whether this arm will have greater or lesser survival and long-term toxicity awaits the completion of this relevant study\",\n",
            "}\n",
            "13660\n",
            "{\n",
            "  \"id\" : \"24692735\",\n",
            "  \"contents\" : \"To determine the treatment outcome of combined androgen blockade CAB therapy using the non-steroidal antiandrogen bicalutamide or the steroidal antiandrogen chlormadinone in patients with prostate cancer In total 124 patients with prostate cancer enrolled in the present study were randomized to receive CAB therapy using a gonadotropin-releasing hormone GnRH agonist combined with bicalutamide or chlormadinone The survival of patients was analyzed The 5-year cancer-specific survival for the bicalutamide - and chlormadinone-treated groups were 917 % and 866 % respectively with no significant difference p = 039 Five-year overall survival was significantly p = 0029 better in the bicalutamide-treated group Moreover M1 patients in the chlormadinone group had significantly lower cancer-specific and overall survival compared to those in the bicalutamide-treated group However in the case of M0 patients no significant difference in cancer-specific nor in overall survival was observed CAB therapy using chlormadinone led to a significantly poorer survival outcome versus the use of bicalutamide However because this survival trend was not observed in M0 cases chlormadinone may still be an option for CAB therapy depending on clinical stage and the severity of adverse effects such as hot flashes\",\n",
            "}\n",
            "13661\n",
            "{\n",
            "  \"id\" : \"24610876\",\n",
            "  \"contents\" : \"We examined risk of newly detected human papillomavirus HPV infection and cervical abnormalities in relation to HPV type 16/18 antibody levels at enrollment in PATRICIA Papilloma Trial Against Cancer in Young Adults NCT00122681 Using Poisson regression we compared risk of newly detected infection and cervical abnormalities associated with HPV-16 / 18 between seronegative vs seropositive women 15-25 years in the control arm DNA negative at baseline for the corresponding HPV type [ HPV-16 n = 8193 HPV-18 n = 8463 ] High titers of naturally acquired HPV-16 antibodies and/or linear trend for increasing antibody levels were significantly associated with lower risk of incident and persistent infection atypical squamous cells of undetermined significance or greater ASCUS + and cervical intraepithelial neoplasia grades 1/2 or greater CIN1 + CIN2 + For HPV-18 although seropositivity was associated with lower risk of ASCUS + and CIN1 + no association between naturally acquired antibodies and infection was demonstrated Naturally acquired HPV-16 antibody levels of 371 95 % confidence interval [ CI ] 242-794 204 95 % CI 129-480 and 480 95 % CI 250-5756 EU/mL were associated with 90 % reduction of incident infection 6-month persistent infection and ASCUS + respectively Naturally acquired antibodies to HPV-16 and to a lesser extent HPV-18 are associated with some reduced risk of subsequent infection and cervical abnormalities associated with the same HPV type\",\n",
            "}\n",
            "13662\n",
            "{\n",
            "  \"id\" : \"24275208\",\n",
            "  \"contents\" : \"To evaluate the effects of a tailored information package for rectal cancer patients on satisfaction with information anxiety and depression and readjustment The study used a randomised control trial method Seventy six patients undergoing surgery and treatment for rectal cancer were randomly assigned to an intervention n = 43 or control group n = 33 The intervention group received an information pack tailored according to their treatment plan and preferred information The control group received the information currently given to these patients Satisfaction with information was measured using the Patient Satisfaction with Cancer Treatment Education PSCaTE scale anxiety and depression were measured using the Hospital Anxiety and Depression Scale HADS and readjustment was measured using the Reintegration to Normal Living Index at three time points There was a statistically significant difference between the intervention and control group on pre and post intervention scores with patients in the intervention group expressing a higher level of satisfaction with information than those in the control group at Times 2 and 3 p = 000 for both The intervention group also had a significantly lower anxiety score than the control group at Time 3 p = 003 There was no difference between depression and readjustment scores in the two groups The results support the hypothesis that a tailored information pack for patients with rectal cancer will positively affect satisfaction with information These results will enhance the knowledge base surrounding the provision of tailored information to specific patient groups\",\n",
            "}\n",
            "13663\n",
            "{\n",
            "  \"id\" : \"22689129\",\n",
            "  \"contents\" : \"Pomegranate juice has been associated with PSA doubling time PSADT elongation in a single-arm phase II trial This study assesses biological activity of two doses of pomegranate extract POMx in men with recurrent prostate cancer using changes in PSADT as the primary outcome This randomized multi-center double-blind phase II dose-exploring trial randomized men with a rising PSA and without metastases to receive 1 or 3 g of POMx stratified by baseline PSADT and Gleason score Patients 104 were enrolled and treated for up to 18 months The intent-to-treat ITT population was 96 % white with median age 745 years and median Gleason score 7 This study was designed to detect a 6-month on-study increase in PSADT from baseline in each arm Overall median PSADT in the ITT population lengthened from 119 months at baseline to 185 months after treatment P < 0001 PSADT lengthened in the low-dose group from 119 to 188 months and 122 to 175 months in the high-dose group with no significant difference between dose groups P = 0554 PSADT increases > 100 % of baseline were observed in 43 % of patients Declining PSA levels were observed in 13 patients 13 % In all 42 % of patients discontinued treatment before meeting the protocol-definition of PSA progression or 18 months primarily due to a rising PSA No significant changes occurred in testosterone Although no clinically significant toxicities were seen diarrhea was seen in 19 % and 135 % of patients in the 1 - and 3-g dose groups respectively POMx treatment was associated with 6 month increases in PSADT in both treatment arms without adverse effects The significance of this on-study slowing of PSADT remains unclear reinforcing the need for placebo-controlled studies in this patient population\",\n",
            "}\n",
            "13664\n",
            "{\n",
            "  \"id\" : \"20585099\",\n",
            "  \"contents\" : \"The Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 MRC CR07/NCIC CTG C016 trial showed that in patients with operable rectal cancer short-course preoperative radiotherapy PRE reduced the rate of local recurrence compared with surgery followed by selective postoperative chemoradiotherapy for patients with a positive circumferential resection margin However the advantages of giving PRE to all patients needs to be balanced against any negative impact on patients quality of life All 1350 patients were asked to complete the Medical Outcomes Study Short-Form 36-item MOS SF-36 and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Colorectal 38-item EORTC QLQ-CR38 questionnaires A priori hypotheses related to the impact of treatment on sexual bowel and physical function and general health Male sexual dysfunction was significantly increased following surgery P < 001 although there was no difference between treatment arms However a treatment difference had emerged at 6 months PRE patients reporting significantly greater dysfunction P = 004 which persisted out to at least 2 years an insufficient number of female patients completed the sexual dysfunction questions to draw firm conclusions Both treatment groups reported similar levels of decreased physical function at 3 months but thereafter it returned to baseline levels There was no evidence of any major changes between treatments or time points in terms of general health or bowel function but exploratory analysis indicated a significant P = 006 at 2 years increase in the level of fecal incontinence with PRE These results from a large randomized trial using validated patient-completed questionnaires show that for males the main adverse effect was sexual dysfunction and the main cause of this was surgery but that PRE also affected sexual and some aspects of bowel functioning\",\n",
            "}\n",
            "13665\n",
            "{\n",
            "  \"id\" : \"24517299\",\n",
            "  \"contents\" : \"Increasing demand for palliative care unit PCU admissions has led to a stronger focus on discharge planning This has resulted in shorter inpatient length of stays LOS and stable patients not requiring specialist palliative care services being referred for placement in residential aged care facilities RACFs The process of placement is time-consuming and can be distressing to patients and families so RACF placement should only be proposed in patients whose prognosis is relatively good ie weeks to months Our aim was to identify the outcomes of palliative care inpatients referred for residential aged care placement A retrospective chart audit was conducted The patients outcomes discharge or death and survival time were recorded and analyzed using SPSS statistical software Subjects were 100 consecutive inpatients from a 30-bed PCU who had been referred for RACF placement Of the 100 patients referred for RACF placement 73 of 100 73 % patients had a malignant diagnosis whereas 27 27 % had a noncancer diagnosis Thirty-eight 38 % patients died before discharge including 33 of 73 45 % patients with cancer and 5 of 27 13 % patients with nonmalignant conditions In particular 12 of 17 71 % patients with metastatic non-small cell lung NCSLC cancer died before or soon after discharge Over one-third of all patients died before discharge to an RACF could take place The rate of death before discharge was higher among patients who had cancer Patients suffering from NCSLC need to be more carefully selected for placement as only one-third of these patients survived to discharge\",\n",
            "}\n",
            "13666\n",
            "{\n",
            "  \"id\" : \"24867693\",\n",
            "  \"contents\" : \"Bleomycin-etoposid-cisplatin BEP chemotherapy is curative in most patients with disseminated germ cell cancer GCC but also associated with toxic actions and dysfunction in non-targeted tissues We investigated changes in muscle function during BEP and the safety and efficacy of resistance training to modulate these changes Thirty GCC patients were randomly assigned to resistance training resistance training group INT n = 15 or usual care CON n = 15 during 9 weeks of BEP therapy Resistance training consisted of thrice weekly sessions of four exercises 3-4 sets/exercise of 10-15 repetitions at 12-15 repetition maximum load The primary endpoint was muscle fibre size assessed in muscle biopsies from musculus vastus lateralis Secondary endpoints were fibre phenotype composition body composition strength blood biochemistry and patient-reported endpoints Healthy age-matched subjects REF n = 19 performed the same RT-programme for comparison purposes Muscle fibre size decreased by -322 m 2 95 % confidence interval CI -899 to 255 P = 0473 in the CON-group and increased by +206 m 2 95 % CI -384 to 796 P = 0257 in the INT-group adjusted mean difference AMD +625 m 2 95 % CI -253 to 1503 P = 0149 Mean differences in type II fibre size AMD +823 m 2 P = 009 and lean mass AMD +149 kg P = 007 in favour of the INT-group approached significance The REF-group improved all muscular endpoints and had significantly superior changes compared with the INT-group P < 005 BEP was associated with significant reduction in lean mass and strength and trends toward unfavourable changes in muscle fibre size and phenotype composition Resistance training was safe and attenuated dysfunction in selected endpoints but BEP blunted several positive adaptations observed in healthy controls Thus our study does not support the general application of resistance training in this setting but larger-scaled trials are required to confirm this finding\",\n",
            "}\n",
            "13667\n",
            "{\n",
            "  \"id\" : \"10470844\",\n",
            "  \"contents\" : \"to compare standard and alternating administration of chemotherapy combinations in small cell lung cancer SCLC patients in a multicenter clinical trial 394 previously untreated SCLC patients were randomised to receive every 4 weeks eight courses of either a standard regimen with CCNU cyclophosphamide adriamycin CCA and VP16 or an alternating regimen CCA regimen alternating with cisplatin-vindesine-VP16 overall response rate was higher in the standard group 78 % than in the alternating group 64 % P = 00001 Complete response rate was also higher in the standard group 32 % than in the alternating group 18 % P = 0004 The median survival in the overall SCLC population was 306 days in the standard group and 272 days in the alternating group P = 008 In limited SCLC patients median survival was higher in the standard group 421 days than in the alternating group 328 days P = 001 Grade III/IV haematological toxicity was lower in patients in the alternating group 25 versus 47 % P < 0001 the standard regimen was better than the alternating regimen for patients with limited forms of SCLC The alternating regimen associated with better haematological safety and ensuring a fairly similar survival may be considered in patients with extensive SCLC Pleiomorphic resistance mechanisms to chemotherapy make it difficult to define a non-cross-resistant chemotherapy regimen\",\n",
            "}\n",
            "13668\n",
            "{\n",
            "  \"id\" : \"12673463\",\n",
            "  \"contents\" : \"The aim of this study was to evaluate the effect of pure natural honey on radiation-induced mucositis Forty patients diagnosed with head and neck cancer requiring radiation to the oropharyngeal mucosal area were divided in to two groups to receive either radiation alone or radiation plus topical application of pure natural honey Patients were treated using a 6-MV linear accelerator at a dose rate of 2 Gy per day five times a week up to a dose of 60-70 Gy In the study arm patients were advised to take 20 ml of pure honey 15 min before 15 min after and 6 h post-radiation therapy Patients were evaluated every week for the development of radiation mucositis using the Radiation Therapy Oncology Group RTOG grading system There was significant reduction in the symptomatic grade 3/4 mucositis among honey-treated patients compared to controls ie 20 % versus 75 % p 000058 The compliance of honey-treated group of patients was better than controls Fifty-five percent of patients treated with topical honey showed no change or a positive gain in body weight compared to 25 % in the control arm p 0053 the majority of whom lost weight Topical application of natural honey is a simple and cost-effective treatment in radiation mucositis which warrants further multi-centre randomised trials to validate our finding\",\n",
            "}\n",
            "13669\n",
            "{\n",
            "  \"id\" : \"20972900\",\n",
            "  \"contents\" : \"To determine the clinical value of C-reactive protein CRP fibrinogen FIB or serum amyloid A protein SAA combined with 64 multi-slice computed tomography MSCT for preoperative staging and operative strategy in colon cancer Patients with colon cancer were prospectively enrolled at the West China Hospital of Sichuan University from November 2007 to July 2009 and were equally randomized into 3 groups undergoing different preoperative evaluation MSCT combined with CRP CRP group MSCT combined with FIB FIB group and MSCT combined with SAA SAA group The agreement between preoperative staging and postoperative pathologic staging and that between expected surgical procedure and procedure adopted were compared Baseline characteristics among three groups were similar P > 005 In CRP group the accuracies of preoperative staging T N M and TNM were 657 % 724 % 100 % and 667 % respectively In FIB group the accuracies of preoperative staging T N M and TNM were 714 % 743 % 990 % and 657 % respectively In SAA group the accuracies of preoperative staging T N M and TNM were 600 % 552 % 962 % and 514 % respectively The accuracies of N and TNM staging in CRP group and FIB group were significantly higher than those in SAA group P < 005 However there were no significant differences between FIB and CRP group P > 005 There were no significant differences in accuracy of predicting surgical procedures among three groups 933 % 923 % and 876 % P > 005 Combined assessment of MSCT and CRP or FIB may improve the accuracy of preoperative staging and procedure prediction and is superior to MSCT combined with SAA\",\n",
            "}\n",
            "13670\n",
            "{\n",
            "  \"id\" : \"9500317\",\n",
            "  \"contents\" : \"Long-term administration of cyclosporin carries a risk of renal toxicity and immunosuppressants are associated with an increased rate of malignant disorders We undertook an open randomised study of the risks and benefits of two long-term maintenance regimens of cyclosporin in kidney-allograft recipients The primary endpoint was graft function secondary endpoints were survival and occurrence of cancer and rejection 231 recipients of a first allograft with at most one previous rejection episode were randomised 1 year after transplantation Most were receiving cyclosporin and azathioprine One group received cyclosporin doses adjusted to yield trough blood concentrations of 75-125 ng/mL low-dose group the second received doses that yielded trough concentrations of 150-250 ng/mL normal-dose group Analysis was by intention to treat At 66 months follow-up the low-dose and normal-dose groups were similar in mean serum creatinine 182 [ SD 160 ] vs 184 [ 157 ] micromol/L p = 09 and mean creatinine clearance 475 [ 251 ] vs 453 225 ] mL/min p = 06 Nine of 116 patients in the low-dose group and one of 115 in the normal-dose group had symptoms of rejection p < 002 There was no difference between the low-dose and normal-dose groups in survival 95 vs 92 % p = 07 or graft survival 89 vs 82 % p = 017 at 6 years 60 patients developed cancers 37 in the normal-dose group and 23 in the low-dose group p < 0034 66 % were skin cancers 26 vs 17 p < 005 We found no evidence that halving of trough blood cyclosporin concentrations significantly changes graft function or graft survival The low-dose regimen was associated with fewer malignant disorders but more frequent rejection The design of long-term maintenance protocols for transplant recipients based on powerful immunosuppressant combinations should take these potential risks into account\",\n",
            "}\n",
            "13671\n",
            "{\n",
            "  \"id\" : \"21334025\",\n",
            "  \"contents\" : \"Posterior rhabdosphincter reconstruction following radical prostatectomy was designed to improve early urinary continence We executed a randomized clinical trial to test this conjecture in men undergoing robotic radical prostatectomy We conducted a phase II randomized clinical trial intended to detect a 25 % difference in 3-month continence outcomes defined by a patient response of 0 or 1 to question 5 of the Expanded Prostate Cancer Index Composite questionnaire urinary domain comparing standard running vesicourethral anastomosis controls to posterior rhabdosphincter reconstruction followed by standard running vesicourethral anastomosis posterior rhabdosphincter reconstruction treated Patients had clinically localized prostate cancer and were blinded Surgeons were notified of computer randomization after prostate excision Further continence outcomes were assessed by analysis of Expanded Prostate Cancer Index Composite questionnaire questions 1 and 12 International Prostate Symptom Score and 24-hour pad weights Statistical significance was defined as p < 005A total of 94 patients were randomized 47 to each arm Preoperative clinical and functional variables were equivalent between study arms There were no complications associated with either anastomotic technique Of the 87 evaluable patients 62 713 % met our 3-month continence definition The null hypothesis was not rejected as 33 81 % controls and 29 63 % posterior rhabdosphincter reconstruction treated patients were continent at 3 months chi-square p = 007 Fisher exact p = 01 Likewise there was no significant difference between arms in 24-hour pad weights p = 014 International Prostate Symptom Score p = 04 absence of daily leaks p = 04 or perception of urinary function p = 04 In this randomized clinical trial posterior rhabdosphincter reconstruction offered no advantage for return of early continence after robotic assisted radical prostatectomy\",\n",
            "}\n",
            "13672\n",
            "{\n",
            "  \"id\" : \"16643492\",\n",
            "  \"contents\" : \"To assess the benefit of an antireflux system in patients with orthotopic ileal neobladders as there is controversy about whether reflux prevention offers any advantages We conducted a randomized prospective study between January 2002 and March 2004 on 60 patients 53 men and seven women with a mean sd age of 527 73 years who were candidates for orthotopic neobladders Patients with comorbidities were excluded Preoperative evaluation included intravenous urography IVU cystoscopic biopsy and radioisotope renography to evaluate the differential glomerular filtration rates GFRs Cases with normal kidneys and ureters and with similar GFRs were enrolled Surgery comprised a standard radical cystectomy with pelvic lymphadenectomy The ureters were randomized to either a direct anastomosis into a 5-cm ileal chimney on one side or to be implanted using the antireflux serous-lined extramural tunnel on the contralateral side in the same patient Regular follow-up included IVU and renography every 6 months in cancer-free patients The mean sd follow-up was 23 96 months There was prolonged urinary leak from a refluxing ureter in one patient that was treated with a temporary percutaneous nephrostomy Symptomatic pelvic collections required tube drainage in six cases Six ureters developed early anastomotic strictures one direct and five antirefluxing and were treated with endoscopic ureterotomy in three and open revision in three Serum creatinine levels were normal in all patients throughout the observation period GFRs were similar in the two groups The mean GFRs before surgery and at 6 12 18 and 24 months after cystectomy were 551 507 494 522 and 539 mL/min for the direct side and 561 53 524 532 and 504 mL/min for renal units with antirefluxing implantation There was a significant deterioration of the GFRs due to anastomotic strictures from 486 67 mL/min before surgery to 318 159 mL/min after the revision P = 001 The antireflux procedures were associated with a higher incidence of anastomotic strictures than the direct methods and there was a significant deterioration of renal function after obstruction The long-term follow-up data are awaited\",\n",
            "}\n",
            "13673\n",
            "{\n",
            "  \"id\" : \"12743150\",\n",
            "  \"contents\" : \"To determine the effect of elevated serum HER-2 / neu on the response of metastatic breast cancer patients to an aromatase inhibitor versus an antiestrogen Five hundred sixty-two estrogen receptor-positive metastatic breast cancer patients were randomized to first-line hormone therapy with either letrozole or tamoxifen An automated enzyme-linked immunosorbent assay was used to detect serum HER-2 / neu For patients with normal serum HER-2 / neu 705 % objective response rate ORR 39 % in letrozole-treated patients v 26 % in tamoxifen-treated patients P = 008 clinical benefit CB 57 % v 45 % P = 016 time to progression TTP median 122 v 85 months P = 0019 and time to treatment failure TTF median 116 v 62 months P = 0066 were significantly better in patients treated with letrozole In the elevated HER-2 / neu group 295 % there was no significant difference in ORR 17 % in letrozole-treated patients v 13 % in tamoxifen-treated patients P = 45 or CB 33 % v 26 % P = 31 but there was a strong trend in favor of a longer TTP with letrozole median 61 v 33 months P = 0596 and a significantly longer TTF with letrozole median 60 v 32 months P = 0418 Multivariate analysis revealed that elevated serum HER-2 / neu was a negative predictor for ORR and TTP Patients with normal serum HER-2 / neu receiving letrozole demonstrated a significantly greater ORR and CB and longer TTP and TTF than patients receiving tamoxifen Although in patients with elevated serum HER-2 / neu there was no significant difference between letrozole and tamoxifen in ORR or CB there was a strong trend favoring longer TTP and significantly longer TTF with letrozole\",\n",
            "}\n",
            "13674\n",
            "{\n",
            "  \"id\" : \"16644631\",\n",
            "  \"contents\" : \"We sought to evaluate the effects of muraglitazar a dual alpha/gamma peroxisome proliferator-activated receptor PPAR activator within the new glitazar class on hyperglycemia and lipid abnormalities A double-blind randomized controlled trial was performed in 1159 patients with type 2 diabetes inadequately controlled with metformin Patients received once-daily doses of either 5 mg muraglitazar or 30 mg pioglitazone for a total of 24 weeks in addition to open-label metformin Patients were continued in a double-blind fashion for an additional 26 weeks Analyses were conducted at week 24 for HbA1c A1C and at week 12 for lipid parameters Mean A1C at baseline was 812 and 813 % in muraglitazar and pioglitazone groups respectively At week 24 muraglitazar reduced mean A1C to 698 % -114 % from baseline and pioglitazone reduced mean A1C to 728 % -085 % from baseline P < 00001 muraglitazar vs pioglitazone At week 12 muraglitazar and pioglitazone reduced mean plasma triglyceride -28 vs -14 % apolipoprotein B -12 vs -6 % and non-HDL cholesterol -6 vs -1 % and increased HDL cholesterol 19 vs 14 % respectively P < 00001 vs pioglitazone for all comparisons At week 24 weight gain 14 and 06 kg respectively and edema 92 and 72 % respectively were observed in the muraglitazar and pioglitazone groups at week 50 weight gain and edema were 25 and 15 kg respectively and 118 and 89 % respectively At week 50 heart failure was reported in seven patients five with muraglitazar and two with pioglitazone and seven deaths occurred three from sudden death two from cerebrovascular accident and one from pancreatic cancer in the muraglitazar group and one from perforated duodenal ulcer in the pioglitazone group We found that 5 mg muraglitazar resulted in greater improvements in A1C and lipid parameters than a submaximal dose of 30 mg pioglitazone when added to metformin Weight gain and edema were more common when muraglitazar was compared with a submaximal dose of pioglitazone\",\n",
            "}\n",
            "13675\n",
            "{\n",
            "  \"id\" : \"21531236\",\n",
            "  \"contents\" : \"The Scleroderma Lung Study SLS was a 1-year randomized controlled trial of oral cyclophosphamide for scleroderma-related pulmonary alveolitis It concluded that oral cyclophosphamide slowed the decline in the forced vital capacity % predicted and had a beneficial effect on dyspnea skin changes and several quality of life measures of systemic sclerosis We now report an in-depth assessment of the toxicity of cyclophosphamide during the year of therapy and the year after therapy was completed during which time the investigators were still masked to the treatment assignment One-year double-blind randomized controlled trial of oral cyclophosphamide versus placebo with 1-year masked follow-up Adverse events AEs were tabulated described and compared using descriptive statistics eg mean and median and t Wilcoxon rank sum chi-squared or Fisher s exact tests as appropriate During year 1 treatment-related overall AEs occurred more frequently in cyclophosphamide CYC - treated patients overall AEs for CYC = 154 events vs placebo = 60 events P = 0002 and especially for mild to moderate leukopenia CYC = 19 subjects vs placebo = 0 subjects P < 0001 For cancer we followed patients beyond 2 years There were no differences in the occurrence of cancer CYC = 4 subjects vs placebo = 2 subjects serious related AEs CYC = 8 events vs placebo = 13 events or deaths CYC = 6 subjects vs placebo = 6 subjects Over 2 years cyclophosphamide was associated with more AEs than placebo including overall AEs and relative leukopenia There were no differences in other AEs including serious AEs cancers or deaths\",\n",
            "}\n",
            "13676\n",
            "{\n",
            "  \"id\" : \"10053098\",\n",
            "  \"contents\" : \"Recombinant human interleukin-6 rhuIL-6 is a glycosylated cytokine with hematopoietic stimulatory effects In particular preclinical studies suggest the agent can stimulate thrombopoiesis even in conjunction with chemotherapy We attempted to determine whether higher dose chemotherapy for ovarian cancer was possible given the pharmacologic use of this important growth factor We conducted a randomized double-blind phase II study of IL-6 plus granulocyte colony-stimulating factor G-CSF versus placebo plus G-CSF in combination with a standard chemotherapy regimen Patients with epithelial ovarian cancer stages Ic to IV were eligible All patients were previously untreated with chemotherapy and had Karnofsky performance status > / = 60 rhuIL-6 Escherichia coli SDZ ILS 969 10 micrograms/kg or placebo was given subcutaneously on days 2-8 every cycle together with G-CSF 50 micrograms/kg subcutaneously days 2-15 following administration of paclitaxel 175 mg/m2 as a 3-h infusion and carboplatin given to a desired AUC of 75 on day 1 every 21 days Fifty patients were entered in this study although the study was temporarily suspended by the FDA in midstudy over manufacturing concerns Therefore 37 patients were evaluable for efficacy of growth factor 19 patients received placebo plus G-CSF and 18 rhIL-6 plus G-CSF There was no difference in prognostic variables between these two groups Platelet nadirs were lower in the first cycle for the placebo group P = 0004 Wilcoxon sum-rank test but not in other cycles There was no statistically significant difference in cycle treatment delays carboplatin dose delivered number of patients with grade 4 thrombocytopenia or platelet transfusion Nonetheless the trend of the data favored IL-6 in all cases This study demonstrated a minimal effect statistically significant in the first cycle only on thrombopoiesis in women undergoing paclitaxel and carboplatin therapy of ovarian cancer No clinically significant effect on actual chemotherapy delivery was demonstrated however Future studies if warranted to ameliorate thrombocytopenia should be carried out with regimens producing even greater thrombocytopenia than the current regimen in the control arm\",\n",
            "}\n",
            "13677\n",
            "{\n",
            "  \"id\" : \"11706524\",\n",
            "  \"contents\" : \"A prospective randomized study was designed to determine whether flutamide FLU administered before treatment with a luteinizing hormone-releasing hormone agonist LH-RHa prevented prostate-specific antigen PSA flare in prostate cancer patients Prostate cancer patients were randomized into two groups and received either FLU n = 11 or no pretreatment n = 13 for 2 weeks before the initial injection of LH-RHa LH-RHa every 4 weeks and FLU every day were administered throughout the period of this study Blood samples for the determination of PSA testosterone T and luteinizing hormone levels were collected before FLU administration and before and 2 7 14 28 56 and 84 days after the first administration of LH-RHa Treatment with FLU prior to LH-RHa induced an early decline in PSA level The mean PSA level showed no significant secondary rise after LH-RHa administration in those patients with FLU pretreatment Patients in both groups showed T flare after the first LH-RHa administration However the number of patients with PSA flare was significantly lower in patients with prior FLU administration than in those with LH-RHa alone These results clearly demonstrate that in patients with prostatic cancer the administration of FLU for 2 weeks prior to the first LH-RHa administration is effective in preventing PSA flare as well as in inducing an early decline in PSA levels\",\n",
            "}\n",
            "13678\n",
            "{\n",
            "  \"id\" : \"18972170\",\n",
            "  \"contents\" : \"This study was undertaken to correlate serum CA 19-9 levels and CA 19-9 velocity with disease-free and overall survival after pancreatectomy for adenocarcinoma From 1997 to 2002 96 patients underwent pancreatectomy without adjuvant chemotherapy as the control arm of a large randomized prospective adjuvant therapy trial After resection CA 19-9 levels were drawn at baseline 4 weeks and 12-week intervals thereafter CA 19-9 velocity denotes rate of change in CA 19-9 levels over a 4-week period Postoperative baseline CA 19-9 levels and CA 19-9 velocity were correlated with disease-free and overall survival Data are presented as median mean + / - SD Disease-free survival was 7 months 14 + / - 137 and overall survival was 12 months 19 + / - 143 with 24 25 % patients alive at 41 months 39 + / - 78 Baseline CA 19-9 levels and CA 19-9 velocity predicted disease-free p < 001 and overall survival p < 001 CA 19-9 velocity was a better predictor of overall survival than baseline CA 19-9 p < 0001 CA 19-9 velocity at disease progression was 131 U/ml/4-weeks 1684 + / - 44748 vs 1 U/ml/4-weeks 1 + / - 38 at 22 months for patients without disease progression p < 0001 CA 19-9 velocity predicts imminent disease progression after resection of pancreatic adenocarcinoma and is a better predictor of overall survival than baseline CA 19-9 levels CA 19-9 velocity is a reliable and relatively inexpensive means of monitoring patients after resection of pancreatic cancer and should be considered in all patients enrolled in clinical trials as well as patients receiving adjuvant therapy\",\n",
            "}\n",
            "13679\n",
            "{\n",
            "  \"id\" : \"12207074\",\n",
            "  \"contents\" : \"Postoperative tissue injury and immunosuppression can occur after major surgery In this study we explore the potential benefits of administering a protease inhibitor to treat immunosuppression caused by surgical stress Sixteen patients with esophageal cancer were preoperatively allocated at random into two equal groups A urinary trypsin inhibitor ulinastatin UTI was intravenously administered to the treatment UTI group at a dose of 150000 U every 12 h from the start of surgery until postoperative day 5 whereas the control group received a placebo One unit of UTI was defined as the amount of UTI necessary to inhibit the activity of 2 microg of bovine pancreatic trypsin by 50 % We measured the plasma levels of polymorphonuclear neutrophil elastase interleukin 8 circulating T lymphocyte subsets and mitogenic activity and in vitro production of tumor necrosis factor alpha in lipopolysaccharide-stimulated whole blood The postoperative serum value of polymorphonuclear neutrophil elastase was significantly lower in the UTI group but the interleukin 8 concentrations did not significantly vary between the two groups On the other hand the severity of the postoperative immunosuppression was reduced in the UTI group and immune functions such as the numbers of T lymphocytes the mitogenic activity of lymphocytes and the level of tumor necrosis factor alpha production in whole blood recovered significantly earlier in the UTI group These data suggest that a protease-modulating therapy may be a new strategy for the treatment of surgical stress induced immune dysfunction\",\n",
            "}\n",
            "13680\n",
            "{\n",
            "  \"id\" : \"18094551\",\n",
            "  \"contents\" : \"For the detection of transitional cell carcinoma TCC of the bladder we compared the sensitivities and specificities between the ThinPrep test and Melanoma Antigen Gene MAGE test with voided urine V drained urine D and irrigated urine I We randomly selected 10 patients of a non-cancer group and 20 patients of a cancer group V D and I were obtained preoperatively and equally divided into two parts for the ThinPrep test and MAGE reverse transcriptase polymerase chain reaction RT-PCR The cystoscopic finding was used as the reference standard for detection of bladder cancer The results of ThinPrep test and MAGE RT-PCR were compared according to cancer grade and stage The overall sensitivities of ThinPrep test were 45 % 85 % and 85 % for V D and I respec-tively while those of MAGE test were 50 % 85 % and 65 % Detection rate from drainage urine was considerably higher than that of voided urine in both methods P < 005 The specificities were 100 % for all types of urine specimens with ThinPrep test and 100 % 90 % and 90 % for V D and I respectively using MAGE test without any statistically significant differences For the detection of bladder cancer MAGE RT-PCR and ThinPrep test showed a comparable sensitivity and specificity and drained urine revealed the best detection rate MAGE RT-PCR might be utilized as another marker of bladder cancer using urine specimens\",\n",
            "}\n",
            "13681\n",
            "{\n",
            "  \"id\" : \"21523716\",\n",
            "  \"contents\" : \"The purpose of this study was to compare 2 weekly docetaxel-based regimens as first-line treatments for advanced gastric cancer and to investigate the expression of secreted protein acidic and rich in cysteine SPARC and its abilities to predict treatment-related clinical outcomes Patients were randomly selected to receive 3 weekly cycles of docetaxel 35 mg/m 2 on days 1 and 8 plus S-1 35 mg/m 2 each twice daily on days 1-14 DS or docetaxel plus cisplatin 35 mg/m 2 each on days 1 and 8 DC Endpoints included overall response rate primary survival toxicity and quality of life secondary SPARC expression in prechemotherapy specimens of primary gastric tumors was evaluated via immunohistochemical analysis Eighty patients were enrolled in the study Confirmed overall response rates were 46 % 95 % confidence interval 30 % -62 % for DS and 24 % 95 % confidence interval 11 % -38 % for DC via intent-to-treat analysis Median progression-free survival was 73 and 49 months and overall survival was 160 and 83 months for DS and DC respectively The most common grade 3 toxicity was neutropenia Grade 3 mucositis 18 % and hand-foot syndrome 8 % were the toxicities most associated with DS whereas anorexia 20 % and lethargy 20 % were more common with DC High SPARC expression was related to early progression hazard ratio 367 P = 042 and poor overall survival hazard ratio 201 P = 010 in docetaxel chemotherapy on multivariate analysis The outcomes in this study favored DS over DC for further phase 3 study The findings suggest that split-dose weekly docetaxel alleviates hematological toxicity without compromising efficacy and that SPARC expression may help individualize therapy in advanced gastric cancer\",\n",
            "}\n",
            "13682\n",
            "{\n",
            "  \"id\" : \"10585065\",\n",
            "  \"contents\" : \"Stage II non-small-cell lung cancer is regarded as one of the early lung cancers Although resection including the mediastinal lymph nodes is currently regarded as the standard treatment the survival rate of this disease is not encouraging It is well known that the most common causes of death are locoregional recurrences or distant metastases or both However the best adjuvant treatment to improve survival is as controversial an issue as ever This study was designed as a randomized blinded two-armed study with operation and adjuvant radiotherapy in one arm versus operation and adjuvant mitomycin C 10 mg/m2 vinblastine 6 mg/m2 and cisplatin 100 mg/m2 MVP chemotherapy in the other arm We assigned 57 resected patients with pathologic proven stage II non-small cell lung cancer to the groups according to our eligibility criteria The most common pattern of recurrence was distant metastases and nearly all the recurrences 17 of 18 patients in both groups were found within 2 years after operation The rates of the locoregional and distant metastases were 36 % and 464 % in the adjuvant radiotherapy group and 69 % and 103 % in the adjuvant chemotherapy group p = 0018 The 5-year disease-free survival rates were 520 % in the adjuvant radiotherapy group and 740 % in the adjuvant chemotherapy group p = 016 log-rank test The 2-year 5-year and 6-year survival portions were 603 % 565 % and 283 % in the adjuvant radiotherapy group and 828 % 701 % and 601 % in the adjuvant chemotherapy group p = 001 p = 017 and p = 003 Z-test The difference of the actuarial survival between these two groups was somewhat significant p = 009 log-rank test Our results suggest that the addition of adjuvant MVP chemotherapy may reduce the distant metastasis rates and prolong the survival of the surgically resected stage II non-small-cell lung cancer patients\",\n",
            "}\n",
            "13683\n",
            "{\n",
            "  \"id\" : \"22885459\",\n",
            "  \"contents\" : \"Electromagnetic EM navigation is increasingly used to assist with bronchoscopic interventions such as biopsy or fiducial placement Electromagnetic navigation can also be a useful adjunct to computed tomography CT - guided thermal ablation and biopsy of lung tumors This study compares procedures carried out using an EM navigation system Veran Medical Technologies Inc St Louis MO with procedures using CT fluoroscopy only Over a 23-month period 17 patients scheduled for thermal ablation were prospectively enrolled in this study The mean age was 72 years range 60-84 years Seven patients were women Patients were randomized to EM navigation n = 7 or CT fluoroscopy alone n = 10 In some cases additional ablation or biopsies were performed with or without EM navigation depending on the randomization arm All procedures were performed under general anesthesia either by a thoracic surgeon or a radiologist A total of 23 procedures were performed in 17 patients 20 were ablation procedures and 3 were biopsies Fourteen were performed for non-small cell lung cancer and 9 for pulmonary metastases from other organs Despite randomization patients receiving EM navigation had a trend for smaller tumors mean diameter 145 vs 290 cm P = 006 For thermal ablation procedures the time to complete intervention was significantly less when EM navigation was used mean 76 vs 19 minutes P = 0022 Although not statistically significant there were fewer skin punctures mean 1 vs 125 P = 0082 fewer adjustments mean 56 vs 118 P = 0203 less CT fluoroscopy time mean 213 vs 343 seconds P = 0345 and fewer CT scans mean 7 vs 15 P = 0204 whenever EM navigation was used Electromagnetic navigation reduces the time to successfully place an ablation probe in a target tumor Further study is required to determine whether EM navigation may also reduce the number of adjustments skin punctures and CT scans as well as decrease CT fluoroscopy time\",\n",
            "}\n",
            "13684\n",
            "{\n",
            "  \"id\" : \"20068078\",\n",
            "  \"contents\" : \"Irinotecan the prodrug of SN-38 is extensively metabolized by cytochrome P450-3A4 CYP3A4 A randomized trial was done to assess the utility of an algorithm for individualized irinotecan dose calculation based on a priori CYP3A4 activity measurements by the midazolam clearance test Patients were randomized to receive irinotecan at a conventional dose level of 350 mg/m 2 group A or doses based on an equation consisting of midazolam clearance gamma-glutamyl-transferase and height group B Pharmacokinetics and toxicities were obtained during the first treatment course Demographics of 40 evaluable cancer patients were balanced between both groups including UGT1A1 * 28 genotype and smoking status The absolute dose of irinotecan ranged from 480 to 800 mg in group A and 380 to 1060 mg in group BThe mean absolute dose and area under the curve of irinotecan and SN-38 were not significantly different in either group P > 018 In group B the interindividual variability in the area under the curve of irinotecan and SN-38 was reduced by 19 % and 25 % respectively P > 022 Compared with group A the incidence of grades 3 to 4 neutropenia was > 4-fold lower in group B 45 versus 10 % P = 0013 The incidence of grades 3 to 4 diarrhea was equal in both groups 10 % Incorporation of CYP3A4 phenotyping in dose calculation resulted in an improved predictability of the pharmacokinetic and toxicity profile of irinotecan thereby lowering the incidence of severe neutropenia In combination with UGT1A1 * 28 genotyping CYP3A4 phenotype determination should be explored further as a strategy for the individualization of irinotecan treatment\",\n",
            "}\n",
            "13685\n",
            "{\n",
            "  \"id\" : \"19436289\",\n",
            "  \"contents\" : \"A dramatic rise in incidence an aging population and expensive palliative treatments have led to an escalating burden on clinicians managing inoperable esophageal cancer with only limited evidence of effectiveness This study compares the clinical effectiveness and cost-effectiveness of self-expanding metal stents SEMSs with other palliative therapies to aid clinicians in making an evidence-based treatment choice We conducted a prospective multicenter randomized controlled clinical trial with 215 patients followed until death or study closure The primary outcome measures were dysphagia quality of life QL 6 weeks following treatment and total cost of treatment Secondary outcome measures included treatment-associated morbidity mortality survival and cost-effectiveness An intention-to-treat analysis was carried out There was a significant difference in mean dysphagia grade between treatment arms 6 weeks following treatment P = 0046 with worse swallowing reported by rigid stent-treated patients mean dysphagia score difference = -049 95 % confidence interval CI -010 to -089 P = 0014 Global QL scores were lower at both 1 and 6 weeks following treatment for patients treated by SEMSs mean difference QL index week 1 = -066 95 % CI -002 to -130 P = 004 mean difference QL index week 6 = -101 95 % CI -030 to -172 P = 0006 These findings were associated with higher post-procedure pain scores in the SEMS patient group mean difference of the European Organisation for Research and Treatment of Cancer QLQ C-30 pain symptom score at week 1 = 1113 95 % CI 289-19 4 P = 001 Although mean EQ-5D QL values differed between the treatments P < 0001 this difference dissipated following generation of quality-adjusted life year values Total costs varied between treatment arms but these findings canceled out when SEMSs were compared with non-SEMS therapies 95 % CI -84515 -133262 These results were robust to sensitivity analysis There were no differences in the in-hospital mortality or early complication rates but late complications were more frequent after rigid stenting risk ratio = 247 95 % CI 188-3 04 There was a survival advantage for non-stent-treated patients log-rank statistic = 421 P = 004 The treatment choice for patients with inoperable esophageal cancer should be between a SEMS or a non-stent treatment after consideration has been given to both patient and tumor characteristics and clinician and patient preferences\",\n",
            "}\n",
            "13686\n",
            "{\n",
            "  \"id\" : \"9197291\",\n",
            "  \"contents\" : \"The safety of low-flow sevoflurane anesthesia during which CF2 = C CF3 - O-CH2F compound A is formed by sevoflurane degradation in humans has been questioned because compound A is nephrotoxic in rats Several reports have evaluated renal function after closed-circuit or low-flow sevoflurane anesthesia using blood urea nitrogen BUN and serum creatinine as markers However these are not the more sensitive tests for detecting renal damage This study assessed the effects of low-flow sevoflurane anesthesia on renal function using not only BUN and serum creatinine but also creatinine clearance and urinary excretion of kidney-specific enzymes and it compared these values with those obtained in high-flow sevoflurane anesthesia and low-flow isoflurane anesthesia Forty-eight patients with gastric cancer undergoing gastrectomy were studied Patients were randomized to receive sevoflurane anesthesia with fresh gas flow of 1 l/min low-flow sevoflurane group n = 16 or 6-10 l/min high-flow sevoflurane group n = 16 or isoflurane anesthesia with a fresh gas flow of 1 l/min low-flow isoflurane group n = 16 In all groups the carrier gas was oxygen/nitrous oxide in the ratio adjusted to ensure a fractional concentration of oxygen in inspired gas FiO2 of more than 03 Fresh Baralyme was used in the low-flow sevoflurane and low-flow isoflurane groups Glass balls were used instead in the high-flow sevoflurane group with the fresh gas flow rate adjusted to eliminate rebreathing The compound A concentration was measured by gas chromatography Gas samples taken from the inspiratory limb of the circle system at 1-h intervals were analyzed Blood samples were obtained before and on days 1 2 and 3 after anesthesia to measure BUN and serum creatinine Twenty-four-hour urine samples were collected before anesthesia and for each 24-h period from 0 to 72 h after anesthesia to measure creatinine N-acetyl-beta-D-glucosaminidase and alanine aminopeptidase The average inspired concentration of compound A was 20 + / - 78 ppm mean + / - SD and the average duration of exposure to this concentration was 611 + / - 177 h in the low-flow sevoflurane group Postanesthesia BUN and serum creatinine concentrations decreased creatinine clearance increased and urinary N-acetyl-beta-D-glucosaminidase and alanine aminopeptidase excretion increased in all groups compared with preanesthesia values but there were no significant differences between the low-flow sevoflurane high-flow sevoflurane and low-flow isoflurane groups for any renal function parameter at any time after anesthesia The only difference between the low-flow and high-flow sevoflurane groups was compound A formation and postanesthesia laboratory data showed no significant effects of compound A formation during sevoflurane anesthesia on renal function No significant effects on renal function were observed in either the low-flow or high-flow sevoflurane groups compared with the low-flow isoflurane group\",\n",
            "}\n",
            "13687\n",
            "{\n",
            "  \"id\" : \"24152483\",\n",
            "  \"contents\" : \"Carers of patients with advanced cancer often have health and psychosocial needs which are frequently overlooked To meet the needs of carers through a GP consultation directed by a self-completed carer needs checklist Randomised controlled trial in general practice with recruitment through specialist oncology clinics in Brisbane Australia Intervention was a carer-GP consultations directed by a self-completed checklist of needs at baseline and 3 months and b a GP-Toolkit to assist GPs to address carer-identified needs Control group received usual care Outcome measures were intensity of needs anxiety and depression and quality of life Total recruitment 392 Overall no significant differences were detected in the number or intensity of need between groups Compared to controls intervention participants with baseline clinical anxiety showed improvements in mental wellbeing P = 0027 and those with baseline clinical depression had slower development of anxiety P = 0044 at 6 months For those not anxious physical wellbeing improved at 1 month P = 0040 Carers looking after patients with poor functional status had more physical needs P = 0037 at 1 month and more psychological and emotional needs at 3 months P = 0034 Those caring for less unwell patients showed improved mental wellbeing at 3 months P = 0022 The intervention did not influence the number or intensity of needs reported by carers of people with advanced cancer There was limited impact in people with pre-existing clinical anxiety and depression For the carer of those most severely affected by advanced cancer it drew attention to the needs arising from the caregiving role\",\n",
            "}\n",
            "13688\n",
            "{\n",
            "  \"id\" : \"18489503\",\n",
            "  \"contents\" : \"To examine the short-term impact of quadrivalent human papillomavirus HPV types 6/11/16 / 18 recombinant vaccination upon HPV disease-related health-care resource utilization and costs among young women We analyzed data from a randomized clinical trial comparing quadrivalent vaccination to placebo among women N = 7861 primarily 16 to 23 years of age at enrollment HPV disease episodes health-care resource utilization and costs associated with cervical vaginal and vulvar precancers and anogenital warts were analyzed over a period of 25 years among women regardless of baseline HPV status Overall there was a 259 % P < 0001 reduction in total HPV disease-related health-care costs among women receiving vaccine versus placebo absolute reduction $ 3939 per 100 trial enrollees We observed similar overall reductions in HPV-disease episodes and resource utilization There was a statistically significant reduction in HPV 6/11-related disease episode costs of 651 % $ 1837 per 100 and a reduction of 514 % $ 1781 per 100 in HPV 16/18-related episode costs Quadrivalent HPV vaccination can reduce HPV disease events resource use and costs when administered to a broad population of young women 16 to 23 years of age Prevention of HPV types 6 and 11 yielded similar value in terms of HPV disease cost offsets compared to protection against HPV 16 and 18 during the years initially after vaccination Over the short-term costs of vaccination exceed cost offsets associated with prevention of HPV disease however quadrivalent HPV vaccination has previously been shown to be cost-effective in the longer term when fully accounting for health benefits and cost offsets\",\n",
            "}\n",
            "13689\n",
            "{\n",
            "  \"id\" : \"24028813\",\n",
            "  \"contents\" : \"Elderly patients are often under-represented in clinical trials of metastatic colorectal cancer We aimed to assess the efficacy and safety of bevacizumab plus capecitabine compared with capecitabine alone in elderly patients with metastatic colorectal cancer For this open-label randomised phase 3 trial patients aged 70 years and older with previously untreated unresectable metastatic colorectal cancer who were not deemed to be candidates for oxaliplatin-based or irinotecan-based chemotherapy regimens were randomly assigned in a 11 ratio via an interactive voice-response system stratified by performance status and geographical region Treatment consisted of capecitabine 1000 mg/m 2 orally twice a day on days 1-14 alone or with bevacizumab 75 mg/kg intravenously on day 1 given every 3 weeks until disease progression unacceptable toxic effects or withdrawal of consent Efficacy analyses were based on the intention-to-treat population The primary endpoint was progression-free survival The trial is registered with ClinicalTrialsgov number NCT00484939 From July 9 2007 to Dec 14 2010 280 patients with a median age of 76 years range 70-87 were recruited from 40 sites across ten countries Patients were randomly assigned to receive either bevacizumab plus capecitabine n = 140 or capecitabine only n = 140 Progression-free survival was significantly longer with bevacizumab and capecitabine than with capecitabine alone median 91 months [ 95 % CI 73-114 ] vs 51 months [ 42-63 ] hazard ratio 053 [ 041-069 ] p < 00001 Treatment-related adverse events of grade 3 or worse occurred in 53 40 % patients in the combination group and 30 22 % in the capecitabine group and treatment-related serious adverse events in 19 14 % and 11 8 % patients The most common grade 3 or worse adverse events of special interest for bevacizumab or chemotherapy were hand-foot syndrome 21 [ 16 % ] vs nine [ 7 % ] diarrhoea nine [ 7 % ] vs nine [ 7 % ] and venous thromboembolic events 11 [ 8 % ] vs six [ 4 % ] Treatment-related deaths occurred in five patients in the combination group and four in the capecitabine group The most common any-grade adverse event of special interest for bevacizumab was haemorrhage 34 [ 25 % ] vs nine [ 7 % ] The combination of bevacizumab and capecitabine is an effective and well-tolerated regimen for elderly patients with metastatic colorectal cancer F Hoffmann-La Roche\",\n",
            "}\n",
            "13690\n",
            "{\n",
            "  \"id\" : \"17717452\",\n",
            "  \"contents\" : \"Colonic pouches have been used for 20 years to provide reservoir function after reconstructive proctectomy for rectal cancer More recently coloplasty has been advocated as an alternative to a colonic pouch However there have been no long-term randomized controlled trials to compare functional outcomes of coloplasty colonic J-Pouch JP or a straight anastomosis SA after the treatment of low rectal cancer To compare the complications long-term functional outcome and quality of life QOL of patients undergoing a coloplasty JP or an SA in reconstruction of the lower gastrointestinal tract after proctectomy for low rectal cancer A multicenter study enrolled patients with low rectal cancer who were randomized intraoperatively to coloplasty CP-1 or SA if JP was not feasible or JP or coloplasty CP-2 if a JP was feasible Patients were followed for 24 months with SF-36 surveys to evaluate the QOL Bowel function was measured quantitatively and using Fecal Incontinence Severity Index FISI Urinary function and sexual function were also assessed Three hundred sixty-four patients were randomized All patients were evaluated for complications and recurrence Mean age was 60 + / -12 years 71 % were male Twenty-three 74 % died within 24 months of surgery No significant difference was observed in the complications among the 4 groups Two hundred ninety-seven of 364 were evaluated for functional outcome at 24 months There was no difference in bowel function between the CP-1 and SA groups JP patients had fewer bowel movements less clustering used fewer pads and had a lower FISI than the CP-2 group Other parameters were not statistically different QOL scores at 24 months were similar for each of the 4 groups In patients undergoing a restorative resection for low rectal cancer a colonic JP offers significant advantages in function over an SA or a coloplasty In patients who can not have a pouch coloplasty seems not to improve the bowel function of patients over that with an SA\",\n",
            "}\n",
            "13691\n",
            "{\n",
            "  \"id\" : \"18316794\",\n",
            "  \"contents\" : \"The third-generation nonsteroidal aromatase inhibitors AIs are increasingly used as adjuvant and first-line advanced therapy for postmenopausal hormone receptor-positive HR + breast cancer Because many patients subsequently experience progression or relapse it is important to identify agents with efficacy after AI failure Evaluation of Faslodex versus Exemestane Clinical Trial EFECT is a randomized double-blind placebo controlled multicenter phase III trial of fulvestrant versus exemestane in postmenopausal women with HR + advanced breast cancer ABC progressing or recurring after nonsteroidal AI The primary end point was time to progression TTP A fulvestrant loading-dose LD regimen was used 500 mg intramuscularly on day 0 250 mg on days 14 28 and 250 mg every 28 days thereafter Exemestane 25 mg orally was administered once daily A total of 693 women were randomly assigned to fulvestrant n = 351 or exemestane n = 342 Approximately 60 % of patients had received at least two prior endocrine therapies Median TTP was 37 months in both groups hazard ratio = 0963 95 % CI 0819 to 1133 P = 6531 The overall response rate 74 % v 67 % P = 736 and clinical benefit rate 322 % v 315 % P = 853 were similar between fulvestrant and exemestane respectively Median duration of clinical benefit was 93 and 83 months respectively Both treatments were well tolerated with no significant differences in the incidence of adverse events or quality of life Pharmacokinetic data confirm that steady-state was reached within 1 month with the LD schedule of fulvestrant Fulvestrant LD and exemestane are equally active and well-tolerated in a meaningful proportion of postmenopausal women with ABC who have experienced progression or recurrence during treatment with a nonsteroidal AI\",\n",
            "}\n",
            "13692\n",
            "{\n",
            "  \"id\" : \"24666552\",\n",
            "  \"contents\" : \"Gastric cancer is a major contributor to cancer deaths in Zambia but as elsewhere no preventive strategies have been identified We set out to investigate the possibility of reducing gastric atrophy a premalignant lesion using micronutrient-antioxidant supplementation We analysed 215 archival samples from a randomised controlled trial of micronutrient-antioxidant supplementation carried out from 2003 to 2006 Participants were randomised to receive either the supplement or placebo and had been taking the allocated intervention for a mean of 18 range 14-27 months when the samples used in this study were taken We used low pepsinogen 1 to 2 PEP1 2 ratio as a surrogate marker of gastric atrophy A PEP 12 ratio of less than three was considered low HIV serology age nutritional status smoking alcohol intake and gastric pH were also analysed Ethical approval was obtained from the University of Zambia Biomedical Research Ethics Committee 011-04-12 The randomized trial was registered ISRCTN31173864 The overall prevalence of low PEP 12 ratio was 15/215 7 % and it did not differ between the placebo 8/103 78 % and micronutrient groups 7/112 63 % HR 124 95 % CI 047-3 3 P = 079 The presence of low PEP 12 ratio was not influenced by HIV infection HR 107 95 % CI 037-3 2 P = 089 or nutritional status but it inversely correlated with gastric pH Spearman s rho = -034 P = 00001 Age above 40 years was associated with atrophy but neither alcohol nor smoking had any influence Short term micronutrient supplementation does not have any impact on PEP 12 ratio a serological marker of gastric atrophy PEP 12 ratio inversely correlates with gastric pH\",\n",
            "}\n",
            "13693\n",
            "{\n",
            "  \"id\" : \"21029314\",\n",
            "  \"contents\" : \"To present long-term efficacy data of intravesical thermochemotherapy vs chemotherapy alone with mitomycin-C MMC randomly administered to patients with non-muscle-invasive bladder cancer NMIBC as an adjuvant treatment after complete transurethral resection In all 83 patients with intermediate - / high-risk NMIBC following complete transurethral resection were randomly assigned to receive either intravesical thermochemotherapy by means of Synergo Medical Enterprises Amsterdam The Netherlands or intravesical chemotherapy alone for prophylaxis of tumour recurrence Two doses of MMC 20 mg dissolved in 50 mL distilled water administered throughout two consecutive sessions was used as the chemotherapeutic agent in both arms In all 75 patients completed the original study 35 of 42 in the treatment arm 40 of 41 in the control arm whose results at minimum 2-year follow-up have already been published Recently the files of these patients have been updated for long-term outcome definition Data on general health follow-up examinations tumour relapse or progression and cause of death were collected and analysed Updated complete data collection was available for 65/75 87 % of the original patients The median follow-up for tumour-free patients was 91 months The 10-year disease-free survival rate for thermochemotherapy and chemotherapy alone were 53 % and 15 % respectively P < 0001 An intent-to-treat analysis performed to overcome the potential bias introduced by the asymmetrical discontinuation rate still showed a significant advantage of the active treatment over the control treatment Bladder preservation rates for thermochemotherapy and chemotherapy alone were 86 % and 79 % respectively This is the first analysis of long-term follow-up of patients treated with intravesical thermochemotherapy The high rate 53 % of patients who were tumour-free 10 years after treatment completion as well as the high rate 86 % of bladder preservation confirms the efficacy of this adjuvant approach for NMIBC at long-term follow-up even in patients with multiple tumours\",\n",
            "}\n",
            "13694\n",
            "{\n",
            "  \"id\" : \"25038914\",\n",
            "  \"contents\" : \"Introducing colonoscopy as part of colorectal cancer screening on a national level we aimed at evaluating the efficacy of the two most common bowel cleansing agents Moviprep and Phosphoral Secondly we evaluated the benefit for the patient and society in terms of sick leave and discomfort In a single-blinded randomized equivalence trial Phosphoral NaP was compared with Moviprep 2 l polyethylene glycol + ascorbic acid in patients undergoing colonoscopy due to suspicion of cancer Patients filled out questionnaires concerning stool consistency discomfort and number of sick days due to bowel cleansing Blinded colonoscopists estimated the efficiency of the cleansing using the validated Harefield Cleansing Scale Two hundred and sixty-six patients were included 250 of whom underwent full colonoscopy There was no difference in the percentage of acceptable bowel cleansings in the two groups however a significantly higher number of A scores were observed in the Moviprep group p = 0028 We found no correlation between stool consistency and outcome of the cleansing and no difference in subjective discomfort during cleansing Vomiting during cleansing occurred more often in the Phosphoral group p = 0002 There was a trend toward a smaller number of sick days in patients who used Moviprep compared with Phosphoral Moviprep and Phosphoral provided equally efficient bowel cleansing in 90 % of patients but Moviprep provided a higher quality of cleansings graded as successful The two agents were equally tolerated and no difference was found in the related number of sick days\",\n",
            "}\n",
            "13695\n",
            "{\n",
            "  \"id\" : \"12941676\",\n",
            "  \"contents\" : \"Estrogen therapy is known to prevent osteoporosis but studies have shown that conventional doses increase adverse events Whether lower doses one quarter of standard treatment prevent bone loss is not known To examine the effect of 3 years of treatment with 025 mg/d of micronized 17beta-estradiol on bone mineral density BMD and bone turnover in healthy older postmenopausal women Randomized double-blind placebo-controlled trial conducted from July 24 1998 through June 14 2002 at a university general clinical research center in the United States Healthy community-dwelling women N = 167 who were older than 65 years at enrollment Dosage of 025 mg/d of micronized 17beta-estradiol n = 83 or placebo n = 84 all women who had not had a hysterectomy received 100 mg/d of oral micronized progesterone for 2-week periods every 6 months The BMD of the hip spine wrist and total body measured annually for 3 years Serum and urine biochemical markers of bone resorption and formation and sex hormones were measured at baseline 3 months and during years 1 and 3 of treatment Mean BMD increased at all sites for participants taking low-dose estrogen 17beta-estradiol compared with placebo P < 001 Compared with participants receiving placebo participants taking low-dose estrogen had BMD increases of 26 % for the femoral neck 36 % total hip 28 % spine and 12 % total body Markers of bone turnover N-telopeptides of type 1 collagen and bone alkaline phosphatase decreased significantly P < 001 in participants taking low-dose estrogen compared with placebo Estradiol estrone and sex hormone-binding globulin levels increased in the estrogen-treated group compared with placebo The adverse effect profile was similar specifically there were no statistically significant differences in breast tenderness changes in endometrial thickness or pathological effects or annual mammographic results between the 2 groups The number of abnormal mammograms over 3 years was 15 for the low-dose estrogen group and 10 for the placebo group 8 occurred at baseline P = 26 There were no reports of breast cancer during the study In older women a dosage of 025 mg/d of 17beta-estradiol increased bone density of the hip spine and total body and reduced bone turnover with minimal adverse effects Future studies evaluating the effect of low-dose estrogen on fractures are indicated\",\n",
            "}\n",
            "13696\n",
            "{\n",
            "  \"id\" : \"20551726\",\n",
            "  \"contents\" : \"The treatment of chronic noncancer pain with chronic opioid therapy has increased rapidly but medicine residents receive little training concerning this therapy Therefore we conducted a trial to determine if an interactive web-based training focusing on shared decision-making for chronic opioid therapy improves knowledge and competence compared with exposure to practice guidelines A randomized controlled educational trial of 213 internal medicine residents from 5 medicine residencies participating in the Residency Review Committee for Internal Medicine s Educational Innovations Project comparing access to interactive web-based training COPE Collaborative Opioid Prescribing Education or access to the Veterans Affairs/Department of Defense Clinical Practice Guideline for the Management of Opioid Therapy for Chronic Pain Pretraining and immediate posttraining knowledge test pretraining and 60-day posttraining self-reported competence satisfaction patient-centeredness and selected clinical behaviors were analyzed using t tests Pearson chi and Generalized Estimating Equations The web training group had greater increase in knowledge with training chi 2 = 7206 P < 000001 and greater self-rated competence in the management of outpatients with chronic pain chi 2 = 648 P = 001 and specifically in the use of opioids in this management chi 2 = 517 P = 002 Residents in both groups reported more satisfaction with managing chronic pain care after training chi 2 = 5272 P < 00001 though the web training was superior on subscales concerning training adequacy chi 2 = 494 P = 0026 and relationship quality chi 2 = 579 P = 0016 Exposure to an interactive web-based training focused on shared decision-making and communication skills was more effective than exposure to compatible practice guidelines for knowledge and self-reported competence in the management of chronic noncancer pain\",\n",
            "}\n",
            "13697\n",
            "{\n",
            "  \"id\" : \"8349904\",\n",
            "  \"contents\" : \"Public skin cancer screening has become increasingly common in recent years However currently there is no standardized procedure for these screenings Full body skin examination as opposed to examination of sun-exposed areas offers several advantages including the opportunity to diagnose early melanoma in areas normally covered by clothing Disadvantages of full body skin examination include patient resistance because of inconvenience and concerns about privacy and modesty The additional time involved in full body skin examination may also be an impediment In a randomized double-armed study we studied whether patients were more likely to develop a positive attitude towards full body skin examination if they were advised beforehand in writing of the logic underlying the need for a complete examination Patients presenting to a public skin cancer screening were divided into two groups Group A N = 111 received a written explanation of the need for full body skin examination and Group B N = 175 received no information Patients were then surveyed after the screening about their attitudes towards full body skin examination Those who received pre-education were less likely P < 05 to be concerned about a genital examination Those who were concerned about a genital exam were compared with those who were not concerned about a genital exam the former patients were 1 younger P < 05 2 more concerned about privacy P < 001 and 3 preferred a physician of the same sex P < 001 Providing patients with information about the need for full body skin examination decreases concern about undergoing a skin genital exam and may minimize resistance to full body skin examination in public skin cancer screenings\",\n",
            "}\n",
            "13698\n",
            "{\n",
            "  \"id\" : \"23773411\",\n",
            "  \"contents\" : \"Addition of carbogen and nicotinamide hypoxia-modifying agents to radiotherapy improves the survival of patients with high risk bladder cancer The study investigated whether histopathological tumour features and putative hypoxia markers predicted benefit from hypoxia modification Samples were available from 231 patients with high grade and invasive bladder carcinoma from the BCON phase III trial of radiotherapy RT alone or with carbogen and nicotinamide RT+CON Histopathological tumour features examined were necrosis growth pattern growing margin and tumour/stroma ratio Hypoxia markers carbonic anhydrase-IX and glucose transporter-1 were examined using tissue microarrays Necrosis was the only independent prognostic indicator P = 004 Necrosis also predicted benefit from hypoxia modification Five-year overall survival was 48 % RT versus 39 % RT+CON P = 032 in patients without necrosis and 34 % RT versus 56 % RT+CON P = 0004 in patients with necrosis There was a significant treatment by necrosis strata interaction P = 0001 adjusted Necrosis was an independent predictor of benefit from RT+CON versus RT hazard ratio [ HR ] 043 95 % CI 025-0 73 P = 0002 This trend was not observed when there was no necrosis HR 164 95 % CI 095-2 85 P = 008 Necrosis predicts benefit from hypoxia modification in patients with high risk bladder cancer and should be used to select patients it is simple to identify and easy to incorporate into routine histopathological examination\",\n",
            "}\n",
            "13699\n",
            "{\n",
            "  \"id\" : \"11008323\",\n",
            "  \"contents\" : \"Glutathione has been shown to be an effective chemoprotector against cisplatin-induced side effects in patients with ovarian cancer In view of this fact we performed a randomized clinical pilot-trial in the management of other solid tumors in order to compare application of Glutathione to intensive hydration in patients undergoing chemotherapy with a regimen including cisplatin Twenty patients suffering from advanced non small cell lung cancer n = 6 or head - and neck cancer n = 14 were enrolled in the study All patients received 80 mg/m2 cisplatin along with etoposide or 5-fluorouracil every 4 weeks Patients randomized to application of Glutathione n = 11 received 5 g of Glutathione immediately before application of cisplatin followed by 2000 ml of normal saline Patients in the control group n = 9 received 2000 ml electrolyte infusion before and 2000 ml of normal saline with forced diuresis after cisplatin The intensity of hematologic toxicity was significantly less pronounced in patients treated with Glutathione than in the control group hemoglobin 107 vs 95 mg % respectively p = 0039 white blood cell count 33 vs 22 x 103/microliter respectively p = 0004 platelets 167 vs 95 x 103/microliter respectively p = 002 whereas in terms of non-hematologic toxicity no difference was observed Objective remission occurred in 6 out of 11 evaluable patients from the group receiving Glutathione 55 % complete remission 9 % partial remission 46 % and in 4 out of 8 evaluable patients from the control group partial remission 50 % However there was no statistical difference in terms of response and overall survival 135 months vs 105 months between the two groups Application of Cisplatin and Glutathione seems to be safe and feasible and the antitumoral efficacy of cisplatin is apparently not impaired by the concomitant use of Glutathione in patients with solid tumors\",\n",
            "}\n",
            "13700\n",
            "{\n",
            "  \"id\" : \"17392697\",\n",
            "  \"contents\" : \"To evaluate the feasibility and long-term compliance with a low-fat diet supplemented with soy protein in men at increased risk for recurrence after radical prostatectomy Randomized control study Academic center in USA Forty men who had undergone radical prostatectomy and were at increased risk for recurrence Low-fat 15 % fat high-fiber 18 g/1000 kcal diet supplemented with 40 g soy protein isolate n = 26 was compared to USDA recommended diet n = 14 Over 4 years subjects in the intervention group but not in the control group made and sustained significant changes in their diet as measured by the dietary assessment instruments and urinary isoflavone excretion In the intervention group dietary fat intake was reduced from 3346 + / -127 % energy/day to 2104 + / -174 % P < 005 fiber intake increased from 146 + / -106 to 2105 + / -229 g/day The insulin growth factor-1 IGF-1 level was decreased from 2604 + / -86 ng/ml at baseline to 2205 + / -79 ng/ml at 6 months P < 005 in the intervention group with no significant change in the control group An ex vivo assay demonstrated inhibition of LNCaP cell growth -200 + / -77 % P < 005 by sera from patients in the intervention group after 6 months of dietary change compared to baseline These data suggest that long-term low-fat dietary interventions as part of prospective randomized trials in prostate cancer survivors are feasible and lead to reductions in circulating hormones or other growth factors stimulating prostate cancer growth ex vivo\",\n",
            "}\n",
            "13701\n",
            "{\n",
            "  \"id\" : \"19114383\",\n",
            "  \"contents\" : \"Between September 2002 and February 2003 the authors assessed the effectiveness of a new age-tailored self-help smoking-cessation program for college students College student smokers N = 216 from 6 Ontario universities participated The researchers used a randomized controlled trial with a 3-month telephone follow-up Interventions included a new program Smoke | Quit the Canadian Cancer Society s self-help program and a usual care quit kit Intention-to-treat analysis of 7-day point prevalence cessation revealed quit rates of 114 % for Smoke | Quit 29 % for the Cancer Society s program and 56 % for the usual care intervention p < 05 Among nonquitters 465 % had made a quit attempt and weekly consumption decreased from 5401 to 4208 cigarettes p < 001 with no differences across interventions Making tailored self-help programs widely available on campus may be an effective way to provide smoking-cessation support to a large segment of the young adult population\",\n",
            "}\n",
            "13702\n",
            "{\n",
            "  \"id\" : \"16735709\",\n",
            "  \"contents\" : \"The European Organisation for Research and Treatment of Cancer and National Cancer Institute of Canada trial on temozolomide TMZ and radiotherapy RT in glioblastoma GBM has demonstrated that the combination of TMZ and RT conferred a significant and meaningful survival advantage compared with RT alone We evaluated in this trial whether the recursive partitioning analysis RPA retains its overall prognostic value and what the benefit of the combined modality is in each RPA class Five hundred seventy-three patients with newly diagnosed GBM were randomly assigned to standard postoperative RT or to the same RT with concomitant TMZ followed by adjuvant TMZ The primary end point was overall survival The European Organisation for Research and Treatment of Cancer RPA used accounts for age WHO performance status extent of surgery and the Mini-Mental Status Examination Overall survival was statistically different among RPA classes III IV and V with median survival times of 17 15 and 10 months respectively and 2-year survival rates of 32 % 19 % and 11 % respectively P < 0001 Survival with combined TMZ/RT was higher in RPA class III with 21 months median survival time and a 43 % 2-year survival rate versus 15 months and 20 % for RT alone P = 006 In RPA class IV the survival advantage remained significant with median survival times of 16 v 13 months respectively and 2-year survival rates of 28 % v 11 % respectively P = 0001 In RPA class V however the survival advantage of RT/TMZ was of borderline significance P = 054 RPA retains its prognostic significance overall as well as in patients receiving RT with or without TMZ for newly diagnosed GBM particularly in classes III and IV\",\n",
            "}\n",
            "13703\n",
            "{\n",
            "  \"id\" : \"22552359\",\n",
            "  \"contents\" : \"We compared the efficacy and safety of 1 - and 3-month depots of the luteinizing hormone-releasing hormone LH-RH agonist goserelin acetate in prostate cancer patients Patients were randomly assigned to the Direct Group that received the goserelin 3-month depot or the Switch Group that began with the 1-month depot for the first 3 months and then switched to the 3-month depot All patients were co-administered the antiandrogen agent bicalutamide Serum testosterone and prostate-specific antigen PSA levels and adverse events were recorded at weeks 4 8 12 and 24 Baseline testosterone levels in the Direct and Switch Groups were 498 and 507 ng/mL respectively P = 0798 At each week the levels in both groups were 050 ng/mL castration level with no significant differences between them All of the patients in the Switch Group and 981 % in the Direct Group had achieved castration levels at week 12 and 100 % had achieved such levels at week 24 Baseline PSA levels in the Direct and Switch Groups were 5237 and 4672 ng/mL respectively P = 0793 Levels in both groups dropped continuously to about 10 ng/mL at week 24 with no significant differences between the groups at any time Three patients in the Direct Group experienced adverse events that were attributed to the co-administered bicalutamide There was no difference in the efficacy or safety between the 1 - and 3-month depots of goserelin when given as initial prostate cancer treatment in combination with bicalutamide Patients must be monitored for adverse events associated with bicalutamide\",\n",
            "}\n",
            "13704\n",
            "{\n",
            "  \"id\" : \"22494623\",\n",
            "  \"contents\" : \"15-20 % of all patients initially diagnosed with colorectal cancer develop metastatic disease and surgical resection remains the only potentially curative treatment available Current 5-year survival following R0-resection of liver metastases is 28-39 % but recurrence eventually occurs in up to 70 % To date adjuvant chemotherapy has not improved clinical outcomes significantly The primary objective of the ongoing LICC trial L-BLP25 In Colorectal Cancer is to determine whether L-BLP25 an active cancer immunotherapy extends recurrence-free survival RFS time over placebo in colorectal cancer patients following R0/R1 resection of hepatic metastases L-BLP25 targets MUC1 glycoprotein which is highly expressed in hepatic metastases from colorectal cancer In a phase IIB trial L-BLP25 has shown acceptable tolerability and a trend towards longer survival in patients with stage IIIB locoregional NSCLC This is a multinational phase II multicenter randomized double-blind placebo-controlled trial with a sample size of 159 patients from 20 centers in 3 countries Patients with stage IV colorectal adenocarcinoma limited to liver metastases are included Following curative-intent complete resection of the primary tumor and of all synchronous/metachronous metastases eligible patients are randomized 21 to receive either L-BLP25 or placebo Those allocated to L-BLP25 receive a single dose of 300 mg/m2 cyclophosphamide CP 3 days before first L-BLP25 dose then primary treatment with sc L-BLP25 930 g once weekly for 8 weeks followed by sc L-BLP25 930 g maintenance doses at 6-week years 1 & 2 and 12-week year 3 intervals unless recurrence occurs In the control arm CP is replaced by saline solution and L-BLP25 by placebo Primary endpoint is the comparison of recurrence-free survival RFS time between groups Secondary endpoints are overall survival OS time safety tolerability RFS/OS in MUC-1 positive cancers Exploratory immune response analyses are planned The primary endpoint will be assessed in Q3 2016 Follow-up will end Q3 2017 Interim analyses are not planned The design and implementation of such a vaccination study in colorectal cancer is feasible The study will provide recurrence-free and overall survival rates of groups in an unbiased fashion EudraCT Number 2011-000218-20\",\n",
            "}\n",
            "13705\n",
            "{\n",
            "  \"id\" : \"16849748\",\n",
            "  \"contents\" : \"Previously we reported results of Intergroup N9741 which compared standard bolus fluorouracil FU leucovorin plus irinotecan IFL with infused FU leucovorin plus oxaliplatin FOLFOX4 and irinotecan plus oxaliplatin in patients with untreated metastatic colorectal cancer High rates of grade > or = 3 toxicity on IFL resulting in some deaths led us to reduce the starting doses of both irinotecan and FU by 20 % rIFL This article compares rIFL with FOLFOX4 The primary comparison was time to progression with secondary end points of response rate RR overall survival and toxicity Three hundred five patients were randomly assigned The North Central Cancer Treatment Group Data Safety Monitoring Committee interrupted enrollment at a planned interim analysis when outcomes crossed predetermined stopping boundaries The results were significantly superior for FOLFOX4 compared with rIFL for time to progression 97 v 55 months respectively P < 0001 RR 48 % v 32 % respectively P = 006 and overall survival 190 v 163 months respectively P = 026 Toxicity profiles were not significantly different between regimens for nausea vomiting diarrhea febrile neutropenia dehydration or 60-day all-cause mortality Sensory neuropathy and neutropenia were significantly more common with FOLFOX4 Approximately 75 % of patients in both arms received second-line therapy 58 % of rIFL patients received oxaliplatin-based second-line therapy and 55 % of FOLFOX4 patients received irinotecan-based regimens as second-line therapy FOLFOX4 led to superior RR time to progression and overall survival compared with rIFL The survival benefit for FOLFOX4 observed in the earlier stage of the study was preserved with equal use of either irinotecan or oxaliplatin as second-line therapy\",\n",
            "}\n",
            "13706\n",
            "{\n",
            "  \"id\" : \"24646327\",\n",
            "  \"contents\" : \"Extended systemic lymphadenectomy D2 is standard procedure for surgical treatment of advanced gastric cancer AGC although less extensive lymphadenectomy D1 can be applied to early gastric cancer Complete D2 lymphadenectomy is the mandatory procedure for studies that evaluate surgical treatment results of AGC However the actual extent of D2 lymphadenectomy varies among surgeons because of a lacking consensus on the anatomical definition of each lymph node station This study is aimed to develop a consensus for D2 lymphadenectomy and also to qualify surgeons that can perform both laparoscopic and open D2 gastrectomy This KLASS-02-QC is a prospective observational multicenter study to qualify the surgeons that will participate in the KLASS-02-RCT which is a prospective randomized clinical trial comparing laparoscopic and open gastrectomy for AGC Surgeons and reviewers participating in the study will be required to complete a questionnaire detailing their professional experience and specific gastrectomy surgical background/training and the gastrectomy metrics of their primary hospitals All surgeons must submit three laparoscopic and three open D2 gastrectomy videos respectively Each video will be allocated to five peer reviewers thus each surgeon s operations will be assessed by a total of 30 reviews Based on blinded assessment of unedited videos by experts review a separate review evaluation committee will decide whether or not the evaluated surgeon will participate in the KLASS-02-RCT The primary outcome measure is each surgeon s proficiency as assessed by the reviewers based on evaluation criteria for completeness of D2 lymphadenectomy We believe that our study for standardization of D2 lymphadenectomy and surgical quality control KLASS-02-QC will guarantee successful implementation of the subsequent KLASS-02-RCT study After making consensus on D2 lymphadenectomy we developed evaluation criteria for completeness of D2 lymphadenectomy We also developed a unique surgical standardization and quality control system that consists of recording unedited surgical videos and expert review according to evaluation criteria for completeness of D2 lymphadenectomy We hope our systematic approach will set a milestone in surgical standardization that is essential for surgical clinical trials Additionally our methods will serve as a novel system for educating surgeons and assessing surgical proficiency NCT01283893\",\n",
            "}\n",
            "13707\n",
            "{\n",
            "  \"id\" : \"21336679\",\n",
            "  \"contents\" : \"Obesity is characterized by chronic mild inflammation and may influence the risk and progression of cancer The current study is an exploratory analysis of the effect of a weight loss intervention that emphasized increased physical activity on inflammatory cytokines tumor necrosis factor - [ TNF - ] interleukin-6 [ IL-6 ] interleukin-8 [ IL-8 ] and vascular endothelial growth factor [ VEGF ] at the end of the 16-week intervention period in overweight breast cancer survivors Study participants averaged 56 years of age N = 68 Intervention participants n = 44 vs 24 controls participated in a cognitive behavioral therapy-based weight management program as part of an exploratory randomized trial The intervention incorporated strategies to promote increased physical activity and diet modification Baseline and 16-week data included height weight body composition physical activity level and biomarkers IL-6 IL-8 TNF - and VEGF Weight loss was significantly greater in the intervention group than controls -57 [ 35 ] vs 02 [ 41 ] kg P < 0001 Paired t tests noted favorable changes in physical activity level P < 0001 intervention P = 070 control marginally lower IL-6 levels P = 006 intervention P = 025 control at 16 weeks for participants in the intervention group and lower TNF - levels for participants in the intervention P < 005 and control groups P < 0001 Increased physical activity was associated with favorable changes in IL-6 for participants in the intervention group R 2 = 018 P < 003 Favorable changes in cytokine levels were observed in association with weight loss in this exploratory study with overweight breast cancer survivors\",\n",
            "}\n",
            "13708\n",
            "{\n",
            "  \"id\" : \"18646345\",\n",
            "  \"contents\" : \"African American men have a significantly higher incidence of prostate cancer are diagnosed at younger ages and more advanced stages and have higher mortality rates from prostate cancer than do White men This community-based intervention study employed a quasiexperimental delayed-control crossover design with randomization at the church level Forty-five African American churches were randomly assigned to two study groups early intervention and delayed intervention A convenience sample of 430 African American male volunteers ages 40-70 was enrolled through the churches and 350 men remained in the study through wave 3 The intervention was a culturally tailored group educational program which included a video and a question-and-answer session with an African American physician Within each group knowledge perceived threat and screening prevalence all increased significantly However the magnitude of increases was similar so the groups did not differ significantly at wave 2 Knowledge at wave 2 was associated with greater odds of having a digital rectal exam by wave 3 only for the early-intervention group The early-intervention group was two times more likely to have talked to a physician about prostate cancer screening by wave 3 The findings suggest that the delayed-intervention group did not function as a pure control and may have unintentionally received a partial intervention This finding demonstrated that a low-cost prostate cancer awareness campaign within a church may be enough to affect prostate cancer knowledge attitudes and behaviors among African American men Further research should examine the church-specific intervention elements cultural appropriateness of the messages and whether group sessions provide additional effect\",\n",
            "}\n",
            "13709\n",
            "{\n",
            "  \"id\" : \"9920950\",\n",
            "  \"contents\" : \"For small-cell lung cancer confined to one hemithorax limited small-cell lung cancer thoracic radiotherapy improves survival but the best ways of integrating chemotherapy and thoracic radiotherapy remain unsettled Twice-daily accelerated thoracic radiotherapy has potential advantages over once-daily radiotherapy We studied 417 patients with limited small-cell lung cancer All the patients received four 21-day cycles of cisplatin plus etoposide We randomly assigned these patients to receive a total of 45 Gy of concurrent thoracic radiotherapy given either twice daily over a three-week period or once daily over a period of five weeks Twice-daily treatment beginning with the first cycle of chemotherapy significantly improved survival as compared with concurrent once-daily radiotherapy P = 004 by the log-rank test After a median follow-up of almost 8 years the median survival was 19 months for the once-daily group and 23 months for the twice-daily group The survival rates for patients receiving once-daily radiotherapy were 41 percent at two years and 16 percent at five years For patients receiving twice-daily radiotherapy the survival rates were 47 percent at two years and 26 percent at five years Grade 3 esophagitis was significantly more frequent with twice-daily thoracic radiotherapy occurring in 27 percent of patients as compared with 11 percent in the once-daily group P < 0001 Four cycles of cisplatin plus etoposide and a course of radiotherapy 45 Gy given either once or twice daily beginning with cycle 1 of the chemotherapy resulted in overall two - and five-year survival rates of 44 percent and 23 percent a considerable improvement in survival rates over previous results in patients with limited small-cell lung cancer\",\n",
            "}\n",
            "13710\n",
            "{\n",
            "  \"id\" : \"7921938\",\n",
            "  \"contents\" : \"To determine the response of a marker tumour to a single instillation of intravesical epirubicin Eighty-one patients 54 men 27 women with a mean age of 693 years range 36-92 with superficial bladder cancer were randomized to receive a single instillation of intravesical epirubicin At the initial cystoscopy all but one papillary marker tumour was resected Subsequently the patients were randomized to receive either intravesical epirubicin at a concentration of 1 mg/ml n = 40 or 2 mg/ml n = 41 in 50 ml of saline for 1 hThe response of the marker tumour was determined at 3 months first check cystoscopy The toxicity associated with both treatments was also recorded A complete response no visible or microscopic bladder carcinoma was observed in 46 % 95 % confidence interval CI 35-57 % of patients No patient experienced systemic side-effects Chemical cystitis and bladder irritability were the most frequent local side-effects occurring in 15 % 95 % CI 8-24 % of the patients A single instillation of intravesical epirubicin has a demonstrable effect in superficial bladder cancer The results compare favourably with more onerous regimes Side-effects were minimal at 1 mg/ml and acceptable at 2 mg/ml\",\n",
            "}\n",
            "13711\n",
            "{\n",
            "  \"id\" : \"21831719\",\n",
            "  \"contents\" : \"Symptomatic brain metastases BM frequently occurs after initial treatment of non-small-cell lung cancer NSCLC Therefore 2 large randomized trials that involved pemetrexed were retrospectively analyzed to determine the pattern of symptomatic relapse in the brain and to gauge if pemetrexed could influence the incidence Two large phase III studies of pemetrexed in advanced NSCLC were included One study compared pemetrexed with docetaxel in previously treated patients n = 571 the other study tested cisplatin plus pemetrexed vs cisplatin plus gemcitabine in chemotherapy-naive patients with advanced NSCLC n = 1725 Patients with known BM at study entry were excluded from this analysis Each study was analyzed separately then jointly to determine the rate of BM reported as the only site of progressive disease by treatment group and histology Logistic regression was used to obtain an odds ratio for the treatment effect on the overall occurrence of BM while controlling for potential confounding factors Overall 715 % of patients in pemetrexed-containing arms 819 of 1145 and 682 % of patients in non-pemetrexed-containing arms 785 of 1151 experienced progressive disease BM recurrence rates were 32 % 95 % confidence interval [ CI ] 21 % -46 % in the pemetrexed-containing arms vs 66 % 95 % CI 50 % -86 % in the non-pemetrexed-containing arms P = 002 The odds ratio for BM recurrence associated with exposure to pemetrexed was 049 95 % CI 032-0 76 P = 001 The beneficial effect of pemetrexed on BM was confined to patients with nonsquamous NSCLC Patients with advanced nonsquamous NSCLC treated with pemetrexed either in first-line or second-line therapy may reduce the risk of developing BM as the first site of progressive disease This retrospective analysis is limited due to the lack of baseline and periodic brain scans and it reflects symptomatic BM only Regardless these findings suggest a potential beneficial effect of pemetrexed-based treatments on the control of BM\",\n",
            "}\n",
            "13712\n",
            "{\n",
            "  \"id\" : \"20598849\",\n",
            "  \"contents\" : \"One potential agent to improve symptoms and quality of life QoL in advanced cancer patients is adenosine 5 - triphosphate ATP Several reports suggest that ATP may positively affect QoL and survival in patients with advanced non-small-cell lung cancer To investigate the effects of ATP infusions on QoL parameters in patients with preterminal cancer of mixed tumor types Ninety-nine preterminal cancer patients were randomly allocated to receive either ATP intravenously weekly 8-10 hours/week with maximum 50 g/kg minute for eight weeks or receive no ATP control group QoL parameters were assessed until eight weeks and analyzed by repeated-measures analysis of covariance Fifty-one patients were randomized to the ATP group and 48 to the control group Unexpectedly in the untreated control group most of the outcome parameters did not deteriorate but remained stable or even significantly improved over time Between the ATP and control groups no statistically significant differences were observed for the large majority of outcome parameters except for the strength of elbow flexor muscles in favor of the control group ATP infusions at the dose and schedule studied did not have a significant effect on QoL functional status or fatigue in preterminal cancer patients of mixed tumor types\",\n",
            "}\n",
            "13713\n",
            "{\n",
            "  \"id\" : \"18341378\",\n",
            "  \"contents\" : \"The aim of present study was to investigate the cytoprotective effect of amifostine on salivary glands in 131I-treated differentiated thyroid cancer DTC patients using serial quantitative analysis of salivary gland scans Serial quantitative salivary scintigraphies were performed in 80 newly diagnosed DTC patients 9 men 71 women mean age 432 years old range 21-58 years old Forty-two patients were assigned randomly to the amifostine treatment group which received 300 mg/m2 amifostine intravenously before 131I administration In both amifostine-treated and nontreated groups statistically significant declines of functional parameters after 131I treatment were revealed by quantitative salivary scintigraphy in DTC patients Amifostine pretreatment did not prevent the parenchymal damage to major salivary gland function after 131I treatment F = 137 p = 02461 However the dose of 131I had significant effects on salivary gland function after 131I treatment F = 972 p = 00002 The present study did not show cytoprotective effects of amifostine for DTC patients treated with 131I\",\n",
            "}\n",
            "13714\n",
            "{\n",
            "  \"id\" : \"17986289\",\n",
            "  \"contents\" : \"To evaluate in a long-term follow-up of T1 high-grade bladder cancer treated in a prospective randomized trial whether fluorescence diagnosis FD increases recurrence-free survival RFS or reduces progression to muscle-invasive stages In all 191 patients with suspected superficial bladder cancer were treated with transurethral resection under white light WL or with FD 46 presented with initial T1 high-grade BC WL 25 FD 21 There were no differences in multifocality of tumours concomitant carcinoma in situ or tumour size in either group Patients were followed for a median of 73 WL and 75 FD years to evaluate RFS In the WL group there were 11 and in the FD group three recurrent tumours of the same stage and grade The RFS at 4 and 8 years was 69 % and 52 % in the WL and 91 % and 80 % in FD group respectively With FD the RFS was significantly longer according to Kaplan-Meier analysis P = 0025 In the WL group three 12 % and in the FD group four 19 % patients progressed to muscle-invasive stages > or = T2 In initial T1 high-grade bladder cancer FD is significantly better than conventional WL transurethral resection for RFS However the progression rate to muscle-invasive disease was not reduced by FD Thus the clinical course progression of T1 high-grade bladder cancer remains unaffected by FD\",\n",
            "}\n",
            "13715\n",
            "{\n",
            "  \"id\" : \"17991659\",\n",
            "  \"contents\" : \"Higher circulating insulin-like growth factor I IGF-I concentrations have been related to a greater risk of cancer Lycopene intake is inversely associated with cancer risk and experimental studies have shown that it may affect the IGF system possibly through an effect on IGF-binding proteins IGFBPs The objective of our study was to investigate the effect of an 8-wk supplementation with tomato-derived lycopene 30 mg/d on serum concentrations of total IGF-I IGF-II IGFBP-1 IGFBP-2 and IGFBP-3 We conducted a randomized placebo-controlled double-blinded crossover study in 40 men and 31 postmenopausal women with a family history of colorectal cancer a personal history of colorectal adenoma or both Lycopene supplementation significantly P = 001 increased serum IGFBP-1 concentrations in women median relative difference between serum IGFBP-1 concentrations after lycopene supplementation and after placebo 217 % Serum IGFBP-2 concentrations were higher in both men and women after lycopene supplementation than after placebo but to a lesser extent mean relative difference 82 % 95 % CI 07 % 156 % in men and 78 % 95 % CI -50 % 206 % in women Total IGF-I IGF-II and IGFBP-3 concentrations were not significantly altered by lycopene supplementation This is the first study known to show that lycopene supplementation may increase circulating IGFBP-1 and IGFBP-2 concentrations Because of high interindividual variations in IGFBP-1 and IGFBP-2 effects these results should be confirmed in larger randomized intervention studies\",\n",
            "}\n",
            "13716\n",
            "{\n",
            "  \"id\" : \"24652690\",\n",
            "  \"contents\" : \"This multicentre international randomized trial compared the impact of gadoxetic acid-enhanced magnetic resonance imaging MRI MRI with extracellular contrast medium ECCM-MRI and contrast-enhanced computed tomography CE-CT as a first-line imaging method in patients with suspected colorectal cancer liver metastases CRCLM Between October 2008 and September 2010 patients with suspected CRCLM were randomized to one of the three imaging modalities The primary endpoint was the proportion of patients for whom further imaging after initial imaging was required for a confident diagnosis Secondary variables included confidence in the therapeutic decision intraoperative deviations from the initial imaging-based surgical plan as a result of additional operative findings and diagnostic efficacy of the imaging modalities versus intraoperative and pathological extent of the disease A total of 360 patients were enrolled Efficacy was analysed in 342 patients 118 112 and 112 with gadoxetic acid-enhanced MRI ECCM-MRI and CE-CT respectively as the initial imaging procedure Further imaging was required in 0 of 118 19 170 per cent of 112 and 44 393 per cent of 112 patients respectively P < 0001 Diagnostic confidence was high or very high in 983 per cent of patients for gadoxetic acid-enhanced MRI 857 per cent for ECCM-MRI and 652 per cent for CE-CT Surgical plans were changed during surgery in 28 32 and 47 per cent of patients in the respective groups The diagnostic performance of gadoxetic acid-enhanced MRI was better than that of CE-CT and ECCM-MRI as the initial imaging modality No further imaging was needed in the gadoxetic acid-enhanced MRI group and comparison of diagnostic efficacy parameters demonstrated the diagnostic superiority of gadoxetic acid-enhanced MRI NCT00764621 http//clinicaltrialsgov EudraCT number 2008-000583-16 https//eudractemaeuropaeu/\",\n",
            "}\n",
            "13717\n",
            "{\n",
            "  \"id\" : \"8381164\",\n",
            "  \"contents\" : \"The importance of the timing of thoracic irradiation TI in the combined modality therapy of limited-stage small-cell lung cancer SCLC was assessed in a randomized trial All 308 eligible patients received cyclophosphamide doxorubicin and vincristine CAV alternating with etoposide and cisplatin EP every 3 weeks for three cycles of each chemotherapy regimen Patients randomized to early TI received 40 Gy in 15 fractions over 3 weeks to the primary site concurrent with the first cycle of EP week 3 and late TI patients received the same radiation concurrent with the last cycle of EP week 15 After completion of all chemotherapy and TI patients without progressive disease received prophylactic cranial irradiation 25 Gy in 10 fractions over 2 weeks Although complete remission rates were not significantly different between the two arms progression-free survival P = 036 and overall survival P = 008 were superior in the early TI arm Patients in the late TI arm had a higher risk of brain metastases P = 006 The early administration of TI in the combined modality therapy of limited-stage SCLC is superior to late or consolidative TI\",\n",
            "}\n",
            "13718\n",
            "{\n",
            "  \"id\" : \"15351581\",\n",
            "  \"contents\" : \"To determine the effects of diets rich in soy and linseed compared with a control diet on biochemical markers of prostate cancer in men diagnosed with prostate cancer Twenty-nine men diagnosed with prostate cancer and scheduled to undergo a radical prostatectomy were randomized to one of three groups soy high phytoestrogen soy and linseed high phytoestrogen or wheat low phytoestrogen A bread was specially manufactured to incorporate 50 g of heat-treated HT soy grits or 50 g of HT soy grits and 20 g of linseed as part of the study participant s daily diet Baseline and preoperative levels of prostate-specific antigen PSA free PSA testosterone sex hormone-binding globulin free androgen index and dihydrotestosterone were measured Statistically significant differences were detected between the HT soy grits group and the control wheat group for the percentage of change in total PSA -127 % versus 40 % P = 002 and the percentage of change in free/total PSA ratio 274 % versus -156 % P = 001 and between the HT soy grits group and the HT soy grits and linseed group for the percentage of change in free androgen index 164 % versus -155 % P = 004 and the percentage of change in free/total PSA ratio 274 % versus -10 % P = 0007 The data from this study indicate that a daily diet containing four slices of a bread rich in HT soy grits favorably influences the PSA level and the free/total PSA ratio in patients with prostate cancer This work provides some evidence to support epidemiologic studies claiming that male populations who consume high phytoestrogen diets have a reduced risk of prostate cancer development and progression\",\n",
            "}\n",
            "13719\n",
            "{\n",
            "  \"id\" : \"25095718\",\n",
            "  \"contents\" : \"Cholangiocellular carcinoma is the second most common primary liver cancer after hepatocellular carcinoma Over the last 30years the incidence of intrahepatic cholangiocellular carcinoma has risen continuously worldwide Meanwhile the intrahepatic cholangiocellular carcinoma has become more common than the extrahepatic growth type and currently accounts for 10-15 % of all primary hepatic malignancies Intrahepatic cholangiocellular carcinoma is typically diagnosed in advanced stages due to late clinical symptoms and an absence of classic risk factors A late diagnosis precludes curative surgical resection There is evidence that transarterial chemoembolization leads to better local tumor control and prolongs survival compared to systemic chemotherapy New data indicates that selective internal radiotherapy also referred to as radioembolization provides promising results for treating intrahepatic cholangiocellular carcinoma This pilot study is a randomized controlled single center phase II trial Twenty-four patients with intrahepatic cholangiocellular carcinoma will be randomized in a 11 ratio to receive either chemoembolization or radioembolization Randomization will be stratified according to tumor load Progression-free survival is the primary endpoint overall survival and time to progression are secondary endpoints To evaluate treatment success patients will receive contrast enhanced magnetic resonance imaging every 3months Currently chemoembolization is routinely performed in many centers instead of systemic chemotherapy for treating intrahepatic cholangiocellular carcinoma confined to the liver Recently radioembolization has been increasingly applied to cholangiocellular carcinoma as second line therapy after TACE failure or even as an alternative first line therapy Nonetheless no randomized studies have compared radioembolization and chemoembolization Considering all this background information we recognized a strong need for a randomized controlled trial RCT to compare the two treatments Therefore the present protocol describes the design of a RCT that compares SIRT and TACE as the first line therapy for inoperable CCC confined to the liver ClinicalTrialsgov Identifier NCT01798147 registered 16th of February 2013\",\n",
            "}\n",
            "13720\n",
            "{\n",
            "  \"id\" : \"16375040\",\n",
            "  \"contents\" : \"The incidence of skin cancer is rising in many populations around the world In Australia men have both the highest incidence of thick melanoma and an increased risk of dying from this disease Skin screening may provide a method for detecting lesions at an earlier stage This study sought to assess the impact of two methods of encouraging men to attend free open-access skin screening clinics A randomised controlled trial of two recruitment methods Subjects comprised all men aged 30 to 79 years n = 1322 from a rural community We randomly allocated 50 % 661 to receive a personalised letter with the remaining 50 % receiving the letter plus an additional brochure Both groups were similar in age distribution A total of 250 men 189 % attended the skin screening clinic Overall there was no difference in rates of attendance between the two groups Younger men 30 to 49 years in the letter and brochure group were more likely to attend a clinic while men > or = 50 years in the letter only group were more likely to attend p = 001 These results indicate that a personalised letter or targeted approach of invitation is effective in encouraging men to attend a skin screening clinic The addition of health information through the use of a glossy brochure did not increase screening participation among men over 50\",\n",
            "}\n",
            "13721\n",
            "{\n",
            "  \"id\" : \"20952020\",\n",
            "  \"contents\" : \"We assessed the cardiovascular safety profile of degarelix a new gonadotropin-releasing hormone antagonist This is the first report to our knowledge on cardiovascular safety data from a completed 1-year randomized controlled trial of leuprolide acetate vs degarelix Outcomes considered in these analyses included the QT interval by central reading and analysis and cardiovascular adverse events On multivariate analyses relationships between selected baseline factors and cardiovascular events were evaluated There were no significant differences between treatment groups for mean change in Fridericia s correction of QT during the trial Markedly abnormal Fridericia s correction of QT values 500 milliseconds or greater were observed in only a small number of subjects by treatment group that is 2 less than 1 % in the pooled degarelix group and 2 1 % in the leuprolide group Supraventricular arrhythmias were the most common type of arrhythmias affecting 2 % of subjects in the pooled degarelix group and 4 % in the leuprolide group Other arrhythmias occurred in 1 % or less of subjects by treatment group The most frequently reported cardiac disorder was ischemic heart disease which occurred in 4 % of subjects treated with degarelix and 10 % of those on leuprolide Cox proportional hazard ratio estimates for selected baseline covariates showed a significantly increased risk of cardiovascular events by age p = 00459 and systolic blood pressure p = 00061 In men with prostate cancer degarelix and leuprolide have similar cardiovascular safety profiles These observations suggest that the cardiovascular events associated with both agents result from hypogonadism rather than a direct drug effect\",\n",
            "}\n",
            "13722\n",
            "{\n",
            "  \"id\" : \"10071295\",\n",
            "  \"contents\" : \"To evaluate alternative automated methods of collecting data on quality of life QOL in cancer patients After initial evaluation of a range of technologies we compared computer touch-screen questionnaires with paper questionnaires scanned by optical reading systems in terms of patients acceptance data quality and reliability In a randomized cross-over trial 149 cancer patients completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 version 20 EORTC QLQ-C30 and the Hospital Anxiety and Depression Scale HADS on paper and on a touch screen In a further test-retest study 81 patients completed the electronic version of the questionnaires twice with a time interval of 3 hours between questionnaires Fifty-two percent of the patients preferred the touch screen to paper 24 % had no preference The quality of the data collected with the touch-screen system was good with no missed responses At the group level the differences between scores obtained with the two modes of administration of the instruments were small suggesting equivalence for most of the QOL scales with the possible exception of the emotional fatigue and nausea/vomiting scales and the appetite item where patients tended to give more positive responses on the touch screen At the individual patient level the agreement was good with a kappa coefficient from 057 to 077 and percent global agreement from 61 % to 97 % The electronic questionnaire had good test-retest reliability with correlation coefficients between the two administrations from 078 to 095 kappa coefficients of agreement from 055 to 090 and percent global agreement from 56 % to 100 % Computer touch-screen QOL questionnaires were well accepted by cancer patients with good data quality and reliability\",\n",
            "}\n",
            "13723\n",
            "{\n",
            "  \"id\" : \"17071935\",\n",
            "  \"contents\" : \"Triplet regimens were occasionally reported to produce a higher response rate RR than doublets in locally advanced or metastatic non-small-cell lung cancer NSCLC This trial was conducted to assess i whether the addition of cisplatin CDDP to either gemcitabine GEM and vinorelbine VNR or GEM and paclitaxel PTX significantly prolongs overall survival OS and ii to compare the toxicity of PTX-containing and VNR-containing combinations Stage III or IV NSCLC patients were randomly assigned to i GEM 1000 mg/m 2 and VNR 25 mg/m 2 on days 1 and 8 GV arm ii GEM 1000 mg/m 2 and PTX 125 mg/m 2 on days 1 and 8 GT arm iii GV plus CDDP 50 mg/m 2 on days 1 and 8 PGV arm and iv GT plus CDDP 50 mg/m 2 on days 1 and 8 PGT arm Treatments were repeated every 3 weeks for a maximum of six cycles A total of 433 stage III 160 stage IV 273 patients were randomly allocated to the study RR was 48 % [ 95 % confidence interval CI 42 % to 54 % ] for triplets and 35 % 95 % CI 32 % to 38 % for doublets P = 0004 Median progression-free survival 61 versus 55 months P = 0706 and median OS 107 versus 105 months P = 0379 were similar CDDP significantly increased the occurrence of severe neutropenia 35 % versus 13 % thrombocytopenia 14 % versus 4 % anaemia 9 % versus 3 % vomiting 6 % versus 05 % and diarrhoea 6 % versus 2 % Conversely frequency of severe neutropenia 30 % versus 17 % and thrombocytopenia 11 % versus 6 % was significantly higher with VNR-containing regimens Adding CDDP to GV or GT significantly increased RR but did not prolong the OS of patients Among doublets the GT regimen should be preferred in view of its better safety profile\",\n",
            "}\n",
            "13724\n",
            "{\n",
            "  \"id\" : \"14637388\",\n",
            "  \"contents\" : \"Randomised trials on breast cancer showed no significant benefit from post-operative follow-up with clinical and/or conventional radiological means We hypothesised that carcinoembryonic antigen CEA tissue polipeptyde antigen TPA breast cancer associated antigen 115 D8/DF3 CA15 3 tumour marker panel is sensitive enough for significantly anticipating salvage treatment and prolonging survival of relapsing breast cancer patients From October 1981 to May 1999 68 62 % of 109 patients with distant metastases were recruited Thirty-six 53 % received salvage treatment at the time of significant increase in one or more components of CEA-TPA-CA15 3 tumour marker panel and negative instrumental examinations tumour marker guided treatment and 32 47 % were treated only after radiological confirmation of metastases conventional treatment The prognostic factors of the two groups did not show any statistically significant difference The time from one or more tumour marker increase to clear clinical and/or radiological signs of distant metastases lead time was significantly prolonged in the 36 patients with tumour marker guided treatment 173 + / - 131 vs 29 + / - 29 months P < 0001 Wilcoxon test as well as the survival curves from salvage therapy and from mastectomy the proportion of survivors was at 36 months from salvage therapy 28 % vs 9 % P = 00094 at 84 months from mastectomy 42 % vs 19 % P = 00017 The multivariate Cox analysis showed that time from mastectomy to tumour marker increase and tumour marker guided salvage treatment were the only significantly different variables P = 000001 and 0005 respectively These data point out that tumour marker guided salvage treatment significantly prolongs disease-free and overall survivals of relapsing responsive patients\",\n",
            "}\n",
            "13725\n",
            "{\n",
            "  \"id\" : \"23032742\",\n",
            "  \"contents\" : \"The progressive immune dysfunctions that occur in patients with advanced melanoma make them unlikely to efficiently respond to cancer vaccines A multicenter randomized phase II trial was conducted to test whether immunization with modified HLA class I tumor peptides in the context of adjuvant therapy results in better immunologic responses and improved clinical outcomes in patients with early melanoma stages IIB/C-III Forty-three patients were enrolled to undergo vaccination n = 22 or observation n = 21 The vaccine included four HLA-A * 0201-restricted modified peptides Melan-A/MART -1 [ 27L ] gp100 [ 210M ] NY-ESO-1 [ 165V ] and Survivin [ 97M ] emulsified in Montanide ISA51 and injected subcutaneously in combination with cyclophosphamide 300 mg/m 2 and low-dose IL-2 3 10 6 IU The immune responses were monitored using ex vivo IFN -- ELISpot HLA/multimer staining and in vitro short-term peptide sensitization assays Vaccination induced a rapid and persistent increase in specific effector memory CD8 + T cells in 75 % of the patients However this immunization was not associated with any significant increase in disease-free or overall survival as compared with the observation group An extensive immunologic analysis revealed a significantly reduced cross-recognition of the corresponding native peptides and most importantly a limited ability to react to melanoma cells Adjuvant setting is an appealing approach for testing cancer vaccines because specific CD8 + T cells can be efficiently induced in most vaccinated patients However the marginal antitumor activity of the T cells induced by modified peptides in this study largely accounts for the observed lack of benefit of vaccination These findings suggest reconsidering this immunization strategy particularly in early disease\",\n",
            "}\n",
            "13726\n",
            "{\n",
            "  \"id\" : \"25811573\",\n",
            "  \"contents\" : \"Placement of a totally implantable venous access device in children with cancer often leads to hypertrophic scars after its removal This study investigates whether the use of silicone gel sheets has a beneficial effect on scar outcome in children with cancer In a three-arm randomized controlled trial the effects of use of silicone gel sheets for 2 and 6 months were assessed and compared with no intervention in children with cancer after removal of the totally implantable venous access device Silicone gel sheets were first administered 14 days after surgery The 1-year follow-up included measurements at seven time points Next to scar size assessment the modified Vancouver Scar Scale was used to assess scar outcome Thirty-six children participated For hypertrophy no significant differences were found between the two intervention groups and the control group However at 1-year follow-up the 2-month application group showed significantly smaller scars compared with the group receiving silicone gel sheet treatment for 6 months p = 004 but not when compared with the control group p = 022 Longitudinal multilevel analyses could not confirm these findings and showed no significant intervention effects on both outcomes This study provides no strong evidence to support the use of silicone gel sheets after totally implantable venous access device removal in children with cancer There seems to be a small benefit for scar width with application for 2 months However for hypertrophy the scar outcome shows no significant difference between the control group and the 2-month and 6-month treatment groups\",\n",
            "}\n",
            "13727\n",
            "{\n",
            "  \"id\" : \"22559752\",\n",
            "  \"contents\" : \"The aim of this study was to evaluate the cost-utility of Docetaxel with doxorubicin and cyclophosphamide TAC and 5-fluorouracil doxorubicin cyclophosphamide FAC in node-positive breast cancer patients in the south of Iran A double blind study was done on a cohort of 100 patients suffering from breast cancer with node-positive over 8 months in the radiotherapy center of Namazi hospital Shiraz-Iran Health-related quality of life was assessed using questionnaire QLQ-C30 from European Organization for Research and Treatment of Cancer EORTC QLQ-C30 scale scores were mapped to 15D and EuroQol 5D utilities to measure the quality-adjusted life-years QALYs Third party payer point of view was applied to measure and value the cost of treatments Cost data were extracted from hospital and health insurance organizations Robustness of the results was checked through a two way sensitivity analysis TAC was associated with higher deterioration in HRQoL during treatment and higher improvements over 4 months follow-up On average the cost of treatment per patient in TAC was 15 times higher than FAC p < 001 In overall TAC was resulted in lower QALYs and higher cost over study period FAC was a dominant option versus TAC in short-term The higher improvement in HRQoL over follow-up in TAC may not compensate the more intensive deterioration caused during treatment in short-term The short time horizon of study may limit the generalizability of our findings and hence there is a need to conduct long-term economic evaluation studies whenever data is available to inform decision making\",\n",
            "}\n",
            "13728\n",
            "{\n",
            "  \"id\" : \"15519794\",\n",
            "  \"contents\" : \"To study whether orgotein is effective in preventing late radiation-induced effects Patients > 18 years old who were diagnosed with rectal cancer had an indication for pelvic irradiation RT after surgery and complied with the selection criteria were randomly assigned at the end of RT to receive orgotein for 7 weeks or no treatment control The Radiation Therapy Oncology Group toxicity scale was used to evaluate the RT-induced side effects for up to 2 years Interruptions due to toxicity concomitant medication and non-RT adverse events were also recorded A total of 100 patients were included with 50 in each group The groups were comparable in terms of the demographic and baseline characteristics The orgotein group had statistically significant less late toxicity than the control group p = 0036 and nontreated patients had a 66 % greater chance of developing late toxicity at 2 years Grouping toxicity as nonrelevant Radiation Therapy Oncology Group Grade 0-1 and relevant Grade 2 or worse patients given orgotein had a lower incidence of late relevant toxicity than did controls with statistical significance reached at all follow-up visits After 2 years patients not treated with orgotein had in general a 37 % greater chance of developing late relevant toxicity this risk was 26 % when referring specifically to GI toxicity No adverse events attributable to orgotein were recorded at any time during the study Orgotein is a safe treatment that significantly prevents the overall occurrence of late toxicity with toxicity reduction particularly evident in the lower GI tract\",\n",
            "}\n",
            "13729\n",
            "{\n",
            "  \"id\" : \"16788341\",\n",
            "  \"contents\" : \"The classic posterior approach of superior hypogastric block has several technical difficulties The transdiscal approach is a novel and easier approach for superior hypogastric which overcome these technical difficulties Thirty patients were randomly allocated to two groups The transdiscal group and the classic group visual analog scale pain scores daily morphine consumption duration of the procedure and side effects were recorded The duration of the procedure was significantly decreased in the transdiscal group 244 + / -56 min compared to the classic group 579 + / -98 min There were no significant differences between the 2 groups in daily morphine consumption and VAS pain scores There was no discitis disc rupture or herniation in the transdiscal group The transdiscal approach for superior hypogastric plexus block in pelvic cancer pain is easier safer and more effective with less side effects than the classic approach\",\n",
            "}\n",
            "13730\n",
            "{\n",
            "  \"id\" : \"25262164\",\n",
            "  \"contents\" : \"We conducted a phase III randomized controlled trial RCT to investigate the efficacy of postsurgical adjuvant immunotherapy combined with chemotherapy The immunotherapy targets were residual micrometastases and clones resistant to chemotherapy Between April 2007 and July 2012 103 postsurgical non-small cell lung cancer patients were randomly assigned to receive either chemo-immunotherapy group A or chemotherapy group B The immunotherapy consisted of the adoptive transfer of autologous activated killer T cells and dendritic cells obtained from the lung cancer patients own regional lymph nodes The 2-year overall survival rates in groups A and B were 934 and 660 % and the 5-year rates were 814 and 483 % respectively The differences were statistically significantly better in group AThe hazard ratio HR was 0229 p = 00013 The 2 - and 5-year recurrence-free survival rates were 685 414 and 568 262 % in groups A and B respectively Those differences were also statistically significant log-rank test p = 00020 The HR was 0423 p = 00027 in favor of group AAs for adverse reactions to immunotherapy of a total of 762 courses 52 68 % were accompanied with chills and shivering and 47 62 % with fever > 38 C Immunotherapy has the potential to improve the postsurgical prognosis of lung cancer patients but a large-scale multi-institutional RCT is awaited for further confirmation of this study\",\n",
            "}\n",
            "13731\n",
            "{\n",
            "  \"id\" : \"21831711\",\n",
            "  \"contents\" : \"The clinical effect of intravesical instillation of chemotherapy immediately after transurethral resection of bladder tumours TURBT has recently been questioned despite its recommendation in guidelines Our aim was to compare TURBT alone with immediate post-TURBT intravesical passive diffusion PD of mitomycin and immediate pre-TURBT intravesical electromotive drug administration EMDA of mitomycin in non-muscle invasive bladder cancer We did a multicentre randomised parallel-group study in patients with primary non-muscle invasive bladder cancer in three centres in Italy between Jan 1 1994 and Dec 31 2003 Patients were randomly assigned to receive treatment by means of stratified blocked randomisation across six strata Patients and physicians giving the interventions were aware of assignment but it was masked from outcome assessors and data analysts Patients were randomly assigned to receive TURBT alone immediate post-TURBT instillation of 40 mg PD mitomycin dissolved in 50 mL sterile water infused over 60 min or immediate pre-TURBT instillation of 40 mg EMDA mitomycin dissolved in 100 mL sterile water with intravesical 20 mA pulsed electric current for 30 min Our primary endpoints were recurrence rate and disease-free interval Analyses were done by intention to treat Follow-up for our trial is complete This study is registered with ClinicalTrialsgov number NCT01149174 124 patients were randomly assigned to receive TURBT alone 126 to receive immediate post-TURBT PD mitomycin and 124 to receive immediate pre-TURBT EMDA mitomycin 22 patients were excluded from our analyses because they did meet our eligibility criteria after TURBT 11 had stage pT2 disease and 11 had carcinoma in situ Median follow-up was 86 months IQR 57-125 Patients assigned to receive EMDA mitomycin before TURBT had a lower rate of recurrence 44 [ 38 % ] of 117 than those assigned to receive PD mitomycin after TURBT 70 [ 59 % ] of 119 and TURBT alone 74 [ 64 % ] of 116 log-rank p < 00001 Patients assigned to receive EMDA mitomycin before TURBT also had a higher disease-free interval 52 months IQR 32-184 than those assigned to receive PD mitomycin after TURBT 16 months 12-168 and TURBT alone 12 months 12-37 log-rank p < 00001 We recorded persistent bladder symptoms after TURBT in 18 16 % of 116 patients in the TURBT-alone group duration 3-7 days 37 31 % of 119 in the PD mitomycin post-TURBT group duration 20-30 days and 24 21 % of 117 in the EMDA mitomycin pre-TURBT group duration 7-12 days haematuria after TURBT in eight 7 % of 116 patients in the TURBT-alone group 16 13 % of 119 in the PD mitomycin post-TURBT group and 11 9 % of 117 in the EMDA mitomycin pre-TURBT group and bladder perforation after TURBT in five 4 % of 116 patients in the TURBT-alone group nine 8 % of 119 in the PD mitomycin post-TURBT group and seven 6 % of 117 in the EMDA mitomycin pre-TURBT group Intravesical EMDA mitomycin before TURBT is feasible and safe moreover it reduces recurrence rates and enhances the disease-free interval compared with intravesical PD mitomycin after TURBT and TURBT alone None\",\n",
            "}\n",
            "13732\n",
            "{\n",
            "  \"id\" : \"25186211\",\n",
            "  \"contents\" : \"Research in health communication has shown that narratives contribute more positively to changing health behaviors than informational messages The main purposes of this study were to examine and to compare the effects of two messages promoting physical activity one narrative and the other informational on the perceptions and behavioral intentions of cancer patients A total of 158 women with breast cancer undergoing chemotherapy and sedentary were assigned to read the testimony of a breast cancer survivor who had been physically active during and after treatment TE group a content-equivalent message composed of expert recommendations about physical activity in breast cancer patients RE group or no message control group Source trust was higher in TE group than RE group p < 0001 Exercise self-efficacy and exercise intention were higher in TE group than RE and control groups p < 0001 However scores in RE group were higher than those of TE group for beliefs about exercise benefits p < 0001 and lower than those of TE and control groups for beliefs about exercise risks p < 0001 Source trust exercise self-efficacy and beliefs about exercise benefits and risks mediated the relationship between the message and exercise intention The results suggest that narratives may be more effective in improving perceived physical abilities and involvement in physical activity whereas informational messages seem to be more appropriate to convey the benefits and the absence of risks related to physical activity\",\n",
            "}\n",
            "13733\n",
            "{\n",
            "  \"id\" : \"9122864\",\n",
            "  \"contents\" : \"Early tracheal extubation after esophagectomy has been postulated to reduce both morbidity rate and the cost of esophageal surgery The purpose of this study was to determine the effect of epidural bupivacaine combined with morphine on extubation time postoperative analgesia respiration and hemodynamics in patients undergoing esophagectomy In a randomized double-blind study twenty patients undergoing esophageal cancer surgery with a thoracoabdominal procedure were studied All patients received epidural morphine 2 mg at T6-7 and 2 mg at L3-4 at the beginning of wound closure Then 3 ml/hr continuous epidural administration of either 025 % bupivacaine group Bup 10 patients or normal saline solution group NS 10 patients through the catheter inserted at T6-7 was continued for 16 hours followed by low-dose epidural buprenorphine-bupivacaine The time from end of operation to tracheal extubation was 44 + / - 67 hours in group Bup and 137 + / - 71 hours in group NS p < 005 All patients in both groups obtained moderate or adequate pain relief visual analog scale of 21 + / - 27 mm without serious side effects There were no significant differences in visual analog scale score for pain on a deep breath blood pressure heart rate or respiratory rate between the two groups Continuous administration of epidural bupivacaine combined with morphine resulted in good analgesia without any respiratory or hemodynamic depression in patients who had undergone esophagectomy and early extubation is related to the efficacy of continuous epidural administration of bupivacaine\",\n",
            "}\n",
            "13734\n",
            "{\n",
            "  \"id\" : \"10699160\",\n",
            "  \"contents\" : \"Alloantigen-activated T cells express the high-affinity interleukin-2 receptor Specific blockade of this receptor with the human IgG1 monoclonal antibody daclizumab may prevent rejection of allografts after cardiac transplantation without inducing global immunosuppression We randomly assigned 55 nonsensitized patients undergoing a first cardiac transplantation to receive either induction therapy with daclizumab 10 mg per kilogram of body weight given intravenously within 24 hours after cardiac-transplantation surgery and every two weeks thereafter for a total of five doses or generalized immunosuppressive therapy Concomitant immunosuppression was achieved in both groups with cyclosporine mycophenolate mofetil and prednisone The primary end points were the incidence and severity of acute rejection and the length of time to a first episode of biopsy-confirmed rejection Of the 55 patients in the study 28 were randomly assigned to receive daclizumab and 27 served as the control group During induction therapy the mean frequency of acute rejection episodes defined as a histologic grade of 2 or higher according to the classification of the International Society of Heart and Lung Transplants was 064 per patient in the control group and 019 per patient in the daclizumab group P = 002 Acute rejection developed in 17 of 27 patients in the control group 63 percent as compared with 5 of 28 patients in the daclizumab group 18 percent relative risk 28 95 percent confidence interval 11 to 74 P = 004 Throughout follow-up there were nine patients with episodes of acute rejection of histologic grade 3 in the control group as compared with two in the daclizumab group P = 003 and the time to a first episode of rejection was significantly longer in the daclizumab group P = 004 There were no adverse reactions to daclizumab and no significant differences between the groups in the incidence of infection or cancer during follow-up Induction therapy with daclizumab safely reduces the frequency and severity of cardiac-allograft rejection during the induction period\",\n",
            "}\n",
            "13735\n",
            "{\n",
            "  \"id\" : \"24983746\",\n",
            "  \"contents\" : \"Semagacestat a - secretase inhibitor demonstrated an unfavorable risk-benefit profile in a Phase 3 study of patients with Alzheimer s disease IDENTITY trials and clinical development was halted To assist in future development of - secretase inhibitors we report detailed safety findings from the IDENTITY study with emphasis on those that might be mechanistically linked to - secretase inhibition The IDENTITY trial was a double-blind placebo-controlled trial of semagacestat 100mg and 140mg in which 1537 patients age 55 years and older with probable Alzheimer s disease were randomized Treatment-emergent adverse events TEAEs are reported by body system along with pertinent laboratory vital sign and ECG findings Semagacestat treatment was associated with increased reporting of suspected Notch-related adverse events gastrointestinal infection and skin cancer related Other relevant safety findings associated with semagacestat treatment included cognitive and functional worsening skin-related TEAEs renal and hepatic changes increased QT interval and weight loss With few exceptions differences between semagacestat and placebo treatment groups were no longer significant after cessation of treatment with active drug Many of these safety findings can be attributed to - secretase inhibition and may be valuable to researchers developing - secretase inhibitors\",\n",
            "}\n",
            "13736\n",
            "{\n",
            "  \"id\" : \"17636399\",\n",
            "  \"contents\" : \"Overexpression of human epidermal growth factor receptor 2 HER2 or amplification of its gene is a prognostic factor in primary breast cancer and a predictor for tamoxifen treatment efficacy in oestrogen receptor ER positive disease In the present study we explored a defined cohort of breast cancer patients included in a randomised trial in order to assess prognostic and tamoxifen treatment information yielded by HER2 status Premenopausal breast cancer patients with stage II tumours n = 564 were included and allocated to 2 years of adjuvant tamoxifen treatment versus no adjuvant treatment ER progesterone receptor PR status and HER2 status was determined by immunohistochemistry using a tissue microarray HER2 amplification was analysed by fluorescent in situ hybridisation and tumours being amplified and/or HER2 3 + were considered HER2 + HER2 status was evaluable in 83 % of the patients and 126 % were HER2 + In untreated patients HER2 was a negative prognostic factor in ER + patients HR 295 95 % CI 161-5 38 p < 0001 but not in ER - patients HR 067 95 % CI 028-1 61 p = 04 and a significant interaction between the two markers was found p < 001 HER2 status was not related to tamoxifen treatment efficacy in ER + patients term of interaction p = 095 When stratifying for PR status similar results were achieved HER2 + and ER + breast cancer constituted a subgroup of tumours with poor prognosis in premenopausal breast cancer whereas no treatment interaction was found between HER2 status and tamoxifen in ER + tumours The poor prognosis in HER2 + and ER + patients may interfere with the interpretation of HER2 data in non-randomised trials of adjuvant tamoxifen\",\n",
            "}\n",
            "13737\n",
            "{\n",
            "  \"id\" : \"17624606\",\n",
            "  \"contents\" : \"This pilot study examined the effects of a self-administered home-based exercise HBE rehabilitation programme designed to help women regain shoulder mobility immediately following surgery for a modified radical mastectomy and axillary node dissection Twenty-seven women who were scheduled for surgery were randomly assigned to either a post-surgical experimental HBE rehabilitation group n = 16 or a usual care group UC n = 11 Women assigned to the HBE group followed an 11 day days 3-14 post-surgery home-based rehabilitation programme consisting of shoulder flexibility and stretching exercises that were described on videotape The videotape programme was modelled after the exercises and guidelines described in a brochure produced by the Canadian Cancer Society As a result of the exercise programme intervention there was a time x group interaction indicating that the HBE group demonstrated a significantly greater increase in shoulder flexion range of motion ROM p = 0003 and abduction ROM p = 0036 when compared to the UC There were no statistical differences in shoulder strength between groups over time External rotation p = 0036 and grip strength p = 0001 significantly increased in both groups during the intervention period but there were no interaction effects With respect to the forearm circumferences there was a significant decrease over time p < 0001 but no interaction between groups This HBE rehabilitation programme is an effective way to improve shoulder mobility and ROM during the immediate 2-week recovery period following surgery\",\n",
            "}\n",
            "13738\n",
            "{\n",
            "  \"id\" : \"8355039\",\n",
            "  \"contents\" : \"In the present phase III study the specific effect of estrogenic recruitment was assessed by comparing two groups of patients with advanced breast cancer receiving either ethinylestradiol EE2 or placebo PL before chemotherapy CT The therapeutic regimen consisted of 1 estrogen suppression by aminoglutethimide AGL 1 g/d plus hydrocortisone HC 40 mg/d with surgical castration performed on premenopausal patients 2 fluorouracil 5-FU 500 mg/m2 doxorubicin 50 mg/m2 and cyclophosphamide CPA 500 mg/m2 FAC intravenously IV every 3 weeks 3 following randomization patients were double-blinded to receive either PL or EE2 50 micrograms exactly 24 hours before receiving FAC All patients had advanced breast cancer presumably sensitive to endocrine therapy estrogen receptor-positive [ ER + ] and/or progesterone receptor-positive [ PgR + ] status with measurable lesions none had received prior systemic antineoplastic therapy for metastatic disease prior adjuvant hormonal therapy HT or CT without anthracyclines was allowed if interval since completion was longer than 1 year Among 154 patients treated according to the protocol tolerance response rates time to progression and median survival duration were identical in the PL and EE2 groups Only performance status dominant metastatic site and menopausal status seemed to influence response overall response 64 % with the highest levels of partial remission PR and complete remission CR being achieved in premenopausal women CR plus PR 26 % plus 55 % and in those with dominant soft tissue lesions CR plus PR 45 % plus 28 % We conclude that the validity of the hormonal recruitment concept has not yet been established in clinical practice so that this approach remains experimental The results achieved by combining near complete estrogenic suppression and cyclical FAC chemotherapy are not significantly different from those to be expected with the more conventional use of HT followed by CT in presumably hormone-responsive ER + patients\",\n",
            "}\n",
            "13739\n",
            "{\n",
            "  \"id\" : \"11162336\",\n",
            "  \"contents\" : \"The effect of community action on cervical cancer screening rates was explored in 20 rural Australian towns Town quarterly Pap test counts from the Australian Health Insurance Commission were converted to town rates using Census populations Pap test rates for 12 quarters before and after mobilization were examined Wilcoxon-Mann-Whitney tests demonstrated significantly higher per capita Pap test rates pre - to postmobilization for intervention towns compared to matched control towns for women whose last Pap test was more than 2 years ago P = 0008 Maximum efficiency robust tests examining the equality of mean differences intervention-control of per capita rates between pre - and post-mobilization periods also found significant differences for Pap tests where last procedure was between 1 and 2 years ago R = 139 P = 0039 and near significance for Pap tests where last procedure was less than one year ago R = 106 P = 0087 It appeared that underscreened women were more likely and overscreened women were less likely to have a Pap test in response to the intervention The results indicate that a community action program can positively impact cervical cancer screening rates\",\n",
            "}\n",
            "13740\n",
            "{\n",
            "  \"id\" : \"15667973\",\n",
            "  \"contents\" : \"To determine whether hypnotherapy reduces anxiety and improves the quality of life in cancer patients undergoing curative radiotherapy RT After providing written informed consent 69 patients were randomized between standard curative RT alone 36 controls and RT plus hypnotherapy 33 patients Patients in the hypnotherapy group received hypnotherapy at the intake before RT simulation before the first RT session and halfway between the RT course Anxiety was evaluated by the State-Trait Anxiety Inventory DY-1 form at six points Quality of life was measured by the Rand Medical Outcomes Study 36-item Health Survey SF-36 at five points Additionally patients answered a questionnaire to evaluate their experience and the possible benefits of this research project No statistically significant difference was found in anxiety or quality of life between the hypnotherapy and control groups However significantly more patients in the hypnotherapy group indicated an improvement in mental p < 005 and overall p < 005 well-being Hypnotherapy did not reduce anxiety or improve the quality of life in cancer patients undergoing curative RT The absence of statistically significant differences between the two groups contrasts with the hypnotherapy patients own sense of mental and overall well-being which was significantly greater after hypnotherapy It can not be excluded that the extra attention by the hypnotherapist was responsible for this beneficial effect in the hypnotherapy group An attention-only control group would be necessary to control for this effect\",\n",
            "}\n",
            "13741\n",
            "{\n",
            "  \"id\" : \"24645632\",\n",
            "  \"contents\" : \"Skin cancer survivors experience an increased risk for subsequent malignancies but the associated risk factors are poorly understood This study examined the risk of a new primary cancer following an initial skin cancer and assessed risk factors associated with second primary cancers All invasive cutaneous malignant melanomas CMM N = 28 069 and squamous cell carcinomas SCC N = 24 620 diagnosed in Norway during 1955-2008 were included Rates of new primary cancers in skin cancer survivors were compared to rates of primary malignancies in the general population using standardized incidence ratios SIR Discrete-time logistic regression models were applied to individual-level data to estimate cancer risk among those with and without a prior skin cancer accounting for residential region education income parenthood marital status and parental cancer status using a 20 % random sample of the entire Norwegian population as reference Further analyses of the skin cancer cohort were undertaken to determine risk factors related to subsequent cancers During follow-up 9608 new primary cancers occurred after an initial skin cancer SIR analyses showed 50 % and 90 % increased risks for any cancer after CMM and SCC respectively p < 001 The logistic regression model suggested even stronger increase after SCC 130 % The highest risk was seen for subsequent skin cancers but several non-skin cancers were also diagnosed in excess oral lung colon breast prostate thyroid leukemia lymphoma and central nervous system Factors that were associated with increased risk of subsequent cancers include male sex older age lower residential latitude being married and low education and income Parental cancer did not increase the risk of a subsequent cancer after SCC but was a significant predictor among younger CMM survivors Our results provide information on shared environmental and genetic risk factors for first and later cancers and may help to identify individuals at high risk for subsequent cancers which will be important as skin cancer incidence continues to rise\",\n",
            "}\n",
            "13742\n",
            "{\n",
            "  \"id\" : \"22075170\",\n",
            "  \"contents\" : \"We evaluated the efficacy of the human papillomavirus HPV-16 / 18 AS04-adjuvanted vaccine against non-vaccine oncogenic HPV types in the end-of-study analysis after 4 years of follow-up in PATRICIA PApilloma TRIal against Cancer In young Adults Healthy women aged 15-25 years with no more than six lifetime sexual partners were included in PATRICIA irrespective of their baseline HPV DNA status HPV-16 or HPV-18 serostatus or cytology Women were randomly assigned 11 to HPV-16 / 18 vaccine or a control hepatitis A vaccine via an internet-based central randomisation system using a minimisation algorithm to account for age ranges and study sites The study was double-blind The primary endpoint of PATRICIA has been reported previously the present analysis evaluates cross-protective vaccine efficacy against non-vaccine oncogenic HPV types in the end-of-study analysis Analyses were done for three cohorts the according-to-protocol cohort for efficacy ATP-E vaccine n = 8067 control n = 8047 total vaccinated HPV-naive cohort TVC-naive no evidence of infection with 14 oncogenic HPV types at baseline approximating young adolescents before sexual debut vaccine n = 5824 control n = 5820 and the total vaccinated cohort TVC all women who received at least one vaccine dose approximating catch-up populations that include sexually active women vaccine n = 9319 control = 9325 Vaccine efficacy was evaluated against 6-month persistent infection cervical intraepithelial neoplasia grade 2 or greater CIN2 + associated with 12 non-vaccine HPV types individually or as composite endpoints and CIN3 + associated with the composite of 12 non-vaccine HPV types This study is registered with ClinicalTrialsgov number NCT00122681 Consistent vaccine efficacy against persistent infection and CIN2 + with or without HPV-16 / 18 co-infection was seen across cohorts for HPV-33 HPV-31 HPV-45 and HPV-51 In the most conservative analysis of vaccine efficacy against CIN2 + where all cases co-infected with HPV-16 / 18 were removed vaccine efficacy was noted for HPV-33 in all cohorts and for HPV-31 in the ATP-E and TVC-naive Vaccine efficacy against CIN2 + associated with the composite of 12 non-vaccine HPV types 31 33 35 39 45 51 52 56 58 59 66 and 68 with or without HPV-16 / 18 co-infection was 468 % 95 % CI 307-594 in the ATP-E 562 % 372-699 in the TVC-naive and 342 % 204-458 in the TVC Corresponding values for CIN3 + were 738 % 483-879 914 % 650-990 and 475 % 228-648 Data from the end-of-study analysis of PATRICIA show cross-protective efficacy of the HPV-16 / 18 vaccine against four oncogenic non-vaccine HPV types-HPV-33 HPV-31 HPV-45 and HPV-51-in different trial cohorts representing diverse groups of women GlaxoSmithKline Biologicals\",\n",
            "}\n",
            "13743\n",
            "{\n",
            "  \"id\" : \"24361787\",\n",
            "  \"contents\" : \"The purpose of this study was to explore in greater depth the outcomes of the Italian randomized trial investigating the role of pelvic lymphadenectomy in clinical early stage endometrial cancer In the attempt to identify the patients with poorer prognosis the impact of age and body mass index were also thoroughly investigated by cancer-specific survival CSS analyses Survival outcomes of trial patients were analyzed in relation to age 65 years and > 65 years in the 2 arms lymphadenectomy and no lymphadenectomy and in the whole population of the trial Univariate and multivariable analyses of CSS and overall survival OS of patients showed that age > 65 years is a strong independent poor prognostic factor 5-y OS 921 % and 784 % in 65 years and > 65 years patients respectively P < 0001 5-y CSS 938 % and 835 % in 65 years and > 65 years patients respectively P = 003 Among women 65 years node negative patients had 944 % 5-y OS and 963 % 5-y CSS vs 743 % 5-y OS and 743 % 5-y CSS for node positive patients P = 009 and P = 002 respectively while among women > 65 y node negative patients had 757 % 5-y OS and 836 % 5-y CSS vs 741 % 5-y OS and 833 % 5-y CSS for node positive patients P = 55 and P = 58 respectively Univariate and multivariable survival analyses in the whole trial population showed that older age and higher tumor grade and stage were significantly associated to a worse prognosis Older women faced an intrinsic poorer survival whether or not they underwent lymphadenectomy and unexpectedly irrespective of the presence of nodal metastasis Only in older patients was obesity body mass index > 30 significantly associated with scarce prognosis\",\n",
            "}\n",
            "13744\n",
            "{\n",
            "  \"id\" : \"18454862\",\n",
            "  \"contents\" : \"Tocopherols may protect against prostate cancer and cardiovascular disease CVD We assessed the effect of walnuts which are rich in tocopherols on markers of prostate and vascular health in men at risk for prostate cancer We conducted an 8-week walnut supplement study to examine effects of walnuts on serum tocopherols and prostate specific antigen PSA Subjects n = 21 consumed in random order their usual diet + / - a walnut supplement 75 g/d that was isocalorically incorporated in their habitual diets Prior to the supplement study 5 fasted subjects participated in an acute timecourse experiment and had blood taken at baseline and 1 2 4 and 8 h after consuming walnuts 75 g During the timecourse experiment triglycerides peaked at 4 h and gamma-tocopherol gamma-T increased from 4 to 8 h Triglyceride - normalized gamma-T was two-fold higher P = 001 after 8 versus 4 hIn the supplement study change from baseline was +083 + / - 052 micromol/L for gamma-T -265 + / - 130 micromol/L for alpha-tocopherol alpha-T and -349 + / - 199 for the tocopherol ratio alpha-T gamma-T A linear mixed model showed that although PSA did not change the ratio of free PSA total PSA increased and approached significance P = 007 The alpha-T gamma-T ratio decreased significantly P = 001 partly reflecting an increase in serum gamma-T which approached significance P = 008 The significant decrease in the alpha-T gamma-T ratio with an increase in serum gamma-T and a trend towards an increase in the ratio of free PSA total PSA following the 8-week supplement study suggest that walnuts may improve biomarkers of prostate and vascular status\",\n",
            "}\n",
            "13745\n",
            "{\n",
            "  \"id\" : \"8874326\",\n",
            "  \"contents\" : \"To compare the efficacy and toxicity profiles of a combination of fluorouracil 5-FU and recombinant human interferon alfa-2a [ IFN alpha 2a ] Roferon-A Hoffmann-LaRoche Basel Switzerland versus 5-FU alone in the treatment of advanced colorectal cancer ACC A total of 245 previously untreated ACC patients were randomized to receive either IFN alpha 2a 9 million IU subcutaneously SC three times weekly with 5-FU 750 mg/m2/d by continuous intravenous CIV infusion on days 1 to 5 and then after a 1-week hiatus as a weekly IV bolus at the same dose IFN / 5-FU or 5-FU alone at the same dose schedule 5-FU There were no significant differences between IFN/5-FU and 5-FU alone in the overall response rate 24 % v 17 % P = 2 duration of response median 64 v 81 months time to response plateau at 3 months time to progressive disease [ PD ] median 48 v 49 months or survival duration median 139 v 132 months Toxicity profiles were not statistically different except for constitutional symptoms which were more frequent and more severe with IFN/5-FU More patients interrupted treatment for adverse events AEs with IFN / 5-FU 34 % than with 5-FU alone 21 % P = 03 The number of deaths mostly unrelated to drug treatment during the study 8 % was similar with both regimens The combination IFN/5-FU produced a response rate response duration and survival duration similar to that of 5-FU alone The addition of IFN to 5-FU in the doses and schedules used in this study did not provide any further benefit over 5-FU alone and can not be recommended for patients with metastatic ACC This study confirms the value of large prospective randomized clinical trials to determine the clinical value of regimens that emerge from smaller single-center phase II studies\",\n",
            "}\n",
            "13746\n",
            "{\n",
            "  \"id\" : \"1494071\",\n",
            "  \"contents\" : \"The aim was to estimate costs and yields of faecal occult blood screening and rescreening for colorectal cancer for differing age cohorts Cost and clinical data were used as the basis for modelling the expected costs and cost savings resulting from the treatment of screen detected cancers as compared with cancers detected by symptomatic presentation Data were derived from the MRC screening trial currently in progress in Nottingham Approximately 140000 subjects age 50-79 years were randomly allocated to a test screened and a control unscreened group The net costs of detecting and treating a cancer following colorectal screening fall as the age of the target population increases owing principally to the increasing incidence of the disease with age Generally the marginal detection and treatment costs falls for all age groups with the first screening round but rises considerably with the second If allowance is made for cancers prevented as a result of early detection and excision of adenomas the costs of screening are substantially reduced for all age groups Assuming a cost per QALY quality adjusted life year gained equivalent to that derived for the breast cancer screening programme and a QALY gain from colorectal screening of one year three screens each separated by two years appear economically justified for populations aged 60 years and above Expected gains from cancer prevention make two screens justifiable for those between 45 and 59 years of age\",\n",
            "}\n",
            "13747\n",
            "{\n",
            "  \"id\" : \"23433446\",\n",
            "  \"contents\" : \"To report the results of a safety analysis from a phase II trial comparing administration of weekly paclitaxel plus S-1 TS versus paclitaxel plus 5-fluorouracil 5-FU / calcium folinate LV TLF as first-line therapy for advanced gastric cancer Patients n = 240 with previously untreated advanced gastric cancer were randomly assigned to receive either TS or TLF in a 28-day cycle for six cycles The clinical features of both sets of patients were similar with the exception of the incidence of prior chemotherapy P > 005 Most treatment-related adverse events occurred at similar rates in both treatment arms However patients receiving TS experienced an increase in all-grade especially grade 3/4 neutropenia with an incidence of 437 % in the TS arm and 163 % in the TLF arm respectively P < 005 Other severe adverse events were infrequent and not significantly different between the groups The safety and tolerance of weekly paclitaxel plus S-1 or 5-FU/LV is well in untreated advanced gastric cancer patients\",\n",
            "}\n",
            "13748\n",
            "{\n",
            "  \"id\" : \"8625038\",\n",
            "  \"contents\" : \"Metastatic colorectal cancer is generally incurable The most active regimen available 5-fluorouracil 5-FU and folinic acid Leucovorin produces response rates of approximately 25 % to 30 % Methyl-lomustine is a nitrosourea with modest activity against colorectal cancer A randomized trial was undertaken to evaluate the impact the addition of methyl-lomustine would have on response duration of survival and survival rates in patients with advanced colorectal cancer The methyl-lomustine/5-FU/Leucovorin MFL regimen consisted of methyl-lomustine 110 mg/m2 administered on Day 1 of each 8-week cycle with six weekly boluses of 5-FU 600 mg/m2 and Leucovorin 500 mg/m2 The FL treatment arm consisted of the administration of 5-FU and Leucovorin as described above Patients were evaluated for response and toxicity after each 8-week cycle Of 319 patients included in this trial 297 931 % had disease evaluable for response and toxicity 145 received MFL and 152 received FL In this trial 526 courses of MFL and 529 courses of FL were administered Methyl-lomustine/5-FU/Leucovorin treatment resulted in 4 complete and 30 partial responses response rate 219 % and FL treatment resulted in 9 complete and 33 partial responses response rate 264 % There was no significant difference in median survival duration between patients in the two arms MFL = 48 weeks FL = 51 weeks However MFL was significantly more toxic with greater myelosuppression than was FL Grade 3-4 neutropenia MFL = 56 patients FL = 27 patients P < 0001 Grade 3-4 thrombocytopenia MFL = 49 patients FL = 2 patients P < 0001 Grade 3-4 anemia MFL = 15 patients FL = 6 patients P < 0001 and more prolonged median duration of granulocytopenia MFL = 9 days FL = 7 days P < 0001 and thrombocytopenia MFL = 14 days FL = 75 days P < 0001 Because the addition of methyl-lomustine in the MFL schedule markedly increased the toxicity of the regimen and because the FL regimen was as effective as MFL the authors recommend that Leucovorin and 5-FU remain the treatment choice for treating patients with metastatic colorectal cancer\",\n",
            "}\n",
            "13749\n",
            "{\n",
            "  \"id\" : \"25231953\",\n",
            "  \"contents\" : \"The BOLERO-2 study previously demonstrated that adding everolimus EVE to exemestane EXE significantly improved progression-free survival PFS by more than twofold in patients with hormone-receptor-positive HR + HER2-negative advanced breast cancer that recurred or progressed during/after treatment with nonsteroidal aromatase inhibitors NSAIs The overall survival OS analysis is presented here BOLERO-2 is a phase III double-blind randomized international trial comparing EVE 10 mg/day plus EXE 25 mg/day versus placebo PBO + EXE 25 mg/day in postmenopausal women with HR + advanced breast cancer with prior exposure to NSAIs The primary end point was PFS by local investigator assessment OS was a key secondary end point At the time of data cutoff 3 October 2013 410 deaths had occurred and 13 patients remained on treatment Median OS in patients receiving EVE + EXE was 310 months [ 95 % confidence interval CI 280-34 6 months ] compared with 266 months 95 % CI 226-33 1 months in patients receiving PBO + EXE hazard ratio = 089 95 % CI 073-1 10 log-rank P = 014 Poststudy treatments were received by 84 % of patients in the EVE + EXE arm versus 90 % of patients in the PBO + EXE arm Types of poststudy therapies were balanced across arms except for chemotherapy 53 % EVE + EXE versus 63 % PBO + EXE No new safety concerns were identified In BOLERO-2 adding EVE to EXE did not confer a statistically significant improvement in the secondary end point OS despite producing a clinically meaningful and statistically significant improvement in the primary end point PFS 46-months prolongation in median PFS P < 00001 Ongoing translational research should further refine the benefit of mTOR inhibition and related pathways in this treatment setting NCT00863655\",\n",
            "}\n",
            "13750\n",
            "{\n",
            "  \"id\" : \"15699479\",\n",
            "  \"contents\" : \"Studies in cancer patients with venous thromboembolism suggested that low molecular weight heparin may prolong survival In a double-blind study we evaluated the effect of low molecular weight heparin on survival in patients with advanced malignancy without venous thromboembolism Patients with metastasized or locally advanced solid tumors were randomly assigned to receive a 6-week course of subcutaneous nadroparin or placebo The primary efficacy analysis was based on time from random assignment to death The primary safety outcome was major bleeding In total 148 patients were allocated to nadroparin and 154 patients were allocated to placebo Mean follow-up was 1 year In the intention-to-treat analysis the overall hazard ratio of mortality was 075 95 % CI 059 to 096 with a median survival of 80 months in the nadroparin recipients versus 66 months in the placebo group After adjustment for potential confounders the treatment effect remained statistically significant Major bleeding occurred in five 3 % of nadroparin-treated patients and in one 1 % of the placebo recipients P = 12 In the a priori specified subgroup of patients with a life expectancy of 6 months or more at enrollment the hazard ratio was 064 95 % CI 045 to 090 with a median survival of 154 and 94 months respectively For patients with a shorter life expectancy the hazard ratio was 088 95 % CI 062 to 125 A brief course of subcutaneous low molecular weight heparin favorably influences the survival in patients with advanced malignancy and deserves additional clinical evaluation\",\n",
            "}\n",
            "13751\n",
            "{\n",
            "  \"id\" : \"23721245\",\n",
            "  \"contents\" : \"Anaplastic thyroid cancer ATC a rare highly vascularized tumor has a dismal outcome We conducted an open-label study of doublet carboplatin/paclitaxel chemotherapy with or without fosbretabulin in patients with ATC Patients were randomly assigned in a 21 ratio to 6 cycles of paclitaxel 200mg/m 2 followed by carboplatin AUC 6 on day 1 every 3 weeks CP or these drugs were given on day 2 after fosbretabulin 60mg/m 2 CP/fosbretabulin on days 1 8 and 15 After 6 cycles patients on the fosbretabulin arm without progression could continue to receive fosbretabulin on days 1 and 8 of a 3-week schedule until progression The primary end point was overall survival OS Eighty patients were assigned planned 180 when enrollment was stopped due to rarity of disease and very low accrual Median OS was 52 months [ 95 % confidence interval CI 31 90 ] for the CP/fosbretabulin arm n = 55 hazard ratio 073 [ 95 % CI 044 121 ] and 40 months [ 95 % CI 28 62 ] for the CP arm n = 25 p = 022 [ log rank test ] One-year survival for CP/fosbretabulin versus CP was 26 % versus 9 % respectively There was no significant difference in progression-free survival between the two arms Grade 1-2 hypertension and grade 3-4 neutropenia were more common with CP/fosbretabulin There were no significant adverse cardiovascular side effects Although the study did not meet statistical significance in improvement in OS with the addition of fosbretabulin to carboplatin/paclitaxel it represents the largest prospective randomized trial ever conducted in ATC The regimen is well tolerated with AEs and deaths primarily related to ATC and disease progression\",\n",
            "}\n",
            "13752\n",
            "{\n",
            "  \"id\" : \"23244208\",\n",
            "  \"contents\" : \"Chemotherapy induced nausea and vomiting CINV remains a major problem that seriously impairs the quality of life QoL in cancer patients receiving chemotherapy regimens Complementary medicines including homeopathy are used by many patients with cancer usually alongside with conventional treatment A randomized placebo-controlled Phase III study was conducted to evaluate the efficacy of a complex homeopathic medicine Cocculine in the control of CINV in non-metastatic breast cancer patients treated by standard chemotherapy regimens Chemotherapy-nave patients with non-metastatic breast cancer scheduled to receive 6 cycles of chemotherapy including at least three initial cycles of FAC 50 FEC 100 or TAC were randomized to receive standard anti-emetic treatment plus either a complex homeopathic remedy Cocculine registered in France for treatment of nausea and travel sickness or the matching placebo NCT00409071 clinicaltrialsgov The primary endpoint was nausea score measured after the 1st chemotherapy course using the FLIE questionnaire Functional Living Index for Emesis with 5-day recall Secondary endpoints were vomiting measured by the FLIE score nausea and vomiting measured by patient self-evaluation EVA and investigator recording NCI-CTC AE V3 0 and treatment compliance From September 2005 to January 2008 431 patients were randomized 214 to Cocculine C and 217 to placebo P Patient characteristics were well-balanced between the 2 arms Overall compliance to study treatments was excellent and similar between the 2 arms A total of 205 patients 509 % 103 patients in the placebo and 102 in the homeopathy arms had nausea FLIE scores > 6 indicative of no impact of nausea on quality of life during the 1st chemotherapy course There was no difference between the 2 arms when primary endpoint analysis was performed by chemotherapy stratum or in the subgroup of patients with susceptibility to nausea and vomiting before inclusion In addition nausea vomiting and global emesis FLIE scores were not statistically different at any time between the two study arms The frequencies of severe Grade 2 nausea and vomiting were low in our study nausea P 176 % vs C 157 % p = 062 vomiting P 108 % vs C 120 % p = 072 during the first course This double-blinded placebo-controlled randomised Phase III study showed that adding a complex homeopathic medicine Cocculine to standard anti-emetic prophylaxis does not improve the control of CINV in early breast cancer patients\",\n",
            "}\n",
            "13753\n",
            "{\n",
            "  \"id\" : \"9790546\",\n",
            "  \"contents\" : \"For patients with metastatic prostate cancer treatment is primarily palliative relying mainly on the suppression of systemic androgen hormone levels To help document the achievement of palliation and to characterize positive and negative effects of treatment we evaluated quality-of-life QOL parameters in patients with metastatic prostate cancer who were randomly assigned to two methods of androgen deprivation Patients n = 739 with stage M1 bone or soft tissue metastasis prostate cancer were enrolled in a QOL protocol that was a companion to Southwest Oncology Group INT-0105 a randomized double-blind trial comparing treatment with bilateral orchiectomy surgical castration plus either flutamide or placebo Patients completed a comprehensive battery of QOL questionnaires at random assignment to treatment and at 1 3 and 6 months later Data were collected on three treatment-specific symptoms diarrhea gas pain and body image on physical functioning and on emotional functioning All P values are two-sided Questionnaire return rates for this study never dropped below 80 % only 2 % of the patients did not submit baseline QOL assessments Cross-sectional analyses corrected for multiple testing identified statistically significant differences that favored orchiectomy plus placebo for two of the five primary QOL parameters as follows patients receiving flutamide reported more diarrhea at 3 months P = 001 and worse emotional functioning at 3 and 6 months both P < 003 Longitudinal analyses replicated these findings Other analyzed QOL parameters favored the group receiving placebo but were not statistically significant after adjustment for multiple testing We found a consistent pattern of better QOL outcomes at each follow-up assessment during the first 6 months of treatment for orchiectomized patients with metastatic prostate cancer who received placebo versus flutamide Improvement over time was evident in both treatment groups but more so for patients receiving placebo\",\n",
            "}\n",
            "13754\n",
            "{\n",
            "  \"id\" : \"20228999\",\n",
            "  \"contents\" : \"Endoscopic submucosal dissection ESD for early gastric cancer EGC generally takes longer to perform than conventional endoscopy and usually requires moderate/deep sedation with close surveillance for patient safety The aim of this study was to compare the safety profiles and recovery scores propofol continuous infusion and intermittent midazolam MDZ injection as sedation for ESD Sixty EGC patients scheduled for ESDs between August and November 2008 were included in this prospective study and randomly divided into a propofol P-group 28 patients and an MDZ M-group 32 patients group using an odd-even system The P-group received a 08 mg/kg induction dose and a 3 mg/kg/h maintenance dose of 1 % propofol using an infusion pump All patients received 15 mg pentazocine at the start of the ESD and at 60-min intervals thereafter We recorded and analyzed blood pressure oxygen saturation and heart rate during and following the procedure and evaluated post-anesthetic recovery scores PARS and subsequent alertness scores The propofol maintenance and total dose amounts were mean + / - standard deviation 37 + / - 06 mg/kg/h and 395 + / - 202 mg respectively The mean total dose of MDZ was 103 + / - 45 mg There were no cases of de-saturation < 90 % or hypotension < 80 mmHg in either group Alertness scores 15 and 60 min after the procedures were significantly higher in the P-group 49 / 49 than in the M-group 46 / 45 p < 005 The mean PARS 15 and 30 min after the ESDs were significantly higher in the P-group 96 / 99 than in the M-group 86 / 92 p < 001 Based on our results the ESDs for EGC performed under sedation using propofol continuous infusion were as safe as those performed using intermittent MDZ injection Propofol-treated patients had a quicker recovery profile than those treated with MDZ We therefore recommend the use of continuous propofol sedation for ESD but sedation guidelines for the use of propofol are necessary\",\n",
            "}\n",
            "13755\n",
            "{\n",
            "  \"id\" : \"10674879\",\n",
            "  \"contents\" : \"The mitoxantrone combination CNF and the epirubicin combination CEF have shown similar activity and less toxicity than the standard CAF combination in metastatic breast cancer MBC A prospective randomised study was started to compare safety and activity between CEF and CNF administered using a classical chemotherapeutic schedule in MBC From December 1987 to June 1993 151 patients were randomised to receive cyclophosphamide C 100 mg m -2 po days 1-14 fluorouracil F 500 mg m -2 iv days 1 and 8 and epirubicin E 30 mg m -2 iv days 1 and 8 or mitoxantrone N 6 mg m -2 iv days 1 and 8 every 4 weeks Seventy-three patients were eligible for CEF and 72 for CNF Objective responses were observed in 616 % of the CEF group and 444 % in CNF group p = 0004 The median duration of response was 64 weeks in CEF and 50 weeks in CNF group p = 002 and median time to progression was 51 and 33 weeks respectively p = 00004 At the time of analysis all except six patients one in CNF and five in CEF had died and the median survival time in the CEF group was longer than in CNF 744 weeks vs 514 weeks log-rank chi2 test p = 0015 CNF produced more hematologic toxicity than CEF WHO scale grades 2-4 leucopenia 84 % vs 68 % p = 003 and thrombocytopenia 17 % vs 45 % p = 001 CEF caused more grade 2 and 3 alopecia 93 % vs 70 % p = 0001 The combination CEF using this schedule and dosage in metastatic breast cancer is more effective with less toxicity than CNF except for alopecia and was associated with longer survival\",\n",
            "}\n",
            "13756\n",
            "{\n",
            "  \"id\" : \"18421053\",\n",
            "  \"contents\" : \"To evaluate whether capecitabine plus oxaliplatin XELOX is noninferior to fluorouracil folinic acid and oxaliplatin FOLFOX-4 as first-line therapy in metastatic colorectal cancer MCRC The initial design of this trial was a randomized two-arm noninferiority phase III comparison of XELOX versus FOLFOX-4 After patient accrual had begun the trial design was amended in 2003 after bevacizumab phase III data became available The resulting 2 x 2 factorial design randomly assigned patients to XELOX versus FOLFOX-4 and then to also receive either bevacizumab or placebo We report here the results of the analysis of the XELOX versus FOLFOX-4 arms The analysis of bevacizumab versus placebo with oxaliplatin-based chemotherapy is reported separately The prespecified primary end point for the noninferiority analysis was progression-free survival The intent-to-treat population comprised 634 patients from the original two-arm portion of the study plus an additional 1400 patients after the start of the amended 2 x 2 design for a total of 2034 patients The median PFS was 80 months in the pooled XELOX-containing arms versus 85 months in the FOLFOX-4-containing arms hazard ratio [ HR ] 104 975 % CI 093 to 116 The median overall survival was 198 months with XELOX versus 196 months with FOLFOX-4 HR 099 975 % CI 088 to 112 FOLFOX-4 was associated with more grade 3/4 neutropenia/granulocytopenia and febrile neutropenia than XELOX and XELOX with more grade 3 diarrhea and grade 3 hand-foot syndrome than FOLFOX-4 XELOX is noninferior to FOLFOX-4 as a first-line treatment for MCRC and may be considered as a routine treatment option for appropriate patients\",\n",
            "}\n",
            "13757\n",
            "{\n",
            "  \"id\" : \"10647800\",\n",
            "  \"contents\" : \"Constipation is the most common chronic adverse effect of opioid pain medications in patients who require long-term opioid administration such as patients with advanced cancer but conventional measures for ameliorating constipation often are insufficient To evaluate the efficacy of methylnaltrexone the first peripheral opioid receptor antagonist in treating chronic methadone-induced constipation Double-blind randomized placebo-controlled trial conducted between May 1997 and December 1998 Clinical research center of a university hospital Twenty-two subjects 9 men and 13 women mean [ SD ] age 432 [ 55 ] years enrolled in a methadone maintenance program and having methadone-induced constipation Laxation response oral-cecal transit time and central opioid withdrawal symptoms were compared between the 2 groups The 11 subjects in the placebo group showed no laxation response and all 11 subjects in the intervention group had laxation response after intravenous methylnaltrexone administration P < 001 The oral-cecal transit times at baseline for subjects in the methylnaltrexone and placebo groups averaged 1323 and 1268 minutes respectively The average SD change in the methylnaltrexone-treated group was -777 372 minutes significantly greater than the average change in the placebo group -14 [ 120 ] minutes P < 001 No opioid withdrawal was observed in any subject and no significant adverse effects were reported by the subjects during the study Our data demonstrate that intravenous methylnaltrexone can induce laxation and reverse slowing of oral cecal-transit time in subjects taking high opioid dosages Low-dosage methylnaltrexone may have clinical utility in managing opioid-induced constipation\",\n",
            "}\n",
            "13758\n",
            "{\n",
            "  \"id\" : \"10423465\",\n",
            "  \"contents\" : \"Intravenously administered antimicrobial agents have been the standard choice for the empirical management of fever in patients with cancer and granulocytopenia If orally administered empirical therapy is as effective as intravenous therapy it would offer advantages such as improved quality of life and lower cost In a prospective open-label multicenter trial we randomly assigned febrile patients with cancer who had granulocytopenia that was expected to resolve within 10 days to receive empirical therapy with either oral ciprofloxacin 750 mg twice daily plus amoxicillin-clavulanate 625 mg three times daily or standard daily doses of intravenous ceftriaxone plus amikacin All patients were hospitalized until their fever resolved The primary objective of the study was to determine whether there was equivalence between the regimens defined as an absolute difference in the rates of success of 10 percent or less Equivalence was demonstrated at the second interim analysis and the trial was terminated after the enrollment of 353 patients In the analysis of the 312 patients who were treated according to the protocol and who could be evaluated treatment was successful in 86 percent of the patients in the oral-therapy group 95 percent confidence interval 80 to 91 percent and 84 percent of those in the intravenous-therapy group 95 percent confidence interval 78 to 90 percent P = 002 The results were similar in the intention-to-treat analysis 80 percent and 77 percent respectively P = 003 as were the duration of fever the time to a change in the regimen the reasons for such a change the duration of therapy and survival The types of adverse events differed slightly between the groups but were similar in frequency In low-risk patients with cancer who have fever and granulocytopenia oral therapy with ciprofloxacin plus amoxicillin-clavulanate is as effective as intravenous therapy\",\n",
            "}\n",
            "13759\n",
            "{\n",
            "  \"id\" : \"20555256\",\n",
            "  \"contents\" : \"There is increasing recognition of mindfulness and mindfulness training as a way to decrease stress and increase psychological functioning The aim of this study was to examine the perceived effects and experiences of mindfulness stress-reduction training as described by patients with cancer participating in a mindfulness-based stress-reduction training program The study is based on analysis of data collected in semistructured interviews of the participants n = 18 after the completion of a mindfulness-meditation training program The intervention consisted of an 8-week mindfulness-training course Most participants expressed a number of perceived positive effects of participating in the mindfulness program including increased calm enhanced sleep quality more energy less physical pain and increased well-being However a few participants experienced no effect Both negative and positive views of the specific meditation and yoga exercises included in the program were expressed Components that were described as of particular importance regarding the experience of participating in the program were the nonjudgmental and accepting approach guiding the program and the instructors the influence of the group process and sharing experiences with patients with similar experiences and the emphasis on increased awareness of the present moment This study gives support for the use of mindfulness programs in reducing stress-related complaints among some patients with a cancer diagnosis The positive experiences of mindfulness training reported by patients with cancer call for further studies examining the possibilities and requirements for implementation of mindfulness programs in clinical practice\",\n",
            "}\n",
            "13760\n",
            "{\n",
            "  \"id\" : \"23645763\",\n",
            "  \"contents\" : \"New strategies are still needed to enhance the treatment outcome for advanced non-small cell lung cancer in spite of recent remarkable developments Cancer immunotherapy has been attractive since a long time with diverse clinical attempts and results In particular natural killer NK cells have received considerable attention because of their potential role in immune surveillance in vivo by destroying infected or transformed cells Major histocompatibility complex class I-related chain A/B MICA/B on tumor cells known as the representative ligand for NKG2D receptor on NK cells has been reported to be modulated by a variety of stress factors including some chemotherapeutic agents and it is anticipated that enhancing MICA/B expression will be contributory to anticancer treatment With recent development of expanding autologous ex vivo NK cell-enriched lymphocytes NKL we designed a trial to augment the anticancer effect by co-administering NKL and docetaxel one of the second-line agents used for treatment of patients with advanced non-small cell lung cancer NSCLC Eligible patients were between the age of 20 and 75 years with an Eastern Cooperative Oncology Group ECOG performance status PS of 0 to 2 and previously received one chemotherapy or two regimens including one epidermal growth factor receptor EGFR tyrosine kinase inhibitor stage IIIB/IV histologically - or cytologically-proven NSCLC with measurable lesions NKL were kindly prepared and provided from NKBIO Co Seongnam City Korea Feasibility adverse effects progression-free survival PFS were evaluated and compared with the historical control of weekly docetaxel regimen Nineteen patients were enrolled before early closure NKL production and administration were feasible in all cases even in those with disseminated disease No additional adverse events were observed in addition to those reported for docetaxel-alone PFS of 3 months and 105 % response rate RR with two cases of partial response were observed and were similar to the historical control PFS = 29 months RR = 80 % To our knowledge this is the first report on the combination of NKL with docetaxel in patients with advanced NSCLC Autologous NKL production and co-administration with docetaxel were feasible without further toxicity or complication Benefit in PFS and RR as compared with the historical control was not detected in this study population with advanced NSCLC In order to determine whether the combination of NKL and chemotherapy has any anticancer effect an additional study should be performed in patients with low tumor burden such as those with less advanced disease or those in remission\",\n",
            "}\n",
            "13761\n",
            "{\n",
            "  \"id\" : \"21061408\",\n",
            "  \"contents\" : \"Cancer coping styles have been associated with several cancer-related outcomes We examined whether baseline lifestyle behaviors differed between cancer survivors with fatalistic vs fighting-spirit coping styles and whether there was differential response to two diet-exercise mailed-print interventions one standardized and another individually tailored Baseline differences by coping style are presented for 628 breast and prostate cancer survivors who participated in the FRESH START trial along with multivariable analyses on rates of uptake by coping style and arm assignment for those completing the 2-year trial At baseline several differences were observed between fighting-spirits and fatalists with the former significantly more likely to be white younger leaner more-educated and at risk for depression and less likely to consume 5 + fruits and vegetables F&V / day p-values < 005 Improvements in physical activity were observed with fighting-spirits exhibiting the greatest gains from baseline to Year-1 regardless of intervention type but by Year-2 these differences diminished as fatalists gained ground Moreover fatalists who received standardized intervention material also charted steady improvements in F&V intake over the study period by Year-2 581 % of fatalists achieved the 5-a-day goal vs 446 % of fighting-spirits p-value < 005 Lifestyle behaviors and health message uptake differs by cancer coping style Although tailored interventions appear most effective and minimize differential uptake standardized interventions also can improve behaviors though fighting-spirits may require additional boosters to maintain change\",\n",
            "}\n",
            "13762\n",
            "{\n",
            "  \"id\" : \"17919542\",\n",
            "  \"contents\" : \"In 2001 a transdermal matrix patch formulation of buprenorphine was approved for the treatment of moderate to severe cancer pain and severe pain that is unresponsive to nonopioid analgesics The primary recommendation contained in the prescribing information was that transdermal patches be worn for a 3-day period before application of a new patch This study was conducted to evaluate the potential for extending the time the buprenorphine patch is worn from 3 to 4 days This single-center randomized open-label crossover Phase III study compared the efficacy and tolerability of the buprenorphine transdermal patch applied for different durations with patch changes every 3 days versus every 4 days 12 days each in patients with chronic moderate or severe pain of malignant or nonmalignant origin Study participants were aged > 18 years had already responded to at least 4 weeks of transdermal buprenorphine and had achieved steady-state conditions for at least 2 weeks before enrollment The primary end point was patients rating of the quality of treatment analgesic efficacy and tolerability rated on a 5-point scale very good good satisfactory poor and inadequate at the completion of each treatment regimen Also recorded were physicians ratings of the quality of treatment pain intensity rated on an 11-point numerical rating scale from 0 = no pain to 10 = worst pain imaginable and on the McGill Pain Questionnaire MPQ maximum pain = 30 health status assessed using the 36-item Short Form Health Survey SF-36 expressed as a percentage of the best health condition 100 % and pain relief 5-point scale complete good satisfactory slight and none Local skin tolerability was evaluated for objective and subjective dermatologic symptoms at the patch application sites Patients recorded daily pain intensities at specified times of day and night pain relief 5-point verbal rating scale and sleep duration < or = 2 hours > 2-3 hours > 3 - < 6 hours or > or = 6 hours in a diary The safety profile was evaluated based on standard monitoring of adverse events vital signs and routine laboratory tests Forty-nine white patients 25 women 24 men were enrolled their mean SD age was 616 115 years and their mean weight was 747 167 kg The most common source of pain was musculoskeletal disorders 40 patients followed by nervous system disorders 10 neoplasms 9 injuries 5 and other causes 6 Forty-one patients completed the study 2 patients discontinued because of adverse events 1 because of lack of efficacy and 5 for nonmedical reasons Thirty-three patients provided data per protocol Patients in the perprotocol population received a mean SD transdermal buprenorphine dose of 499 389 microg/h The proportion of patients in the per-protocol population rating the quality of treatment as adequate combined ratings of very good good and satisfactory was 939 % 31/33 for both regimens The physicians ratings indicated adequate quality of treatment in 938 % 30/32 of patients applying 4 patches for 3 days each and 970 % 32/33 of patients applying 3 patches for 4 days each Mean SD pain intensity scores on the numerical rating scale were similar after completion of the 3 - and 4-day regimens 373 [ 188 ] and 388 [ 175 ] points respectively as were MPQ scores 079 [ 067 ] and 079 [ 078 ] The mean SD proportion of days with at least satisfactory pain relief was 839 % 261 % and 856 % 244 % for the 3 - and 4-day regimens the corresponding proportions of nights with at least satisfactory pain relief were 852 % 266 % and 881 % 214 % Continuously assessed pain intensities at specified times of day and night numerical rating scale did not differ significantly between regimens Mean SF-36 health status scores did not differ significantly between regimens total score 377 % [ 170 % ] and 377 % [ 173 % ] Mean rates of nights with good sleep quality were 285 % 399 % for the 3-day regimen and 360 % 426 % for the 4-day regimen Local skin tolerability was comparable for the 3 - and 4-day regimens with objective findings mainly erythema at the patch-application sites in 17 of 32 and 11 of 33 patients respectively and subjective symptoms mainly itching in 16 of 32 and 13 of 33 patients The most common adverse events in the safety population were nausea dizziness/giddiness and malaise/fatigue 3/49 [ 61 % ] each Analgesic efficacy patients satisfaction with the quality of treatment and skin tolerability did not differ significantly between 3 and 4 days of patch application in these patients with chronic pain who had been previously stabilized on transdermal buprenorphine\",\n",
            "}\n",
            "13763\n",
            "{\n",
            "  \"id\" : \"20679600\",\n",
            "  \"contents\" : \"Sentinel lymph node resection SNR may reduce morbidity while providing the same clinical utility as conventional axillary dissection AD National Surgical Adjuvant Breast and Bowel Project NSABP B-32 is a randomized phase III trial comparing SNR immediately followed by AD SNAD to SNR and subsequent AD if SN is positive We report the definitive patient-reported outcomes PRO comparisons Eligible patients had clinically node-negative operable invasive breast cancer The PRO substudy included all SN-negative participants enrolled May 2001 to February 2004 at community institutions in the United States n = 749 78 % age > or = 50 87 % clinical tumor size < or = 20 cm 84 % lumpectomy 87 % white They completed questionnaires presurgery 1 and 2 to 3 weeks postoperatively and every 6 months through year 3 Arm symptoms arm use avoidance activity limitations and quality of life QOL were compared with intent-to-treat two-sample t-tests and repeated measures analyses Arm symptoms were significantly more bothersome for SNAD compared with SNR patients at 6 months mean 48 v 30 P < 001 and at 12 months 36 v 25 P = 006 Longitudinally SNAD patients were more likely to experience ipsilateral arm and breast symptoms restricted work and social activity and impaired QOL P < or = 002 all items From 12 to 36 months fewer than 15 % of either SNAD or SNR patients reported moderate or greater severity of any given symptom or activity limitation Arm morbidity was greater with SNAD than with SNR Despite considerable fears about complications from AD for breast cancer this study demonstrates that initial problems with either surgery resolve over time\",\n",
            "}\n",
            "13764\n",
            "{\n",
            "  \"id\" : \"8874336\",\n",
            "  \"contents\" : \"Although psychosocial intervention can reduce psychosocial distress following breast cancer many women who are experiencing problems are not identified and offered additional help This trial assessed effects on quality of life of psychologic distress screening among newly diagnosed nonmetastatic breast cancer patients From 1990 to 1992 all eligible patients in one regional breast cancer center were identified and offered study participation Women in both control and experimental groups received brief psychosocial intervention from a social worker at initial treatment The experimental group also had monthly telephone screening of distress levels using a brief validated instrument with additional psychosocial intervention offered only to those with high distress at screening Among 282 eligible patients 89 % were randomized and completed the study Participants psychologic distress levels decreased over the study period P = 0001 However no between-group differences were observed Mean distress scores among control and experimental women at 0 - 3 - and 12-month interviews were 207 and 204 155 and 150 and 146 and 135 respectively No between-group differences were observed with respect to physical health functional status social and leisure activities return to work or marital satisfaction Our results indicate that among patients who receive a minimal psychosocial intervention as part of their initial cancer care a distress screening program does not improve quality of life Minimal psychosocial intervention at initial treatment may be effective in reducing distress thus making it difficult to obtain additional benefit from a screening program\",\n",
            "}\n",
            "13765\n",
            "{\n",
            "  \"id\" : \"23224142\",\n",
            "  \"contents\" : \"The objective of this study was to compare the effects of two types of enteral supplements an antioxidant-enriched enteral nutrition AeEN and an immune-enhancing enteral nutrition IeEN on the nutrition immunoinflammatory response antioxidant capacity and clinical outcomes in patients after esophagectomy for cancer Patients n = 20 undergoing esophagectomy for cancer were randomized in this single-center open-label study Two types of enteral supplements were used for 5 days before surgery and 7 days after surgery The circulating levels of nutritional markers immunoinflammatory markers oxidative stress markers and the antioxidant capacity were compared throughout the perioperative period and the patients clinical outcomes were also compared The circulating levels of nutritional markers decreased after surgery but the changes were not significantly different between the AeEN group and the IeEN group throughout the perioperative period Surgery increased the immunoinflammatory markers and the levels were not significantly different between the groups after surgery Surgery also increased the levels of oxidative stress markers but there were no significant differences between the groups throughout the study period The results of this pilot study suggest that AeEN and IeEN have a similar effect on nutrition the immunoinflammatory response antioxidant capacity and clinical outcomes after esophagectomy for cancer These findings therefore warrant further studies on a larger scale\",\n",
            "}\n",
            "13766\n",
            "{\n",
            "  \"id\" : \"16514482\",\n",
            "  \"contents\" : \"Bryostatin-1 is a PKC modulator with direct anti-tumor activity and immunomodulatory properties We combined different doses of Bryostatin-1 with IL-2 to determine effects on clinical response rate and T cell phenotype in patients with advanced kidney cancer IL-2 nave patients were given 11 x 10 6 IU subcutaneously of IL-2 on days 1-4 8-11 and 15-18 of every 28-day cycle Twenty four patients were randomized to treatment cohorts of 5 15 or 25 mcg/m2 of Bryostatin-1 on days 1 8 and 15 starting in the second cycle An additional nine non-randomized patients were given 35 mcg/m2 Lymphocytes were analyzed for number activation status and production of IL-2 IL-4 and IFN-gamma Response evaluation was performed every 3 cycles Common grade 3 toxicities included fatigue 5 nausea/vomiting 5 myopathy 3 dyspnea 3 and syncope 3 Four patients in the two highest dose cohorts demonstrated evidence of tumor shrinkage although there was only 1 objective PR The median time to progression was 104 days 95 % CI 88-120 and the median survival was 452 days 95 % CI = 424-480 There was no significant boosting effect of Bryostatin-1 on lymphocytes The addition of Bryostatin-1 to IL-2 was well tolerated but the overall response rate was low 32 % indicating that further studies with this combination are not warranted\",\n",
            "}\n",
            "13767\n",
            "{\n",
            "  \"id\" : \"14996106\",\n",
            "  \"contents\" : \"Many patients find topical 5-aminolaevulinic acid ALA photodynamic therapy PDT painful Local anaesthetics are not routinely used and their effect on PDT pain has not been examined To evaluate the efficacy of tetracaine gel Ametop for pain relief during and after PDT A prospective double-blind placebo-controlled study of 42 patients with lesions < or = 2 cm diameter of superficial nonmelanoma skin cancer or dysplasia Patients were randomized to either tetracaine 4 % w/w n = 22 or vehicle n = 20 gel under occlusion for 1 h pre-irradiation Pain was assessed during and after irradiation using a visual analogue scale VAS and faces pain scale Patients who received tetracaine gel experienced only slightly less pain during PDT median VAS 4 compared with those who received placebo median VAS 45 95 % confidence interval for difference 0-3 P = 008 No significant difference in pain was experienced between the treatment groups immediately after irradiation or later When compared with placebo tetracaine gel did not significantly reduce pain during or after PDT for small lesions of superficial basal cell carcinoma Bowen s disease or actinic keratosis\",\n",
            "}\n",
            "13768\n",
            "{\n",
            "  \"id\" : \"25323620\",\n",
            "  \"contents\" : \"Many patients with lung cancer are deconditioned with poor physical fitness Lung resection reduces physical fitness further impairing the patient s ability to function in daily life We conducted a single-blind randomised controlled trial of high-intensity endurance and strength training 60min three times a week 20weeks starting 5-7weeks after surgery The control group received standard postoperative care The primary outcome was the change in peak oxygen uptake measured directly during walking until exhaustion Other outcomes included changes in pulmonary function muscular strength by one-repetition maximum 1RM total muscle mass measured by dual energy X-ray absorptiometry daily physical functioning and quality of life QoL The intention-to-treat analysis of the 61 randomised patients showed that the exercise group had a greater increase in peak oxygen uptake 34 mL/kg/min between-group difference p = 0002 carbon monoxide transfer factor Tlco 52 % predicted p = 0007 1RM leg press 295 kg p < 0001 chair stand 21 times p < 0001 stair run 43 steps p = 0002 and total muscle mass 136 kg p = 0012 compared with the controls The meanSD QoL SF-36 physical component summary score was 51855 and 433113 p = 0006 and the mental component summary score was 55553 and 466140 p = 0015 in the exercise and control groups respectively In patients recently operated for lung cancer high-intensity endurance and strength training was well tolerated and induced clinically significant improvements in peak oxygen uptake Tlco muscular strength total muscle mass functional fitness and QoL This study may provide a basis for exercise therapy after lung cancer surgery NCT01748981\",\n",
            "}\n",
            "13769\n",
            "{\n",
            "  \"id\" : \"8839902\",\n",
            "  \"contents\" : \"Node-negative breast cancers are considered to comprise a subgroup which is amenable to cure with local-regional therapy alone However approximately 30 % of affected patients present new disease manifestations within 10 years after surgery To test the hypothesis that node-negative and estrogen receptor-negative breast cancer patients can benefit from adjuvant chemotherapy a prospective randomized study was activated at the Istituto Nazionale Tumori of Milan in 1980 The study was conducted in 90 patients operated on for unilateral breast cancer who were then assigned to receive either 12 intravenous cycles of cyclophosphamide methotrexate and fluorouracil CMF every three weeks or no further treatment Adjuvant chemotherapy was administered in the outpatient clinic of the Division of Medical Oncology Patient characteristics were fairly well balanced between the two treatment groups except for primary tumor size 58 % of those with a primary tumor measuring > 2 cm in its largest diameter were randomized in the control group compared with 38 % in the CMF regimen P = 006 At 12 years after surgery treatment outcome was significantly superior for patients given adjuvant CMF The relapse-free survival rate was 71 % 95 % confidence limits CL 56-86 versus 43 % 95 % CL 28-58 and total survival was 80 % 95 % CL 68-92 versus 50 % 95 % CL 34-66 respectively The benefit from the administration of CMF was evident in all patient subsets and was not influenced by menopausal status The long-term results of this trial of adjuvant combination chemotherapy confirm our previous observations on the efficacy of adjuvant chemotherapy in node-negative breast cancer patients at high risk of early disease relapse\",\n",
            "}\n",
            "13770\n",
            "{\n",
            "  \"id\" : \"21284343\",\n",
            "  \"contents\" : \"Patients with head and neck cancer undergoing surgery have a high incidence of postoperative complications The aim of our study was to investigate whether postoperative nutrition of head and neck cancer patients using an enteral high dose of arginine 20 g per day vs a medium dose 123 g per day could improve nutritional variables as well as clinical outcome A population of 115 patients with oral and laryngeal cancer was enrolled At surgery patients were randomly allocated to two groups group I 58 patients received an enteral diet supplements with a high dose of arginine 20 g per day and group II 57 patients received an isocaloric isonitrogenous enteral formula with a medium dose of arginine 123 g per day Gastrointestinal tolerance diarrhea of both formulas was good 344 % group I and 351 % group II ns The postoperative infections complications were similar in both groups 86 % group I and 122 % group II ns Fistula was less frequent in enriched nutrition group 34 % group I and 105 % group II p = 0006 The length of postoperative stay was similar in both groups 272 + / - 178 days in group I vs 257 + / - 188 days in group II ns Enriched arginine formula improves fistula wound complications in postoperative head and neck cancer patients Our results suggest that these patients could benefit from a high dose of arginine enhanced enteral formula\",\n",
            "}\n",
            "13771\n",
            "{\n",
            "  \"id\" : \"12006526\",\n",
            "  \"contents\" : \"The purpose of this study is to evaluate HER-2 and topoisomerase IIalpha topo IIalpha as candidates for predicting the activity of anthracyclines in the adjuvant treatment of breast cancer patients In this study we evaluated HER-2 and topo IIalpha gene aberrations by fluorescence in situ hybridization in a series of 430 primary breast cancer samples Samples came from node-positive breast cancer patients randomly treated either with one of two anthracycline-based regimens [ full-dose epirubicin-cyclophosphamide HEC and moderate-dose epirubicin-cyclophosphamide EC ] or with cyclophosphamide methotrexate and 5-fluorouracil CMF in the context of a Phase III adjuvant therapy trial Event-free survival comparisons were performed between the three study arms in the subgroups of HER-2-amplified and nonamplified tumors An explorative analysis was also performed to evaluate the predictive value of topo IIalpha in the cohort of HER-2-amplified patients HER-2 amplification was observed in 73 of the 354 evaluable samples 21 % whereas topo IIalpha amplification was found in 23 of the 61 evaluable HER-2-amplified tumors 38 % The three event-free survival comparisons were CMF versus HEC CMF versus EC and EC versus HEC Hazard ratios HRs and 95 % confidence intervals CIs were as follows a CMF versus HEC HR = 142 for HER-2-amplified tumors 95 % CI 054-3 76 P = 048 and 084 for HER-2-nonamplified tumors 95 % CI 049-1 44 P = 053 b CMF versus EC HR = 165 for HER-2-amplified tumors 95 % CI 066-4 13 P = 029 and 066 for HER-2-nonamplified tumors 95 % CI 039-1 10 P = 011 and c EC versus HEC HR = 093 for HER-2-amplified tumors 95 % CI 031-2 77 P = 090 and 133 for HER-2-nonamplified tumors 95 % CI 082-2 14 P = 025 Observed HRs suggest that the anthracycline-based therapy could be more effective than CMF in the subgroup of HER-2-amplified patients whereas treatments could be equally active in the HER-2-nonamplified cohort topo IIalpha evaluation suggests that the superiority of anthracyclines over CMF in HER-2-amplified patients could be confined to the subgroup of topo IIalpha-amplified tumors HER-2 could have a predictive value for the activity of anthracycline-based regimens in the adjuvant therapy of breast cancer patients The predictive value of HER-2 would most likely be related to the concomitant amplification of the topo IIalpha gene\",\n",
            "}\n",
            "13772\n",
            "{\n",
            "  \"id\" : \"22718278\",\n",
            "  \"contents\" : \"A rare mutation G84E in HOXB13 was recently identified to be associated with prostate cancer PCa in Caucasians The goal of this study is to test association between HOXB13 genetic variants and PCa risk in Chinese men All study subjects were part of the Chinese Consortium for Prostate Cancer Genetics ChinaPCa In the first stage we screened for mutations by sequencing the HOXB13 coding region in 96 unrelated PCa patients In stage 2 G84E and novel mutations found in stage 1 were genotyped in 671 PCa patients and 1536 controls In stage 3 mutation status in 751 additional PCa patients was imputed via haplotype The G84E mutation was not detected in this study However a novel mutation G135E was identified among 96 patients in stage 1 It was also observed twice in 575 additional PCa patients but not in 1536 control subjects of stage 2 The frequency of G135E was significantly different between cases and controls with a P-value of 0027 based on Fisher s exact test Haplotype estimation showed that G135E mutation carriers shared a unique haplotype that was not observed in other subjects In stage 3 two more PCa patients were predicted to carry the G135E mutation We identified a novel rare mutation in the HOXB13 gene G135E which appears to be a founder mutation This mutation is associated with increased PCa risk in Chinese men Consistent with a previous report our findings provide further evidence that rare mutations in HOXB13 contribute to PCa risk\",\n",
            "}\n",
            "13773\n",
            "{\n",
            "  \"id\" : \"23777741\",\n",
            "  \"contents\" : \"Axillary dissection is increasingly forgone in early breast cancer patients with a clinically negative axilla The GRISO 053 randomised trial recruited 435 patients of age over 45 years tumour 14 cm and clinically negative axilla to assess the importance of axillary radiotherapy versus no axillary radiotherapy in patients not given axillary dissection In the present study on a subgroup GRISO cases our aim was to assess the prognostic importance of tumour biological factors after more than 10 years of follow-up We retrospectively assessed biological factors in a subgroup of 285 GRISO cases 145 given axillary radiotherapy 140 not given axillary radiotherapy with complete biologic therapeutic and follow-up information using multivariable Cox proportional hazards regression modelling Only 10-year cumulative incidence of distant metastasis was lower in the axillary radiotherapy 1 % than no axillary radiotherapy arm 7 % p = 0037 Irrespective of study arm hormone receptor positivity had significantly favourable effects on 10-year disease-free survival DFS and overall survival human epidermal growth factor receptor 2 HER2 - positive and triple-negative subtypes were associated with lower 10-year DFS 60 % and 76 % respectively than luminal A 96 % and B 91 % p = 0001 Ten-year DFS for high 14 % Ki67 cancers was lower than for low Ki67 cancers p = 0027 however this effect was mainly confined to the no axillary radiotherapy arm For patients with clinically node-negative small breast cancer not given axillary dissection 10-year DFS is worsened by HER2 positivity triple-negative phenotype and high Ki67 Axillary radiotherapy counteracts the negative prognostic effect of high Ki67 in patients not receiving axillary dissection\",\n",
            "}\n",
            "13774\n",
            "{\n",
            "  \"id\" : \"8973673\",\n",
            "  \"contents\" : \"To compare the pharmacodynamics and tolerability of the new goserelin acetate 108-mg depot with the 36-mg depot in patients with advanced prostate cancer during the first 3 months of therapy One hundred sixty patients were randomized in two comparative studies to receive either the 108-mg goserelin acetate depot every 12 weeks or the 36-mg goserelin acetate depot every 4 weeks for 12 weeks and then the 108-mg depot every 12 weeks thereafter Data for pharmacodynamic assessments were collected prospectively whereas clinical response data were collected retrospectively Serum testosterone profiles of the 108-mg goserelin acetate depot and the 36-mg goserelin acetate depot were similar testosterone levels in both groups fell below castrate levels by day 21 after administration Decreases in serum prostate-specific antigen level after 3 months of therapy were also similar in both groups 94 % with the 108-mg depot and 925 % with the 36-mg depot For all patients the median time to progression was 1527 weeks and the median time to death was 2136 weeks The safety profile of the 108-mg goserelin acetate depot was similar to that of the 36-mg depot hot flashes was the most common adverse event The incidence of injection site reactions was very low 2 [ 03 % ] of 614 administrations The new 108-mg depot was pharmacodynamically equivalent to the current 36-mg depot and was well tolerated both locally and systemically The observed times to progression and survival were as expected in this patient population The 108-mg goserelin-acetate depot provided a dosing schedule that was convenient for the patient and the physician and it has the potential to reduce health care costs while maintaining the quality of life in patients being treated for advanced prostate cancer\",\n",
            "}\n",
            "13775\n",
            "{\n",
            "  \"id\" : \"17591482\",\n",
            "  \"contents\" : \"The growing demand for endoscopy associated with colorectal cancer screening has resulted in busier endoscopy units and an increase in the practice of open-access endoscopy in which patients are referred for procedures without prior consultation by the gastroenterologist all of which may result in less-informed patients We sought to determine whether providing patients with a written copy of their standard endoscopy report at the conclusion of their procedure enhanced recall of the findings and recommendations Eighty consecutive outpatients who presented to 3 endoscopists were randomized to receive the results of their upper or lower endoscopy via standard verbal report VR or by standard VR followed by receipt of a computer-generated endoscopy report VR+WR from the Olympus ImageManager report generator The endoscopist communicated the VR after a standard postprocedure recovery period of 30 to 60 minutes and routinely discussed all findings and recommendations as mentioned in the WR The endoscopist was blinded as to whether the patient subsequently received the WR Recall of the endoscopic procedure was assessed by using a piloted 11-question survey instrument to be filled out 3 days after the procedure Results were calculated by using the Fisher exact and Wilcoxon rank sum tests Referral for endoscopy from University of Chicago physicians Seventy-eight of 80 patients 98 % approached about the study agreed to participate The response rate was 77 % Patients in the VR+WR group overall had a greater composite score than patients in the VR group 89 / 10 vs 77 / 10 P < 01 Patients in the VR+WR group were also significantly more likely to recall the recommendations for therapy or follow-up 72 % vs 42 % P < 01 and the name of the endoscopist 97 % vs 74 % P < 05 Patients with an education beyond the 10th-grade level were not formally accessed in this study Because of this we could not evaluate whether differences in educational attainment affected patient understanding of endoscopy procedure details and findings A computer-generated endoscopy report WR significantly improved patient recall of endoscopic procedure information compared with a VR alone Despite this patients were unable to recall 28 % of recommendations Additional study to determine if such enhanced physician-patient communication improves patient satisfaction or follow-up and whether more specific patient-directed results further improve recall needs to occur\",\n",
            "}\n",
            "13776\n",
            "{\n",
            "  \"id\" : \"24007947\",\n",
            "  \"contents\" : \"Analgesia and early quality of recovery may be improved by epidural analgesia We aimed to assess the effect of receiving epidural analgesia on surgical adverse events and quality of life after laparotomy for endometrial cancer Patients were enrolled in an international multicentre prospective randomised trial of outcomes for laparoscopic versus open surgical treatment for the management of apparent stage I endometrial cancer LACE trial The current analysis focussed on patients who received an open abdominal hysterectomy via vertical midline incision only n = 257 examining outcomes in patients who did n = 108 and did not n = 149 receive epidural analgesia Baseline characteristics were comparable between patients with or without epidural analgesia More patients without epidural 34 % ceased opioid analgesia 3-5 days after surgery compared to patients who had an epidural 7 % p < 001 Postoperative complications any grade occurred in 86 % of patients with and in 66 % of patients without an epidural p < 001 but there was no difference in serious adverse events p = 019 Epidural analgesia was associated with increased length of stay up to 48 days compared to up to 34 days in the non-epidural group There was no difference in postoperative quality of life up to six months after surgery Epidural analgesia was associated with an increase in any but not serious postoperative complications and length of stay after abdominal hysterectomy Randomised controlled trials are needed to examine the effect of epidural analgesia on surgical adverse events especially as the present data do not support a quality of life benefit with epidural analgesia\",\n",
            "}\n",
            "13777\n",
            "{\n",
            "  \"id\" : \"20084725\",\n",
            "  \"contents\" : \"The objective of this study was to evaluate the role of neoadjuvant chemotherapy in the treatment of locally advanced non small cell lung cancer NSCLC followed by radiotherapy versus radiotherapy alone Sixty nine patients were randomized to chemotherapy group A or radiotherapy alone group B The induction chemotherapy consists of cisplatin 80 mg/m2 day 1 and Gemcitabine 1250 mg/m2 infusion day 1 and 8 Cycles were repeated every 3 weeks Radiotherapy was given 4-6 weeks after chemotherapy to a dose of 60 Gy/30 fractions/6 weeks A total of 66 patients were evaluable for response 34 in group A and 32 in group BThe overall response rate was 412 % for group A and 218 % for group B P < 05 but with no complete response observed in either group At a median follow up of 15 months the overall survival was 65 % and median survival was 12 months for group AHowever in group B the overall survival at 15 months was 30 % and the median survival was 9 nt P < 0001 Treatment toxicity in group A was mainly haemotological in 79 % of patients none of them was grade II or IV Grade Nausea and vomiting was reported in 735 % of patients grade I esophagitis in 58 % of patients grade I radiation pneumonitis in 264 % of patients Alopecia was observed in 294 % of patients nephrotoxicity in 174 % Treatment toxicity in group B were generally less than in group A but not statistically significant except fr grade III vomiting 156 % and alopecia 0 % Combination chemotherapy of cisplatin and gemcitabine is a tolerable and active induction chemotherapy regimen for patients with locally advanced NSCLC Sequential radiotherapy given after induction chemotherapy is tolerable and offers a hope of improved locoregional control and survival compared with radiotherapy alone\",\n",
            "}\n",
            "13778\n",
            "{\n",
            "  \"id\" : \"11370551\",\n",
            "  \"contents\" : \"The standard treatment for patients with clinically resectable rectal cancer is surgery Postoperative radiochemotherapy is recommended for patients with advanced disease pT3/4 or pN + In recent years encouraging results of preoperative radiotherapy have been reported This prospective randomized phase-III trial CAO/ARO/AIO -94 compares the efficacy of neoadjuvant radiochemotherapy to standard postoperative radiochemotherapy We report on the design of the study and first results with regard to toxicity of radiochemotherapy and postoperative morbidity Patients with locally advanced operable rectal cancer uT3/4 or uN + Mason CS III/IV were randomly assigned to pre - or postoperative radiochemotherapy A total dose of 504 Gy single dose 18 Gy was applied to the tumor and the pelvic lymph nodes 5-FU 1000 mg/m2/d was administered concomitantly in the first and fifth week of radiation as 120-h continuous infusion Four additional cycles of 5-FU chemotherapy 500 mg/m2/d iv bolus were applied Radiochemotherapy was identical in both arms except for a small-volume boost of 54 Gy in the postoperative setting Time interval between radiochemotherapy and surgery was 4-6 weeks in both arms Techniques of surgery were standardized and included total mesorectal excision In addition stratification according to surgeons involved has been provided for Primary endpoints of the study are 5-year overall-survival local and distant control secondary endpoints include rate of curative R0 resections and sphincter saving procedures toxicity of radiochemotherapy surgical complications and quality of life As of 15th November 2000 628 patients were randomized from 26 participating institutions 310 patients were randomized to postoperative radiochemotherapy 318 patients to preoperative radiochemotherapy Acute toxicity WHO of radiochemotherapy was low with less than 15 % of patients experiencing Grade 3 or higher toxicity The principal toxicity was diarrhea with 12 % in the postoperative radiochemotherapy arm and 10 % in the preoperative radiochemotherapy arm having Grade-3 and 1 % in either arm having Grade-4 diarrhea Erythema nausea and leukopenia were the next common toxicities with less than 3 % of patients in either arm suffering Grade 3 or greater leukopenia or nausea Postoperative complication rates were similar in both arms with 12 % postoperative radiochemotherapy and 13 % preoperative radiochemotherapy of patients respectively suffering from anastomotic leakage 4 % postoperative radiochemotherapy and 3 % preoperative radiochemotherapy from postoperative bleeding and 6 % postoperative radiochemotherapy and 5 % preoperative radiochemotherapy from delayed wound healing The patient accrual of our trial is satisfactory neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity\",\n",
            "}\n",
            "13779\n",
            "{\n",
            "  \"id\" : \"22258366\",\n",
            "  \"contents\" : \"Cancer patients want access to reliable information about currently recruiting clinical trials Oncologists and their patients were randomly assigned to access a consumer-friendly cancer clinical trials web site [ Australian Cancer Trials ACT wwwaustraliancancertrialsgovau ] or to usual care in a cluster randomized controlled trial The primary outcome measured from audio recordings of oncologist-patient consultations was the proportion of patients with whom participation in any clinical trial was discussed Analysis was by intention-to-treat accounting for clustering and stratification Thirty medical oncologists and 493 patients were recruited Overall 46 % of consultations in the intervention group compared with 34 % in the control group contained a discussion about clinical trials P = 008 The mean consultation length in both groups was 29 min P = 069 The proportion consenting to a trial was 10 % in both groups P = 065 Patients knowledge about randomized trials was lower in the intervention than the control group mean score 30 versus 33 P = 003 but decisional conflict scores were similar mean score 42 versus 43 P = 083 Good communication between patients and physicians is essential Within this context a web site such as Australian Cancer Trials may be an important tool to encourage discussion about clinical trial participation\",\n",
            "}\n",
            "13780\n",
            "{\n",
            "  \"id\" : \"22529265\",\n",
            "  \"contents\" : \"This randomized multicenter blinded placebo-controlled phase III trial tested the efficacy and safety of bevacizumab BV with gemcitabine and carboplatin GC compared with GC in platinum-sensitive recurrent ovarian primary peritoneal or fallopian tube cancer ROC Patients with platinum-sensitive ROC recurrence 6 months after front-line platinum-based therapy and measurable disease were randomly assigned to GC plus either BV or placebo PL for six to 10 cycles BV or PL respectively was then continued until disease progression The primary end point was progression-free survival PFS by RECIST secondary end points were objective response rate duration of response DOR overall survival and safety Overall 484 patients were randomly assigned PFS for the BV arm was superior to that for the PL arm hazard ratio [ HR ] 0484 95 % CI 0388 to 0605 log-rank P < 0001 median PFS was 124 v 84 months respectively The objective response rate 785 % v 574 % P < 0001 and DOR 104 v 74 months HR 0534 95 % CI 0408 to 0698 were significantly improved with the addition of BV No new safety concerns were noted Grade 3 or higher hypertension 174 % v < 1 % and proteinuria 85 % v < 1 % occurred more frequently in the BV arm The rates of neutropenia and febrile neutropenia were similar in both arms Two patients in the BV arm experienced GI perforation after study treatment discontinuation GC plus BV followed by BV until progression resulted in a statistically significant improvement in PFS compared with GC plus PL in platinum-sensitive ROC\",\n",
            "}\n",
            "13781\n",
            "{\n",
            "  \"id\" : \"7712435\",\n",
            "  \"contents\" : \"From 1980 to 1987 849 patients with clinically resectable rectal adenocarcinoma were randomized into a controlled clinical trial to evaluate the role of preoperative radiotherapy Patients were given either 25 Gy during 5 to 7 days before surgery or underwent surgery alone At a median follow-up time of 107 months range 62-144 months the incidence of pelvic recurrence among 684 curatively operated patients was significantly lower among those who also received radiotherapy P < 0001 in all Dukes stages No significant difference was observed between the treatment groups with regard to frequency of distant metastases or overall survival The time to local recurrence or distant metastasis and survival was significantly prolonged in the irradiated group However the postoperative mortality was 8 % in the radiotherapy group compared with 2 % in the surgery only group P = 001 Preoperative short term radiotherapy reduced the incidence of pelvic recurrences and prolonged survival related to rectal cancer compared with surgery alone The postoperative morbidity was significantly higher in the irradiated group\",\n",
            "}\n",
            "13782\n",
            "{\n",
            "  \"id\" : \"22943949\",\n",
            "  \"contents\" : \"To compare docetaxel plus prednisone with mitoxantrone plus prednisone as first-line chemotherapy for metastatic hormone-refractory prostate cancer mHRPC From January 2007 through August 2010 62 patients with mHRPC received 5 mg of prednisone twice daily were randomly assigned to receive mitoxantrone 12 mg/m every three weeks group A or 75 mg/m every three weeks group B The cycles of each regimen were less than 10 times The primary end point was overall survival The secondary end points were the prostate-specific antigen PSA response rate the duration of PSA response and the objective tumor response rate ORR All the t test test and Fisher s exact test were performed between 2 groups Thirty-one patients enrolled in group A received a median 4 cycles of regimen range 1 - 10 whereas 30 patients enrolled in group B received a median of 7 cycles of regimen range 2 - 10 There were 452 % patients in group A and 700 % in group B had PSA response = 385 P < 005 The duration time of PSA response was 121 days range 20-323 days in group A and 168 days range 42 - 447 days in group B respectively The ORR was 150 3/20 in group A and 103 % 3/29 in group B respectively The median survival was 511 days 95 % CI 357 - 665 days in group A and 833 days 95 % CI 634 - 1032 days in group B respectively = 420 P = 0040 The incidence of thrombocytopenia in group A was higher than group B = 560 P = 0018 the incidences of nausea and vomiting = 432 P = 0038 diarrhea P = 0024 fatigue = 590 P = 0015 and alopecia = 542 P = 0020 in group B were higher than group ADocetaxel plus prednisone can lead to superior overall survival and PSA response rate in patients with mHRPC\",\n",
            "}\n",
            "13783\n",
            "{\n",
            "  \"id\" : \"17264337\",\n",
            "  \"contents\" : \"Appropriate therapy for Eastern Cooperative Oncology Group ECOG performance status PS -2 patients with advanced non-small-cell lung cancer NSCLC remains challenging PS-2 patients on ECOG 1594 had a median survival MS of only 41 months and 1-year overall survival OS of 19 % Three percent had grade 5 toxicity ECOG 1599 the first PS 2-specific US cooperative group trial for treatment-nave advanced NSCLC randomly assigned patients to dose-attenuated carboplatin/paclitaxel the least toxic regimen in ECOG 1594 or gemcitabine/cisplatin which yielded an MS of 79 months in PS-2 patients Patients received either carboplatin area under the concentration-time curve 6 and paclitaxel 200 mg/m2 every 3 weeks CbP or gemcitabine 1 g/m2 days 1 and 8 and cisplatin 60 mg/m2 day 1 every 3 weeks CG One hundred three patients were enrolled 100 proved eligible Median age was 66 years 46 % had at least 5 % weight loss 88 % had stage IV or recurrent disease Median number of cycles administered was three per arm CbP featured more grade 3 neutropathy 10 % v 0 % and more grade > or = 3 neutropenia 59 % v 33 % whereas CG yielded more grade 3 thrombocytopenia 33 % v 14 % more grade 3 fatigue 22 % v 14 % and more grade > or = 1 creatinine elevations 43 % v 6 % One grade 5 toxicity confined to the CbP arm occurred Response rate time to progression MS and 1-year OS rates for CG and CbP were 23 % 48 months 69 months and 25 % and 14 % 42 months 62 months and 19 % respectively Platinum-based combination chemotherapy for PS-2 patients with NSCLC is feasible with acceptable toxicity but survival in these patients remains inferior to that of PS-0 to -1 patients\",\n",
            "}\n",
            "13784\n",
            "{\n",
            "  \"id\" : \"20637539\",\n",
            "  \"contents\" : \"The performance characteristics of serum prostate-specific antigen PSA as a diagnostic test for prostate cancer PCa are poor The performance of the PCa antigen 3 PCA3 gene as a primary diagnostic is unknown Assess the value of PCA3 as a first-line diagnostic test Participants included men aged 63-75 who were invited for rescreening in the period from September 2007 to February 2009 within the European Randomised Study of Screening for Prostate Cancer Rotterdam section Lateral sextant biopsies were performed if the serum PSA value was > or = 30 ng/ml and/or the PCA3 score was > or = 10 Measurements included distribution and correlation of PSA value and PCA3 score and their relation to the number of cases and the characteristics of PCa detected Additional value of PCA3 was included in men with previous negative biopsy and/or PSA < 30 ng/ml In 721 men all biopsied 122 PCa cases 169 % were detected Correlation between PSA and PCA3 is poor Spearman rank correlation = 014 p < 00001 A PSA > or = 30 ng/ml misses 647 % of the total PCa that can be detected with the sextant biopsy technique and 579 % of serious PCa T2a or higher and/or Gleason grade > or = 4 n = 19 and 682 % of biopsies could have been avoided the respective data for PCA3 > or = 35 are 32 % 263 % and 517 % Performance of PCA3 in men with low PSA area under the curve [ AUC ] 063 and/or previous negative biopsy AUC 068 is unclear but has limited reliability due to small numbers PCA3 as a first-line screening test shows improvement of the performance characteristics and identification of serious disease compared with PSA in this prescreened population\",\n",
            "}\n",
            "13785\n",
            "{\n",
            "  \"id\" : \"16959304\",\n",
            "  \"contents\" : \"1 Evaluation of the influence of hemostatic disorders on renal function in patients with FIGO stage IIB-IIIB cervical cancer treated with radiochemotherapy 2 Identifying methods of improving renal function in this patients group Treatment design assumes the administration of a total radiation dose of 46-65 Gy and additionally cisplatin 40 mg/m2 every 7 days in patients with normal plasma creatinine level Renal function was assessed with the aid of dynamic scintigraphy with glomerular filtration rate GFR evaluation Analysis of serum hemostatic system covered D-dimers PAP PAI-1 tPA FDP F1 +2 and TAT The same hemostatic parameters were also evaluated in urine The patients were divided into two groups the study group - ie patients with affected GFR and the control group - with normal GFR Half of study group patients throughout the entire treatment receive nadroparine 2850 units aXa/0 3 ml every 24 h during and 6 weeks after the treatment There are significant decreases of GFR in control median -97 % and study group without nadroparine median -99 % and increase in the GFR median 223 % in study group with nadroparine p = 00001 Plasma and urine hemostatic parameter analysis showed activation of fibrinolysis in patients treated with nadroparine and fibrinolysis inhibition in remaining groups 1 Inhibition of fibrinolysis may cause subclinical renal insufficiency in patients with advanced cervical cancer 2 Insufficiency increases after the end of radiochemotherapy in patients as well with normal GFR as with primary decreased GFR 3 Application of nadroparine causes fibrinolysis activation and increase in the GFR\",\n",
            "}\n",
            "13786\n",
            "{\n",
            "  \"id\" : \"9570192\",\n",
            "  \"contents\" : \"Improvement in endothelial function may be an important mechanism by which estrogen replacement therapy protects postmenopausal women against coronary artery disease However combined hormone replacement therapy is more frequently used owing to the risk of uterine cancer with estrogen-only therapy Concurrent progesterone treatment may attenuate the beneficial effects of estrogens not only on the lipid profile but also on the endothelium We studied endothelial vasomotor function in 100 healthy postmenopausal women aged 533 + / -29 years randomized to either combined hormone replacement therapy n = 46 or no substitution n = 54 29 + / -05 years earlier In addition 30 healthy premenopausal women aged 303 + / -42 years were studied With external ultrasound brachial artery diameter was measured at rest during reactive hyperemia with increased flow causing endothelium-dependent dilation and after sublingual nitroglycerin causing endothelium-independent dilation Compared with premenopausal women flow-mediated dilation was significantly reduced in both postmenopausal groups In the postmenopausal women total cholesterol was lower in the treated women 566 + / -083 versus 613 + / -092 mmol/L P = 025 whereas HDL cholesterol was similar 191 + / -053 versus 185 + / -046 mmol/L P = NS Dilation to flow and to nitroglycerin was similar in the two postmenopausal groups flow 25 + / -29 % versus 22 + / -22 % P = NS nitrate 187 + / -59 % versus 172 + / -62 % P = NS Long-term combined oral hormone replacement therapy is without beneficial effects on endothelial vasomotor function in healthy postmenopausal women This supports the view that progesterone may attenuate the beneficial effects of unopposed estrogen replacement\",\n",
            "}\n",
            "13787\n",
            "{\n",
            "  \"id\" : \"22699129\",\n",
            "  \"contents\" : \"Breast cancer surgery is associated with a high incidence of persistent postsurgical pain PPSP The aim of this study was to evaluate the impact of intravenous IV lidocaine on acute and PPSP analgesic requirements and sensation abnormalities in patients undergoing surgery for breast cancer Thirty-six patients participated in this randomized double-blinded study Before induction of general anesthesia patients received a bolus of intravenous lidocaine 15 mg/kg followed by a continuous infusion of lidocaine 15 mg/kgh lidocaine group or an equal volume of saline control group The infusion was stopped 1 hour after the skin closure Pain scores and analgesic consumption were recorded at 2 4 24 hours and then daily for 1 week postoperatively Three months later patients were assessed for PPSP and secondary hyperalgesia Two 118 % patients in the lidocaine group and 9 474 % patients in the control group reported PPSP at 3 months follow-up P = 0031 McGill Pain Questionnaire revealed greater present pain intensity-visual analog scale in the control group 146 225 vs 26 75 P = 0025 Secondary hyperalgesia area of hyperalgesia/length of surgical incision was significantly less in the lidocaine group compared with control group 02 08 vs 32 45 cm P = 0002 The 2 groups were similar in terms of analgesic consumption during the early postoperative period Intravenous perioperative lidocaine decreases the incidence and severity of PPSP after breast cancer surgery Prevention of the induction of central hyperalgesia is a potential mechanism\",\n",
            "}\n",
            "13788\n",
            "{\n",
            "  \"id\" : \"22395580\",\n",
            "  \"contents\" : \"The efficacy and safety profile of ustekinumab with up to three years of exposure suggested a favorable benefit-risk profile in patients with moderate to severe psoriasis To evaluate the safety of ustekinumab in patients with moderate to severe psoriasis treated for up to four years Safety data were pooled across four Phase II/III randomized controlled trials Rates over time and cumulative rates of adverse events AEs AEs leading to treatment discontinuation serious adverse events SAEs serious infections malignancies and major adverse cardiovascular events MACE ie cardiovascular death myocardial infarction [ MI ] or stroke as adjudicated by an independent panel of academic cardiologists were evaluated Observed rates of AEs of interest were compared with those expected in the general malignancies MI and stroke and psoriasis serious infections MI and stroke populations Overall 3117 patients were followed for up to four years 6791 patient-years Rates of AEs AEs leading to treatment discontinuation and SAEs remained stable over time whereas cumulative rates were generally comparable between patients who received 45 mg and 90 mg of ustekinumab The rates of AEs of interest also remained stable over time and cumulative rates per 100 patient-years were 080 and 132 serious infections 070 and 053 nonmelanoma skin cancer 063 and 061 other malignancies and 056 and 046 MACE in patients treated with 45 mg and 90 mg respectively Rates of AEs of interest were consistent with those in the general and psoriasis populations The safety profile of long-term ustekinumab treatment with up to four years of continuous use remains consistent with previous reports with no evidence of cumulative toxicity\",\n",
            "}\n",
            "13789\n",
            "{\n",
            "  \"id\" : \"19738125\",\n",
            "  \"contents\" : \"This study investigated whether sequential administration of erlotinib and chemotherapy improves clinical outcomes versus chemotherapy alone in unselected chemotherapy-nave patients with advanced non-small-cell lung cancer NSCLC Previously untreated patients n = 154 with stage IIIB or IV NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomly assigned to receive erlotinib 150 mg/d or placebo on days 15 to 28 of a 4-week cycle that included gemcitabine 1250 mg/m 2 days 1 and 8 and either cisplatin 75 mg/m 2 day 1 or carboplatin 5 x area under the serum concentration-time curve day 1 The primary end point was nonprogression rate NPR at 8 weeks Secondary end points included tumor response rate NPR at 16 weeks duration of response progression-free survival PFS overall survival OS and safety The NPR at 8 weeks was 803 % in the gemcitabine plus cisplatin or carboplatin GC - erlotinib arm n = 76 and 769 % in the GC-placebo arm n = 78 At 16 weeks the NPR was 645 % for GC-erlotinib versus 538 % for GC-placebo The response rate was 355 % for GC-erlotinib versus 244 % for GC-placebo PFS was significantly longer with GC-erlotinib than with GC-placebo adjusted hazard ratio 047 log-rank P = 0002 median 294 v 234 weeks this benefit was consistent across all clinical subgroups There was no significant difference in OS The addition of erlotinib to chemotherapy was well tolerated with no increase in hematologic toxicity and no treatment-related interstitial lung disease Sequential administration of erlotinib following gemcitabine/platinum chemotherapy led to a significant improvement in PFS This treatment approach warrants further investigation in a phase III study\",\n",
            "}\n",
            "13790\n",
            "{\n",
            "  \"id\" : \"15736522\",\n",
            "  \"contents\" : \"The convergent validity between utility assessment methods was assessed Investigated were patients with esophageal cancer treated surgically with curative intent Patients were interviewed in a period from 3 to 12 months after surgical resection Patients evaluated their actual health and seven other states Visual analogue scale VAS and standard gamble SG utilities were obtained for the health states in an interview Patients also indicated whether or not they preferred death to living in a health state worse than dead [ WTD ] preferences Fifty patients completed the interview Convergent validity was excellent at the aggregate and individual level However the relation between VAS and SG differed strongly across individuals On a scale from 0 dead to 100 perfect health SG scores were lower for patients with WTD preferences mean difference d = 35 p = 002 however VAS scores did not vary by WTD preferences In general there is good agreement between VAS and SG measures although patients disagree about how the VAS and SG are related The standard gamble varied by WTD preferences however the VAS did not\",\n",
            "}\n",
            "13791\n",
            "{\n",
            "  \"id\" : \"9679262\",\n",
            "  \"contents\" : \"To test the efficacy of structured symptom assessment on level and rate of change in symptom distress over time Prospective six-month randomized control trial Outpatient oncology offices and clinics in California 48 subjects newly diagnosed with advanced lung cancer predominantly non-small cell Most subjects received chemotherapy 50 % were women and their average age was 62 years 190 observations were analyzed Subjects were assigned randomly to structured assessment or usual care Both groups completed the Symptom Distress Scale SDS monthly After bivariate screening of potential predictors a multivariate regression model for level and rate of change in SDS scores was created Symptom distress functional status and emotional distress Fatigue was the most common severely distressing symptom In a multivariate model chemotherapy and systematic assessment were associated with less symptom distress over time Higher scores in depression and more functional limitations were related to higher levels of overall distress Weight loss had a small impact Systematic use of structured symptom assessment forestalled increased symptom distress over time Chemotherapy lessened symptom distress but the impact diminished with time Subjects with more depression and greater functional limitations had greater symptom distress During the course of advanced lung cancer systematic ongoing nursing assessment of symptoms may be the first step in enhancing interventions to decrease distress Patients at highest risk for symptom distress are those who experience emotional distress and functional limitations\",\n",
            "}\n",
            "13792\n",
            "{\n",
            "  \"id\" : \"24055415\",\n",
            "  \"contents\" : \"5-year results of the UK Standardisation of Breast Radiotherapy START trials suggested that lower total doses of radiotherapy delivered in fewer larger doses fractions are at least as safe and effective as the historical standard regimen 50 Gy in 25 fractions for women after primary surgery for early breast cancer In this prespecified analysis we report the 10-year follow-up of the START trials testing 13 fraction and 15 fraction regimens From 1999 to 2002 women with completely excised invasive breast cancer pT1-3a pN0-1 M0 were enrolled from 35 UK radiotherapy centres Patients were randomly assigned to a treatment regimen after primary surgery followed by chemotherapy and endocrine treatment where prescribed Randomisation was computer-generated and stratified by centre type of primary surgery breast-conservation surgery or mastectomy and tumour bed boost radiotherapy In START-A a regimen of 50 Gy in 25 fractions over 5 weeks was compared with 416 Gy or 39 Gy in 13 fractions over 5 weeks In START-B a regimen of 50 Gy in 25 fractions over 5 weeks was compared with 40 Gy in 15 fractions over 3 weeks Eligibility criteria included age older than 18 years and no immediate surgical reconstruction Primary endpoints were local-regional tumour relapse and late normal tissue effects Analysis was by intention to treat Follow-up data are still being collected This study is registered as an International Standard Randomised Controlled Trial number ISRCTN59368779 START-A enrolled 2236 women Median follow-up was 93 years IQR 80-100 after which 139 local-regional relapses had occurred 10-year rates of local-regional relapse did not differ significantly between the 416 Gy and 50 Gy regimen groups 63 % 95 % CI 47-85 vs 74 % 55-100 hazard ratio [ HR ] 091 95 % CI 059-138 p = 065 or the 39 Gy 88 % 95 % CI 67-114 and 50 Gy regimen groups HR 118 95 % CI 079-176 p = 041 In START-A moderate or marked breast induration telangiectasia and breast oedema were significantly less common normal tissue effects in the 39 Gy group than in the 50 Gy group Normal tissue effects did not differ significantly between 416 Gy and 50 Gy groups START-B enrolled 2215 women Median follow-up was 99 years IQR 75-101 after which 95 local-regional relapses had occurred The proportion of patients with local-regional relapse at 10 years did not differ significantly between the 40 Gy group 43 % 95 % CI 32-59 and the 50 Gy group 55 % 95 % CI 42-72 HR 077 95 % CI 051-116 p = 021 In START-B breast shrinkage telangiectasia and breast oedema were significantly less common normal tissue effects in the 40 Gy group than in the 50 Gy group Long-term follow-up confirms that appropriately dosed hypofractionated radiotherapy is safe and effective for patients with early breast cancer The results support the continued use of 40 Gy in 15 fractions which has already been adopted by most UK centres as the standard of care for women requiring adjuvant radiotherapy for invasive early breast cancer Cancer Research UK UK Medical Research Council UK Department of Health\",\n",
            "}\n",
            "13793\n",
            "{\n",
            "  \"id\" : \"16447306\",\n",
            "  \"contents\" : \"Active for Life After Cancer is a randomized trial evaluating the efficacy of a 6-month group-based lifestyle physical activity program Lifestyle for prostate cancer patients to improve quality of life QOL including physical and emotional functioning compared to a group-based Educational Support Program and a Standard Care Program no group A total of 134 prostate cancer patients receiving continuous androgen-ablation were randomly assigned to one of the three study conditions Results indicated no significant improvements in QOL at 6 or 12 months Both group-based programs were positively received and yielded good attendance and retention Lifestyle participants demonstrated significant improvements in most theoretical mediators proposed by the Transtheoretical Model and Social Cognitive Theory to affect physical activity Despite these improvements no significant changes were found for most physical activity measures Results suggest a lifestyle program focusing on cognitive-behavioral skills training alone is insufficient for promoting routine physical activity in these patients\",\n",
            "}\n",
            "13794\n",
            "{\n",
            "  \"id\" : \"14584060\",\n",
            "  \"contents\" : \"The first analysis of the ATAC Arimidex Tamoxifen Alone or in Combination trial median follow-up 33 months demonstrated that in adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer anastrozole was superior to tamoxifen in terms of disease-free survival DFS time to recurrence TTR and incidence of contralateral breast cancer CLBC In the current article the results of the first efficacy update based on a median follow-up period of 47 months are reported along with the results of an updated safety analysis performed 7 months after the first analysis median duration of treatment 369 months DFS TTR CLBC incidence and safety were assessed in the same patient group as in the first analysis of the ATAC trial DFS estimates at 4 years remained significantly more favorable 869 % vs 845 % respectively for patients receiving anastrozole compared with those receiving tamoxifen hazard ratio [ HR ] 086 95 % confidence interval [ CI ] 076-0 99 P = 003 The benefit generated by anastrozole in terms of DFS was even greater in patients with hormone receptor-positive tumors HR 082 95 % CI 070-0 96 P = 0014 The HR for TTR also indicated a significant benefit for patients receiving anastrozole compared with those receiving tamoxifen HR 083 95 % CI 071-0 96 P = 0015 with additional benefit for patients with hormone receptor-positive tumors HR 078 95 % CI 065-0 93 P = 0007 CLBC incidence data also continued to favor anastrozole odds ratio [ OR ] 062 95 % CI 038-1 02 P = 0062 and statistical significance was achieved in the hormone receptor-positive subgroup OR 056 95 % CI 032-0 98 P = 0042 The updated safety analysis also confirmed the findings of the first analysis in that endometrial cancer P = 0007 vaginal bleeding and discharge P < 0001 for both cerebrovascular events P < 0001 venous thromboembolic events P < 0001 and hot flashes P < 0001 all occurred less frequently in the anastrozole group whereas musculoskeletal disorders and fractures P < 0001 for both continued to occur less frequently in the tamoxifen group These results indicated that the safety profile of anastrozole remained consistent After an additional follow-up period anastrozole continues to show superior efficacy which is most apparent in the clinically relevant hormone receptor-positive population Furthermore anastrozole has numerous noteworthy advantages in terms of tolerability compared with tamoxifen These findings suggest that the benefits of anastrozole are likely to be maintained in the long term and provide further support for the status of anastrozole as a valid treatment option for postmenopausal women with hormone-sensitive early-stage breast cancer\",\n",
            "}\n",
            "13795\n",
            "{\n",
            "  \"id\" : \"21415357\",\n",
            "  \"contents\" : \"The human papillomavirus HPV Persistence and Progression Cohort is a natural history study of carcinogenic HPV positive women Here we present the HPV genotypes found in first 500 cases of cervical intraepithelial neoplasia grade 3 CIN3 or more severe disease CIN3 + diagnosed at the study baseline Women aged 30 and older were screened for cervical cancer using Pap smears and tested for carcinogenic HPV using Hybrid Capture 2 HC2 Qiagen We randomly selected women who tested HPV positive and were diagnosed with CIN3 + n = 448 or without CIN3 + < CIN3 n = 830 Residual cervical Pap specimens were HPV genotyped using a MY09/11 L1-targeted PCR method Among HC2-positive women HPV16 489 % HPV31 92 % and HPV18 85 % were the most common HPV genotypes in CIN3 + There was a decrease at older ages in the fraction of CIN3 P trend = 0006 adenocarcinoma in situ AIS P trend = 008 and CIN3/AIS P trend = 0002 associated with HPV16 Compared to the other carcinogenic HPV genotypes in aggregate HPV18 was strongly associated with CIN3 + in women with a normal Pap [ odds ratio OR = 57 95 % CI = 12-26 ] but not in women with abnormal Pap OR = 13 95 % CI = 074-2 3 HPV16 is more strongly associated with cervical precancer diagnosed in younger women vs older women HPV18 infections were linked to precancerous lesions that were missed by cytology The progression timeline of HPV16 differs from other carcinogenic HPV genotypes which may impact the use of HPV16 detection in the management of HPV-positive women\",\n",
            "}\n",
            "13796\n",
            "{\n",
            "  \"id\" : \"11269737\",\n",
            "  \"contents\" : \"Clinical toxicity associated with 5-fluorouracil 5-FU is related to the area under the plasma concentration-time curve AUC Recently short-term infusions of 5-FU given over 30 or 60 min have been substituted for conventional bolus 5-FU given over 3-5 min in randomized clinical trials but there are only limited pharmacokinetic data for these altered infusion durations We therefore wished to determine the pharmacokinetics and toxicity associated with 5-FU given as a 1-h intravenous iv infusion A group of 22 adults with advanced gastrointestinal tract cancers and no prior systemic chemotherapy for advanced disease received interferon alpha-2a 5 MU/m2 sc days 1-7 leucovorin 500 mg/m2 iv over 30 min days 2-6 and 5-FU 370 mg/m2 iv over 1 h days 2-6 The doses of 5-FU and interferon-alpha were adjusted according to individual tolerance The pharmacokinetics and clinical toxicity were retrospectively compared with patients receiving the same regimen under the same treatment guidelines except that 5-FU was given over 5 min The regimen was well tolerated and 41 % of the patients tolerated 5-FU dose escalations to 425-560 mg/m2 per day Grade 3 or worse diarrhea and fatigue ultimately occurred in 14 % of the patients each Granulocytopenia mucositis and diarrhea appeared to be appreciably milder in the present trial compared with our prior phase II experience in colorectal cancer The peak 5-FU plasma levels and AUC with 370 mg/m2 5-FU given over 1 h were 73-fold and 24-fold lower than previously measured in 31 patients who received 5-FU over 5 min Increasing the length of 5-FU infusion to 1 h seemed to substantially reduce the clinical toxicity with this modulated 5-FU regimen likely due to markedly lower peak 5-FU plasma levels and AUC Changes in the duration of a short infusion of 5-FU clearly affects the clinical toxicity but raises the concern of a potentially adverse impact on its antitumor activity These results suggest the importance of including precise guidelines concerning the time over which 5-FU is given in clinical trials Having a specified duration of 5-FU infusion is also important if 5-FU dose escalation is considered\",\n",
            "}\n",
            "13797\n",
            "{\n",
            "  \"id\" : \"19276396\",\n",
            "  \"contents\" : \"The study compared the efficacy of a first-line treatment with day 1 iv vinorelbine NVBiv and day 8 oral vinorelbine NVBo versus docetaxel DCT in a cisplatin-based combination in advanced non-small-cell lung cancer in terms of time to treatment failure TTF overall response progression-free survival PFS overall survival OS tolerance and quality of life QoL Patients were randomly assigned to receive cisplatin 80 mg/m2 with NVBiv 30 mg/m2 on day 1 and NVBo 80 mg/m2 on day 8 every 3 weeks after a first cycle of NVBiv 25 mg/m2 on day 1 and NVBo 60 mg/m2 on day 8 arm A or cisplatin 75 mg/m2 and DCT 75 mg/m2 on day 1 every 3 weeks arm B for a maximum of six cycles in both arms From 2 February 2004 to 1 January 2006 390 patients were entered in a randomised study and 381 were treated The patient characteristics are as follows arms A/B metastatic % 805 / 848 patients with three or more organs involved % 453 / 408 median age 594 / 621 years male 139/146 squamous % 342 / 335 adenocarcinoma % 416 / 393 median TTF arms A/B in months [ 95 % confidence interval CI ] 32 30-4 2 41 34-4 5 P = 019 overall response arms A/B 95 % CI 274 % 212 % to 342 % 272 % 210 % to 342 % median PFS arms A/B in months 95 % CI 49 44-5 9 51 43-6 1 P = 099 and median OS arms A/B in months 95 % CI 99 84-11 6 98 88-11 5 P = 058 The median survival for squamous histology was 887 / 982 months and for adenocarcinoma 1173 / 1160 months for arms A and B respectively Main haematological toxicity was grade 3-4 neutropenia 244 % arm A and 288 % arm B QoL as measured by the Lung Cancer Symptom Scale was similar in both arms Both arms provided similar efficacy in terms of response time-related parameters and QoL with an acceptable tolerance profile In the current Global Lung Oncology Branch trial 3 NVBo was shown to be effective as a substitute for the iv formulation This can relieve the burden of the iv injection on day 8 and can optimise the hospital s resources and improve patient convenience\",\n",
            "}\n",
            "13798\n",
            "{\n",
            "  \"id\" : \"16770976\",\n",
            "  \"contents\" : \"To prospectively assess whether low-molecular-weight heparin LMWH provides a survival benefit in patients with advanced cancer Between December 1998 and June 2001 we performed a randomized controlled study of patients with advanced cancer Initially the study was double blinded and placebo controlled with the patients receiving daily injections of 5000 U of LMWH or saline However because of low accrual midway through the study the placebo injection arm was eliminated and the study became open labeled with patients receiving either LMWH injections plus standard clinical care or standard clinical care alone The primary study end point was overall survival Of 141 patients randomized to this clinical trial 3 dropped out leaving 138 patients The median survival time was 105 months 95 % confidence interval 76-12 2 months for the combined standard care and placebo groups The median survival time for the combined LMWH arms was 73 months 95 % confidence interval 48-12 2 months These median survival times were not significantly different log-rank P = 46 The median survival times for the blinded and unblinded LMWH groups were 62 months and 90 months respectively The median survival times were 103 months for the blinded placebo arm and 105 months for the standard care arm The rate of severe or life-threatening venous thromboembolism was 6 % in the LMWH arms and 7 % in the control arms The rate of severe or life-threatening bleeding was 3 % in the LMWH arms and 7 % in the control arms\",\n",
            "}\n",
            "13799\n",
            "{\n",
            "  \"id\" : \"18987368\",\n",
            "  \"contents\" : \"The efficacy and safety of testosterone treatment for hypoactive sexual desire disorder in postmenopausal women not receiving estrogen therapy are unknown We conducted a double-blind placebo-controlled 52-week trial in which 814 women with hypoactive sexual desire disorder were randomly assigned to receive a patch delivering 150 or 300 microg of testosterone per day or placebo Efficacy was measured to week 24 safety was evaluated over a period of 52 weeks with a subgroup of participants followed for an additional year The primary end point was the change from baseline to week 24 in the 4-week frequency of satisfying sexual episodes At 24 weeks the increase in the 4-week frequency of satisfying sexual episodes was significantly greater in the group receiving 300 microg of testosterone per day than in the placebo group an increase of 21 episodes vs 07 P < 0001 but not in the group receiving 150 microg per day 12 episodes P = 011 As compared with placebo both doses of testosterone were associated with significant increases in desire 300 microg per day P < 0001 150 microg per day P = 004 and decreases in distress 300 microg per day P < 0001 150 microg per day P = 004 The rate of androgenic adverse events - primarily unwanted hair growth - was higher in the group receiving 300 microg of testosterone per day than in the placebo group 300 % vs 231 % Breast cancer was diagnosed in four women who received testosterone as compared with none who received placebo one of the four received the diagnosis in the first 4 months of the study period and one in retrospect had symptoms before undergoing randomization In postmenopausal women not receiving estrogen therapy treatment with a patch delivering 300 microg of testosterone per day resulted in a modest but meaningful improvement in sexual function The long-term effects of testosterone including effects on the breast remain uncertain ClinicalTrialsgov number NCT00131495\",\n",
            "}\n",
            "13800\n",
            "{\n",
            "  \"id\" : \"25225010\",\n",
            "  \"contents\" : \"Sarcopenia is a defining feature of cancer cachexia associated with physical decline poor quality of life and poor prognosis Thus maintaining muscle mass is an important aim of cachexia treatment Many patients at risk for developing cachexia or with cachexia experience side effects of chemotherapy that might aggravate the development of cachexia However achieving tumor control might reverse the catabolic processes causing cachexia There is limited knowledge about muscle mass changes during chemotherapy or whether changes in muscle mass are associated with response to chemotherapy In this pilot study patients with advanced non-small cell lung cancer NSCLC receiving three courses of palliative chemotherapy were analyzed Muscle mass was measured as skeletal muscle cross sectional area SMCA at the level of the third lumbar vertebrae using CT images taken before and after chemotherapy In total 35 patients 48 % women mean age 67 years range 56-86 participated 83 % had stage IV disease and 71 % were sarcopenic at baseline Mean reduction in SMCA from pre - to post-chemotherapy was 46 cm2 CI 95 % -73 -- 19 p < 0002 corresponding to a 14 kg loss of whole body muscle mass Sixteen patients remained stable or gained SMCA Of these 14 56 % responded to chemotherapy while two progressed p = 0071 Maintaining or gaining SMCA resulted in longer median overall survival loss 58 months stable/gain 107 months p = 0073 Stage of disease p = 0003 treatment regimen p = 0023 response to chemotherapy p = 0007 and SMCA change p = 0040 but not sarcopenia at baseline were significant prognostic factors in the multivariate survival analyses Almost half of the patients had stable or increased muscle mass during chemotherapy without receiving any cachexia treatment Nearly all of these patients responded to the chemotherapy Increase in muscle mass but not sarcopenia at baseline was a significant prognostic factor\",\n",
            "}\n",
            "13801\n",
            "{\n",
            "  \"id\" : \"8186168\",\n",
            "  \"contents\" : \"Active participation and asking questions are important ways in which patients can ensure they understand what the doctor has said This study evaluated a question prompt sheet designed to encourage patients to ask questions in the cancer consultation Patients n = 142 were randomised to receive i a question prompt sheet or ii a general sheet informing patients of services available through the regional Cancer Council Recall of information was assessed in a structured interview 4-20 days after the consultation Questionnaires to assess patient satisfaction and adjustment to cancer were sent by mail The question prompt sheet had a significant effect in one content area prognosis Thirty-five percent of patients who received the question handout asked questions about prognosis compared to 16 % of those receiving the information handout The prompt sheet did not increase the mean number of questions asked overall Age in/out-patient status gender and involvement preference were predictive of both number and duration of patient questions A question prompt sheet has a limited but important effect on patient question asking behaviour in the cancer consultation\",\n",
            "}\n",
            "13802\n",
            "{\n",
            "  \"id\" : \"8909381\",\n",
            "  \"contents\" : \"Pegylated recombinant human megakaryocyte growth and development factor PEG-rHuMGDF is a potent stimulator of megakaryocyte colony formation and platelet production It is likely to be useful in the management of severe thrombocytopenia To determine its clinical activity and safety we gave it to patients with advanced cancer before chemotherapy Patients were randomly assigned to receive either PEG-rHuMGDF or placebo in a three to one ratio PEG-rHuMGDF was given at a dose of 003 01 03 or 10 microgram/kg body weight The study drug or placebo were administered daily by subcutaneous injection for up to 10 days or until a target platelet count was reached 17 patients median age 59 years received either PEG-rHuMGDF 13 patients or placebo four patients PEG-rHuMGDF produced a dose-dependent increase in platelet counts Patients given placebo 003 and 01 microgram/kg of PEG-rHuMGDF had median increases in platelet counts of 16 % 12 % and 39 % Those receiving 03 and 10 microgram/kg of PEG-rHuMGDF had an increase in blood platelets of between 51 % and 584 % Platelets rose from day 6 of PEG-rHuMGDF administration and continued to rise after stopping the drug The platelet count peaked between days 12 and 18 and remained above 450 x 10 9 / L for up to 21 days There were no alterations in white-blood-cell count or haematocrit and low toxicity Platelets taken from patients during PEG-rHuMGDF administration and at the time of peak platelet count were morphologically and functionally normal The potency with which PEG-rHuMGDF stimulates platelet production and its low toxicity indicate that this is likely to be a useful agent for the management of thrombocytopenia\",\n",
            "}\n",
            "13803\n",
            "{\n",
            "  \"id\" : \"21598237\",\n",
            "  \"contents\" : \"Controversies exist with regard to thoracic radiotherapy volumes for limited-stage small cell lung cancer SCLC This study compared locoregional progression and overall survival between limited-stage SCLC patients who received thoracic radiotherapy to different target volumes after induction chemotherapy Chemotherapy consisted of 6 cycles of etoposide and cisplatin After 2 cycles of etoposide and cisplatin patients were randomly assigned to receive thoracic radiotherapy to either the postchemotherapy or prechemotherapy tumor extent as study arm or control Elective nodal irradiation was omitted for both arms Forty-five Gy/30Fx/19 days thoracic radiotherapy was administered concurrently with cycle 3 chemotherapy Prophylactic cranial irradiation was administered to patients who achieved complete remission An interim analysis was planned when the first 80 patients had been followed for at least 6 months for consideration of potential inferiority in the study arm Forty-two and 43 patients were randomly assigned to a study arm and a control respectively The local recurrence rates were 316 % 12 of 38 and 286 % 12 of 42 respectively P = 81 The isolated nodal failure rates were 26 % 1 of 38 and 24 % 1 of 42 respectively P = 100 All isolated nodal failure sites were in the ipsilateral supraclavicular fossa Mediastinal N3 was the only factor to predict isolated nodal failure P = 004 odds ratio [ OR ] 2933 95 % CI 294-292 38 One-year and 3-year overall survival rates were 806 % 362 % and 789 % 364 % respectively P = 54 Preliminary results indicated that irradiated postchemotherapy tumor extent and omitted elective nodal irradiation did not decrease locoregional control in the study arm and the overall survival difference was not statistically significant between the 2 arms Further investigation is warranted\",\n",
            "}\n",
            "13804\n",
            "{\n",
            "  \"id\" : \"25964246\",\n",
            "  \"contents\" : \"To determine the prognostic and predictive value of intrinsic subtyping by using immunohistochemical IHC biomarkers for ipsilateral breast relapse IBR in participants in an early breast cancer randomized trial of tamoxifen with or without breast radiotherapy RT IHC analysis of estrogen receptor progesterone receptor human epidermal growth factor receptor 2 HER2 cytokeratin 5/6 epidermal growth factor receptor and Ki-67 was conducted on 501 of 769 available blocks Patients were classified as luminal A n = 265 luminal B n = 165 or high-risk subtype luminal HER2 n = 22 HER2 enriched n = 13 basal like n = 30 or triple-negative nonbasal n = 6 Median follow-up was 10 years Classification by subtype was prognostic for IBR 10-year estimates luminal A 52 % luminal B 105 % high-risk subtypes 213 % P < 001 Luminal subtypes seemed to derive less benefit from RT luminal A hazard ratio [ HR ] 040 luminal B HR 051 than high-risk subtypes HR 013 however the overall subtype-treatment interaction term was not significant P = 26 In an exploratory analysis of women with clinical low-risk age older than 60 years T1 grade 1 or 2 luminal A tumors n = 151 10-year IBR was 31 % versus 118 % for the high-risk cohort n = 341 P = 0063 Clinical low-risk luminal A patients had a 10-year IBR of 13 % with tamoxifen versus 50 % with tamoxifen plus RT P = 42 Multivariable analysis showed that RT HR 031 P < 001 clinical risk group HR 22 P = 025 and luminal A subtype HR 025 P < 001 were significantly associated with IBR IHC subtyping was prognostic for IBR but was not predictive of benefit from RT Further studies may validate the exploratory finding of a low-risk luminal A group who may be spared breast RT\",\n",
            "}\n",
            "13805\n",
            "{\n",
            "  \"id\" : \"19010349\",\n",
            "  \"contents\" : \"Fruit and vegetable FV intake in black men are far below national recommendations Urban primarily immigrant black men n = 490 from the New York City metropolitan area participating in the Cancer Awareness and Prevention CAP Trial 2005-2007 were randomly assigned to one of two intervention groups 1 FV Education FVE or 2 Prostate Education PE Both interventions entailed a mailed brochure plus two tailored telephone education TTE calls Outcomes measured at baseline and at eight months included knowledge of FV recommendations perceived benefits stage of readiness to adopt recommendations and self-reported FV consumption At follow-up the FVE group consumed an average of 12 more FV servings per day than the PE group P < 0001 adjusted for baseline The FVE group also demonstrated increases in knowledge about recommended FV amounts P < 001 and appropriate serving sizes P < 005 and in the percent of participants moving from a lower to a higher stage of readiness to adopt FV recommendations P < 005 The FVE group did not demonstrate increases in knowledge related to the importance of eating a colorful variety or in the ability to name potential health benefits TTE can be a practical and moderately effective intervention for raising awareness of FV recommendations and for promoting FV consumption in urban and primarily immigrant black men\",\n",
            "}\n",
            "13806\n",
            "{\n",
            "  \"id\" : \"17952589\",\n",
            "  \"contents\" : \"Raloxifene is a second-generation selective estrogen receptor modulator that reduces the incidence of breast cancer in postmenopausal women Exemestane a steroidal aromatase inhibitor decreases contralateral new breast cancers in postmenopausal women when taken in the adjuvant setting Preclinical evidence suggests a rationale for coadministration of these agents to achieve complete estrogen blockade We tested the safety and tolerability of combination exemestane and raloxifene in 11 postmenopausal women with a history of hormone receptor-negative breast cancer Patients were randomized to either raloxifene 60 mg PO daily or exemestane 25 mg PO daily for 2 weeks Patients then initiated combination therapy at the same dose levels for a minimum of 1 year Pharmacokinetic and pharmacodynamic data for plasma estrogens raloxifene exemestane and their metabolites were collected at the end of single-agent therapy and during combination therapy Plasma concentration-time profiles for each drug were unchanged with monotherapy versus combination therapy Raloxifene did not affect plasma estrogen levels Plasma estrogen concentrations were suppressed below the lower limit of detection by exemestane as monotherapy and when administered in combination with raloxifene The most common adverse events of any grade included arthralgias hot flashes vaginal dryness and myalgias In this small study coadministration of raloxifene and exemestane did not affect the pharmacokinetics or pharmacodynamics of either agent to a significant degree in postmenopausal women The combination of estrogen receptor blockade and suppression of estrogen synthesis is well tolerated and warrants further investigation\",\n",
            "}\n",
            "13807\n",
            "{\n",
            "  \"id\" : \"19629539\",\n",
            "  \"contents\" : \"The purpose of this present study was to evaluate Self-care Improvement through Oncology Nursing SCION program to reduce distressing anorexia nausea and emesis ANE in cancer patients undergoing chemotherapy Two hundred eight patients receiving chemotherapy with moderate to high emetogenic potential participated in a cluster randomized trial on 14 wards in two German university hospitals Additionally to standard antiemetic treatment patients from the intervention wards received the SCION program consisting of four modules advisory consultation optimizing emesis prophylaxis nutrition counseling and relaxation Patients from the control group received standard antiemetic treatment and standard care Primary outcome was the group difference in ANE intensity assessed by Common Terminology Criteria for adverse events CTCAE The SCION program did not result in a significant difference in the incidence of ANE symptoms as compared to standard care mean difference on CTCAE scale was 024 pts 95 % CI -117 to 166 pts P = 0733 No difference could be found regarding patients knowledge of side effects self-care interventions and agency Health-related quality of life was significantly better for patients in the control group mean difference 102 pts 95 % CI 19 to 185 P = 0017 Contrary to our expectations the groups did not differ in ANE intensity caused by the overall low acute or delayed symptom intensity Symptom hierarchy in cancer patients alters and challenges nursing interventions targeting the patients self-care strategies\",\n",
            "}\n",
            "13808\n",
            "{\n",
            "  \"id\" : \"22574757\",\n",
            "  \"contents\" : \"Psychological distress is common in cancer survivors Although there is some evidence on effectiveness of psychosocial care in distressed cancer patients referral rate is low Lack of adequate screening instruments in oncology settings and insufficient availability of traditional models of psychosocial care are the main barriers A stepped care approach has the potential to improve the efficiency of psychosocial care The aim of the study described herein is to evaluate efficacy of a stepped care strategy targeting psychological distress in cancer survivors The study is designed as a randomized clinical trial with 2 treatment arms a stepped care intervention programme versus care as usual Patients treated for head and neck cancer HNC or lung cancer LC are screened for distress using OncoQuest a computerized touchscreen system After stratification for tumour HNC vs LC and stage stage I/II vs III/IV 176 distressed patients are randomly assigned to the intervention or control group Patients in the intervention group will follow a stepped care model with 4 evidence based steps 1 Watchful waiting 2 Guided self-help via Internet or a booklet 3 Problem Solving Treatment administered by a specialized nurse and 4 Specialized psychological intervention or antidepressant medication In the control group patients receive care as usual which most often is a single interview or referral to specialized intervention Primary outcome is the Hospital Anxiety and Depression Scale HADS Secondary outcome measures are a clinical level of depression or anxiety CIDI quality of life EQ-5D EORTC QLQ-C30 QLQ-HN35 QLQ-LC13 patient satisfaction with care EORTC QLQ-PATSAT and costs health care utilization and work loss TIC-P and PRODISQ modules Outcomes are evaluated before and after intervention and at 3 6 9 and 12months after intervention Stepped care is a system of delivering and monitoring treatments such that effective yet least resource-intensive treatment is delivered to patients first The main aim of a stepped care approach is to simplify the patient pathway provide access to more patients and to improve patient well-being and cost reduction by directing where appropriate patients to low cost self - management before high cost specialist services NTR1868\",\n",
            "}\n",
            "13809\n",
            "{\n",
            "  \"id\" : \"19963436\",\n",
            "  \"contents\" : \"Hot flushes are the most common complaints reported by men undergoing androgen suppression treatment for prostate cancer We designed a randomised double-blind trial to compare the efficacy of three drugs each of which has proven effective for preventing hot flushes in previous studies Men with prostate cancer with an indication for androgen suppression were enrolled in the study at 106 urology centres in France between April 14 2004 and April 20 2007 All patients were treated for 6 months with leuprorelin 1125 mg At month 6 patients who spontaneously asked for treatment or those who presented with 14 hot flushes or more during the week before the visit were randomly assigned to either venlafaxine 75 mg daily medroxyprogesterone acetate 20 mg daily or cyproterone acetate 100 mg daily All patients received two indistinguishable pills in the morning and one in the evening from week 1 to week 8 and one indistinguishable pill in the morning from week 9 to week 10 to comply with the double-blind design Random assignment with a block size of three was done centrally by fax and each patient was given a randomisation number The allocation sequence was stratified by centre Assessment was done at inclusion at randomisation and then at 4 weeks 8 weeks and 12 weeks after randomisation Participants completed a daily hot-flush diary for 1 week and a quality of life questionnaire before each visit throughout the study The primary outcome was the change in median daily hot-flush score between randomisation and 1 month All patients who received at least one study treatment dose were included in the efficacy analysis This trial is registered with ClinicalTrialsgov number NCT01011751 Of the 919 men initially enrolled 311 were randomly assigned to one of the study treatments at 6 months 102 to venlafaxine 101 to cyproterone and 108 to medroxyprogesterone 309 patients were included in the efficacy analysis since two were excluded for protocol deviations one in the cyproterone and one in the medroxyprogesterone group both were excluded because they were already undergoing treatment with serotonin reuptake inhibitor antidepressants at randomisation The change in median daily hot-flush score between randomisation and 1 month was -472 % IQR -743 to -25 in the venlafaxine group -945 % -1000 to -745 in the cyproterone group and -837 % -989 to -643 in the medroxyprogesterone group The decrease from baseline was significant for all three groups p < 00001 Pairwise comparison of treatment groups adjusted by the Bonferroni method confirmed that the decreases in hot-flush score were significantly larger in the cyproterone and medroxyprogesterone groups than in the venlafaxine group regardless of the interval considered p < 00001 in all cases There was no significant difference between the cyproterone and medroxyprogesterone groups p > 02 in all cases Serious side-effects occurred in four seven and five patients in the venlafaxine cyproterone and medroxyprogesterone groups respectively of which none one dyspnoea and one urticaria were considered related to the drug respectively After 6 months of treatment with leuprorelin venlafaxine cyproterone and medroxyprogesterone proved to be effective in reducing hot flushes However the hormonal treatments cyproterone and medroxyprogesterone were significantly more effective than venlafaxine As cyproterone is a recognised treatment in prostate cancer and its use could interfere with hormonal therapy medroxyprogesterone could be considered to be the standard treatment for hot flushes in men undergoing androgen suppression for prostate cancer Takeda Laboratories Puteaux France\",\n",
            "}\n",
            "13810\n",
            "{\n",
            "  \"id\" : \"8113844\",\n",
            "  \"contents\" : \"We designed a prospective randomized trial to compare vinorelbine and cisplatin NVB-P with vindesine and cisplatin VDS-P and to evaluate whether the best of these regimens affords a survival benefit compared with vinorelbine alone NVB an outpatient regimen in patients with non-small-cell lung cancer NSCLC Forty-five centers included 612 patients in this study 206 on NVB-P 200 on VDS-P and 206 on NVB Vinorelbine was administered at a dose of 30 mg/m2 weekly cisplatin at 120 mg/m2 on days 1 and 29 and then every 6 weeks and vindesine at 3 mg/m2 weekly for 6 weeks and then every other week Treatment was continued until progression or toxicity Four percent of the patients entered were ineligible and 59 % had metastatic disease An objective response rate was observed in 30 % of patients in the NVB-P arm versus 19 % in the VDS-P arm P = 02 and 14 % in the NVB arm P < 001 The median duration of survival was 40 weeks in the NVB-P arm compared with 32 weeks in the VDS-P arm and 31 weeks in the NVB arm Comparison of survival among the three groups demonstrated an advantage for NVB-P compared with VDS-P P = 04 and NVB P = 01 Neutropenia was significantly higher in the NVB-P group P < 001 and neurotoxicity was more frequent with VDS-P P < 004 Since our results have demonstrated that NVB-P yields a longer survival duration and a higher response rate than VDS-P or NVB alone with acceptable toxicity this combination should be considered a relevant regimen in advanced NSCLC\",\n",
            "}\n",
            "13811\n",
            "{\n",
            "  \"id\" : \"25986854\",\n",
            "  \"contents\" : \"The objective of this study was to determine the effects of axillary lymph node dissection ALND versus sentinel lymph node biopsy alone SLNB on the survival of patients with 3 or more metastatic lymph nodes MLN in invasive breast cancer Data of 9521 patients with invasive T1-2M0 breast carcinoma and initial treatment with SLNB completed or not by ALND and 3 or more MLN were extracted from the SEER database Univariate and multivariate analyses were performed Overall 9521 patients were included in the study SLNB-alone compared with ALND did not result in different overall survival OS or specific survival SS for patients with 3 or more MLN p = 046 and 058 respectively In subgroup analyses OS was comparable between SLNB-alone and ALND when patients had only 3 or more than 3 MLN When patients had 3 MLN the 5-year SS was significantly better for patients with ALND compared with SLNB-alone 915 % and 851 % respectively p = 002 The Hazard Ratio HR for OS comparing SLNB-alone with ALND adjusting for age adjuvant radiotherapy tumor size estrogen receptor status grade and tumor type resulted in an HR of 105 95 % CI 072-1 54 p = 077 In conclusion patients with a T1-T2 invasive breast cancer and at least 3 MLN do not benefit from ALND after SLNB for specific and overall survival thus limiting ALND to a staging procedure A subgroup of patients with 3 MLN had a better SS with ALND possibly due to an under-staging of the SLNB-alone group\",\n",
            "}\n",
            "13812\n",
            "{\n",
            "  \"id\" : \"25084776\",\n",
            "  \"contents\" : \"The quality of surgery with D3 resection in randomized controlled clinical trial [ Japan Clinical Oncology Group study JCOG0404 ] was assessed by evaluation of the photo documentation of both open and laparoscopic surgeries A multi-institutional randomized-controlled trial JCOG0404 was conducted to evaluate open and laparoscopic D3 resection complete mesocolic excision + ligation and dissection at the root of the main vessels for Stage II/III colon cancer UMIN-CTR number C000000105 A total of 1057 open 528 laparoscopic 529 eligible patients were enrolled For quality control it was ensured that the surgeries were performed by accredited surgeons and a central committee reviewed each surgery on the basis of the submitted photographs of the resected field specimen and skin incision For right-sided tumors the rate of D3 resection was 985 % 131/133 in the open arm and 100 % 136/136 in the laparoscopic arm and for left-sided tumors they were 979 % 322/329 and 982 % 320/326 respectively Sufficient length of the resected longitudinal margin was ensured in all cases The skin incisions made in all the cases were < 8 cm as defined in the protocol in laparoscopic arm Completion of high quality surgery with D3 resection was confirmed in JCOG0404 by central peer review of photographs of the surgical procedures in addition to operator regulations This study suggests that the central review of the photo documentation is one of the important tools to assure a quality control of surgical technique in the Phase III randomized-controlled study\",\n",
            "}\n",
            "13813\n",
            "{\n",
            "  \"id\" : \"17761978\",\n",
            "  \"contents\" : \"This randomized double-blind placebo-controlled phase III study aimed to determine whether thalidomide prolongs survival of patients with extensive-disease small-cell lung cancer SCLC One hundred nineteen patients received two courses of etoposide cisplatin cyclophosphamide and 4 - epidoxorubicin PCDE Responder patients who had recovered from chemotherapy toxicity were randomly assigned to receive four additional PCDE cycles plus thalidomide 400 mg daily or placebo After the first two PCDE cycles objective response rate was 815 % and 92 patients were randomly assigned to placebo n = 43 or thalidomide n = 49 Median exposure duration to placebo was 45 months and median exposure to thalidomide was 49 months Patients treated with thalidomide had a longer survival compared with patients who received placebo although the difference was not statistically significant minimal follow-up 3 years median survival time 117 v 87 months respectively log-rank test hazard ratio [ HR ] = 074 95 % CI 049 to 112 P = 16 Patients with a performance status PS of 1 or 2 who received thalidomide had a significantly longer survival HR = 059 95 % CI 037 to 092 P = 02 The disease also progressed slower in patients with PS of 1 or 2 receiving thalidomide HR = 054 95 % CI 036 to 087 P = 02 whereas the difference did not reach statistical significance for the whole population HR = 074 95 % CI 049 to 112 P = 15 Neuropathy occurred more frequently in the thalidomide group compared with the placebo group 33 % v 12 % respectively Treatment with thalidomide was not associated with a significant improvement in survival of SCLC patients There was pronounced heterogeneity in survival outcomes between groups of patients Some benefit was observed among patients with a PS of 1 or 2 exploratory analyses deserving further studies targeting angiogenesis in this disease\",\n",
            "}\n",
            "13814\n",
            "{\n",
            "  \"id\" : \"25317990\",\n",
            "  \"contents\" : \"Constitutive activation of the epidermal growth factor receptor EGFR is prevalent in epithelial cancers particularly in non-small cell lung carcinoma NSCLC Mutations identified in EGFR predict the sensitivity to EGFR-targeted therapy Detection of these mutations is mainly based on tissue biopsy which is invasive expensive and time consuming Noninvasive real-time inexpensive detection and monitoring of EGFR mutations in patients with NSCLC is highly desirable We developed a novel core technology electric field-induced release and measurement EFIRM which relies on a multiplexible electrochemical sensor that can detect EGFR mutations directly in bodily fluids We established EFIRM for the detection of the EGFR mutations in vitro and correlated the results with tumor size from xenografted mice In clinical application we demonstrated that EFIRM could detect EGFR mutations in the saliva and plasma of 22 patients with NSCLC Finally a blinded test was performed on saliva samples from 40 patients with NSCLC The receiver operating characteristic analysis indicated that EFIRM detected the exon 19 deletion with an area under the curve of 094 and the L858R mutation with an area under the curve of 096 Our data indicate that EFIRM is effective accurate rapid user-friendly and cost effective for the detection of EGFR mutations in the saliva of patients with NSCLC We termed this saliva-based EGFR mutation detection SABER\",\n",
            "}\n",
            "13815\n",
            "{\n",
            "  \"id\" : \"24182765\",\n",
            "  \"contents\" : \"Head and neck cancer surgery is affected by complications in 20-60 % of cases with risk factors being malnutrition alcoholism and immunosuppression due to cancer The aim of the study was to investigate whether preoperative or perioperative immunonutrition could reduce postoperative infectious complications IC and surgical-site infections SSI in this population This was a multicenter prospective randomized double-blind study Patients with oropharyngeal and pharyngolaryngeal tumour were randomly allocated to three groups a perioperative formula of Impact without immune nutrients named reference diet group A control b preoperative Impact and reference diet postoperatively group B c Impact perioperatively group C Products were available in oral and enteral formula and were given 7 days before surgery and for 7-15 days postoperatively The primary and secondary endpoints were the incidence of IC and SSI respectively Of 312 randomized patients 205 were evaluable for ITT analysis There was no significant difference in IC and SSI However out of this population only 64 patients had taken at least 75 % of the theoretical intake from surgery to day 10 per-protocol population In this condition a significant difference in IC OR = 024 p = 005 SSI OR = 017 p = 004 and also in the median length of postoperative stay 18 vs 25 days p = 005 was demonstrated between groups A and CIn the ITT population no significant difference in IC SSI and LOS was demonstrated Positive exploratory results on the perioperative Impact per-protocol population encourage further study in head and neck cancer patients Registered under ClinicalTrialsgov Identifier no NCT00765440\",\n",
            "}\n",
            "13816\n",
            "{\n",
            "  \"id\" : \"22862951\",\n",
            "  \"contents\" : \"Hepatic resection is currently still the best choice of therapeutic strategies for liver cancer but the long-term survival rate after surgery is unsatisfactory Most patients develop intra - and/or extrahepatic recurrence The reasons for this high recurrence rate are not entirely clear Recent studies have indicated that ischemia-reperfusion injury to the liver may be a significant factor promoting tumor recurrence and metastasis in animal models If this is also true in humans the effects of the Pringle maneuver which has been widely used in hepatectomy for the past century should be examined To date there are no reported data or randomized controlled studies examining the relationship between use of the Pringle maneuver and local tumor recurrence We hypothesize that the long-term prognosis of patients with liver cancer could be worsened by use of the Pringle maneuver due to an increase in the rate of tumor recurrence in the liver remnant We designed a multicenter prospective randomized surgical trial to test this hypothesis At least 498 eligible patients from five participating centers will be enrolled and randomized into either the Pringle group or the non-Pringle group in a ratio of 11 using a permuted-blocks randomization protocol After the completion of surgical intervention patients will be included in a 3-year follow-up program This multicenter surgical trial will examine whether the Pringle maneuver has a negative effect on the long-term outcome of hepatocellular carcinoma patients The trial will also provide information about prognostic differences safety advantages and disadvantages between Pringle and non-Pringle surgical procedures Ultimately the results will increase the available information about the effects of ischemia-reperfusion injury on tumor recurrence which will be of immense benefit to general surgery http//wwwclinicaltrialsgov NCT00725335\",\n",
            "}\n",
            "13817\n",
            "{\n",
            "  \"id\" : \"17704421\",\n",
            "  \"contents\" : \"We update Radiation Therapy Oncology Group trial 8911 USA Intergroup 113 a comparison of chemotherapy plus surgery versus surgery alone for patients with localized esophageal cancer The relationship between resection type and between tumor response and outcome were also analyzed The chemotherapy group received preoperative cisplatin plus fluorouracil Outcome based on the type of resection R0 R1 R2 or no resection was evaluated The main end point was overall survival Disease-free survival relapse pattern the influence of postoperative treatment and the relationship between response to preoperative chemotherapy and outcome were also evaluated Two hundred sixteen patients received preoperative chemotherapy 227 underwent immediate surgery Fifty-nine percent of surgery only and 63 % of chemotherapy plus surgery patients underwent R0 resections P = 5137 Patients undergoing less than an R0 resection had an ominous prognosis 32 % of patients with R0 resections were alive and free of disease at 5 years only 5 % of patients undergoing an R1 resection survived for longer than 5 years The median survival rates for patients with R1 R2 or no resections were not significantly different While as initially reported there was no difference in overall survival for patients receiving perioperative chemotherapy compared with the surgery only group patients with objective tumor regression after preoperative chemotherapy had improved survival For patients with localized esophageal cancer whether or not preoperative chemotherapy is administered only an R0 resection results in substantial long-term survival Even microscopically positive margins are an ominous prognostic factor After a R1 resection postoperative chemoradiotherapy therapy offers the possibility of long-term disease-free survival to a small percentage of patients\",\n",
            "}\n",
            "13818\n",
            "{\n",
            "  \"id\" : \"21915616\",\n",
            "  \"contents\" : \"Studies suggest a decreased risk of high-grade prostate cancer in men with lower circulating total cholesterol and that statins may protect against aggressive disease Confirmation in additional populations and examination of associations for lipoprotein subfractions are needed We examined prostate cancer risk and serum total and HDL cholesterol in the ATBC Study cohort n = 29093 Cox proportional hazards models were used to estimate the relative risk of total n = 2041 non-aggressive n = 829 aggressive n = 461 advanced n = 412 and high-grade n = 231 prostate cancer by categories of total and HDL cholesterol After excluding the first 10years of follow-up men with higher serum total cholesterol were at increased risk of overall 240 vs < 200mg/dl HR = 122 95 % CI 103-1 44 p-trend = 001 and advanced 240 vs < 200mg/dl HR = 185 95 % CI 113-3 03 p-trend = 005 prostate cancer Higher HDL cholesterol was suggestively associated with a decreased risk of prostate cancer regardless of stage or grade In this population of smokers high serum total cholesterol was associated with higher risk of advanced prostate cancer and high HDL cholesterol suggestively reduced the risk of prostate cancer overall These results support previous studies and indirectly support the hypothesis that statins may reduce the risk of advanced prostate cancer by lowering cholesterol\",\n",
            "}\n",
            "13819\n",
            "{\n",
            "  \"id\" : \"18843872\",\n",
            "  \"contents\" : \"The authors determined the efficacy and safety of oral pilocarpine tablet in symptomatic relief of post-radiation xerostomia in head and neck cancer patients Thirty-three radiation-induced xerostomia patients were enrolled in a single-blind method to receive placebo 1-tablet three times daily in the first month and then oral pilocarpine 5 mg 1-tablet three times daily for the next three months Patients were evaluated for subjective symptomatic relief of xerostomia using questionnaires Objective findings of xerostomia were also evaluated at the same time by two radiation oncologists All 33 patients had received radiotherapy doses at least 4000 cGy to the parotid glands Improvement of xerostomia symptoms was observed with a mean total subjective xerostomia score improvement at the first 4 weeks of oral pilocarpine treatment p = 0001 and later throughout the present study Objective xerostomia score also showed statistically significant improvement at the same time point Adverse effects of pilocarpine included sweating nausea palpitation and tearing with sweating as the most common side effect Adverse effects of placebo included mild headache nausea and vomiting Oral pilocarpine was effective and well tolerated in the treatment of radiation-induced xerostomia symptoms\",\n",
            "}\n",
            "13820\n",
            "{\n",
            "  \"id\" : \"16991107\",\n",
            "  \"contents\" : \"The purpose of this investigation was to systematically examine the efficacy of providing men with prostate cancer with an audiotape of their primary treatment consultation Participants included 425 men newly diagnosed with prostate cancer and 15 radiation oncologists from 4 cancer centers in Canada Patients were block randomized to one of four consultation groups 1 Standard care control -- not audio-taped 2 Audio-taped -- no audiotape given 3 Audio-taped -- patient given audiotape and 4 Audio-taped -- patient offered choice of receiving audiotape or not 4 patients declined 94 accepted Patient outcomes were measured at 12 weeks post-consultation perceived degree of information provision audiotape satisfaction and use communication satisfaction with oncologist mood state and cancer-specific quality of life Patients receiving the consultation audiotape reported having been provided with significantly more disease and treatment information in general p = 004 and more information about treatment alternatives p = 004 and treatment side effects p = 001 in particular than patients who did not receive the audiotape Audiotape benefit was not significantly related to patient satisfaction with communication mood state or quality of life at 12 weeks post-consultation and was not significantly affected by choice of receiving the audiotape Patients rated the audiotape intervention positively with an average score of 830 out of 100 Consultation audiotapes are rated highly by men with prostate cancer and these audiotapes help to enhance their perception of having been provided with critical disease - and treatment-related information\",\n",
            "}\n",
            "13821\n",
            "{\n",
            "  \"id\" : \"12142389\",\n",
            "  \"contents\" : \"Serum HER-2 / neu antigen concentrations have been reported to correlate with increased tumor volume in patients with breast cancer We measured serum CA 15-3 a surrogate marker of disease burden and correlated serum CA 15-3 with serum HER-2 / neu and analyzed the association of both markers with clinical outcomes Pretreatment serum samples from 566 patients were retrospectively analyzed from 2 phase III clinical trials of estrogen receptor-positive ER + ER - / progesterone receptor-positive or ER status unknown metastatic breast cancer patients randomized in two similar studies to receive second-line hormone therapy with either megestrol acetate or an aromatase inhibitor fadrozole The extracellular domain of the HER-2 / neu c-erbB-2 oncogene and serum CA 15-3 were measured by ELISA on the Bayer Immuno 1 Serum HER-2 / neu protein was increased in 168 patients 30 % and CA 15-3 was increased in 337 60 % patients Serum CA 15-3 and HER-2 / neu were weakly correlated r = 039 P < 00001 The clinical benefit complete responses plus partial responses plus stable disease of endocrine therapy was significantly lower in patients with increased serum HER-2 / neu When adjusted for serum HER-2 / neu serum CA 15-3 was not predictive of response rates The median time to progression was shorter in patients with increased serum HER-2 / neu 89 days compared with patients with normal serum HER-2 / neu 176 days Survival was significantly shorter in patients with increased serum HER-2 / neu 513 vs 869 days P < 00001 or increased serum CA 15-3 689 vs 939 days P < 00001 This observation was confirmed by multivariate analysis Serum HER-2 / neu is a significant independent predictive and prognostic factor in hormone receptor-positive metastatic breast cancer even when adjusted for tumor burden as measured by CA 15-3 The combination of increased serum HER-2 / neu and increased serum CA 15-3 predicts a worse prognosis than does increased CA 15-3 alone\",\n",
            "}\n",
            "13822\n",
            "{\n",
            "  \"id\" : \"24080920\",\n",
            "  \"contents\" : \"This open-label randomized phase III trial evaluated larotaxel/cisplatin versus gemcitabine/cisplatin as first-line treatment for locally advanced T4b or metastatic urothelial tract or bladder cancer Patients were randomized to larotaxel 50 mg/m 2 with cisplatin 75 mg/m 2 every 3 weeks larotaxel/cisplatin or gemcitabine 1000 mg/m 2 on days 1 8 and 15 with cisplatin 70 mg/m 2 on day 1 every 4 weeks gemcitabine/cisplatin The primary endpoint was overall survival OS The trial was prematurely closed following the sponsor s decision to stop clinical development of larotaxel n = 337 randomized The larotaxel dose was reduced to 40 mg/m 2 and cisplatin to 60 mg/m 2 following a data monitoring committee safety review of the first 97 patients At the time of analysis the median OS was 137 months [ 95 % confidence interval CI 112-17 1 ] with larotaxel/cisplatin and 143 months 95 % CI 105 to not reached with gemcitabine/cisplatin [ hazard ratio HR 121 95 % CI 083-1 76 p = 033 ] The median progression-free survival PFS was 56 months 95 % CI 41-6 2 with larotaxel/cisplatin and 76 months 95 % CI 66-9 1 with gemcitabine/cisplatin HR 167 95 % CI 124-2 25 More myelosuppression was observed with gemcitabine/cisplatin There was no difference in OS Although the trial was closed prematurely PFS appeared worse with larotaxel/cisplatin suggesting that larotaxel/cisplatin does not improve outcomes versus cisplatin/gemcitabine\",\n",
            "}\n",
            "13823\n",
            "{\n",
            "  \"id\" : \"25383780\",\n",
            "  \"contents\" : \"Early detection of lung cancer is crucial as the prognosis depends on the disease stage Chest radiographs has been the principal diagnostic tool for general practitioners GPs but implies a potential risk of false negative results while computed tomography CT has a higher sensitivity The aim of this study was to describe the implementation of direct access to low-dose CT LDCT from general practice We conducted a cohort study nested in a randomised study A total of 119 general practices with 266 GPs were randomised into two groups Intervention GPs were offered direct access to chest LDCT combined with a Continuing Medical Education CME meeting on lung cancer diagnosis During a 19-month period 648 patients were referred to LDCT 018 / 1000 adults on GP list/month Half of the patients needed further diagnostic work-up and 15 23 % 95 % CI 13-3 8 % of the patients had lung cancer 60 % 95 % CI 323-83 7 % in a localised stage The GP referral rate was 61 % higher for CME participants compared to non-participants Of all patients referred to LDCT 23 % were diagnosed with lung cancer with a favourable stage distribution Half of the referred patients needed additional diagnostic work-up There was an association between participation in CME and use of CT scan The proportion of cancers diagnosed through the usual fast-track evaluation was 22 times higher in the group of CME-participating GPs The question remains if primary care case-finding with LDCT is a better option for patients having signs and symptoms indicating lung cancer than a screening program Whether open access to LDCT may provide earlier diagnosis of lung cancer is yet unknown and a randomised trial is required to assess any effect on outcome Clinicaltrialsgov NCT01527214\",\n",
            "}\n",
            "13824\n",
            "{\n",
            "  \"id\" : \"9722130\",\n",
            "  \"contents\" : \"The effect of tamoxifen on cyclic mastalgia and on chemoprophylaxis against breast cancer is little known mainly due to the difficulties in studying the normal human gland We proposed to evaluate the mitotic index and the nuclear volume of the lobule of women medicated with tamoxifen only during the luteal phase of the menstrual cycle in order to observe the effect of tamoxifen on the normal human mammary gland Twenty-four premenopausal women with fibroadenoma diagnosed via biopsy were studied The phase of the cycle was determined by the date of menstruation and serum progesterone level in the luteal phase > or = 3 ng/ml The patients admitted to the study and were given written informed consent to participate in the investigation which was previously approved of by the hospital Ethics Committee Patients were divided at random into two groups Group I consisted of 12 untreated women control and Group II consisted of 12 patients treated with 20 mg/day tamoxifen for 10 consecutive days beginning on the 13th day of the menstrual cycle In both groups the patients were submitted to biopsies of the nodule and of a 1-cm3 fragment of adjacent mammary parenchyma between the 23rd and 26th day of the cycle The mitotic index number of mitoses/1000 nuclei counted and mean nuclear volume mean of 10 nuclear volumes for each case were measured No mitosis was observed in Group II There was a reduction in the mean nuclear volume in Group II Mann-Whitney test Tamoxifen when administered only during the luteal phase of the menstrual cycle significantly reduces the nuclear volume and mitotic activity of the epithelium This data demonstrates an antagonistic action of tamoxifen on estrogen even when administered for short periods of time\",\n",
            "}\n",
            "13825\n",
            "{\n",
            "  \"id\" : \"7837388\",\n",
            "  \"contents\" : \"To improve current adjuvant results in patients with resectable mammary carcinoma and more than three positive axillary lymph nodes A prospective randomized study was carried out to compare the effectiveness of four courses of doxorubicin hydrochloride followed by eight courses of cyclophosphamide methotrexate and fluorouracil CMF sequential regimen vs two courses of CMF alternated with one course of doxorubicin for a total of 12 courses alternating regimen All drug courses were recycled every 3 weeks The median duration of follow-up at the time of current analysis was 9 years The study was conducted on patients operated on for primary unilateral breast cancer at the Istituto Nazionale Tumori of Milan Italy Adjuvant chemotherapy was delivered in the outpatient clinic of the Division of Medical Oncology A total of 405 women were entered into the study 403 of whom met the protocol criteria Patient characteristics were fairly well balanced between the two treatment groups with the exception of extent of nodal involvement 38 % with more than 10 positive nodes were randomized to the alternating regimen compared with 29 % in the sequential regimen P = 08 Relapse-free and total survival at 10 years after surgery estimated according to the Kaplan-Meier product limit method Treatment outcome was significantly superior for patients who received the sequential regimen compared with those given the alternating chemotherapy The relapse-free survival was 42 % vs 28 % P = 002 and total survival was 58 % vs 44 % P = 002 respectively The benefit of the sequential regimen was evident in all patient subsets Treatment was fairly well tolerated but we documented four cases of congestive heart failure which was fatal in two patients Current findings indicate that in women with extensive nodal involvement sequential chemotherapy with doxorubicin followed by CMF yields superior results compared with the alternating administration of the same regimens or with classical CMF\",\n",
            "}\n",
            "13826\n",
            "{\n",
            "  \"id\" : \"12867608\",\n",
            "  \"contents\" : \"Colon cancers with high-frequency microsatellite instability have clinical and pathological features that distinguish them from microsatellite-stable tumors We investigated the usefulness of microsatellite-instability status as a predictor of the benefit of adjuvant chemotherapy with fluorouracil in stage II and stage III colon cancer Tumor specimens were collected from patients with colon cancer who were enrolled in randomized trials of fluorouracil-based adjuvant chemotherapy Microsatellite instability was assessed with the use of mononucleotide and dinucleotide markers Of 570 tissue specimens 95 167 percent exhibited high-frequency microsatellite instability Among 287 patients who did not receive adjuvant therapy those with tumors displaying high-frequency microsatellite instability had a better five-year rate of overall survival than patients with tumors exhibiting microsatellite stability or low-frequency instability hazard ratio for death 031 [ 95 percent confidence interval 014 to 072 ] P = 0004 Among patients who received adjuvant chemotherapy high-frequency microsatellite instability was not correlated with increased overall survival hazard ratio for death 107 [ 95 percent confidence interval 062 to 186 ] P = 080 The benefit of treatment differed significantly according to the microsatellite-instability status P = 001 Adjuvant chemotherapy improved overall survival among patients with microsatellite-stable tumors or tumors exhibiting low-frequency microsatellite instability according to a multivariate analysis adjusted for stage and grade hazard ratio for death 072 [ 95 percent confidence interval 053 to 099 ] P = 004 By contrast there was no benefit of adjuvant chemotherapy in the group with high-frequency microsatellite instability Fluorouracil-based adjuvant chemotherapy benefited patients with stage II or stage III colon cancer with microsatellite-stable tumors or tumors exhibiting low-frequency microsatellite instability but not those with tumors exhibiting high-frequency microsatellite instability\",\n",
            "}\n",
            "13827\n",
            "{\n",
            "  \"id\" : \"8625152\",\n",
            "  \"contents\" : \"For patients with Stage III nonsmall cell lung cancer NSCLC radiation is the standard treatment but survival remains poor The authors performed a meta-analysis study using clinical trials that evaluated combined radiotherapy plus chemotherapy versus radiotherapy alone in patients with Stages IIIa and IIIb NSCLC For the meta-analysis study and the point estimates essential data were extracted directly from published reports Survival probabilities at 1 2 3 and 5 years as estimated from published survival curves were considered as the endpoints of interest For survival at 3 and 5 years the point estimates and the confidence intervals were used Quality scoring of the studies also was performed Fourteen trials were selected comprising 1887 patients in the meta-analysis For the cisplatin-based group the estimated pooled odds ratio of death at 1 and 2 years was 076 06-0 9 CI and 070 05-0 9 CI with a reduction in mortality of 24 % and 30 % respectively For the noncisplatin-based group the estimated pooled odds ratio at 1 and 2 years was 105 07-1 5 CI and 082 05-1 3 CI with a reduction in mortality of 5 % and 18 % respectively However no significant differences were found between the percentage of survival and the CI at 3 and 5 years using the point estimates These results favor combined cisplatin-based chemotherapy and radiotherapy although it was not so at 3 and 5 years of survival These data must however be considered in the light of their clinical relevance and of the balance between quality of life toxicity and costs of chemotherapy\",\n",
            "}\n",
            "13828\n",
            "{\n",
            "  \"id\" : \"25686117\",\n",
            "  \"contents\" : \"We planned a randomized open-label trial to evaluate differences between pre-emptive and reactive skin treatment for panitumumab Pmab - associated skin toxicities in Japanese patients with metastatic colorectal cancer Patients receiving third-line Pmab-containing regimens were randomized to pre-emptive or reactive treatment The primary end point was the cumulative incidence of grade 2 skin toxicities during 6 weeks Retrospectively a dermatologist reviewed skin toxicities in a blinded manner A total of 95 patients were enrolled pre-emptive 47 reactive 48 The primary end point was achieved 213 and 625 % [ risk ratio 034 p < 0001 ] for pre-emptive and reactive treatment respectively A similar trend was observed in central review Pre-emptive skin treatment could reduce the severity of Pmab-associated skin toxicities in Japanese metastatic colorectal cancer patients\",\n",
            "}\n",
            "13829\n",
            "{\n",
            "  \"id\" : \"8625171\",\n",
            "  \"contents\" : \"The biochemical modulation of 5-fluorouracil 5-FU by the reduced folate folinic acid FA in the treatment of patients with advanced gastric cancer was examined The Southwest Oncology Group performed parallel randomized Phase II trials of two schedules of 5-FU and FA in 80 patients with advanced gastric cancer Of 76 analyzable patients 36 were randomized to receive bolus FA 200 mg/m2 days 1-4 along with continuous infusion 5-FU 1000 mg/m2 days 1-4 and 40 were randomized to receive bolus FA 200 mg/m2 days 1-5 before the bolus 5-FU 375 mg/m2 days 1-5 There were three 8 % partial responses 95 % confidence interval [ CI ] 2 % -22 % on the continuous infusion arm The bolus arm had two 5 % complete responses and six 15 % partial responses for an overall response rate of 20 % 95 % CI 9 % -36 % The median duration of response was 46 months for the infusion patients and 166 months for the bolus patients Survival was poor with median survival of 5 months on both regimens Gastrointestinal toxicity was substantial with Grade 3 mucositis observed in 36 % of patients on the continuous infusion regimen versus only 10 % of patients on the bolus regimen Grade 3 or higher hematologic toxicity occurred more often in the bolus arm than in the continuous infusion arm 28 % vs 14 % respectively Two toxic deaths occurred one related to sepsis the other secondary to coronary insufficiency Biochemical modulation of 5-FU by FA using the dose and schedules tested has only modest activity in the treatment of advanced gastric cancer\",\n",
            "}\n",
            "13830\n",
            "{\n",
            "  \"id\" : \"19755646\",\n",
            "  \"contents\" : \"Optimizing participant response rates is important for obtaining representative samples and the timely completion of studies It is a common practice to use participant incentives to boost response rates but few studies have systematically examined their effectiveness particularly among minority groups We experimentally tested three incentive strategies for their effectiveness in improving response rates among colorectal cancer cases n = 3816 and their relatives n = 2353 A 2 x 2 x 2 factorial design compared a registered versus first class mail b $ 5 cash with the initial mailing yes/no and c $ 20 promise yes/no upon completion of the information form for cases or $ 10 promise yes/no upon completion of the baseline survey for relatives Outcome measures were provision of contact information on first-degree relatives for cases and completion of the baseline survey for relatives The response rate among cases was low in all ethnic groups 28-37 % and incentive strategies did not have an effect Among relatives the overall baseline survey response rate was 71 % ranging from 66 % among Asians to 76 % among Whites Modest absolute increases were observed for payment schedules that included a $ 5 cash enclosure with the initial mailing in the total sample [ odds ratio OR 165 and 147 ] and among Latinos OR 194 and 174 but not among Asians OR 161 and 155 or African Americans OR 119 and 102 Response rates were not influenced by registered versus first-class mailing The effects of incentives in this study were modest with some suggestion of differences by ethnic group and type of incentive\",\n",
            "}\n",
            "13831\n",
            "{\n",
            "  \"id\" : \"21607939\",\n",
            "  \"contents\" : \"Information is crucial for increasing the patients empowerment and autonomy in relevant decision-making processes especially in malignant diseases However the extent to which information should be delivered is debated The objective of this study was to assess the impact of providing systematic full access SFA to the medical record on anxiety quality of life and satisfaction Patients with newly diagnosed breast cancer colon cancer or lymphoma who had received adjuvant chemotherapy in an outpatient setting were included in a randomized controlled trial comparing those who requested access RA and those who provided SFA to the medical record Anxiety was assessed using the Spielberger State-Trait Anxiety Inventory before during and at the end of treatment Quality of life was evaluated using the European Organization for Research and Cancer quality-of-life questionnaire EORTC QLQ-C30 before and at the end of treatment Patients satisfaction and perception of the organized medical record OMR were evaluated using a specifically designed questionnaire at the end of treatment Most patients 98 % who had the opportunity to obtain the OMR chose to do so Anxiety levels did not increase in the SFA arm although they did not differ significantly compared with anxiety levels in the RA arm The patients who had full access to their medical record were more satisfied with information odds ratio 168 95 % confidence interval 098-2 9 and felt sufficiently informed more often odds ratio 186 95 % confidence interval 108-3 19 but the differences were not statistically significant at the 5 % level Allowing full access to personal medical records increased satisfaction without increasing anxiety in patients with newly diagnosed cancer\",\n",
            "}\n",
            "13832\n",
            "{\n",
            "  \"id\" : \"12854145\",\n",
            "  \"contents\" : \"To assess the feasibility and efficacy of laparoscopic total mesorectal excision LTME of low rectal cancer with preservation of anal sphincter From June 2001 to June 2003 82 patients with low rectal cancer underwent laparoscopic total mesorectal excision with preservation of anal sphincter The lowest edge of tumors was below peritoneal reflection and 15-7 cm from the dentate line 15-5 cm in 48 cases 5-7 cm in 34 cases LTME with anal sphincter preservation was performed on 82 randomized patients with low rectal cancer and 100 % sphincter preservation rate was achieved There were 30 patients with laparoscopic low anterior resection LLAR at the level of the anastomosis below peritoneal reflection and 2 cm above from the dentate line 27 patients with laparoscopic ultralow anterior resection LULAR at the level of anastomoses 2 cm below from the dentate line and 25 patients with laparoscopic coloanal anastomoses LCAA at the level of the anastomoses at or below the dentate line No defunctioning ileostomy was created in any case The mean operating time was 120 minutes ranged from 110-220 min and the mean operative blood loss was 20 mL ranged from 5-120 mL Bowel function was restored and diet was resumed on day 1 or 2 after operation The mean hospital stay was 8 days ranged from 5-14 Postoperative analgesics were used in 45 patients After surgery 2 patients had urinary retention one had anastomotic leakage and another 2 patients had local recurrence one year later No interoperative complication was observed LTME with preservation of anal sphincter is a feasible safe and minimally invasive technique with less postoperative pain and rapid recovery and importantly it has preserved the function of the sphincter\",\n",
            "}\n",
            "13833\n",
            "{\n",
            "  \"id\" : \"18826631\",\n",
            "  \"contents\" : \"Vascular endothelial growth factor VEGF is a potent angiogenic cytokine produced physiologically by the uterus Pathological secretion by tumours promotes growth and metastasis High circulating VEGF levels potentially have a deleterious effect on breast cancer by promoting disease progression The aims of this study were to investigate circulating VEGF levels in breast cancer patients and assess the effect of menopause or hysterectomy on systemic VEGF Patients undergoing primary surgery for breast cancer and controls matched for age menopausal and hysterectomy status were prospectively recruited Serum VEGF FSH LH estrogen progesterone and platelet levels were measured Serum VEGF was corrected for platelet load sVEGFp to provide a biologically relevant measurement of circulating VEGF SVEGFp levels were analyzed with respect to tumor characteristics menopausal status and hysterectomy status Two hundred women were included in the study 89 breast cancer patients and 111 controls SVEGFp levels were significantly higher in breast cancer patients compared to controls p = 00001 but were not associated with clinico-pathological tumor characteristics Systemic VEGF levels reduced significantly in the breast cancer patients following tumor excision p = 0018 The highest systemic VEGF levels were observed in postmenopausal breast cancer patients Postmenopausal women who had had a previous hysterectomy had significantly higher VEGF levels than those with an intact postmenopausal uterus p = 0001 This study identifies an intact postmenopausal uterus as a potential means of reducing circulating levels of VEGF which could confer a protective effect against breast cancer metastatic potential\",\n",
            "}\n",
            "13834\n",
            "{\n",
            "  \"id\" : \"10979376\",\n",
            "  \"contents\" : \"To determine patient preferences and cost differences between home-based and hospital-based chemotherapy Randomised crossover trial A tertiary cancer hospital in Melbourne Victoria 20 patients who required chemotherapy suitable for administration at home Patients were assigned at random to receive their first chemotherapy treatment in either the home or the hospital and the second treatment in the alternative setting Patient preference costs There was universal agreement by the 20 patients in the randomised trial that home-based chemotherapy was the preferred option P < 00001 No problems were nominated by the patients as being associated with home-based chemotherapy Home-based treatment was estimated to result in an increased cost of $ 83 P = 00002 for each chemotherapy treatment compared with hospital-based treatment Reported advantages for chemotherapy in the home included the elimination of travel reduction in treatment-associated anxiety reduction in the burden on carers and family and the ability to continue other duties There were no significant complications associated with administration of chemotherapy in the home Patients prefer home-based chemotherapy to hospital-based treatment The future of chemotherapy-in-the-home programs in Australia will depend on whether patient preferences are deemed to offset any potential increase in costs\",\n",
            "}\n",
            "13835\n",
            "{\n",
            "  \"id\" : \"16140071\",\n",
            "  \"contents\" : \"To evaluate the response rate for intravesical gemcitabine given in three different schedules to patients with recurrent multiple carcinoma of the urinary bladder Stage Ta grade 1-2 in whom all but one marker lesion was removed Furthermore we sought to define the safety profile This was a multicenter open-label randomized Phase II study in which gemcitabine 2000 mg in 100 mL of unbuffered saline was instilled as a single dose n = 11 two doses per week for 3 weeks n = 11 or once weekly for 6 weeks n = 10 Efficacy was evaluated using cystoscopy after 9 weeks Toxicity was evaluated by assessing the liver kidney bone marrow and coagulation function at defined intervals and by questionnaire A total of 32 patients were included 2 of whom were subsequently excluded because of protocol violations The overall complete remission rate was 31 % The respective subgroup response rate was 10 % in the single-dose group 44 % in the once-weekly group and 40 % in the twice-weekly group The most common side effect was nausea One patient withdrew because of nausea and fever and an additional 2 patients had reversible hematologic toxicity mild thrombocytopenia causing delayed instillation and mild anemia The side effects were generally in the multiple-dose groups with an overrepresentation in women Ten patients were unable to retain the drug intravesically for the full hour The results of our study have shown that gemcitabine has a tumor ablative effect when given intravesically for bladder cancer A single dose seemed ineffective and the multiple dosing regimens seemed effective The side effects were generally mild\",\n",
            "}\n",
            "13836\n",
            "{\n",
            "  \"id\" : \"15767334\",\n",
            "  \"contents\" : \"In some studies high calcium intake has been associated with an increased risk of prostate cancer but no randomized studies have investigated this issue We randomly assigned 672 men to receive either 3 g of calcium carbonate 1200 mg of calcium or placebo daily for 4 years in a colorectal adenoma chemoprevention trial Participants were followed for up to 12 years and asked periodically to report new cancer diagnoses Subject reports were verified by medical record review Serum samples collected at randomization and after 4 years were analyzed for 125 - OH 2 vitamin D 25 - OH vitamin D and prostate-specific antigen PSA We used life table and Cox proportional hazard models to compute rate ratios for prostate cancer incidence and generalized linear models to assess the relative risk of increases in PSA levels After a mean follow-up of 103 years there were 33 prostate cancer cases in the calcium-treated group and 37 in the placebo-treated group [ unadjusted rate ratio 083 95 % confidence interval 95 % CI 052-1 32 ] Most cases were not advanced the mean Gleason s score was 62 During the first 6 years until 2 years post-treatment there were significantly fewer cases in the calcium group unadjusted rate ratio 052 95 % CI 028-0 98 The calcium risk ratio for conversion to PSA > 40 ng/mL was 063 95 % CI 033-1 21 Baseline dietary calcium intake plasma 125 - OH 2 vitamin D and 25 - OH vitamin D levels were not materially associated with risk In this randomized controlled clinical trial there was no increase in prostate cancer risk associated with calcium supplementation and some suggestion of a protective effect\",\n",
            "}\n",
            "13837\n",
            "{\n",
            "  \"id\" : \"1530798\",\n",
            "  \"contents\" : \"The study investigated the therapeutic effects of fadrozole CGS 16949A a new aromatase inhibitor in women who had received prior treatment for metastatic breast cancer Eighty postmenopausal women who had received prior treatment for metastatic breast cancer were randomized to receive fadrozole 1 mg/d or 4 mg/d per day orally Seventy-eight patients were assessable for toxicity and response Toxicity was limited to mild grade 1 to moderate grade 2 hot flashes in 28 % nausea and vomiting in 13 % fatigue in 8 % and mild loss of appetite in 5 % of patients No electrolyte or unanticipated hormonal changes occurred The overall response was 23 % complete response 10 % partial response 13 % In addition 45 % of the patients had a no change status There was no difference in response rate between the patients randomized to the two different doses of fadrozole Only dominant site of metastases significantly affected response The median time to treatment failure TTF was 44 months 47 months on 1 mg/d and 37 months on 4 mg/d The median survival was 226 months 175 months on 1 mg/d median survival has not been reached in patients on 4 mg/d The response and survival in patients with estrogen receptor ER - positive and ER-unknown disease were not significantly different Fadrozole has good therapeutic effect as a second-line treatment in postmenopausal women with metastatic breast cancer In this study there was no significant difference in toxicity or response between 1 mg/d and 4 mg/d Further trials comparing fadrozole to other hormone treatment are indicated\",\n",
            "}\n",
            "13838\n",
            "{\n",
            "  \"id\" : \"16119667\",\n",
            "  \"contents\" : \"Evaluation of quality of life appraisal of pain quality and intensity assessment of treatment and care effectiveness in palliative care patients treated at the in-patient Palliative Care Department in Czestochowa Province Hospital The study was performed in 50 randomly chosen patients at the in-patient Palliative Care Department in Czestochowa Province Hospital The studied group comprised 22 women and 28 men The trial lasted since October 2003 till April 2004 and this was longitudinal study At the first assessment patients filled Modified Sheet Pain Assessment Support Team Assessment Schedule STAS and Rotterdam Symptom Checklist RSCL At the second third and fourth appraisal patients filled RSCL and STAS In patients surveyed by STAS at the second assessment 52 % of patients achieved very high scores poor effectiveness of treatment and care 32 % high scores - unsatisfactory treatment and care 15 % average results average treatment and care Results of RSCL indicate for decrease in physical activity and global quality of life of terminal patients At the fourth assessment after 4 weeks of the treatment nearly 80 % patients assessed their physical state as low The results indicate that patients have poor performance status no effective treatment is provided psychological state is significantly impaired and patients were forced to resign from social life because of cancer progression\",\n",
            "}\n",
            "13839\n",
            "{\n",
            "  \"id\" : \"1837743\",\n",
            "  \"contents\" : \"To determine the contribution of dexamethasone to the efficacy of the 5-hydroxytryptamine antagonist ondansetron in control of cisplatin induced nausea and vomiting Randomised double blind crossover study Two cancer centres in teaching hospitals one in the United Kingdom and the other in Germany 100 patients 53 men and 47 women new to cisplatin chemotherapy 84 of whom completed two consecutive courses of chemotherapy Patients were given intravenous dexamethasone 20 mg or physiological saline with intravenous ondansetron 8 mg before cisplatin then ondansetron 1 mg/h for 24 hours Oral ondansetron 8 mg was taken three times daily on days 2-6 Incidence of complete or major control of emesis 0-2 episodes in the 24 hours after chemotherapy Complete or major control was obtained in 49 out of 71 69 % of patients after receiving ondansetron plus dexamethasone compared with 40 out of 71 56 % when they were given ondansetron alone p = 0012 This effect was most pronounced in the first 12 hours after chemotherapy Patients receiving the combination also had significantly less nausea Of the 53 patients who expressed a preference 38 72 % preferred the combination treatment p = 0002 to ondansetron alone The effect of ondansetron on delayed emesis was less pronounced Dexamethasone makes a significant contribution to the efficacy of ondansetron in the control of acute platinum induced emesis\",\n",
            "}\n",
            "13840\n",
            "{\n",
            "  \"id\" : \"22678326\",\n",
            "  \"contents\" : \"To compare the perioperative parameters and short-term outcomes of hand-assisted laparoscopic colectomy HALC and open colectomy OC for the treatment of patients with cancer of the right hemicolon Patients who were scheduled to perform right hemicolectomy between August 2009 and December 2010 were randomized into either HALC or OC group Patients were excluded if they had synchronous cancers hepatic metastases acute intestinal obstruction or intestinal perforations All the operations in the 2 groups were performed by a single surgical team Measured outcomes included the demographic variables and perioperative parameters The former included age sex body mass index American Society of Anesthesiologists class prior abdominal surgery distribution of tumors and histopathologic stage whereas the latter included length of incision operative time estimated blood loss conversion rate number of lymph nodes retrieved postoperative pain score time to return of bowel function postoperative complications duration of hospital stay and total cost One hundred sixteen patients with cancer of the right hemicolon HALC = 59 OC = 57 were recruited The 2 groups of patients were similar in age sex distribution body mass index American Society of Anesthesiologists class and previous abdominal surgery No significant difference was observed between the 2 groups in terms of distribution of tumors and the final histopathologic staging HALC had a significantly shorter incision length and longer operative time than OC Patients in the HALC group had significantly less operative blood loss less pain and earlier passage of flatus after operation than those in the OC group The number of lymph nodes recovered in the specimen and the overall postoperative complications was comparable in the 2 groups The postoperative duration of hospital stay was significantly shorter in the HALC group whereas the median overall costs in the HALC group were significantly higher than that in the OC group The results from the present study demonstrate that the HALC is a valid surgical approach for cancer of the right hemicolon that retains the benefits of minimally invasive surgery We believe that this technique is a safe useful and feasible method for patients with right-sided colonic cancer If practiced more it might be advocated as a bridge between traditional laparoscopic surgery and conventional open procedures\",\n",
            "}\n",
            "13841\n",
            "{\n",
            "  \"id\" : \"12131291\",\n",
            "  \"contents\" : \"Endoscopy done under fluorescence induced by 5-aminolevulinic acid has proved to be a procedure with high sensitivity for detecting transitional cell carcinoma of the bladder In this multicenter parallel group phase III study we compared 5-aminolevulinic acid fluorescence endoscopy guided transurethral bladder resection with transurethral bladder resection done using only white light endoscopy The proportion of tumor-free resected cases in the 2 groups was evaluated After patient stratification according to participating centers and European Organization for the Research and Treatment of Cancer risk score 65 and 64 were randomized to the 5-aminolevulinic acid fluorescence and white light endoscopy groups respectively Residual tumor was evaluated in the 2 groups by repeat transurethral resection 10 to 14 days later Analysis was performed according to the intent to treat principle with all patients randomized followed by per protocol analysis Intent to treat analysis revealed that in the white light endoscopy group 406 % of cases were resected tumor-free at primary resection whereas with 5-aminolevulinic acid fluorescence endoscopy guided transurethral resection 615 % were resected tumor-free p < 0014 On protocol analysis 469 % patients in the white light and 673 % in the 5-aminolevulinic acid fluorescence endoscopy groups were resected tumor-free p < 0031 No difference was noted in the 2 groups in regard to side effects or laboratory findings The risk of residual tumor after transurethral resection of transitional cell carcinoma is significantly decreased by 5-aminolevulinic acid fluorescence endoscopy\",\n",
            "}\n",
            "13842\n",
            "{\n",
            "  \"id\" : \"18525300\",\n",
            "  \"contents\" : \"To determine whether treatment gap between supplemental beam radiation and brachytherapy implant affects rectal morbidity and likelihood of cure in the treatment of intermediate-risk prostate cancer Five hundred sixty-eight patients with AJCC clinical stage T1c-T2a prostate cancer Gleason score 7 to 9 and/or prostate-specific antigen PSA 10 to 20 ng/mL were randomized to implantation with Pd-103 90 vs 115 Gy with 44 Gy versus 20 Gy preimplant supplemental beam radiation respectively Treatment-related morbidity was monitored by mailed questionnaires using a modified Radiation Therapy Oncology Group rectal morbidity criteria at 1 3 6 12 18 and 24 months Patients who reported grade 1 or worse rectal morbidity were interviewed by telephone to clarify details regarding their rectal bleeding Persistent rectal bleeding occurred in 36 of the 548 evaluable patients 7 % The mean gap among rectal bleeders was 38 days and among nonbleeders was 48 days P = 0236 Higher R100 and external beam dose of 44 Gy were significant predictors of rectal bleeding on univariate and multivariate analysis Log-rank analysis did not demonstrate any improvement in biochemical failure free survival BFFS with shorter gap interval On univariate analysis Gleason score > 7 PSA > 10 D90 < 100 % and treatment gap were all predictive of biochemical failure On multivariate analysis only Gleason score PSA and D90 remained significant predictors of BFFS Shorter gap intervals between supplemental beam radiation and brachytherapy implant are safe Shorter gap intervals do not improve BFFS however they do allow for treatment completion in a more timely fashion\",\n",
            "}\n",
            "13843\n",
            "{\n",
            "  \"id\" : \"21953275\",\n",
            "  \"contents\" : \"This Phase I study assessed whether food influences the rate and extent of selumetinib absorption in patients with advanced solid malignancies and determined the safety tolerability and pharmacokinetic PK profile of selumetinib and its active metabolite N-desmethyl-selumetinib in fed and fasted states A single dose of 75 mg selumetinib was to be taken with food on Day 1 followed by a single dose of 75 mg after fasting for at least 10 h on Day 8 or vice versa followed by twice daily dosing of 75 mg selumetinib from Day 10 Plasma concentrations and PK parameters were determined on Days 1 and 8 Patients could continue to receive selumetinib for as long as they benefitted from treatment In total 31 patients were randomized to receive selumetinib 15 to fed/fasted sequence and 16 to fasted/fed sequence Comprehensive PK sampling was performed on 11 and 10 patients respectively The geometric least-squares means of C max and AUC for selumetinib were reduced by 62 % ratio 038 90 % CI 029 050 and 19 % ratio 081 90 % CI 074 088 respectively under fed compared with fasting conditions The rate of absorption t max of selumetinib fed was delayed by approximately 25 h median The food effect was also observed for the active metabolite N-desmethyl-selumetinib Selumetinib was well tolerated The presence of food decreased the extent of absorption of selumetinib It is recommended that for further clinical studies selumetinib be taken on an empty stomach Selumetinib demonstrated an acceptable safety profile in the advanced cancer population\",\n",
            "}\n",
            "13844\n",
            "{\n",
            "  \"id\" : \"24998106\",\n",
            "  \"contents\" : \"the medications used according to the recommendation of the World Health Organization do not promote pain relief in a number of patients with cancer pain The aim of this study was to evaluate the use of morphine as first medication for the treatment of moderate cancer pain in patients with advanced and/or metastatic disease as an option to the recommendations of the World Health Organization analgesic ladder sixty patients without opioid therapy with 18 years of age were randomized into two groups G1 patients received medication according to the analgesic ladder and started treatment with non-opioids in the first weak opioids in the second and strong opioids in the third step G2 patients received morphine as first analgesic medication The efficacy and tolerability of initial use of morphine were evaluated every two weeks for three months the groups were similar with respect to demographic data There was no significant difference between the groups regarding pain intensity quality of life physical capacity satisfaction with treatment need for complementation and dose of morphine In G1 there was a higher incidence of nausea p = 00088 drowsiness p = 00005 constipation p = 00071 and dizziness p = 00376 in the second visit and drowsiness p = 005 in the third the use of morphine as first medication for pain treatment did not promote better analgesic effect than the ladder recommended by World Health Organization with higher incidence of adverse effects\",\n",
            "}\n",
            "13845\n",
            "{\n",
            "  \"id\" : \"23883379\",\n",
            "  \"contents\" : \"Alzheimer s disease is characterized by the presence of cortical amyloid-beta A protein plaques which result from the sequential action of - secretase and - secretase on amyloid precursor protein Semagacestat is a small-molecule - secretase inhibitor that was developed as a potential treatment for Alzheimer s disease We conducted a double-blind placebo-controlled trial in which 1537 patients with probable Alzheimer s disease underwent randomization to receive 100 mg of semagacestat 140 mg of semagacestat or placebo daily Changes in cognition from baseline to week 76 were assessed with the use of the cognitive subscale of the Alzheimer s Disease Assessment Scale for cognition ADAS-cog on which scores range from 0 to 70 and higher scores indicate greater cognitive impairment and changes in functioning were assessed with the Alzheimer s Disease Cooperative Study-Activities of Daily Living ADCS-ADL scale on which scores range from 0 to 78 and higher scores indicate better functioning A mixed-model repeated-measures analysis was used The trial was terminated before completion on the basis of a recommendation by the data and safety monitoring board At termination there were 189 patients in the group receiving placebo 153 patients in the group receiving 100 mg of semagacestat and 121 patients in the group receiving 140 mg of semagacestat The ADAS-cog scores worsened in all three groups mean change 64 points in the placebo group 75 points in the group receiving 100 mg of the study drug and 78 points in the group receiving 140 mg P = 015 and P = 007 respectively for the comparison with placebo The ADCS-ADL scores also worsened in all groups mean change at week 76 -90 points in the placebo group -105 points in the 100-mg group and -126 points in the 140-mg group P = 014 and P < 0001 respectively for the comparison with placebo Patients treated with semagacestat lost more weight and had more skin cancers and infections treatment discontinuations due to adverse events and serious adverse events P < 0001 for all comparisons with placebo Laboratory abnormalities included reduced levels of lymphocytes T cells immunoglobulins albumin total protein and uric acid and elevated levels of eosinophils monocytes and cholesterol the urine pH was also elevated As compared with placebo semagacestat did not improve cognitive status and patients receiving the higher dose had significant worsening of functional ability Semagacestat was associated with more adverse events including skin cancers and infections Funded by Eli Lilly ClinicalTrialsgov number NCT00594568\",\n",
            "}\n",
            "13846\n",
            "{\n",
            "  \"id\" : \"20679619\",\n",
            "  \"contents\" : \"Epirubicin oxaliplatin and capecitabine EOC is a standard treatment in advanced esophagogastric cancer Panitumumab P is a fully human immunoglobulin G2 monoclonal antibody targeting epidermal growth factor receptor Randomized Trial of EOC + / - Panitumumab for Advanced and Locally Advanced Esophagogastric Cancer REAL-3 will evaluate whether the addition of P to EOC improves survival in patients with advanced esophagogastric adenocarcinoma and undifferentiated carcinoma The original design of REAL-3 added P 9 mg/kg to the standard dose of EOC dose level [ DL ] + 1 Due to toxicity a dose de-escalation was made to EOC + P DL-1 epirubicin 50 mg/m 2 oxaliplatin130 mg/m 2 capecitabine 1000 mg/m 2 / d + P 9 mg/kg every 3 weeks After additional toxicity was observed the study was amended to include two additional EOC + P dose levels Using a 3 + 3 design dose-limiting toxicities DLTs were assessed weekly during cycle 1 Patients were randomly assigned 11 to EOC + / - PBetween July 2008 and October 2009 29 patients were randomly selected for standard-dose EOC n = 13 or EOC + P n = 16 Five patients were treated at DL + 1 with grade 3 diarrhea in four of five patients by cycle 4 At DL-1 one patient had grade 3 diarrhea and grade 5 infection Three patients were treated at DL-3 and then six were treated at DL-2 without DLTs The recommended dose for EOC + P is epirubicin 50 mg/m 2 oxaliplatin 100 mg/m 2 capecitabine 1000 mg/m 2 / d and P 9 mg/kg every 3 weeks This dose has been selected for the ongoing phase II/III REAL-3 study\",\n",
            "}\n",
            "13847\n",
            "{\n",
            "  \"id\" : \"9719081\",\n",
            "  \"contents\" : \"Both total dose and dose intensity of adjuvant chemotherapy are postulated to be important variables in the outcome for patients with operable breast cancer The Cancer and Leukemia Group B study 8541 examined the effects of adjuvant treatment using conventional-range dose and dose intensity in female patients with stage II axillary lymph node-positive breast cancer Within 6 weeks of surgery radical mastectomy modified radical mastectomy or lumpectomy 1550 patients with unilateral breast cancer were randomly assigned to one of three treatment arms high - moderate - or low-dose intensity The patients received cyclophosphamide doxorubicin and 5-fluorouracil on day 1 of each chemotherapy cycle with 5-fluorouracil administration repeated on day 8 The high-dose arm had twice the dose intensity and twice the drug dose as the low-dose arm The moderate-dose arm had two thirds the dose intensity as the high-dose arm but the same total drug dose Disease-free survival and overall survival were primary end points of the study At a median follow-up of 9 years disease-free survival and overall survival for patients on the moderate - and high-dose arms are superior to the corresponding survival measures for patients on the low-dose arm two-sided P < 0001 and two-sided P = 004 respectively with no difference in disease-free or overall survival between the moderate - and the high-dose arms At 5 years overall survival average + / - standard error is 79 % + / - 2 % for patients on the high-dose arm 77 % + / - 2 % for the patients on the moderate-dose arm and 72 % + / - 2 % for patients on the low-dose arm disease-free survival is 66 % + / - 2 % 61 % + / - 2 % and 56 % + / - 2 % respectively Within the conventional dose range for this chemotherapy regimen a higher dose is associated with better disease-free survival and overall survival\",\n",
            "}\n",
            "13848\n",
            "{\n",
            "  \"id\" : \"1332022\",\n",
            "  \"contents\" : \"Adherence interventions were implemented in a 1-year community-based colon cancer prevention clinical trial n = 110 using wheat bran fiber and calcium dietary supplements The adherence promotion strategy was guided by a theoretical model The adherence intervention contains both a generalized portion given to all participants and an individualized portion given to marginal 50-74 % intake and low under 50 % intake adherers A regression model was employed to assess the effectiveness of the interventions both at the first intervention and at subsequent times The Health Behavior in Cancer Prevention Model-based adherence promotion intervention was associated with retention of participants both during the run-in period and after randomization P = 005 and maximization of the percentage of the 135-g recommended fiber supplement consumed during the trial 925 % The positive effects of the adherence intervention were greater with first-time nonadherers and the control group than with the experimental group The high-fiber group had notably more biological GI effects from the increased fiber intake more preexisting comorbidities and lower perceived cognitive and physical health status Randomized participants had excellent adherence overall Retention rates in the trial were better than would be expected without the adherence intervention especially among those participants who may have been at higher risk for dropping out of the study This suggests that a systematic theoretically based adherence strategy should be further tested in clinical trial settings in which lower adherence is a problem\",\n",
            "}\n",
            "13849\n",
            "{\n",
            "  \"id\" : \"9407641\",\n",
            "  \"contents\" : \"Immunosuppression associated with blood transfusion may influence postoperative infection rates It may also affect the prognosis of patients treated surgically for colorectal cancer To control this effect study protocols have applied autologous blood donation programs which are thought to be immunologically neutral However evidence has emerged that blood donation itself might have suppressive effects on natural killer NK cell activities At present there are no data available on the effects of autologous blood transfusion on NK or lymphokine-activated killer LAK cells This might be of interest as LAK cells may be active in tumor control 26 patients who underwent surgical resection for colorectal cancer were assigned at random into two groups 1 autologous blood donation and transfusion or 2 allogeneic blood transfusion NK and LAK activities were determined before blood donation at surgery and on the 3rd and 8th postoperative day Blood donation induced a small decrease in NK and LAK activities The postoperative courses of the two groups differed In the allogeneic group NK activity -50 % p = 0018 and LAK activity decreased -607 % p = 0043 whereas in the autologous group the decline in LAK was less pronounced -337 % p = 0091 and their NK activity even increased +174 % p = 0315 NK activity was modulated differently in the two study groups 00036 Differences in LAK activities were found between the 3rd and 8th day postoperatively p = 0354 In patients receiving autologous blood transfusion postoperative suppressed NK and LAK activities were modulated This implies that autologous blood transfusion is not immunologically neutral but has an intrinsic immunomodulatory potential\",\n",
            "}\n",
            "13850\n",
            "{\n",
            "  \"id\" : \"15774776\",\n",
            "  \"contents\" : \"There is a wide spectrum of tumor responsiveness of rectal adenocarcinomas to preoperative chemoradiotherapy ranging from complete response to complete resistance This study aimed to investigate whether parallel gene expression profiling of the primary tumor can contribute to stratification of patients into groups of responders or nonresponders Pretherapeutic biopsies from 30 locally advanced rectal carcinomas were analyzed for gene expression signatures using microarrays All patients were participants of a phase III clinical trial CAO/ARO/AIO -94 German Rectal Cancer Trial and were randomized to receive a preoperative combined-modality therapy including fluorouracil and radiation Class comparison was used to identify a set of genes that were differentially expressed between responders and nonresponders as measured by T level downsizing and histopathologic tumor regression grading In an initial set of 23 patients responders and nonresponders showed significantly different expression levels for 54 genes P < 001 The ability to predict response to therapy using gene expression profiles was rigorously evaluated using leave-one-out cross-validation Tumor behavior was correctly predicted in 83 % of patients P = 02 Sensitivity correct prediction of response was 78 % and specificity correct prediction of nonresponse was 86 % with a positive and negative predictive value of 78 % and 86 % respectively Our results suggest that pretherapeutic gene expression profiling may assist in response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy The implementation of gene expression profiles for treatment stratification and clinical management of cancer patients requires validation in large independent studies which are now warranted\",\n",
            "}\n",
            "13851\n",
            "{\n",
            "  \"id\" : \"19412843\",\n",
            "  \"contents\" : \"Patients of head and neck cancer undergoing radiotherapy develop oral mucositis The severity of mucositis may also depend on the time of administration of radiation apart from patient-related factors The most radiosensitive phase of the cell cycle G2-M occurs in the late afternoon and evening in human oral mucosa therefore it is more vulnerable to radiation injury in the evening The present study evaluated prospectively the severity of acute oral mucositis in head and neck carcinoma patients irradiated in the morning 0800 -1100 h versus late afternoon/evening 1500 -1800 h A total of 212 patients of head and neck carcinoma were randomised to morning 0800 -1100 h and evening 1500 -1800 h groups The grades of oral mucosa ulceration were compared in the two groups The grades of mucositis were marginally higher in the evening-irradiated group than in the morning-irradiated group 38 % vs 26 % p = 008 The observed incidence of grade III/IV mucositis in morning vs evening irradiated patients may be because of the existence of circadian rhythm in the cell cycle of normal mucosa This knowledge may provide a possibility of treating the patients with decreased toxicity to oral mucosa\",\n",
            "}\n",
            "13852\n",
            "{\n",
            "  \"id\" : \"19747781\",\n",
            "  \"contents\" : \"To report from Cancer and Leukemia Group B Protocol 9082 the impact of high-dose cyclophosphamide cisplatin and BCNU HD-CPB vs intermediate-dose CPB ID-CPB on the ability to start and complete the planned course of local-regional radiotherapy RT for women with breast cancer involving > or = 10 axillary nodes From 1991 to 1998 785 patients were randomized The HD-CPB and ID-CPB arms were balanced regarding patient characteristics The HD-CPB and ID-CPB arms were compared on the probability of RT initiation interruption modification or incompleteness The impact of clinical variables and interactions between variables were also assessed Radiotherapy was initiated in 82 % 325 of 394 of HD-CPB vs 92 % 360 of 391 of ID-CPB patients p = 0001 On multivariate analyses RT was less likely given to patients who were randomized to HD treatment odds ratio [ OR ] = 0 38 p < 0001 older p = 0005 African American p = 0003 postmastectomy p = 002 or estrogen receptor positive p = 003 High-dose treatment had a higher rate of RT interruption 21 % vs 12 % p = 0001 OR = 205 modification 29 % vs 14 % p = 0001 OR = 246 and early termination of RT 9 % vs 2 % p = 00001 OR = 535 compared with ID Treatment arm significantly related to initiation interruption modification and early termination of RT Patients randomized to HD-CPB were less likely to initiate RT and of those who did they were more likely to have RT interrupted modified and terminated earlier than those randomized to ID-CPB The observed lower incidence of RT usage in African Americans vs non-African Americans warrants further study\",\n",
            "}\n",
            "13853\n",
            "{\n",
            "  \"id\" : \"22221173\",\n",
            "  \"contents\" : \"Patients with primary sclerosing cholangitis PSC and inflammatory bowel disease IBD have a high risk of developing colorectal cancer and dysplasia Ursodeoxycholic acid UDCA has been suggested to have chemopreventive effects on the development of colorectal cancer and dysplasia but long-term data and larger trials are lacking To evaluate the effect of high dose 17-23mg / kg/day UDCA on colorectal neoplasia in a cohort of patients with PSC and IBD From our previous 5-year randomised controlled trial of UDCA vs placebo in PSC we performed a follow-up of 98 patients with concomitant IBD from entry of the trial 1996-1997 until 2009 for development of colorectal cancer or dysplasia The total follow-up time was 760 person-years Dysplasia/cancer-free survival was compared between placebo - n = 50 and UDCA-treated n = 48 patients There was a similar frequency of dysplasia or cancer after 5years between patients originally assigned to UDCA or placebo 13 % vs 16 % and no difference in dysplasia/cancer-free survival P = 046 log rank test At the end of 2009 no difference in cancer-free survival was detected 30 % of the placebo patients compared with 27 % of UDCA patients had developed colorectal cancer or dysplasia Long-term high dose ursodeoxycholic acid does not prevent colorectal cancer or dysplasia in patients with primary sclerosing cholangitis-associated inflammatory bowel disease\",\n",
            "}\n",
            "13854\n",
            "{\n",
            "  \"id\" : \"23742877\",\n",
            "  \"contents\" : \"Docetaxel plus prednisone is standard first-line chemotherapy for men with metastatic castrate-resistant prostate cancer Aflibercept is a recombinant human fusion protein that binds A and B isoforms of VEGF and placental growth factor thereby inhibiting angiogenesis We assessed whether the addition of aflibercept to docetaxel and prednisone would improve overall survival in men with metastatic castrate-resistant prostate cancer compared with the addition of placebo to docetaxel and prednisone VENICE was a phase 3 multicentre randomised double-blind placebo-controlled parallel group study done in 31 countries 187 sites Men with metastatic castrate-resistant prostate cancer adequate organ function and no prior chemotherapy were treated with docetaxel 75 mg/m 2 intravenously every 3 weeks and oral prednisone 5 mg twice daily and randomly allocated 11 to receive aflibercept 6 mg/kg or placebo intravenously every 3 weeks Treatment allocation was done centrally via an interactive voice response system using a computer-generated sequence with a permuted-block size of four and stratified according Eastern Co-operative Group performance status 0-1 vs 2 Patients investigators and other individuals responsible for study conduct and data analysis were masked to treatment assignment Aflibercept or placebo vials were supplied in identical boxes The primary endpoint was overall survival using intention-to-treat analysis This is the primary analysis of the completed trial The study is registered with ClinicalTrialsgov number NCT00519285 FINDINGS Between Aug 17 2007 and Feb 11 2010 1224 men were randomly allocated to treatment 612 to each group At final analysis median follow-up was 35 months IQR 29-41 and 873 men had died Median overall survival was 221 months 956 % CI 203-241 in the aflibercept group and 212 months 196-238 in the placebo group stratified hazard ratio 094 956 % CI 082-108 p = 038 We recorded a higher incidence of grade 3-4 gastrointestinal disorders 182 [ 30 % ] vs 48 [ 80 % ] haemorrhagic events 32 [ 52 % ] vs ten [ 17 % ] hypertension 81 [ 13 % ] vs 20 [ 33 % ] fatigue 97 [ 16 % ] vs 46 [ 77 % ] infections 123 [ 20 % ] vs 60 [ 10 % ] and treatment-related fatal adverse events 21 [ 34 % ] vs nine [ 15 % ] in the aflibercept group than in the placebo group Aflibercept in combination with docetaxel and prednisone given as first-line chemotherapy for men with metastatic castrate-resistant prostate cancer resulted in no improvement in overall survival and added toxicity compared with placebo Docetaxel plus prednisone remains the standard treatment for such men who need first-line chemotherapy Sanofi and Regeneron Pharmaceuticals Inc\",\n",
            "}\n",
            "13855\n",
            "{\n",
            "  \"id\" : \"23717406\",\n",
            "  \"contents\" : \"One key aspect of cancer survivorship is return-to-work Unfortunately many cancer survivors face problems upon their return-to-work For that reason we developed a hospital-based work support intervention aimed at enhancing return-to-work We studied effectiveness of the intervention compared to usual care for female cancer patients in a multi-centre randomised controlled trial Breast and gynaecological cancer patients who were treated with curative intent and had paid work were randomised to the intervention group n = 65 or control group n = 68 The intervention involved patient education and support at the hospital and improvement of communication between treating and occupational physicians In addition we asked patient s occupational physician to organise a meeting with the patient and the supervisor to make a concrete gradual return-to-work plan Outcomes at 12 months of follow-up included rate and time until return-to-work full or partial quality of life work ability work functioning and lost productivity costs Time until return-to-work was analyzed with Kaplan-Meier survival analysis Return-to-work rates were 86 % and 83 % p = 06 for the intervention group and control group when excluding 8 patients who died or with a life expectancy of months at follow-up Median time from initial sick leave to partial return-to-work was 194 days range 14-435 versus 192 days range 82-465 p = 090 with a hazard ratio of 103 95 % CI 064-1 6 Quality of life and work ability improved statistically over time but did not differ statistically between groups Work functioning and costs did not differ statistically between groups The intervention was easily implemented into usual psycho-oncological care and showed high return-to-work rates We failed to show any differences between groups on return-to-work outcomes and quality of life scores Further research is needed to study which aspects of the intervention are useful and which elements need improvement Nederlands Trial Register NTR 1658\",\n",
            "}\n",
            "13856\n",
            "{\n",
            "  \"id\" : \"15852407\",\n",
            "  \"contents\" : \"A Phase III trial was conducted by the North Central Cancer Treatment Group to determine whether chemotherapy etoposide and cisplatin plus either twice-daily radiotherapy BIDRT or once-daily radiotherapy QDRT resulted in a better outcome for patients with limited-stage small cell lung carcinoma LD-SCLC No difference in survival was identified between the two arms The current analysis examined the relation between age and outcome for patients treated during this trial The current study included 263 patients with LD-SCLC and an Eastern Cooperative Oncology Group performance status of < or = 2 who were randomized to receive QDRT or split-course BIDRT The outcomes of the 209 79 % younger patients age < 70 years old were compared with the 54 21 % elderly patients age > or = 70 years old Elderly patients presented with significantly greater weight loss and poorer performance status The 2-year and 5-year survival rates were 48 % and 22 % for younger patients compared with 33 % and 17 % for older patients P = 014 One specific toxicity ie Grade > or = 4 pneumonitis [ according to National Cancer Institute Common Toxicity Criteria ] occurred in 0 % of those patients age < 70 years compared with 6 % of older patients P = 0008 Grade 5 toxicity occurred in 1 of 209 05 % patients age < 70 years compared with 3 of 54 56 % older patients P = 003 Despite having more weight loss poorer performance status increased pulmonary toxicity and more deaths due to treatment survival was not found to be significantly worse in older individuals Fit elderly patients with LD-SCLC can receive combined-modality therapy with the expectation of relatively favorable long-term survival Future research should focus on ways to decrease toxicity especially in the elderly\",\n",
            "}\n",
            "13857\n",
            "{\n",
            "  \"id\" : \"25605628\",\n",
            "  \"contents\" : \"The optimal surgical approach for treatment of oesophagogastric junction OGJ cancer is controversial A randomized clinical trial JCOG9502 comparing transhiatal TH and left thoracoabdominal LTA approaches was stopped after the first interim analysis owing to limited efficacy for LTA resections Complete 10-year follow-up data are now available Patients with histologically proven adenocarcinoma of the OGJ or gastric cardia with oesophageal invasion of 3cm or less were randomized to a TH or LTA approach Both groups underwent total gastrectomy and splenectomy with D2 nodal dissection plus para-aortic lymphadenectomy above the left renal vein For LTA a thorough mediastinal lymphadenectomy below the left inferior pulmonary vein was also mandatory The primary endpoint was overall survival A total of 167 patients 82 TH 85 LTA were enrolled The 10-year overall survival rate was 37 95 per cent ci 26 to 47 per cent for the TH approach and 24 15 to 34 per cent for the LTA technique P = 0060 The hazard ratio for death was 142 098 to 205 for the LTA technique Subgroup analysis based on the Siewert classification indicated non-significant survival advantages in favour of the TH approach LTA resections should be avoided in the treatment of adenocarcinoma of the OGJ or gastric cardia NCT00149266 https//wwwclinicaltrialsgov\",\n",
            "}\n",
            "13858\n",
            "{\n",
            "  \"id\" : \"19090531\",\n",
            "  \"contents\" : \"To determine whether sleep quality and fatigue associated with breast cancer adjuvant chemotherapy treatments can be improved with behavioral therapy BT [ Individualized Sleep Promotion Plan ISPP ] including modified stimulus control modified sleep restriction relaxation therapy and sleep hygiene Randomized-controlled trial based on Piper Integrated Fatigue Model 219 stages I-IIIA breast cancer patients Prior to the initial chemotherapy treatment BT participants developed an ISPP plan that was regularly reinforced and revised Controls received healthy eating information and attention Pittsburgh Sleep Quality Index PSQI daily diary actigraph and Piper Fatigue Scale PFS data were collected 2 days prior during the 7 days after each treatment and 30 days after the last treatment Repeated measures analysis of variance was used Prior to chemotherapy participants reported mild fatigue and fairly poor sleep quality All variables changed over time A group by time interaction was found for sleep quality PSQI improving in the BT group Diary revealed group differences on number of awakenings minutes awake after sleep onset and sleep efficiency Fatigue PFS was similar between groups The BT group showed improved sleep quality over time and better sleep diary Perceptions of improved sleep quality over time are not consistently associated with diary or actigraph or result in lower fatigue\",\n",
            "}\n",
            "13859\n",
            "{\n",
            "  \"id\" : \"16688811\",\n",
            "  \"contents\" : \"To investigate the effect of three-dimensional conformal radiotherapy 3-DCRT in combination with FOLFOX4 chemotherapy for unresectable recurrent rectal cancer Forty-eight patients with unresectable recurrent rectal cancer were randomized and treated by 3-DCRT or 3-DCRT combined with FOLFOX4 chemotherapy between September 2001 and October 2003 For the patients without prior radiation history the initial radiation was given to the whole pelvis by traditional methods with tumor dose of 40 Gy followed by 3-DCRT for the recurrent lesions to the median total cumulative tumor dose of 60 Gy range 56-66 Gy for the post-radiation recurrent patients 3-DCRT was directly given for the recurrent lesions to the median tumor dose of 40 Gy 36-46 Gy For patients in the study group two cycles chemotherapy with FOLFOX4 regimen were given concurrently with radiotherapy with the first cycle given simultaneously with the initiation of radiation and the second cycle given in the fifth week for patients receiving conventional pelvis radiation or given in the last week of 3-DCRT for patients receiving 3-DCRT directly Another 2-4 cycles average 36 cycles sequential FOLFOX4 regimen chemotherapy were given to the patients in the study group beginning at 2-3 wk after chemoradiation The outcomes of symptoms relieve tumor response survival and toxicity were recorded and compared between the study group and the control group For the study group and the control group the pain-alleviation rates were 952 % and 913 % P > 005 the overall response rates were 565 % and 400 % P > 005 the 1-year and 2-year survival rates were 869 % 502 % and 800 % 239 % with median survival time of 25 mo and 16 mo P < 005 the 2-year distant metastasis rates were 391 % and 560 % P = 0054 respectively The side effects except peripheral neuropathy which was relatively severer in the study group were similar in the the two groups and well tolerated Three-dimensional conformal radio-therapy combined with FOLFOX4 chemotherapy for unresectable recurrent rectal cancer is a feasible and effective therapeutic approach and can reduce distant metastasis rate and improve the survival rate\",\n",
            "}\n",
            "13860\n",
            "{\n",
            "  \"id\" : \"16934392\",\n",
            "  \"contents\" : \"Randomized controlled trials are currently conducted to assess whether the mortality from prostate cancer is reduced by early detection with the use of prostate-specific antigen PSA measurements in serum To be effective such a program should be able to reduce the absolute number of men diagnosed with metastatic prostate cancer for which no cure is available The aim of the present report is to evaluate whether PSA-based screening reduces the risk of being diagnosed with metastatic prostate cancer A population-based prospective randomized controlled screening trial for prostate cancer started in 1995 the Gteborg branch of the European Randomized Study of Screening for Prostate Cancer [ ERSPC ] Ten thousand randomly selected men aged 50-66 yr were invited for biennial PSA testing with 10000 men serving as passive controls for whom diagnosis of metastatic prostate cancer was monitored by using the Swedish Cancer Registry After a follow-up of 10 yr the risk of being diagnosed with metastatic prostate cancer was reduced by 489 % - that is decreasing from 47 cases in the control group to 24 cases in the group randomized to PSA-based screening p = 00084 However the risk of being diagnosed with prostate cancer increased 18-fold with PSA-based screening Biennial PSA screening reduces the risk of being diagnosed with metastatic prostate cancer the first prerequisite for achieving decreased cancer mortality in younger men This putative benefit is balanced by a 18-fold increased risk for diagnosis of prostate cancer\",\n",
            "}\n",
            "13861\n",
            "{\n",
            "  \"id\" : \"24894850\",\n",
            "  \"contents\" : \"To test the hypothesis that observation with early salvage radiotherapy SRT is not inferior to standard treatment with adjuvant RT ART with respect to biochemical failure in patients with pT3 disease and/or positive surgical margins SMs after radical prostatectomy RP To compare the following secondary endpoints between the two arms patient-reported outcomes adverse events biochemical failure-free survival overall survival disease-specific survival time to distant failure time to local failure cost utility analysis quality adjusted life years and time to androgen deprivation The Radiotherapy - Adjuvant Versus Early Salvage RAVES trial is a phase III multicentre randomised controlled trial led by the Trans Tasman Radiation Oncology Group TROG in collaboration with the Urological Society of Australia and New Zealand USANZ and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group ANZUP In all 470 patients are planned to be randomised 11 to either ART commenced at 4 months of RP standard of care or close observation with early SRT triggered by a PSA level of > 020 ng/mL experimental arm Eligible patients have had a RP for adenocarcinoma of the prostate with at least one of the following risk factors positive SMs extraprostatic extension seminal vesicle involvement The postoperative PSA level must be 010 ng/mL Rigorous investigator credentialing and a quality assurance programme are designed to promote consistent RT delivery among patients Trial is currently underway with 258 patients randomised as of 31 October 2013 International collaborations have developed including a planned meta-analysis to be undertaken with the UK Medical Research Council/National Cancer Institute of Canada Clinical Trials Group RADICALS Radiotherapy and Androgen Deprivation In Combination with Local Surgery trial and an innovative psycho-oncology sub-study to investigate a patient decision aid resource On the current evidence available it remains unclear if ART is equivalent or superior to observation with early SRT\",\n",
            "}\n",
            "13862\n",
            "{\n",
            "  \"id\" : \"19934295\",\n",
            "  \"contents\" : \"Immunotherapeutic agents produce antitumor effects by inducing cancer-specific immune responses or by modifying native immune processes Resulting clinical response patterns extend beyond those of cytotoxic agents and can manifest after an initial increase in tumor burden or the appearance of new lesions progressive disease Response Evaluation Criteria in Solid Tumors or WHO criteria designed to detect early effects of cytotoxic agents may not provide a complete assessment of immunotherapeutic agents Novel criteria for the evaluation of antitumor responses with immunotherapeutic agents are required The phase II clinical trial program with ipilimumab an antibody that blocks CTL antigen-4 represents the most comprehensive data set available to date for an immunotherapeutic agent Novel immune therapy response criteria proposed based on the shared experience from community workshops and several investigators were evaluated using data from ipilimumab phase II clinical trials in patients with advanced melanoma Ipilimumab monotherapy resulted in four distinct response patterns a shrinkage in baseline lesions without new lesions b durable stable disease in some patients followed by a slow steady decline in total tumor burden c response after an increase in total tumor burden and d response in the presence of new lesions All patterns were associated with favorable survival Systematic criteria designated immune-related response criteria were defined in an attempt to capture additional response patterns observed with immune therapy in advanced melanoma beyond those described by Response Evaluation Criteria in Solid Tumors or WHO criteria Further prospective evaluations of the immune-related response criteria particularly their association with overall survival are warranted\",\n",
            "}\n",
            "13863\n",
            "{\n",
            "  \"id\" : \"9209661\",\n",
            "  \"contents\" : \"There is no clear data on the optimum number of courses of platinum chemotherapy required for treating advanced ovarian cancer A prospective randomised trial was performed to compare five with eight courses of either carboplatin 400 mg/m2 or cisplatin 75 mg/m2 given four-weekly to patients with stage IC-IV ovarian cancer 225 patients were entered into the study and 233 were eligible for randomisation 118 to five courses and 115 to eight courses In each randomisation half the patients received carboplatin and half received cisplatin The mean number of courses received on the five arm was 474 and on the eight arm 642 an increase of 35 % The median survival for all patients was 24 months with the median survival for the 156 patients with stage 3 disease being 21 months No difference was detected in survival P = 053 or time to progression from initial surgery P = 029 between the two arms of the trial False-negative calculations based on a multivariate analysis show that the trial currently has 95 % power for excluding a difference of 10 % in favour of the eight course arm at three years There is insufficient evidence at the present time to justify more than five courses of first-line single agent platinum chemotherapy in the management of advanced ovarian cancer\",\n",
            "}\n",
            "13864\n",
            "{\n",
            "  \"id\" : \"25577838\",\n",
            "  \"contents\" : \"To compare the perioperative data pathological results and functional outcomes of transvesical single - site laparoscopic radical prostatectomy TVSSLRP with those of nerve-sparing extraperitoneal laparoscopic radical prostatectomy nsELRP in the treatment of low-risk prostate cancer PCa Fifty patients with low-risk organ-confined PCa were randomly assigned to two groups of equal number to receive TVSSLRP and nsELRP respectively Comparisons were made between the two groups of patients in such demographic and baseline data as age comorbidity body mass index BMI serum prostate-specific antigen PSA prostate volume bioptic Gleason score clinical stage IIEF-5 score nocturnal penile tumescence NPT penile brachial index PBI and penile arterial blood flow velocity as well as in such surgery-related parameters as operation duration blood loss blood transfusion intraoperative complications positive surgical margin catheterization time hospital stay and postoperative Gleason score pathologic stage urinal pad use PSA level IIEF-5 score NPT PBI and PABFV All the operations were successfully performed There were no statistically significant differences between the two groups either in the demographic and baseline data or in intraoperative blood loss blood transfusion rate complications and positive surgical margin No intraoperative complications and positive surgical margins were found in either group Compared with nsELRP TVSSLRP achieved a significantly shorter operation duration [ 15146 4068 ] min vs [ 10592 2621 ] min P < 005 catheterization time [ 1301 164 ] d vs [ 1124 117 ] d P < 005 and hospital stay [ 1576 465 ] d vs [ 1292 429 ] d P < 005 On the first day and at 1 3 and 6 months after catheter removal the urinary continence rates in the TVSSLRP and nsELRP groups were 84 % vs 52 % P < 005 100 % vs 84 % 100 % vs 96 % and 100 % vs 96 % respectively and at 3 6 and 12 months after surgery the erectile potency rates were 48 % vs 28 % P < 005 64 % vs 52 % and 76 % vs 68 % respectively with an IIEF-5 score 18 all evidently higher in the TVSSLRP than in the nsELRP group The penile brachial index and arterial blood flow velocity of the two groups of patients exhibited no significant differences before and after surgery nor did postoperative complications grade II between the TVSSLRP and nsELRP groups 32 % vs 40 % P > 005 The Gleason score and pathologic stage were increased after surgery but with remarkable differences between the two groups P > 005 No biochemical recurrence was found in either group during a 12-month follow-up With the advantages of safety and rapid postoperative recovery both TVSSLRP and nsELRP are feasible for the treatment of low-risk organ-confined PCa but the former may achieve an earlier recovery of urinary continence and erectile function than the latter\",\n",
            "}\n",
            "13865\n",
            "{\n",
            "  \"id\" : \"19941668\",\n",
            "  \"contents\" : \"Men with prostate cancer are often challenged to choose between conservative management and a range of available treatment options each carrying varying risks and benefits The trade-offs are between an improved life-expectancy with treatment accompanied by important risks such as urinary incontinence and erectile dysfunction Previous studies of preference elicitation for prostate cancer treatment have found considerable heterogeneity in individuals preferences for health states given similar treatments and clinical risks Using latent class mixture model LCA we first sought to understand if there are unique patterns of heterogeneity or subgroups of individuals based on their prostate cancer treatment utilities calculated time trade-off utilities for various health states and if such unique subgroups exist what demographic and urological variables may predict membership in these subgroups The sample N = 244 included men with prostate cancer n = 188 and men at-risk for disease n = 56 The sample was predominantly white 77 % with mean age of 60 years SD + / -95 Most 859 % were married or living with a significant other Using LCA a three class solution yielded the best model evidenced by the smallest Bayesian Information Criterion BIC substantial reduction in BIC from a 2-class solution and Lo-Mendell-Rubin significance of < 001 The three identified clusters were named high-traders n = 31 low-traders n = 116 and no-traders n = 97 High-traders were more likely to trade survival time associated with treatment to avoid potential risks of treatment Low-traders were less likely to trade survival time and accepted risks of treatment The no-traders were likely to make no trade-offs in any direction favouring the status quo There was significant difference among the clusters in the importance of sexual activity Pearson s chi2 = 1655 P = 0002 Goodman and Kruskal tau = 0039 P < 0001 In multinomial logistic regression the level of importance assigned to sexual activity remained an independent predictor of class membership Age and prostate cancer/at-risk status were not significant factors in the multinomial model Most existing utility work is undertaken focusing on how people choose on average Distinct clusters of prostate cancer treatment utilities in our sample point to the need for further understanding of subgroups and need for tailored assessment and interventions\",\n",
            "}\n",
            "13866\n",
            "{\n",
            "  \"id\" : \"15498633\",\n",
            "  \"contents\" : \"Sentinel lymph node biopsy in breast cancer can be used to select patients in which axillary lymph node dissection could be avoided In this study we compared the value of two methods for identification of sentinel node SN using either only blue dye or combination of blue dye and radioactive tracer All patients were women with clinically T 1-2 N 0 M 0 breast cancer They were randomized into two groups In Group A 50 patients SN marking was performed only with blue dye and in Group B 100 patients combined SN marking with blue dye and radiotracer was done We used 2 ml of blue dye Patentblau V Byk Gulden Radiotracer was Antimony sulfide marked with Tc 99m and of 03 mCy 111 MBq activity Application method of both contrasts was peritumoral After SN biopsy all patients underwent mastectomy or conservative surgery with axillary lymph node dissection of levels I and II In Group A mean of 17 SNs were identified median 1 range 1-4 False-negative rate in this group was 3/17 176 % with negative-predictive value 20/23 869 % sensitivity 14/17 82 % specificity 20/33 60 % and accuracy 34/50 68 % In Group B mean number of SNs excised per case was 16 median 1 range 1-5 False-negative rate was 2/44 45 % negative-predictive value 41/43 953 % sensitivity 42/44 95 % specificity 41/56 73 % and accuracy 83/100 83 % The combination technique was significantly superior to blue-dye alone technique for negative-predictive value p = 0033 and overall accuracy p = 0048 The prediction of axillary lymph node status in breast cancer patients using combined technique has significantly higher accuracy than marking of SN with blue dye alone and therefore should be preferred\",\n",
            "}\n",
            "13867\n",
            "{\n",
            "  \"id\" : \"19638909\",\n",
            "  \"contents\" : \"This prospective randomized multicenter study aims to evaluate the efficacy of extensive intraoperative peritoneal lavage followed by intraperitoneal chemotherapy EIPL-IPC on the overall 5-year survival of advanced gastric cancer patients with intraperitoneal free cancer cells without overt peritoneal metastasis CY + / P - The study also aims to determine the merit and reliability of EIPL-IPC therapy as a prophylactic strategy for peritoneal metastasis Although the prognosis of advanced gastric cancer patients with CY + / P - is extremely poor a suitable standard regimen for treating such patients has not yet been established A total of 88 patients with CY + / P - from 1522 patients with advanced gastric cancer at multicenters were enrolled in this study and were randomly allocated to 3 groups surgery alone group surgery plus intraperitoneal chemotherapy IPC group and surgery plus EIPL and IPC EIPL-IPC group Prognostic significance of EIPL-IPC therapy was evaluated by Kaplan-Meier curves and its value as an independent prognostic factor was assessed by univariate and multivariate analyses The overall 5-year survival rate of the patients with EIPL-IPC was 438 % and this data were significantly better than that of the IPC group 46 % P < 00001 and the surgery alone group 0 % P < 00001 Among various recurrent patterns the EIPL-IPC group had a significantly lower incidence of peritoneal recurrence than both of the other groups P < 00001 Univariate and multivariate analyses revealed that EIPL was the most significant impact factor The present study clearly revealed that EIPL-IPC therapy significantly improved the 5-year survival span of advanced gastric cancer patients with CY + / P - Thus EIPL-IPC therapy is strongly recommended as a standard prophylactic strategy for peritoneal dissemination\",\n",
            "}\n",
            "13868\n",
            "{\n",
            "  \"id\" : \"19756426\",\n",
            "  \"contents\" : \"To assess the late effect of a prostaglandin given rectally during irradiation on late rectal toxicity In the acute treatment setting no significant differences in reducing the incidence of acute proctitis symptoms in patients receiving misoprostol however significantly more rectal bleeding had been reported A total of 100 patients who had undergone radiotherapy for prostate cancer had been entered into this phase III randomized placebo-controlled double-blind study with misoprostol or placebo suppositories The toxicity was evaluated yearly after cessation of irradiation by the RTOG/LENT-SOMA scale The median follow-up was 50 months 20 patients suffered from grade 1 four patients from grade 2 as well and three patients only from grade 2 toxicity Frequency bleeding and urgency were the most commonly reported symptoms In keeping with other studies and clinical experience the symptoms peaked within the first 2 years with a median for grade 1 of 13 months and for grade 2 of 15 months The presence of acute toxicity grade 2 showed a correlation with the development of any late toxicity p = 003 Any acute rectal bleeding was significant correlated with any late rectal bleeding p = 0017 Misoprostol given as once-daily suppository for prevention of acute radiation-induced proctitis does neither influence the incidence and severity of radiation-induced acute nor late rectal toxicity Misoprostol has no negative impact on the incidence and severity of late rectal bleeding in contrast to acute rectal bleeding The routine clinical use of misoprostol suppositories can not be recommended\",\n",
            "}\n",
            "13869\n",
            "{\n",
            "  \"id\" : \"7538237\",\n",
            "  \"contents\" : \"To compare the efficacy and safety of bicalutamide and flutamide each used in combination with luteinizing hormone-releasing analogue LHRH-A therapy in patients with untreated metastatic Stage D2 prostate cancer Randomized double-blind for antiandrogen therapy multicenter study with a 2 x 2 factorial design Eight hundred thirteen patients were allocated 11 to bicalutamide 50 mg once daily and flutamide 250 mg three times daily and 21 to goserelin acetate 36 mg every 28 days and leuprolide acetate 75 mg every 28 days With a median duration of follow-up of 49 weeks time to treatment failure the primary endpoint was significantly P = 0005 better for the bicalutamide plus LHRH-A group than for the flutamide plus LHRH-A group Patients in the flutamide plus LHRH-A group were 34 % more likely to fail treatment over the given time period as indicated by the hazard ratio of 0749 95 % confidence interval 061 to 092 for bicalutamide plus LHRH-A to flutamide plus LHRH-A Results for secondary endpoints survival quality of life and subjective response were similar between groups Diarrhea occurred in 24 % of patients in the flutamide plus LHRH-A group compared with 10 % of patients in the bicalutamide plus LHRH-A group P < 0001 In patients with metastatic prostate cancer bicalutamide plus LHRH-A is well tolerated and provides superior efficacy to flutamide plus LHRH-A with respect to time to treatment failure Assessment of the effects of these regimens on longer term survival requires additional time for follow-up\",\n",
            "}\n",
            "13870\n",
            "{\n",
            "  \"id\" : \"17338829\",\n",
            "  \"contents\" : \"The disappointing results of surgical therapy alone of ductal pancreatic cancer can only be improved using multimodal approaches In contrast to adjuvant therapy neoadjuvant chemoradiation is able to facilitate resectability with free margins and to lower lymphatic spread Another advantage is better tolerability which consecutively allows applying multimodal treatment in a higher number of patients Furthermore the synopsis of the overall survival results of neoadjuvant trials suggests a higher rate compared to adjuvant trials As there are no prospectively randomised studies for neoadjuvant therapy the Interdisciplinary Study Group of Gastrointestinal Tumours of the German Cancer Aid has started such a trial The study investigates the effect of neoadjuvant chemoradiation in locally resectable or probably resectable cancer of the pancreatic head without distant metastasis on median overall survival time compared to primary surgery Adjuvant chemotherapy is integrated into both arms The protocol of the study is presented in condensed form after an introducing survey on adjuvant and neoadjuvant therapy in pancreatic cancer\",\n",
            "}\n",
            "13871\n",
            "{\n",
            "  \"id\" : \"17031646\",\n",
            "  \"contents\" : \"To evaluate the toxicity profile and pharmacological properties of oral CP-547 632 alone and in combination with paclitaxel and carboplatin administered every 3 weeks and to assess efficacy as measured by the objective response and progressive disease rates of oral CP-547 632 administered in combination with paclitaxel and carboplatin Patients with stage IIIB/IV or recurrent non-small cell lung cancer receiving first-line chemotherapy were treated with oral daily CP-547 632 in combination with paclitaxel 225 mg/m 2 and carboplatin AUC = 6 every 3 weeks Pharmacokinetics parameters for CP-547 632 and paclitaxel were determined independently and during co-administration Seventy patients were enrolled and 68 patients were treated 37 in phase 1 and 31 in phase 2 14 with the combination and 17 with chemotherapy alone Dose-limiting toxicity of CP-547 632 250 mg by mouth daily in combination with paclitaxel and carboplatin was grade 3 rash and grade 3 diarrhea despite medical intervention CP-547 632 did not significantly affect the pharmacologic profiles of paclitaxel and carboplatin No subject had CR In phase I seven subjects 226 % had a confirmed partial response In phase II four subjects 286 % receiving CP-547 632 plus chemotherapy had a confirmed partial response In the phase II chemotherapy alone group four subjects 25 % had a confirmed partial response The combination of CP-547 632 and paclitaxel and carboplatin was well-tolerated at doses up to 200 mg by mouth daily Dose-limiting toxicity of CP-547 632 at 250 mg consisted of diarrhea and rash CP-547 632 did not increase the objective response rate to chemotherapy alone in patients with advanced non-small cell lung cancer\",\n",
            "}\n",
            "13872\n",
            "{\n",
            "  \"id\" : \"12519430\",\n",
            "  \"contents\" : \"It is not known whether increasing the dose of filgrastim after mobilizing chemotherapy improves collection of peripheral blood progenitor cells PBPC and leads to faster hematopoietic engraftment after autologous transplantation A randomized open-label multicenter trial was carried out in patients with breast cancer multiple myeloma and lymphoma in which patients were randomized to receive 5 or 10 microg per kg per day of filgrastim after standard chemotherapy to mobilize PBPCs After high-dose chemotherapy the components from the first two leukapheresis procedures were returned and all patients received 5 microg per kg day of filgrastim after transplantation A total of 131 patients were randomized of whom 128 were mobilized Group A 5 microg/kg n = 66 Group B 10 microg/kg n = 62 and 112 were transplanted Only six patients were not transplanted because of insufficient CD34 + cell numbers The median number of CD34 + cells collected in the first two leukapheresis procedures tended to be higher in Group B than in Group A 120 vs 72 x 10 6 / kg NS but after transplantation there was no significant difference in median times to platelet 9 days in both groups or neutrophil 8 days in both groups engraftment or the number of platelet transfusions three in both groups A subsequent subgroup analysis separating patients transplanted after first - or second-line chemotherapy also showed no measurable impact of filgrastim dose on the median CD34 + cell yield or on platelet engraftment in either subgroup PBPC mobilization with chemotherapy and 5 microg per kg of filgrastim is very efficient and 10 microg per kg of filgrastim does not provide additional clinical benefit\",\n",
            "}\n",
            "13873\n",
            "{\n",
            "  \"id\" : \"12631604\",\n",
            "  \"contents\" : \"Tamoxifen TAM is increasingly administered to new early breast cancer patients Because it is not devoid of toxic effects we studied factors potentially predictive of its efficacy From 1978 to 1983 433 patients were enrolled in the GUN randomized trial 206 were assigned to TAM versus 227 controls no-TAM Premenopausal patients with axillary lymph node involvement 60 TAM versus 65 no-TAM also received nine CMF cycles Eight biological markers were retrospectively assayed for most patients estrogen progesterone prolactin receptors PrlRs microvessel count MVC S-phase fraction tumor ploidy epidermal growth factor receptor EGFR and HER2 We performed a multivariate test of the TAM/covariate interactions to establish whether these variables predicted for TAM efficacy Estimates of the TAM effect were expressed as hazard ratio HR of death of TAM over no-TAM patients with 95 % confidence intervals 95 % CIs At a median follow-up of 15 years PrlRs MVC S-phase fraction ploidy and EGFR did not influence TAM efficacy Differently HER2 had an overall significant predictive effect HR = 059 95 % CI 040-0 87 in HER2-negative subjects versus HR = 109 95 % CI 063-1 87 in HER2-positive subjects interaction test P = 004 The predictive effect of HER2 was also evident in the subgroup of patients with steroid receptor-positive tumors HER2 positive HR = 133 95 % CI 070-2 51 HER2 negative HR = 073 95 % CI 047-1 14 With the statistical power of the present randomized trial S-phase ploidy EGFR PrlR and MVC do not seem to predict for TAM efficacy Conversely our data support the hypothesis that tumors overexpressing HER2 might not benefit from adjuvant TAM\",\n",
            "}\n",
            "13874\n",
            "{\n",
            "  \"id\" : \"21682627\",\n",
            "  \"contents\" : \"We aimed to explore the effect of a poetry writing program for people who had experienced a serious illness For this study we randomly assigned 28 volunteer participants with a history of serious illness usually cancer to one of two poetry writing workshops Each group met weekly for 2 hours for 8 weeks The second group was wait-listed to enable comparison between the two groups We used the Kessler-10 a measure of wellbeing before and after the workshops and also interviewed the participants at these times Participants responded enthusiastically and each group demonstrated an increase in wellbeing over the course of their workshop moving them from medium to low risk on the K10 Participants enjoyed the challenge of writing and the companionship of other group members Psychiatrists especially those working in liaison psychiatry are in a position to encourage patients who have experienced a serious illness to explore writing as a way of coming to terms with their experiences\",\n",
            "}\n",
            "13875\n",
            "{\n",
            "  \"id\" : \"20356491\",\n",
            "  \"contents\" : \"To explore a chemotherapeutic regimen suitable for non-small cell lung cancer NSCLC in elderly patients A total of 68 elderly patients with NSCLC stage IIIb/IV were equally and randomly divided into single-agent and combined groups Patients in single-agent group received gemcitabine 1000 mg/m 2 at Days 1 and 8 for a 21-day cycle Those in combined group received gemcitabine 1000 mg/m 2 at Days 1 and 8 in combination carboplatin AUC5 at Day 2 for a 21-day cycle The drugs were intravenously administered All patients received 3 cycles of treatment In single-agent and combined groups CR 1 and 1 PR 12 and 13 response rates 38 % and 41 % were respectively observed There was no statistically significant difference between two groups P > 005 The 1-year and 2-year survival rates of single-agent and combined groups were 31 % vs 32 % and 12 % vs 14 % with a median survival of 99 and 98 months without a statistically significant difference P > 005 The rates of leucopenia and thrombocytopenia III-IV degree were 47 % and 38 % in combined group and they were higher than 24 % and 15 % in single-agent group with a statistically significant difference P < 005 The observer scale of lung cancer symptom scale showed that the post-treatment scores of appetite fatigue and pain significantly improved in single-agent group while no improvement was observed in combined group Also the scores of appetite fatigue and pain of single-agent group were higher than those of combined group after chemotherapy P < 005 Single-agent gemcitabine regimen is more suitable for advanced NSCLC in elderly patients\",\n",
            "}\n",
            "13876\n",
            "{\n",
            "  \"id\" : \"17716994\",\n",
            "  \"contents\" : \"Colorectal adenomas are well-established precursor lesions for colorectal cancer and removal of polyps is deemed to reduce the risk of colorectal cancer However benefit of colorectal polypectomy in routine practice is still uncertain We therefore investigated subsite-specific risks of colorectal cancer in relation to history of colorectal polypectomy in a case-control study Both case patients and control subjects were residents aged 20-74 years in Fukuoka City and three adjacent areas The case group comprised 840 patients undergoing surgery for a first diagnosis of colorectal cancer while the control subjects were 833 residents who were selected in the community by two-stage random sampling Past history of selected diseases surgery and lifestyle factors were ascertained by in-person interview Statistical adjustment was made for sex 5-year age class residence smoking alcohol drinking physical activity body mass index and parental history of colorectal cancer Overall 74 case patients 9 % and 85 control subjects 10 % reported a prior history of colorectal polyps and 50 cases 6 % and 64 controls 8 % had a history of colorectal polypectomy The adjusted odds ratio associated with colorectal polypectomy was 071 95 % confidence interval [ CI ] 048-1 06 for the overall risk of colorectal cancer The corresponding values for cancer of the proximal colon distal colon and rectum were 168 95 % CI 098-2 88 071 95 % CI 041-1 26 and 024 95 % CI 011-0 52 respectively The findings indicate that colorectal polypectomy in current practice confers a decreased risk of rectal cancer and possibly of distal colon cancer\",\n",
            "}\n",
            "13877\n",
            "{\n",
            "  \"id\" : \"18988231\",\n",
            "  \"contents\" : \"Optimal patient decision making requires integration of patient values goals and preferences with information received from the physician In the case of a life-threatening illness such as cancer the weights placed on quality of life QOL and length of life LOL represent critical values The objective of the current study was to describe cancer patient values regarding QOL and LOL and explore associations with communication preferences Patients with advanced cancer completed a computer-based survey before the initial consultation with a medical oncologist Assessments included sociodemographics physical and mental health state values regarding quality and length of life communication preferences and cancer-related distress Among 459 patients with advanced cancer 55 % placed equal valued on QOL and LOL 27 % preferred QOL and 18 % preferred LOL Patients with a QOL preference had lower levels of cancer-related distress P < 001 A QOL preference was also associated with older age P = 001 male sex P = 003 and higher educational level P = 062 Patients who preferred LOL over QOL desired a more supportive and less pessimistic communication style from their oncologists These data indicate that a values preference for LOL versus QOL may be simply measured and is associated with wishes regarding the nature of oncologist communication Awareness of these values during the clinical encounter could improve decision making by influencing the style and content of the communication between oncologists and their patients\",\n",
            "}\n",
            "13878\n",
            "{\n",
            "  \"id\" : \"19194150\",\n",
            "  \"contents\" : \"Excessive intraoperative bleeding is associated with significant morbidity and mortality The authors and others have shown that fibrin monomer allows preoperative risk stratification for intraoperative blood loss likely due to an imbalance between available factor XIII and prothrombin conversion The authors hypothesized that the use of factor XIII would delay the decrease of clot firmness in high-risk patients The concept was tested in a prospective randomized double-blind placebo-controlled trial in elective gastrointestinal cancer surgery Patients were randomized to receive factor XIII 30 U/kg or placebo in addition to controlled standard therapy Twenty-two patients were evaluable for a planned interim analysis For the primary outcome parameter maximum clot firmness patients receiving factor XIII showed a nonsignificant 8 % decrease and patients receiving placebo lost 38 % a highly significantly difference between the two groups P = 0004 A reduction in the nonprimary outcome parameters fibrinogen consumption -28 % P = 001 and blood loss -29 % P = 0041 was also observed in the factor XIII group Three patients experienced adverse events that seemed unrelated to factor XIII substitution The trial was stopped early after a planned interim analysis with the primary endpoint reached This proof of concept study confirms the hypothesis that patients at high risk for intraoperative blood loss show reduced loss of clot firmness when factor XIII is administered early during surgery Further clinical trials are needed to assess relevant clinical endpoints such as blood loss loss of other coagulation factors and use of blood products\",\n",
            "}\n",
            "13879\n",
            "{\n",
            "  \"id\" : \"14630265\",\n",
            "  \"contents\" : \"To compare prostate cancer control rates in patients who received 125 I vs 103 Pd Of a planned total of 600 patients with 1997 American Joint Committee on Cancer clinical Stage T1c-T2a prostate carcinoma Gleason score 5-6 prostate-specific antigen [ PSA ] 4-10 ng/mL 126 were randomized to implantation with 125 I 144 Gy vs 103 Pd 125 Gy The prostate biopsies were reviewed for Gleason score by one of us LT A single manufacturer of 125 I sources Model 6711 Amersham Chicago IL and 103 Pd sources Theraseed Theragenics Buford Georgia was used Isotope implantation was performed with standard techniques using a modified peripheral loading pattern Of a total of 126 patients randomized 11 were excluded leaving 115 randomized patients for this analysis Twenty patients received a short course of preimplant hormonal therapy none of whom continued hormonal therapy after their implant procedure Postimplant CT was obtained 2-4 hours after implantation The dosimetric parameters analyzed included the percentage of the postimplant prostate or rectal volume covered by the prescription dose V 100 and the dose that covered 90 % of the postimplant prostate volume D 90 Freedom from biochemical failure was defined as a serum PSA level < or = 05 ng/mL at last follow-up Patients were censored at last follow-up if their serum PSA level was still decreasing Patients whose serum PSA had reached a nadir at a value > 05 ng/mL were scored as having failure at the time at which their PSA had reached a nadir The follow-up period for patients without failure ranged from 20 to 49 years median 29 Freedom-from-failure curves were calculated by the Kaplan-Meier method Differences between groups were determined by the log-rank method The actuarial biochemical freedom-from-failure rate at 3 years was 89 % for 125 I patients vs 91 % for 103 Pd patients p = 076 The 3-year biochemical freedom-from-failure rate for patients with a D 90 < 100 % of the prescription dose was 82 % vs 97 % for patients with a D 90 > or = 100 % of the prescription dose p = 001 Similarly the 3-year biochemical freedom-from-failure rate for patients with a V 100 < 90 % of the prescription dose was 87 % vs 97 % for patients with a V 100 > or = 90 % of the prescription dose p = 001 The effect of the dosimetric parameters on biochemical control was most pronounced for 125 I but also apparent for 103 Pd The 3-year actuarial biochemical control rates for low early-stage prostate cancer are similar after 125 I and 103 Pd\",\n",
            "}\n",
            "13880\n",
            "{\n",
            "  \"id\" : \"16170175\",\n",
            "  \"contents\" : \"To evaluate the effect of BLP25 liposome vaccine L-BLP25 on survival and toxicity in patients with stage IIIB and IV non-small-cell lung cancer NSCLC Secondary objectives included health-related quality of life QOL and immune responses elicited by L-BLP25 Patients with an Eastern Cooperative Oncology Group performance status of 0 to 2 and stable or responding stage IIIB or IV NSCLC after any first-line chemotherapy were prestratified by stage and randomly assigned to either L-BLP25 plus best supportive care BSC or BSC alone Patients in the L-BLP25 arm received a single intravenous dose of cyclophosphamide 300 mg/m2 followed by eight weekly subcutaneous immunizations with L-BLP25 1000 microg Subsequent immunizations were administered at 6-week intervals The survival results indicate a median survival time of 44 months longer for patients randomly assigned to the L-BLP25 arm 88 patients compared with patients assigned to the BSC arm 83 patients adjusted hazard ratio [ HR ] = 0739 95 % CI 0509 to 1073 P = 112 The greatest effect was observed in stage IIIB locoregional LR patients for whom the median survival time for the L-BLP25 arm has not yet been reached compared with 133 months for the BSC arm adjusted HR = 0524 95 % CI 0261 to 1052 P = 069 No significant toxicity was observed QOL was maintained longer in patients on the L-BLP25 arm L-BLP25 maintenance therapy in patients with advanced NSCLC is feasible with minimal toxicity The survival difference of 44 months observed with the vaccine did not reach statistical significance In the subgroup of patients with stage IIIB LR disease a strong trend in 2-year survival in favor of L-BLP25 was observed\",\n",
            "}\n",
            "13881\n",
            "{\n",
            "  \"id\" : \"11077903\",\n",
            "  \"contents\" : \"The aims of this study were to investigate the motives for refusing or attending population-based screening for prostate cancer in relation to various background characteristics The present study is part of the European Randomized Study of Screening for Prostate Cancer ERSPC and took place in 1995-1996 Men aged 55-75 years were invited using the Rotterdam population registry 100 per cent coverage of whom 42 per cent gave written informed consent These men were randomized to receive either determination of prostate specific antigen PSA digital rectal examination DRE transrectal ultrasound TRUS and biopsy on indication screening group or no screening control group To 626 consecutive men of the screening group a questionnaire was sent before the screening To 500 randomly selected refusers no written informed consent a similar questionnaire was sent followed by two reminders In both refusers and attenders we addressed motives knowledge of prostate cancer attitudes towards screening background characteristics and urological complaints American Urological Association symptom index AUA7 Response rates for questionnaires were 48 per cent in refusers and 99 per cent in attenders Main reported motives for refusing were absence of urological complaints 57 per cent and anticipated pain or discomfort 18 per cent Main reported motives for attending were personal benefit 82 per cent contribution to science 49 per cent and presence of urological complaints 25 per cent Compared with attenders refusers were slightly and significantly older less often married and had a lower level of education they had less knowledge about prostate cancer and a less positive attitude towards screening they had worse general health but fewer urological complaints AUA7 median 2 versus 4 p < 0001 In refusing or attending population-based prostate cancer screening urological complaints but also knowledge attitudes and sociodemographic factors seem to play a role Therefore the approach of the general population should be carefully considered\",\n",
            "}\n",
            "13882\n",
            "{\n",
            "  \"id\" : \"17868721\",\n",
            "  \"contents\" : \"We evaluated the effect of body mass index on prostate specific antigen response and progression-free and overall survival in men with androgen dependent or androgen independent metastatic prostate cancer We examined the prognostic impact of body mass index in patient cohorts from phase III randomized studies coordinated by the Southwest Oncology Group The first study included 1006 men treated with androgen deprivation for metastatic prostate cancer The second study included 671 patients treated with chemotherapy for metastatic androgen independent prostate cancer Among men with androgen dependent disease higher body mass index was associated with longer overall p < 0001 and progression-free p = 0009 survival as well as with an increased likelihood of achieving a prostate specific antigen nadir less than 4 ng/ml p = 0008 In multivariate analysis adjusting for risk factors increasing body mass index was positively correlated with overall survival p < 001 and overweight but not obese patients body mass index 27 to 299 had a significantly improved outcome compared to normal weight patients with hazard ratios for risk of progression and death of 082 95 % CI 069 098 and 075 95 % CI 063 089 respectively Among men with androgen independent prostate cancer no clear association could be detected between body mass index and progression-free survival overall survival or prostate specific antigen response This study revealed higher body mass index to be associated with better overall and progression-free survival in patients with androgen dependent metastatic prostate cancer Among men who had androgen independent disease no significant association was found between body mass index and survival\",\n",
            "}\n",
            "13883\n",
            "{\n",
            "  \"id\" : \"20403600\",\n",
            "  \"contents\" : \"To examine effects of sedative music on cancer pain A randomized controlled trial Two large medical centers in Kaoshiung City in southern Taiwan 126 hospitalized persons with cancer pain Participants were randomly assigned to an experimental n = 62 or a control group n = 64 with computerized minimization stratifying on gender pain and hospital unit Music choices included folk songs Buddhist hymns Taiwanese music plus harp and piano American The experimental group listened to music for 30 min the control group rested in bed Sensation and distress of pain were rated on 100mm VAS before and after the 30-min test Using MANCOVA there was significantly less posttest pain in the music versus the control group p < 001 Effect sizes were large Cohen s d = 64 sensation d = 70 distress indicating that music was very helpful for pain Thirty minutes of music provided 50 % relief in 42 % of the music group compared to 8 % of the controls The number needed to treat NNT to find one with 50 % sensation relief was three patients More patients chose Taiwanese music 71 % than American music 29 % but both were liked and effective Offering a choice of familiar culturally appropriate music was a key element of the intervention Findings extend the Good and Moore theory 1996 to cancer pain Soft music was safe effective and liked by participants It provided greater relief of cancer pain than analgesics alone Thus nurses should offer calming familiar music to supplement analgesic medication for persons with cancer pain\",\n",
            "}\n",
            "13884\n",
            "{\n",
            "  \"id\" : \"18570223\",\n",
            "  \"contents\" : \"Women with gynecological cancers have reported poor health-related quality of life QOL with complex physical and psychological needs post-surgery and during chemotherapy treatment There are no studies reporting interventions addressing these needs post-hospital discharge in this population Patients were randomized into two groups The intervention group received 6 months of specialized care by an Advanced Practice Nurse APN in addition women with high distress were evaluated and monitored by a psychiatric consultation-liaison nurse PCLN The attention control group was assisted with symptom management by a research assistant The effects of the 6-month intervention were evaluated using self-report questionnaires at baseline 24-48 h after surgery 1 3 and 6 months post - surgery QOL assessments included the Center for Epidemiological Studies-Depression Scale the ambiguity subscale of the Mishel Uncertainty in Illness Scale the Symptom Distress Scale and the Short-Form Health Survey SF-12 The sample for the longitudinal analysis included 123 who completed QOL outcome measures across three occasions post-surgery The APN intervention resulted in significantly less uncertainty than the attention control intervention 6 months after surgery When the sub-group who received the APN plus PCLN intervention was compared with the total attention control group the sub-group had significantly less uncertainty less symptom distress and better SF-12 mental and physical QOL over time Nurse tailored interventions that target both physical and psychological aspects of QOL in women recovering from cancer surgery and undergoing chemotherapy produce stronger outcomes than interventions that target solely one QOL aspect\",\n",
            "}\n",
            "13885\n",
            "{\n",
            "  \"id\" : \"23154516\",\n",
            "  \"contents\" : \"The majority of cancer treatment is provided in outpatient settings Family caregivers FCs knowledge and beliefs about pain and its management are critical components of effective care This study s aim was to evaluate the efficacy of a psychoeducational intervention compared with control to increase FCs knowledge of cancer pain management Family caregivers of oncology outpatients were randomized together with the patients into the PRO-SELF Pain Control Program n = 58 or a control group n = 54 Family caregivers completed a demographic questionnaire and the Family Pain Questionnaire FPQ at the beginning and end of the study to assess their knowledge about pain and its management The intervention consisted of nurse coaching home visits and phone calls that occurred over 6 weeks One hundred twelve FCs 60 % female with a mean age of 63 SD 107 years participated Compared with FCs in the control group FCs in the PRO-SELF group had significantly higher knowledge scores on all of the single items on the FPQ except for the item cancer pain can be relieved as well as for the total FPQ score The use of a knowledge and attitude survey like the FPQ as part of a psychoeducational intervention provides an effective foundation for FC education about cancer pain management Oncology nurses can use FCs responses to the FPQ to individualize teaching and spend more time on identified knowledge deficits This individualized approach to FC education may save staff time and improve patient outcomes\",\n",
            "}\n",
            "13886\n",
            "{\n",
            "  \"id\" : \"22213153\",\n",
            "  \"contents\" : \"Enzastaurin and bevacizumab have demonstrated synergistic antitumor effects and in phase 1 studies the combination was well tolerated This phase 2 study assessed enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab as maintenance therapy for metastatic colorectal cancer MCRC Patients with locally advanced or MCRC and stable or responding disease after completing 6 cycles of first-line chemotherapy randomly received a loading dose of enzastaurin 1125 mg followed by 500 mg/d subsequent doses or placebo Both arms received 5-fluorouracil/leucovorin leucovorin 400 mg/m 2 intravenously [ IV ] 5-fluorouracil 400-mg/m 2 bolus 5-fluorouracil 2400 mg/m 2 IV plus bevacizumab 5 mg/kg IV every 2 weeks The primary endpoint was progression-free survival PFS from randomization Overall survival OS and PFS were also assessed from start of first-line therapy Enrollment was stopped and the final analysis was conducted after 73 PFS events Fifty-eight patients were randomized to enzastaurin and 59 to placebo For the enzastaurin and placebo arms respectively the median cycles received were 9 and 10 and the median PFS was 58 and 81 months hazard ratio [ HR ] 135 95 % confidence interval [ CI ] 084-2 16 P = 896 Median OS was not calculable because of high censoring 776 % enzastaurin 915 % placebo The median PFS from start of first-line therapy was 89 months for enzastaurin and 113 months for placebo HR 139 95 % CI 086-2 23 P = 913 More enzastaurin patients developed thrombosis or embolism compared with placebo 158 % and 17 % P = 008 One possibly enzastaurin-related death occurred because of arrhythmia Enzastaurin combined with bevacizumab-based therapy is tolerable but does not improve PFS during maintenance therapy in patients with MCRC compared with bevacizumab-based therapy alone\",\n",
            "}\n",
            "13887\n",
            "{\n",
            "  \"id\" : \"23399476\",\n",
            "  \"contents\" : \"Women who undergo radiotherapy for gynaecological cancer GC can experience distressing side effects which impact on psychosocial functioning and intimate relationships Cancer-related distress may be ameliorated by comprehensive preparation for treatment and addressing women s informational physical psychological and psychosexual needs This paper describes the protocol for a multisite randomised controlled trial RCT testing a novel intervention package which combines tailored specialist nursing consultations and telephone peer support with the primary aim to reduce psychological distress Secondary aims assess patient quality of life symptom distress unmet supportive care needs preparation for treatment psychosexual functioning and vaginal stenosis This multifaceted intervention comprises four nurse-led consultations coupled with four phone calls from a peer support volunteer GC survivor The evidence-based intervention will be delivered at critical points in the illness trajectory pre-treatment mid-treatment treatment completion and post-treatment Nurses and peers undergo 2-day intensive training workshops are guided by comprehensive study intervention manuals and receive ongoing supervision and support Eligible patients will have a diagnosis of GC be scheduled to receive curative radiotherapy be aged 18 years or over and speak English Three-hundred and six participants will be randomized to receive usual care or usual care with the intervention package Study outcome measures will be collected at baseline day 1 of radiotherapy and 1 6 and 12 months post radiotherapy Clinical assessments of vaginal toxicity will occur at baseline and 3 6 and 12 months post radiotherapy This timely research has the potential to substantially reduce the physical psychosexual and supportive care needs of women with GC Using a telephone peer support model the intervention package ensures equitable access to support services for geographically isolated patients The novel intervention engages peer volunteers who liaise with nurses to encourage adherence to professionally-delivered information and provide emotional support It has been designed to be potentially transferable to a range of treatment settings and diseases Based on pilot data the proposed intervention was found to be useful and acceptable to patients and clinicians If effective and feasible in the multisite RCT the program could be widely disseminated Australian New Zealand Clinical Trial Registry ACTRN12611000744954\",\n",
            "}\n",
            "13888\n",
            "{\n",
            "  \"id\" : \"23213105\",\n",
            "  \"contents\" : \"This phase III trial compared adjuvant whole-brain radiotherapy WBRT with observation after either surgery or radiosurgery of a limited number of brain metastases in patients with stable solid tumors Here we report the health-related quality-of-life HRQOL results HRQOL was a secondary end point in the trial HRQOL was assessed at baseline at 8 weeks and then every 3 months for 3 years with the European Organisation for Research and Treatment of Cancer EORTC Quality of Life Questionnaire C30 and Brain Cancer Module The following six primary HRQOL scales were considered global health status physical cognitive role and emotional functioning and fatigue Statistical significance required P 05 and clinical relevance required a 10-point difference Compliance was 883 % at baseline and dropped to 450 % at 1 year thus only the first year was analyzed Overall patients in the observation only arm reported better HRQOL scores than did patients who received WBRT The differences were statistically significant and clinically relevant mostly during the early follow-up period for global health status at 9 months physical functioning at 8 weeks cognitive functioning at 12 months and fatigue at 8 weeks Exploratory analysis of all other HRQOL scales suggested worse scores for the WBRT group but none was clinically relevant This study shows that adjuvant WBRT after surgery or radiosurgery of a limited number of brain metastases from solid tumors may negatively impact some aspects of HRQOL even if these effects are transitory Consequently observation with close monitoring with magnetic resonance imaging as done in the EORTC trial is not detrimental for HRQOL\",\n",
            "}\n",
            "13889\n",
            "{\n",
            "  \"id\" : \"22395644\",\n",
            "  \"contents\" : \"Adjuvant tamoxifen therapy is effective for postmenopausal women with endocrine-responsive breast cancer Cytochrome P450 2D6 CYP2D6 enzyme metabolizes tamoxifen to clinically active metabolites and CYP2D6 polymorphisms may adversely affect tamoxifen efficacy In this study we investigated the clinical relevance of CYP2D6 polymorphisms We obtained tumor tissues and isolated DNA from 4861 of 8010 postmenopausal women with hormone receptor-positive breast cancer who enrolled in the randomized phase III double-blind Breast International Group BIG 1-98 trial between March 1998 and May 2003 and received tamoxifen and/or letrozole treatment Extracted DNA was used for genotyping nine CYP2D6 single-nucleotide polymorphisms using polymerase chain reaction-based methods Genotype combinations were used to categorize CYP2D6 metabolism phenotypes as poor intermediate and extensive metabolizers PM IM and EM respectively n = 4393 patients Associations of CYP2D6 metabolism phenotypes with breast cancer-free interval referred to as recurrence and treatment-induced hot flushes according to randomized endocrine treatment and previous chemotherapy were assessed Cox proportional hazards models were used to calculate hazard ratios HRs and 95 % confidence intervals CIs All statistical tests were two-sided No association between CYP2D6 metabolism phenotypes and breast cancer-free interval was observed among patients who received tamoxifen monotherapy without previous chemotherapy P = 35 PM or IM phenotype had a non-statistically significantly reduced risk of breast cancer recurrence compared with EM phenotype PM or IM vs EM HR of recurrence = 086 95 % CI = 060 to 124 CYP2D6 metabolism phenotype was associated with tamoxifen-induced hot flushes P = 020 Both PM and IM phenotypes had an increased risk of tamoxifen-induced hot flushes compared with EM phenotype PM vs EM HR of hot flushes = 124 95 % CI = 096 to 159 IM vs EM HR of hot flushes = 123 95 % CI = 105 to 143 CYP2D6 phenotypes of reduced enzyme activity were not associated with worse disease control but were associated with increased hot flushes contrary to the hypothesis The results of this study do not support using the presence or absence of hot flushes or the pharmacogenetic testing of CYP2D6 to determine whether to treat postmenopausal breast cancer patients with tamoxifen\",\n",
            "}\n",
            "13890\n",
            "{\n",
            "  \"id\" : \"9630850\",\n",
            "  \"contents\" : \"Preservation of the intercostal-brachial nerve is advocated to reduce side effects of axillary dissection for breast cancer We conducted a prospective randomized trail to compare functional results sensory deficit and/or shoulder pain in preserved group I vs sacrificed group II intercostal-brachial nerve IBN From July 1993 to April 1994 128 patients presenting with an invasive operable breast cancer were operated on by mastectomy n = 28 or lumpectomy n = 100 and axillary dissection The patients were eligible for randomization when the IBN was preserved at the end of the axillary dissection Group I nerve preservation included 66 patients and group II nerve section 62 patients The two groups were well balanced for TNM type of surgery number of nodes dissected and positive post-operative adjuvant treatment Examinations were conducted at 3 6 and 12 months after surgery Sensory deficit in the IBN area was reported by one patient in group I and four patients in group II at 3 months P = 036 NS No patients apart from one in group II reported functional trouble at 18 months Major shoulder motion limitation and pain developed in four patients in group I and three in group II NS This was attributed to depression and treated adequately Analysis of sensory deficit was impossible in these patients Conservation of the IBN while anatomically preferable is not functionally necessary during axillary dissection for breast cancer\",\n",
            "}\n",
            "13891\n",
            "{\n",
            "  \"id\" : \"11789188\",\n",
            "  \"contents\" : \"To study the dynamic changes and its clinical significance of integrated traditional Chinese and western medicine TCM-WM on IL-2 system T cell and erythrocyte immune system in patients of lung cancer Forty-eight cases with lung cancer were randomly divided into two groups TCM-WM group group I and the chemotherapy group group II and 20 healthy subjects were simultaneously compared The relevant immune indices clinical symptoms and signs changes of solid tumor and living quality were dynamically observed 1 The serum IL-2 level of lung cancer patients were significantly lower while sIL-2R level higher than that of the healthy subjects And they were raised and lowered respectively after treatment especially in the group I but different from the control group yet And there were highly negative correlation between IL-2 and sIL-2R levels 2 The percentage of CD3 CD4 and the ratio CD4/CD8 were decreased markedly in both groups except CD8 which was increased markedly And the percentage of RBC-C3b RR was obviously lower while that of RBC-ICR was obviously higher But the above-mentioned indices could be improved after treatment especially in the group I and there were highly positive correlation between CD4/CD8 ratio and RBC-C3bRR 3 After treatment all above-mentioned indices were changed significantly to their corresponding opposites However in regard to the degree of improvement the patients of group I were in a better position than those of group II At the same time improvement of their clinical symptoms and signs change of solid tumor and living quality also showed advantageous The therapeutic superiority of TCM-WM on lung cancer may be related with the modulation on immune function Thus we can say that the effect of TCM-WM is better than that of chemotherapy alone\",\n",
            "}\n",
            "13892\n",
            "{\n",
            "  \"id\" : \"7543605\",\n",
            "  \"contents\" : \"Prostate specific antigen PSA exists in the serum in several molecular forms that can be measured by immunodetectable assays free PSA PSA complexed to alpha 1-antichymotrypsin complexed PSA and total PSA which represents the sum of the free and complexed forms We determined the normal distribution of values and established the appropriate reference ranges for these 3 molecular forms of PSA and their ratios free-to-total complexed-to-total and free-to-complexed PSA Knowing the amount and ratio of these molecular forms appears to be useful in enhancing the ability of PSA to distinguish potentially curable prostate cancer from benign prostatic hyperplasia and in decreasing the number of unnecessary prostate biopsies A total of 422 healthy men 40 to 79 years old was randomly chosen from the male population of Olmsted County Minnesota and underwent a detailed clinical examination that included digital rectal examination serum PSA determination and transrectal ultrasound to exclude the presence of prostate cancer Using newly developed monoclonal-monoclonal immunofluorometric assays for each molecular form the free complexed and total PSA and the ratios of these 3 forms were determined for each study participant All 3 molecular forms correlated directly with patient age r = 045 r = 043 and r = 045 respectively Using the 95th percentile the recommended age-specific reference ranges for the free complexed and total PSA forms respectively are 05 10 and 20 ng / ml for men 40 to 49 years old 07 15 and 30 ng / ml for men 50 to 59 years old 10 20 and 40 ng / ml for men 60 to 69 years old and 12 30 and 55 ng / ml for men 70 to 79 years old With regard to each of the ratios free-to-total complexed-to-total and free-to-complexed PSA none correlated with patient age As a result the appropriate upper limit of normal 95th percentile for all 3 ratios is constant for men of all ages These reference ranges are greater than 015 for free-to-total PSA ratio less than 070 for complexed-to-total PSA ratio and greater than 025 for free-to-complexed PSA ratio The free-to-total PSA ratio will have its greatest value for men with a serum PSA value between 2 and 10 ng / ml The establishment of appropriate reference ranges for free complexed and total PSA as well as the ratios will allow the practicing urologist to incorporate these new parameters into the diagnostic evaluation of men at risk for early potentially curable prostate cancer\",\n",
            "}\n",
            "13893\n",
            "{\n",
            "  \"id\" : \"24284150\",\n",
            "  \"contents\" : \"Theory suggests the uptake of a medical innovation is influenced by how potential adopters perceive innovation characteristics and by characteristics of potential adopters Innovation adoption is slow among the first 20 % of individuals in a target group and then accelerates The Quality Initiative in Rectal Cancer QIRC trial assessed if rectal cancer surgery outcomes could be improved through surgeon participation in the QIRC strategy We tested if traditional uptake of innovation concepts applied to surgeons in the experimental arm of the trial The QIRC strategy included workshops access to opinion leaders intraoperative demonstrations postoperative questionnaires and audit and feedback For intraoperative demonstrations a participating surgeon invited an outside surgeon to demonstrate optimal rectal surgery techniques We used surgeon timing in a demonstration to differentiate early and late adopters of the QIRC strategy Surgeons completed surveys on perceptions of the strategy and personal characteristics Nineteen of 56 surgeons 34 % requested an operative demonstration on their first case of rectal surgery Early and late adopters had similar perceptions of the QIRC strategy and similar characteristics Late adopters were less likely than early adopters to perceive an advantage for the surgical techniques promoted by the trial p = 0023 Most traditional diffusion of innovation concepts did not apply to surgeons in the QIRC trial with the exception of the importance of perceptions of comparative advantage\",\n",
            "}\n",
            "13894\n",
            "{\n",
            "  \"id\" : \"19878605\",\n",
            "  \"contents\" : \"Graded health benefits of physical activity have been demonstrated for the reduction of coronary heart disease some cancers and type-2 diabetes and for injury reduction and improvements in mental health Older adults are particularly at risk of physical inactivity and would greatly benefit from successful targeted physical activity interventions The Healthy Steps study is a 12-month randomized controlled trial comparing the efficacy of a pedometer-based Green Prescription with the conventional time-based Green Prescription in increasing and maintaining physical activity levels in low-active adults over 65 years of age The Green Prescription interventions involve a primary care physical activity prescription with 3 follow-up telephone counselling sessions delivered by trained physical activity counsellors over 3 months Those in the pedometer group received a pedometer and counselling based around increasing steps that can be monitored on the pedometer while those in the standard Green Prescription group received counselling using time-based goals Baseline 3 month end of intervention and 12 month measures were assessed in face-to-face home visits with outcomes measures being physical activity Auckland Heart Study Physical Activity Questionnaire quality of life SF-36 and EQ-5D depressive symptoms Geriatric Depression Scale blood pressure weight status functional status gait speed chair stands and tandem balance test and falls and adverse events self-report Utilisation of health services was assessed for the economic evaluation carried out alongside this trial As well a process evaluation of the interventions and an examination of barriers and motives for physical activity in the sample were conducted The perceptions of primary care physicians in relation to delivering physical activity counselling were also assessed The findings from the Healthy Steps trial are due in late 2009 If successful in improving physical activity in older adults the pedometer-based Green Prescription could assist in reducing utilisation of health services and improve cardiovascular health and reduction of risk for a range of non-communicable lifestyles diseases Australian and New Zealand Clinical Trials Registry ACTRN012606000023550\",\n",
            "}\n",
            "13895\n",
            "{\n",
            "  \"id\" : \"23265945\",\n",
            "  \"contents\" : \"We studied oral cancer incidence and mortality and the impact of compliance to repeat screening rounds during a 15-year follow-up in a cluster-randomized controlled trial in Trivandrum district Kerala India Healthy individuals aged 35 and above in seven clusters randomized to the intervention arm received four rounds of oral visual inspection by trained health workers at 3-year intervals and those in six clusters randomized to the control arm received routine care during 1996-2005 and one round of visual screening during 2006-2009 Screen-positive persons were referred for diagnosis and treatment Oral cancer incidence and mortality were compared between the study arms by intention to treat analysis Of the 96517 eligible subjects in the intervention arm 25144 261 % had one 22382 232 % had two 22008 228 % had three and 19288 200 % had four rounds of screening Of the 95356 eligible subjects in the control group 43992 461 % received one round of screening Although the 12 % reduction in oral cancer mortality in all individuals did not reach statistical significance there was a 24 % reduction in oral cancer mortality 95 % CI 3-40 % in users of tobacco and/or alcohol in the intervention arm after 4-rounds of screening there was 38 % reduction in oral cancer incidence 95 % CI 8-59 % and 81 % reduction in oral cancer mortality 95 % CI 69-89 % in tobacco and/or alcohol users adhering to four screening rounds Sustained reduction in oral cancer mortality during the 15-year follow-up with larger reductions in those adhering to repeated screening rounds support the introduction of population-based screening programs targeting users of smoking or chewing tobacco or alcohol or both in high-incidence countries\",\n",
            "}\n",
            "13896\n",
            "{\n",
            "  \"id\" : \"10604410\",\n",
            "  \"contents\" : \"To study the influence of perfluoroalkylsiloxane PA surface modification of silicone rubber voice prostheses on biofouling Placebo-controlled clinical trial Tertiary referral center with specialization in head and neck cancer treatment Eighteen consecutive patients with laryngectomies and experienced in the use of a voice prosthesis who visited the outpatient clinic for prosthesis replacement Eighteen partially surface-modified voice prostheses 3 with short-chain PAs [ 1 fluorocarbon unit ] and 15 with long-chain PAs [ 8 fluorocarbon units ] were inserted via the patients tracheoesophageal shunts and remained in place for 2 to 8 weeks Replacement of the prostheses Evaluation of biofilm formation on short - and long-chain PA-modified and original silicone rubber surfaces on the esophageal side of the voice prosthesis The planimetrical biofilm scores of the surfaces of all 3 short-chain PA-treated voice prostheses indicated more biofouling on the treated surfaces than on the untreated surfaces of the same prostheses For the long-chain PA-treated prostheses the planimetrical biofilm scores as well as the numbers of colony-forming units per cm -2 for bacteria and yeasts indicated less biofouling on the treated side than on the control side for 9 of the 13 prostheses that could be analyzed 2 were lost to analysis Identical fungal strains mainly Candida sp were isolated from biofilms on each side of the esophageal flange Chemisorption of long-chain PAs by the silicone rubber used for voice prostheses reduces biofilm formation in vivo and therefore can be expected to prolong the life of these prostheses Chemisorption of short-chain PAs by silicone rubber seems to have an adverse effect\",\n",
            "}\n",
            "13897\n",
            "{\n",
            "  \"id\" : \"15367922\",\n",
            "  \"contents\" : \"Although alcohol intake has been positively associated with breast cancer risk in epidemiologic studies the mechanisms mediating this association are speculative The Postmenopausal Women s Alcohol Study was designed to explore the effects of moderate alcohol consumption on potential risk factors for breast cancer In the present analysis we evaluated the relationship of alcohol consumption with antioxidant nutrients and a biomarker of oxidative stress Participants n = 53 consumed a controlled diet plus each of three treatments 15 or 30 g alcohol/day or a no-alcohol placebo beverage during three 8-week periods in random order We measured the antioxidants vitamin E alpha alpha - and gamma gamma - tocopherols selenium and vitamin C in fasting blood samples which were collected at the end of diet periods treated and frozen for assay at the end of the study We also measured 15-F 2t - IsoP isoprostane produced by lipid peroxidation which serves as an indicator of oxidative stress and may serve as a biomarker for conditions favorable to carcinogenesis After adjusting for BMI all models and total serum cholesterol tocopherol and isoprostane models we observed a significant 46 % decrease P = 002 in alpha-tocopherol and a marginally significant 49 % increase P = 007 in isoprostane levels when women consumed 30 g alcohol/day P = 006 and 005 for overall effect of alcohol on alpha-tocopherol and isoprostanes respectively The other antioxidants were not significantly modified by the alcohol treatment These results suggest that moderate alcohol consumption increases some biomarkers of oxidative stress in postmenopausal women\",\n",
            "}\n",
            "13898\n",
            "{\n",
            "  \"id\" : \"15329598\",\n",
            "  \"contents\" : \"Oral transmucosal fentanyl citrate OTF was developed to provide rapid analgesia and is specifically approved for treating breakthrough cancer pain Fentanyl in OTF is absorbed across the oral mucosa but a considerable portion is swallowed and absorbed enterally Fentanyl metabolism is catalyzed by cytochrome P4503A4 CYP3A The role of intestinal or hepatic first-pass metabolism and CYP3A activity in OTF disposition is unknown This investigation examined the influence of hepatic and intestinal CYP3A activity on the disposition and clinical effects of OTF Healthy volunteers n = 12 were studied in an Institutional Review Board-approved randomized balanced four-way crossover They received OTF 10 microg/kg after hepatic/intestinal CYP3A induction by rifampin hepatic/intestinal CYP3A inhibition by troleandomycin selective intestinal CYP3A inhibition by grapefruit juice or nothing control Plasma fentanyl and norfentanyl concentrations were determined by mass spectrometry Fentanyl effects were measured by dark-adapted pupil diameter and subjective self-assessments using visual analog scales Peak plasma fentanyl concentrations time to peak and maximum pupil diameter change from baseline were unchanged after rifampin troleandomycin and grapefruit juice Fentanyl elimination however was significantly affected by CYP3A alterations After control rifampin troleandomycin and grapefruit juice respectively area under the curve of plasma fentanyl versus time was 59 + / - 37 22 + / - 08 * 104 + / - 89 * and 58 + / - 33 h x ng/ml norfentanyl/fentanyl plasma area under the curve ratios were 092 + / - 063 32 + / - 18 * 008 + / - 014 * and 067 + / - 033 * P < 005 versus control Peak fentanyl concentrations and clinical effects after OTF were minimally affected by altering both intestinal and hepatic CYP3A activity whereas fentanyl metabolism elimination and duration of effects were significantly affected selective intestinal CYP3A inhibition had minimal effects This suggests that first-pass metabolism minimally influences OTF bioavailability When treating breakthrough pain with careful attention to maximal mucosal absorption and minimal swallowing CYP3A variability and drug interactions are unlikely to affect the onset or magnitude of OTF analgesia however duration may be affected\",\n",
            "}\n",
            "13899\n",
            "{\n",
            "  \"id\" : \"12177103\",\n",
            "  \"contents\" : \"This Children s Cancer Group group-wide phase II trial evaluated the efficacy and toxicity of two chemotherapy arms administered before hyperfractionated external-beam radiotherapy HFEBRT Thirty-two patients with newly diagnosed brainstem gliomas were randomly assigned to regimen A and 31 to regimen B Regimen A comprised three courses of carboplatin etoposide and vincristine regimen B comprised cisplatin etoposide cyclophosphamide and vincristine Both arms included granulocyte colony-stimulating factor Patients were evaluated by magnetic resonance imaging after induction chemotherapy and HFEBRT at a dose of 72 Gy Ten percent + / - 5 % of regimen A patients objectively responded to chemotherapy For combined induction and radiotherapy 27 % + / - 9 % of patients improved The neuroradiographic response rate for regimen B was 19 % + / - 8 % for chemotherapy and 23 % + / - 9 % after HFEBRT Response rates were not statistically significant between regimens after induction or chemotherapy/HFEBRT Event-free survival was 17 % + / - 5 % estimate + / - SE at 1 year and 6 % + / - 3 % at 2 years Survival was significantly longer among patients who responded to chemotherapy P < 05 Among patients who received regimen A induction grades 3 and 4 leukopenia were observed in 50 % to 65 % with one toxicity-related death For regimen B severe leukopenia occurred in 86 % to 100 % with febrile neutropenia in 48 % to 60 % per course Neither chemotherapy regimen meaningfully improved response rate event-free survival or overall survival relative to previous series of patients with brainstem gliomas who received radiotherapy with or without chemotherapy\",\n",
            "}\n",
            "13900\n",
            "{\n",
            "  \"id\" : \"25491069\",\n",
            "  \"contents\" : \"High levels of emotional distress in cancer patients often goes unnoticed in daily clinical routine resulting in severe undertreatment of mental health problems in this patient group Screening tools can be used to increase case identification however screening alone does not necessarily translate into better mental health for the patient Doctors play a key role in providing basic emotional support and transferring the patients in need of such specific support to mental health professionals This study investigates whether a stepped care model combining screening doctor consultation and professional psycho-oncological service in a structured way improves the emotional wellbeing of cancer patients This study is a cluster randomized trial with two parallel groups intervention vs care as usual set in an academic hospital Participants are cancer patients a total of 1000 at baseline The intervention consists of stepped psychosocial care Step one screening for distress step two feedback of screening results to the doctor in charge of the patient and consultation with the patient and step three based on a shared patient-doctor decision either transferal to the consultation liaison CL service or not The outcome will be emotional well-being half a year after baseline ascertained with the Hospital Anxiety and Depression Scale Randomization will be done by the cluster randomization of wards Mental health problems not only cause emotional suffering but also direct and indirect costs This calls for timely and adequate psychosocial support especially as we know that such support is effective However not every cancer patient can and must be treated by a mental health professional Allocating limited resources most sensibly and economically is of crucial importance for our healthcare system to ensure the best quality of care to as many patients as possible It is the hope of the STEPPED CARE trial that this model is both effective and efficient and that it can be implemented in other hospitals as well if proven to be effective Clinical Trials Register Clinicaltrialsgov identifier NCT01859429 registration date 17 May 2013\",\n",
            "}\n",
            "13901\n",
            "{\n",
            "  \"id\" : \"17886253\",\n",
            "  \"contents\" : \"The objective of this study was to evaluate the efficacy and safety of atrasentan Xinlay a selective endothelin-A receptor antagonist in patients with metastatic hormone-refractory prostate cancer HRPC This multinational double-blind placebo-controlled trial enrolled 809 men with metastatic HRPC Patients were randomized 11 to receive either atrasentan 10 mg per day or placebo The primary endpoint was time to disease progression TTP which was determined according to radiographic and clinical measures Analyses of overall survival and changes in biomarkers also were performed Atrasentan did not reduce the risk of disease progression relative to placebo hazards ratio 089 95 % confidence interval 076-1 04 P = 136 Most patients progressed radiographically at the first 12-week bone scan without concomitant clinical progression In exploratory analyses increases from baseline to final bone alkaline phosphatase BAP and prostate-specific antigen PSA levels were significantly lower with atrasentan treatment P < 05 for each The median time to BAP progression > / = 50 % increase from nadir was twice as long with atrasentan treatment 505 days vs 254 days P < 01 The delay in time to PSA progression did not reach statistical significance Atrasentan generally was tolerated well and the most common adverse events associated with treatment were headache rhinitis and peripheral edema reflecting the vasodilatory and fluid-retention properties of endothelin-A receptor antagonism Atrasentan did not delay disease progression in men with metastatic HRPC despite evidence of biologic effects on PSA and BAP as markers of disease burden\",\n",
            "}\n",
            "13902\n",
            "{\n",
            "  \"id\" : \"21039051\",\n",
            "  \"contents\" : \"Breast cancer is the leading cancer in women today and the major challenge is late presentation then later contributes to poor outcome and high fatality rate Mammography is effective in early detection of breast cancer and consequently significantly improves the breast cancer survival This cross-sectional study was used to study the knowledge and awareness towards mammogram amongst women aged 15 years old and above A systemic random sampling was applied and information gathered through guided interview by using a structured questionnaire Eighty-six respondents were recruited The mean age of respondents was 405 years SD 1551 and more than 80 % had secondary and tertiary level of education The percentage of respondents ever performed mammogram was 105 % 95 % CI 40 % -170 % The rate of correct answers was between 81 % and 488 % Most of the respondents do not sure the answer 453 % -616 % rather than wrongly answer 47 % -430 % Only about 8 % truly answer that mammogram should be done once in a life There are 105 % of women claimed that mammogram had no serious side effect and not a painful procedure Nearly half of respondents 488 % correctly mentioned that Mammogram can detect breast cancer in early stage Only a small percentage of women ever performed mammogram and there are seriously unaware and poor knowledge pertaining to mammography screening for breast cancer among women in sub urban area A massive health education campaign through multiple methods and agencies are needed to enhance the knowledge and awareness on mammogram\",\n",
            "}\n",
            "13903\n",
            "{\n",
            "  \"id\" : \"18420499\",\n",
            "  \"contents\" : \"We compared the efficacy of two different taxanes docetaxel and paclitaxel given either weekly or every 3 weeks in the adjuvant treatment of breast cancer We enrolled 4950 women with axillary lymph node-positive or high-risk lymph node-negative breast cancer After randomization all patients first received 4 cycles of intravenous doxorubicin and cyclophosphamide at 3-week intervals and were then assigned to intravenous paclitaxel or docetaxel given at 3-week intervals for 4 cycles or at 1-week intervals for 12 cycles The primary end point was disease-free survival As compared with patients receiving standard therapy paclitaxel every 3 weeks the odds ratio for disease-free survival was 127 among those receiving weekly paclitaxel P = 0006 123 among those receiving docetaxel every 3 weeks P = 002 and 109 among those receiving weekly docetaxel P = 029 with an odds ratio > 1 favoring the groups receiving experimental therapy As compared with standard therapy weekly paclitaxel was also associated with improved survival odds ratio 132 P = 001 An exploratory analysis of a subgroup of patients whose tumors expressed no human epidermal growth factor receptor type 2 protein found similar improvements in disease-free and overall survival with weekly paclitaxel treatment regardless of hormone-receptor expression Grade 2 3 or 4 neuropathy was more frequent with weekly paclitaxel than with paclitaxel every 3 weeks 27 % vs 20 % Weekly paclitaxel after standard adjuvant chemotherapy with doxorubicin and cyclophosphamide improves disease-free and overall survival in women with breast cancer ClinicalTrialsgov number NCT00004125 [ ClinicalTrialsgov ]\",\n",
            "}\n",
            "13904\n",
            "{\n",
            "  \"id\" : \"11419846\",\n",
            "  \"contents\" : \"Understanding the epidemiology of colorectal adenomas is a prerequisite for designing follow-up programs after polypectomy The aim of the study was to investigate the effect of polypectomy on the long-term prevalence of adenomas In 1983 a total of 799 men and women aged 50-59 yr were drawn from the general population register Of these 400 comprised a screening group and 399 a matched control group The screenees were invited to undergo a once-only flexible sigmoidoscopy Persons with polyps had a baseline colonoscopy with follow-ups in 1985 and 1989 In 1996 both the screenees and the controls were invited to a colonoscopic examination In 1996 a total of 451 71 % individuals attended Adenomas were found in 78 37 % individuals in the screening group and 103 43 % in the control group relative risk 95 % confidence interval 09 07-1 1 p = 03 and high-risk adenomas severe dysplasia adenomas > or = 10 mm villous components were found in 16 8 % and 32 13 % respectively relative risk 95 % confidence interval 06 03-1 0 p = 007 There was no significant difference in adenoma prevalence between the group after the screening program and the controls after the usual care There was a trend toward more high-risk adenomas in the control group This suggests a very limited effect of one-time screening sigmoidoscopy with surveillance colonoscopy on the prevalence of adenomas but a preventive effect on the development of high-risk adenomas consistent with the reported effect on cancer prevention\",\n",
            "}\n",
            "13905\n",
            "{\n",
            "  \"id\" : \"12794603\",\n",
            "  \"contents\" : \"Radiologic assessment of response-to-treatment during clinical trials of anticancer drugs has been conventionally based on bidirectional tumor measurement Recently the revised guidelines were published which recommended unidirectional tumor measurements The purpose of this study was to compare response to treatment between the two measurement techniques in breast cancer patients with lung and liver metastases Contrast-enhanced computed tomography studies of 86 breast cancer patients who had lung n = 27 and liver n = 59 metastases and who were enrolled in a phase-III oncology trial were evaluated before initiation of treatment and at 6 months after treatment Lesions were measured by subspecialist radiologists on digitized images using electronic calipers The largest diameter of the lesions was extracted from bidimensional measurements Response to treatment was categorized into one of four categories complete response indicating lesion disappearance partial response indicating > 30 % decrease in tumor diameter or > 50 % reduction in tumor area disease progression indicating > 20 % increase in tumor diameter or > 25 % increase in tumor area and stable disease neither complete response partial response nor disease progression Response to treatment between the two measurement techniques was compared statistically using the chi2 test Response to treatment was concordant in 76 patients between unidimensional and bidimensional measurement techniques In 5 patients 2 lung and 3 liver metastases the response assessment was improved using unidimensional criteria and in 5 patients 2 lung and 3 liver metastases the response was worse using unidimensional guidelines Thus the overall response rate was 50 % for both unidimensional and bidimensional measurement techniques There was no statistical difference between the two techniques Unidimensional measurements are appropriate for measuring the size of liver and lung metastases for determining response to treatment during clinical testing of oncologic drugs\",\n",
            "}\n",
            "13906\n",
            "{\n",
            "  \"id\" : \"23708054\",\n",
            "  \"contents\" : \"Screening for colorectal cancer with sigmoidoscopy benefits from the fact that distal findings predict the risk of advanced proximal neoplasms APNs This study was aimed at comparing the existing strategies of postsigmoidoscopy referral to colonoscopy in terms of accuracy and resources needed Asymptomatic individuals aged 50-69 years were eligible for a randomized controlled trial designed to compare colonoscopy and fecal immunochemical test Sigmoidoscopy yield was estimated from results obtained in the colonoscopy arm according to three sets of criteria of colonoscopy referral from those proposed in the UK Flexible Sigmoidoscopy Screening for COlon REctum [ SCORE ] and Norwegian Colorectal Cancer Prevention [ NORCCAP ] trials Advanced neoplasm detection rate sensitivity specificity and number of individuals needed to refer for colonoscopy to detect one APN were calculated Logistic regression analysis was performed to identify distal findings associated with APN All statistical tests were two-sided APN was found in 255 of 5059 50 % individuals Fulfillment of UK 62 % SCORE 120 % and NORCCAP 179 % criteria varied statistically significantly P < 001 The NORCCAP strategy obtained the highest sensitivity for APN detection 369 % and the UK approach reached the highest specificity 946 % The number of individuals needed to refer for colonoscopy to detect one APN was 6 95 % confidence interval [ CI ] = 4 to 7 8 95 % CI = 6 to 9 and 10 95 % CI = 8 to 12 when the UK SCORE and NORCCAP criteria were used respectively The logistic regression analysis identified distal adenoma 10 mm odds ratio = 377 95 % CI = 252 to 565 as the strongest independent predictor of APN Whereas the NORCCAP criteria achieved the highest sensitivity for APN detection the UK recommendations benefited from the lowest number of individuals needed to refer for colonoscopy\",\n",
            "}\n",
            "13907\n",
            "{\n",
            "  \"id\" : \"16143229\",\n",
            "  \"contents\" : \"To evaluate the efficacy and tolerability of long-term treatment with venlafaxine at low dose for the reduction of vasomotor symptoms in breast cancer survivors Forty consecutive breast cancer patients suffering troublesome hot flushes have been treated for 8 weeks with venlafaxine XR 375 mg/day in an open-label study Vasomotor symptoms have been evaluated before starting treatment and every 4 weeks with a hot flushes diary pointing out the number and the severity of vasomotor symptoms A Beck Depression Inventory BDI was completed at baseline and at the end of the treatment Thirty patients had completed the first 4 weeks of treatment reporting a reduction of hot flushes frequency of 39 % as compared to baseline p < 0001 After 8 weeks of treatment a further significant reduction was observed both for the hot flushes frequency -53 % p < 0001 and for the hot flushes score -59 % p < 0001 a measure which reflects both the number and the severity of hot flushes Very few side effects were reported mostly nausea in the first 2 weeks of assumption and mouth dryness Only 23 women had completed BDI at week 8 a reduction of 23 % was observed p = 0000 Venlafaxine is an effective treatment for the relief of vasomotor symptoms in patients previously treated for breast cancer A favourable effect is maintained also in those patients using tamoxifen as adjuvant therapy The use of the low dose 375 mg/day is associated with minimal side effects and produces a good improvement in hot flushes if pursued over 8 weeks\",\n",
            "}\n",
            "13908\n",
            "{\n",
            "  \"id\" : \"21138561\",\n",
            "  \"contents\" : \"Cancer chemotherapy is frequently associated with a decline in general physical condition exercise tolerance and muscle strength and with an increase in fatigue While accumulating evidence suggests that physical activity and exercise interventions during chemotherapy treatment may contribute to maintaining cardiorespiratory fitness and strength the results of studies conducted to date have not been consistent Additional research is needed to determine the optimal intensity of exercise training programs in general and in particular the relative effectiveness of supervised outpatient hospital - or physical therapy practice-based versus home-based programs This multicenter prospective randomized trial will evaluate the effectiveness of a low to moderate intensity home-based self-management physical activity program and a high intensity structured supervised exercise program in maintaining or enhancing physical fitness cardiorespiratory fitness and muscle strength in minimizing fatigue and in enhancing the health-related quality of life HRQoL Patients receiving adjuvant chemotherapy for breast or colon cancer n = 360 are being recruited from twelve hospitals in the Netherlands and randomly allocated to one of the two treatment groups or to a usual care control group Performance-based and self-reported outcomes are assessed at baseline at the end of chemotherapy and at six month follow-up This large multicenter randomized clinical trial will provide additional empirical evidence regarding the effectiveness of physical exercise during adjuvant chemotherapy in enhancing physical fitness minimizing fatigue and maintaining or enhancing patients quality of life If demonstrated to be effective exercise intervention programs will be a welcome addition to the standard program of care offered to patients with cancer receiving chemotherapy This study is registered at the Netherlands Trial Register NTR 2159\",\n",
            "}\n",
            "13909\n",
            "{\n",
            "  \"id\" : \"17467426\",\n",
            "  \"contents\" : \"To improve the prognosis of cN2 N3 non-small cell lung cancer we performed induction chemoradiotherapy carboplatin-taxane chemotherapy and concurrent 50-Gy radiation followed by surgery Patients with pathologically proven non-small cell lung cancer with bulky cN2 N3 disease were enrolled Forty-one patients underwent an operation after chemoradiotherapy from January 2000 to April 2006 Either carboplatin-paclitaxel n = 19 or carboplatin-docetaxel n = 22 chemotherapy was randomly used Two cycles of chemotherapy were performed with concurrent radiation 50 Gy In all cases conventional radiological reevaluations were performed in the latest 21 cases reevaluations with positron-emission tomography with fludeoxyglucose F 18 were also performed In all 41 cases complete resections were performed with no operative mortality The histologically complete response rate major response rate and minor response rate were 171 % 7/41 561 % 23/41 and 268 % 11/41 respectively The 5-year overall survival was 527 % There were no differences in survival between taxane groups Both the complete response and the major response groups revealed a significantly better 5-year survivals than the minor response group 857 % P = 044 524 % P = 01 Even with persistent N2 disease the 5-year survival in the major response group 66 % was promising With the combination of conventional computed tomography and positron-emission tomography with fludeoxyglucose F 18 for reevaluation eligible patients could be selected for this protocol Surgery after chemoradiotherapy carboplatin-taxane and 50-Gy radiation for bulky cN2 N3 non-small cell lung cancer can be safely performed with promising results Even with persistent N2 disease the survival in the major response group was promising\",\n",
            "}\n",
            "13910\n",
            "{\n",
            "  \"id\" : \"20165821\",\n",
            "  \"contents\" : \"To investigate the lung tissue response measured with computed tomography CT after radiotherapy RT combined with metoclopramide Patients with non-small cell lung cancer tumor stage IIIA and IIIB included in a multicenter randomized phase III trial investigating the use of metoclopramide as a radiosensitizing agent were examined with repetitive post-RT CT scans The analysis comprised data up to 100 days after RT for a subgroup of 16 patients treated with a total dose of 60 Gy given in 182 Gy per fraction Large radiation doses to subvolumes were associated with denser lung tissue measured with CT p < 0001 Opposed to this finding the volume of lung tissue irradiated with significant doses V 40Gy was negatively correlated with the average increase in lung tissue density p = 0003 Patients randomized to metoclopramide injections also experienced less increase in lung tissue density p = 001 There was an increase in the density of irradiated lung tissue with radiation dose and time after RT Metoclopramide and significant radiation doses to larger lung volumes V 40Gy seemed to protect against fibrosis development\",\n",
            "}\n",
            "13911\n",
            "{\n",
            "  \"id\" : \"23994107\",\n",
            "  \"contents\" : \"The EORTC 55971 trial compared primary debulking surgery PDS versus neo-adjuvant chemotherapy NACT followed by interval debulking surgery IDS The impact of both treatment arms on quality of life QOL is reported Patients with stages IIIc or IV ovarian cancer completed the EORTC QLQ-C30 before treatment at the third and sixth cycle of chemotherapy and at 6 - and 12-month follow-up Data of 404 patients N = 201 PDS arm N = 203 IDS arm were included in the QOL analysis Between treatment arms no statistically significant differences were found in any of the QOL functioning scales Patients showed a clinically relevant improvement > 10 points on the global health/QOL role functioning emotional functioning and social functioning scales during and after treatment independent of the type of treatment Clinically relevant differences from baseline to the follow-up assessments were noted for fatigue pain insomnia appetite loss constipation diarrhea indicating symptom control in both treatment arms Institutions with good QOL compliance were associated with better outcomes There was a statistical significant difference in the overall debulking status with 399 % optimal debulking surgery in institutions with good QOL compliance compared to 199 % in institutions with poor QOL compliance p = 00011 Overall survival median 3230 versus 2329 months p = 00006 and progression free survival median 1235 versus 992 months p = 00002 were also significantly better Survival and QOL after NACT followed by surgery was similar to survival and QOL after PDS followed by chemotherapy However institutions with good QOL compliance had better survival outcomes\",\n",
            "}\n",
            "13912\n",
            "{\n",
            "  \"id\" : \"17909199\",\n",
            "  \"contents\" : \"Bevacizumab a humanized anti-vascular endothelial growth factor monoclonal antibody and erlotinib a reversible orally available epidermal growth factor receptor tyrosine kinase inhibitor have demonstrated evidence of a survival benefit in the treatment of non-small-cell lung cancer NSCLC A single-arm phase I and II study of bevacizumab plus erlotinib demonstrated encouraging efficacy with a favorable safety profile A multicenter randomized phase II trial evaluated the safety of combining bevacizumab with either chemotherapy docetaxel or pemetrexed or erlotinib and preliminarily assessed these combinations versus chemotherapy alone as measured by progression-free survival PFS All patients had histologically confirmed nonsquamous NSCLC that had progressed during or after one platinum-based regimen One hundred twenty patients were randomly assigned and treated No unexpected adverse events were noted Fewer patients 13 % in the bevacizumab-erlotinib arm discontinued treatment as a result of adverse events than in the chemotherapy alone 24 % or bevacizumab-chemotherapy 28 % arms The incidence of grade 5 hemorrhage in patients receiving bevacizumab was 51 % Although not statistically significant relative to chemotherapy alone the risk of disease progression or death was 066 95 % CI 038 to 116 among patients treated with bevacizumab-chemotherapy and 072 95 % CI 042 to 123 among patients treated with bevacizumab-erlotinib One-year survival rate was 574 % for bevacizumab-erlotinib and 538 % for bevacizumab-chemotherapy compared with 331 % for chemotherapy alone Results for PFS and overall survival favor combination of bevacizumab with either chemotherapy or erlotinib over chemotherapy alone in the second-line setting No unexpected safety signals were noted The rate of fatal pulmonary hemorrhage was consistent with previous bevacizumab trials The toxicity profile of the bevacizumab-erlotinib combination is favorable compared with either chemotherapy-containing group\",\n",
            "}\n",
            "13913\n",
            "{\n",
            "  \"id\" : \"19933933\",\n",
            "  \"contents\" : \"Smoking increases platelet aggregability and the degree of platelet inhibition by clopidogrel on ex vivo platelet function tests Whether smoking status affects the relationship between clopidogrel and clinical outcomes is unknown We evaluated the relationship between smoking status current smoker former smoker or never-smoker and treatment with clopidogrel on the risk of all-cause cardiovascular and cancer mortality among the 12 152 participants from the CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization Management and Avoidance trial who had established cardiovascular disease Current smoking was associated with an increase in all-cause adjusted hazard ratio [ HR ] 258 95 % confidence interval [ CI ] 185 to 360 cardiovascular HR 226 95 % CI 148 to 345 and cancer HR 356 95 % CI 196 to 646 mortality compared with never smoking The impact of clopidogrel on mortality differed by smoking status P for interaction = 0018 for current smokers Among current smokers clopidogrel was associated with a reduction in all-cause mortality HR 068 95 % CI 049 to 094 clopidogrel did not reduce all-cause mortality among former smokers HR 095 95 % CI 075 to 119 or never-smokers HR 114 95 % CI 083 to 158 A similar pattern was noted for cardiovascular mortality As expected no relationship was observed between clopidogrel and cancer mortality by smoking status The risk of bleeding appeared to differ according to smoking status randomized clopidogrel was associated with a significantly increased risk of severe or moderate bleeding HR 162 P = 004 among current smokers but a smaller and nonsignificant increase among never-smokers HR 131 P = 015 Clopidogrel therapy may be more effective in current smokers but it may also confer a greater bleeding risk than in nonsmokers Further studies are needed to investigate this possibility\",\n",
            "}\n",
            "13914\n",
            "{\n",
            "  \"id\" : \"23892298\",\n",
            "  \"contents\" : \"Peak VO2 as measure of physical performance is central to a correct preoperative evaluation in patients with both non-small-cell lung cancer NSCLC and chronic obstructive pulmonary disease COPD because it is closely related both to operability criteria and the rate of postoperative complications Strategies to improve peak VO2 as a preoperative pulmonary rehabilitation programme PRP should be considered favourably in these patients In order to clarify the role of pulmonary rehabilitation we have evaluated the effects of 3-week preoperative high-intensity training on physical performance and respiratory function in a group of patients with both NSCLC and COPD who underwent lobectomy We studied 40 patients with both NSCLC and COPD age < 75 years TNM stages I-II who underwent lobectomy Patients were randomly divided into two groups R and S Group R underwent an intensive preoperative PRP while Group S underwent only lobectomy We evaluated peak VO2 in all patients at Time 0 T0 after PRP/before surgery in Group R/S T1 and 60 days after surgery respectively in both groups T2 There was no difference between groups in peak VO2 at T0 while a significant difference was observed both at T1 and T2 In Group R peak VO2 improves significantly from T0 to T1 149 23-17 8 21 ml/kg/min standard deviation SD P < 0001 645 165-76 1 149 % predicted SD P < 005 and deteriorates from T1 to T2 178 21-15 1 24 P < 0001 761 149-64 6 155 P < 005 reverting to a similar value to that at T0 while in Group S peak VO2 did not change from T0 to T1 and significantly deteriorates from T1 to T2 145 12-11 4 12 ml/kg/min SD P < 000001 606 84-47 4 69 % predicted SD P < 000001 PRP was a valid preoperative strategy to improve physical performance in patients with both NSCLC and COPD and this advantage was also maintained after surgery\",\n",
            "}\n",
            "13915\n",
            "{\n",
            "  \"id\" : \"8230265\",\n",
            "  \"contents\" : \"Chemotherapy with or without radiotherapy results in a 30 % -40 % complete response rate in small-cell lung cancer SCLC but approximately 90 % of patients who have complete remission die within 2 years after relapse with chemoresistant disease Randomized clinical studies of maintenance chemotherapy after complete response have failed to demonstrate survival advantage However studies have shown that the human cytokine interferon gamma IFN-gamma induces immune response in humans including T-cell activation and expression of class II major histocompatibility complex HLA-DR and receptor for the Fc portion of immunoglobulin on monocytes It has also been demonstrated that recombinant IFN-gamma rIFN-gamma induces immunomodulation and has antiproliferative activity In vivo effects of rIFN-gamma treatment were characterized by flow cytometric analysis of peripheral blood mononuclear cells in patients with SCLC who received rIFN-gamma as maintenance treatment After induction chemotherapy and radiotherapy 100 patients who achieved a complete remission were randomly assigned to receive rIFN-gamma at a dose of 02 mg 4 x 10 6 units once a day subcutaneously for 6 months or observation only In 31 patients peripheral mononuclear cells were obtained prior to the study and at weeks 4 8 and 12 for serial monitoring of immune response By flow cytometric analysis we identified the lymphocyte and monocyte populations using characteristic differences in electronic volume and right-angle scatter In these populations we determined the mean fluorescence channel after staining for CD14 antigen expressed on monocytes CD3 antigen expressed on T lymphocytes and HLA-DR HLA class II expressed by monocytes and activated lymphocytes To determine the number of Fc receptors per cell an Fc receptor assay was performed using the monocyte cell line U937 as a standard At weeks 4 8 and 12 expression of HLA-DR and Fc receptors on monocytes in patients who received rIFN-gamma was significantly higher than that in untreated patients and the difference was statistically significant The number of Fc receptors per monocyte consistently increased during the rIFN-gamma treatment and reached a fivefold elevation at week 12 There was no statistically significant difference in lymphocyte surface antigen expression between the treated and untreated groups The dose of rIFN-gamma used in this study resulted in immune stimulation in patients with SCLC who had complete remission after induction therapy The in vivo immunomodulatory activity of rIFN-gamma in such patients is characterized by a strong monocyte activation but no significant alteration in T-cell activation\",\n",
            "}\n",
            "13916\n",
            "{\n",
            "  \"id\" : \"22399076\",\n",
            "  \"contents\" : \"Neuroendocrine dysregulation influenced by psychosocial stress is related to breast cancer recurrence Very few studies examine the impacts of psychotherapy on diurnal cortisol patterns among breast cancer survivors Forty-eight breast cancer patients who completed active cancer treatment were randomly assigned to receive either 8 weekly body-mind-spirit BMS group therapy sessions or 1 educational EDU session Self-report measures included the Beck Depression Inventory-II BDI-II and the Meaning in Life questionnaire MLQ including two subscales MLQ-Presence and MLQ-Search Salivary cortisol levels were collected by the subjects in their homes at the time of awakening 30 and 45 min after awakening and at 1200 1700 and 2100 h Measurement time points include baseline the 2nd month completion of BMS therapy the 5th month and the 8th month There were no significant differences in BDI-II scores p > 005 and MLQ-Presence scores p > 005 between BMS and EDU groups at baseline or across the three follow-ups Nevertheless greater MLQ-Search scores were found in the BMS group compared to the EDU group during the 5th month of follow-up p < 001 The higher level of cortisol at 2100 h p < 001 and a flatter diurnal cortisol pattern were more likely to occur in EDU than in BMS participants p < 005 at the 8th month of follow-up BMS group therapy likely contributed to enhancing an active search for meaning in life toward more opportunities for personal growth and to maintaining stable cortisol responses to everyday life stress for breast cancer survivors\",\n",
            "}\n",
            "13917\n",
            "{\n",
            "  \"id\" : \"18707785\",\n",
            "  \"contents\" : \"To assess the impact of the boost dose in patients with involved surgical margins In the EORTC boost versus no boost trial 251 patients with a microscopically incomplete tumour excision were randomised to receive either a low boost dose of 10 Gy 126 patients or a high boost dose of 26 Gy 125 patients Overall survival and the cumulative incidence of local recurrence as first event were compared by Logrank and Gray test respectively 2-sided alpha = 005 with a median follow-up of 113 years The planned sample size was 660 patients but only 251 were recruited The median age at randomisation was 54 years Thirty-seven patient initially relapsed locally At 10 years the cumulative incidence of local recurrence was 175 % 95 % CI 104-24 6 % versus 108 % 95 % CI 52-16 4 % for the low and high boost dose groups respectively HR = 083 95 % CI 043-1 57 Gray p > 01 Overall 64 patients have died 255 % 47 of them of breast cancer without a difference in duration of survival between the two groups HR = 097 95 % CI = 059-1 5 p > 01 Severe fibrosis was palpated in the breast in 1 % versus 5 % and in the boost area in 3 % versus 13 % in the low and high boost dose groups respectively There was no statistically significant difference in local control or survival between the high boost dose of 26 Gy and the low boost dose of 10 Gy in patients with microscopically incomplete excision of early breast cancer Fibrosis however was noted significantly more frequently in cases treated with the high boost dose\",\n",
            "}\n",
            "13918\n",
            "{\n",
            "  \"id\" : \"19086814\",\n",
            "  \"contents\" : \"A causal association links high-risk human papillomavirus HR-HPV and cervical cancer which is a major public health problem The objective of the present study was to investigate the association between male circumcision MC and the prevalence of HR-HPV among young men We used data from a MC trial conducted in Orange Farm South Africa among men aged 18-24 years Urethral swab samples were collected during a period of 262 consecutive days from participants in the intervention circumcised and control uncircumcised groups who were reporting for a scheduled follow-up visit Swab samples were analyzed using polymerase chain reaction HR-HPV prevalence rate ratios PRRs were assessed using univariate and multivariate log Poisson regression In an intention-to-treat analysis the prevalences of HR-HPV among the intervention and control groups were 148 % 94/637 and 223 % 140/627 respectively with a PRR of 066 051-0 86 P = 002 Controlling for propensity score and confounders ethnic group age education sexual behavior [ including condom use ] marital status and human immunodeficiency virus status had no effect on the results This is the first randomized controlled trial to show a reduction in the prevalence of urethral HR-HPV infection after MC This finding explains why women with circumcised partners are at a lower risk of cervical cancer than other women\",\n",
            "}\n",
            "13919\n",
            "{\n",
            "  \"id\" : \"17118319\",\n",
            "  \"contents\" : \"To compare the dose coverage conformity and homogeneity between high-dose-rate HDR brachytherapy and permanent prostate implant PPI in the treatment of prostate adenocarcinoma From January 2003 to August 2004 54 patients 108 implants underwent HDR brachytherapy of prostate cancer with iridium-192 stepping source Of patients who underwent PPI brachytherapy with iodine-125 72 patients were randomly selected for the purpose of dosimetric comparison PPI preplan was done based on transrectal ultrasound study and postplan was done using CT 1 month after implant Dosimetric parameters of HDR were compared to that of PPI preplan and postplan HDR brachytherapy had lower D90 1115 % vs 1202 % lower V100 972 % vs 996 % lower natural dose ratio 103 vs 113 higher conformal index 069 vs 062 and higher homogeneity index 063 vs 052 than PPI preplan all p < 00001 All the dosimetric parameters of PPI postplan including D90 867 % V100 820 % natural dose ratio 092 conformal index 053 and homogeneity index 042 were inferior to HDR brachytherapy all p < 00001 HDR brachytherapy of the prostate can provide better dose coverage conformity and homogeneity compared to PPI\",\n",
            "}\n",
            "13920\n",
            "{\n",
            "  \"id\" : \"22516832\",\n",
            "  \"contents\" : \"Postoperative atrial fibrillation occurs in 5 % to 65 % of patients undergoing thoracic surgery Although postoperative atrial fibrillation often is regarded as a temporary benign operation-related problem it is associated with a twofold to threefold increase in risk of adverse events including transient or permanent stroke acute myocardial infarction and death A total of 254 consecutively eligible enrolled patients undergoing surgery for lung cancer were included in this randomized controlled double-blinded trial Patients received 300 mg of amiodarone or placebo intravenously over 20 minutes immediately after surgery and an oral dose of 600 mg of amiodarone or placebo twice daily during the first 5 postoperative days The patients in the amiodarone prophylaxis group had a reduction in the risk of atrial fibrillation of 23 % 12 to 31 number needed to treat was 44 31 to 78 A total of 38 in the control group and 11 in the amiodarone group experienced atrial fibrillation p < 0001 Adverse effects were observed in 10 patients equally distributed in both trial arms Postoperative prophylaxis with a high dose of oral amiodarone after an intravenous bolus infusion is a safe practical feasible and effective regimen for patients with lung cancer undergoing surgery It significantly reduced the incidence of postoperative atrial fibrillation\",\n",
            "}\n",
            "13921\n",
            "{\n",
            "  \"id\" : \"24188328\",\n",
            "  \"contents\" : \"Inclusion of antioxidants in topical formulations can contribute to minimize oxidative stress in the skin which has been associated with photoaging several dermatosis and cancer A Castanea sativa leaf extract with established antioxidant activity was incorporated into a semisolid surfactant-free formulation The objective of this study was to perform a comprehensive characterization of this formulation Physical microbiological and functional stability were evaluated during 6months storage at 20C and 40C Microstructure elucidation cryo-SEM in vitro release and in vivo moisturizing effect Corneometer CM 825 were also assessed Minor changes were observed in the textural and rheological properties of the formulation when stored at 20C for 6months and the antioxidant activity of the plant extract remained constant throughout the storage period Microbiological quality was confirmed at the end of the study Under accelerated conditions higher modifications of the evaluated parameters were observed Cryo-SEM analysis revealed the presence of oil droplets dispersed into a gelified external phase The release rate of the antioxidant compounds 61070gh -05 followed Higuchi model A significant in vivo moisturizing effect was demonstrated that lasted at least 4h after product s application The physical functional and microbiological stability of the antioxidant formulation was established Specific storage conditions should be recommended considering the influence of temperature on the stability A skin hydration effect and good skin tolerance were also found which suggests that this preparation can be useful in the prevention or treatment of oxidative stress-mediated dysfunctions\",\n",
            "}\n",
            "13922\n",
            "{\n",
            "  \"id\" : \"8437596\",\n",
            "  \"contents\" : \"Thrombocytopenia is a frequent side effect of cancer chemotherapy and commonly limits attempts to escalate drug doses To determine whether interleukin-1 alpha could ameliorate carboplatin-induced thrombocytopenia we combined it with high-dose carboplatin in 43 patients with advanced neoplasms High-dose carboplatin 800 mg per square meter of body-surface area was administered alone to a control group Subsequent patients were randomly assigned to receive the same dose of carboplatin with interleukin-1 alpha administered either before or after carboplatin Interleukin-1 alpha was given intravenously at a dose of 003 01 or 03 microgram per kilogram of body weight per day for five days Carboplatin alone consistently produced thrombocytopenia with a median nadir of 19000 platelets per cubic millimeter and a median of 10 days with less than 100000 platelets per cubic millimeter All 15 patients receiving interleukin-1 alpha before carboplatin had similar findings In contrast 5 of the 15 patients given one of the two higher doses of interleukin-1 alpha after carboplatin had minimal thrombocytopenia nadir 91000 to 332000 platelets per cubic millimeter In the 10 patients given 03 microgram of interleukin-1 alpha per kilogram after carboplatin treatment the platelet count recovered to 100000 per cubic millimeter significantly earlier than in either the control group P = 0002 or the patients who received interleukin-1 alpha before carboplatin P = 0003 with the median times to recovery in the three groups being 16 21 and 23 days respectively At the highest dose of interleukin-1 alpha toxicity was substantial but reversible requiring inpatient support for hypotension supraventricular arrhythmias and pulmonary-capillary leak Interleukin-1 alpha can accelerate the recovery of platelets after high-dose carboplatin therapy and may be clinically useful in preventing or treating thrombocytopenia induced by chemotherapy\",\n",
            "}\n",
            "13923\n",
            "{\n",
            "  \"id\" : \"21684068\",\n",
            "  \"contents\" : \"Standard treatment for upper urinary tract urothelial carcinoma UUTUC is nephroureterectomy Subsequently around 40 % of patients will develop a bladder tumour potentially because of implantation from the primary tumour To prevent bladder tumour after nephroureterectomy with a single postoperative dose of intravesical mitomycin C MMC A prospective randomised nonblinded trial ODMIT-C One Dose Mitomycin C was undertaken in 46 British centres between July 2000 and December 2006 The study recruited 284 patients with no previous or concurrent history of bladder cancer undergoing nephroureterectomy for suspected UUTUC A single postoperative intravesical dose of MMC 40 mg in 40 ml saline or standard management on removal of the urinary catheter Bladder tumour formation was judged by visual appearance at cystoscopy at 3 6 and 12 mo following nephroureterectomy One hundred forty-four patients were randomised to receive MMC and 140 patients to receive standard care In the MMC arm 105 of 144 patients 73 % and 115 of 140 patients 82 % in the standard care arm received their allocated treatment Thirteen of 105 patients who received MMC and 20 of 115 patients allocated to standard treatment did not complete follow-up By modified intention-to-treat analysis 21 of 120 patients 17 % in the MMC arm developed a bladder recurrence in the first year compared to 32 of 119 patients 27 % in the standard treatment arm p = 0055 By treatment as per protocol analysis 17 of 105 patients 16 % in the MMC arm and 31 of 115 patients 27 % in the standard treatment arm developed a recurrence p = 003 No serious adverse events were reported A limitation is that histologic proof of recurrence was not required in this trial A single postoperative dose of intravesical MMC appears to reduce the risk of a bladder tumour within the first year following nephroureterectomy for UUTUC The absolute reduction in risk is 11 % the relative reduction in risk is 40 % and the number needed to treat to prevent one bladder tumour is nine\",\n",
            "}\n",
            "13924\n",
            "{\n",
            "  \"id\" : \"19747744\",\n",
            "  \"contents\" : \"To assess the feasibility and efficacy of the COX-2 inhibitor celecoxib in conjunction with preoperative chemoradiation for patients with locally advanced rectal cancer in a double blind randomized phase II study Thirty-five patients of the initially planned 80 patients with locally advanced rectal cancer were treated with preoperative radiation 45 Gy 18 Gy/fraction 5 days/week combined with 5-fluorouracil continuous infusion 225 mg/m 2 / day and celecoxib 2 x 400 mg/day or placebo Pathological response and toxicity of study treatment were evaluated as well as expression of COX-2 and Ki67 in tumor tissue and IL-6 in plasma as possible molecular correlates and predictors of response to treatment Patients treated with celecoxib tended to show a better response 61 % when compared to those treated with placebo 35 % although not significant p = 013 T-downstaging and N-downstaging were also slightly higher with celecoxib Plasma IL-6 levels and intratumoral COX2 or Ki67 were altered by chemoradiation but were not further altered by celecoxib treatment and therefore not useful for prediction of treatment benefit Celecoxib therapy in conjunction with chemoradiation was not associated with additional toxicity and seemed to help mitigate therapy-related pain Addition of celecoxib to preoperative chemoradiation is feasible for patients with locally advanced rectal cancer To study the individual effect of COX-2 inhibitors on pathological response phase III studies are required\",\n",
            "}\n",
            "13925\n",
            "{\n",
            "  \"id\" : \"19046724\",\n",
            "  \"contents\" : \"The third-generation aromatase inhibitor exemestane represents a new development in the treatment of estrogen-positive breast cancer The aim of this study was to evaluate the effects on lipid profile and body composition of the shift from tamoxifen to exemestane After 2-3 years of tamoxifen adjuvant treatment 68 postmenopausal women were randomly assigned to either continue tamoxifen 20 mg/day n = 35 or to switch to exemestane 25 mg/day n = 33 No significant changes in lipid profile were found in patients continuing on tamoxifen In the exemestane group serum HDL-cholesterol HDL-C and triglycerides TG decreased significantly p < 001 and serum LDL-cholesterol LDL-C increased significantly p < 005 with respect to baseline The difference between the two groups was significant Moreover in the exemestane group fat mass FM and fat-free mass FFM showed an opposite trend which determined a progressive and significant increase in the FFM/FM ratio This study shows that the choice of first-line treatment or adjuvant therapy for breast cancer should also take the individual lipid and body composition profile into account\",\n",
            "}\n",
            "13926\n",
            "{\n",
            "  \"id\" : \"17583416\",\n",
            "  \"contents\" : \"This population-based study provides comparisons of prostate cancer characteristics at diagnosis of two cohorts of men from two well-defined geographical areas exposed to different intensities of prostate cancer screening Overall survival in both cohorts was compared with that in the general population A cohort of 822 men randomized to the intervention arm of a prostate cancer screening trial and subsequently diagnosed with prostate cancer was compared with a nonrandomized cohort of 947 men who were clinically diagnosed with prostate cancer in a geographically neighboring region In both cohorts cases were diagnosed with prostate cancer between January 1989 and December 1997 A partitioning of overall survival by variables associated with cancer onset such as age at diagnosis stage at diagnosis and grade at diagnosis was performed Age at diagnosis tumor extent at diagnosis and grade at diagnosis were significantly different between the screened and clinically diagnosed cohort The 5 - and 10-yr survival rates were higher in the screened cohort than in the clinically diagnosed cohort 888 % vs 524 % and 684 % vs 296 % respectively Significant differences in survival were evident for all age stage and grade subgroups except for metastatic disease at diagnosis Differences in overall survival favoring the screened population were observed for all baseline characteristics age stage and grade of disease and these variables may all explain differences in overall survival because screening achieves early diagnosis as well as a stage and grade shift As observed survival rates in the screened population mirrored those within the general population the contribution of lead time and overdiagnosis to final patient outcome is considered to be large as well\",\n",
            "}\n",
            "13927\n",
            "{\n",
            "  \"id\" : \"24903230\",\n",
            "  \"contents\" : \"To study the effect of inspiration on airway dimensions measured in voluntary inspiration breath-hold examinations 961 subjects with normal spirometry were selected from the Danish Lung Cancer Screening Trial Subjects were examined annually for five years with low-dose CT Automated software was utilized to segment lungs and airways identify segmental bronchi and match airway branches in all images of the same subject Inspiration level was defined as segmented total lung volume TLV divided by predicted total lung capacity pTLC Mixed-effects models were used to predict relative change in lumen diameter ALD and wall thickness AWT in airways of generation 0 trachea to 7 and segmental bronchi R1-R10 and L1-L10 from relative changes in inspiration level Relative changes in ALD were related to relative changes in TLV/pTLC and this distensibility increased with generation p < 0001 Relative changes in AWT were inversely related to relative changes in TLV/pTLC in generation 3 -- 7 p < 0001 Segmental bronchi were widely dispersed in terms of ALD 5707 mm AWT 086007 mm and distensibility 23577 % Subjects who inspire more deeply prior to imaging have larger ALD and smaller AWT This effect is more pronounced in higher-generation airways Therefore adjustment of inspiration level is necessary to accurately assess airway dimensions Airway lumen diameter increases and wall thickness decreases with inspiration The effect of inspiration is greater in higher-generation more peripheral airways Airways of generation 5 and beyond are as distensible as lung parenchyma Airway dimensions measured from CT should be adjusted for inspiration level\",\n",
            "}\n",
            "13928\n",
            "{\n",
            "  \"id\" : \"15249451\",\n",
            "  \"contents\" : \"Low-radiation-dose spiral CT LDCT scanning is capable of detecting lung neoplasms in asymptomatic individuals To determine whether such detection can reduce lung cancer mortality a randomized controlled trial RCT of LDCT scanning is necessary The feasibility of conducting an RCT in asymptomatic individuals who are at high risk for lung cancer was explored in the Lung Screening Study LSS a 12-month special project of the ongoing Prostate Lung Colorectal and Ovarian PLCO cancer screening trial During the fall of 2000 six PLCO screening centers recruited a total of 3318 heavy or long-term smokers who were not participants in the PLCO trial and randomized them to receive either a screening LDCT scan 1660 participants or screening posteroanterior view chest radiograph CXR [ 1658 participants ] The screens were completed on 96 % of subjects in the LDCT scan arm and 93 % of subjects in the CXR arm A total of 205 % of screened subjects in the LDCT scan arm and 98 % of those in the CXR arm had findings that were suspicious for lung cancer Thirty lung cancers in subjects in the LDCT arm and 7 lung cancers in patients in the CXR arm were diagnosed following a positive screening result Additional data from the LSS indicated that among persons who were at elevated risk for lung cancer CT scan use was not pervasive interest in participating in an RCT of LDCT scanning was strong and few subjects randomized to CXR either refused their examination or sought a CT scan after their study CXR The results of the LSS demonstrated convincingly the feasibility of an RCT of LDCT scanning in the United States\",\n",
            "}\n",
            "13929\n",
            "{\n",
            "  \"id\" : \"24997476\",\n",
            "  \"contents\" : \"Exercise is beneficial for breast cancer patients during chemotherapy but adherence to different types and doses of exercise is a challenge The purpose of this study was to examine predictors of adherence to different types and doses of exercise during breast cancer chemotherapy in a multicenter randomized controlled trial Breast cancer patients in Edmonton Vancouver and Ottawa Canada receiving chemotherapy N = 301 were randomized to a standard dose of 25-30 minutes of aerobic exercise STAN a higher dose of 50-60 minutes of aerobic exercise HIGH or a higher dose of 50-60 minutes of combined aerobic and resistance exercise COMB Predictors included demographic medical fitness and quality of life variables Exercise adherence was measured as the percentage of supervised exercise sessions completed Overall adherence to the supervised exercise sessions was 73 % SD = 24 % In a multivariate regression model six independent predictors explained 264 % p < 0001 of the variance in exercise adherence Higher exercise adherence was achieved by breast cancer patients in Vancouver p < 0001 with fewer endocrine symptoms p = 0009 randomized to STAN p = 0009 with fewer exercise limitations p = 0009 receiving shorter chemotherapy protocols p = 0015 and with higher VO2peak p = 0017 Disease stage p for interaction = 0015 and body mass index p for interaction = 0030 interacted with group assignment to predict adherence For disease stage patients with stage I/IIa disease adhered equally well to all three exercise interventions whereas patients with stage IIb/III disease adhered better to the STAN intervention than the two higher dose exercise interventions For body mass index healthy weight patients adhered equally well to all three exercise interventions whereas overweight patients adhered best to STAN and worst to COMB and obese patients adhered best to STAN and worst to HIGH Determinants of exercise adherence in breast cancer patients receiving chemotherapy are multidisciplinary and may vary by the exercise prescription\",\n",
            "}\n",
            "13930\n",
            "{\n",
            "  \"id\" : \"9037359\",\n",
            "  \"contents\" : \"Cisplatin-based combination chemotherapy will cure 70 % to 80 % of patients with metastatic non-seminomatous germ cell tumors but is associated with the possibility of severe neuro - oto - and nephro-toxicities Carboplatin a cisplatin analogue is an active drug in testicular cancer with a more favourable spectrum of side effects In a randomized trial the German Testicular Cancer Study Group compared a combination regimen of carboplatin etoposide and bleomycin CEB to standard cisplatin etoposide and bleomycin PEB chemotherapy for patients with minimal - and moderate-disease non-seminomatous germ cell tumors according to the Indiana University classification PEB was given for three cycles at standard doses given days 1-5 and the CEB regimen consisted of carboplatin target AUC of 5 mg/ml x min on day 1 etoposide 120 mg/m2 on days 1 to 3 and bleomycin 30 mg on days 1 8 and 15 Four cycles of CEB were given with the omission of bleomycin in the fourth cycle Thus the cumulative doses of etoposide and bleomycin applied in the two treatment arms were comparable Fifty-four patients were entered on the trial 29 were treated with PEB and 25 with CEB chemotherapy Patients were stratified according to disease extent minimal versus moderate and the degree of tumor marker elevation Thirty-two patients 59 % belonged to the group with minimal disease and low markers No significant difference in response to chemotherapy was seen between the two arms with CR rates of 81 % for the PEB arm and 76 % for CEB treatment However more patients treated with CEB 32 % versus 13 % have relapsed after therapy and 4 patients 16 % have died of disease progression after CEP in contrast to 1 3 % after PEB therapy The first interim analysis of negative events relapse vital tumor at secondary resection death from disease and therapy-associated death showed a significantly higher rate after CEB than after PEB therapy and the trial was terminated early After a median follow-up of 33 months for all patients the calculation of negative events is still significantly in favour of PEB-treated patient particularly since three late relapses > 2 years have been observed in the CEB arm P = 003 This randomized trial demonstrates that even with the use of adequate doses of etoposide and full-dose bleomycin carboplatin can not altogether replace cisplatin in patients with testicular cancer Treatment with the PEB regimen remains the standard approach in patients with good-risk non-seminomatous germ cell tumors\",\n",
            "}\n",
            "13931\n",
            "{\n",
            "  \"id\" : \"21739158\",\n",
            "  \"contents\" : \"Inhaled chemotherapy is under investigation as an alternative therapeutic modality for Non-Small Cell Lung Cancer 60 NSCLC patients were randomized into 3 groups in this study 20/60 patients group A-control group received IV chemotherapy carboplatin AUC 55 D1 20/60 group B received 2/3 of IV predicted carboplatin dose by IV infusion and the rest 1/3 as aerosol jet nebulised D1 and 20/60 group C received all the predicted IV dose of carboplatin as aerosol in 3 equally divided fractions D1-3 In all patients IV docetaxel 100/m 2 was as well administered D1 Lung functional tests were performed in all groups before chemotherapy in the 3rd and 6th cycles Group B had a statistically significant increase in survival compared to control group A [ 275 days 95 % CI 249-300 vs 211 95 % CI 185-236 ] In regard to lung functional tests a statistically significant decline was observed only in FEV1 of group C in 6 months compared to the initial measurement Inhaled carboplatin could be given as an alternative root of pulmonary drug delivery in selected patients but further randomized studies remain to prove whether the inhaled chemotherapy is an efficient and safe treatment modality\",\n",
            "}\n",
            "13932\n",
            "{\n",
            "  \"id\" : \"21429025\",\n",
            "  \"contents\" : \"Although the treatment of early gastric cancer with endoscopic submucosal dissection ESD has been widely carried out a standardized method of sedation for ESD has not been established The purpose of the present study was to evaluate the efficacy and safety of sedation with dexmedetomidine DEX We conducted a randomized study involving 90 patients with gastric tumors who were intended to be treated with ESD The patients were sedated either with DEX iv infusion of 30 g/kg per h over 5 min followed by continuous infusion at 04 g/kg per h [ n = 30 ] propofol PF [ n = 30 ] or midazolam MDZ [ n = 30 ] In all groups 1 mg MDZ was added iv as needed En bloc resection of the gastric tumor was achieved in 88 98 % patients None of the DEX-sedated patients showed a significant reduction of the oxygen saturation level The percentage of patients who showed body movement in the DEX group was significantly lower than those in the PF and MDZ groups and the mean dose of additional MDZ in the DEX group was significantly smaller than that in the MDZ group The rate of effective sedation was significantly higher in the DEX group compared with the MDZ or PF group The mean length of ESD in the DEX group was 65 min which was significantly shorter than in the other two groups No DEX-sedated patient developed major surgical complications Sedation with DEX is effective and safe for patients with gastric tumors who are undergoing ESD\",\n",
            "}\n",
            "13933\n",
            "{\n",
            "  \"id\" : \"16752076\",\n",
            "  \"contents\" : \"To evaluate the hypothesis that telomere DNA content TC in breast tumor tissue correlates with TNM staging and prognosis Slot blot assay was used to quantitate TC in 70 disease-free normal tissues from multiple organ sites and two independent sets of breast tumors containing a total of 140 samples Non-parametric Rank-Sums tests logistic regression and Cox proportional hazards models were used to evaluate the relationships between TC and tumor size nodal involvement TNM stage 5-year survival and disease-free interval TC in 95 % of normal tissues was 75-143 % of that in the placental DNA standard whereas only 50 % of tumors had TC values in this range TC was associated with tumor size p = 002 nodal involvement p < 00001 TNM stage p = 0004 5-year overall survival p = 00001 and 5-year disease-free survival p = 00004 A multivariable Cox model was developed using age at diagnosis TNM stage and TC as independent predictors of breast cancer-free survival Relative to the high TC group > 123 % of standard low TC < 101 % of standard conferred an adjusted relative hazard of 443 95 % CI 14-13 6 p = 0009 Receiver operating characteristic curves using thresholds defined by the TC distribution in normal tissues predicted 5-year breast cancer-free survival with 50 % sensitivity and 95 % specificity and predicted death due to breast cancer with 75 % sensitivity and 70 % specificity TC in breast cancer tissue is an independent predictor of clinical outcome and survival interval and may discriminate by stage\",\n",
            "}\n",
            "13934\n",
            "{\n",
            "  \"id\" : \"25481829\",\n",
            "  \"contents\" : \"The study aimed to determine the effect of preference-based tailored navigation on colorectal cancer CRC screening adherence and related outcomes among African Americans AAs We conducted a randomized controlled trial that included 764 AA patients who were age 50 to 75 years were eligible for CRC screening and had received care through primary care practices in Philadelphia Consented patients completed a baseline telephone survey and were randomized to either a Standard Intervention SI group n = 380 or a Tailored Navigation Intervention TNI group n = 384 The SI group received a mailed stool blood test kit plus colonoscopy instructions and a reminder The TNI group received tailored navigation a mailed stool blood test kit or colonoscopy instructions based on preference plus telephone navigation and a reminder A six-month survey and a 12-month medical records review were completed to assess screening adherence change in overall screening preference and perceptions about screening Multivariable analyses were performed to assess intervention impact on outcomes At six months adherence in the TNI group was statistically significantly higher than in the SI group OR = 21 95 % CI = 15 to 29 Positive change in overall screening preference was also statistically significantly greater in the TNI group compared with the SI group OR = 15 95 % CI = 10 to 23 There were no statistically significant differences in perceptions about screening between the study groups Tailored navigation in primary care is a promising approach for increasing CRC screening among AAs Research is needed to determine how to maximize intervention effects and to test intervention impact on race-related disparities in mortality and survival\",\n",
            "}\n",
            "13935\n",
            "{\n",
            "  \"id\" : \"15164445\",\n",
            "  \"contents\" : \"Peritoneal carcinomatosis in the absence of distant metastasis occurs in approximately 8 per cent of patients with colorectal cancer Cytoreduction followed by hyperthermic intraperitoneal chemotherapy HIPEC is a new treatment option Patient selection is crucial to outcome Cytoreduction followed by HIPEC was performed in 102 patients with peritoneal carcinomatosis The following factors were studied for association with survival perforation and obstruction of the primary lesion location of the primary lesion obstruction associated with carcinomatosis presentation tumour differentiation and histological type Extent of disease and completeness of cytoreduction were also studied Hazard ratios HRs were used to study these factors Location of the primary tumour in rectum HR 314 95 per cent confidence interval ci 111 to 891 P = 0069 poor differentiation HR 173 95 per cent ci 104 to 288 P = 0031 and signet cell histological type HR 224 95 per cent ci 121 to 416 P = 0008 were associated with shorter survival Important factors predicting survival were the number of affected regions HR 138 95 per cent ci 120 to 159 P < 0001 the simplified peritoneal cancer score HR 119 95 per cent ci 112 to 126 P < 0001 and completeness of cytoreduction HR 854 95 per cent ci 401 to 1818 P < 0001 No other factor correlated with survival The survival of patients with peritoneal carcinomatosis of colorectal origin is dominated by the extent of disease and the amount of residual tumour after cytoreduction\",\n",
            "}\n",
            "13936\n",
            "{\n",
            "  \"id\" : \"22943926\",\n",
            "  \"contents\" : \"Intranasal fentanyl spray INFS Instanyl was developed to treat cancer patients with Breakthrough Pain BTP INFS is delivered via a multi-dose delivery system MDS that is available in various dose strengths The aim of this study was to demonstrate the pharmacokinetic bioequivalence of INFS single dose delivery system SDS in relation to the currently marketed MDS device In a randomized single-center single-dose open label comparative four-period two-sequence replicate cross-over study 48 healthy subjects 24 male and 24 female mean age of 281 years mean bodyweight 698 kg received 200 g/100 l fentanyl administered via SDS and via MDS in one of two alternating treatment sequences Naltrexone was given to all subjects to prevent potential fentanyl adverse drug reactions Blood samples were frequently taken up to 72 hours post INFS administration and analyzed by liquid chromatography with tandem mass spectrometric detection Primary pharmacokinetic parameters were area under the curve extrapolated to infinity AUC0 - and peak plasma concentration Cmax Statistical analyses of the primary pharmacokinetic parameters were performed using a linear mixed effect model applied to the natural log-transformed data Healthy subjects showed very similar plasma concentration over time profiles for both delivery systems The mean fentanyl Cmax and AUC0 - values for SDS and MDS were 948 pg/ml 949 pg/ml and 4439 pgh/ml 4489 pgh/ml respectively Point estimates and 90 % confidence intervals for AUC and Cmax were 097 093 - 102 and 100 092 - 109 and therefore in the bioequivalence range of 080 - 125 Results of this study show that SDS and MDS met the pre-defined regulatory criteria for bioequivalence Safety profiles were consistent between both devices and no safety concerns were identified with INFS administered in combination with oral naltrexone\",\n",
            "}\n",
            "13937\n",
            "{\n",
            "  \"id\" : \"9210704\",\n",
            "  \"contents\" : \"Cimetidine preserves postoperative immune function and inhibits the growth of some cancers In this study the effect of cimetidine on the local immune response to colorectal carcinoma was investigated Forty-two patients scheduled for elective resection of colorectal carcinoma were randomized either to receive cimetidine for 1 week perioperatively or to act as controls A lymphocyte density of 50 cells per high-power field approximately 50 % of the tumor/tissue interface was considered a positive response Patient survival was determined by Kaplan-Meier life table analysis The effects of histamine and cimetidine on normal subject lymphocyte function was determined in a mitogen-stimulated proliferation assay A positive lymphocyte response was observed in 5 of 24 control carcinoma patients 21 % and 10 of 18 cimetidine-treated carcinoma patients 56 % P = 003 The presence of a lymphocyte response correlated with a better survival P = 002 Histamine had an inhibitory effect on lymphocyte proliferation with a median effective dose of 5 x 10 -7 M Cimetidine antagonized this effect with a negative logarithm of the cimetidine molar concentration required to reduce the effect of histamine in half of 655 Histamine inhibits normal lymphocyte function antagonized by cimetidine at a histamine type 2 receptor Cimetidine increases lymphocyte infiltration of primary colorectal carcinoma possibly by overcoming the immunosuppressive effects of high local histamine concentrations The presence of a local lymphocyte response correlates with an improved 3-year survival\",\n",
            "}\n",
            "13938\n",
            "{\n",
            "  \"id\" : \"24332581\",\n",
            "  \"contents\" : \"The TARGIT TARGeted Intraoperative Radiotherapy trial was designed to compare local recurrence and complication rates in breast cancer patients prospectively randomised to either EBRT external beam whole breast radiotherapy or a single dose of IORT intraoperative radiotherapy The aim of our study was to compare follow-up mammographic findings ultrasound and biopsy rates in each group Follow-up imaging and breast biopsies of women from one centre participating in the TARGIT-A trial were independently reviewed by two radiologists blinded to the radiotherapy treatment received The cohort consisted of 141 patients EBRT n = 80/IORT n = 61 There was no significant difference in the patient or disease characteristics of the two groups The number of follow-up mammograms and length of follow-up was similar EBRT/IORT n = 20 / 24 43 yr/5 1 yr p = 0386 2 test There were no significant differences in mammographic scar or calcification appearances of the post-operative site Generalised increase in breast density and skin thickening were more common in the EBRT compared to the IORT group p = 0002 p = 0030 2 test respectively A trend towards additional ultrasound at follow-up was observed in the IORT group 15 of 61 [ 246 % ] versus 11 of 80 [ 138 % ] however this was not statistically significant p = 0100 2 test No disease recurrence was demonstrated on any of the breast biopsies taken Only one biopsy was reported as fat necrosis in the IORT group Mammographic changes were more common following EBRT although more additional follow-up ultrasounds were performed in the IORT group IORT is not detrimental to subsequent radiological follow up\",\n",
            "}\n",
            "13939\n",
            "{\n",
            "  \"id\" : \"24592967\",\n",
            "  \"contents\" : \"Physical inactivity and a poor diet predict lifestyle diseases such as diabetes cardiovascular disease and certain types of cancer Marked declines in physical activity occur during late adolescence coinciding with the point at which many young people leave school and enter the workforce and begin to take greater control over their lifestyle behaviours The work outlined within this paper sought to test a theoretically-informed intervention aimed at supporting increased engagement in physical activity and healthy eating habits in young people at the point of transition from school to work or work-based learning As actively engaging young people in initiatives based on health messages is challenging we also tested the efficacy of financial incentives in promoting initial engagement with the programme A three-arm cluster-randomised design was used Participants were school pupils from Year 11 and 13 ie in their final year of study aged 16-18years To reduce contamination effects the unit of randomisation was school Participants were randomly allocated to receive i a 12-week behavioural support intervention consisting of six appointments ii a behavioural support intervention plus incentives totalling 40 or iii an information-only control group Behavioural support was provided by fitness advisors at local leisure centres following an initial consultation with a dietician Sessions focused on promoting habit formation through setting implementation intentions as part of an incremental goal setting process Consistent with self-determination theory all advisors were trained to provide guidance in an autonomy-supportive manner so that they were equipped to create a social context supportive of autonomous forms of participant motivation The primary outcome was objectively assessed physical activity via GT1M accelerometers Secondary outcome measures were diet motivation and habit strength Data were collected at baseline post-intervention 12weeks and 12months Findings of this trial will provide valuable insight into the feasibility of promoting autonomous engagement in healthy physical activity and dietary habits among school leavers The research also provides much needed data and detailed information related to the use of incentives for the initial promotion of young peoples behaviour change during this important transition The trial is registered as Current Controlled Trials ISRCTN55839517\",\n",
            "}\n",
            "13940\n",
            "{\n",
            "  \"id\" : \"10840536\",\n",
            "  \"contents\" : \"Postoperative nausea and vomiting PONV after tonsillectomy is a common problem in children Tropisetron is a new 5HT3 receptor antagonist and is successfully used in paediatric patients receiving cancer therapy The aim of the study was to assess efficacy and safety of a single intravenous dose of tropisetron for prevention of PONV in paediatric patients at risk for postoperative vomiting In a randomised double-blind placebo-controlled trial we studied 98 children aged 2-12 years undergoing tonsillectomy or adenotonsillectomy Patients received placebo or tropisetron 01 mg = 01 ml / kg body weight immediately after induction of anesthesia A standard general anesthetic technique Sevoflurane/N2O/O2 without neuromuscular blockers or opioids was used Perioperative vital signs grade of sedation and episodes of postoperative nausea and vomiting were recorded No vomiting episodes occurred in 653 % of the tropisetron treated patients compared to 347 % of the placebo group p = 00024 Only 102 % of the tropisetron treated patients vomited more than 3 times compared to 224 % of the control patients p = 00004 The need for antiemetic rescue medication was significantly lower in the study group 104 % compared to 286 % p = 0025 No significant adverse effects of the study medication were shown A single intravenous prophylactic dose of tropisetron effectively reduces the incidence of PONV during the first 24 postoperative hours after tonsillectomy and/or adenoidectomy Because of the low incidence of adverse effects the prophylactic use of tropisetron seems to be safe and justified in paediatric surgical patients at high risk for postoperative vomiting\",\n",
            "}\n",
            "13941\n",
            "{\n",
            "  \"id\" : \"21790680\",\n",
            "  \"contents\" : \"Radiotherapy is an established treatment modality for prostate cancer however up to a third of patients develops a radiation-induced proctopathy To assess the effect of topical beclomethasone dipropionate BDP in the prevention of radiation-induced proctopathy in patients undergoing radiotherapy for prostate cancer through a double-blind placebo-controlled randomised trial Patients were randomised either to BDP or to placebo PL Patients received daily a 3mg BDP enema or identical-looking PL during radiotherapy and subsequently two 3mg BDP suppositories or PL for 4 more weeks Clinical and endoscopic evaluations before 3 and 12months after the end of radiotherapy were assessed with the RTOG/EORTC toxicity scales the modified Simple Clinical Colitis Activity Index SCCAI the modified Inflammatory Bowel disease Quality of Life Index IBDQ and the Vienna Rectoscopy Score VRS From June 2007 to October 2008 120 patients were randomised to the BDP n = 60 and PL n = 60 arms and were followed up for 12months The overall assessment of rectal side effects did not show significant differences between the two groups of treatment However when only rectal bleeding was considered a significantly reduced risk was observed in patients on BDP OR 038 95 % CI 017-0 86 P = 002 NNT = 5 Patients on BDP had also significantly lower VRS scores P = 0028 and significantly higher IBDQ scores P = 0034 Preventive treatment with topical rectal BDP during radiotherapy for prostate cancer significantly reduces the risk of rectal bleeding and radiation-induced mucosal changes and improves patient s quality of life but does not influence other radiation-induced symptoms\",\n",
            "}\n",
            "13942\n",
            "{\n",
            "  \"id\" : \"15234027\",\n",
            "  \"contents\" : \"This Phase III study was performed to determine whether twice-daily bid radiotherapy RT resulted in better survival than once-daily qd RT for patients with limited-stage small-cell lung cancer LD-SCLC A total of 310 patients with LD-SCLC initially received three cycles of etoposide and cisplatin Subsequently the 261 patients without significant progression were randomized to two cycles of etoposide and cisplatin plus either qd RT 504 Gy in 28 fractions or split-course bid RT 24 Gy in 16 fractions a 25-week break and 24 Gy in 16 fractions to the chest Patients then received a sixth cycle of etoposide and cisplatin followed by prophylactic cranial RT Follow-up ranged from 46 to 119 years median 74 years The median survival and 5-year survival rate from randomization was 206 months and 21 % for patients who received qd RT compared with 206 months and 22 % for those who received bid RT p = 068 respectively No statistically significant differences were found in the rates of progression p = 068 intrathoracic failure p = 045 in-field failure p = 062 or distant failure p = 082 between the two treatment arms No statistically significant difference was found in the overall rate of Grade 3 or worse p = 083 or Grade 4 or worse toxicity p = 095 Grade 3 or worse esophagitis p = 005 was more common in the bid arm Grade 5 toxicity occurred in 4 3 % of 130 patients who received bid RT compared with 0 0 % of 131 who received qd RT p = 004 Although this study did not demonstrate an advantage to split-course bid RT the long-term survival was favorable likely reflecting the positive influences of concurrent combined modality therapy and prophylactic cranial RT\",\n",
            "}\n",
            "13943\n",
            "{\n",
            "  \"id\" : \"15222004\",\n",
            "  \"contents\" : \"As a single agent 100 mg/m 2 of docetaxel every 3 weeks remains the standard schedule in the first-line treatment for metastatic disease At this dose level the major limiting toxicity is neutropenia The current study was conducted to assess the feasibility of reducing time intervals between cycles while delivering standard doses of docetaxel with granulocyte-colony-stimulating factor G-CSF lenograstim In the first part of the study 24 patients were randomized to receive 1 of 4 schedules 100 mg/m 2 of docetaxel every 21 days without lenograstim 100 mg/m 2 of docetaxel every 18 days with lenograstim 100 mg/m 2 of docetaxel every 14 days with lenograstim or 100 mg/m 2 of docetaxel every 10 days with lenograstim In the second part of the study 15 additional patients were included to confirm the feasibility of the recommended interval between cycles Of the 39 patients treated 14 patients 36 % withdrew from therapy because of Grade 3 according to standard World Health Organization criteria nonhematologic limiting toxicities Only 3 patients were treated in the 10-day interval arm and were withdrawn because of toxicity -- 1 patient had Grade 3 asthenia after the second cycle and 2 patients had Grade 3 dermatitis after 4 cycles Of the 24 patients treated in the 14-day intervals Grade 3 limiting toxicities occurred in 8 patients 33 % including dermatitis in 3 patients diarrhea myalgia/arthralgia or asthenia in 4 patients and ungual toxicity in 1 patient Introduction of G-CSF lenograstim as primary prophylaxis allowed the administration of docetaxel every 14 days with manageable toxicities Further studies are now required to assess the impact in terms of response rates and survival in patients with cancer\",\n",
            "}\n",
            "13944\n",
            "{\n",
            "  \"id\" : \"17224195\",\n",
            "  \"contents\" : \"Radiation dose distributions created by two dimensional 2D treatment planning are responsible for partial volumes receiving > 107 % of the prescribed dose in a proportion of patients prescribed whole breast radiotherapy after tumour excision of early breast cancer These may contribute to clinically significant late radiation adverse effects To test three dimensional 3D intensity modulated radiotherapy IMRT against 2D dosimetry using standard wedge compensators in terms of late adverse effects after whole breast radiotherapy Three hundred and six women prescribed whole breast radiotherapy after tumour excision for early stage cancer were randomised to 3D IMRT test arm or 2D radiotherapy delivered using standard wedge compensators control arm All patients were treated with 6 or 10MV photons to a dose of 50Gy in 25 fractions to 100 % in 5 weeks followed by an electron boost to the tumour bed of 111 Gy in 5 fractions to 100 % The primary endpoint was change in breast appearance scored from serial photographs taken before radiotherapy and at 1 2 and 5 years follow up Secondary endpoints included patient self-assessments of breast discomfort breast hardness quality of life and physician assessments of breast induration Analysis was by intention to treat 240 79 % patients with 5-year photographs were available for analysis Change in breast appearance was identified in 71/122 58 % allocated standard 2D treatment compared to only 47/118 40 % patients allocated 3D IMRT The control arm patients were 17 times more likely to have a change in breast appearance than the IMRT arm patients after adjustment for year of photographic assessment 95 % confidence interval 12-2 5 p = 0008 Significantly fewer patients in the 3D IMRT group developed palpable induration assessed clinically in the centre of the breast pectoral fold infra-mammary fold and at the boost site No significant differences between treatment groups were found in patient reported breast discomfort breast hardness or quality of life This analysis suggests that minimisation of unwanted radiation dose inhomogeneity in the breast reduces late adverse effects Incidence of change in breast appearance was statistically significantly higher in patients in the standard 2D treatment arm compared with the IMRT arm A beneficial effect on quality of life remains to be demonstrated\",\n",
            "}\n",
            "13945\n",
            "{\n",
            "  \"id\" : \"15284269\",\n",
            "  \"contents\" : \"To evaluate the efficacy of long-term nontunneled silicone catheters impregnated with minocycline and rifampin M-R in reducing catheter-related bloodstream infections This prospective randomized double-blind clinical trial was conducted at MD Anderson Cancer Center a tertiary care hospital in Houston TX All patients in the trial had a malignancy Between September 1999 and May 2002 356 assessable catheters were used 182 M-R and 174 nonimpregnated The patients characteristics were comparable between the two study groups The mean + / - standard deviation duration of catheterization with M-R catheters was comparable to that of nonimpregnated catheters 6621 + / - 3088 v 6301 + / - 3080 days A total of 17 catheter-related bloodstream infections occurred during the course of the study Three were associated with the use of M-R catheters and 14 were associated with the nonimpregnated catheters with a rate of catheter-related bloodstream infection of 025 and 128 / 1000 catheter-days respectively P = 003 Gram-positive cocci accounted for the majority of the organisms causing the infections There were no allergic reactions associated with M-R catheters Long-term nontunneled central venous catheters impregnated with minocycline and rifampin are efficacious and safe in reducing catheter-related bloodstream infections in cancer patients\",\n",
            "}\n",
            "13946\n",
            "{\n",
            "  \"id\" : \"18783735\",\n",
            "  \"contents\" : \"Prostate cancer is the most common noncutaneous malignancy and the second leading cause of cancer death in men Ninety percent of men with prostate cancer are over aged 60 years diagnosed by early detection with the prostate specific antigen PSA blood test and have disease believed confined to the prostate gland clinically localized Common treatments for clinically localized prostate cancer include watchful waiting surgery to remove the prostate gland radical prostatectomy external beam radiation therapy and interstitial radiation therapy brachytherapy and androgen deprivation Little is known about the relative effectiveness and harms of treatments due to the paucity of randomized controlled trials The VA/NCI/AHRQ Cooperative Studies Program Study # 407 Prostate cancer Intervention Versus Observation Trial PIVOT initiated in 1994 is a multicenter randomized controlled trial comparing radical prostatectomy to watchful waiting in men with clinically localized prostate cancer We describe the study rationale design recruitment methods and baseline characteristics of PIVOT enrollees We provide comparisons with eligible men declining enrollment and men participating in another recently reported randomized trial of radical prostatectomy versus watchful waiting conducted in Scandinavia We screened 13022 men with prostate cancer at 52 United States medical centers for potential enrollment From these 5023 met initial age comorbidity and disease eligibility criteria and a total of 731 men agreed to participate and were randomized The mean age of enrollees was 67 years Nearly one-third were African-American Approximately 85 % reported they were fully active The median prostate specific antigen PSA was 78 ng/mL mean 102 ng/mL In three-fourths of men the primary reason for biopsy leading to a diagnosis of prostate cancer was a PSA elevation or rise Using previously developed tumor risk categorizations incorporating PSA levels Gleason histologic grade and tumor stage approximately 43 % had low risk 36 % had medium risk and 20 % had high-risk prostate cancer Comparison to our national sample of eligible men declining PIVOT participation as well as to men enrolled in the Scandinavian trial indicated that PIVOT enrollees are representative of men being diagnosed and treated in the US and quite different from men in the Scandinavian trial PIVOT enrolled an ethnically diverse population representative of men diagnosed with prostate cancer in the United States Results will yield important information regarding the relative effectiveness and harms of surgery compared to watchful waiting for men with predominately PSA detected clinically localized prostate cancer\",\n",
            "}\n",
            "13947\n",
            "{\n",
            "  \"id\" : \"25273343\",\n",
            "  \"contents\" : \"Longer duration of first-line chemotherapy for patients with metastatic breast cancer is associated with prolonged overall survival and improved progression-free survival We investigated capecitabine added to maintenance bevacizumab after initial treatment with bevacizumab and docetaxel in this setting We did this open-label randomised phase 3 trial at 54 hospitals in Brazil China Egypt France Hong Kong India Italy Poland Spain and Turkey We enrolled patients with HER2-negative measurable metastatic breast cancer each received three to six cycles of first-line bevacizumab 15 mg/kg and docetaxel 75-100 mg/m 2 every 3 weeks Progression-free patients were randomly assigned with an interactive voice-response system by block size four randomisation 11 to receive either bevacizumab and capecitabine or bevacizumab only bevacizumab 15 mg/kg on day 1 capecitabine 1000 mg/m 2 twice per day on days 1-14 every 3 weeks until progression stratified by oestrogen receptor status positive vs negative visceral metastases present vs absent response status stable disease vs response vs non-measurable and lactate dehydrogenase concentration 15 vs > 15upper limit of normal Neither patients nor investigators were masked to allocation The primary endpoint was progression-free survival from randomisation in the intention-to-treat population This trial is registered with ClinicalTrialsgov NCT00929240 Between July 16 2009 and March 7 2011 when enrolment was prematurely terminated 284 patients received initial bevacizumab and docetaxel 185 65 % were randomly assigned 91 to bevacizumab and capecitabine versus 94 to bevacizumab only Progression-free survival was significantly longer in the bevacizumab and capecitabine group than in the bevacizumab only group median 119 months [ 95 % CI 98-154 ] vs 43 months [ 39-68 ] stratified hazard ratio 038 [ 95 % CI 027-055 ] two-sided log-rank p < 00001 as was overall survival median 390 months [ 95 % CI 323-not reached ] vs 237 months [ 185-317 ] stratified HR 043 [ 95 % CI 026-069 ] two-sided log-rank p = 00003 Results for time to progression were consistent with those for progression-free survival 78 86 % patients in the bevacizumab and capecitabine group and 72 77 % in the bevacizumab only group had an objective response Clinical benefit was recorded in 92 98 % patients in the bevacizumab alone group and 90 99 % in the bevacizumab and capecitabine group Mean change from baseline in global health score did not differ significantly between groups Grade 3 or worse adverse events during the maintenance phase were more common with bevacizumab and capecitabine than with bevacizumab only 45 [ 49 % ] of 91 patients vs 25 [ 27 % ] of 92 patients The most common grade 3 or worse events were hand-foot syndrome 28 [ 31 % ] in the bevacizumab and capecitabine group vs none in the bevacizumab alone group hypertension eight [ 9 % ] vs three [ 3 % ] and proteinuria three [ 3 % ] vs four [ 4 % ] Serious adverse events were reported by ten 11 % patients in the bevacizumab and capecitabine group and seven 8 % patients in the bevacizumab only group Despite prematurely terminated accrual and the lack of information about post-progression treatment both progression-free survival and overall survival were significantly improved with bevacizumab and capecitabine compared with bevacizumab alone as maintenance treatment These results might inform future maintenance trials and current first-line treatment strategies for HER2-negative metastatic breast cancer F Hoffmann-La Roche\",\n",
            "}\n",
            "13948\n",
            "{\n",
            "  \"id\" : \"23374559\",\n",
            "  \"contents\" : \"Erectile dysfunction ED is a common adverse event associated with treatment for prostate cancer This study aimed to identify whether early regular use of sildenafil after radiation treatment for prostate cancer is effective at reducing the rate of ED at 2 years A randomised controlled trial with 27 men planned for radiation treatment for localised prostate cancer recruited from a single radiotherapy centre in Australia Men were randomised to receive daily sildenafil or a placebo tablet for 6 months The primary end-point was erectile function as measured by the International Index of Erectile Function IIEF score at 2-year follow-up The abridged IIEF-5 survey was also used during the treatment period and could be derived from the full IIEF at other time-points Two-sided Student s t-tests and Mann-Whitney U-tests were used for the analysis of continuous outcomes with Fisher s exact test for dichotomous outcomes No difference was seen at 2 years in the primary end-point and IIEF scores did not differ significantly between groups during the study Men in the sildenafil group exhibited significantly better IIEF-5 scores at 4 weeks P = 002 and 6 months P = 002 There was no difference in erectile function scores between the two groups throughout the treatment period No significant difference in adverse events was identified between the two groups There was no evidence from this trial that sildenafil provides long-term erectile function for patients while on medication Regular use of sildenafil may improve short-term sexual function for patients while on medication Larger trials are required to examine the effectiveness of implementing sildenafil for prostate cancer patients undergoing radiation treatment\",\n",
            "}\n",
            "13949\n",
            "{\n",
            "  \"id\" : \"15330214\",\n",
            "  \"contents\" : \"This prospective semi-randomized study was undertaken to assess the effects and effectiveness of alkylating drugs in a preoperative setting During a 6-year period preceding February 2000 80 patients with Stage II-IVa AJCC 2002 squamous cell cancer of the oral cavity were treated Thirty patients Group N received a combination of bleomycin vincristine and methotrexate BVM In the alkylating group thirty patients Group A/M received BVM and mitolactol dibromodulcitol while twenty patients Group A/C received BVM and cisplatin Patients underwent surgery within 3 weeks after chemotherapy Clinical response rate and tumour-free survival were investigated Clinical complete response was 30 % -36 % Group N-A Partial response was 57 % -56 % Group N-A Side-effects were moderate and reversible Nausea anaemia and leucopenia were observed in the alkylating A group while other side-effects alopecia mucositis gastritis were similar in both groups The observation time was 36 months Regional disease-free survival showed a significant difference favouring the non-alkylating N group p = 003 A higher metastasis rate was observed in the alkylating A group Cisplatin and mitolactol in combination with BVM showed higher local control and lower disease-free survival than BVM alone That was mostly due to a higher rate of regional metastatis formation in the alkylating-treated patients This may be a late side-effect caused by the immunosuppressive and myelosuppressive effect of alkylating agents\",\n",
            "}\n",
            "13950\n",
            "{\n",
            "  \"id\" : \"24609851\",\n",
            "  \"contents\" : \"Community-based participatory research CBPR approaches that involve community and academic partners in activities ranging from protocol design through dissemination of study findings can increase recruitment of medically underserved and underrepresented racial/ethnic minority populations into biomedical research Five cancer screening and prevention trials in three National Cancer Institute Bethesda MD - funded Community Networks Program Centers CNPC in Florida Kansas and South Carolina were conducted across diverse populations Data were collected on total time period of recruitment ratios of participants enrolled over potential participants approached selected CBPR strategies capacity-building development and systematic procedures for community stakeholder involvement Community-engaged approaches used included establishing colearning opportunities participatory procedures for community-academic involvement and community and clinical capacity building A relatively large proportion of individuals identified for recruitment was actually approached between 50 % and 100 % The proportion of subjects who were eligible among all those approached ranged from 25 % to more than 70 % in the community setting Recruitment rates were very high 78 % -100 % of eligible individuals approached and the proportion who refused or who were not interested among those approached was very low 5 % -11 % Recruitment strategies used by the CNPCs were associated with low refusal and high enrollment ratios of potential subjects Adherence to CBPR principles in the spectrum of research activities from strategic planning to project implementation has significant potential to increase involvement in biomedical research and improve our ability to make appropriate recommendations for cancer prevention and control programming in underrepresented diverse populations CBPR strategies should be more widely implemented to enhance study recruitment\",\n",
            "}\n",
            "13951\n",
            "{\n",
            "  \"id\" : \"16476893\",\n",
            "  \"contents\" : \"To describe health - and vision-targeted quality of life following treatment with iodine 125 brachytherapy vs enucleation for choroidal melanoma in a subgroup of patients who were treated and observed prospectively as part of a large randomized clinical trial Difficulty with driving near vision activities and activities using stereopsis or binocularity anxiety and depression Two hundred nine patients who enrolled in the Collaborative Ocular Melanoma Study trial for medium-sized tumors between March 1995 and July 1998 and gave informed consent prior to randomization to participation in an ancillary study of quality of life Patients were interviewed by telephone by a trained interviewer from the Collaborative Ocular Melanoma Study Coordinating Center at baseline prior to randomization at 6 months and on annual anniversaries of enrollment The questionnaire battery included the Medical Outcomes Study Short Form 36 the Activities of Daily Vision Scale the National Eye Institute Visual Function Questionnaire and the Hospital Anxiety and Depression Scale Additional questions concerning satisfaction with posttreatment appearance and concerns about cancer recurrence also were included in posttreatment interviews There was a significant increase in both treatment groups in levels of reported difficulty for most vision-oriented activities and in bodily and ocular pain 6 months following treatment Differences in visual function between treatment groups reported during follow-up were relatively small but significant differences favoring brachytherapy-treated patients were observed for driving during the first year of follow-up and for peripheral vision during the first 2 years of follow-up Anxiety levels in both groups decreased significantly following treatment but patients treated with brachytherapy with symptoms of anxiety were less likely to report later resolution of symptoms than patients with symptoms of anxiety who were treated with enucleation This study was unable to assess impact of treatment on satisfaction with appearance and concern about cancer recurrence during the first year after treatment but no treatment-related differences were found on these measures at 2 years and later follow-up times Patients treated with brachytherapy reported significantly better visual function than patients treated with enucleation with respect to driving and peripheral vision for up to 2 years following treatment Differences between treatments in visual function diminished by 3 to 5 years posttreatment paralleling decline in visual acuity in brachytherapy-treated eyes Patients treated with brachytherapy were more likely to have symptoms of anxiety during follow-up than patients treated with enucleation Given that no significant differences in survival between enucleation and brachytherapy have been found the differences demonstrated here for driving and anxiety will allow the individual patient and physician to make informed choices regarding treatment based on personal preferences\",\n",
            "}\n",
            "13952\n",
            "{\n",
            "  \"id\" : \"22853014\",\n",
            "  \"contents\" : \"The aromatase inhibitor anastrozole inhibits estrogen synthesis Fulvestrant binds and accelerates degradation of estrogen receptors We hypothesized that these two agents in combination might be more effective than anastrozole alone in patients with hormone-receptor HR - positive metastatic breast cancer Postmenopausal women with previously untreated metastatic disease were randomly assigned in a 11 ratio to receive either 1 mg of anastrozole orally every day group 1 with crossover to fulvestrant alone strongly encouraged if the disease progressed or anastrozole and fulvestrant in combination group 2 Patients were stratified according to prior or no prior receipt of adjuvant tamoxifen therapy Fulvestrant was administered intramuscularly at a dose of 500 mg on day 1 and 250 mg on days 14 and 28 and monthly thereafter The primary end point was progression-free survival with overall survival designated as a prespecified secondary outcome The median progression-free survival was 135 months in group 1 and 150 months in group 2 hazard ratio for progression or death with combination therapy 080 95 % confidence interval [ CI ] 068 to 094 P = 0007 by the log-rank test The combination therapy was generally more effective than anastrozole alone in all subgroups with no significant interactions Overall survival was also longer with combination therapy median 413 months in group 1 and 477 months in group 2 hazard ratio for death 081 95 % CI 065 to 100 P = 005 by the log-rank test despite the fact that 41 % of the patients in group 1 crossed over to fulvestrant after progression Three deaths that were possibly associated with treatment occurred in group 2 The rates of grade 3 to 5 toxic effects did not differ significantly between the two groups The combination of anastrozole and fulvestrant was superior to anastrozole alone or sequential anastrozole and fulvestrant for the treatment of HR-positive metastatic breast cancer despite the use of a dose of fulvestrant that was below the current standard Funded by the National Cancer Institute and AstraZeneca SWOG ClinicalTrialsgov number NCT00075764\",\n",
            "}\n",
            "13953\n",
            "{\n",
            "  \"id\" : \"23943258\",\n",
            "  \"contents\" : \"To evaluate the effects of mode order of administration and the interaction of mode and order on health-related quality of life scales when self-administered by mixed mode paper-mode and web-mode for measurement equivalence Health-related quality of life data was analyzed from the Cancer of the Prostate Strategic Urologic Research Endeavor using the Medical Outcomes Study MOS Short Form-36 SF-36 and the University of California Los Angeles Prostate Cancer Index UCLA-PCI A randomized crossover design assigned participants to two groups with a preferred 2-5-day washout period Cognitive debriefing evaluated participants mode preference Of the 245 men enrolled 85 % completed both modes The majority were White 97 % college educated 66 % reported an annual income > $ 75000 46 % and a median age of 69 years Intraclass correlation coefficients were high for each item on both instruments r = 54 -97 Exact percentage agreement for yes/no items was high 88 For the SF-36 significant differences were observed for order of administration physical component and physical function scores and for the interaction between mode and order mental component role emotional social function vitality and mental health scores For the UCLA-PCI the largest difference was 128 points lower for sexual bother for order of administration by web-mode first p = 03 Seventy percent preferred the web-mode 21 % had no preference and 9 % preferred the paper-mode Web-mode and paper-mode administrations of the SF-36 and UCLA-PCI are equivalent in men with prostate cancer implying that mixed-mode survey administration is warranted\",\n",
            "}\n",
            "13954\n",
            "{\n",
            "  \"id\" : \"25139338\",\n",
            "  \"contents\" : \"Although the relationship between smoking and prostate cancer risk is inconsistent some studies show that smoking is associated with prostate cancer mortality Whether this reflects delayed diagnosis or direct smoking-related effects is unknown REDUCE which followed biopsy-negative men with protocol-dictated prostate-specific antigen PSA - independent biopsies at 2 and 4 years provides an opportunity to evaluate smoking and prostate cancer diagnosis with minimal confounding from screening biases Logistic regression was conducted to test the association between smoking and cancer on the first on-study biopsy no cancer low-grade Gleason 4-6 high-grade Gleason 7-10 in REDUCE Of 6240 men with complete data and 1 on-study biopsy 2937 458 % never smoked 929 145 % were current smokers and 2554 398 % were former smokers Among men with negative first on-study biopsies smokers were 36 % less likely to receive a second on-study biopsy P < 0001 At first on-study biopsy 941 147 % men had cancer Both current and former smoking were not significantly associated with either total or low-grade prostate cancer all P > 036 Current OR = 144 P = 0028 but not former smokers OR = 121 P = 012 were at increased risk of high-grade disease On secondary analysis there was an interaction between smoking and body mass index BMI Pinteraction = 0017 current smokers with BMI 25 kg/m 2 had an increased risk of low-grade OR = 154 P = 0043 and high-grade disease OR = 245 P = 0002 with null associations for BMI 25 kg/m 2 Among men with elevated PSA and negative pre-study biopsy in REDUCE in which biopsies were largely PSA independent smoking was unrelated to overall prostate cancer diagnosis but was associated with increased risk of high-grade prostate cancer\",\n",
            "}\n",
            "13955\n",
            "{\n",
            "  \"id\" : \"21169619\",\n",
            "  \"contents\" : \"Informatics applications have the potential to improve participation in clinical trials but their design must be based on user-centered research This research used a fully counterbalanced experimental design to investigate the effect of changes made to the original version of a website http//BreastCancerTrialsorg/ and confirm that the revised version addressed and reinforced patients needs and expectations Participants included women who had received a breast cancer diagnosis within the last 5 years N = 77 They were randomized into two groups one group used and reviewed the original version first followed by the redesigned version and the other group used and reviewed them in reverse order The study used both quantitative and qualitative measures During use participants click paths and general reactions were observed After use participants were asked to answer survey items and open-ended questions to indicate their reactions and which version they preferred and met their needs and expectations better Overall the revised version of the site was preferred and perceived to be clearer easier to navigate more trustworthy and credible and more private and safe overall However users who viewed the original version last had similar attitudes toward both versions By applying research findings to the redesign of a website for clinical trial searching it was possible to re-engineer the interface to better support patients decisions to participate in clinical trials The mechanisms of action in this case appeared to revolve around creating an environment that supported a sense of personal control and decisional autonomy\",\n",
            "}\n",
            "13956\n",
            "{\n",
            "  \"id\" : \"17971595\",\n",
            "  \"contents\" : \"To compare the efficacy of arzoxifene with tamoxifen for the treatment of locally advanced or metastatic breast cancer Women with estrogen - or progesterone-receptor-positive breast cancer who had not received prior systemic therapy or who had relapsed more than 12 months after stopping adjuvant hormonal therapy were randomly assigned to receive 20 mg arzoxifene or 20 mg tamoxifen daily Each treatment arm was to have 240 patients enrolled The primary end point was progression-free survival Secondary end points included other measures of tumor response overall survival and safety Enrollment was stopped when a planned interim analysis of the first 200 patients suggested arzoxifene to be significantly inferior to tamoxifen The median progression-free survival for the 352 patients who had been randomly assigned when enrollment was stopped was 40 months 95 % CI 34 to 56 months for the arzoxifene group and 75 months 95 % CI 59 to 88 months for the tamoxifen group On-study progression-free survival P = 011 and time to treatment failure P = 029 also favored tamoxifen Overall tumor response rate and median response duration were comparable between the groups Adverse events were similar between the treatments except for nausea more frequent with arzoxifene and vaginal discharge more frequent with tamoxifen Tamoxifen produced significantly longer progression-free survival and time to treatment failure compared with arzoxifene in the treatment of locally advanced and metastatic breast cancer There were no significant differences between tumor response rate clinical benefit rate or median response duration\",\n",
            "}\n",
            "13957\n",
            "{\n",
            "  \"id\" : \"17698116\",\n",
            "  \"contents\" : \"We tested whether the addition of preoperative circulating plasminogen activator inhibitor type I levels improves the accuracy of standard preoperative and postoperative models for prediction of biochemical recurrence after radical prostatectomy Preoperative plasma levels of plasminogen activator inhibitor type I were measured in 429 consecutive patients treated with radical prostatectomy for clinically localized prostate cancer The patients were randomly divided into a development 67 % 286 and a split sample validation cohort 33 % 143 Cox regression analysis was used to develop prognostic nomograms for prediction of biochemical recurrence In standard univariate analyses categorically coded preoperative plasminogen activator inhibitor type I was significantly associated with biochemical recurrence p < 0001 In standard preoperative and postoperative multivariate analyses preoperative plasminogen activator inhibitor type I was independently associated with biochemical recurrence p < 0001 and p = 0002 respectively In the split sample validation cohort the addition of plasminogen activator inhibitor type I increased the predictive accuracy of the preoperative multivariate model by 12 % 77 % 103 % 67 % and 54 % at 1 2 3 4 and 5 years respectively p values < 0001 Moreover the addition of plasminogen activator inhibitor type I increased the predictive accuracy of the postoperative model by 05 % 11 % 40 % 24 % and 36 % at 1 2 3 4 and 5 years respectively p values < 0001 Preoperative circulating plasminogen activator inhibitor type I is a predictor of biochemical recurrence and it enhances the accuracy of preoperative and postoperative nomograms After external validation these nomograms may assist clinical decision making regarding treatment choice and followup as well as identification of patients at high risk for biochemical recurrence who may benefit from neoadjuvant and/or adjuvant treatment\",\n",
            "}\n",
            "13958\n",
            "{\n",
            "  \"id\" : \"8254858\",\n",
            "  \"contents\" : \"To develop and validate a new Simplified Acute Physiology Score the SAPS II from a large sample of surgical and medical patients and to provide a method to convert the score to a probability of hospital mortality The SAPS II and the probability of hospital mortality were developed and validated using data from consecutive admissions to 137 adult medical and/or surgical intensive care units in 12 countries The 13152 patients were randomly divided into developmental 65 % and validation 35 % samples Patients younger than 18 years burn patients coronary care patients and cardiac surgery patients were excluded Vital status at hospital discharge The SAPS II includes only 17 variables 12 physiology variables age type of admission scheduled surgical unscheduled surgical or medical and three underlying disease variables acquired immunodeficiency syndrome metastatic cancer and hematologic malignancy Goodness-of-fit tests indicated that the model performed well in the developmental sample and validated well in an independent sample of patients P = 883 and P = 104 in the developmental and validation samples respectively The area under the receiver operating characteristic curve was 088 in the developmental sample and 086 in the validation sample The SAPS II based on a large international sample of patients provides an estimate of the risk of death without having to specify a primary diagnosis This is a starting point for future evaluation of the efficiency of intensive care units\",\n",
            "}\n",
            "13959\n",
            "{\n",
            "  \"id\" : \"15100340\",\n",
            "  \"contents\" : \"Although mammographic breast density is associated with the risk of breast cancer and is influenced by hormone levels the effects of tamoxifen on breast density in healthy women and whether tamoxifen-induced density changes are associated with breast cancer risk are unclear We investigated mammographic breast density in healthy women with an increased risk of breast cancer at baseline and during 54 months of tamoxifen treatment Mammograms were reviewed from 818 breast cancer-free women 388 in the tamoxifen group and 430 in the placebo group at high risk for breast cancer from the International Breast Cancer Intervention Study I a trial of tamoxifen for breast cancer prevention Breast density measurements at baseline and during treatment were obtained at 12 - to 18-month intervals Multivariable analysis was used to assess associations with breast density All statistical tests were two-sided Breast density at baseline was similar in placebo 426 % 95 % confidence interval [ CI ] = 396 % to 456 % and tamoxifen 419 % 95 % CI = 388 % to 450 % groups The main determinants of breast density at baseline were age menopausal status body mass index and previous atypical hyperplasia A greater density reduction in the tamoxifen group 79 % 95 % CI = 69 % to 89 % than in the placebo group 35 % 95 % CI = 27 % to 43 % was apparent within 18 months of treatment P < 001 the reduction in density continued until 54 months of treatment After 54 months of tamoxifen treatment breast density was 282 % decrease from baseline = 137 % 95 % CI = 123 % to 151 % P < 001 in the tamoxifen group and 353 % decrease from baseline = 73 % 95 % CI = 61 % to 84 % P < 001 in the placebo group The tamoxifen-associated density reduction was apparent in all subgroups but there was a statistically significant interaction with age In women aged 45 years or younger at entry the net reduction with tamoxifen was 134 % 95 % CI = 86 % to 181 % whereas in women older than 55 years it was 11 % 95 % CI = -30 % to 51 % Tamoxifen treatment was associated with reduction in breast density most of which occurred during the first 18 months of treatment\",\n",
            "}\n",
            "13960\n",
            "{\n",
            "  \"id\" : \"22548398\",\n",
            "  \"contents\" : \"Evidence suggests that skin surface microtopography is a valid measure of photoaging among young adults but whether this applies to older adults is unknown We investigated the association between degree of photoaging as measured by histological dermal elastosis and skin microtopography grades by decade of age from 40 to 89 years in a community sample in Australia Skin surface replicas and punch biopsies were taken from 664 participants of the Nambour Skin Cancer Study The association was assessed using ordinal logistic regression with proportional odds assumption using histological dermal elastosis grades as outcome There was significant increase in odds of higher skin surface microtopography grades with higher dermal elastosis grades for age groups below 70 years [ 40 to 49 years odds ratio OR 296 95 % confidence interval CI 168-5 22 50 to 59 years OR 378 95 % CI 228-6 26 60 to 69 years OR 247 95 % CI 141-4 35 The association was not significant for those 70 years or older Skin surface microtopography grading system is a valid measure of degree of dermal elastosis for middle-aged and older adults up to 69 years but appears not to be valid for adults 70 years or more living in a high sun exposure setting\",\n",
            "}\n",
            "13961\n",
            "{\n",
            "  \"id\" : \"23078958\",\n",
            "  \"contents\" : \"Many patients with advanced non-small-cell lung cancer NSCLC receive only active supportive care because of poor performance status or presence of several comorbidities We investigated whether erlotinib improves clinical outcome in these patients TOPICAL was a double-blind randomised placebo-controlled phase 3 trial done at 78 centres in the UK Eligibility criteria were newly diagnosed pathologically confirmed NSCLC stage IIIb or IV chemotherapy naive no symptomatic brain metastases deemed unsuitable for chemotherapy because of poor 2 Eastern Cooperative Oncology Group performance status or presence of several comorbidities or both and estimated life expectancy of at least 8 weeks Patients were randomly assigned by phone call in a 11 ratio stratified by disease stage performance status smoking history and centre block size 10 to receive oral placebo or erlotinib 150 mg per day until disease progression or unacceptable toxicity Investigators clinicians and patients were masked to assignment The primary endpoint was overall survival Analyses were by intention to treat and prespecified subgroup analyses included development of a rash due to erlotinib within 28 days of starting treatment This study is registered number ISRCTN 77383050 Between April 14 2005 and April 1 2009 we randomly assigned 350 patients to receive erlotinib and 320 to receive placebo We followed up patients until March 31 2011657 patients died median overall survival did not differ between groups erlotinib 37 months 95 % CI 32-42 vs placebo 36 months 32-39 unadjusted hazard ratio [ HR ] 094 95 % CI 081-110 p = 046 59 % 178 of 302 of patients assigned erlotinib and who were assessable at 1 month developed first-cycle rash which was the only independent factor associated with overall survival Patients with first-cycle rash had better overall survival HR 076 95 % CI 063-092 p = 00058 compared with placebo Compared with placebo overall survival seemed to be worse in the group that did not develop first-cycle rash 130 105-161 p = 0017 Grade 3 or 4 diarrhoea was more common with erlotinib than placebo 8 % [ 28 of 334 ] vs 1 % [ four of 313 ] p = 00001 as was high-grade rash 23 % [ 79 of 334 ] vs 2 % [ five of 313 ] p < 00001 other adverse events were much the same between groups Patients with NSCLC who are deemed unsuitable for chemotherapy could be given erlotinib Patients who develop a first-cycle rash should continue to receive erlotinib whereas those who do not have a rash after 28 days should discontinue erlotinib because of the possibility of decreased survival Cancer Research UK Roche\",\n",
            "}\n",
            "13962\n",
            "{\n",
            "  \"id\" : \"7736883\",\n",
            "  \"contents\" : \"To evaluate the influence of a H2 receptor antagonist cimetidine on survival in patients with colorectal carcinoma a randomized controlled pilot study was performed in three university hospitals in Copenhagen Denmark A total of 192 patients who had undergone a resection or an exploratory operation for adenocarcinoma of the colon or rectum between May 1988 and May 1991 were enrolled in the study After a median observation time of 40 months outcome was noted for each patient concerning cancer-specific mortality rate In patients operated with curative intent n = 148 no difference was found in cancer-specific mortality between the two treatments However a tendency toward reduction in mortality rate was found in patients with curatively operated Dukes Stage C carcinoma P = 011 log-rank test difference 29 percent 90 percent confidence interval 2 to 57 percent in the cimetidine-treated group In patients with disseminated disease no total difference was found between the two treatment groups Cimetidine does not seem to reduce mortality in patients with colorectal cancer but there seems to be a tendency toward a survival benefit in patients undergoing surgery for Dukes Stage C carcinoma Results seem to justify trials in this patient category to reveal a benefit of H2 receptor antagonists in adjuvant therapy of colorectal carcinoma\",\n",
            "}\n",
            "13963\n",
            "{\n",
            "  \"id\" : \"24778393\",\n",
            "  \"contents\" : \"Fatigue is a distressing symptom occurring in more than 60 % of patients with cancer The CNS stimulants modafinil and methylphenidate are recommended for the treatment of cancer-related fatigue despite a limited evidence base We aimed to evaluate the efficacy and tolerability of modafinil in the management of fatigue in patients with non-small-cell lung cancer NSCLC Adults with advanced NSCLC and performance status of 0 to 2 who were not treated with chemotherapy or radiotherapy within the last 4 weeks were randomly assigned to daily modafinil 100 mg on days 1 to 14 200 mg on days 15 to 28 or matched placebo The primary outcome was change in Functional Assessment of Chronic Illness Therapy FACIT - Fatigue score from baseline to 28 days adjusted for baseline fatigue and performance status Secondary outcomes included safety and patient-reported measures of depression daytime sleepiness and quality of life A total of 208 patients were randomly assigned and 160 patients modafinil n = 75 placebo n = 85 completed questionnaires at both baseline and day 28 and were included in the modified intention-to-treat analysis FACIT-Fatigue scores improved from baseline to day 28 mean score change modafinil 529 95 % CI 257 to 802 placebo 509 95 % CI 254 to 765 but there was no difference between treatments 020 95 % CI -356 to 397 There was also no difference between treatments for the secondary outcomes 47 % of the modafinil group and 23 % of the placebo group stated that the intervention was not helpful Modafinil had no effect on cancer-related fatigue and should not be prescribed outside a clinical trial setting Its use was associated with a clinically significant placebo effect\",\n",
            "}\n",
            "13964\n",
            "{\n",
            "  \"id\" : \"7680947\",\n",
            "  \"contents\" : \"Effective palliation of malignant ascites remains a difficult management problem Eighty-five patients with malignant ascites were studied Forty-two patients had peritoneovenous shunts PVS inserted 16 LeVeen 17 single-valve Denver 9 double-valve Denver Shunt patency was not related to the type of shunt type of cancer or any characteristic of the ascitic fluid Ascites was controlled in 64 % of patients with shunts and serum albumin levels were preserved Survival and quality of life were not significantly different in comparison with those of patients treated by abdominal paracentesis PVS allowed many patients to be treated successfully outside the hospital and are indicated in carefully selected cases\",\n",
            "}\n",
            "13965\n",
            "{\n",
            "  \"id\" : \"10204971\",\n",
            "  \"contents\" : \"Previous research has indicated low rates of adherence to monthly breast self-examination BSE in women with a family history of breast cancer and anxiety has been identified as a major factor that may interfere with regular self-examination However the direction of the relationship between anxiety and BSE frequency remains unclear with some studies indicating that high anxiety promotes adherence and others indicating that it leads to avoidance The aim of the present study was to clarify the relationship between anxiety and adherence to breast self-examination by comparing the impact of general anxiety with that of cancer-specific anxiety on BSE frequency A sample of at-risk women N = 833 completed a questionnaire regarding BSE frequency general anxiety breast cancer worries perceived risk of breast cancer and family history of breast cancer Women who self-examined infrequently N = 211 appropriately N = 462 or excessively N = 156 were compared on these variables Statistical analyses indicated that general anxiety differentiated only between excessive self-examiners and less frequent self-examiners with excessive self-examiners reporting significantly higher general anxiety Breast cancer worries differentiated between all three groups in a linear fashion with increasing cancer worries associated with higher levels of BSE In some at-risk women high cancer anxiety may lead to high general anxiety and precipitate hypervigilant breast self-examination rather than avoidance These findings are discussed in relation to psychoeducational interventions and genetic counseling services for women with a family history of breast cancer\",\n",
            "}\n",
            "13966\n",
            "{\n",
            "  \"id\" : \"8040676\",\n",
            "  \"contents\" : \"We studied all salvage therapies given until death or the end of follow-up evaluation in women who failed to respond to the same first-line cytotoxic therapy for metastatic breast cancer The study cohort consisted of 140 women who had received the fluorouracil epirubicin and cyclophosphamide FEC regimen for metastatic breast cancer Eight patients were excluded No exclusions with respect to disease site performance status or biochemical abnormalities were made The median follow-up time was 29 months for surviving patients Most patients 88 % died during the follow-up period Patients received a median of three salvage therapies range zero to eight during the course of disease Most courses 52 % were not assessable for response Fifty-percent of courses consisted of chemotherapy 35 % of hormonal and 15 % of combination of cytotoxic and hormonal therapies The median duration of therapy DT ranged from 4 to 1 months and decreased with advancing stages of therapy Similarly median time to treatment failure TTF ranged from 3 to 05 months For unknown causes patients who received second-line hormonal therapy fared better than those who received other forms of therapy Of 366 analyzed courses only one complete response CR and 18 partial responses PRs were observed response rate 11 % for assessable and 5 % for all courses Stable disease for at least 3 months was found in 20 % to 25 % of courses Most responses n = 10 occurred during first salvage therapy and no responses were observed after third salvage therapy Response rates for salvage therapies were low and median treatment times short The value of offering more than two salvage chemotherapy regimens to an unselected group of patients is questionable\",\n",
            "}\n",
            "13967\n",
            "{\n",
            "  \"id\" : \"21330082\",\n",
            "  \"contents\" : \"This study compares proton magnetic resonancespectroscopic imaging 1H-MRSI and dynamic contrast-enhanced magnetic resonance imaging DCE-MRI combined techniques at 3T magnet versus [ 18 F ] choline PET/computed tomography CT in the detection of local prostate cancer recurrence in patients with biochemical progression after radical retropubic prostatectomy RRP 84 consecutive patients at high risk of local recurrence underwent combined 1HMRSI-DCEMR and 18-Fcholine - PET/CT MR scan protocol included turbo spin echo TSE T2-weighted sequences in the axial sagittal and coronal planes three-dimensional 3D chemical shift imaging CSI sequences with spectral/spatial pulses optimized for quantitative detection of choline and citrate dynamic contrast enhanced gradient-echo GRE T1-weighted sequence The population was divided into two groups Group A included 28 patients with a lesion size ranging between 500 mm and 72 mm and PSA reduction following radiation therapy Group B included 56 patients with a lesion size between 76 mm and 194 mm Sensitivity specificity positive predictive value PPV and accuracy were evaluated and receiver operating characteristic ROC curves were performed In Group A combined 1H-MRSI and DCE-MRI showed a sensitivity of 92 % a specificity of 75 % PPV 96 % while PET-CT examination showed a sensitivity of 62 % and a specificity of 50 % PPV 88 % in identifying local recurrence The accuracy of MRI was 89 % while PET-CT showed an accuracy of 60 % Areas under the ROC curve AUC values for MR and PET-CT were 0833 and 0562 respectively In Group B combined 1H-MRSI and DCEMR showed a sensitivity of 94 % and a specificity of 100 % PPV 100 % with accuracy of 94 % PET-CT had a sensitivity of 92 % and a specificity of 33 % PPV 98 % with accuracy of 91 % The AUCs for MR and PET-CT values were 0971 and 0837 respectively The diagnostic accuracy of combined 1HMRSI-DCEMR was higher than PET/CT to identify local prostate cancer recurrence mostly in patients with low biochemical progression after RRP 02-2ng / mL\",\n",
            "}\n",
            "13968\n",
            "{\n",
            "  \"id\" : \"12963704\",\n",
            "  \"contents\" : \"This trial was conducted to determine whether high-dose fluorouracil FU given as a weekly 24-hour infusion is more active than bolus FU + leucovorin LV and whether high-dose infusional FU can be modulated by LV A total of 497 patients with previously untreated metastatic colorectal cancer were randomly assigned to receive bolus FU 425 mg/m2 intravenously + LV 20 mg/m2 on days 1 to 5 and repeated on day 28 FU + LV or FU 2600 mg/m2 as a 24-hour infusion alone FU24h or in combination with 500 mg/m2 LV FU24h + LV - all given weekly x6 followed by a 2-week rest period Survival was the major study end point With a median follow-up of more than 3 years survival did not differ among the treatment groups median FU + LV 111 months [ 95 % CI 102 to 150 months ] FU24h 130 months [ 95 % CI 104 to 154 months ] FU24h + LV 137 months [ 95 % CI 120 to 164 months ] P = 724 Progression-free survival PFS was significantly longer for FU24h + LV median FU + LV 40 months [ 95 % CI 34 to 49 ] FU24h 41 months [ 95 % CI 34 to 50 ] FU24h + LV 56 months [ 95 % CI 44 to 67 ] P = 029 The response rates in the subgroup of patients with measurable disease were 12 % 10 % and 17 % for FU + LV FU24h and FU24h + LV respectively not significant Occurrence of grade 3 and 4 diarrhea was higher in the FU24h + LV arm 22 % compared with the FU24h 6 % or FU + LV 9 % arms however stomatitis 11 % in FU + LV v 3 % in FU24h v 5 % in FU24h + LV arms and hematologic toxicity were higher in the bolus FU + LV arm Global quality of life did not differ within the three arms Neither FU24h + LV nor FU24h prolong survival relative to bolus FU + LV Leucovorin increases PFS if added to FU24h but increases toxicity\",\n",
            "}\n",
            "13969\n",
            "{\n",
            "  \"id\" : \"9234029\",\n",
            "  \"contents\" : \"To examine lipid parameters that are affected in women with insulin-dependent diabetes mellitus IDDM who engaged in disordered eating behaviours Randomized unmatched Tertiary care Ninety women 18-46 y with IDDM Classification of subjects based on severity of eating disorder clinical n = 14 subclinical n = 13 and control n = 63 Blood was analysed for glycosylated haemoglobin HbA1c and serum for triglycerides and cholesterol Carotenoid and tocopherol concentrations were analysed by high performance liquid chromatography HPLC Dietary intake was assessed by the National Cancer Institute food frequency questionnaire HbA1c was significantly increased im women demonstrating clinical and subclinical symptoms compared to control 104 + / - 26 100 + / - 15 and 83 + / - 16 % respectively P < 005 Triglycerides concentrations were significantly increased in women with subclinical eating disorders compared to controls In women who intentionally omitted or reduced insulin triglyceride cholesterol and HbA1c were significantly increased compared to controls Women with IDDM and eating disorders who exhibited bulimic behaviours consumed significantly more energy total fat and cholesterol compared to controls and women with eating disorders who were restrained eaters While IDDM is known to perturb lipid metabolism these data demonstrate that eating disorders in combination with IDDM results in additional alterations in lipid metabolism\",\n",
            "}\n",
            "13970\n",
            "{\n",
            "  \"id\" : \"1739355\",\n",
            "  \"contents\" : \"Neutropenic patients with cancer are traditionally treated with empiric antibiotic combinations when they become febrile The availability of broad-spectrum antibiotics such as ceftazidime and imipenem has made it possible to initiate therapy with a single agent monotherapy The objectives of this trial were to compare ceftazidime and imipenem as single agents for the therapy of febrile episodes in neutropenic patients and to ascertain whether the addition of an aminoglycoside amikacin to either of these agents would provide an advantage A prospective clinical trial was conducted in which eligible neutropenic patients with cancer were randomized to one of four treatment arms ceftazidime alone imipenem alone ceftazidime plus amikacin and imipenem plus amikacin Efficacy analysis was done for 750 assessable episodes A multivariate logistic-regression analysis was also performed to examine the unique contribution of various prognostic factors The overall response rates were 76 % with imipenem plus amikacin 72 % with imipenem 71 % with ceftazidime plus amikacin and 59 % with ceftazidime alone Single-organism gram-positive infections occurred in 101 of 750 episodes Without a change in antibiotics the response rates were 50 % with imipenem 40 % with imipenem plus amikacin 39 % with ceftazidime plus amikacin and 38 % with ceftazidime Most responded to vancomycin or other antibiotics and the mortality associated with gram-positive infections was only 5 % Regardless of the antibiotic regimen the majority of uncomplicated gram-negative infections responded to therapy and the majority of complicated gram-negative infections failed to respond Multivariate logistic-regression analysis showed that recovery of the neutrophil count was the most favorable prognostic factor in a patient s response to infection whereas the presence of gram-positive infection acute leukemia pulmonary or enteric infection and therapy with ceftazidime were unfavorable factors Single-agent therapy with imipenem is as effective as more conventional combination antibiotic therapy for the empirical treatment of febrile episodes in neutropenic patients with cancer\",\n",
            "}\n",
            "13971\n",
            "{\n",
            "  \"id\" : \"25556490\",\n",
            "  \"contents\" : \"To observe treatment effects and safety of fluvoxamine combined with oxycodone prolonged-release tablets in treating patients with moderate to severe cancer pain Patients confirmed pathologically with cancer and complicated with moderate to severe pain were divided into control and experimental groups Oxycodone prolonged-release tablets with or without fluvoxamine were administrated to all study patients until pain relief Degree of pain relief dose of oxycodone prolonged-release tablets side effects and quality of life were compared before and after treatment In total 120 patients were recruited No statistically significant difference was detected regarding age gender types of cancer KPS between two groups of patients P > 005 Baseline pain score of patients with moderate pain in treatment and control group was 4908 and 5108 respectively and decreased to 1811 and 1211 after treatment respectively Pain intensity was significantly reduced in the treatment group P = 0028 Average daily consumption of oxycodone prolonged - release tablets was 540196 mg and 447 187 mg respectively which is lower in treatment grpup than in control group but the difference was not statistically significant P = 0065 Baseline pain score of patients with severe pain in treatment and control groups were 8311 and 8311 respectively and pain intensity after treatment decreased to 2910 and 2310 Pain intensity was significantly reduced in the treatment group with statistical significance P = 0026 Average daily consumption of oxycodone prolonged-release tablets was 1320422 mg and 1107339 mg respectively which is lower in treatment group than in control group and the difference was statistically significant P = 0035 In terms of quality of life patients in treatment group had better performance status daily activity mood and sleep than that in control group P < 005 Patients in two groups had similar side effects eg constipation nausea/vomiting lethargy dizziness itchy skin dysuria and ataxia Lower incidence of nausea/vomiting lethargy was obtained from patients in treatment than in control group while significant low constipation was observed in treatment than in control group 350 % vs 492 % P = 0026 Fluvoxamine combined with oxycodone prolonged-release tablets could be more effective in treating patients with cancer pain and could reduce the dosage of oxycodone prolonged-release tablets and thus be associated with lower side effects and improved quality of life\",\n",
            "}\n",
            "13972\n",
            "{\n",
            "  \"id\" : \"17548243\",\n",
            "  \"contents\" : \"Depression anxiety fatigue and impaired wellbeing are common important and closely related in advanced cancer We aimed to identify the effects of an established antidepressant on these symptoms and survival in patients with advanced cancer who did not have major depression as assessed by clinicians Between July 2001 and February 2006 189 patients with advanced cancer were randomly assigned sertraline 50 mg n = 95 or placebo n = 94 once per day The primary outcome was depression as assessed by the Centre for Epidemiologic Studies Depression scale CES-D the main secondary outcomes were anxiety as assessed by Hospital Anxiety and Depression Scales HADS-A overall quality of life and fatigue as assessed by Functional Assessment of Cancer Therapy General and Fatigue scales FACT-G and FACT-F respectively and clinicians ratings of quality of life by use of Spizter s Quality of Life Index SQLI Multiple measures were used for corroboration of the most important outcomes Primary analyses were done by intention to treat and were based on scale scores at 4 weeks and 8 weeks The benefits of sertraline compared with placebo are expressed on a range from +100 ie maximum benefit to -100 ie maximum harm a difference of 10 was deemed clinically significant This clinical trial is registered at Current Controlled Trials website http//wwwcontrolled-trialscom/ISRCTN72466475 Sertraline had no significant effect scale benefit over placebo [ 95 % CI ] on depression CES-D 04 [ -26 to 34 ] anxiety HADS-A 20 [ -15 to 55 ] fatigue FACT-F 03 [ -43 to 49 ] overall quality of life FACT-G 17 [ -13 to 47 ] or clinicians ratings SQLI 20 [ -25 to 65 ] and the 95 % CI ruled out a clinically significant benefit for all main outcomes Sertraline was discontinued more often and earlier than was placebo hazard ratio 146 [ 103-2 06 ] p = 003 Recruitment was stopped after the first planned interim analysis in February 2006 n = 150 showed that survival was longer in patients assigned placebo than in patients assigned sertraline unadjusted hazard ratio 160 [ 95 % CI 104-2 45 ] log-rank p = 004 adjusted hazard ratio 162 [ 106-2 41 ] Cox model p = 002 However at the final analysis in July 2006 of all patients n = 189 and with longer follow-up survival did not differ significantly between the treatment groups unadjusted hazard ratio 135 [ 095-1 91 ] log-rank p = 009 adjusted hazard ratio 127 [ 087-1 84 ] Cox model p = 020 The trial was closed because it had ruled out a significant benefit of sertraline Sertraline did not improve symptoms wellbeing or survival in patients with advanced cancer who do not have major depression and should be reserved for those with a proven indication\",\n",
            "}\n",
            "13973\n",
            "{\n",
            "  \"id\" : \"10561339\",\n",
            "  \"contents\" : \"This is the initial report from the health-related quality of life HRQL component of the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial This report provides an overview of HRQL findings comparing tamoxifen and placebo groups and advice to clinicians counseling women about the use of tamoxifen in a prevention setting This report covers the baseline and the first 36 months of follow-up data on 11064 women recruited over the first 24 months of the study Findings are presented from the Center for Epidemiological Studies-Depression Scale CES-D the Medical Outcomes Study 36-Item Short Form Health Status Survey MOS SF-36 and sexual functioning scale and a symptom checklist No differences were found between placebo and tamoxifen groups for the proportion of participants scoring above a clinically significant level on the CES-D No differences were found between groups for the MOS SF-36 summary physical and mental scores The mean number of symptoms reported was consistently higher in the tamoxifen group and was associated with vasomotor and gynecologic symptoms Significant increases were found in the proportion of women on tamoxifen reporting problems of sexual functioning at a definite or serious level although overall rates of sexual activity remained similar Women need to be informed of the increased frequency of vasomotor and gynecologic symptoms and problems of sexual functioning associated with tamoxifen use Weight gain and depression two clinical problems anecdotally associated with tamoxifen treatment were not increased in frequency in this trial in healthy women which is good news that also needs to be communicated\",\n",
            "}\n",
            "13974\n",
            "{\n",
            "  \"id\" : \"23686379\",\n",
            "  \"contents\" : \"Mucosal damage is an important and debilitating side effect when treating head and neck cancer patients with chemo - radiation The aim of this randomized clinical trial was to investigate whether the addition of a neutral supersaturated calcium phosphate CP mouth rinse benefits the severity and duration of acute mucositis in head and neck cancer patients treated with chemo radiation A total of 60 patients with malignant neoplasms of the head and neck receiving chemo radiation were included in this study Fifty-eight patients were randomized into two treatment arms a control group receiving standard of care n = 31 and a study group receiving standard of care + daily CP mouth rinses n = 27 starting on the first day of chemo - radiation Oral mucositis and dysphagia were assessed twice a week using the National Cancer Institute common toxicity criteria scale version 3 oral pain was scored with a visual analogue scale No significant difference in grade III mucositis 59 vs 71 % p = 025 and dysphagia 33 vs 42 % p = 039 was observed between the study group compared to the control group Also no significant difference in time until development of peak mucositis 286 vs 287 days p = 048 duration of peak mucositis 227 vs 246 days p = 031 recuperation of peak dysphagia 205 vs 242 days p = 013 and occurrence of severe pain 56 vs 52 % p = 05 In this randomized study the addition of CP mouth rinse to standard of care did not improve the frequency duration or severity of the most common acute toxicities during and early after chemo radiation There is currently no evidence supporting its standard use in daily practice\",\n",
            "}\n",
            "13975\n",
            "{\n",
            "  \"id\" : \"14722144\",\n",
            "  \"contents\" : \"Although chronic Helicobacter pylori infection is associated with gastric cancer the effect of H pylori treatment on prevention of gastric cancer development in chronic carriers is unknown To determine whether treatment of H pylori infection reduces the incidence of gastric cancer Prospective randomized placebo-controlled population-based primary prevention study of 1630 healthy carriers of H pylori infection from Fujian Province China recruited in July 1994 and followed up until January 2002 A total of 988 participants did not have precancerous lesions gastric atrophy intestinal metaplasia or gastric dysplasia on study entry Patients were randomly assigned to receive H pylori eradication treatment a 2-week course of omeprazole 20 mg a combination product of amoxicillin and clavulanate potassium 750 mg and metronidazole 400 mg all twice daily n = 817 or placebo n = 813 The primary outcome measure was incidence of gastric cancer during follow-up compared between H pylori eradication and placebo groups The secondary outcome measure was incidence of gastric cancer in patients with or without precancerous lesions compared between the 2 groups Among the 18 new cases of gastric cancers that developed no overall reduction was observed in participants who received H pylori eradication treatment n = 7 compared with those who did not n = 11 P = 33 In a subgroup of patients with no precancerous lesions on presentation no patient developed gastric cancer during a follow-up of 75 years after H pylori eradication treatment compared with those who received placebo 0 vs 6 P = 02 Smoking hazard ratio [ HR ] 62 95 % confidence interval [ CI ] 23-16 5 P < 001 and older age HR 110 95 % CI 105-1 15 P < 001 were independent risk factors for the development of gastric cancer in this cohort We found that the incidence of gastric cancer development at the population level was similar between participants receiving H pylori eradication treatment and those receiving placebo during a period of 75 years in a high-risk region of China In the subgroup of H pylori carriers without precancerous lesions eradication of H pylori significantly decreased the development of gastric cancer Further studies to investigate the role of H pylori eradication in participants with precancerous lesions are warranted\",\n",
            "}\n",
            "13976\n",
            "{\n",
            "  \"id\" : \"17459064\",\n",
            "  \"contents\" : \"This study aimed to assess the utility of a standardised risk information tool with respect to the uptake of screening activities administered to an accessible population of first-degree relatives of patients with sporadic colorectal cancer Patients admitted for colorectal cancer resection were invited to enroll their family unit in the study Families were randomised either to receive standard care or the intervention tool The intervention group received a structured one page pamphlet outlining the risk associated with a family history of colorectal cancer and the availability of and potential benefits from screening Three months after the initial contact with the index patient family members were invited to participate in a telephone interview Primary end-points were both intention to screen and uptake of screening activities Forty-seven families had 156 eligible first degree relatives Ninety-one consented to participate and were enrolled 59 received standard care 32 received the intervention Age and sex were similar between groups There was no significant difference in previous screening activities The intervention tool had no influence on perceived self-risk of developing colorectal cancer or uptake of screening activities within the study period This study suggests that the provision of targeted risk information to first-degree relatives is not likely to positively influence screening behaviour Health care providers need to find alternative methods of disseminating information to this high-risk group\",\n",
            "}\n",
            "13977\n",
            "{\n",
            "  \"id\" : \"21558406\",\n",
            "  \"contents\" : \"Sipuleucel-T an autologous cellular immunotherapy was investigated in a randomized double-blind controlled trial to determine its biologic activity in androgen-dependent prostate cancer ADPC Patients with prostate cancer detectable by serum prostate-specific antigen PSA following radical prostatectomy received 3 to 4 months of androgen suppression therapy and were then randomized 21 to receive sipuleucel-T n = 117 or control n = 59 The primary endpoint was time to biochemical failure BF defined as serum PSA 30 ng/mL PSA doubling time PSADT time to distant failure immune response and safety were also evaluated Median time to BF was 180 months for sipuleucel-T and 154 months for control HR = 0936 P = 0737 Sipuleucel-T patients had a 48 % increase in PSADT following testosterone recovery 155 vs 105 days P = 0038 With only 16 % of patients having developed distant failure the treatment effect favored sipuleucel-T HR = 0728 P = 0421 The most frequent adverse events in sipuleucel-T patients were fatigue chills and pyrexia Immune responses to the immunizing antigen were greater in sipuleucel-T patients at Weeks 4 and 13 P < 0001 all and were sustained prior to boosting as measured in a subset of patients a median of 226 months range 143-67 3 months following randomization No significant difference in time to BF could be shown The finding of increased PSADT in the sipuleucel-T arm is consistent with its biologic activity in ADPC Long-term follow-up will be necessary to determine if clinically important events such as distant failure are affected by therapy Treatment was generally well tolerated\",\n",
            "}\n",
            "13978\n",
            "{\n",
            "  \"id\" : \"17922560\",\n",
            "  \"contents\" : \"Tegafur is an oral fluorouracil prodrug used in the treatment of colorectal cancer The aim of this phase II crossover bioequivalence study was to compare the pharmacokinetics primary objective and tolerability secondary objective of tegafur-uracil UFT given as three daily doses tid reference schedule with those obtained using a more convenient schedule of two daily doses bid new schedule Twenty-one patients with metastatic colorectal cancer median age 63 years received the same oral daily dose of UFT 300 mg/m 2 / day plus leucovorin 90 mg/day divided into two or three daily doses Patients were randomised to receive the first cycle either tid 12 patients or bid 9 patients The eligibility criteria included an Eastern Co-operative Oncology Group performance status of < or = 1 and adequate bone-marrow hepatic and renal function The pharmacokinetics of uracil fluorouracil and tegafur high-performance liquid chromatography assays were evaluated at steady state over 24 hours area under the plasma concentration-time curve from 0 to 24 hours [ AUC 24 ] minimum plasma concentration [ C min ] and maximum plasma concentration [ C max ] The pharmacokinetic parameters were analysed after logarithmic transformation according to a general linear model The AUC 24 values of fluorouracil p < 00001 uracil p < 00001 and tegafur p = 0058 were greater with the bid schedule than the tid schedule The bid tid AUC 24 ratio 90 % CI was 18 155 210 with fluorouracil 20 159 257 with uracil and 12 102 136 with tegafur indicating that the bid and tid schedules were not bioequivalent No major toxicity grade 4 was reported and grade 3 adverse events accounted for 9 % of the total adverse events Intra-patient comparison of the maximum toxicity grade did not demonstrate a significant difference between the bid and tid schedules p = 018 A 2-fold increase in the fluorouracil and uracil AUC values was observed with UFT administered bid compared with tid without a significant impact on tolerability suggesting that the more convenient bid schedule may improve the UFT therapeutic index\",\n",
            "}\n",
            "13979\n",
            "{\n",
            "  \"id\" : \"10615075\",\n",
            "  \"contents\" : \"Two years after undergoing resection of liver metastases from colorectal cancer about 65 percent of patients are alive and 25 percent are free of detectable disease We tried to improve these outcomes by treating patients with hepatic arterial infusion of floxuridine plus systemic fluorouracil after liver resection We randomly assigned 156 patients at the time of resection of hepatic metastases from colorectal cancer to receive six cycles of hepatic arterial infusion with floxuridine and dexamethasone plus intravenous fluorouracil with or without leucovorin or six weeks of similar systemic therapy alone Patients were stratified according to previous treatment and the number of liver metastases identified at operation The study end points were overall survival survival without recurrence of hepatic metastases and survival without any metastases at two years The actuarial rate of overall survival at two years was 86 percent in the group treated with local plus systemic chemotherapy and 72 percent in the group given systemic therapy alone P = 003 The median survival was 722 months in the combined-therapy group and 593 months in the monotherapy group with a median follow-up of 627 months After two years the rates of survival free of hepatic recurrence were 90 percent in the monotherapy group and 60 percent in the monotherapy group P < 0001 and the respective rates of progression-free survival were 57 percent and 42 percent P = 007 At two years the risk ratio for death was 234 among patients treated with systemic therapy alone as compared with patients who received combined therapy 95 percent confidence interval 110 to 498 P = 0027 after adjustment for important variables The rates of adverse effects of at least moderate severity were similar in the two groups except for a higher frequency of diarrhea and hepatic effects in the combined-therapy group For patients who undergo resection of liver metastases from colorectal cancer postoperative treatment with a combination of hepatic arterial infusion of floxuridine and intravenous fluorouracil improves the outcome at two years\",\n",
            "}\n",
            "13980\n",
            "{\n",
            "  \"id\" : \"23182660\",\n",
            "  \"contents\" : \"This randomized open-label study compared pemetrexed versus docetaxel as second-line therapy for Chinese patients with locally advanced or metastatic non-small cell lung cancer NSCLC The primary endpoint tested non-inferiority of overall survival OS on the combined data from these patients and those in the global registration trial Data from patients in the current study only Chinese patients were the basis for the study s secondary objectives Patients with stage IIIB/IV disease were randomized 11 to receive pemetrexed 500 mg/m 2 107 randomized 106 treated or docetaxel 75 mg/m 2 104 randomized 102 treated on Day 1 of each 21-day cycle Treatment continued until progressive disease unacceptable toxicity or patient/investigator decision All efficacy and safety data were analyzed at the pre-specified study completion supplementary OS analyses were performed later after additional events had been recorded The primary endpoint of OS noninferiority of pemetrexed to docetaxel was not met the lower CL was < 50 % and P > 0025 efficacy retained = 979 % [ 95 % CLs 471 1419 ] P = 00276 in the combined population pemetrexed n = 390 docetaxel n = 392 Supplementary values were 1013 % 95 % CLs 579 1488 P = 00186 For the secondary objectives assessed in the population from the current study pemetrexed n = 107 docetaxel n = 104 median OS was 117 and 122 months for the pemetrexed and docetaxel arms respectively HR [ 95 % CLs ] 114 [ 078 168 ] P = 0492 Supplementary values were 114 and 115 months respectively HR [ 95 % CLs ] 102 [ 074 140 ] P = 0926 Median PFS values were 28 and 31 months HR [ 95 % CLs ] 105 [ 075 146 ] P = 0770 and ORR values were 96 % and 41 % odds ratio [ 95 % CLs ] 250 [ 076 825 ] P = 0133 for pemetrexed and docetaxel respectively Pemetrexed-treated patients had significantly fewer drug-related grade 3-4 adverse events pemetrexed 208 % docetaxel 402 % P = 0003 Few drug-related serious adverse events were reported pemetrexed 5 patients docetaxel 8 patients The comparable efficacy and superior tolerability of pemetrexed compared with docetaxel in this study supports the use of single-agent second-line pemetrexed for advanced non-squamous NSCLC in Chinese patients ClinicalTrialsgov NCT00391274\",\n",
            "}\n",
            "13981\n",
            "{\n",
            "  \"id\" : \"25439691\",\n",
            "  \"contents\" : \"Dacomitinib is an irreversible pan-EGFR family tyrosine kinase inhibitor Findings from a phase 2 study in non-small cell lung cancer showed favourable efficacy for dacomitinib compared with erlotinib We aimed to compare dacomitinib with erlotinib in a phase 3 study In a randomised multicentre double-blind phase 3 trial in 134 centres in 23 countries we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer progression after one or two previous regimens of chemotherapy Eastern Cooperative Oncology Group ECOG performance status of 0-2 and presence of measurable disease We randomly assigned patients in a 11 ratio to dacomitinib 45 mg/day or erlotinib 150 mg/day with matching placebo Treatment allocation was masked to the investigator patient and study funder Randomisation was stratified by histology adenocarcinoma vs non-adenocarcinoma ethnic origin Asian vs non-Asian and Indian sub-continent performance status 0-1 vs 2 and smoking status never-smoker vs ever-smoker The coprimary endpoints were progression-free survival per independent review for all randomly assigned patients and for all randomly assigned patients with KRAS wild-type tumours The study has completed accrual and is registered with ClinicalTrialsgov number NCT01360554 Between June 22 2011 and March 12 2013 we enrolled 878 patients and randomly assigned 439 to dacomitinib 256 KRAS wild type and 439 263 KRAS wild type to erlotinib Median progression-free survival was 26 months 95 % CI 19-28 in both the dacomitinib group and the erlotinib group stratified hazard ratio [ HR ] 0941 95 % CI 0802-1104 one-sided log-rank p = 0229 For patients with wild-type KRAS median progression-free survival was 26 months for dacomitinib 95 % CI 19-29 and erlotinib 95 % CI 19-30 stratified HR 1022 95 % CI 0834-1253 one-sided p = 0587 In patients who received at least one dose of study drug the most frequent grade 3-4 adverse events were diarrhoea 47 [ 11 % ] patients in the dacomitinib group vs ten [ 2 % ] patients in the erlotinib group rash 29 [ 7 % ] vs 12 [ 3 % ] and stomatitis 15 [ 3 % ] vs two [ < 1 % ] Serious adverse events were reported in 52 12 % patients receiving dacomitinib and 40 9 % patients receiving erlotinib Irreversible EGFR inhibition with dacomitinib was not superior to erlotinib in an unselected patient population with advanced non-small-cell lung cancer or in patients with KRAS wild-type tumours Further study of irreversible EGFR inhibitors should be restricted to patients with activating EGFR mutations Pfizer\",\n",
            "}\n",
            "13982\n",
            "{\n",
            "  \"id\" : \"20931294\",\n",
            "  \"contents\" : \"Lower mammography screening rates among minority and low income women contribute to increased morbidity and mortality from breast cancer To evaluate the effect of a patient navigation intervention on adherence rates to biennial screening mammography among women engaged in primary care at an inner-city academic medical center Quality improvement intervention with a concurrent control group conducted from February to November of 2008 All women in a hospital-based primary care practice aged 51-70 years Subjects were randomized at the level of their primary care provider such that half of the patients in the practice received the intervention while the other half received usual care Intervention subjects whose last mammogram was > 18 months prior received a combination of telephone calls and reminder letters from patient navigators trained to identify barriers to care Navigators were integrated into primary care teams and interacted directly with patients providers and radiology to coordinate care Navigators utilized an electronic report to track subjects Adherence rates to biennial mammography were assessed in intervention and control groups at baseline and post-intervention A total of 3895 women were randomized to intervention n = 1817 and control n = 2078 groups Mean age was 60 71 % were racial/ethnic minorities 23 % were non-English speaking and 63 % had public or no health insurance At baseline there was no difference in mammography adherence between the control and intervention groups 78 % respectively p = 055 After the 9-month intervention mammogram adherence was higher in the intervention group compared with the control group 87 % vs 76 % respectively p < 0001 Except among Hispanic women who demonstrated high rates in both the intervention and control groups 85 % and 83 % respectively all racial/ethnic and insurance groups demonstrated higher adherence in the intervention group Patient navigation improves biennial mammography rates for inner city low income minority populations\",\n",
            "}\n",
            "13983\n",
            "{\n",
            "  \"id\" : \"24884563\",\n",
            "  \"contents\" : \"Insight in the natural course of care dependency of vulnerable older persons in long-term care facilities LTCF is essential to organize and optimize individual tailored care We examined changes in care dependency in LTCF residents over two 6-month periods explored the possible predictive factors of change and the effect of care dependency on mortality A prospective follow-up study in 21 Dutch long-term care facilities 890 LTCF residents median age 84 Interquartile range 79-88 years participated At baseline 6 and 12 months care dependency was assessed by the nursing staff with the Care Dependency Scale CDS range 15-75 points Since the median CDS score differed between men and women 475 vs 430 P = 0013 CDS groups low middle and high were based on gender-specific 33 % of CDS scores at baseline and 6 months At baseline the CDS groups differed in median length of stay on the ward urine incontinence and dementia all P < 0001 participants in the low CDS group stayed longer had more frequent urine incontinence and more dementia They had also the highest mortality rate log rank 322 df = 2 P for trend < 0001 Per point lower in CDS score the mortality risk increased with 2 % 95 % CI 1 % -3 % Adjustment for age gender cranberry use LTCF length of stay comorbidity and dementia showed similar results A one point decrease in CDS score between 0 and 6 months was related to an increased mortality risk of 4 % 95 % CI 3 % -6 % At the 6-month follow-up 10 % improved to a higher CDS group 65 % were in the same and 25 % had deteriorated to a lower CDS group a similar pattern emerged at 12-month follow-up Gender age urine incontinence dementia cancer and baseline care dependency status predicted an increase in care dependency over time The majority of residents were stable in their care dependency status over two subsequent 6-month periods Highly care dependent residents showed an increased mortality risk Awareness of the natural course of care dependency is essential to residents and their formal and informal caregivers when considering therapeutic and end-of-life care options\",\n",
            "}\n",
            "13984\n",
            "{\n",
            "  \"id\" : \"8466067\",\n",
            "  \"contents\" : \"Different types of analgesia have been proposed for the prevention of postoperative respiratory complications The aim of this prospective double-blind randomized study was to compare the impact of epidural bupivacaine and opioids versus parenteral opioids on respiratory complications in patients who had undergone major abdominal surgery One hundred fifty-three patients undergoing abdominal surgery for cancer were randomly allocated to receive either general anesthesia with intravenous fentanyl and postoperative analgesia with subcutaneous morphine SC group or general anesthesia combined with epidural bupivacaine and epidural bupivacaine plus morphine for postoperative pain relief EP group Analgesia was tested on a visual analog pain scale Pulmonary complications were evaluated according to clinical complications chest radiographs arterial blood gas analysis and pulmonary function tests The evaluation was carried out on the day before the operation and on the first 5 postoperative days Particular attention also was paid to the episodes of arterial hypotension and hemoglobin oxygen desaturation during the 1st postoperative night Pain relief was significantly better in the EP group than in the SC group P < 005 especially during recovery and on the 1st and 2nd postoperative days In the EP group vital capacity decreased less on the 1st postoperative day P < 005 and arterial oxygen tension was greater in the recovery room P < 005 However no statistically significant difference was observed between the SC and EP groups in the incidence of clinical pulmonary complications 31 % and 27 % respectively and radiographic chest abnormalities 52 % and 46 % respectively The EP group recovered intestinal function earlier P < 005 but significantly more patients in this group had episodes of systolic hypotension 21 % vs 8 % P < 005 during the 1st postoperative night The length of the hospital stay was similar in both groups of treatment Epidural analgesia with a combination of local anesthetic and opioid improves patient comfort However this type of analgesia does not decrease the incidence of postoperative pulmonary complications does not reduce the length of the hospital stay and carries the risk of complications from episodic systemic hypotension\",\n",
            "}\n",
            "13985\n",
            "{\n",
            "  \"id\" : \"23107971\",\n",
            "  \"contents\" : \"Gemcitabine in low-dose prolonged infusion is a treatment with documented activity against a variety of tumors The present study was conducted to evaluate the efficacy and safety of the combination of gemcitabine at a low-dose prolonged infusion in comparison with standard dose gemcitabine with carboplatin in chemonaive patients with advanced non-small cell lung cancer NSCLC Sixty chemonaive patients with stage IIIB or IV NSCLC were included Patients were randomly assigned 11 to receive 350 mg/m 2 gemcitabine in a 6-h infusion on days 1 and 8 and carboplatin area under the serum concentration time curve AUC 5 on day 1 versus gemcitabine 1000 mg/m 2 on days 1 and 8 and carboplatin AUC 5 on day 1 3-week cycle both A total of 118 chemotherapy cycles with a median of 4 cycles per patient range 2-6 and 134 chemotherapy cycles with a median of 447 cycles per patient range 3-6 were administered in standard and low infusional dose arm respectively Among patients in the standard arm 40 % had overall response rate ORR 333 % had stable disease and 266 % had progressive disease while in low-dose infusional arm 366 % had ORR 363 % had stable disease and 266 % had progressive disease P = 0992 Median progression-free survival was 55 months and 54 months median overall survival was 97 months and 107 months and 1-year survival was 337 % and 366 % in standard arm and low-dose infusion arm respectively Grade 3/4 toxicity was rare In NSCLC gemcitabine low-dose prolonged infusion with carboplatin has low toxicity especially thrombocytopenia and has an activity comparable with gemcitabine given in higher dose in standard infusion\",\n",
            "}\n",
            "13986\n",
            "{\n",
            "  \"id\" : \"24837860\",\n",
            "  \"contents\" : \"The aim of this work was to investigate cardiorespiratory fitness in breast cancer patients at different time points of anti-cancer treatment Non-metastatic breast cancer patients n = 222 mean age 55 years were categorized into four subgroups according to their treatment status Cardiopulmonary exercise testing CPET was used to measure patients cardiorespiratory fitness including oxygen delivery and metabolic muscle function Testing was performed by bicycle ergometry and maximal oxygen uptake VO2peak was measured Heart rate during exercise at 50 watts HR50 was assessed as a cardiocirculatory parameter and ventilatory threshold VT was used as an indicator of the O2 supply to muscle Analysis of covariance was used to estimate the impact of different cancer treatments on cardiorespiratory fitness with adjustment for clinical factors Submaximal measures were successfully assessed in 220 99 % and 200 90 % patients for HR50 and VT while criteria for maximal exercise testing were met by 176 patients 79 % respectively The mean VO2peak was 206 67 ml/kg/min mean VT 107 29 ml/min/kg and mean HR50 112 16 beats/min Chemotherapy was significantly associated with decreased VO2peak with significantly lower adjusted mean VO2peak among patients post adjuvant chemotherapy compared to patients with no chemotherapy or those who just started chemotherapy regime all p < 001 Patients post adjuvant chemotherapy reached only 63 % of the VO2peak level expected for their age - and BMI-category mean VO2peak 155 48 ml/kg/min Similarly HR50 was significantly associated with treatment However VT was not associated with treatment Breast cancer patients have marked and significantly impaired cardiopulmonary function during and after chemotherapy Hereby chemotherapy appears to impair cardiorespiratory fitness by influencing the oxygen delivery system rather than impacting metabolic muscle function Our findings underline the need of exercise training in breast cancer patients to counteract the loss of cardiorespiratory fitness during the anti-cancer treatment\",\n",
            "}\n",
            "13987\n",
            "{\n",
            "  \"id\" : \"23159582\",\n",
            "  \"contents\" : \"Orthotopic neobladder reconstruction is the preferred method of urinary diversion after radical cystoprostatectomy We evaluated urinary functional outcomes in male patients after orthotopic neobladder using a patient questionnaire Between 2002 and 2009 patients with bladder cancer were enrolled in a clinical trial randomly assigned to undergo T pouch or Studer pouch diversion after radical cystoprostatectomy Male patients were mailed a questionnaire 12 or more months after surgery including items on urinary function intermittent catheterization number/size/wetness of pads and mucus leakage The questionnaire response rate was 68 % Mean followup was 45 years range 1 to 8 Only 223 % of patients did not use pads In the daytime 47 % of patients used at least 1 pad 322 % used small/mini pads and 226 % used diapers At night 72 % used pads 147 % used small/mini pads and 389 % used diapers During the day and night 47 % said their pads were dry/barely wet Overall 625 % of patients reported mucus leakage Only 95 % of patients performed clean intermittent self-catheterization of whom 706 % started clean intermittent self-catheterization within the first year after surgery Increasing age and diabetes mellitus were predictors of urinary function p = 0005 and 003 respectively but did not affect pad use Ileal orthotopic neobladder offers good functional results but most patients wear at least 1 pad and many require diapers at night Increasing age and diabetes mellitus predict worse urinary function but are not associated with pad use Emptying failure is uncommon and occurs early in the postoperative period Pad size/wetness and mucus leakage should be considered when evaluating urinary incontinence\",\n",
            "}\n",
            "13988\n",
            "{\n",
            "  \"id\" : \"17852440\",\n",
            "  \"contents\" : \"Patients receiving chemotherapy for cancer often develop anemia which can contribute to increased morbidity and reduced quality of life QOL Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin rHuEPO To demonstrate the effectiveness of once-weekly QW rHuEPO dosing to effect improved hemoglobin levels decreased transfusion use and improved functional outcomes and QOL in pediatric leukemic patients ALL receiving maintenance chemotherapy This was a prospective randomized single-center open-label 12-week case-control study of epoetin alfa in pediatric patients with acute lymphoblastic leukemia ALL in remission receiving maintenance chemotherapy Sixty patients were randomly assigned to receive either epoetin alfa rHuEPO group = 30 cases 17 males and 13 females age 68 + / - 233 years or no epoetin alfa control group = 30 cases 16 males and 14 females age 676 + / - 228 years Both groups were matched as regard age sex baseline Hb concentration remission state chemotherapy regimen numbers and amount of blood transfusion and leukemia state both were low and standard risk Epoetin alfa was administered at a dose of 450 IU/kg once weekly subcutaneously sc for 12 consecutive weeks Endpoints were changes in hematologic and QOL parameters Among the 30 patients evaluable for hematologic response the mean increase in Hb from baseline to time of final evaluation was 308 + / - 148 g/dl p < 0001 An increase in Hb of > or = 2 g/dl in the absence of blood transfusion occurred in 70 % of patients 21 of 30 patients who were on the study for > or = 30 days The overall response rate Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion was 90 % 27 of 30 patients In 30 patients who were evaluable for QOL assessment epoetin-alpha therapy was found to significantly p < 0001 improve mean cancer linear analog scale CLAS scores for energy level ability to perform daily activity and overall QOL from baseline to the time of final evaluation QW epoetin-alpha was found to be well tolerated Treatment with QW epoetin-alpha was found to increase Hb levels decrease transfusion requirement and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy The once-weekly schedule is convenient safe and may reduce the burden on patients parents and their caregivers by reducing the number of visits to the clinic\",\n",
            "}\n",
            "13989\n",
            "{\n",
            "  \"id\" : \"17566842\",\n",
            "  \"contents\" : \"An International Atomic Energy Agency IAEA - sponsored multi-institutional prospective randomized trial was conducted to clarify whether the combination of hyperthermia and radiotherapy improves the local response rate of locally advanced non-small cell lung cancer NSCLC compared with that obtained by radiotherapy alone Between October 1998 and April 2002 80 patients with locally advanced NSCLC were randomized to receive either standard radiation therapy alone RT or radiation therapy combined with hyperthermia RT + HT The primary endpoint was the local response rate The secondary endpoints were local progression-free survival and overall survival The median follow-up period was 204 days for all patients and 450 days for surviving patients There were no significant differences between the two arms with regard to local response rate P = 049 or overall survival rate P = 0868 However local progression-free survival was significantly better in the RT+HT arm P = 0036 Toxicity was generally mild and no grade 3 late toxicity was observed in either arm Although improvement of local progression-free survival was observed in the RT+HT arm this prospective randomized study failed to show any substantial benefit from the addition of hyperthermia to radiotherapy in the treatment of locally advanced NSCLC\",\n",
            "}\n",
            "13990\n",
            "{\n",
            "  \"id\" : \"20739842\",\n",
            "  \"contents\" : \"Sentinel lymph node dissection SLND has eliminated the need for axillary dissection ALND in patients whose sentinel node SN is tumor-free However completion ALND for patients with tumor-involved SNs remains the standard to achieve locoregional control Few studies have examined the outcome of patients who do not undergo ALND for positive SNs We now report local and regional recurrence information from the American College of Surgeons Oncology Group Z0011 trial American College of Surgeons Oncology Group Z0011 was a prospective trial examining survival of patients with SN metastases detected by standard H and E who were randomized to undergo ALND after SLND versus SLND alone without specific axillary treatment Locoregional recurrence was evaluated There were 446 patients randomized to SLND alone and 445 to SLND + ALND Patients in the 2 groups were similar with respect to age Bloom-Richardson score estrogen receptor status use of adjuvant systemic therapy tumor type T stage and tumor size Patients randomized to SLND + ALND had a median of 17 axillary nodes removed compared with a median of only 2 SN removed with SLND alone P < 0001 ALND also removed more positive lymph nodes P < 0001 At a median follow-up time of 63 years there were no statistically significant differences in local recurrence P = 011 or regional recurrence P = 045 between the 2 groups Despite the potential for residual axillary disease after SLND SLND without ALND can offer excellent regional control and may be reasonable management for selected patients with early-stage breast cancer treated with breast-conserving therapy and adjuvant systemic therapy\",\n",
            "}\n",
            "13991\n",
            "{\n",
            "  \"id\" : \"22926460\",\n",
            "  \"contents\" : \"To evaluate the effect of 4 weeks of pulmonary rehabilitation PR versus chest physical therapy CPT on the preoperative functional capacity and postoperative respiratory morbidity of patients undergoing lung cancer resection Randomized single-blinded study A teaching hospital Patients undergoing lung cancer resection N = 24 Patients were randomly assigned to receive PR strength and endurance training versus CPT breathing exercises for lung expansion Both groups received educational classes Functional parameters assessed before and after 4 weeks of PR or CPT phase 1 and pulmonary complications assessed after lung cancer resection phase 2 Twelve patients were randomly assigned to the PR arm and 12 to the CPT arm Three patients in the CPT arm were not submitted to lung resection because of inoperable cancer During phase 1 evaluation most functional parameters in the PR group improved from baseline to 1 month forced vital capacity FVC 147 L [ 127-2 33 L ] vs 171 L [ 165-2 80 L ] respectively P = 02 percentage of predicted FVC FVC % 625 % [ 49 % -71 % ] vs 76 % [ 65 % -797 % ] respectively P < 05 6-minute walk test 4255853 m vs 475865 m respectively P < 05 maximal inspiratory pressure 90459 cmH 2 O vs 1175365 cmH 2 O respectively P < 05 and maximal expiratory pressure 797171 cmH 2 O vs 929214 cmH 2 O respectively P < 05 During phase 2 evaluation the PR group had a lower incidence of postoperative respiratory morbidity P = 01 a shorter length of postoperative stay 12236 d vs 7848 d respectively P = 04 and required a chest tube for fewer days 7426 d vs 4529 d respectively P = 03 compared with the CPT arm These findings suggest that 4 weeks of PR before lung cancer resection improves preoperative functional capacity and decreases the postoperative respiratory morbidity\",\n",
            "}\n",
            "13992\n",
            "{\n",
            "  \"id\" : \"21565651\",\n",
            "  \"contents\" : \"Colorectal cancer CRC screening reduces mortality yet remains underutilized Low health literacy may contribute to this underutilization by interfering with patients ability to understand and receive preventive health services To determine if a web-based multimedia CRC screening patient decision aid developed for a mixed-literacy audience could increase CRC screening RCT Patients aged 50-74 years and overdue for CRC screening were randomized to the web-based decision aid or a control program seen immediately before a scheduled primary care appointment A large community-based university-affiliated internal medicine practice serving a socioeconomically disadvantaged population Patients completed surveys to determine their ability to state a screening test preference and their readiness to receive screening Charts were abstracted by masked observers to determine if screening tests were ordered and completed Between November 2007 and September 2008 a total of 264 patients enrolled in the study Data collection was completed in 2009 and data analysis was completed in 2010 A majority of participants mean age = 578 years were female 67 % African-American 74 % had annual household incomes of < $ 20000 76 % and had limited health literacy 56 % When compared to control participants more decision-aid participants had a CRC screening preference 84 % vs 55 % p < 00001 and an increase in readiness to receive screening 52 % vs 20 % p = 00001 More decision-aid participants had CRC screening tests ordered 30 % vs 21 % and completed 19 % vs 14 % but no statistically significant differences were seen AOR = 16 95 % CI = 097 28 and AOR = 17 95 % CI = 088 32 respectively Similar results were found across literacy levels The web-based decision aid increased patients ability to form a test preference and their intent to receive screening regardless of literacy level Further study should examine ways the decision aid can be combined with additional system changes to increase CRC screening\",\n",
            "}\n",
            "13993\n",
            "{\n",
            "  \"id\" : \"7931478\",\n",
            "  \"contents\" : \"In 1984 the German Breast Cancer Study Group GBSG started a multicenter randomized clinical trial to compare the effectiveness of three versus six cycles of 500 mg/m2 cyclophosphamide 40 mg/m2 methotrexate and 600 mg/m2 fluorouracil CMF on day 1 and 8 starting perioperatively with or without tamoxifen TAM 3 x 10 mg/d for 2 years The aim of the trial was to compare recurrence-free and overall survival between the different treatment modalities During 5 years 41 institutions randomized 473 patients 3 x CMF 145 3 x CMF + TAM 93 6 x CMF 144 6 x CMF + TAM 91 Until March 31 1992 median follow-up time was 56 months with 197 events for disease-free survival and 116 deaths observed This provides a power of approximately 80 % to detect a potential treatment difference corresponding to a relative risk RR of 067 for recurrence-free survival Treatment modalities and various patient characteristics were evaluated by means of a multivariate Cox regression analysis No significant difference in recurrence-free survival was observed with respect to hormonal therapy RR = 075 TAM v no TAM 95 % confidence interval [ CI ] 054 to 104 P = 08 as well as duration of chemotherapy RR = 090 of 6 x CMF v 3 x CMF 95 % CI 067 to 119 P = 45 Similar results were obtained for overall survival The multivariate analysis revealed a significant prognostic impact of the number of positive lymph nodes and the progesterone receptor level on recurrence-free survival Compliance with chemotherapy within the range of 85 % to 115 % of the target dose was achieved in 94 % and 78 % of the patients randomized to 3 x CMF and 6 x CMF respectively Sufficient compliance with TAM was reported for 141 patients 93 % At this stage of follow-up six courses of CMF are not superior to three courses with respect to recurrence-free survival\",\n",
            "}\n",
            "13994\n",
            "{\n",
            "  \"id\" : \"20824720\",\n",
            "  \"contents\" : \"National Cancer Institute of Canada Clinical Trials Group PA 3 NCIC CTG PA 3 was a phase 3 study n = 569 that demonstrated benefits for overall survival and progression-free survival with the addition of the epidermal growth factor receptor EGFR tyrosine kinase inhibitor TKI erlotinib to gemcitabine in patients with advanced pancreatic carcinoma APC Mutation status of the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog KRAS and EGFR gene copy number GCN were evaluated as predictive markers in 26 % of patients who had tumor samples available for analysis KRAS mutation status was evaluated by direct sequencing of exon 2 and EGFR GCN was determined by fluorescence in situ hybridization FISH analysis The results were correlated with survival which was the primary endpoint of the trial KRAS analysis was successful in 117 patients and EGFR FISH analysis was successful in 107 patients KRAS mutations were identified in 92 patients 786 % and EGFR amplification or high polysomy FISH-positive results was identified in 50 patients 467 % The hazard ratio of death between gemcitabine/erlotinib and gemcitabine/placebo was 066 95 % confidence interval [ CI ] 028-1 57 for patients with wild-type KRAS and 107 95 % CI 068-1 66 for patients with mutant KRAS P value for interaction = 38 and the hazard ratio was 06 95 % CI 034-1 07 for FISH-negative patients and 090 95 % CI 049-1 65 for FISH-positive patients P value for interaction = 32 In a molecular subset analysis of patients from NCIC CTG PA 3 EGFR GCN and KRAS mutation status were not identified as markers predictive of a survival benefit from the combination of erlotinib with gemcitabine for the first-line treatment of APC\",\n",
            "}\n",
            "13995\n",
            "{\n",
            "  \"id\" : \"21257305\",\n",
            "  \"contents\" : \"An economic evaluation was performed alongside a randomised controlled trial ISRCTN 74071417 investigating the cost-effectiveness of nurse-led telephone follow-up instead of hospital visits and of a short educational group programme EGP in the first year after breast cancer treatment This economic evaluation n = 299 compared the one-year costs and the effects of four follow-up strategies 1 hospital follow-up 2 nurse-led telephone follow-up 3 hospital follow-up plus EGP and 4 nurse-led telephone follow-up plus EGP Costs were measured using cost diaries and hospital registrations Quality-adjusted life years QALYs were measured using the EQ-5D Outcomes were expressed in incremental cost-effectiveness ratios ICERs and cost-effectiveness acceptability curves Hospital follow-up plus EGP yielded most QALYs 0776 but also incurred the highest mean annual costs 4914 The ICER of this strategy versus the next best alternative nurse-led telephone follow-up plus EGP 0772 QALYs and 3971 amounted to 235750 / QALY Hospital and telephone follow-up without EGP both incurred higher costs and less QALYs than telephone follow-up plus EGP and were judged inferior Hospital follow-up plus EGP was not considered cost-effective therefore telephone follow-up plus EGP was the preferred strategy The probability of telephone follow-up plus EGP being cost-effective ranged from 49 % to 62 % for different QALY threshold values Secondary and sensitivity analyses showed that results were robust Nurse-led telephone follow-up plus EGP seems an appropriate and cost-effective alternative to hospital follow-up for breast cancer patients during their first year after treatment\",\n",
            "}\n",
            "13996\n",
            "{\n",
            "  \"id\" : \"24267731\",\n",
            "  \"contents\" : \"Diabetic patients treated with metformin have a lower risk of developing BC or a better BC prognosis Metformin might reduce cancer growth through direct antiproliferative effects or through indirect mechanisms particularly the reduction of insulin In a randomized study on nondiabetic BC patients in natural menopause with hightestosterone levels we observed a significant decrease in insulin and in testosterone levels with metformin 1500mg/d compared with 1000 mg/d We present the results of a new analysis of our study on the effect of metformin on the bioavailability of sex hormones One hundred twenty-four eligible women were initiallyinvited to take metformin 500 mg/d for 3 months The 108 women who completed the first 3 months continued the study using 1000 mg/d for 1 month The women were then randomized into 2 groups and for the subsequent 5months 1 group increased the dose to 1500 mg/d and the other group continued with 1000 mg/d Ninety-six women completed the study 43 receiving metformin 1500 mg/day and 53 receiving 1000 mg/day The women receiving 1500 mg/d showed a greater and significant reduction of free testosterone -29 % and estradiol -38 % a borderline significant reduction of estrone and insulin-like growth factor-1 and a nonsignificant reduction of androstenedione They also showed a nonsignificant increase of dehydroepiandrosterone sulfate Metformin does not interfere with the production of dehydroepiandrosterone sulfate Besides it decreases estradiol levels basically through the reduction of testosterone These hormonal changes might have clinical relevance\",\n",
            "}\n",
            "13997\n",
            "{\n",
            "  \"id\" : \"11753990\",\n",
            "  \"contents\" : \"Treatment of localized prostate carcinoma LPC using radiotherapy RT can induce disturbances in a patient s quality of life QOL and urinary and intestinal function Late symptoms and QOL were evaluated in a randomized trial between RT and deferred treatment DT Quality of life was evaluated with European Organization for Research and Treatment of Cancer s QLQ-C30 +3 formula Urinary and intestinal problems were evaluated with a validated symptom specific self-assessment questionnaire QUFW94 The questionnaires were sent to 108 randomized patients with LPC and to an age-matched control group n = 68 Mean age was 72 years Mean total dose was 65 grays Gy 623-70 Gy The median follow-up time from randomization was 406 months for the RT group and 304 months for the DT group Social functioning was the only QOL scale in which a significant difference was found between the two patient groups and compared with the control group Multivariate regression analysis showed that hematuria incontinence mucus and planning of daily activities in response to intestinal problems caused this decrease in QOL in the RT group A significant increase of intestinal problems was observed in the RT versus DT groups regarding mucus stool leakage intestinal blood and planning of daily activity in response to intestinal problems The RT patients showed increased levels of minor intestinal side effects compared with the DT patients and the controls but the RT patients reported no decreased QOL except for decreased social functioning This could be because this group developed coping skills or because of a low magnitude of side effects to influence the QOL\",\n",
            "}\n",
            "13998\n",
            "{\n",
            "  \"id\" : \"7848404\",\n",
            "  \"contents\" : \"To evaluate the effectiveness of early detection of intrathoracic and bone metastases in reducing mortality in breast cancer patients Randomized clinical trial allocating breast cancer patients to two alternative follow-up protocols intensive vs clinical for at least 5 years Twelve breast clinics referral centers in different areas in Italy A total of 1243 consecutive patients either premenopausal or postmenopausal surgically treated for unilateral invasive breast carcinoma with no evidence of metastases The two study groups were well balanced in terms of clinical and prognostic characteristics Patients in both treatment groups had physical examination and mammography while patients of the intensive follow-up group had in addition chest roentgenography and bone scan every 6 months Vital status at 5 years was the main outcome information was available for all except five patients 04 % Relapse-free survival was also analyzed Overall 393 recurrences 104 local and 289 distant were observed during the study Increased detection of isolated intrathoracic and bone metastases was evident in the intensive follow-up group compared with the clinical follow-up group 112 vs 71 cases while no difference was observed for other sites and for local and/or regional recurrences The 5-year relapse-free survival rate was significantly higher for the clinical follow-up group with patients in the intensive follow-up group showing earlier detection of recurrences No difference in 5-year overall mortality 186 % vs 195 % was observed between the two follow-up groups Periodic chest roentgenography and bone scan allow earlier detection of distant metastases but anticipated diagnosis appears to be the only effect of intensive follow-up and no impact on prognosis is evident after 5 years Periodic intensive follow-up with chest roentgenography and bone scan should not be recommended as a routine policy\",\n",
            "}\n",
            "13999\n",
            "{\n",
            "  \"id\" : \"18725832\",\n",
            "  \"contents\" : \"Increasing colorectal cancer screening CRCS can have a substantial positive impact on morbidity and mortality The purpose of this report is to describe the development and feasibility testing of a computer-based theory-guided educational program designed to increase CRCS This mixed-methods study used focus groups and subsequent randomized controlled trial design Participants N = 199 were randomized to an intervention or control group 75 % were African American mean age was 5736 SD = 68 71 % were male Previously validated measures on knowledge beliefs and screening test adherence were used to establish pre - and post-intervention perceptions Feasibility was measured by response and completion rates and participants perceptions of the program Before feasibility testing the program was presented to 2 focus groups Changes were made to the program based on discussion leading to a visually appealing easy to understand and navigate self-paced program In the RCT pilot test that followed of the participants in the intervention group 80 % said the education helped them decide to get CRCS 49 % agreed it helped them overcome barriers 91 % agreed it was useful 68 % thought it raised new concerns about cancer but only 30 % said it made them worry about CRC 95 % agreed their doctor s office should continue giving such education and 99 % said they would inform family about the program The response rate of 83 % demonstrated feasibility of conducting colorectal cancer education in the primary care setting overall the program was well received participants averaged 23 minutes to complete it Participants sought no help from attending data collectors and navigated the revised touch screen program with ease Computer-based education is feasible in primary care clinics\",\n",
            "}\n",
            "14000\n",
            "{\n",
            "  \"id\" : \"24661661\",\n",
            "  \"contents\" : \"To report late toxicity outcomes from a randomized trial comparing conventional and hypofractionated prostate radiation therapy and to identify dosimetric and clinical parameters associated with late toxicity after hypofractionated treatment Men with localized prostate cancer were enrolled in a trial that randomized men to either conventionally fractionated intensity modulated radiation therapy CIMRT 756 Gy in 18-Gy fractions or to dose-escalated hypofractionated IMRT HIMRT 72 Gy in 24-Gy fractions Late 90 days after completion of radiation therapy genitourinary GU and gastrointestinal GI toxicity were prospectively evaluated and scored according to modified Radiation Therapy Oncology Group criteria 101 men received CIMRT and 102 men received HIMRT The median age was 68 and the median follow-up time was 60 years Twenty-eight percent had low-risk 71 % had intermediate-risk and 1 % had high-risk disease There was no difference in late GU toxicity in men treated with CIMRT and HIMRT The actuarial 5-year grade 2 GU toxicity was 165 % after CIMRT and 158 % after HIMRT P = 97 There was a nonsignificant numeric increase in late GI toxicity in men treated with HIMRT compared with men treated with CIMRT The actuarial 5-year grade 2 GI toxicity was 51 % after CIMRT and 100 % after HIMRT P = 11 In men receiving HIMRT the proportion of rectum receiving 369 Gy 462 Gy 646 Gy and 739 Gy was associated with the development of late GI toxicity P < 05 The 5-year actuarial grade 2 GI toxicity was 273 % in men with R64 6 Gy 20 % but only 60 % in men with R64 6 Gy < 20 % P = 016 Dose-escalated IMRT using a moderate hypofractionation regimen 72 Gy in 24-Gy fractions can be delivered safely with limited grade 2 or 3 late toxicity Minimizing the proportion of rectum that receives moderate and high dose decreases the risk of late rectal toxicity after this hypofractionation regimen\",\n",
            "}\n",
            "14001\n",
            "{\n",
            "  \"id\" : \"17224859\",\n",
            "  \"contents\" : \"Women with higher mammographic breast density have increased risk for breast cancer and there is some evidence that a change in breast density may be a marker for change in risk for breast cancer The purpose of this study was to determine whether 2 years of treatment with ultra-low-dose transdermal estradiol results in a change in breast density The Ultra-Low-dose Transdermal Estradiol Assessment was a randomized blinded placebo-controlled trial of 2 years of treatment with unopposed ultra-low-dose 0014 mg/d transdermal estradiol for prevention of osteoporosis in 417 postmenopausal women with no history of breast cancer who had not had a hysterectomy We obtained mammograms at baseline and after 1 and 2 years of treatment from 276 of the participants Right craniocaudal views were analyzed at a central radiology facility by a trained clinician blinded to treatment group and order of acquisition Contour analysis was performed to define dense areas versus fatty tissue Between-group differences in mean change in percent breast density from baseline to 1 and to 2 years of follow-up were assessed using linear regression models adjusted for clinical site Participants were 66 + / - 5 years old and 94 % were white The average percent breast density at baseline was 34 % There was no significant difference between treatment groups in change in percent breast density after 1 year between-group difference 01 % 95 % confidence interval -13 % to 16 % or 2 years of treatment 08 % -06 % to 21 % Two years of treatment with ultra-low-dose transdermal estradiol did not increase breast density\",\n",
            "}\n",
            "14002\n",
            "{\n",
            "  \"id\" : \"8827017\",\n",
            "  \"contents\" : \"Increased proliferation of endogenous bone marrow progenitor cells in response to the administration of hematopoietic growth factors followed by reduced cell cycling or entrance of the cells into a quiescent state upon withdrawal of the growth factors may have clinically relevant effects on the tolerance of the hematopoietic system to subsequent myelotoxic treatments We investigated the ability of granulocyte colony-stimulating factor G-CSF to protect progenitor cells in the bone marrow of cancer patients from the toxic effects of subsequent treatments with chemotherapeutic agents Thirty-six patients with histologically documented locally advanced or metastatic breast cancer were randomly assigned to receive doxorubicin once every 3 weeks at a dose of 75 mg/m2 and cyclophosphamide at a dose of 1000 mg/m2 with G-CSF administered either before and after chemotherapy 18 patients or after chemotherapy only 18 patients For prechemotherapy administration of G-CSF recombinant human methionyl r-met Hu G-CSF was administered subcutaneously to patients twice per day for 5 days at a dose of 5 micrograms/kg with the last dose given 48 hours before the start of chemotherapy For postchemotherapy administration of G-CSF r-met Hu G-CSF was administered subcutaneously to patients once per day for 7 days at a dose of 5 micrograms/kg with the first dose given 24 hours after chemotherapy The incidence or the duration of grade 4 neutropenia was not reduced in all patients by the use of prechemotherapy G-CSF the incidence over all cycles of chemotherapy was 74 % for patients treated with prechemotherapy and postchemotherapy G-CSF and 66 % for patients treated with postchemotherapy G-CSF only two-sided P adjusted for dose = 21 and the median duration in both treatment arms was 3 days two-sided P = 19 Unexpectedly the incidence of grades 3 and 4 thrombocytopenia was much greater in patients who received prechemotherapy G-CSF compared with those who did not 54 % versus 6 % respectively over all chemotherapy cycles two-sided P adjusted for dose < 001 No difference in the decrease in hemoglobin level adjusted for red blood cell transfusions between patients in the two treatment arms was observed No beneficial effects were associated with the administration of G-CSF to cancer patients prior to chemotherapy The observation of more severe thrombocytopenia in patients treated with prechemotherapy G-CSF led us to conclude that the proliferation of progenitor cells was still increased 48 hours after the last dose of G-CSF and that the administration of chemotherapy at or within this time period actually worsens the toxic effects on bone marrow This result has important ramifications for the design of clinical cancer treatment protocols especially those that involve shortened intervals between cycles of chemotherapeutic agent administration\",\n",
            "}\n",
            "14003\n",
            "{\n",
            "  \"id\" : \"9565385\",\n",
            "  \"contents\" : \"To study the effects of three approaches to increasing utilization of screening mammography in a public hospital setting in Northwest Louisiana Randomized intervention study Four hundred forty-five women aged 40 years and over predominantly low-income and with low literacy skills who had not had a mammogram in the preceding year All interventions were chosen to motivate women to get a mammogram Group 1 received a personal recommendation from one of the investigators Group 2 received the recommendation plus an easy-to-read National Cancer Institute NCI brochure Group 3 received the recommendation the brochure and a 12-minute interactive educational and motivational program including a soap-opera-style video developed in collaboration with women from the target population Mammography utilization was determined at 6 months and 2 years after intervention A significant increase p = 05 in mammography utilization was observed after the intervention designed in collaboration with patients 29 % as compared with recommendation alone 21 % or recommendation with brochure 18 % at 6 months However at 2 years the difference favoring the custom-made intervention was no longer significant At 6 months there was at least a 30 % increase in the mammography utilization rate in the group receiving the intervention designed in collaboration with patients as compared with those receiving the recommendation alone or recommendation with brochure Giving patients an easy-to-read NCI brochure and a personal recommendation was no more effective than giving them a recommendation alone suggesting that simply providing women in a public hospital with a low-literacy-level culturally appropriate brochure is not sufficient to increase screening mammography rates In a multivariate analysis the only significant predictor of mammography use at 6 months was the custom-made intervention\",\n",
            "}\n",
            "14004\n",
            "{\n",
            "  \"id\" : \"8018682\",\n",
            "  \"contents\" : \"Toward developing attractive and effective means to reduce cancer risks faced by Native American people this study developed and tested interactive computer software to improve dietary choices and prevent tobacco use among Native American adolescents Based on a legend of the Seneca Nation a cancer prevention lesson was developed and programmed for software A sample of 368 Native American adolescents were divided randomly into intervention and control arms Youths in both arms were pre-tested youths in the intervention arm interacted with the software and all youths were post-tested Pre-test and post-test measures covered information and attitudes about cancer risks from dietary practices and tobacco use Pre-test scores differed between the two arms on youths age and on one outcome variable Relative to their counterparts in the control arm youths in the intervention arm increased their post-test scores on 8 of 12 outcome measurement variables Process data gathered during intervention delivery indicated that nearly all youths were involved with the interactive software and lesson Interactive computer software holds promise for delivering cancer risk reduction intervention aimed at modifying dietary habits and preventing tobacco use among Native American youth\",\n",
            "}\n",
            "14005\n",
            "{\n",
            "  \"id\" : \"23883162\",\n",
            "  \"contents\" : \"Cancer patients and survivors regularly feel anxious about cancer recurrence or death even after the conclusion of medical treatment and they are often highly physiologically and psychologically stressed Massage therapy is one of the most widely used complementary and alternative therapies used in the hope of alleviating such stress and physical and psychological complaints and to improve health-related quality of life This randomized phase III two-armed parallel group clinical trial was designed after obtaining positive findings in a preliminary study The primary objective is to verify the effects of continuous Japanese massage therapy referred to as Anma therapy for cancer survivors The secondary objective is to confirm the immediate effects of a single Anma massage session for cancer survivors Sixty cancer survivors older than 20 years of age who have had histologically confirmed uterine cervical endometrial ovarian fallopian tube or peritoneal cancer in the past but with no recurrence for more than 3 years since receiving standard medical treatment are being recruited by gynecologists in medical facilities In the coordinating office they are randomly allocated to two groups n = 30 each an Anma massage group receiving a 40-min Anma massage session once weekly over a 2-month intervention period total of eight Anma massage sessions and a control group being followed by medical doctors and receiving no Anma massage sessions The primary end point is the severity of physical subjective symptoms that cancer survivors report in daily life assessed using a Visual Analogue Scale Secondary end points are urine and saliva analyses psychological condition and health-related quality-of-life scores as determined on the basis of a self-report questionnaire Using the evidence-based findings of this trial medical professionals should be able to explain the benefits conferred by Anma massage to cancer survivors and provide higher-quality information to better inform patients regarding their decisions about whether to receive such therapy This trial is registered with the UMIN Clinical Trials Registry as UMIN000009097\",\n",
            "}\n",
            "14006\n",
            "{\n",
            "  \"id\" : \"19336728\",\n",
            "  \"contents\" : \"Men with elevated prostate-specific antigen PSA and negative prostate biopsies are at risk for prostate cancer The antiandrogen bicalutamide has a prolonged half-life thus potentially allowing an intermittent administration to retain activity while reducing toxicity We conducted a phase I-II trial of weekly bicalutamide in men with PSA > 4 ng/mL and negative biopsies Eighty subjects were nonrandomly assigned to a three-arm trial to either bicalutamide 50 mg/wk n = 26 or 100 mg/wk n = 28 or no treatment n = 26 for 6 months Blood samples were obtained at 0 3 and 6 months and prostate biopsies were repeated after 6 months The outcome measures were 6-month changes of tissue Ki-67 primary end point high-grade prostatic intraepithelial neoplasia HG-PIN proliferative inflammatory atrophy circulating PSA and sex hormones Ki-67 expression was higher in HG-PIN than in normal tissue 10 % versus 3 % P < 001 but was not modulated by bicalutamide in normal luminal cells A trend toward an improvement of HG-PIN status was found in treated subjects 26 % improved 60 % had no change 15 % worsened as compared with the no-treatment arm 4 % improved 83 % had no change 13 % worsened P = 007 Proliferative inflammatory atrophy prevalence was not reduced by bicalutamide Bicalutamide reduced PSA by 50 % in both arms and raised testosterone and estradiol levels Asymptomatic breast swelling was noted in 40 % of the treated cases A weekly administration of bicalutamide seems to be reasonably safe and shows an encouraging signal of activity on HG-PIN prevalence supporting further studies of this schedule in men at high risk despite the negative primary end-point findings on Ki-67\",\n",
            "}\n",
            "14007\n",
            "{\n",
            "  \"id\" : \"15163773\",\n",
            "  \"contents\" : \"The optimal upper limit of the normal range for prostate-specific antigen PSA is unknown We investigated the prevalence of prostate cancer among men in the Prostate Cancer Prevention Trial who had a PSA level of 40 ng per milliliter or less Of 18882 men enrolled in the prevention trial 9459 were randomly assigned to receive placebo and had an annual measurement of PSA and a digital rectal examination Among these 9459 men 2950 men never had a PSA level of more than 40 ng per milliliter or an abnormal digital rectal examination had a final PSA determination and underwent a prostate biopsy after being in the study for seven years Among the 2950 men age range 62 to 91 years prostate cancer was diagnosed in 449 152 percent 67 of these 449 cancers 149 percent had a Gleason score of 7 or higher The prevalence of prostate cancer was 66 percent among men with a PSA level of up to 05 ng per milliliter 101 percent among those with values of 06 to 10 ng per milliliter 170 percent among those with values of 11 to 20 ng per milliliter 239 percent among those with values of 21 to 30 ng per milliliter and 269 percent among those with values of 31 to 40 ng per milliliter The prevalence of high-grade cancers increased from 125 percent of cancers associated with a PSA level of 05 ng per milliliter or less to 250 percent of cancers associated with a PSA level of 31 to 40 ng per milliliter Biopsy-detected prostate cancer including high-grade cancers is not rare among men with PSA levels of 40 ng per milliliter or less -- levels generally thought to be in the normal range\",\n",
            "}\n",
            "14008\n",
            "{\n",
            "  \"id\" : \"9605644\",\n",
            "  \"contents\" : \"Colony-stimulating factors promote the proliferation of certain bone marrow cell populations The primary objective of treating patients with these factors prophylactically following chemotherapy is to reduce the risk of infection thereby minimizing the need for hospitalization and parenteral antibiotics The use of colony-stimulating factors in children is widespread despite the absence of conclusive supportive data and the high cost of these drugs Consequently the cost-benefit ratio of using prophylactic colony-stimulating factors is an important issue in cancer therapy During the period from January 1994 through June 1996 149 afebrile children with newly diagnosed non-Hodgkin s lymphoma were randomly assigned either to receive granulocyte colony-stimulating factor G-CSF lenograstim 5 microg/kg body weight per day subcutaneously or not to receive it the control at the end of the first two courses of induction chemotherapy with cyclophosphamide vincristine prednisone doxorubicin and methotrexate A cost-minimization analysis was performed to assess the cost of chemotherapy in each group and to quantify how much could be economized by prescribing G-CSF The total cost for induction chemotherapy was $ 29765 in the G-CSF-treated group and $ 30774 in the control group indicating that the treatment strategy with G-CSF was slightly less expensive than the strategy without G-CSF mean difference = $ 1009 95 % confidence interval = - $ 1474 to $ 3492 Treatment with G-CSF following chemotherapy in children with non-Hodgkin s lymphoma -- previously shown to be of limited clinical benefit -- also does not appear to reduce the costs of chemotherapy\",\n",
            "}\n",
            "14009\n",
            "{\n",
            "  \"id\" : \"16860521\",\n",
            "  \"contents\" : \"a To determine which of two values clarification exercises VCE based on theoretical decision rules used naturally by people would be more helpful to patients making a treatment decision and b to evaluate the convergent validity of the most helpful VCE when part of a decision aid for the treatment of early-stage prostate cancer Two studies were completed Study 1 Ninety community volunteers were assigned at random to one of three groups and all made a hypothetical treatment decision Two groups received VCEs one with a summary and one without and the third was a control group Study 2 In a multi-centre phase II trial 69 patients used the decision aid that included the exercise ranked most helpful in Study 1 Decision aid assessments included the decisional conflict scale treatment valuation assessment and regret Study 1 Most participants in each group ranked the VCE with the summary as most helpful Study 2 VCE outputs such as the size of the summary were associated in predictable ways with the decision aid assessments The VCE ranked most helpful in Study 1 showed convergent validity with decision aid assessments With the interpretation of the VCE outputs now validated a randomized controlled trial is required to determine if the exercise helps patients more than the aid without the exercise\",\n",
            "}\n",
            "14010\n",
            "{\n",
            "  \"id\" : \"19100647\",\n",
            "  \"contents\" : \"To compare the efficacy and safety profile of irinotecan I versus the combination of irinotecan/gemcitabine IG as second-line treatment of patients with extensive stage small-cell lung cancer SCLC Patients with SCLC who have received at least one chemotherapy regimen were randomized to receive either the IG regimen gemcitabine 1000mg/m 2 intravenous iv on days 1 and 8 and irinotecan 300mg/m 2 iv on day 8 or I monotherapy 300mg/m 2 iv on day 1 both every 3 weeks Thirty-eight patients were enrolled in the IG and 31 in the I arm Due to slow accrual an early closure of the study was decided Response rate was significantly higher in the IG than in I arm 237 % vs 0 % p = 0004 The median time to progression TTP was 39 months range 05-14 5 months 95 % CI 14-6 6 and 17 months range 05-9 9 months 95 % CI 12-2 3 p = 0010 for the IG and I arms respectively There was no difference in terms of median overall survival between the two arms 68 months and 46 months for the IG and I arm respectively The most frequent toxicities were grade III/IV neutropenia and grade III/IV diarrhea Although the IG regimen seems to be more active than the I monotherapy the premature closure of the study prevents the drawing of definitive conclusions\",\n",
            "}\n",
            "14011\n",
            "{\n",
            "  \"id\" : \"15681529\",\n",
            "  \"contents\" : \"Matrix metalloproteinases MMPs degrade extracellular proteins and facilitate tumor growth invasion metastasis and angiogenesis This trial was undertaken to determine the effect of prinomastat an inhibitor of selected MMPs on the survival of patients with advanced non-small-cell lung cancer NSCLC when given in combination with gemcitabine-cisplatin chemotherapy Chemotherapy-naive patients were randomly assigned to receive prinomastat 15 mg or placebo twice daily orally continuously in combination with gemcitabine 1250 mg/m2 days 1 and 8 plus cisplatin 75 mg/m2 day 1 every 21 days for up to six cycles The planned sample size was 420 patients Study results at an interim analysis and lack of efficacy in another phase III trial prompted early closure of this study There were 362 patients randomized 181 on prinomastat and 181 on placebo One hundred thirty-four patients had stage IIIB disease with T4 primary tumor 193 had stage IV disease and 34 had recurrent disease one enrolled patient was ineligible with stage IIIA disease Overall response rates for the two treatment arms were similar 27 % for prinomastat v 26 % for placebo P = 81 There was no difference in overall survival or time to progression for prinomastat versus placebo patients the median overall survival times were 115 versus 108 months P = 82 1-year survival rates were 43 % v 38 % P = 45 and progression-free survival times were 61 v 55 months P = 11 respectively The toxicities of prinomastat were arthralgia stiffness and joint swelling Treatment interruption was required in 38 % of prinomastat patients and 12 % of placebo patients Prinomastat does not improve the outcome of chemotherapy in advanced NSCLC\",\n",
            "}\n",
            "14012\n",
            "{\n",
            "  \"id\" : \"16216315\",\n",
            "  \"contents\" : \"The Gynecologic Oncology Group GOG compared methotrexate vinblastine doxorubicin and cisplatin MVAC with topotecan and cisplatin TC or cisplatin alone C in advanced cervical cancer The primary endpoint was overall survival OS with response rate progression-free survival PFS and quality of life QOL as secondary objectives Eligible patients were randomly allocated to receive either cisplatin 50 mg/m2 q 3 weeks C or cisplatin 50 mg/m2 day 1 and topotecan 075 mg/m2 days 1-3 q 3 weeks TC or methotrexate 30 mg/m2 days 1 15 and 22 vinblastine 3 mg/m2 days 2 15 and 22 doxorubicin 30 mg/m2 day 2 and cisplatin 70 mg/m2 day 2 q 4 weeks MVAC QOL was assessed at four time points using the Functional Assessment of Cancer Therapy-Cervix FACT-Cx Neurotoxicity Subscale FACT/GOG-NTX subscale and Brief Pain Inventory BPI One hundred eighty-six patients C = 60 TC = 63 MVAC = 63 were enrolled before MVAC was closed by the GOG Data Safety Monitoring Board after four treatment-related deaths occurred on that arm MVAC produced a 22 % overall response rate 95 % CI 013 to 034 and median PFS and OS of 44 months and 94 months respectively Compared with C and TC there was more hematologic toxicity with MVAC There were no appreciable differences in QOL scores after controlling for baseline scores MVAC s clinical activity tended to be similar to that of TC but with an unacceptable risk of death from sepsis at this dose and schedule Nevertheless QOL as measured by these instruments was not substantially impaired by this regimen\",\n",
            "}\n",
            "14013\n",
            "{\n",
            "  \"id\" : \"22271481\",\n",
            "  \"contents\" : \"Anastrozole ANA alone delivers significant disease-free survival benefits over tamoxifen TAM monotherapy in postmenopausal women with early estrogen receptor-positive breast cancer The ABCSG-8 Austrian Breast and Colorectal Cancer Study Group 8 study is a large phase III clinical trial addressing the sequence strategy containing ANA in comparison with 5 years of TAM in a low - to intermediate-risk group of postmenopausal patients Endocrine receptor-positive patients with G1 or G2 tumors were eligible After surgery patients were randomly assigned to 5 years of TAM or 2 years of TAM followed by 3 years of ANA Adjuvant chemotherapy and G3 and T4 tumors were exclusion criteria Intention-to-treat and censored analyses of on-treatment recurrence-free survival RFS were performed and exploratory survival end points and toxicity were investigated Information from 3714 patients including 17563 woman-years with a median of 60 months of follow-up was available for this analysis Median age was 638 years 75 % were node negative and 75 % had T1 tumors Sequencing of ANA after identical 2-year treatment with TAM in both arms did not result in a statistically significant improvement of RFS hazard ratio [ HR ] 080 95 % CI 063 to 101 P = 06 Exploratory analyses of distant relapse-free survival indicated a 22 % improvement HR 078 95 % CI 060 to 100 On-treatment adverse events and serious adverse events were consistent with known toxicity profiles of ANA and TAM treatment Despite a low overall rate of recurrence in a population with breast cancer at limited risk of relapse the a priori sequence strategy of 2 years of TAM followed by 3 years of ANA led to small outcome and toxicity benefits\",\n",
            "}\n",
            "14014\n",
            "{\n",
            "  \"id\" : \"16437370\",\n",
            "  \"contents\" : \"To study the gastric function after esophagectomy and cardiectomy with vagus nerve preserved and reconstruction of gastric funds VPRG in patients with esophageal cancer EC and cardiac cancer CC Sixty-eight patients with early or middle staged EC or CC received esophagectomy and cardiectomy with vagus nerve preserved and reconstruction of gastric funds VPRG while other 68 patients esophagectomy and cardiectomy with vagus nerve severed and no reconstruction of gastric funds VSNG as control The symptoms the pressure of the residual esophagus and thoracic stomach 24-hour pH monitoring mean basic gastric acid output gastric emptying time of the intrathoracic stomach fasting serum gastrin level fibreoptic endoscopic results were compared before and after operation between the two groups The patients with VPRG had less symptoms after operation than those with VSNG such as anorexia belch reflux heartburn nausea diarrhea postcibal satiety P < 001 In VPRG group compared with the results before operation there were no significant differences in 24-hour pH monitoring the mean basic gastric acid output the fasting serum gastrin level the gastric emptying time of intrathoracic stomach one month and one year after operation both P > 005 The pressure of the residual esophagus above the anastomosis in VPRG group was significantly higher than that in VSNG group both P < 005 Fibreoptic endoscopic examination revealed higher incidences of postoperative atrophic gastritis and reflux esophagitis in VPRG group one month and one year after operation than those in VSNG group P < 001 Preservation of the vagus nerve and reconstruction of gastric funds after esophagectomy and cardiectomy for esophageal and cardiac cancer can prevent digestive disorder and improve the life quality of the patients\",\n",
            "}\n",
            "14015\n",
            "{\n",
            "  \"id\" : \"25609264\",\n",
            "  \"contents\" : \"A lipid emulsion composed of soybean oil long-chain triglycerides LCT medium-chain triglycerides MCT and n-3 poly-unsaturated fatty acids PUFAs was evaluated for immune-modulation efficacy safety and tolerance in patients undergoing major surgery for gastric and colorectal cancer In a prospective randomized double-blind study 99 patients with gastric and colorectal cancer receiving elective surgery were recruited and randomly assigned to either the study group receiving the n-3 PUFAs enriched intravenous fat emulsion IVFE or the control group receiving a lipid emulsion comprised of soybean oil and MCTs 08 - 15gkg-1day-1 as part of total parenteral nutrition TPN regimen from surgery day -1 up to post-operative day 7 Safety and efficacy parameters were assessed on day -1 and post-operative visits on day 1 3 and 7 Adverse events were documented daily and compared between the groups Pro-inflammatory markers laboratory parameters and adverse events did not differ prominently between the 2 groups with the exception of net changes day 7 minus day -1 of free fatty acids FFAs triglyceride and high-density lipoprotein HDL Net decrease of FFAs was remarkably higher in the study group while the net increase of triglyceride and decrease of HDL was significantly lower The n-3 PUFA-enriched IVFE showed improvements in lipid metabolism In respect of efficacy safety and tolerance both IVFE were comparable In patients with severe stress there is an inflammation-attenuating effect of n-3 PUFAs Further adequately powered clinical trials will be necessary to address this question in postsurgical GI cancer patients US ClinicalTrialsgov NCT00798447\",\n",
            "}\n",
            "14016\n",
            "{\n",
            "  \"id\" : \"11408507\",\n",
            "  \"contents\" : \"To compare a full-dose epirubicin-cyclophosphamide HEC regimen with classical cyclophosphamide methotrexate and fluorouracil CMF therapy and with a moderate-dose epirubicin-cyclophosphamide regimen EC in the adjuvant therapy of node-positive breast cancer Node-positive breast cancer patients who were aged 70 years or younger were randomly allocated to one of the following treatments CMF for six cycles oral cyclophosphamide EC for eight cycles epirubicin 60 mg/m 2 cyclophosphamide 500 mg/m 2 day 1 every 3 weeks and HEC for eight cycles epirubicin 100 mg/m 2 cyclophosphamide 830 mg/m 2 day 1 every 3 weeks Two hundred fifty-five 267 and 255 eligible patients were treated with CMF EC and HEC respectively Patient characteristics were well balanced among the three arms One and three cases of congestive heart failure were reported in the EC and HEC arms respectively Three cases of acute myeloid leukemia were reported in the HEC arm After 4 years of median follow-up no statistically significant differences were observed between HEC and CMF event-free survival [ EFS ] hazards ratio [ HR ] = 096 95 % confidence interval [ CI ] 070 to 131 P = 80 distant-EFS HR = 097 95 % CI 070 to 134 P = 87 overall survival [ OS ] HR = 097 95 % CI 065 to 144 P = 87 HEC is more effective than EC EFS HR = 073 95 % CI 054 to 099 P = 04 distant-EFS HR = 075 95 % CI 055 to 102 P = 06 OS HR = 069 95 % CI 047 to 100 P = 05 This three-arm study does not show an advantage in favor of an adequately dosed epirubicin-based regimen over classical CMF in the adjuvant therapy of node-positive pre - and postmenopausal women with breast cancer Moreover this study confirms that there is a dose-response curve for epirubicin in breast cancer adjuvant therapy\",\n",
            "}\n",
            "14017\n",
            "{\n",
            "  \"id\" : \"18234424\",\n",
            "  \"contents\" : \"To assess the safety tolerability and clinical outcomes of an adjuvant chemotherapy regimen designed to incorporate a non-cross-resistant agent paclitaxel T with a maximally dose-intensified regimen of doxorubicin and cyclophosphamide AC in conjunction with hematopoietic growth factor support recombinant human granulocyte-colony stimulating factor G-CSF Filgrastim A secondary aim was to assess if a higher dose 10 mcg/kg/day of G-CSF is more efficacious than the conventional dose 5 mcg/kg/day in this setting Female patients with early-stage node-positive invasive breast cancer were eligible for this multicenter cooperative group feasibility trial that was designed as the pilot study for a larger randomized clinical trial The protocol treatment comprised five cycles of dose-intensified AC 75 and 2000 mg/m 2 / cycle respectively intravenously every three weeks with G-CSF support followed by an additional four cycles of T 175 mg/m 2 by 3h intravenous infusion every three weeks Patients were randomized to receive one of two dose levels of G-CSF 5 vs 10 mcg/kg/day during AC chemotherapy Data on both short-term toxicity and long-term survival were collected One hundred and seventy two node-positive patients with operable primary breast cancer were accrued to this trial between February 1993 and April 1994130 of the 172 patients 76 % completed all protocol-specified therapy Of the 42 early study withdrawals 23 were due to unacceptable acute treatment-related toxicity No differences in toxicities or clinical outcomes were noted between the two different dose levels of G-CSF support At 68 years median follow-up relapse-free survival RFS and overall survival OS rates for all patients are 70 % and 78 % respectively Ten patients developed second malignancies during follow-up including three cases with a hematologic malignancy 2 % incidence The delivery of dose-intensified AC followed by T was feasible in this large-scale pilot trial although significant acute toxicities were commonly encountered The data confirmed the acceptable tolerability of T after aggressive myelotoxic therapy in the adjuvant setting leading to a larger randomized clinical trial comparing three dose levels of doxorubicin in AC with or without the addition of T CALGB 9344 Supportive care using twice the conventional dose of G-CSF did not significantly improve the tolerability or change the toxicities of this regimen and the occurrence of secondary malignancies is consistent with the emerging risk profile of dose-intensive regimens with growth factor support With long-term follow-up the clinical outcomes remain relatively favorable and correlate with such expected prognostic factors as the number of involved nodes and hormone receptor status\",\n",
            "}\n",
            "14018\n",
            "{\n",
            "  \"id\" : \"24347519\",\n",
            "  \"contents\" : \"This randomized phase III trial compared pathologic complete response pCR rates of early breast cancer EBC following neoadjuvant epirubicin-docetaxel ED capecitabine C and evaluated the addition of trastuzumab in HER2-positive tumors Patients with invasive breast cancer except T4d were randomly assigned to receive six 3-weekly cycles of ED both 75 mg/m2 C 1000 mg/m2 twice daily days 1-14 Patients with HER2-positive disease were further randomized to receive trastuzumab 8 mg/kg then 6 mg/kg every 3 weeks or not Primary end point pCR rate at the time of surgery Five hundred thirty-six patients were randomized to ED n = 266 or EDC n = 270 93 patients were further randomized to trastuzumab n = 44 or not n = 49 pCR rate was significantly increased with EDC 230 % versus 154 % ED P = 0027 and nonsignificantly further increased with trastuzumab 386 % EDC versus 265 % ED P = 0212 Rates of axillary node involvement at surgery and breast conservation were improved with EDC versus ED but not significantly the addition of trastuzumab had no further impact Hormone receptor status tumor size grade and C all P0 035 were independent prognostic factors for pCR Trastuzumab added to EDC significantly increased the number of serious adverse events 35 versus 18 P = 0020 mainly due to infusion-related reactions These findings show that the integration of C into a neoadjuvant taxane - / anthracycline-based regimen is a feasible safe and effective treatment option with incorporation of trastuzumab in HER2-positive disease NCT00309556 wwwclinicaltrialsgov\",\n",
            "}\n",
            "14019\n",
            "{\n",
            "  \"id\" : \"15365065\",\n",
            "  \"contents\" : \"To examine the effects on bone mineral density of 2 years of treatment with a luteinizing hormone-releasing hormone LHRH agonist alone or in combination with tamoxifen or tamoxifen alone in premenopausal breast cancer We recruited 89 women from two centers in Stockholm participating in a randomized multicenter trial of three different endocrine approaches in the adjuvant setting Zoladex in Premenopausal Patients Trial The women were assigned to receive the LHRH agonist goserelin with or without tamoxifen tamoxifen alone or no endocrine therapy The treatment was given for 2 years We measured total-body bone density before start of treatment and at 12 24 and 36 months After 2 years of treatment there was a significant loss of bone mineral density mean change -5 % P < 001 in the women receiving goserelin alone The combined goserelin and tamoxifen treatment as well as tamoxifen alone resulted in a lesser but statistically significant decline in bone mineral density mean change -14 % P = 02 and -15 % P < 001 One year after cessation of treatment the goserelin group alone showed a partial recovery from bone loss mean change 15 % P = 02 Two years of ovarian ablation from goserelin treatment caused a significant reduction in bone mineral density but there was a partial recovery from the bone loss 1 year after cessation of treatment The addition of tamoxifen seems to partially counteract the demineralizing effects of goserelin\",\n",
            "}\n",
            "14020\n",
            "{\n",
            "  \"id\" : \"20516432\",\n",
            "  \"contents\" : \"The objective of this study was to compare the efficacy and safety of trabectedin plus pegylated liposomal doxorubicin PLD with that of PLD alone in women with recurrent ovarian cancer after failure of first-line platinum-based chemotherapy Women > or = 18 years stratified by performance status 0 to 1 v 2 and platinum sensitivity were randomly assigned to receive an intravenous infusion of PLD 30 mg/m 2 followed by a 3-hour infusion of trabectedin 11 mg/m 2 every 3 weeks or PLD 50 mg/m 2 every 4 weeks The primary end point was progression-free survival PFS by independent radiology assessment Patients N = 672 were randomly assigned to trabectedin/PLD n = 337 or PLD n = 335 Median PFS was 73 months with trabectedin/PLD v 58 months with PLD hazard ratio 079 95 % CI 065 to 096 P = 0190 For platinum-sensitive patients median PFS was 92 months v 75 months respectively hazard ratio 073 95 % CI 056 to 095 P = 0170 Overall response rate ORR was 276 % for trabectedin/PLD v 188 % for PLD P = 0080 for platinum-sensitive patients it was 353 % v 226 % P = 0042 respectively ORR PFS and overall survival among platinum-resistant patients were not statistically different Neutropenia was more common with trabectedin/PLD Grade 3 to 4 transaminase elevations were also more common with the combination but were transient and noncumulative Hand-foot syndrome and mucositis were less frequent with trabectedin/PLD than with PLD alone When combined with PLD trabectedin improves PFS and ORR over PLD alone with acceptable tolerance in the second-line treatment of recurrent ovarian cancer\",\n",
            "}\n",
            "14021\n",
            "{\n",
            "  \"id\" : \"16174858\",\n",
            "  \"contents\" : \"Increased mammographic density reduces the sensitivity of screening mammography is associated with increased breast cancer risk and may be hormone related We assessed the effect of estrogen-plus-progestin therapy on mammographic density In a racially and ethnically diverse ancillary study of the Women s Health Initiative we examined data from 413 postmenopausal women who had been randomly assigned to receive daily combined conjugated equine estrogens 0625 mg plus medroxyprogesterone acetate ie progestin 25 mg n = 202 or daily placebo n = 211 We assessed the effect of estrogen plus progestin on measured mammographic percent density and abnormal findings over a 1-year and 2-year period All tests of statistical significance were two-sided and were based on F tests or t tests from mixed-effects models Mean mammographic percent density increased by 60 % at year 1 compared with baseline in the estrogen-plus-progestin group but decreased by 09 % in the placebo group difference = 69 % 95 % confidence interval [ CI ] = 53 % to 85 % P < 001 The mean changes in mammographic density persisted but were attenuated slightly after 2 years with an absolute increase of 49 % in the estrogen-plus-progestin group and a decrease of 08 % in the placebo group difference = 57 % 95 % CI = 43 % to 73 % P < 001 These effects were consistent across racial/ethnic groups but were higher among women aged 70-79 years in the estrogen-plus-progestin group mean increase at year 1 = 116 % than in the placebo group mean decrease at year 1 = 01 % difference of the means = 117 % 95 % CI = 82 % to 154 % P < 001 comparing across age groups At year 1 women who were adherent to treatment in the estrogen-plus-progestin group had a mean increase in density of 77 % 95 % CI = 59 % to 95 % and women in the placebo group had a mean decrease in density of 11 % 95 % CI = 03 % to 19 % Use of estrogen plus progestin was associated with an increased risk of having an abnormal mammogram at year 1 relative risk = 39 95 % CI = 15 to 102 P = 003 compared with placebo that was not explained by an increase in density Use of up to 2 years of estrogen plus progestin was associated with increases in mammographic density\",\n",
            "}\n",
            "14022\n",
            "{\n",
            "  \"id\" : \"20162706\",\n",
            "  \"contents\" : \"The efficacy of intravesical gemcitabine was evaluated compared with repeated administration of bacille Calmette-Gurin BCG after BCG failure in high-risk non-muscle-invasive bladder cancer BC In this multicenter prospective randomized phase 2 trial eligible patients were those with high-risk non-muscle-invasive BC failing 1 course of BCG therapy All patients were randomly allocated to Group A receiving intravesical gemcitabine at a dose of 2000 mg/50 mL twice weekly for 6 consecutive weeks and then weekly for 3 consecutive weeks at 3 6 and 12 months or Group B receiving intravesical BCG Connaught strain 81 mg/50 mL over a 6-week induction course and each week for 3 weeks at 3 6 and 12 months Outcome measures were recurrence rate time to first recurrence and progression rate Treatment-related complications were also evaluated Eighty participants were enrolled 40 for each group 525 % in Group A developed disease recurrence versus 875 % of those in Group B P = 002 There was no statistically significant difference in mean time to the first recurrence Group A 39 months Group B 31 months P = 09 Kaplan-Meier analysis of 2-year recurrence-free survival showed significant differences between Group A and B 19 % and 3 % respectively P < 008 Seven of 21 33 % patients in Group A and 13 of 35 375 % patients in Group B had disease progression and underwent radical cystectomy P = 12 Both intravesical administrations were generally well tolerated Gemcitabine might represent a second-line treatment option after BCG failure in high-risk non-muscle-invasive BC patients\",\n",
            "}\n",
            "14023\n",
            "{\n",
            "  \"id\" : \"11932472\",\n",
            "  \"contents\" : \"Familial adenomatous polyposis is caused by a germ-line mutation in the adenomatous polyposis coli gene and is characterized by the development of hundreds of colorectal adenomas and eventually colorectal cancer Nonsteroidal antiinflammatory drugs can cause regression of adenomas but whether they can prevent adenomas is unknown We conducted a randomized double-blind placebo-controlled study of 41 young subjects age range 8 to 25 years who were genotypically affected with familial adenomatous polyposis but phenotypically unaffected The subjects received either 75 or 150 mg of sulindac orally twice a day or identical-appearing placebo tablets for 48 months The number and size of new adenomas and side effects of therapy were evaluated every four months for four years and the levels of five major prostaglandins were serially measured in biopsy specimens of normal-appearing colorectal mucosa After four years of treatment the average rate of compliance exceeded 76 percent in the sulindac group and mucosal prostaglandin levels were lower in this group than in the placebo group During the course of the study adenomas developed in 9 of 21 subjects 43 percent in the sulindac group and 11 of 20 subjects in the placebo group 55 percent P = 054 There were no significant differences in the mean number P = 069 or size P = 017 of polyps between the groups Sulindac did not slow the development of adenomas according to an evaluation involving linear longitudinal methods Standard doses of sulindac did not prevent the development of adenomas in subjects with familial adenomatous polyposis\",\n",
            "}\n",
            "14024\n",
            "{\n",
            "  \"id\" : \"18612787\",\n",
            "  \"contents\" : \"Daily divided dose cisplatin DDD-P is used as an efficient modulator of fluorouracil 5-FU as is leucovorin LV We performed a randomized trial to compare the efficacy 5-FU plus DDD-P DDD-FP therapy with 5-FU alone in resected colorectal cancer as the adjuvant therapy One hundred and eighty-eight stage II or III colorectal cancer patients were enrolled Patients were randomly assigned to receive DDD-FP 5-FU 320 mg / m 2 daily for 21 days CDDP 35 mg/m 2 daily for 21 days followed by oral 5-FU 200 mg/body daily for 2 years DDD-FP arm or oral 5-FU therapy 200 mg / body daily for 2 years exclusively oral 5-FU arm The 5-year disease-free survival DFS rates and the overall survival OS rates indicated no significant difference between the two arms By stratified analysis in the colon cancer patients the DFS and the OS for the DDD-FP arm were significantly increased 935 % and 957 % in the DDD-FP arm as compared with 769 % and 822 % in the oral 5-FU arm P = 0024 and P = 0038 Regarding adverse effects grade 3-4 toxicities were not significant in two arms DDD-FP followed by oral 5-FU therapy suggested a feasible regimen for patients with resected colon cancer as the adjuvant therapy\",\n",
            "}\n",
            "14025\n",
            "{\n",
            "  \"id\" : \"8874327\",\n",
            "  \"contents\" : \"To investigate if double modulation of fluorouracil 5-FU with leucovorin folinic acid [ FA ] and interferon alfa-2b IFN 2b improves responses and survival in comparison to single modulation of 5-FU with FA One hundred six patients with histologically confirmed advanced colorectal cancer measurable disease and without previous chemotherapy were prospectively randomized into two groups Patients in group A received 5-FU 450 mg/m2 as an intravenous bolus in the midinfusion of FA weekly FA was given at a dose of 200 mg/m2 in 500 mL 09 % normal saline solution in 2-hour infusion Patients in group B received exactly the same regimen plus IFN 2b 5 million units subcutaneously three times weekly All patients were well balanced in both groups regarding age sex performance status number and site of metastasis One hundred two patients were assessable All patients have died There was no difference in response between the two groups 78 % v 98 % Median survival was 101 months in group A and 72 months in group B P = 00189 Median time to progression was 84 and 52 months respectively P = 00196 Overall better performance status and older age had a positive impact on survival Toxicity was the most important and catastrophic aspect of this study Patients who received IFN 2b had significantly worse anemia neutropenia diarrhea anorexia weight loss flu-like syndrome and psychological reactions Based on this final analysis the addition of IFN 2b to the combination of 5-FU and FA enhances toxicity and contributes to decreased survival\",\n",
            "}\n",
            "14026\n",
            "{\n",
            "  \"id\" : \"22072272\",\n",
            "  \"contents\" : \"Xerostomia dry mouth after head/neck radiation is a common problem among cancer patients and available treatments are of little benefit The objective of this trial was to determine whether acupuncture can prevent xerostomia among head/neck patients undergoing radiotherapy A randomized controlled trial among patients with nasopharyngeal carcinoma was conducted comparing acupuncture to standard care Participants were treated at Fudan University Shanghai Cancer Center Shanghai China Forty patients were randomized to acupuncture treatment and 46 to standard care Patients were treated 3/wk on the same days they received radiotherapy Subjective measures included the Xerostomia Questionnaire and MD Anderson Symptom Inventory-Head and Neck MDASI-HN Objective measures were unstimulated and stimulated whole salivary flow rates Patients were followed for 6 months after the end of radiotherapy Xerostomia Questionnaire scores for acupuncture were statistically significantly lower than for controls starting in week 3 through the 6 months P = 003 at week 3 all other P < 0001 with clinically significant differences as follows week 11 relative risk RR 063 95 % confidence interval [ CI ] 045-0 87 6 months RR 038 95 % CI 019-0 76 Similar findings were seen for MDASI-HN scores Group differences emerged as early as 3 weeks into treatment for saliva unstimulated whole salivary flow rate P = 0004 with greater saliva flow in the acupuncture group at week 7 unstimulated whole salivary flow rate P < 0001 stimulated whole salivary flow rate P = 002 and 11 unstimulated whole salivary flow rate P < 02 stimulated whole salivary flow rate P < 03 and at 6 months stimulated whole salivary flow rate P < 003 Acupuncture given concurrently with radiotherapy significantly reduced xerostomia and improved quality of life\",\n",
            "}\n",
            "14027\n",
            "{\n",
            "  \"id\" : \"12488294\",\n",
            "  \"contents\" : \"To compare the efficacy safety and tolerability of letrozole an advanced non-steroidal aromatase inhibitor and fadrozole hydrochloride an older-generation drug in this class we conducted a randomised double-blind trial in postmenopausal women with advanced breast cancer One hundred and fifty-seven postmenopausal women with advanced breast cancer were enrolled and randomly assigned to receive letrozole or fadrozole in a multicentre randomised double-blind trial in Japan One hundred and fifty-four eligible patients were treated with either letrozole 10 mg once daily n = 77 or fadrozole 10 mg twice daily n = 77 for a minimum of 8 weeks Letrozole showed a significantly higher overall objective response rate [ complete response CR + partial response PR ] than fadrozole 312 % and 130 % respectively P = 0011 Fisher s exact test Clinical benefits defined as CR PR and stable disease no change in status for more than 24 weeks were also higher in patients treated with letrozole 506 % than fadrozole 351 % Letrozole was significantly superior to fadrozole in terms of the dominant lesion in soft tissue bone and viscera P = 0011 stratified Mantel-Haenszel test Median time to progression was 211 days in the letrozole group and 113 days in the fadrozole group with no significant difference P = 0175 log-rank test Letrozole markedly reduced the estradiol estrone and estrone sulfate levels in peripheral blood within 4 weeks The suppressive effect of fadrozole on these hormone levels was insufficient Adverse drug reactions were observed in 359 % of the patients treated with letrozole and in 395 % of those treated with fadrozole with no significant difference between the two groups P = 074 Fisher s exact test Most of the adverse drug reactions were rated as grade 1 or 2 The results show letrozole at a dose of 10 mg once daily to be more effective in treating postmenopausal women with advanced breast cancer than fadrozole at 10 mg twice daily with similar safety and tolerability profiles\",\n",
            "}\n",
            "14028\n",
            "{\n",
            "  \"id\" : \"17264336\",\n",
            "  \"contents\" : \"In 1996 we initiated the French multicenter phase III randomized trial to compare the effect on disease-free survival DFS of concurrent versus sequential chemotherapy CT and radiotherapy RT after breast-conserving surgery for stages I and II breast cancer This report presents the clinical results with a median follow-up of 60 months Between February 1996 and April 2000 716 patients were entered onto this trial Adjuvant treatment began within 6 weeks after surgery Sequential treatment of CT administered first followed by RT was compared with concurrent treatment of CT administered with RT The CT regimen consisted of mitoxantrone 12 mg/m2 fluorouracil 500 mg/m2 and cyclophosphamide 500 mg/m2 on day 1 and it was repeated every 21 days for six courses RT was delivered to the breast and when indicated to the regional lymphatics There was no statistically significant difference in treatment in the 5-year DFS 80 % in both groups P = 83 locoregional recurrence-free survival LRFS 92 % in sequential v 95 % in concurrent P = 76 metastasis-free survival 87 % in sequential v 84 % in concurrent P = 55 or overall survival 90 % in sequential v 91 % in concurrent P = 76 Nevertheless in the node-positive subgroup the 5-year LRFS was statistically better in the concurrent arm 97 % in concurrent v 91 % in sequential P = 02 corresponding to a risk of locoregional recurrence decreased by 39 % hazard ratio 061 95 % CI 038 to 093 This treatment protocol remains an appealing clinical option for many women with operable breast cancer at a high risk of recurrence Combination treatments with new drugs for breast cancer are warranted\",\n",
            "}\n",
            "14029\n",
            "{\n",
            "  \"id\" : \"8692117\",\n",
            "  \"contents\" : \"Despite its low antineoplastic activity 5-fluorouracil remains the most active compound for the treatment of patient with metastatic colorectal cancer Within 5 consecutive trials 2 were randomized 174 patients have been treated with bolus 5-FU 600 mg/m2 plus folinic acid 300 mg/m2 day 2 to 4 with or without dipyridamole 3 x 75 mg po day 1 to 5 74 patients with bolus 5-FU 300 to 350 mg/m2 folinic acid 200 mg/m2 and interferon 5 x 109 U/m2 sc day 1 to 5 18 patients with PALA 250 mg/m2 MTX 250 mg/m2 day 1 and bolus FU 600 mg/m2 day 2 q day 14 and 86 patients with FU 26 g/m2 given as 24-h infusion plus interferon 3 x 10 9 Ul sc and 133 patients with FU 26 g/m2 given as 24-h infusion folinic acid 500 mg/m2 as 2-h infusion with or without interferon 3 x 10 9 U scThe response rate was 11 to 14 % for the iv push schedules and 21 to 36 % for the 24-h continuous infusion regimens The responses lasted for a median of 45 months and 12 months respectively if bolus or infusion schedules were applied Median time to tumor progression was 45 months and 7 months for continuous infusion The median patient survival was 10 to 127 months bolus regimens and 13 to 15 months for infusional 5-FU schedules By weekly high dose infusional 5-FU the response rate response duration time to tumor progression and patient survival may be prolonged especially when modulated by folinic acid compared to modulated bolus regimens This retrospective comparison however needs to be confirmed by the intergroup trial of AIO # 1/95 and EORTC # 40952\",\n",
            "}\n",
            "14030\n",
            "{\n",
            "  \"id\" : \"7651057\",\n",
            "  \"contents\" : \"One of the major side effects of photodynamic therapy PDT employing Photofrin as the sensitizer is enhanced photosensitivity of the skin The basic mechanism in PDT damage is believed to be the formation of singlet oxygen and radical species N-acetylcystene NAC increases glutathione levels and is known to prevent pathology elicited by radicals and reactive species NAC was tested in a randomized open label study for its protective effect on skin photosensitivity Twenty-seven patients treated with PDT for central obstructive lung cancer or esophageal cancer received either early or delayed NAC starting 5 or 10 days after Photofrin in a dose of 3 x 600 mg per day for 5 days Light obtained from a halogen lamp fluence rate 200 mWcm-2 was used to illuminate skin patches of 25 cm2 on the back 10 25 and 50 Jcm-2 Skin response was measured by using a visual scoring system and by measuring the redness using a reflectance meter Skin responses varied from no changes at 10 Jcm-2 to redness with edema at energies of 50 Jcm-2 In the absence of edema measurements with the reflectance meter appeared to be more sensitive than visual scoring In a limited number of patients there was a trend for decreased sensitivity after NAC but statistical analysis failed to show any significant protective effect of this short course of NAC\",\n",
            "}\n",
            "14031\n",
            "{\n",
            "  \"id\" : \"22331983\",\n",
            "  \"contents\" : \"To advance knowledge about the cancer-chemopreventive potential of individual nutrients we investigated the effects of B vitamin and/or -3 fatty acid supplements on cancer outcomes among survivors of cardiovascular disease This was an ancillary study of the Supplementation With Folate Vitamins B 6 and B 12 and/or Omega-3 Fatty Acids SUFOLOM3 secondary prevention trial 2003-2009 In all 2501 individuals aged 45 to 80 years were randomized in a 22 factorial design to one of the following 4 daily supplementation groups 1 5-methyltetrahydrofolate 056 mg pyridoxine hydrochloride vitamin B 6 3 mg and cyanocobalamin vitamin B 12 002 mg 2 eicosapentaenoic and docosahexaenoic acid 600 mg in a 21 ratio 3 B vitamins and -3 fatty acids or 4 placebo Overall and sex-specific hazard ratios HRs and 95 % CIs regarding the cancer outcomes were estimated with Cox proportional hazards models After 5 years of supplementation incident cancer was validated in 70 % of the sample 145 events in men and 29 in women and death from cancer occurred in 23 % of the sample There was no association between cancer outcomes and supplementation with B vitamins HR 115 [ 95 % CI 085-1 55 ] and/or -3 fatty acids HR 117 [ 95 % CI 087-1 58 ] There was a statistically significant interaction of treatment by sex with no effect of treatment on cancer risk among men and increased cancer risk among women for -3 fatty acid supplementation HR 302 [ 95 % CI 133-6 89 ] We found no beneficial effects of supplementation with relatively low doses of B vitamins and/or -3 fatty acids on cancer outcomes in individuals with prior cardiovascular disease Trial Registration isrctnorg Identifier ISRCTN41926726\",\n",
            "}\n",
            "14032\n",
            "{\n",
            "  \"id\" : \"1548519\",\n",
            "  \"contents\" : \"The chemotherapy regimens of high-dose methotrexate high-dose fluorouracil FU Adriamycin doxorubicin Adria Laboratories Columbus OH and leucovorin FAMTX and etoposide Adriamycin and cisplatin EAP have both been reported in nonrandom assignment trials to have high overall response rates and substantial complete response rates in patients with gastric cancer as well as major toxicities of myelosuppression Here we report a prospective stratified random-assignment comparison of the two combinations in previously untreated patients with advanced gastric cancer Sixty patients were entered onto the trial 30 receiving EAP and 30 FAMTX All patients had measurable or assessable tumor masses Patient entry was stopped at the point when significant toxicity differences were seen at interim analysis Response rates were similar between the two arms FAMTX 33 % [ 95 % confidence interval CI 16 % to 50 % ] EAP 20 % [ 95 % Cl 6 % to 34 % ] Three FAMTX and no EAP patients had complete remissions The median survival for the two arms were similar EAP 61 months FAMTX 73 months At 1 year 7 % of EAP and 17 % of FAMTX patients were alive EAP caused significantly more myelosuppression leukopenia P = 002 anemia P = 03 thrombocytopenia P = 0001 than did FAMTX EAP also resulted in significantly longer hospitalizations per study month 8 v 5 days Four EAP patients died of lethal toxicity whereas no FAMTX patients died of treatment-related causes P = 04 FAMTX is at least as active as EAP and is significantly less toxic Although both regimens remain investigational the toxicities of FAMTX are more manageable Further studies involving FAMTX in both the adjuvant and advanced disease setting are underway\",\n",
            "}\n",
            "14033\n",
            "{\n",
            "  \"id\" : \"24512643\",\n",
            "  \"contents\" : \"Prostate cancer screening depends on a careful balance of benefits in terms of reduced prostate cancer mortality and harms in terms of overdiagnosis and overtreatment We aimed to estimate the effect on overdiagnosis of restricting prostate specific antigen PSA testing by age and baseline PSA Estimates of the effects of age on overdiagnosis were based on population based incidence data from the US Surveillance Epidemiology and End Results database To investigate the relationship between PSA and overdiagnosis we used two separate cohorts subject to PSA testing in clinical trials n = 1577 and n = 1197 and a population-based cohort of Swedish men not subject to PSA-screening followed for 25 years n = 1162 If PSA testing had been restricted to younger men the number of excess cases associated with the introduction of PSA in the US would have been reduced by 85 % 68 % and 42 % for age cut-offs of 60 65 and 70 respectively The risk that a man with screen-detected cancer at age 60 would not subsequently lead to prostate cancer morbidity or mortality decreased exponentially as PSA approached conventional biopsy thresholds For PSAs below 1 ng/ml the risk of a positive biopsy is 65 95 % CI 182 729 times greater than subsequent prostate cancer mortality Prostate cancer overdiagnosis has a strong relationship to age and PSA level Restricting screening in men over 60 to those with PSA above median > 1 ng/ml and screening men over 70 only in selected circumstances would importantly reduce overdiagnosis and change the ratio of benefits to harms of PSA-screening\",\n",
            "}\n",
            "14034\n",
            "{\n",
            "  \"id\" : \"17033207\",\n",
            "  \"contents\" : \"It was the aim of this study to prospectively study the effects on hematocrit levels transfusion rates and quality of life QOL indices in men preoperatively supplemented with recombinant erythropoietin rEPO undergoing radical prostatectomy for clinically localized prostate cancer Thirty men undergoing radical prostatectomy were randomized either to receive rEPO n = 25 or to serve as controls n = 25 Outcome measurements obtained preoperatively as well as 10 days and 6 weeks postoperatively included serum hematocrit levels transfusion rates and QOL indices using SF-12 validated questionnaires The rEPO group had a significant increase in preoperative hematocrit median increase = 4 points p = 0002 Although there were no significant differences in hematocrit at 10 days the rEPO had a significantly higher hematocrit value at 6 weeks p = 00086 No differences were observed in transfusions rates between groups 4 % in each group SF-12 mental and SF-12 physical scores were not different between the two groups at any time point Preoperative administration of rEPO significantly increases preoperative and postoperative hematocrit levels However no differences were observed with regard to transfusion rates or postoperative QOL indices despite these higher hematocrit values\",\n",
            "}\n",
            "14035\n",
            "{\n",
            "  \"id\" : \"8567331\",\n",
            "  \"contents\" : \"This article is a prospective trial of hyperfractional radiotherapy with bronchial arterial infusion of anticancer drugs to treat locally advanced bronchogenic cancer The treatment results the complications of bronchial arterial infusion the failure patterns the relationship of technical aspects of delivery of radiotherapy and the protocol of anticancer drugs are presented One hundred and twenty-six patients with locally advanced bronchogenic cancer treated from January 1988 to January 1990 were divided randomly into four groups in our hospital Group 1 combination of hyperfractional radiotherapy with bronchial arterial infusion of anticancer drugs 30 cases Group 2 combination of conventional radiotherapy with bronchial arterial infusion of anticancer 33 cases Group 3 combination of systemic chemotherapy and split-course radiotherapy 33 cases Group 4 conventional radiotherapy only 30 cases All the patients were followed for 3 years The 1-year survival rates for Groups 1 2 3 and 4 are 80 636 485 and 30 % respectively The 2-year survival rates for Groups 1 2 3 and 4 are 233 1515 91 and 66 % respectively The 3-year survival rates for Groups 1 2 3 and 4 are 10 33 0 and 0 % respectively This study demonstrated that the combination of hyperfractional radiotherapy with bronchial arterial infusion anticancer drugs can be performed safely and effectively for locally advanced bronchogenic carcinoma\",\n",
            "}\n",
            "14036\n",
            "{\n",
            "  \"id\" : \"11561868\",\n",
            "  \"contents\" : \"Based on in vitro and on clinical evidence of protection against acute side effects of radiation a prospective randomized open study was performed to determine the efficacy of an oral proteolytic enzyme preparation in patients with head and neck cancer receiving conventional fractionated radiation therapy Patients with stage T3/T4 head and neck cancer were eligible One hundred patients from two centres were entered into the study 60Co gamma-radiation was delivered at a standard daily radiation dose of 2 Gy in 25-35 fractions over a period of 6-7 weeks Two lateral parallel opposing fields were used with a portal area of 10 x 15 cm Patients assigned to the test group arm additionally received enzyme tablets orally tid starting 3 days prior to radiation therapy and continuing up to 5 days after completion of the course of radiation therapy Patients in the control arm were not given any drug or placebo Acute radiation side effects were described as mucositis skin reaction dysphagia and were graded at each visit during and after radiation therapy following RTOG/EORTC criteria The severity maximum extent of acute radiation therapy side effects was significantly less in enzyme-treated patients than in control patients mucositis mean 13 vs 22 P < 0001 skin reaction 12 vs 24 P < 0001 and dysphagia 14 vs 22 P < 0001 The duration of these side effects as well as the sum scores of side effects were also less in the study arm Combination of enzyme therapy with conventional fractionated radiation therapy was feasible and well-tolerated There was significant protection against acute side effects of radiation therapy in the study arm Not only was the severity of acute side effects less but the duration was shorter and the time to onset was also delayed Prospective randomized double-blind studies would verify this role of an oral enzyme therapy as standard co-medication with radiation therapy to the head and neck region\",\n",
            "}\n",
            "14037\n",
            "{\n",
            "  \"id\" : \"17054108\",\n",
            "  \"contents\" : \"The authors evaluated the long-term efficacy and side effects in patients with nonmetastatic unilateral inflammatory breast cancer IBC who received homogeneous treatment with intensive induction chemotherapy followed by a maintenance regimen One hundred twenty patients were randomized to receive high-dose fluorouracil epirubicin and cyclophosphamide FEC-HD fluorouracil 750 mg/m 2 on Days 1 to 4 epirubicin 35 mg/m 2 on Days 2 to 4 and cyclophosphamide 400 mg/m 2 on Days 2 to 4 for 4 cycles every 21 days with or without lenograstim Locoregional treatment consisted of surgery and/or radiotherapy Maintenance chemotherapy was FEC 75 fluorouracil 500 mg/m 2 epirubicin 75 mg/m 2 and cyclophosphamide 500 mg/m 2 on Day 1 every 21 days for 4 cycles No hormone treatment was allowed The safety of the FEC-HD regimen was described previously Among 102 patients who underwent surgery a pathologic complete response pCR was achieved by 235 % of patients with breast tumors and by 314 % of patients with involved axillary lymph nodes The overall pCR rate was 147 % One hundred nine patients received FEC 75 After a median 10 years of follow-up the disease-free survival DFS and overall survival OS rates were 357 % and 412 % respectively The median DFS was 39 months 95 % confidence interval [ 95 % CI ] 25-53 months and the median survival was 61 months 95 % CI 43-79 months Five patients developed a temporary decrease in left ventricular ejection fraction without congestive heart failure In the lenograstim group 1 patient developed acute myeloblastic leukemia M2 and 1 patient developed myelodysplastic syndrome FEC-HD induction chemotherapy followed by FEC 75 maintenance regimen had moderate and acute long-term toxicities and lead to high DFS and OS rates in patients with IBC\",\n",
            "}\n",
            "14038\n",
            "{\n",
            "  \"id\" : \"22684982\",\n",
            "  \"contents\" : \"This randomized controlled trial tested the efficacy of parent-based behavioral counseling for reducing secondhand smoke exposure SHSe among children with cancer It also examined predictors of smoking and SHSe outcomes Participants were 135 parents or guardians of nonsmoking children with cancer < 18 years at least 30 days postdiagnosis and living with at least one adult smoker Parents were randomized to either a standard care control group or an intervention consisting of six counseling sessions delivered over 3 months Parent-reported smoking and child SHSe levels were obtained at baseline 3 6 9 and 12 months Children provided urine samples for cotinine analyses Reductions in parent-reported smoking and exposure were observed in both the intervention and control conditions There was a significantly greater reduction in parent-reported smoking and child SHSe at 3 months for the intervention group compared with the control group Child SHSe was significantly lower at 12 months relative to baseline in both groups Children s cotinine levels did not show significant change over time in either group Exposure outcomes were influenced by the number of smokers at home smoking status of the parent participating in the trial and the child s environment home versus hospital the day before the assessment Children s SHSe can be reduced by advising parents to protect their child from SHSe combined with routine reporting of their child s exposure and cotinine testing when delivered in the context of the pediatric cancer setting More intensive interventions may be required to achieve greater reductions in SHSe\",\n",
            "}\n",
            "14039\n",
            "{\n",
            "  \"id\" : \"9167772\",\n",
            "  \"contents\" : \"Treatment of prostatic disease with GnRH agonists or by orchidectomy affects bone mass negatively Estrogen treatment has beneficial effects on bone mass in women and might hypothetically have a bone preserving capacity also in patients with prostatic cancer We followed serum markers for bone and collagen metabolism and sex steroids for 18 months in patients with prostatic cancer treated by orchidectomy N = 13 or by single-drug parenteral polyestradiol phosphate 240 mg intramuscularly every second week for the first two months and then every fourth week N = 17 Total and free testosterone reached castration levels within 15 months of estrogen treatment Four patients developing progressive disease and/or signs of metastasis were excluded from the analysis In the remaining patients serum osteocalcin procollagen IIIP PIIINP procollagen PICP and the crosslinked carboxyterminal telopeptide of type I collagen ICTP increased significantly over time following orchidectomy N = 11 Serum osteocalcin and PICP decreased significantly over time during estrogen treatment N = 15 Treatment values of all four markers were significantly lower in estrogen-treated than in orchidectomized patients The changes in serum bone and collagen markers indicate an increased bone turnover in orchidectomized subjects The opposite pattern was found in the estrogen-treated patients indicating a reduced turnover Estrogens may also have a bone mass-preserving capacity in elderly males with prostatic cancer\",\n",
            "}\n",
            "14040\n",
            "{\n",
            "  \"id\" : \"22042783\",\n",
            "  \"contents\" : \"To compare the pathologic complete response pCR rate of patients treated with 5-fluorouracil 5-FU doxorubicin and cyclophosphamide FAC versus dose-intense FAC plus G-CSF in the neoadjuvant setting and to compare the delivered dose intensity disease-free survival DFS and overall survival OS times and toxicity between treatment arms in patients with breast cancer Patients were randomized to receive preoperative FAC 5-FU 500 mg/m 2 doxorubicin 50 mg/m 2 cyclophosphamide 500 mg/m 2 every 21 days for four cycles or dose-intense FAC 5-FU 600 mg/m 2 doxorubicin 60 mg/m 2 cyclophosphamide 1000 mg/m 2 plus G-CSF every 18 days for four cycles Two hundred two patients were randomly assigned The median follow-up was 75 years Patients randomized to FAC plus G-CSF had a higher pCR rate as well as clinical complete response rate however these differences were not statistically different from those with the FAC arm Patients in the FAC + G-CSF arm had a higher delivered dose intensity of doxorubicin in the neoadjuvant and adjuvant settings than those in the standard FAC arm DFS and OS times were not significantly different between the two groups However the OS and DFS rates were significantly higher for patients who achieved a pCR than for those who did not Thrombocytopenia febrile neutropenia and infection rates were higher in the FAC + G-CSF arm A higher delivered dose intensity of doxorubicin with the FAC + G-CSF regimen did not result in a statistically significant higher pCR rate However patients who achieved a pCR experienced longer DFS and OS times\",\n",
            "}\n",
            "14041\n",
            "{\n",
            "  \"id\" : \"14706014\",\n",
            "  \"contents\" : \"The present study was undertaken mainly to investigate whether chemohormonal therapy with estramustine phosphate plus luteinizing hormone-releasing hormone LHRH agonist has a more beneficial effect than the hormonal therapy with flutamide plus LHRH agonist for newly diagnosed patients with metastatic prostate cancer A total of 57 patients with metastatic prostate cancer aged 59-80 years median 74 years were entered in the study and were randomized to the treatment of estramustine phosphate 560 mg/day plus LHRH agonist estramustine group or flutamide 375 mg/day plus LHRH agonist flutamide group with stratification for the degree of performance status histological differentiation and bone metastasis Both of the treatment regimens were well tolerated with similar incidences of adverse drug reactions The overall response rates complete response plus partial response at 12 weeks after treatment in the estramustine and flutamide groups were 76 and 55 % respectively The median time to objective progression for the estramustine group 254 months was longer than that of the flutamide group 146 months The serum levels of follicle stimulating hormone and testosterone were significantly lower in the estramustine group Chemohormonal therapy with estramustine phosphate plus LHRH agonist showed longer clinical progression-free survival than the hormonal therapy with flutamide plus LHRH agonist P = 003 although there was no significant difference in the overall survival A larger-scaled trial with more statistical power is required to clarify that the former regimen is more beneficial than the latter for newly diagnosed patients with advanced prostate cancer\",\n",
            "}\n",
            "14042\n",
            "{\n",
            "  \"id\" : \"19850639\",\n",
            "  \"contents\" : \"Circulation of cancer cells in the blood is a mandatory step for metastasis but circulating tumor cells CTC have a low metastatic efficiency in preclinical animal models In this prospective study we reported the clinical outcome of nonmetastatic breast cancer patients according to CTC detection In 115 nonmetastatic patients diagnosed with large operable or locally advanced breast cancer we prospectively detected CTC using the CellSearch system before and after neoadjuvant chemotherapy in a phase II trial REMAGUS02 At baseline 23 % of patients were CTC positive but only 10 % had > 1 CTC/7 5 ml of blood After a median follow-up of 36 months CTC detection before chemotherapy was an independent prognostic factor for both distant metastasis-free survival [ DMFS P = 001 relative risk RR = 50 95 % confidence interval CI 14-17 ] and overall survival OS P = 0007 RR = 9 95 % CI 18-45 CTC detection after chemotherapy was of less significance P = 007 and 009 respectively Moreover CTC detection showed interesting characteristics as an individual predictive test for metastatic relapses sensibility 55 % specificity 81 % and global accuracy 77 % Detection of > or = 1 CTC/7 5 ml before neoadjuvant chemotherapy can accurately predict OS Our findings may change the clinical management of nonmetastatic breast cancer and indicate that the metastatic efficiency of CTC could be higher than previously reported\",\n",
            "}\n",
            "14043\n",
            "{\n",
            "  \"id\" : \"14551299\",\n",
            "  \"contents\" : \"To determine if circadian timed CT chemotherapy results in improved response progression-free survival PFS overall survival OS and lower toxicity when compared with standard timed ST chemotherapy Eligibility criteria were stage III IV or recurrent endometrial cancer with poor potential for cure by radiation therapy or surgery measurable disease and no prior chemotherapy Therapy was randomized to schedules of ST doxorubicin 60 mg/m2 plus cisplatin 60 mg/m2 or CT doxorubicin 60 mg/m2 at 600 am plus cisplatin 60 mg/m2 at 600 pm Cycles were repeated every 3 weeks to a maximum of eight cycles The ST arm included 169 patients and the CT arm included 173 patients The objective response rate complete responses plus partial responses was 46 % in the ST group compared with 49 % in the CT group P = 26 one tail Median PFS and OS were 65 and 112 months respectively in the ST group and 59 and 132 months respectively in the CT group PFS P = 31 OS P = 21 one tail Median total doses were 209 mg/m2 doxorubicin and 349 mg/m2 cisplatin in the ST group versus 246 mg/m2 doxorubicin and 354 mg/m2 cisplatin in the CT group Grade 3 or 4 leukopenia occurred in 73 % of patients in the ST arm and in 63 % of patients in the CT arm There were eight treatment-related deaths In this trial no significant benefit in terms of response rate PFS or OS or toxicity profile was observed with CT doxorubicin plus cisplatin in patients with advanced or recurrent endometrial carcinoma\",\n",
            "}\n",
            "14044\n",
            "{\n",
            "  \"id\" : \"20704726\",\n",
            "  \"contents\" : \"Treatment with Androgen Deprivation Therapy ADT for prostate cancer is associated with changes in body composition including increased fat and decreased lean mass increased fatigue and a reduction in quality of life No study to date has evaluated the effect of dietary and physical activity modification on the side-effects related to ADT The aim of this study is to evaluate the efficacy of a 6-month dietary and physical activity intervention for prostate cancer survivors receiving ADT to minimise the changes in body composition fatigue and quality of life typically associated with ADT Men are recruited to this study if their treatment plan is to receive ADT for at least 6 months Men who are randomised to the intervention arm receive a home-based tailored intervention to meet the following guidelines a > or = 5 servings vegetables and fruits/day b 30 % -35 % of total energy from fat and < 10 % energy from saturated fat/day c 10 % of energy from polyunsaturated fat/day d limited consumption of processed meats e 25-35 gm of fibre/day f alcoholic drinks < or = 28 units/week g limited intake of foods high in salt and/or sugar They are also encouraged to include at least 30 minutes of brisk walking 5 or more days per week The primary outcomes are change in body composition fatigue and quality of life scores Secondary outcomes include dietary intake physical activity and perceived stress Baseline information collected includes socio-economic status treatment duration perceived social support and health status family history of cancer co-morbidities medication and supplement use barriers to change and readiness to change their health behaviour Data for the primary and secondary outcomes will be collected at baseline 3 and 6 months from 47 intervention and 47 control patients The results of this study will provide detailed information on diet and physical activity levels in prostate cancer patients treated with ADT and will test the feasibility and efficacy of a diet and physical activity intervention which could provide essential information to develop guidelines for prostate cancer patients to minimise the side effects related to ADT ISRCTN trial number ISCRTN75282423\",\n",
            "}\n",
            "14045\n",
            "{\n",
            "  \"id\" : \"2679288\",\n",
            "  \"contents\" : \"To determine whether in the previous National Surgical Adjuvant Breast and Bowel Project NSABP studies of node-negative breast cancer there were either cohorts of patients with a prognosis favorable enough to preclude using systemic therapy or subsets of patients who failed to benefit from the treatments Randomized clinical trials with stratification after surgery NSABP trials at institutions in the United States and Canada Data were collected on 731 eligible patients Protocol B-13 with estrogen-receptor-negative tumors who randomly received either no therapy after surgery or sequential methotrexate and fluorouracil M -- F followed by leucovorin Data were also collected on 2834 patients Protocol B-14 with estrogen-receptor-positive tumors who randomly received either placebo or tamoxifen treatment The percentage of patients surviving disease-free was determined through 4 years of follow-up using life-table estimates Protocol B-13 patients received 12 courses of M -- F given intravenously on days 1 and 8 every 4 weeks Leucovorin therapy was begun 24 hours after M -- F administration Protocol B-14 patients received 5-year treatment with either tamoxifen 10 mg twice daily by mouth or placebo When the outcome of untreated patients in either trial was related to the stratification variables women were found to have a disease-free survival of less than 80 % through 4 years of follow-up This percentage is apt to decrease because the probability of treatment failure increases with time In both trials all subsets of women benefited from M -- F or tamoxifen therapy The disease-free survival of all cohorts of node-negative patients with estrogen-receptor-negative or estrogen-receptor-positive tumors was poor enough to justify systemic treatment The benefits of the therapies used are insufficient to eliminate the need for assessing putatively better regimens\",\n",
            "}\n",
            "14046\n",
            "{\n",
            "  \"id\" : \"8616760\",\n",
            "  \"contents\" : \"Information regarding prognostic factors and survival in elderly women with metastatic breast cancer treated with tamoxifen is limited The data from 4 prospective clinical trials were analyzed including information on 396 postmenopausal women with advanced breast cancer who received tamoxifen as initial therapy for metastatic disease Emphasis was placed on 184 elderly patients age greater than 65 years to characterize the response to therapy time to progression TTP overall survival OS prognostic factors and treatment-related toxicity Among 363 patients with measurable or evaluable disease the objective response rates were higher in the elderly patients 46 % versus 33 % P = 006 but age did not achieve significance in a logistic regression analysis P = 01 The median TTP 105 months versus 62 months log rank P = 0002 and OS 357 months versus 288 months log rank P = 002 were superior in the elderly cohort In multivariate analysis age at diagnosis approached statistical significance P = 0055 for TTP but was not significant for OS P = 017 Among elderly patients disease free interval DFI greater than 5 years dominant disease site soft tissue prior adjuvant chemotherapy positive estrogen/progesterone receptor ER/PgR and performance status PS were independent prognostic factors Hot flashes were common in both younger and older cohorts 25 % versus 33 % P = 014 while anorexia 14 % versus 22 % P = 004 and mood changes 2 % versus 6 % P = 003 were more common in the elderly patients There was no indication that elderly women with metastatic breast cancer treated with tamoxifen have a poorer outcome with regard to response rate TTP or OS in fact they appeared to have a slightly better prognosis although this was not significant after adjustment for other prognostic factors In elderly patients DFI PS positive ER or PGR and dominant disease site are independent prognostic factors\",\n",
            "}\n",
            "14047\n",
            "{\n",
            "  \"id\" : \"17578316\",\n",
            "  \"contents\" : \"To study the effect of Shenqi Fuzheng Injection SFI on cellular immune in patients with mammary cancer MC after chemotherapy One hundred and ten patients with MC were randomly assigned to two groups The 58 patients in the tested group were treated with SFI in cooperation with chemotherapy of CAF protocol Cyclophosphamide Doxorubicin and Fluorouracil while the 52 patients in the control group were treated with chemotherapy of the same protocol alone Changes of the patients quality of life QOF adverse reaction that occurred peripheral lymphocyte count and killing activity of single karyocyte before and after treatment between the two groups were compared Patients QOF elevating rate after treatment in the tested group and the control group was 345 % and 135 % respectively The lowering of peripheral blood cell count of WBC platelet and lymphocyte as well as that of the killing activity of single peripheral karyocyte on various kinds of MC cells were all milder and recovery sooner than those in the control group SFI in combination with chemotherapy in treating MC could reduce the occurrence of adverse reaction to chemotherapy improve clinical symptoms elevate QOF and enhance immunity in patients with MC\",\n",
            "}\n",
            "Elapsed time : 0.6489365100860596 s\n"
          ]
        }
      ]
    }
  ]
}